# Patent

## Title
Flap modulators

## Abstract

The present invention relates to compounds of Formula (I), or a form thereof wherein ring A1, R1, R2, R3, R3′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase of International Application No. PCT/US2014/014111 filed on Jan. 31, 2014, which claims the benefit of U.S. Provisional Application No. 61/760,627 filed on Feb. 4, 2013 and U.S. Provisional Application No. 61/800,353 filed on Mar. 15, 2013, each of which is incorporated herein by reference in its entirety.


FIELD OF THE INVENTION
The present invention relates to substituted compounds useful as 5-lipoxygenase-activating protein (FLAP) modulators, pharmaceutical compositions of such compounds, methods of preparation and use thereof. More particularly, FLAP modulators are useful for preventing, treating or ameliorating FLAP-mediated diseases and/or disorders, including those inflammation diseases and/or disorders associated with dermatological and respiratory disorders, allergic disorders, autoimmunity, cancer, cardiovascular and metabolic disorders.
BACKGROUND OF THE INVENTION
FLAP is a key initiator of the leukotriene synthesis pathway that binds and then transfers arachidonic acid to 5-lipoxygenase (M. Abramovitz et al., “5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase,” Eur. J. Biochem., 1993, 215, 105-11). FLAP has been demonstrated to interact with LTC4 synthase, and could putatively modulate the production of LTC4 (T. Strid et al., “Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein,” Biochem. Biophys. Res. Comm., 2009, 381(4), 518-22). Modulation (including without limitation inhibition) or genetic deletion of FLAP blocks leukotriene production, specifically LTB4, the cysteinyl leukotrienes (LTC4, LTD4 and LTE4) as well as 5-oxo-ETE (J. Z. Haeggström et al., “Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease,” Chem Rev., 2011, 111(10), 5866-98).
Leukotrienes are immune-modulating lipids formed from arachidonic acid (reviewed in Samuelsson, “Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation,” Science, 1983, 220, 568-75). They are synthesized primarily by eosinophils, neutrophils, mast cells, basophils, dendritic cells, macrophages and monocytes. Leukotrienes mediate multiple biological effects including, by way of example only, smooth muscle contraction, leukocyte recruitment and activation, cytokine secretion, fibrosis, mucous secretion, and vascular function (J. Z. Haeggström, at 5866-98).
FLAP-deficient mice are healthy and reproduce normally. They do not produce leukotrienes and have decreased susceptibility in mouse models of arthritis (R. J. Griffiths et al., “Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice,” J. Exp. Med., 1997, 185, 1123-29). In humans, FLAP itself has been linked by genetic studies to respiratory disorders and cardiovascular disease, including myocardial infarction, atherosclerosis, cerebral infarctions, coronary artery disease and stroke (A. Helgadottir et al., “The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction, atherosclerosis and stroke,” Nat. Genet., 2004, 36, 233-39; A. S. Tulah et al., “The role of ALOX5AP, LTA4H and LTB4R polymorphisms in determining baseline lung function and COPD susceptibility in UK smokers,” BMC Med. Genet., 2011, 29(12), 173; R. Ji et al., “Genetic variants in the promoter region of the ALOX5AP gene and susceptibility of ischemic stroke,” Cerebrovasc. Dis., 2011, 32(3), 261-68; J. W. Holloway et al., “The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility,” Allergy. 2008, 63(8), 1046-53; J. Nair et al., “Expression analysis of leukotriene-inflammatory gene interaction network in patients with coronary artery disease,” J Atheroscler. Thromb., 2013; L. F. Chi et al., “Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese,” Neuroreport., 2013). In addition, studies using animal models support a causative role for leukotrienes in aortic aneurisms, atherosclerosis, pulmonary arterial hypertension, myocardial infarction, atherosclerosis, and stroke (reviewed in J. Z. Haeggström, at 5866-98).
Leukotrienes also play a role in autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease and multiple sclerosis (S. Chwieśko-Minarowska et al., “The role of leukotrienes in the pathogenesis of systemic sclerosis,” Folia Histochem. Cytobiol., 2012, 50(2), 180-85; M. Rosnowska et al., “Leukotrienes C4 and B4 in cerebrospinal fluid of patients with multiple sclerosis,” Pol. Merkuriusz Lek., 1997, 2, 254-55; and reviewed in J. Z. Haeggström, at 5866-98; I. Loell et al., “Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis,” Ann. Rheum. Dis., 2013, 72(2), 293-99; J. Chu et al., “Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model,” J. Neuroinflammation, 2012, 9, 127). Leukotrienes have also been implicated in several aspects of carcinogenesis including tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells (D. Wang and R. N. Dubois, “Eicosanoids and cancer,” Nat. Rev. Cancer, 2010, 10(3), 181-93).
Leukotrienes play a key role in allergic disorders such as allergic rhinitis, allergic dermatitis and asthma, as well as respiratory disorders such as exacerbations, non-allergic asthma, aspirin exacerbated respiratory disease, fibrotic lung diseases, acute respiratory distress syndrome and chronic obstructive pulmonary disease (reviewed in J. Z. Haeggström at 5866-98). Approved antagonists of the LTC4 receptor and leukotriene synthesis modulators such as zileuton have shown clinical efficacy in a variety of respiratory disorders (reviewed in M. E. Krawiec and S. E. Wenzel, “Leukotriene modulators and non-steroidal therapies in the treatment of asthma,” Expert. Opin. Pharmacotherapy, 2001, 2(1), 47-65).
All the above evidence supports a key role of leukotrienes in a variety of human diseases and/or disorders, and FLAP modulation would be effective for the prevention, treatment, or amelioration of these immune-mediated inflammatory diseases and/or disorders. Furthermore, there still remains a need for FLAP modulator compounds that have pharmacokinetic and pharmacodynamic properties suitable for use as human pharmaceuticals.
SUMMARY OF THE INVENTION
In its many embodiments, the present invention provides novel compounds useful as, for example, FLAP modulators (including without limitation novel compounds that inhibit FLAP), methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical compositions comprising one or more such compounds, and methods of prophylaxis, treatment, amelioration, including without limitation inhibition, of one or more diseases and/or disorders associated with FLAP using such compounds or pharmaceutical compositions.
One aspect of the present invention is directed to compounds, methods, and compositions for the treatment or prophylaxis or amelioration of a variety of diseases and/or disorders that are mediated or sustained through the activity of leukotrienes, including pulmonary, allergic, fibrotic, neurological, inflammatory, autoimmune and cardiovascular diseases and cancer or associated symptoms or complications thereof. More specifically, this invention is directed to a method of treating exacerbations, non-allergic asthma, fibrotic lung diseases, acute respiratory distress syndrome and chronic obstructive pulmonary disease, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering a FLAP modulator.
Another aspect of the present invention is directed to compounds, methods, and compositions for the treatment or prophylaxis or amelioration of cardiac and cardiovascular diseases and/or disorders, or associated symptoms or complications thereof, that include but are not limited to myocardial infarction, atherosclerosis and stroke aortic aneurisms, atherosclerosis, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering a FLAP modulator.
Yet another aspect of the present invention is directed to compounds, methods, and compositions for the prophylaxis, treatment, or amelioration of autoimmune diseases and/or disorders, or associated symptoms or complications thereof, that include but are not limited to rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis or allergic disorders that include but are not limited to allergic rhinitis, allergic dermatitis and asthma, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering a FLAP modulator.
Finally, one aspect of the present invention is directed to compounds, methods, and compositions for the prophylaxis, treatment, or amelioration of carcinogenesis including but not limited to tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering a FLAP modulator.
Another aspect of the present invention features a compound of Formula (I)




wherein

    
    
        L is a bond, —CH2—, —SO2—, —CH2—SO2—, —SO2—CH2—, —SO2—NR—,
    
    


—SO2—NR—CH2—, —CH2—SO2—NR—, —NR—, —NR—SO2—, —NR—SO2—NR—, —S—, —S—CH2—, —CH2—S—,
—C(═O)—, —C(═O)—O—, —O—, —O—CH2—, —NR—C(═O)—, —NR—C(═O)—NR—, or —C(═O)—NR—, wherein R is H,
C1-2alkyl, C1-2alkyl-OH or cyclopropyl;

    
    
        R1 is H, halo, methyl, CF3, —O—CF3, or —O— CH3;
        R2 is H, cyano, halo, —SO2—CH3, 2-(trimethylsilyl)ethoxy, phenyl, C1-6alkyl, heteroaryl, heterocyclyl, C3-9cycloalkyl, provided R2 is not H if L is a bond, and wherein said phenyl, C1-6alkyl, heteroaryl, heterocycyl or C3-9cycloalkyl is optionally and independently substituted with 1-4 substituents selected from the group consisting of:
        methyl, ethyl, oxo, fluoro, hydroxyl, cyano, amino, methoxy, tert-butoxy, acetyl, cyclopropyl, cyclobutyl, cyclohexyl, phenyl, azetidin-1-yl, azetidin-3-yl, pyrrolidin-1-yl, 2,4-dihydro-3H-1,2,4-triazol-3-one-4-yl, 1H-imidazol-4-yl, pyrazin-2-yl, pyrimidin-2-yl, 1,3-oxazolidin-2-one-5-yl, N-benzamide, benzo[d]imidazol-2(3H)-one, 4-methylpiperazin-1-yl, morpholin-4-yl, CF3, —SO2—CH3, —C(═O)-cyclopropyl, —SO2-cyclohexyl, —NHCH3, —N(CH3)2, —NHAc, —NHCO2t-Bu, —CH2—NH2, —C(═O)—NH2, —C(═O)—N(ethyl)2, —NH—C(═O)—NH2, —NH—C(═O)—CH3, —C(═O)—(C1-C4alkyl), —C(═O—OH, —C(═O)—NH(C1-C4alkyl)-(CH2)n—OH, and —(CH2)n—CN, wherein n is 1 or 2;
        V is CH, CR′, or N, wherein R′ is methyl or F;
        W is CR′′ or N, wherein R′′ is H, F, hydroxyl, amino, CH3 or —O—CH3;
        ring A is selected from the group consisting of:
    
    









    
    
        R3 is H, F, methyl, or —O—CH3;
        R3′ is H or F;
        R4 is H, methyl, cyano, amino, halo, —COOH, or —O—CH3;
        R5 is H, methyl, cyano, or —CF3;
        R6 is H, cyano, amino, halo, or —CF3; and
        R7 is halo, amino, —CONH2, cyano, —O—CH3, —CF3, or —COO-ethyl;
    
    


or an optical isomer, hydrate, metabolite, enantiomer, diastereomer, cis-trans isomer, racemate, prodrug or pharmaceutically acceptable salt thereof.
Another aspect of the present invention features a pharmaceutical composition comprising at least one compound of Formula (I) and at least one pharmaceutically acceptable carrier. The invention is also directed towards providing a process for formulating a pharmaceutical composition, comprising formulating a pharmaceutical composition of at least one compound of Formula (I) and at lease one pharmaceutically acceptable carrier. The present invention further relates to a process for making a pharmaceutical composition comprising mixing any of the compounds according to Formula (I) and a pharmaceutically acceptable carrier.
The present invention also features a method of treating a subject suffering from or diagnosed with a disease and/or disorder mediated by FLAP activity, comprising administering to the subject a therapeutically effective amount of at least one compound of Formula (I). Such a disease and/or disorder can include, but is not limited to respiratory disorders, cardiac and cardiovascular diseases, autoimmune disorders, carcinogenesis or associated symptoms or complications. More specifically, this invention is directed to a method of treating exacerbations, non-allergic asthma, fibrotic lung diseases, acute respiratory distress syndrome, chronic obstructive pulmonary disease myocardial infarction, atherosclerosis and stroke aortic aneurisms, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis, allergic rhinitis, allergic dermatitis and asthma, tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, or associated symptoms or complications thereof, wherein the method comprises administering a FLAP modulator to a subject in need thereof, a therapeutically effective amount of at least one compound of Formula (I), preferably in a pharmaceutical composition comprising at least one compound of Formula (I).
Additional embodiments and advantages of the invention will become apparent from the detailed discussion, schemes, examples, and claims below.


DETAILED DESCRIPTION OF THE INVENTION
This invention relates to novel FLAP modulators and compositions thereof for the prophylaxis, treatment, or amelioration of numerous diseases and/or disorders, including but not limited to respiratory diseases and/or disorders, cardiac and cardiovascular diseases and/or disorders, autoimmune diseases and/or disorders, carcinogenesis, and associated symptoms or complications thereof.
One aspect of the present invention features a compound of Formula (I)




wherein

    
    
        L is a bond, —CH2—, —SO2—, —CH2—SO2—, —SO2—CH2—, —SO2—NR—,
    
    


—SO2—NR—CH2—, —CH2—SO2—NR—, —NR—, —NR—SO2—, —NR—SO2—NR—, —S—, —S—CH2—, —CH2—S—,
—C(═O)—, —C(═O)—O—, —O—, —O—CH2—, —NR—C(═O)—, —NR—C(═O)—NR—, or —C(═O)—NR—, wherein R is H,
C1-2alkyl, C1-2alkyl-OH or cyclopropyl;

    
    
        R1 is H, halo, methyl, CF3, —O—CF3, or —O— CH3;
        R2 is H, cyano, halo, —SO2—CH3, 2-(trimethylsilyl)ethoxy, phenyl, C1-6alkyl, heteroaryl, heterocyclyl, C3-9cycloalkyl, provided R2 is not H if L is a bond, and wherein said phenyl, C1-6alkyl, heteroaryl, heterocyclyl or C3-9cycloalkyl is optionally and independently substituted with 1-4 substituents selected from the group consisting of:
        methyl, ethyl, oxo, fluoro, hydroxyl, cyano, amino, methoxy, tert-butoxy, acetyl, cyclopropyl, cyclobutyl, cyclohexyl, phenyl, azetidin-1-yl, azetidin-3-yl, pyrrolidin-1-yl, 2,4-dihydro-3H-1,2,4-triazol-3-one-4-yl, 1H-imidazol-4-yl, pyrazin-2-yl, pyrimidin-2-yl, 1,3-oxazolidin-2-one-5-yl, N-benzamide, benzo[d]imidazol-2(3H)-one, 4-methylpiperazin-1-yl, morpholin-4-yl, CF3, —SO2—CH3, —C(═O)-cyclopropyl, —SO2-cyclohexyl, —NHCH3, —N(CH3)2, —NHAc, —NHCO2t-Bu, —CH2—NH2, —C(═O)—NH2, —C(═O)—N(ethyl)2, —NH—C(═O)—NH2, —NH—C(═O)—CH3, —C(═O)—(C1-C4alkyl), —C(═O)—OH, —C(═O)—NH(C1-C4alkyl)-(CH2)n—OH, and —(CH2)n—CN, wherein n is 1 or 2;
        V is CH, CR′, or N, wherein R′ is methyl or F;
        W is CR′′ or N, wherein R′′ is H, F, hydroxyl, amino, CH3 or —O—CH3;
        ring A is selected from the group consisting of:
    
    









    
    
        R3 is H, F, methyl, or —O—CH3;
        R3′ is H or F;
        R4 is H, methyl, cyano, amino, halo, —COOH, or —O—CH;
        R5 is H, methyl, cyano, or —CF3;
        R6 is H, cyano, amino, halo, or —CF3; and
        R7 is halo, amino, —CONH2, cyano, —O—CH3, —CF3, or —COO-ethyl.
    
    


Some embodiments are given by compounds of Formula (I), wherein ring A is




In some of these embodiments, wherein ring A is




R4 is H or cyano.

In some of these embodiments, wherein ring A is




R5 is H or —CF3.

In some of these embodiments, wherein ring A is




R6 is H, fluoro, chloro, or cyano.

Some embodiments are given by compounds of Formula (I), wherein ring A is




Some embodiments are given by compounds of Formula (I), wherein V is CH and R1 is H, halo, methyl, or CF3.
Some embodiments are given by compounds of Formula (I), wherein R3′ is H.
In some of these embodiments, wherein V is CH and R1 is H, halo, methyl, or CF3, the attachment point of R1 to the phenyl ring is in the ortho position with regard to V.
Some embodiments are given by compounds of Formula (I), wherein W is CF, R3 is H, and R3′ is H.
Some embodiments are given by compounds of Formula (I), wherein L is a bond, —CH2—, —SO2—, —SO2—NH—, —SO2—NR—CH2—, —CH2—SO2—NR—, —S—, —CH2—S—, —O—, or
—O—CH2—.
In another embodiment, the present invention includes a compound of Formula (I) wherein
L is a bond, —O—, —SO2—NH—, —NH—SO2—, —SO2—, —S—, —C(═O)—, fluoro or —C(═O)—NH—;
R1 is H, bromo or CF3;
R2 is H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, tetrahydro-2H-thiopyran-4-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, pyrazin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl, provided R2 is not H if L is a bond, and wherein R2 is optionally substituted with hydroxyl, fluoro, amino, oxo, methyl, or —CH2—NH2;
V is CH or N;
W is CR′′ or N, wherein R′′ is H or F;
ring A is




R3′ is H;
R4 is H or cyano; and
R5 is H or cyano.
In yet another embodiment, the present invention includes a compound of Formula (I) wherein
L is a bond, —O—, —SO2—NH—, —NH—SO2—, —SO2—, —S—, or —C(═O)—;
R1 is H or CF3;
R2 is H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, tetrahydro-2H-thiopyran-4-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, pyrazin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl, provided R2 is not H if L is a bond, and wherein R2 is optionally substituted with hydroxyl, fluoro, amino, oxo, methyl, or —CH2—NH2;
V is CH or N;
W is CR′′ or N, wherein R′′ is H or F;
ring A is




R3 is H, and R3′ is H.
The embodiments of the present invention also include the optical isomers, hydrates, metabolites, enantiomers, diastereomers, cis-trans isomers, racemates, prodrugs or pharmaceutically acceptable salts thereof.
It is an embodiment of the present invention to provide a compound selected from the compounds listed in Table 1.







TABLE 1







5-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]methanesulfonamide,


6-Amino-3-[3-fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazine-2-


carbonitrile,


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-


methylethyl)biphenyl-2-sulfonamide (racemic),


4′-(5-Aminopyrazin-2-yl)-N-(cyclobutylmethyl)-3′-fluorobiphenyl-2-


sulfonamide,


(endo)-4′-(5-Aminopyrazin-2-yl)-N-bicyclo[2.2.1]hept-2-yl-3′-


fluorobiphenyl-2-sulfonamide (racemic),


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-methylcyclobutyl)biphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-(1,1-dimethylpropyl)-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1-


dimethylethyl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-cyclopentyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-phenylethyl)biphenyl-2-


sulfonamide,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-


phenylethyl]biphenyl-2-sulfonamide,


(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-


phenylethyl]biphenyl-2-sulfonamide,


(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-(2,3-dihydro-1H-inden-2-yl)-3′-


fluorobiphenyl-2-sulfonamide,


(S)-4′-(5-Aminopyrazin-2-yl)-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-3′-


fluorobiphenyl-2-sulfonamide,


(R)-4′-(5-Aminopyrazin-2-yl)-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-3′-


fluorobiphenyl-2-sulfonamide,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-phenylethyl]biphenyl-


2-sulfonamide,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide,


(S)-4′-(5-Aminopyrazin-2-yl)-N-[(3S)-1-ethyl-2-oxoazepan-3-yl]-3′-


fluorobiphenyl-2-sulfonamide,


(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-2-oxoazepan-3-


yl]biphenyl-2-sulfonamide,


(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-1-methyl-2-oxoazepan-


3-yl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1,2,2,6,6-pentamethylpiperidin-4-


yl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-pyridin-3-ylbiphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfamide,


N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)propane-2-


sulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanesulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]propane-1-


sulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-2-methylpropane-1-


sulfonamide,


N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)cyclopropanesulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]hexane-1-


sulfonamide,


N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)cyclobutanesulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1,1,1-


trifluoromethanesulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-dimethylbiphenyl-2-


sulfonamide,


5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide,


5-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


5-{2′-[(4,4-Difluoropiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


5-{2′-[(3,3-Difluoropiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


5-{2′-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


5-{2′-[(3,3-Difluoroazetidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-


2-amine,


5-[2′-(Azepan-1-ylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,


5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-


2-amine,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-


(trifluoromethyl)piperidin-4-ol,


5-(3-Fluoro-2′-{[4-(methylsulfonyl)piperazin-1-yl]sulfonyl}biphenyl-4-


yl)pyrazin-2-amine,


5-{2′-[(4-Acetylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-


amine,


5-(2′-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]sulfonyl}-3-


fluorobiphenyl-4-yl)pyrazin-2-amine,


2-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperazin-1-yl)ethanol,


5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


racemic 5-[3-Fluoro-2′-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-


ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


5-{2′-[(3,5-Dimethylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidine-3-carbonitrile,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-


4-carbonitrile,


5-{2′-[(4-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-


amine,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-


2-one,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-


ol,


(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-


4-yl)methanol,


2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-4-yl)ethanol,


racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-ol,


racemic 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-yl)ethanol,


5-(3-Fluoro-2′-{[4-(methylamino)piperidin-1-yl]sulfonyl}biphenyl-4-


yl)pyrazin-2-amine,


5-(2′-{[4-(Dimethylamino)piperidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-


yl)pyrazin-2-amine,


racemic 5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


N-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-4-yl)acetamide,


racemic (1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-yl)methanol,


racemic tert-Butyl (1-{[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-yl)carbamate,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-


(hydroxymethyl)-2-phenylethyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-3-


methylbutyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxypropyl)biphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


phenylethyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


phenylethyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2R)-2-hydroxy-1-methyl-2-


phenylethyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-


methylbutyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2R)-2-


hydroxycyclohexyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-


(hydroxymethyl)propyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2S)-2-


hydroxycyclohexyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2-


sulfonamide,


(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)pyrrolidin-2-yl)methanol,


(R)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4-


yl)pyrazin-2-amine,


(S)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4-


yl)pyrazin-2-amine,


(R) 5-(2′-{[2-(Aminomethyl)pyrrolidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-


yl)pyrazin-2-amine,


(S)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)pyrrolidin-2-yl)methanol,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(methylsulfonyl)biphenyl-2-


sulfonamide,


(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′-


biphenyl]-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′-


biphenyl]-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1-


hydroxycyclohexyl)methyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-1,1-


dimethylethyl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-


methylpropyl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-1,1-


dimethylpropyl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-


dimethylpropyl)biphenyl-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′-


biphenyl]-2-sulfonamide,


(R)-4′-(5-aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′-


biphenyl]-2-sulfonamide,


(trans)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrrolidine-3,4-diol,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopyrrolidin-3-yl)-[1,1′-


biphenyl]-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)-[1,1′-


biphenyl]-2-sulfonamide,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-(hydroxymethyl)-2-


methylpropyl]biphenyl-2-sulfonamide,


trans 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-


hydroxycyclohexyl)biphenyl-2-sulfonamide,


(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)pyrrolidin-3-yl)methanol,


(S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrrolidin-3-yl)methanol,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)biphenyl-


2-sulfonamide,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3-


ylbiphenyl-2-sulfonamide,


(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3-


ylbiphenyl-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-phenylpropan-2-


yl)-[1,1′-biphenyl]-2-sulfonamide,


(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-phenylethyl)-


[1,1′-biphenyl]-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-


phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-3-


ol,


racemic (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-


hydroxycyclohexyl)biphenyl-2-sulfonamide,


racemic (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-


(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide,


racemic (cis)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-


(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-piperidin-4-ylbiphenyl-2-


sulfonamide,


5-(2′-{[3-(Aminomethyl)azetidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-


yl)pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-N-(azetidin-3-ylmethyl)-3′-fluorobiphenyl-2-


sulfonamide,


(R)-5-(3-Fluoro-2′-{[3-(methylamino)pyrrolidin-1-yl]sulfonyl}biphenyl-4-


yl)pyrazin-2-amine,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-


methylethyl)biphenyl-2-sulfonamide,


5-[3-Fluoro-2′-(1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-


ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


4-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-4-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one,


5-(2′-((1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)-3-fluoro-


[1,1′-biphenyl]-4-yl)pyrazin-2-amine,


5-(2′-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)-3-fluoro-


[1,1′-biphenyl]-4-yl)pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-hydroxypentyl)biphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(6-hydroxyhexyl)biphenyl-2-


sulfonamide,


N-(4-Aminocyclohexyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


sulfonamide,


(S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2,3-


dihydro-1H-indol-2-yl)methanol,


4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluoro-N-(2-


hydroxyethyl)biphenyl-2-sulfonamide,


(S)-5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-bis(2-hydroxyethyl)biphenyl-2-


sulfonamide,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidine-2-


carboxamide,


4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluoro-N-(tetrahydro-2H-


pyran-4-yl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1-


methylethyl)biphenyl-2-sulfonamide,


racemic (4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}morpholin-2-yl)methanol,


(1R,5S)-3-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)-3-azabicyclo[3.1.0]hexan-6-amine,


(S)-5-(3-fluoro-2′-((2-methylpiperazin-1-yl)sulfonyl)-[1,1′-biphenyl]-4-


yl)pyrazin-2-amine,


(R)-5-(3-fluoro-2′-((2-methylpiperazin-1-yl)sulfonyl)-[1,1′-biphenyl]-4-


yl)pyrazin-2-amine,


(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)piperazin-2-yl)methanol,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1-


methylethyl]biphenyl-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-methylbutan-2-


yl)-[1,1′-biphenyl]-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan-


2-yl)-[1,1′-biphenyl]-2-sulfonamide,


(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan-


2-yl)-[1,1′-biphenyl]-2-sulfonamide,


tert-Butyl [2-({[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}amino)ethyl]carbamate,


N-(2-Aminoethyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxybutan-2-yl)-[1,1′-


biphenyl]-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(pyrrolidin-3-yl)-[1,1′-


biphenyl]-2-sulfonamide,


N-[2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}amino)ethyl]acetamide,


(S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


ylsulfonamido)propanoic acid,


4′-(5-Aminopyrazin-2-yl)-N-[2-(carbamoylamino)ethyl]-3′-


fluorobiphenyl-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxy-2,3-dihydro-


1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2R)-2-hydroxy-2,3-dihydro-


1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2R)-2-hydroxy-2,3-dihydro-


1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2S)-2-hydroxy-2,3-dihydro-


1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxycyclohexyl)-


[1,1′-biphenyl]-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[6-(trifluoromethyl)pyridin-3-


yl]biphenyl-2-sulfonamide,


5-(3-Fluoro-2′-{[4-(1H-imidazol-4-yl)piperidin-1-yl]sulfonyl}biphenyl-4-


yl)pyrazin-2-amine,


N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4′-(5-aminopyrazin-2-yl)-


3′-fluorobiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-(2,6-dimethoxypyrimidin-4-yl)-3′-


fluorobiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-methylpyrazin-2-yl)biphenyl-2-


sulfonamide,


(S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


ylsulfonamido)-4-methylpentanamide,


4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-


sulfonamide,


(R)-4′-(5-aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′-


biphenyl]-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′-


biphenyl]-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′-


fluorobiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-methyloxetan-3-yl)biphenyl-2-


sulfonamide,


3-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperazin-1-yl)propanenitrile,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-methoxypropan-2-yl)-[1,1′-


biphenyl]-2-sulfonamide,


5-{3-Fluoro-2′-[(4-pyrazin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-


yl}pyrazin-2-amine,


5-{3-Fluoro-2′-[(4-pyrimidin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-


yl}pyrazin-2-amine,


5-(2′-Amino-3-fluorobiphenyl-4-yl)pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-


(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3-


phenylpyrrolidin-3-ol,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1-


sulfonamide,


N′-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,N-


dimethylsulfamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]morpholine-4-


sulfonamide,


(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrrolidin-3-ol,


(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrrolidin-3-ol,


(3′S,4′S)-1′-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-


1,3′-bipyrrolidin-4′-ol,


(3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-


morpholin-4-ylpyrrolidin-3-ol,


(3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-


(4-methylpiperazin-1-yl)pyrrolidin-3-ol,


5-{3-Fluoro-2′-[(trifluoromethyl)-sulfanyl]biphenyl-4-yl}pyrazin-2-


amine,


5-[2′-(tert-Butylsulfanyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,


5-[2′-(Ethylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(propylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


5-{3,-Fluoro-2′-[(2-methylpropyl)sulfonyl]biphenyl-4-yl}pyrazin-2-


amine,


5-[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,


5-[2′-(Cyclopentylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,


5-[2′-(Cyclobutylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,


5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,


5-{3-Fluoro-2′-[(1-methylethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,


5-{3-Fluoro-2′-[(trifluoromethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}acetamide,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}-N,N-


diethylacetamide,


5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfanyl]biphenyl-4-


yl}pyrazin-2-amine,


(racemic) 5-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfanyl}methyl)-1,3-oxazolidin-2-one,


N-(2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfanyl}ethyl)benzamide,


5-(3-Fluoro-2′-{[4-(methylsulfonyl)benzyl]sulfanyl}biphenyl-4-


yl)pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


sulfonamide,


5-[3-Fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-4-


(trifluoromethyl)biphenyl-2-sulfonamide,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]sulfonyl}piperazin-2-one,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-


(trifluoromethyl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-


2-sulfonamide,


5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′-


(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine,


5-[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine


hydrochloride,


5-[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine


formate salt,


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4-


amine hydrochloride,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4-


amine hydrochloride,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-


amine hydrochloride,


5-[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine


hydrochloride,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-


amine hydrochloride,


1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-


methylmethanesulfonamide formic acid salt,


1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(2-


hydroxyethyl)methanesulfonamide formic acid salt,


1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]methyl}sulfonyl)azetidin-3-ol formic acid salt,


4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]methyl}sulfonyl)piperazin-2-one formic acid salt,


(S)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1-


hydroxypropan-2-yl)methanesulfonamide,


(R)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1-


hydroxypropan-2-yl)methanesulfonamide hydrochloride,


1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(trans-4-


hydroxycyclohexyl)methanesulfonamide,


(S)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2-


hydroxypropyl]methanesulfonamide hydrochloride,


(R)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2-


hydroxypropyl]methanesulfonamide,


5-(2′-{[(4-Aminopiperidin-1-yl)sulfonyl]methyl}-3-fluorobiphenyl-4-


yl)pyrazin-2-amine hydrochloride,


1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide


hydrochloride,


1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-


ethylmethanesulfonamide formate salt,


1-[1-({[4′-(5-Aminopyrazin-2-yl)-3-fluorobiphenyl-2-


yl]methyl}sulfonyl)piperidin-4-yl]urea hydrochloride,


N-[1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]methyl}sulfonyl)piperidin-4-yl]acetamide formate salt,


5-{2′-[(Ethylsulfanyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine


formate salt,


5-{3-Fluoro-2′-[(methylsulfanyl)methyl]biphenyl-4-yl}pyrazin-2-amine


hydrochloride,


5-(3-Fluoro-2′-{[(1-methylethyl)sulfanyl]methyl}biphenyl-4-yl)pyrazin-


2-amine hydrochloride,


2-(((4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)methyl)thio)pyrimidin-4-amine hydrochloride,


6-(((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)methyl)thio)pyrimidin-4-amine hydrochloride,


5-(3-fluoro-2′-((pyridazin-3-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin-


2-amine hydrochloride,


6-(((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)methyl)thio)pyridazin-3-amine hydrochloride,


5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-


fluorobiphenyl-4-yl}pyrazin-2-amine,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2-


amine hydrochloride,


5-(3-fluoro-2′-((pyrimidin-4-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin-


2-amine hydrochloride,


5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4-


yl]pyrazin-2-amine,


5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfonyl)biphenyl-4-


yl]pyrazin-2-amine hydrochloride,


5-(3-Fluoro-2′-{[3-(methylsulfonyl)propyl]sulfonyl}biphenyl-4-


yl)pyrazin-2-amine hydrochloride,


5-(3-Fluoro-2′-{[(2R)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4-


yl)pyrimidin-2-amine,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-


(hydroxymethyl)propyl]biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′-


fluorobiphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-


sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(3-hydroxy-2,2-


dimethylpropyl)biphenyl-2-sulfonamide,


racemic (4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}morpholin-2-yl)methanol,


5-(3-Fluoro-2′-{[(2S)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4-


yl)pyrimidin-2-amine,


5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine,


4′-(2-Aminopyrimidin-5-yl)-3-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1-


methylethyl]biphenyl-2-sulfonamide,


4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3S)-piperidin-3-


yl]biphenyl-2-sulfonamide,


4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3R)-piperidin-3-


yl]biphenyl-2-sulfonamide,


[(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperazin-2-yl]methanol,


racemic cis 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(cis)-2-


hydroxycyclohexyl]biphenyl-2-sulfonamide,


racemic trans 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(trans)-2-


hydroxycyclohexyl]biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1-


methylethyl)biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(trans-4-


hydroxycyclohexyl)biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopyrrolidin-3-


yl]biphenyl-2-sulfonamide,


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-


2-sulfonamide,


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-


3-ol trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3R)-2-oxopiperidin-3-


yl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopiperidin-3-


yl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)-2,2-


dimethylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2,2-


dimethylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2-


methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-2-


methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)-2-


methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-N-[(2S)-2,3-dihydroxypropyl]-3′-


fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-


sulfonamide trifluoroacetic acid salt,


[(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt,


[(2S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-


2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-1,1-


dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,


5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine trifluoroacetic acid salt,


2-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperazin-1-yl)ethanol trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2-


sulfonamide trifluoroacetic acid,


4′-(2-Aminopyrimidin-5-yl)-N-cyclopropyl-3′-fluorobiphenyl-2-


sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide


trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-N-tert-butyl-3′-fluoro-3-methylbiphenyl-2-


sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide


trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-


phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-


phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


5-[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine


trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2-


sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide


trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1-


dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


5-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N,N-dimethylbiphenyl-2-


sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide


trifluoroacetic acid salt,


5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-sulfonamide


trifluoroacetic acid salt,


5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


trifluoroacetic acid salt,


5-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


trifluoroacetic acid salt,


4′-(2-aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-


sulfonamide trifluoroacetic acid salt,


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-


2-one trifluoroacetic acid salt,


tert-Butyl N-{[4′-(2-aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}-L-alaninate,


N-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L-


alanine,


N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1-


sulfonamide,


N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]morpholine-4-


sulfonamide,


N′-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N,N-


dimethylsulfamide,


5-(2′-(2-oxa-6-azaspiro[3.3]heptan-6-ylsulfonyl)-3-fluoro-[1,1′-


biphenyl]-4-yl)pyrimidin-2-amine,


6-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-2-


thia-6-azaspiro[3.3]heptane 2,2-dioxide,


1-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)azetidine-3-carbonitrile,


1-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-


(trifluoromethyl)azetidin-3-ol,


5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-


fluorobiphenyl-4-yl}pyrimidin-2-amine hydrochloride,


2-(((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)methyl)quinazolin-4(3H)-one,


1-(3-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one,


5-(2′-{[3-(Cyclohexylsulfonyl)propyl]sulfonyl}-3-fluorobiphenyl-4-


yl)pyrimidin-2-amine,


5-{3-Fluoro-2′-[(1-methyl-1H-benzimidazol-2-yl)sulfonyl]biphenyl-4-


yl}pyrimidin-2-amine,


5-(2′-{[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]sulfonyl}-3-


fluorobiphenyl-4-yl)pyrimidin-2-amine,


4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


sulfonamide,


5-[3-fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrimidin-2-amine,


4-{[4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]sulfonyl}piperazin-2-one,


4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-4-


(trifluoromethyl)biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-


(trifluoromethyl)biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluoro-4-


(trifluoromethyl)biphenyl-2-sulfonamide,


5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′-


(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine,


5-{2′-[(5-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine formate salt,


5-{2′-[(4-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine formate salt,


5-{2′-[(5-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine formate salt,


5-[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine


hydrochloride,


5-[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine


hydrochloride,


5-{2′-[(6-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine formate salt,


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrimidin-2-amine formate salt,


5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine formate salt,


5-{2′-[(5-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine hydrochloride,


5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfonyl)biphenyl-4-


yl]pyrimidin-2-amine formate salt,


5-{2′-[(5-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine hydrochloride,


5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4-


yl]pyrimidin-2-amine,


5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine,


4′-(6-aminopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-


sulfonamide,


4′-(6-aminopyridin-3-yl)-N,N-diethyl-3′-fluoro-[1,1′-biphenyl]-2-


sulfonamide,


5-(3-fluoro-2′-(pyrrolidin-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-


amine,


5-(3-fluoro-2′-(piperidin-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-


amine,


4′-(6-aminopyridin-3-yl)-N-cyclohexyl-3′-fluoro-[1,1′-biphenyl]-2-


sulfonamide,


(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′-


biphenyl]-2-sulfonamide,


4′-(6-aminopyridin-3-yl)-3′-fluoro-N-isobutyl-[1,1′-biphenyl]-2-


sulfonamide,


4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(tert-pentyl)-[1,1′-biphenyl]-2-


sulfonamide,


4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1,1,1-trifluoro-2-methylpropan-2-


yl)-[1,1′-biphenyl]-2-sulfonamide,


(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-phenylethyl)-


[1,1′-biphenyl]-2-sulfonamide,


(R)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′-


biphenyl]-2-sulfonamide,


4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-methylcyclobutyl)-[1,1′-


biphenyl]-2-sulfonamide,


4-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)thiomorpholine 1,1-dioxide,


(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1,1,1-trifluoropropan-2-yl)-


[1,1′-biphenyl]-2-sulfonamide,


5-(2′-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)-3-fluoro-


[1,1′-biphenyl]-4-yl)pyridin-2-amine,


tert-butyl 3-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


ylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate,


4′-(6-aminopyridin-3-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)-


[1,1′-biphenyl]-2-sulfonamide,


2-(1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)piperidin-4-yl)ethanol,


1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)piperidin-4-ol,


(1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)piperidin-4-yl)methanol,


3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3-


b]pyridin-5-yl)biphenyl-2-sulfonamide,


3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3-


b]pyridin-5-yl)biphenyl-2-sulfonamide,


3′-Fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]-4′-(1H-pyrrolo[2,3-b]pyridin-5-


yl)biphenyl-2-sulfonamide,


5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]-1H-pyrrolo[2,3-


b]pyridine,


3′-Fluoro-N-(2-hydroxyethyl)-4′-(1H-pyrrolo[2,3-b]pyridin-5-


yl)biphenyl-2-sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-


sulfonamide,


3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,


N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-


yl]methanesulfonamide,


3′-Fluoro-N,N-dimethyl-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-


sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-


sulfonamide,


2-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine,


N,N-Diethyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-


sulfonamide,


2-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine,


2-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine,


3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-N-(2,2,2-trifluoro-1-


methylethyl)biphenyl-2-sulfonamide,


2-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine,


3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-


b]pyrazin-2-yl)biphenyl-2-sulfonamide,


3′-Fluoro-N-methyl-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-


sulfonamide,


3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-


b]pyrazin-2-yl)biphenyl-2-sulfonamide,


1-{[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-


yl]sulfonyl}piperidin-4-amine,


2-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-


5H-pyrrolo[2,3-b]pyrazine,


2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine,


2-[2′-(Ethylsulfanyl)-3-fluorobiphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,


7-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H-


pyrido[3,2-b][1,4]oxazine,


7-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H-


pyrido[3,2-b][1,4]oxazine,


4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2-


sulfonamide,


4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)-2-


hydroxy-1-methylethyl]biphenyl-2-sulfonamide,


1-{[4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-


2-yl]sulfonyl}piperidin-4-amine,


4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1R)-2-


hydroxy-1-methylethyl]biphenyl-2-sulfonamide,


4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-N,N-diethyl-3′-


fluorobiphenyl-2-sulfonamide,


7-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-


3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine,


N-tert-Butyl-4′-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-


fluorobiphenyl-2-sulfonamide,


2-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]-5-(trifluoromethyl)pyridin-3-


yl}phenyl)-5H-pyrrolo[2,3-b]pyrazine,


5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-


amine,


5-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]pyridin-3-yl}phenyl)pyrazin-2-


amine,


2-{2-Fluoro-4-[2-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl}-5H-


pyrrolo[2,3-b]pyrazine,


2-{2-Fluoro-4-[2-(2-methylpropoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-


b]pyrazine,


2-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-


b]pyrazine,


2-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}-5H-


pyrrolo[2,3-b]pyrazine,


5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrazin-2-amine,


5-{4-[2-(Cyclopentyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,


5-{4-[2-(Cyclohexyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,


5-[2-Fluoro-4-(2-methoxypyridin-3-yl)phenyl]pyrazin-2-amine,


5-{4-[2-(Cyclobutyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,


tert-Butyl 3-[({3-[4-(5-aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)methyl]pyrrolidine-1-carboxylate,


5-{2-Fluoro-4-[2-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]phenyl}pyrazin-2-


amine,


5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrimidin-2-


amine,


5-[4-(2-Aminopyridin-3-yl)-2-fluorophenyl]pyrimidin-2-amine,


4′-(5-amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide,


3-Amino-6-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-


carbonitrile,


4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide,


4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-(2-


hydroxyethyl)biphenyl-2-sulfonamide,


3-Amino-6-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]biphenyl-4-


yl}pyrazine-2-carbonitrile,


4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-


hydroxypropyl]biphenyl-2-sulfonamide,


3-Amino-6-[3-fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazine-


2-carbonitrile,


4′-(6-Aminopyridazin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(7H-pyrrolo[2,3-d]pyrimidin-2-yl)biphenyl-2-


sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(1,8-naphthyridin-3-yl)biphenyl-2-sulfonamide,


N-tert-Butyl-3′-fluoro-4′-quinoxalin-6-ylbiphenyl-2-sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(1H-indol-5-yl)biphenyl-2-sulfonamide,


4′-(1H-Benzimidazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(1H-Benzimidazol-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide,


4′-(1,3-Benzothiazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(1H-pyrrolo[3,2-b]pyridin-6-yl)biphenyl-2-


sulfonamide,


3′-Fluoro-N-methyl-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-


sulfonamide,


4′-(5-Aminopyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,


N-tert-Butyl-4′-(5,6-diaminopyrazin-2-yl)-3′-fluorobiphenyl-2-


sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-


5-yl)biphenyl-2-sulfonamide,


4′-(6-Amino-5-fluoropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


N-tert-Butyl-4′-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-3′-


fluorobiphenyl-2-sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(3H-imidazo[4,5-b]pyridin-6-yl)biphenyl-2-


sulfonamide,


4′-(5-Amino-6-methoxypyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Amino-6-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Amino-3-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(6-Amino-4-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(6-amino-2-cyanopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-


2-sulfonamide,


4′-(5-amino-1,3,4-thiadiazol-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-


biphenyl]-2-sulfonamide,


(R)-4′-(5-amino-1,3,4-thiadiazol-2-yl)-3′-fluoro-N-(1-hydroxypropan-2-


yl)-[1,1′-biphenyl]-2-sulfonamide,


4-((4′-(5-amino-1,3,4-thiadiazol-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)thiomorpholine 1,1-dioxide,


4′-(5-Amino-6-chloropyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Amino-6-bromopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


6-amino-3-(2′-(cyclopropylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-


yl)picolinonitrile,


N-tert-Butyl-3′-fluoro-4′-[1,2,4]triazolo[4,3-a]pyridin-7-ylbiphenyl-2-


sulfonamide,


4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide,


N-tert-Butyl-3′-fluoro-4′-(1H-imidazo[4,5-b]pyrazin-5-yl)biphenyl-2-


sulfonamide,


N-tert-Butyl-4′-(5,6-diaminopyridin-3-yl)-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-


sulfonamide,


4′-(6-Amino-5-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide trifluoroacetic acid salt,


4′-(6-Amino-5-chloropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide trifluoroacetic acid salt,


4′-[6-Amino-5-(trifluoromethyl)pyridin-3-yl]-N-tert-butyl-3′-


fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-[2-Amino-4-(trifluoromethyl)pyrimidin-5-yl]-N-tert-butyl-3′-


fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Amino-4-methylpyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide trifluoroacetic acid salt,


N-tert-Butyl-3′-fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-


yl]biphenyl-2-sulfonamide,


4′-(7-Amino-1H-indol-5-yl)-3′-fluoro-N-[1-


(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide,


3′-Fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-


methylbiphenyl-2-sulfonamide,


4′-(7-Amino-1H-indol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]acetamide,


1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]urea,


5-[2,3-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-


sulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methylbiphenyl-2-


yl]methanesulfonamide,


4′-(5-Aminopyrazin-2-yl)-2′,3′-difluorobiphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-2′,3′-difluoro-N-methylbiphenyl-2-


sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-


sulfonamide trifluoroacetic acid salt,


5-[2′,3-Difluoro-4′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine,


5-(2′,3-Difluorobiphenyl-4-yl)pyrazin-2-amine,


5-(2′-Chloro-3-fluorobiphenyl-4-yl)pyrazin-2-amine,


5-(3-Fluoro-2′-methylbiphenyl-4-yl)pyrazin-2-amine,


5-[2′,3-Difluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,


5-(3-Fluoro-2′-methoxybiphenyl-4-yl)pyrazin-2-amine,


5-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-ol,


5-[3-Fluoro-2′-(phenylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


5-(2′,3,6′-Trifluorobiphenyl-4-yl)pyrazin-2-amine,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]benzenesulfonamide,


5-(2′-Ethyl-3-fluorobiphenyl-4-yl)pyrazin-2-amine,


{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid,


5-[3-Fluoro-2′-(1-methylethyl)biphenyl-4-yl]pyrazin-2-amine,


1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanone,


5-[3-Fluoro-2′-(2,2,2-trifluoroethoxy)biphenyl-4-yl]pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxylic acid,


4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxamide,


5-[3-Fluoro-2′-(1-methylethoxy)biphenyl-4-yl]pyrazin-2-amine,


5-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-


amine,


2-[3,4′-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-


methylmethanesulfonmide,


N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-


yl]ethanesulfonamide,


N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N-


methylmethanesulfonamide,


N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N-


methylethanesulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-


methylethanesulfonamide,


N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-2-


methylpropane-1-sulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-


ethylmethanesulfonamide,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,2-


dimethylpropane-1-sulfonamide,


5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-1H-pyrrolo[2,3-


b]pyridine,


5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrimidin-2-


amine,


2-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine,


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-carboxamide,


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2-


carboxamide,


4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-carboxamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-carboxamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-carboxamide,


5-[3-Fluoro-2′-(piperazin-1-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine,


5-{2′-[(4-Acetylpiperazin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-


2-amine,


4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2-


carboxamide,


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-carboxamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-carboxamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-carboxamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-carboxamide,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-


4-ol,


5-{2′-[(4-Aminopiperidin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-


amine,


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-carboxamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-carboxamide,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperazin-


2-one,


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperazin-2-one,


5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrimidin-2-amine,


4-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-


yl]oxy}pyrimidin-2-amine,


2-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-


yl]oxy}pyrimidin-4-amine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-pyrrolo[2,3-


b]pyridine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrimidin-2-amine,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4-


amine,


5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine,


6-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]oxy}methyl)pyridine-2-carbonitrile,


2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]oxy}methyl)pyridine-3-carbonitrile,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-


carbonitrile,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-


amine,


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-


amine,


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4-


amine,


5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-


carbonitrile,


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-


carbonitrile,


5-{2′-[(6-Azetidin-1-ylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-


2-amine,


5-{2′-[(6-Azetidin-1-ylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine,


5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrazin-2-


amine,


5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrimidin-2-


amine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-benzimidazole,


6-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-3H-imidazo[4,5-


b]pyridine,


5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2-


amine,


5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2-


amine,


5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}biphenyl-4-


yl)pyrazin-2-amine,


5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}biphenyl-4-


yl)pyrimidin-2-amine,


5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2-


amine,


5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-


2-amine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrimidin-2-amine,


5-[3-Fluoro-2′-methoxy-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-


amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]oxy}pyrimidin-2-amine,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]oxy}pyrimidin-4-amine,


5-[3-Fluoro-4′-(trifluoromethyl)-2′-{[2-


(trimethylsilyl)ethoxy]methoxy}biphenyl-4-yl]pyrimidin-2-amine,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol,


5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl-


4-yl}pyrimidin-2-amine,


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]oxy}pyrimidin-2-amine,


5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl-


4-yl}pyrimidin-2-amine,


5-[3-Fluoro-2′,4′-bis(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


carbonitrile,


5-{5-[2-(Pyrimidin-2-yloxy)-4-(trifluoromethyl)phenyl]pyridin-2-


yl}pyrimidin-2-amine,


4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-5-


(trifluoromethyl)phenoxy}pyrimidin-2-amine,


5-{5-[2-(Pyrimidin-2-yloxy)phenyl]pyridin-2-yl}pyrimidin-2-amine,


4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenoxy}pyrimidin-2-


amine,


5-(5-{2-[(4-Aminopyrimidin-2-yl)oxy]phenyl}pyridin-2-yl)pyrimidin-2-


amine,


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methylbiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methoxybiphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N,N-dimethylbiphenyl-2-sulfonamide,


5-[2′-(Morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′-fluorobiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-2′-fluoro-N,N-dimethylbiphenyl-2-


sulfonamide,


4′-(2-Amino-1,3-oxazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(2-Amino-1,3-thiazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(2-Amino-1,3-thiazol-4-yl)-N,N-diethyl-3′-fluorobiphenyl-2-


sulfonamide,


4-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]-1,3-thiazol-2-


amine,


N-tert-Butyl-3′-fluoro-4′-(8-fluoroimidazo[1,2-a]pyridin-2-yl)biphenyl-2-


sulfonamide,


4′-(5-Aminoimidazo[1,2-a]pyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-


6-carboxamide,


2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-


6-carboxamide,


N-tert-Butyl-4′-(5-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2-


sulfonamide,


N-tert-Butyl-4′-(6-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2-


sulfonamide,


N-tert-Butyl-3′-fluoro-4′-[6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-


yl]biphenyl-2-sulfonamide,


Ethyl 2-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-


a]pyridine-5-carboxylate, and


N-tert-Butyl-3′-fluoro-4′-(5-methoxyimidazo[1,2-a]pyridin-2-yl)biphenyl-


2-sulfonamide.


5-[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine.


5-[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine.


4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide.


4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide.


N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide.


4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide.


N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-indol-5-yl)biphenyl-2-


sulfonamide.


N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′-


fluorobiphenyl-2-sulfonamide.


4′-(3-Amino-1H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide.


3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2-


carboxylic acid.


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}acetamide.


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N-


diethylacetamide.


5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4-


yl}pyrimidin-2-amine.


5,5′-(3,3′′-Difluoro-1,1′:2′,1′′-terphenyl-4,4′′-diyl)dipyrazin-2-amine.


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


carboxylic acid.


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


carbaldehyde.


5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrazin-2-amine.


5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′-


(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine.


2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]methyl}amino)ethanol.


5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-


2-amine.


5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine.


5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-


yl)pyrazin-2-amine.


5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-


yl)pyrimidin-2-amine.


5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-


yl)pyrazin-2-amine.


5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-


yl)pyrimidin-2-amine.


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5-


amine.


5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine.


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6-


methylpyrimidin-4-amine.


5-{2′-[(4-Amino-6-methylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine.


6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-


carbonitrile.


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-


carbonitrile.


5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine.


5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine.


5-{2′-[(6-Amino-2-methylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine.


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-2-


methylpyrimidin-4-amine.


5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-


yl)pyrimidin-2-amine.


5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-


yl)pyrazin-2-amine.


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-


carbonitrile.


6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-


carbonitrile.


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol.


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol.


5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine.


5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine.


5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine.


5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine.


5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine.


5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine.


5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine.


5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine.


5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine.


5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine.


5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine.


5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine.


{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile.


{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile.


{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid.


5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine.


5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-


2-amine.


5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-


fluorophenyl)pyrazin-2-amine.


5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-


fluorophenyl)pyrimidin-2-amine.


2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)ethanol.


2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol.


5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-


fluorophenyl)pyrimidin-2-amine.


5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-


fluorophenyl)pyrazin-2-amine formic acid salt.


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-


yl]phenyl}pyrazin-2-amine.


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-


yl]phenyl}pyrimidin-2-amine.


(2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)propan-1-ol.


(2R)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)propan-1-ol.


(2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)propan-1-ol.


(2I)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)propan-1-ol.


N-(4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)methanesulfonamide


5-(3-Fluoro-2′-(morpholinosulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine


4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-


sulfonamide


4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide


trifluoroacetate


5-(2′-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)-3-fluoro-


[1,1′-biphenyl]-4-yl)pyridin-2-amine


4′-(6-Aminopyrazin-2-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)-


[1,1′-biphenyl]-2-sulfonamide


4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)-


[1,1′-biphenyl]-2-sulfonamide


4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-


phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide


4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-


methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide


(racemic)-1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-


biphenyl]-2-yl)sulfonyl)piperidin-3-ol


4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-


phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide


N-(1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)piperidin-4-yl)acetamide


racemic 2-(1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-


biphenyl]-2-yl)suifonyl)piperidin-3-yl)ethanol.


racemic 1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)piperidin-3-yl)methanol.


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2-


hydroxypropyl]benzenesulfonamide.


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5-


(trifluoromethyl)benzenesulfonamide.


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert-


butylbenzenesulfonamide.


5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2-


yl}pyrimidin-2-amine.


5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine.


5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine.


5-(5-{2-[(3,3-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-


yl)pyrimidin-2-amine trifluoroacetic acid salt.


5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl}pyridin-2-


yl)pyrimidin-2-amine trifluoroacetic acid salt.


5-{5-[2-(Azepan-1-ylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine


trifluoroacetic acid salt.


5-(5-{2-[(4,4-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-


yl)pyrimidin-2-amine trifluoroacetic acid salt.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide


trifluoroacetic acid salt.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-


(dicyclopropylmethyl)benzenesulfonamide trifluoroacetic acid salt.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-


methylethyl]benzenesulfonamide trifluoroacetic acid salt.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1-


methylethyl]benzenesulfonamide trifluoroacetic acid salt.


4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin-


2-one.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2-


hydroxypropyl]benzenesulfonamide.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2-


hydroxypropyl]benzenesulfonamide.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(2-hydroxyethyl)-5-


(trifluoromethyl)benzenesulfonamide.


5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine


trifluoroacetic acid salt.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5-


(trifluoromethyl)benzenesulfonamide trifluoroacetic acid salt.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]N-tert-


butylbenzenesulfonamide.


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2-hydroxy-1-


methylethyl]benzenesulfonamide.


3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrazine-2-carbonitrile trifluoroacetic acid salt.


5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)pyrazin-2-amine.


5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1H-pyrrolo[2,3-b]pyridine.


5-(3-fluoro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)pyrazin-


2-amine.


5-(2′,3,4′-Trifluorobiphenyl-4-yl)pyrazin-2-amine


racemic 5-[3-Fluoro-2′-(methylsulfinyl)biphenyl-4-yl]pyrazin-2-amine


4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile


1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)imidazolidin-


2-one


4′-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide


6-Amino-3-{2′-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-3-


fluorobiphenyl-4-yl}pyrazine-2-carbonitrile


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N-


methylazetidine-3-carboxamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-


2-sulfonamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2-


hydroxypropyl]biphenyl-2-sulfonamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-


hydroxypropyl]biphenyl-2-sulfonamide


1-((4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)piperidine-4-carboxamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-


(trifluoromethyl)biphenyl-2-sulfonamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)-


[1,1′-biphenyl]-2-sulfonamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-


dimethylpropyl)biphenyl-2-sulfonamide


6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]-4′-


(trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile


N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}ethyl)benzamide


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3,3-


dimethylbutan-2-one


5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine


5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine


5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrimidin-2-amine


5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-


4-amine


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-


4-amine


5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


6-Amino-3-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-


carbonitrile


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}cyclopentanecarbonitrile


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}cyclopentanecarboxamide


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-


methylpropanenitrile


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-


methylpropanamide


5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-


methylpropanenitrile


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-


methylpropanamide


5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}cyclopentanecarbonitrile


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}cyclopentanecarboxamide


5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl}-3-fluorobiphenyl-4-


yl)pyrimidin-2-amine


5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrazin-2-amine


5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-


amine


5-(3-Fluoro-2′-(pyrimidin-4-ylthio)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine


5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrazine-2-carbonitrile


8-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′-


(trifluoromethyl)biphenyl-4-yl]pyrazine-2-carbonitrile


6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2-


carbonitrile


N-(tert-Butyl)-3′-fluoro-4′-(5-(methylsulfonamido)pyrazin-2-yl)-[1,1′-


biphenyl]-2-sulfonamide


5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine


hydrogen chloride salt


5-{3-Fluoro-2′-[(methylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine


5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyl}biphenyl-4-yl)pyrazin-


2-amine


5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methyl]biphenyl-4-yl}pyrazin-


2-amine


2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]methyl}sulfonyl)pyrimidin-4-amine


racemic 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-


yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}azetidin-3-ol


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4-


yl)biphenyl-2-carboxamide


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′-


(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine


1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture).


1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture).


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-


2-carboxamide


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-


carboxamide


(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperidin-3-ol


(cis/trans) 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-


hydroxycyclohexyl)biphenyl-2-carboxamide


(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperidin-3-ol


(cis/trans) 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4-


hydroxycyclohexyl)biphenyl-2-carboxamide


racemic 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-


yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine


(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperidin-3-ol


(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperidin-3-ol


(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}pyrrolidin-3-ol


(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}pyrrolidin-3-ol


(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}pyrrolidin-3-ol


(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}pyrrolidin-3-ol


5-{2′-[(2,8-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine (diastereoisomeric mixture).


5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrazin-2-amine


5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrazin-2-amine


5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrazin-2-amine


5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrimidin-2-amine


5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrimidin-2-amine


5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrimidin-2-amine


5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine (diastereoisomeric mixture)


5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H-


pyrrolo[2,3-b]pyridine


5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-


yl]phenyl}pyrimidin-2-amine


5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin-


2-amine


2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-tert-butyl-5-


(trifluoromethyl)benzamide


2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1R)-2-hydroxy-1-


methyl-ethyl]-5-(trifluoromethyl)benzamide


2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1S)-2-hydroxy-1-


methyl-ethyl]-5-(trifluoromethyl)benzamide


2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1R)-


2,2,2-trifluoro-1-methyl-ethyl]benzamide


2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-


[(1S)-2,2,2-trifluoro-1-methyl-ethyl]benzamide


2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-


[(1R)-2,2,2-trifluoro-1-methyl-ethyl]benzamide


2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1S)-


2,2,2-trifluoro-1-methyl-ethyl]benzamide


[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-(3-


hydroxyazetidin-1-yl)methanone


[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[4-


(methylamino)-1-piperidyl]methanone


[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-


(trifluoromethyl)phenyl]-(1,1-dioxo-1,4-thiazinan-4-yl)methanone


2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tert-butyl-5-


(trifluoromethyl)benzamide


[2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-


(trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone


[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-


(trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone


2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tetrahydropyran-4-yl-


benzamide


racemic [2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]phenyl]-[2-


(hydroxymethyl)morpholin-4-yl]methanone


racemic [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[2-


(hydroxymethyl)morpholin-4-yl]methanone


N-{3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-


dimethylpropanamide


N-{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-


dimethylpropanamide


N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2-


yl}-2,2-dimethylpropanamide


racemic 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-


yl)phenyl)pyrazin-2-amine hydrochloride


5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrimidin-


2-amine formic acid salt.


5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-


2-amine hydrochloride.


5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-


2-amine hydrochloride


5-(4-(2-(Cyclohexlsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-


2-amine hydrochloride


5-(4-(2-(Cyclohexylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine


hydrochloride


5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidine-


2-amine hydrochloride


5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-


2-amine hydrochloride


5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine


formic acid salt.


5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-


2-amine formic acid salt.


racemic 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-


fluorophenyl)pyrimidin-2-amine formate


racemic 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-


amine formate


1-((3-(4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2-


yl)sulfonyl)piperidin-1-yl)ethanone


1-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2-


yl)sulfonyl)piperidin-1-yl)ethanone hydrogen chloride salt


5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3-


yl)phenyl)pyrimidin-2-amine hydrogen chloride salt.


5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3-


yl)phenyl)pyrazin-2-amine hydrogen chloride salt.


4-((3-(4-(2-aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2-


yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide


4-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2-


yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide


5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3-


yl)phenyl)pyrimidin-2-amine formic acid salt.


5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3-


yl)phenyl)pyrazin-2-amine


5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3-


yl)pyrimidin-2-amine formic acid salt.


5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3-


yl)pyrazin-2-amine formic acid salt.


5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-


yl}phenyl)pyrimidin-2-amine


5-(2-Fluoro-4-(2-(isopropylsulfonyl)pyridine-3-yl)phenyl)-1H-pyrrolo[2,3-


b]pyridine


5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-


2-amine formic acid salt.


5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-


2-amine formic acid salt.


5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-


2-amine formic acid salt.


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-


yl]phenyl}pyrazin-2-amine hydrochloride


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-


yl]phenyl}pyrimidin-2-amine formic acid salt.


5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-


2-amine hydrochloride


5-(2,3-Difluorobiphenyl-4-yl)pyrazin-2-amine.


5-(3-Fluoro-2-methoxybiphenyl-4-yl)pyrazin-2-amine.


5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine.


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2-


sulfonamide.


N-[4′-(5-Aminopyrazin-2-y)-3′-fluoro-2′-methoxybiphenyl-2-


yl]methanesulfonamide.


5-(3-Fluoro-2′-(pyrazin-2-yl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine


5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4-yl)pyrimidin-2-amine.


5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrazin-2-amine.


5-[2′-(5-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine.


5-[2′-(6-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine.


5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine.


5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrimidin-2-amine.


5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2-


yl]pyrimidin-2-amine.


5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine.


5-[3-Fluoro-2′-(1-methyl-1H-pyrazol-4-yl)bipheny-4-yl]pyrazin-2-amine.


5-(3-Fluoro-2′-pyrimidin-5-ylbiphenyl-4-yl)pyrazin-2-amine.


5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidine-2-


carbonitrile.


5-[3-Fluoro-2′-(2-morpholin-4-ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin-


2-amine.


1-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-


1-yl}-2-methylpropan-2-ol.


5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′-


(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine.


5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]pyrimidin-2-amine.


5-{2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]phenyl}pyrmidin-2-


amine.


5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine.


5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-


yl]pyrazin-2-amine


5-[2′-(1,1-Dioxido-1,2-thiazinan-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-


amine


5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-


amine


5-[2-Fluoro-4-(2-pyrrolidin-1-ylpyridin-3-y)phenyl]pyrazin-2-amine


1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidin-2-one


5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1H-pyrrolo[2,3-b]pyridine


5-(2′3,4′-Trifluorobiphenyl-4-yl)pyrazin-2-amine


5-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine


5-[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine


5-[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine


4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide


N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide


4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide


4′-(6-Aminopyridazin-3-yl)-3′-fluorobiphenyl-2-sulfonamide


N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′-


fluorobiphenyl-2-sulfonamide


3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2-


carboxylic acid


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-


(trifluoromethyl)biphenyl-2-sulfonamide


5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}acetamide


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N-


diethylacetamide


5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4-


yl}pyrimidin-2-amine


5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine


5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine


4′-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide


5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}ethyl)benzamide


5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine


5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine


5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine


5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


5-(2-Fluoro-4-{2-[(2-morpholin-4-ylethyl)sulfonyl]pyridin-3-


yl}phenyl)pyrimidin-2-amine


5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2-


yl]pyrimidin-2-amine


5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrimidin-2-amine


5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin-


2-amine


5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrimidin-


2-amine


5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrimidin-2-amine


5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-


amine


(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}pyrrolidin-3-ol


(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}pyrrolidin-3-ol


(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}pyrrolidin-3-ol


2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)ethanol


5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine


(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperidin-3-ol


5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-


methylpropanamide


5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine


5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl}-3-fluorobiphenyl-4-


yl)pyrimidin-2-amine


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-


2-carboxamide


(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperidin-3-ol.


{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid.


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-


carboxamid


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-


carboxamide


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4-


yl)biphenyl-2-carboxamide


5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine


5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine


2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine


N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]methanesulfonamide


4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide


4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide


N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-indol-5-yl)biphenyl-2-


sulfonamide


4′-(3-Amino-1H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide


5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrimidin-2-amine


5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrimidin-2-amine


5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methoxybiphenyl-2-


yl]methanesulfonamide


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}azetidin-3-


ol


(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}pyrrolidin-3-ol


4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile


(2R)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)propan-1-ol


5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-


amine


5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


4′-(6-Aminopyridin-3-yl)-3′-fluorobiphenyl-2-sulfonamide


5-{3-Fluoro-2′-[(methylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine


5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-


carboxamide


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3,3-


dimethylbutan-2-one


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-


4-amine


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol


2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol


5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


N-[4′-(6-Aminopyridin-3-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide


4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin-


2-one


5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H-


pyrrolo[2,3-b]pyridine


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2-


hydroxypropyl]benzenesulfonamide


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2-hydroxy-1-


methylethyl]benzenesulfonamide


5-{2-Fluoro-4-[2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-


2-amine


5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl}pyridin-2-


yl)pyrimidin-2-amine


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide


(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperidin-3-ol.


(2S)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)propan-1-ol


2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-


methylpropanenitrile


(2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)propan-1-ol


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2-


hydroxypropyl]benzenesulfonamide


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-


4-amine


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-methoxybiphenyl-2-


sulfonamide


5-(2-Fluoro-4-{2-[(3-methoxypropyl)sulfonyl]pyridin-3-


yl}phenyl)pyrimidin-2-amine


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}cyclopentanecarboxamide


5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-


amine


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1-


methylethyl]benzenesulfonamide


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-


methylpropanamide


{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile


5-{4-[2-(tert-Butylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-


amine


5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine


5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-


fluorophenyl)pyrimidin-2-amine


5-(2-Fluoro-4-{2-[(2-morpholin-4-ylethyl)sulfonyl]pyridin-3-


yl}phenyl)pyrazin-2-amine


5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-


2-amine


5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]pyridin-3-yl}-2-


fluorophenyl)pyrimidin-2-amine


5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)pyrazin-2-amine


5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-


yl)pyrimidin-2-amine


5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-


2-amine


5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}cyclopentanecarbonitrile


(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrrolidine-3-carboxamide


5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2-


yl}pyrimidin-2-amine


5-(5-{2-[(4,4-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-


yl)pyrimidin-2-amine


5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine


5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-


yl)pyrimidin-2-amine


(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}pyrrolidine-3-carboxamide


5-(2-Fluoro-4-{2-[(tetrahydro-2H-pyran-4-ylmethyl)sulfonyl]pyridin-3-


yl}phenyl)pyrimidin-2-amine


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(2-hydroxyethyl)-5-


(trifluoromethyl)benzenesulfonamide


(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}piperidin-3-ol


5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine


2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]methyl}amino)ethanol


5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-


amine


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2-


hydroxypropyl]benzenesulfonamide


5-(5-{2-[(3,3-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-


yl)pyrimidin-2-amine


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-


yl]phenyl}pyrimidin-2-amine


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-


yl]phenyl}pyrimidin-2-amine


5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′-


(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine


5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-


amine


5-{2-Fluoro-4-[2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-


amine


6-Amino-3-{2′-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-3-


fluorobiphenyl-4-yl}pyrazine-2-carbonitrile


N-(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-4-yl)acetamide


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N-


methylazetidine-3-carboxamide


5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyridin-2-amine


5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyl}biphenyl-4-yl)pyrazin-


2-amine


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-


hydroxyethyl)biphenyl-2-sulfonamide


{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile


(2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-


yl}oxy)propan-1-ol


6-Amino-3-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-


carbonitrile


5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-


fluorophenyl)pyrazin-2-amine


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5-


(trifluoromethyl)benzenesulfonamide


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-


methylethyl]benzenesulfonamide


5-{5-[2-(Azepan-1-ylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-tert-


butylbenzenesulfonamide


2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-


(dicyclopropylmethyl)benzenesulfonamide


5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′-


(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine


5-{2′-[(6-Amino-2-methylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine


6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-


carbonitrile


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide


5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]pyridin-3-


yl}-2-fluorophenyl)pyrimidin-2-amine


5-(2-Fluoro-4-{2-[(1-methylpropyl)sulfonyl]pyridin-3-


yl}phenyl)pyrimidin-2-amine


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2-


hydroxypropyl]biphenyl-2-sulfonamide


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-


methylpropanenitrile


5-{4-[2-(Cyclobutylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-


amine


5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-


amine


5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-


amine


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


carboxylic acid


5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-


yl)pyrazin-2-amine


5-(2-Fluoro-4-{2-[(3-methoxypropyl)sulfonyl]pyridin-3-


yl}phenyl)pyrazin-2-amine


6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2-


carbonitrile


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2-


sulfonamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-


hydroxypropyl]biphenyl-2-sulfonamide


1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-ol


5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]pyridin-3-yl}-2-


fluorophenyl)pyrazin-2-amine


5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-


yl]phenyl}pyrazin-2-amine


2-(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-yl)ethanol


5-{2′-[(5-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}cyclopentanecarboxamide


6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-


carbonitrile


5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-


yl)pyrazin-2-amine


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide


(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-yl)methanol


6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrazine-2-carbonitrile


5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine


5-(2-Fluoro-4-{2-[(tetrahydro-2H-pyran-4-ylmethyl)sulfonyl]pyridin-3-


yl}phenyl)pyrazin-2-amine


5-{4-[2-(tert-Butylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine


3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrazine-2-carbonitrile


6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]-4′-


(trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-4-


(trifluoromethyl)biphenyl-2-carboxamide


5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-


yl)pyrazin-2-amine


5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}cyclopentanecarbonitrile


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-


carbonitrile


4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(2-hydroxy-1,1-


dimethylethyl)biphenyl-2-sulfonamide


5-{4-[2-(Cyclohexylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-


amine


5-{3-Fluoro-2′-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-


ylsulfonyl]biphenyl-4-yl}pyrazin-2-amine


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidine-4-carboxamide


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


carbaldehyde


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3-hydroxyazetidin-3-


yl)methyl]biphenyl-2-sulfonamide


5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrazin-2-


amine


5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-


2-amine


2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]methyl}sulfanyl)pyrimidin-4-amine


4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-


methyl-2-phenylethyl]-N-methylbiphenyl-2-sulfonamide


5-{4-[2-(Cyclopentylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-


amine


2-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-


carbonitrile


5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]pyridin-3-


yl}-2-fluorophenyl)pyrazin-2-amine


5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-


amine


4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-methyl-2-


phenylethyl]-N-methylbiphenyl-2-sulfonamide


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′-


(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine


N,N-Diethyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-


sulfonamide


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-


yl]phenyl}pyrazin-2-amine


5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrazin-2-


amine


5-(2-Fluoro-4-{2-[(1-methylpropyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-


2-amine


4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(2-hydroxy-1,1-


dimethylethyl)biphenyl-2-sulfonamide


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5-


(trifluoromethyl)benzenesulfonamide


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-


dimethylpropyl)biphenyl-2-sulfonamide


6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-


4-yl]pyrazine-2-carbonitrile


5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrazin-2-amine


4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-


(trifluoromethyl)biphenyl-2-sulfonamide


5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine


5-{4-[2-(Cyclobutylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-


amine


4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4-


(trifluoromethyl)biphenyl-2-sulfonamide


5-[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine


1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-


(pentafluoroethyl)piperidin-4-ol


5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine


5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)-1H-


pyrrolo[2,3-b]pyridine


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert-


butylbenzenesulfonamide


tert-Butyl (1-{[3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-


yl]sulfonyl}piperidin-4-yl)carbamate


5-{4-[2-(Cyclopentylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-


amine


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3,3′-difluorobiphenyl-2-


sulfonamide


5-{4-[2-(Cyclohexylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-


amine


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2-


sulfonamide


5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrimidin-2-amine


5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrazin-2-amine


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5-


amine


5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine


5-(2-fluoro-4-(2-(piperidin-4-yloxy)pyridin-3-yl)phenyl)pyrazin-2-amine


5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-


amine


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6-


methylpyrimidin-4-amine


5-{2′-[(4-Amino-6-methylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine


5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrazin-2-amine


5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-


fluorophenyl)pyrazin-2-amine


5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrazin-2-amine


5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-


fluorophenyl)pyrimidin-2-amine


5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-


yl)pyrimidin-2-amine


5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine


1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}morpholin-2-yl)ethanol


1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]carbonyl}morpholin-2-yl)ethanol


5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-


yl)pyrazin-2-amine


N-{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-


dimethylpropanamide


N-{3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-


dimethylpropanamide


5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine


5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine


N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2-yl}-


2,2-dimethylpropanamide









Particularly, an embodiment of the present invention comprises a compound selected from the compounds listed in Table 2.







TABLE 2







N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide,


5-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide,


4′-(2-aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro-


[1,1′-biphenyl]-2-sulfonamide trifluoroacetic acid salt,


(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1-


dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluorobiphenyl-2-


sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide


trifluoroacetic acid salt,


5-{2′-[(4-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-


amine,


4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-2′,3′-difluoro-N-methylbiphenyl-


2-sulfonamide trifluoroacetic acid salt,


4′-(5-Amino-6-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-


one,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-


2-amine,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide triflucroacetic acid salt,


4′-(5-Amino-3-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide,


5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,


5-[2,3-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-


4-amine,


5-{4-[2-(Cyclopentyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,


(R)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′-


biphenyl]-2-sulfonamide,


4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-methylcyclobutyl)-[1,1′-biphenyl]-


2-sulfonamide,


4-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)thiomorpholine 1,1-dioxide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


5-{3-Fluoro-2′-[(trifluoromethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,


N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1,1,1-


trifluoromethanesulfonamide,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-4-ol,


(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-


yl)methanol,


2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-4-yl)ethanol,


racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-ol,


racemic 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-3-yl)ethanol,


racemic 5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


N-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}piperidin-4-yl)acetamide,


(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)pyrrolidin-2-yl)methanol,


(S)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro[1,1′-biphenyl]-4-


yl)pyrazin-2-amine,


(S)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)pyrroidin-2-yl)methanol,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxypropyl)biphenyl-2-


sulfonamide,


(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′-


biphenyl]-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′-


biphenyl]-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-1,1-


dimethylethyl)biphenyl-2-sulfonamide,


(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)pyrrolidin-3-yl)methanol,


N-tert-Butyl-3′-fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-


yl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-


(hydroxymethyl)-2-phenylethyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


phenylethyl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2R)-2-hydroxy-1-methyl-2-


phenylethyl]biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-


2-sulfonamide trifluoroacetic acid salt,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-


sulfonamide trifluoroacetic acid salt,


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine,


(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)biphenyl-2-


sulfonamide,


trans 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4


-hydroxycyclohexyl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-


methylpropyl)biphenyl-2-sulfonamide,


1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]sulfonyl}azetidin-3-ol,


(R) 5-(2′-{[2-(Aminomethyl)pyrrolidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-


yl)pyrazin-2-amine,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-2-


methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,


N-(2-Aminoethyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(pyrrolidin-3-yl)-[1,1′-


biphenyl]-2-sulfonamide,


3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-b]pyrazin-


2-yl)biphenyl-2-sulfonamide,


(cis)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N[2-


(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopiperidin-3-


yl]biphenyl-2-sulfonamide trifluoroacetic acid salt,


(S)-5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)-2-


hydroxy-1-methylethyl]biphenyl-2-sulfonamide,


(1R,5S)-3-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)-3-azabicyclo[3.1.0]hexan-6-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-


(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopyrrolidin-3-yl)-[1,1′-


biphenyl]-2-sulfonamide,


(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)-[1,1′-


biphenyl]-2-sulfonamide,


5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-


amine,


2-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-


yl}-5H-pyrrolo[2,3-b]pyrazine,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2R)-2-hydroxy-2,3-dihydro-1H-


inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxycyclohexyl)-[1,1′-


biphenyl]-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2S)-2-hydroxy-2,3-dihydro-1H-


inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,


(S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-ylsulfonamido)-


4-methylpentanamide,


2-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-


b]pyrazine,


4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-


sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopyrrolidin-3-


yl]biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


sulfonamide,


5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-methyloxetan-3-yl)biphenyl-2-


sulfonamide,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-


methylethyl]biphenyl-2-carboxamide,


5-[3-Fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazin-2-amine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrimidin-2-amine,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


yl]sulfonyl}piperazin-2-one,


4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-4-


(trifluoromethyl)biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(trans-4-


hydroxycyclohexyl)biphenyl-2-sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-


(trifluoromethyl)biphenyl-2-sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluoro-4-


(trifluoromethyl)biphenyl-2-Sulfonamide,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-


(trifluoromethyl)biphenyl-2-sulfonamide,


4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


sulfonamide,


5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrazin-2-


amine,


6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-


4-amine,


5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine,


4′-(5-amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-


methylethyl]biphenyl-2-sulfonamide,


4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-


hydroxypropyl]biphenyl-2-sulfonamide,


N′-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,N-


dimethylsulfamide,


5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-


amine,


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-


amine,


5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrimidin-2-amine,


4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2R)-2-


hydroxypropyl]biphenyl-2-sulfonamide,


5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrazin-2-amine,


5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluoro-4′-


(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine,


5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2-


amine,


5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-


yl]pyrazin-2-amine,


5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine,


5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-


fluorobiphenyl-4-yl}pyrazin-2-amine,


5-{3-Fluoro-2′-[(4-pyrimidin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-


yl}pyrazin-2-amine,


5-{2′-[(5-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-


yl}pyrimidin-2-amine formate salt,


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]sulfanyl}pyrimidin-2-amine formate salt,


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2-


amine hydrochloride,


4′-(5-amino-1,3,4-thiadiazol-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-


biphenyl]-2-sulfonamide,


2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-


amine hydrochloride,


4-((4′-(5-amino-1,3,4-thiadiazol-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-


yl)sulfonyl)thiomorpholine 1,1-dioxide,


4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-


sulfonamide,


4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide, and


4′-(5-Amino-6-chloropyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-


sulfonamide.









Further, an embodiment of the present invention comprises a compound selected from the compounds listed in Table 1A.







TABLE 1A







5-[2′-Amino-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-


amine


5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)methoxy]-3-


fluorobiphenyl-4-yl}pyrazin-2-amine


5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]-3-


fluorobiphenyl-4-yl}pyrazin-2-amine


4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-


yl]oxy}methyl)benzoic acid


4-({[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]oxy}methyl)benzoic acid


4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic


acid


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic


acid


2-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-


yl}sulfonyl)piperidin-1-yl]ethanol


4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-


amine


1-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-


yl}sulfonyl)piperidin-1-yl]propan-2-ol


5-[3-Fluoro-2′-(1H-pyrazol-4-yl)biphenyl-4-yl]pyrazin-2-amine


5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine


5-{3-Fluoro-2′-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]biphenyl-4-


yl}pyrazin-2-amine


5-{5-[2-(Cyclopropylsulfonyl)phenyl]-3-fluoropyridin-2-


yl}pyrimidin-2-amine


4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-


yl]oxy}benzamide


5-{2′-[(trans-4-Aminocyclohexyl)oxy]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine


5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-


amine


6-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyridazin-3-


amine


{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-


yl}acetonitrile


5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-


methylpyrimidin-2-amine


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2,2,2-


trifluoro-1-methylethyl]benzenesulfonamide


5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-


amine


5-[3-Fluoro-2′-(2-piperazin-1-ylpyrimidin-5-yl)biphenyl-4-


yl]pyrazin-2-amine


5-{2′-[1-(2-Aminoethyl)-1H-pyrazol-4-yl]-3-fluorobiphenyl-4-


yl}pyrazin-2-amine


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2S)-2-


hydroxypropyl]benzenesulfonamide


5-(3-Fluoro-2′-isothiazol-4-ylbiphenyl-4-yl)pyrazin-2-amine


5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrazin-2-amine


5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrimidin-2-amine


2-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-


1-yl}ethanol


5-(4-{2-[(1-Acetylpiperidin-3-yl)sulfonyl]pyridin-3-yl}-2-


fluorophenyl)pyrazin-2-amine


5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]-6-


(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2-


hydroxy-1-methylethyl]benzenesulfonamide


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2-


hydroxy-1-methylethyl]benzenesulfonamide


5-[2-Fluoro-4-(2-phenylpyridin-3-yl)phenyl]pyrazin-2-amine


5-(2-Fluoro-4-{2-[(1-methylpyrrolidin-3-yl)sulfonyl]pyridin-3-


yl}phenyl)pyrazin-2-amine


5-{2-Fluoro-4-[2-(pyridin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-


2-amine


5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6-


(trifluoromethyl)pyridin-3-yl}phenyl)pyrazin-2-amine


5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]-6-


(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine


5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-


amine


5-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N-


methylpyrimidin-2-amine


5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6-


(trifluoromethyl)pyridin-3-yl}phenyl)pyrimidin-2-amine


{4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-


1-yl}acetonitrile


5-[3-Fluoro-2′-(1H-pyrazol-4-yl)biphenyl-4-yl]pyrimidin-2-amine


4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-


amine


5-{2-Fluoro-4-[2-(pyridin-3-yloxy)pyridin-3-yl]phenyl}pyrazin-2-


amine


5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-


(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine


5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4-


yl]sulfonyl}pyridin-3-yl)phenyl]pyrazin-2-amine


5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-


(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-


(trifluoromethyl)pyridin-3-yl]phenyl}pyrazin-2-amine


5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-


(trifluoromethyl)pyridin-3-yl]phenyl}pyrimidin-2-amine


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-(2-


hydroxyethyl)benzenesulfonamide


2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2,2,2-


trifluoro-1-methylethyl]benzenesulfonamide


5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4-


yl]sulfonyl}pyridin-3-yl)phenyl]pyrimidin-2-amine









Additionally, an embodiment of the present invention comprises a compound selected from the compounds listed in Table 1, Table 2 and Table 1A.
The invention is also directed to a pharmaceutical composition which include, without limitation, one or more of the disclosed compounds, and pharmaceutically acceptable carriers or excipients.
Another embodiment of the present invention is a pharmaceutical composition of the present invention that comprises at least a compound selected from the compounds listed in Table 1. Another embodiment of the present invention is a pharmaceutical composition of the present invention that comprises at least a compound selected from the compounds listed in Table 3.
Particularly, an embodiment of the present invention is a pharmaceutical composition of the present invention that comprises at least a compound selected from the compounds listed in Table 2.
The present invention also features a method of treating a subject suffering from or diagnosed with a disease and/or disorder mediated by FLAP activity, comprising administering to the subject a therapeutically effective amount of at least one compound of Formula (I).
The present invention also features a method for preventing, treating, ameliorating, including without limitation inhibiting, the progression of an FLAP-mediated disease and/or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of at least one compound of Formula (I). Such a disease and/or disorder includes, but is not limited to diabetes, respiratory disorders, and associated symptoms or complications thereof. More specifically, this invention is directed to a method of treating, but not limited to, exacerbations, non-allergic asthma, fibrotic lung diseases, acute respiratory distress syndrome and chronic obstructive pulmonary disease, and their associated symptoms or complications, in a subject afflicted with such a disease and/or disorder.
In another embodiment, the compounds of the present invention are useful for the amelioration of symptoms associated with and/or the treatment of the following cardiac and cardiovascular diseases and/or disorders: myocardial infarction, atherosclerosis and stroke aortic aneurisms, atherosclerosis, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder.
In another embodiment, the compounds of the present invention are useful for the amelioration of symptoms associated with and/or the treatment of autoimmune or allergic diseases and/or disorders, wherein said autoimmune or allergic diseases and/or disorders include, but are not limited to, rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis, allergic rhinitis, allergic dermatitis and asthma, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder. In a further embodiment, the compounds of the present invention are useful for the amelioration of symptoms associated with and/or the prophylaxis or treatment of carcinogenesis, wherein said carcinogenesis include, but is not limited to, tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells.
It is a further embodiment of the invention to provide a process for making a pharmaceutical composition comprising admixing any of the compounds according to Formula (I) and a pharmaceutically acceptable carrier.
In a further embodiment of the invention, a method for treating or ameliorating an FLAP-mediated disease and/or disorder in a subject in need thereof comprises administering to the subject a therapeutically effective amount of at least one compound of Formula (I), wherein the therapeutically effective amount of the compound of Formula (I) is from about 0.1 mg/dose to about 5 g/dose. In particular, the therapeutically effective amount of the compound of Formula (I) is from about 0.5 mg/dose to about 1000 mg/dose.
More particularly, the therapeutically effective amount of the compound of Formula (I) is from about 1 mg/dose to about 100 mg/dose. In a further embodiment of the invention, the number of doses per day of a compound of Formula (I) is from 1 to 3 doses. In a further embodiment of the invention, the therapeutically effective amount of the compound of Formula (I) is from about 0.001 mg/kg/day to about 30 mg/kg/day. More particularly, the therapeutically effective amount of the compound of Formula (I) is from about 0.01 mg/kg/day to about 2 mg/kg/day.
The invention is further described below.
A) Terms
Some terms are defined below and by their usage throughout this disclosure.
It should also be noted that any atom with unsatisfied valences in the text, schemes, examples, structural formulae and any tables herein is assumed to have the hydrogen atom or atoms to satisfy the valences.
As used herein, the following terms are intended to have the following definitions. The definitions herein may specify that a chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term. The scope of the per se definition of the term is intended to include the plurality of variations expected to be included by one of ordinary skill in the art.
The term “C1-6alkyl” means a saturated branched or straight-chain hydrocarbon radical having from 1 up to 6 carbon atoms in a linear or branched arrangement, selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, and hexyl. Examples include isopropyl, isobutyl, tert-butyl, sec-butyl, n-butyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1,2-dimethylpropyl, butan-2-yl, 2-methylbutyl, 2-methylbutan-2-yl, 1-methyl-3-methylbutyl, 3,3-dimethylbutan-2-yl, and the like, and all that are exemplified in the below examples. An alkyl radical may be attached to a core molecule by any atom where allowed by available valences. The term “C1-4alkyl” means a saturated branched or straight-chain hydrocarbon radical having from 1 up to 4 carbon atoms in a linear or branched arrangement,
The term “C3-9cycloalkyl” means a saturated or partially unsaturated, monocyclic, polycyclic or benzofused hydrocarbon ring system radical. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptan-2-yl, 2,3-dihydro-1H-inden-2-yl, and the like, and all that are exemplified in the below examples. A C3-9cycloalkyl radical may be attached to a core molecule by any ring atom where allowed by available valences.
The term “aryl” means an unsaturated, aromatic monocyclic or polycyclic hydrocarbon ring system radical. Examples include phenyl and the like, and all that are exemplified in the below examples. An aryl radical may be attached to a core molecule by any ring atom where allowed by available valences.
The term “hetero”, when used as a prefix for a ring system, refers to the replacement of at least one carbon atom member in the ring system with a heteroatom selected from N, O, S, S(O), or SO2. A hetero ring may have 1, 2, 3 or 4 carbon atom members replaced by a nitrogen atom. Alternatively, a ring may have 1, 2 or 3 nitrogen atom members and 1 oxygen or sulfur atom member. Alternatively, a ring may have 1 oxygen or sulfur atom member. Alternatively, up to two adjacent ring members may be heteroatoms, wherein one heteroatom is nitrogen and the other heteroatom is selected from N, S or O.
The term “heteroaryl” means an unsaturated monocyclic, polycyclic aromatic “hetero” ring system radical, selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, and tetrazolyl. Examples include pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-4-yl, pyrazin-2-yl, pyrazin-4-yl, pyrimidin-2-yl, pyridazin-3-yl, 1H-benzimidazol-2-yl, 2H-tetrazol-5-yl, and the like, and all that are exemplied in the below examples. A heteroaryl radical may be attached to a core molecule by any ring atom where allowed by available valences.
The term “heterocycyl” means a saturated monocyclic or polycyclic “hetero” ring system radical, selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrazoyl, thiomorpholinyl, azepanyl, hexahydropyrrolo[1,2-a]pyrazinyl, tetrahydropyrazolo[4,3-c]pyridinyl, diazabicyclo[2.2.1]-heptanyl, dihydro-indolyl, tetrahydropyranyl, azabicyclo[3.1.0]hexanyl, oxetanyl, isothiazolidinyl, thiazinanyl, thiopyranyl, thia-azaspiro[3.3]heptanyl, oxa-azaspiro[3.3]heptanyl, tetrahydro-thiopyranyl, dihydroquinazolinyl, oxadiazolyl, oxa-azabicylco[2.2.1]heptanyl, piperazin-2-one-yl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, pyrrolidin-2-one-yl, imidazolidin-2-one-yl, 1,2-thiazinane 1,1-dioxide-yl, isothiazolidine 1,1-dioxide-yl, 1,2,3,6-tetrahydropyridinyl, and imidazolidinyl. Examples include azetidin-1-yl, azetidin-3-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, azepan-1-yl, azepan-3-yl, hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl, 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 2,3-dihydro-1H-indol-2-yl, tetrahydro-2H-pyran-4-yl, 3-azabicyclo[3.1.0]hexan-3-yl, oxetan-3-yl, isothiazolidin-2-yl, 1,2-thiazinan-2-yl, 2H-thiopyran-4-yl, 2-thia-6-azaspiro[3.3]heptan-6-yl, 2-oxa-6-azaspiro[3.3]heptan-6-yl, tetrahydro-2H-thiopyran-4-yl, 3,4-dihydroquinazolin-2-yl, 1,2,3-oxadiazol-5-yl, 2-oxa-5-azabicylco[2.2.1]heptan-5-yl, imidazolidin-1-yl, thiomorpholine 1,1-dioxide-yl, 4-amino-tetrahydro-2H-pyran-yl, tetrahydro-2H-thiopyran 1,1-dioxide-yl, and the like, and all that are exemplied in the below examples. A heterocyclyl radical may be attached to a core molecule by any ring atom where allowed by available valences.
The term “carboxy” means a radical of the formula: —C(O)OH.
The term “halogen” or “halo” means a radical selected from the group consisting of chloro, bromo, fluoro or iodo.
The term “oxo” means a radical of the formula: ═O.
The term “substituted” refers to a radical in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s). In a preferred embodiment, up to three hydrogen atoms are each independently replaced.
With reference to substituents, the term “independently” means that when more than one of such substituent is possible, such substituents may be the same or different from each other.
It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.
In general, unless otherwise specified, IUPAC nomenclature rules are used herein.
The term “about,” whether used explicitly or not in reference to a quantitative expression given herein, means that every quantity given herein qualified with the term or otherwise is meant to refer both to the actual given value and the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including approximations due to experimental and/or measurement conditions for such given value.
The term “form” means, in reference to compounds of the present invention, such may exist as, without limitation in the following states, a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof.
The term “isolated form” means, in reference to compounds of the present invention, such may exist in an essentially pure state such as, without limitation, an enantiomer, a racemic mixture, a geometric isomer (such as a cis or trans stereoisomer), a mixture of geometric isomers, and the like. The present invention encompasses all such compound forms and mixtures thereof.
The term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
The term “subject” as used herein, refers to a patient, such as an animal, a mammal or a human, who has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing an FLAP-mediated disorder.
The term “administering” further means that the individual ingredients to be combined may be administered at the same time or at different times during the treatment period, either as one preparation or as different preparations. Accordingly, the invention should be so interpreted that it encompasses any and every administration mode at the same time or at different times. The range of the combination of the compound of the invention and the other therapeutic agent useful for the above-mentioned disorders encompasses, in principle, all combinations of the compound of the invention and any and every pharmaceutical agent useful for the above-mentioned disorders.
The term “treating” refers, without limitation, to facilitating the eradication of, preventing, ameliorating or otherwise inhibiting the progression of or promoting stasis of an FLAP-mediated disease and/or disorder, or associated symptoms or complications thereof.
The term “prodrug” means a compound of Formula (I) or a form thereof that is converted in vivo into a functional derivative form that may contribute to therapeutic biological activity, wherein the converted form may be: 1) a relatively active form; 2) a relatively inactive form; 3) a relatively less active form; or, 4) any form which results, directly or indirectly, from such in vivo conversions. Prodrugs are useful when said compound may be either too toxic to administer systemically, absorbed poorly by the digestive tract or broken down by the body before it reaches its target. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
The term “metabolite” means a prodrug form of a compound of Formula (I) or a form thereof converted by in vivo metabolism or a metabolic process to a relatively less active functional derivative of said compound.
The term “medicament” or “medicine” refers to a product containing a compound of Formula (I) or a form thereof. The present invention includes use of such a medicament for treating an FLAP-mediated disorder.
The term “combination form” refers to the use of a combination product comprising a compound of Formula (I) or a form, pharmaceutical composition, medicine or medicament thereof and at least one therapeutic agent for treating an FLAP-mediated disorder.
Methods are known in the art for determining effective doses for therapeutic and prophylactic purposes for the disclosed pharmaceutical compositions or the disclosed drug combinations, whether or not formulated in the same composition.
For therapeutic purposes, the term “therapeutically effective amount” or “effective amount” as used herein, means that amount of each active compound or pharmaceutical agent, alone or in combination, that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease and/or disorder being treated. For prophylactic purposes (i.e., inhibiting the progression of a disorder), the term “therapeutically effective amount” refers to that amount of each active compound or pharmaceutical agent, alone or in combination, that treats or inhibits in a subject the progression of a disorder as being sought by a researcher, veterinarian, medical doctor or other clinician. Thus, the present invention provides combinations of two or more drugs wherein, for example, (a) each drug is administered in an independently therapeutically or prophylactically effective amount; (b) at least one drug in the combination is administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but is therapeutic or prophylactic when administered in combination with the second or additional drugs according to the invention; or (c) both (or more) drugs are administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but are therapeutic or prophylactic when administered together. The effective amount of said compound is from about 0.001 mg/kg/day to about 300 mg/kg/day.
Advantageously, the effective amount of a combination product for treating an FLAP-mediated disease and/or disorder, or associated symptoms or complications thereof, may be a reduced amount of either or both, the compound or therapeutic agent, compared to the effective amount of the compound or therapeutic agent otherwise recommended for treating the disease and/or disorder, or associated symptoms or complications thereof. Therefore, it is contemplated that the compound is administered to the subject before, during or after the time the agent is administered.
The term “pharmaceutically acceptable salt” refers to non-toxic pharmaceutically acceptable salts (Ref. Int'l J. Pharm., 1986, 33: 201-217; J. Pharm. Sci., 1997 (January), 66(1): 1). Other salts well known to those in the art may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts. Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. Representative organic or inorganic bases include, but are not limited to, basic or cationic salts such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.
The compounds of the invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the “pharmaceutically acceptable salts” of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms.
Suitable salt forms include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of an acid such as acetic acid, adipic acid, benzoic acid, carbonic acid, citric acid, fumaric acid, glycolic acid, hydrochloric acid, maleic acid, malonic acid, phosphoric acid, saccharinic acid, succinic acid, sulphuric acid, tartaric acid, trifluoroacetic acid and the like.
Furthermore when the compounds of the present invention carry an acidic moiety, suitable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis. 3rd Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known in the art. The scope of the present invention encompasses all such protected compound forms and mixtures thereof.
The invention includes compounds of various isomers and mixtures thereof. The term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (optical isomers).
The term “stereoisomer” refers to isomers that have the same molecular formula and the same sequence of covalently bonded atoms but a different spatial orientation.
The term “optical isomer” means isomers of identical constitution that differ only in the spatial arrangement of their groups. Optical isomers rotate the plane of polarized light in different directions. The term “optical activity” means the degree to which an optical isomer rotates the plane of polarized light.
The term “racemate” or “racemic” means an equimolar mixture of two enantiomeric species, wherein each of the isolated species rotates the plane of polarized light in the opposite direction such that the mixture is devoid of optical activity.
The term “enantiomer” means an isomer having a nonsuperimposable mirror image. The term “diastereomer” means stereoisomers that are not enantiomers.
The term “chiral” means a molecule that, in a given configuration, cannot be superimposed on its mirror image. This is in contrast to achiral molecules that can be superimposed on their mirror images.
The two distinct mirror image versions of the chiral molecule are also known as levo (left-handed), abbreviated L, or dextro (right-handed), abbreviated D, depending on which way they rotate polarized light. The symbols “R” and “S” represent the configuration of groups around a stereogenic carbon atom(s).
The term “geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration according to the Cahn-Ingold-Prelog priority rules. In the “E” configuration, the substituents having the highest priorities are on opposite sides in relationship to the carbon-carbon double bond. In the “Z” configuration, the substituents having the highest priorities are oriented on the same side in relationship to the carbon-carbon double bond.
Substituent atoms (other than hydrogen) attached to a ring system may be in a cis or trans configuration. In the “cis” configuration, the substituents are on the same side in relationship to the plane of the ring; in the “trans” configuration, the substituents are on opposite sides in relationship to the plane of the ring. Compounds having a mixture of “cis” and “trans” species are designated “cis/trans”.
The isomeric descriptors (“R,” “S,” “E,” and “Z”) indicate atom configurations and are intended to be used as defined in the literature.
The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include combining the free base (or free acid) of each isomer of an isomeric pair using an optically active acid (or base) to form an optically active salt (followed by fractional crystallization and regeneration of the free base), forming an ester or amide of each of the isomers of an isomeric pair by reaction with an appropriate chiral auxiliary (followed by fractional crystallization or chromatographic separation and removal of the chiral auxiliary), or separating an isomeric mixture of either an intermediate or a final product using various well known chromatographic methods.
Furthermore, compounds of the present invention may have one or more polymorph or amorphous crystalline forms and, as such, are intended to be included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like) and, as such, are also intended to be encompassed within the scope of this invention.
B) Compounds
Representative compounds of the present invention are listed in Table 3 below:









TABLE 3






COM-




POUND



STRUCTURE
#
NAME





















1
5-(3-fluoro-2′-(methylsulfonyl)-[1,1′- biphenyl]-4-yl)pyrazin-2-amine


 






2
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methanesulfonamide


 






3
6-Amino-3-[3.-fluoro-2′- (methylsulfonyl)biphenyl-4- yl]pyrazine-2-carbonitrile


 






4
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-fluorobiphenyl-2-sulfonamide


 






5
4′-(5-aminopyrazin-2-yl)-3′-fluoro- [1.1′-biphenyl]-2-sulfonamide


 






6
4′-(5-Aminopyrazin-2-yl)-N- cyclohexyl-3′-fluorobiphenyl-2- sulfonamide


 






7
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-methylpropyl)biphenyl-2- sulfonamide


 






8
(racemic)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide racemic


 






9
4′-(5-Aminopyrazin-2-yl)-N- (cyclobutylmethyl)-3′-fluorobiphenyl- 2-sulfonamide


 






10
(racemic)-(endo)-4′-(5- Aminopyrazin-2-yl)-N- bicyclo[2.2.1]hept-2-yl-3′- fluorobiphenyl-2-sulfonamide racemic


 






11
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (1-methylcyclobutyl)biphenyl-2- sulfonamide


 






12
4′-(5-Aminopyrazin-2-yl)-N-(1,1- dimethylpropyl)-3′-fluorobiphenyl-2- sulfonamide


 






13
4′-(5-4minopyrazin-2-yl)-3′-fluoro-N- (2,2,2-trifluoro-1,1- dimethylethyl)biphenyl-2-sulfonamide


 






14
4′-(5-Aminopyrazin-2-yl)-N- cyclopentyl-3′-fluorobiphenyl-2- sulfonamide


 






15
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- methylbiphenyl-2-sulfonamide


 






16
4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′- fluorobiphenyl-2-sulfonamide


 






17
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-phenylethyl)biphenyl-2- sulfonamide


 






18
(R)-4′-5-Aminopyrazin-2-yl)-3′- fluoro-N-[(1R)-2,2,2-trifluoro-1- phenylethyl]biphenyl-2-sulfonamide


 






19
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-[(1S)-2,2,2-trifluoro-1- phenylethyliblphenyl-2-sulfonamide


 






20
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-[(S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide


 






21
4′-(5-Aminopyrazin-2-yl)-N-(2,3- dihydro-1H-inden-2-yl)-3′- fluorobiphenyl-2-sulfonamide


 






22
(S)-4′-(5-Aminopyrazin-2-yl)-N-[(1S)- 2,3-dihydro-1H-inden-1-yl]-3′- fluorobiphenyl-2-sulfonamide


 






23
(R)-4′-(5-Aminopyrazin-2-yl|)-N-[(1R)- 2,3-dihydro-1H-inden-1-yl]-3′- fluorobiphenyl-2-sulfonamide


 






24
(R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-[(1R)-1- phenylethyl]biphenyl-2-sulfonamide


 






25
(R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-[(1R)-2-hydroxy-1- methylethyl]piphenyl-2-sulfonamicie


 






26
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- phenylbiphenyl-2-sulfonamide


 






27
(S)-4′-(5-Aminopyrazin-2-yl)-N-[((3S)- 1-ethyl-2-oxoazepan-a-y]-3′- fluorobiphenyl-2-sulfonamide


 






28
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-[(3S)-2-oxoazepan-3-yl]biphenyl-2- sulfonamide


 






29
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-[(3S)-1-methyl-2-oxoazepan-3- yl]biphenyl-2-sulfonamide


 






30
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (1,2,2,6,6-pentamethylpiperidin-4- yl)biphenyl-2-sulfonamide


 






31
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- pyridin-3-ylbiphenyl-2-sulfonamide


 






32
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-2-hydroxy-1- methylethyl]piphenyl-2-sulfonamide


 






33
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfamide


 






34
N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro- [1,1′-biphenyl]-2-yl)propane-2- sulfonamide


 






35
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]ethanesulfonamide


 






36
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]propane-1- sulfonamide


 






37
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-2- methylpropane-1-sulfonamide


 






38
N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro- [1,1′-biphenyl]-2- yl)cyclopropanesulfonamide


 






39
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]hexane-1- sulfonamide


 






40
N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro- [1,1′-biphenyl]-2- yl)cyclobutanesulfonamide


 






41
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-1,1,1- trifluoromethanesulfonamide


 






42
4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N,N-dimethylbiphenyl-2-sulfonamide


 






43
5-[3-fluoro-2′-(piperidin-1- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine


 






44
5-[3-Fluoro-2′-(morpholin-4- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine


 






45
5-{2′-[(1,1-Dioxidothiomorpholin-4- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






46
5-[3-Fluoro-2′-(piperazin-1- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine


 






47
4′-(5-Aminopyrazin-2-yl)-N,N-diethyl- 3′-fluorobiphenyl-2-sulfonamide


 






48
5-[3-Fluoro-2′-(pyrrolidin-1- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine


 






49
5-{2′-[(4,4-Difluoropiperidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






50
5-{2′-[(3,3-Difluoropiperidin-1- yl)sulfonyl)-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






51
5-{2′-[(3,3-Difluoropyrrolidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






52
5-{2′-[(3,3-Difluoroazetidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






53
5-[2′-(Azepan-1-ylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine


 






54
5-{3-Fluoro-2′-[(4-methylpiperazin-1- yl)sulfonyl]biphenyl4-yl}pyrazin-2- amine


 






55
1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-4- (trifluoromethyl)piperidin-4-ol


 






56
5-(3-Fluoro-2′-{[4- (methylsulfonyl)piperazin-1- yl]sulfonyl}biphenyl-4-yl)pyrazin-2- amine


 






57
5-{2′-[(4-Acetylpiperazin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






58
5-(2′-{[4- (Cyclopropylcarbonyl)piperazin-1- yl]sulfonyl}-3-fluoroblphenyl-4- yl)pyrazin-2-amine


 






59
2-(4-{[4′-[5-Aminopymzin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperazin- 1-yl)ethanol


 






60
5-{2′-[(4-Cyclopropylpiperazin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






61
racemic 5-[3-Fluoro-2′- (hexahydropyrrolo[1,2-a]pyrazin- 2(1H)-ylsulfonyl)biphenyl-4- yl]pyrazin-2-amine


 






62
5-{2′-[(3,5-Dimethylpiperazin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






63
racemic 1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}piperidine-3-carbonitrile


 






64
1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]sulfonyl}piperidine-4-carbonitrile


 






65
5-{2′-[(4-Aminopiperidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






66
4-{1,4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-ylisulfonyl}piperazin- 2-one


 






67
1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-ol


 






68
(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)methanol


 






69
2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)ethanol


 






70
racemic 1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-ol


 






71
racemic 2-(1-{[4′-(5-Aminopyrazin-2- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}piperidin-3-yl)ethanol


 






72
5-{3-Fluoro-2′-{[4- (methylamino)piperidin-1- yl]sulfonyl}biphenyl-4-yl)pyrazin.-2- amine


 






73
5-(2′-{[4-(Dimethylamino)piperidin-1- yl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine


 






74
racemic 5-{2′-[(3-Aminopiperidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






75
N-(1-{[4′-(5-Aminopyrazin-2′yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)acetamide


 






76
racemic (1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}piperldin-3-yl)methanol


 






77
racemic tert-Butyl (1-{[4′-(5- aminopyrazin-2-yl)-3′-fluorobiphenyl- 2-yl]sulfonyl}piperidin-3-yl)carbamate


 






78
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S,2S)-2-hydroxy-1- (hydroxymethyl)-2- phenylethyl]biphenyl-2-sulfonamide


 






79
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-1-(hydroxymethyl)-3- methylbutyl]biphenyl-2-sulfonamide


 






80
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (3-hydroxypropyl)biphenyl-2- sulfonamide


 






81
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-2-hydroxy-1- phenylethyl]biphenyl-2-sulfonamide


 






82
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R)-2-hydroxy-1- phenylethyl]biphenyl-2-sulfonamide


 






83
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S,2R)-2-hydroxy-1-methyl-2- phenylethyl]biphenyl-2-sulfonamide


 






84
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S,2S)-1-(hydroxymethyl)-2- methylbutyl]blphenyl-2-sulfonamide


 






85
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R,2R)-2- hydroxycyclohexyl]biphenyl-2- sulfonamide


 






86
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R)-1- (hydroxymethyl)propyl]biphenyl-2- sulfonamide


 






87
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R,2S)-2- hydroxycyclohexyl]biphenyl-2- sulfonamide


 






88
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxyethyl)biphenyl-2- sulfonamide


 






89
4′-(5-Aminopyrazin-2-yl)-N- cyclopropyl-3′-fluoroblphenyl-2- sulfonamide


 






90
4′-(5-Aminopyrazin-2-yl)-N- (cyclopropylmethyl)-3′-fluorobiphenyl- 2-sulfonamide


 






91
(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-2-yl)methanol


 






92
(R)-5-(2′-((3-aminopyrrolidin-1- yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine


 






93
(S)-5-(2′-((3-aminopyrrolidin-1- yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine


 






94
(R) 5-(2′-{[2-(Aminomethyl)pyrrolidin- 1-yl]sulfonyl}-3-fluorobiphenyl-4- yl)pyrazin-2-amine


 






95
(S)-(1-((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2′- yl)sulfonyl)pyrrolidin-2-yl)methanol


 






96
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (methylsulfonyl)biphenyl-2- sulfonamide


 






97
(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-hydroxypropyl)-[1,1′-biphenyl]-2- sulfonamide


 






98
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-hydroxypropyl)-[1,1′-biphenyl]-2- sulfonamide


 






99
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1- hydroxycyclohexyl)methyl]biphenyl- 2-sulfonamide


 






100
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide


 






101
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxy-2-methylpropyl)biphenyl- 2-sulfonamide


 






102
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (3-hydroxy-1,1- dimethylpropyl)biphenyl-2- sulfonamide


 






103
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (3-hydroxy-2,2- dimethylpropyl)biphenyl-2- sulfonamide


 






104
(S)-4′-(5-aminopyrazin-2-yl)-N-(2,3- dihydroxypropyl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide


 






105
(R)-4′-(5-aminopyrazin-2-yl|)-N-(2,3- dihydroxypropyl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide


 






106
(trans)-1-{[4′-(5-Aminopyrazin-2-yl|)- 3′-fluorobiphenyl-2- yl]suifonyl}pyrrolidine-3,4-diol


 






107
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-oxopyrrolidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide


 






108
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-oxopiperidin-3-yl)-[1,1′- biphenyl]-2-sulfonamide


 






109
(R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-[1-(hydroxymethyl)-2′- methylpropypiphenyl-2-sulfonamide


 






110
trans 4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-(4- hydroxycyclohexyl)biphenyl-2- sulfonamide


 






111
(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)pyrrolidin-3-yl)methanol


 






112
(S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}pyrrolidin- 3-yl)methanol


 






113
(R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-(2-oxopipendin-3- yl)biphenyl-2-sulfonamide


 






114
(R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-methyl-N-piperidin-3- ylbiphenyl-2-sulfonamide


 






115
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N-methyl-N-piperidin-3-ylbiphenyl-2′- sulfonamide


 






116
(3),4-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxy-3-phenylpropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide


 






117
(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(2-hydroxy-2-phenylethyl)-[1,1′- biphenyl]-2-sulfonamide


 






118
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1S,2S)-1-hydroxy-1-phenylpropan- 2-yl)-N-methyl-[1,1′-biphenyl)-2- sulfonamide


 






119
1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}azetidin- 3-ol


 






120
racemic (trans)-4′-(5-Aminopyrazin-2- yl)-3′-fluoro-N-(2- hydroxycyclohexyl)biphenyl-2- sulfonamide


 






121
racemic (trans)-4′-(5-Aminopyrazin-2- yl)-3′-fluoro-N-[2- (hydroxymethyl)cyclohexyl]biphenyl- 2-sulfonamide


 






122
racemic (cis)-4′-(5-Aminopyrazin-2- yl)-3′-fluoro-N-[2- (hydroxymethyl)cyclohexyl]biphenyl- 2-sulfonamide


 






123
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- piperidin-4-ylbiphenyl-2-sulfonamide


 






124
5-(2′-{[3-(Aminomethyl)azetidin-1- yl]sulfonyl}-fluorobiphenyl-4- yl)pyrazin-2-amine


 






125
4′-(5-Aminopyrazin-2-yl)-N-(azetidin- 3-ylmethyl)-3′-fluorobiphenyl-2- sulfonamide


 






126
(R)-5-(3-Fluoro-2′-{[3- (methylamino)pyrrolidin-1- yl]sulfonyl}biphenyl-4-yl)pyrazin-2- amine


 






127
(R)-4′-(5-Aminopyrazin-2-yl)-3′- fluoro-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide


 






128
5-[3-Fluoro-2′-(1,4,6,7-tetrahydro-5H- pyrazolo[4,3-c]pyridin-5- ylsulfonyl)biphenyl-4-yl]pyrazin-2- amine


 






129
4-(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperidin- 4-yl)-2,4-dihydro-3H-1,2,4-triazol-3- one


 






130
5-(2′-((1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2- ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine


 






131
5-(2′-((1S,4S)-2,5- diazabicyclo[2.2.1]heptan-2- ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrazin-2-amine


 






132
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (5-hydroxypentyl)biphenyl-2- sulfonamide


 






133
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (6-hydroxyhexyl)biphenyl-2′- sulfonamide


 






134
N-(4-Aminocyclohexyl)-4′-(5- aminopyrazin-2-yl)-3′-fluorobiphenyl- 2-sulfonamide


 






135
(S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-2,3- dihydro-1H-indol-2-yl)methanol


 






136
4′-(5-Aminopyrazin-2-yl)-N- cyclohexyl-3′-fluoro-N-(2- hydroxyethyl)biphenyl-2-sulfonamide


 






137
(S)-5-{2′-[(3-Aminopiperidin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






138
4′-(5-Aminopyrazin-2-yl)-3′-fluoro- N,N-bis(2-hydroxyethyl)biphenyl-2- sulfonamide


 






139
1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl)sulfonyl}azetidine- 2-carboxamide


 






140
4′-(5-Aminopyrazin-2-yl)-N- cyclopropyl-3′-fluoro-N-(tetrahydro- 2H-pyran-4-yl)biphenyl-2- sulfonamide


 






141
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxyethyl)-N-(1- methylethyl)biphenyl-2-sulfonamide


 






142
racemic (4-{[4′-(5.-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}morpholin-2-yl)methanol


 






143
(1R,5S)-3-((4′-(5-aminopyrazin-2-yl)- 3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)- 3-azabicyclo[3.1.0]hexan-6-amine


 






144
(S)-5-(3-fluoro-2′-((2-methylpiperazin- 1-yl)sulfonyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine


 






145
(R)-5-(3-fluoro-2′-((2- methylpiperazin-1-yl)sulfonyl)-[1,1′- biphenyl]-4-yl)pyrazin-2-amine


 






146
(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperazin-2-yl)methanol


 






147
4′-(5-Aminopyrazin-2-yl)-3′-fluora-N- [2-hydroxy-1-(hydroxymethyl)-1- methylethyl]piphenyl-2-sulfonamide


 






148
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxy-3-methylbutan-2-yl)- [1,1′-biphenyl]-2-sulfonamide


 






149
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxy-3,3-dimethylbutan-2- yl)-[1,1′-biphenyl]-2-sulfonamide


 






150
(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxy-3,3-dimethylbutan-2- yl)-[1,1′-biphenyl]-2-sulfonamide


 






151
tert-Butyl [2-({4′-(5-aminopyrazin-2- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}amino)ethyl]carbamate


 






152
N-(2-Aminoethyl)-4′-(5-aminopyrazin- 2-yl)-3′-fluorobiphenyl-2-sulfonamide


 






153
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-hydroxybutan-2-yl)-[1,1′- biphenyl]-2-suifonamide


 






154
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(pyrrolidin-3-yl)-[1,1′-biphenyl]-2- sulfonamide


 






155
N-[2-({(4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]sulfonyl}amino)ethyl]acetamide


 






156
(S)-2-(4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- ylsulfonamido)propanoic acid


 






157
4′-(5-Aminopyrazin-2-yl)-N-[2- (carbamoylamino)ethyl]-3′- fluorobiphenyl-2-sulfonamide


 






158
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1S,2S-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2- sulfonamide


 






159
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1R,2R)-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2- sulfonamide


 






160
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1S,2R)-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2- sulfonamide


 






161
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1R,2S)-2-hydroxy-2,3-dihydro-1H- inden-1-yl)-[1,1′-biphenyl]-2- sulfonamide


 






162
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- ((1S,2S)-2-hydroxycyclohexyl)-[1,1′- biphenyl]-2-sulfonamide


 






163
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [6-(trifluoromethyl)pyridin-3- yl]biphenyl-2-sulfonamide


 






164
5-(3-Fluoro-2′-{[4-(1H-imidazol-4′- yl)piperidin-1-yl]sulfonyl}biphenyl-4- yl)pyrazin-2-amine


 






165
N-[(4-Amino-2-methylpyrimidin-5- yl)methyl]-4′-(5-aminopyrazin-2-yl)-3′- fluorobiphenyl-2-sulfonamide


 






166
4′-(5-Aminopyrazin-2-yl)-N-(2,6- dimethoxypyrimidin-4-yl)-3′- fluorobiphenyl-2-sulfonamide


 






167
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (5-methylpyrazin-2-yl)biphenyl-2- sulfonamide


 






168
(S)-2-(4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- ylsulfonamido)-4-methylpentanamide


 






169
4′-(5-Aminopyrazin-2-yl)-N-(2- cyanoethyl)-3′-fluorobiphenyl-2- sulfanamide


 






170
(R)-4′-(5-aminopyrazin-2-yl)-N-(1- cyanopropan-2-yl)-3′-fluoro-[1,1′- biphenyl)-2-sulfonamide


 






171
(S)-4′-(5-aminopyrazin-2-yl)-N-(1- cyanopropan-2-yl)-3′-fluoro-[1,1′- biphenyl]-2-sulfonamide


 






172
4′-(5-Aminopyrazin-2-yl)-N-(2- cyanoethyl)-N-cyclopropyl-3′- fluorobiphenyl-2-suifonamide


 






173
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (3-methyloxetan-3-yl)biphenyl-2- sulfonamide


 






174
3-(4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluoroblphenyl-2-yl]sulfonyl}piperazin- 1-yl)propanenitrile


 






175
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro- N-(1-methoxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide


 






176
5-{3-Fluoro-2′-[(4-pyrazin-2- ylpiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine


 






177
5-{3-Fluoro-2′-(4-pyrimidin-2- ylpiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine


 






178
5-(2′-Amino-3-fluorobiphenyl-4- yl)pyrazin-2-amine


 






179
4′-(5-Aminepyrazin-2-yl)-3′-fluoro-N- [1- hydroxymethyl)cyclopentyl]biphenyl- 2-sulfonamide


 






180
1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-3- phenylpyrrolidin-3-ol


 






181
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrroildine-1- sulfonamide


 






182
N′-[4′-(5-Aminopyrazin-2-yl)-3′- fluoroblphenyl-2-yl]-N,N- dimethylsulfamide


 






183
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]morpholine-4- sulfonamide


 






184
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}pyrrolidin- 3-ol


 






185
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluoroblphenyl-2-yl]sulfonyl}pyrrolidin- 3-ol


 






186
(3′S,4′S)-1′-{[4′-(5-Aminopyrazin-2- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}- 1,3′-bipyrrolidin-4′-ol


 






187
(3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-yl]sulfonyl}-4- morpholin-4-ylpyrrolidin-3-ol


 






188
(3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-yl]sulfonyl}-4-(4- methylpiperazin-1-yl)pyrrolidin-3-ol


 






189
5-{3-Fluoro-2′-[(trifluoromethyl)- sulfanyl]biphenyl-4-yl}pyrazin-2- amine


 






190 
5-[2′-(tert-Butylsulfanyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine


 






191
5-[2′-(Ethylsulfonyl)-3-fluorobiphenyl- 4-yl]pyrazin-2-amine


 






192
5-[3-Fluoro-2′- (propylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine


 






193
5-{3-Fluoro-2′-[(2- methylpropyl)sulfonyyl]iphenyl-4- yl}pyrazin-2-amine


 






194
5-[2′-(tert-Butylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine


 






195
5-[2′-(Cyclopentylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine


 






196
5-[2′-(Cyclobutylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine


 






197
5-[2′-(Cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine


 






198
5-[3-Fluoro-2′- (hexylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine


 






199
5{3Fluoro-2′-[(1- methylethyl)sulfonyl]biphenyl-4- yl}pyrazin-2-amine


 






200
2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]sulfanyl}acetamide


 






201
2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}-N,N- diethylacetemide


 






202
5-{3-Fluoro-2′-[(2-morpholin-4-yl-2- oxoethyl)sulfanyl]biphenyl-4- yl}pyrazin-2-amine


 






203
(racemic) 5-({[4′-(5-Aminopyrazin-2- yl)-3′-fluorobiphenyl-2- yl]sulfanyl}methyly)-1,3-oxazolidin-2- one


 






204
N-(2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]sulfanyl}ethyl)benzamide


 






205
5-(3-Fluoro-2′-{[4- (methylsulfonyl)benzyl]sulfanyl}biphenyl- 4-yl)pyrazin-2-amine


 






206
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2- sulfonamide


 






207
5-[3-Fluoro-2′-(methylsulfonyl)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine


 






208
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- methyl-4-(trifluoromethyl)biphenyl-2- sulfonamide


 






209
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 4-(trifluoromethyl)biphenyl-2- yl]sulfonyl}piperazin-2-one


 






210
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2- sulfonamide


 






211
4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′- fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide


 






212
5-{3-Fluoro-2′-[(4-methylpiperazin-1- yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin- 2-amine


 






213
5-[3-Fluoro-2′-(pyrimidin-2- ylsulfanyl)biphenyl-4-yl]pyrazin-2- amine hydrochloride


 






214
5-[3-Fluoro-2′-(pyrimidin-4- ylsulfanyl)biphenyl-4-yl]pyrimidin-2- amine formate salt


 






215
6-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 4-amine hydrochloride


 






216
2-{1,4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 4-amine hydrochloride


 






217
4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 5-amine hydrochloride


 






218
5-[3-Fluoro-2′-(pyrazin-2- ylsulfanyl)biphenyl-4-yl]pyrazin-2′ amine hydrochloride


 






219
2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 5-amine hydrochloride


 






220
1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorotiphenyl-2-yl]-N- methylmethanesulfonamide formic acid salt


 






221
1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N-(2- hydroxyethyl)methanesulfonamide formic acid salt


 






222
1-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methyl}sulfonyl)azetidin-3-ol formic acid salt


 






223
4-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methyl}sulfonyl)piperazin-2-one formic acid salt


 






224
(S)-1-(4′-(5-Aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2-yl)-N-(1- hydroxypropan-2- yl)methanesulfonamide


 






225
(R)-1-(4′-(5-Aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2-yl)-N-(1- hydroxypropan-2- yl)methanesulfonamide hydrochloride


 






226
1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N-(trans-4- hydroxycyclohexyl)methanesulfon- amide


 






227
(S)-1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N-[(2S)-2- hydroxypropyl]methanesulfonamide hydrochloride


 






228
(R)-1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N-[(2S)-2- hydroxypropyl]methanesulfonamide


 






229
5-(2′-{[(4-Aminopiperidin.-1- yl)sulfonyl]methyl}-3-fluorobiphenyl- 4-yl)pyrazin-2-amine hydrochloride


 






230
1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methanesulfonamide hydrochloride


 






231
1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- ethylmethanesulfonamide formate salt


 






232
1-[1-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methyl}sulfonyl)piperidin4-yl]urea hydrochloride


 






233
N-[1-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]methyl}sulfonyl)piperidin-4- yl]acetamide formate salt


 






234
5-{2′-[(Ethylsulfanyl)methyl-3- fluorobiphenyl-4-yl}pyrazin-2-amine formate salt


 






235
5-{3-Fluoro-2′- [(methylsulfanyl)methylibiphenyl-4- yl}pyrazin-2-amine hydrochloride


 






236
5-(3-Fluoro-2-{[(1- methylethyl)sulfanyl]methyl}biphenyl- 4-yl)pyrazin-2-amine hydrochloride


 






237
2-(((4′-(5-Aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyrimidin-4-amine hydrochloride


 






238
6-(((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyrimidin-4-amine hydrochloride


 






239
5-(3-fluoro-2′-((pyridazin-3- ylthio)methyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine hydrochloride


 






240
6-(((4′-(5-aminopyrazin-2-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)methyl)thio)pyridazin-3-amine hydrochloride


 






241
5-{2′-[(1,1-Dioxidotatrahydro-2H- thiopyran-4-yl)sulfonyl)-3- fluorobiphenyl-4-yl}pyrazin-2-amine


 






242
4-{[4′(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 2-amine hydrochloride


 






243
5-(3-fluoro-2′-((pyrimidin-4- ylthio)methyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine hydrochloride


 






244
5-[3-Fluoro-2′-({[2- (trimethylsilyl)ethoxy]methyl}sulfanyl) biphenyl-4-yl]pyrazin-2-amine


 






245
5-[3-Fluoro-2′-({[2- (trimethylsilyl)ethoxy]methyl}sulfonyl) biphenyl-4-yl]pyrazin-2-amine hydrochloridee


 






246
5-(3-Fluoro-2′-{[3- (methylsulfonyl)propyl]sulfonyl}bi- phenyl-4yl)pyrazin-2-amine hydrochloride


 






247
5-(3-Fluoro-2′-{[(2R)-2- methylpiperazn-1- yl)sulfonyl)biphenyl-4-yl)pyrimidin-2- amine


 






248
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-1- (hydroxymethyl)propyl]biphenyl-2- sulfonamide


 






249
4′-(2-Aminopyrimidin-5-yl)-N-(2- cyanoethyl)-N-cyclopropyl-3′- fluorobiphenyl-2-sulfonamide


 






250
4′-(2-Aminopyrimidin-5-yl)-N-(2- cyanoethyl)-3′-fluorobiphenyl-2- sulfonamide


 






251
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(3-hydroxy-2,2- dimethylpropyl)biphenyl-2- sulfonamide


 






252
racemic (4-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}morpholin-2-yl)methanol


 






253
5-(3-Fluoro-2′-{[(2S)-2- methylpiperazin-1- yl)sulfonyl}biphenyl-4-yl)pyrimidin-2′- amine


 






254
5-[2′-(Cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]pyrimidin-2-amine


 






255
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[2-hydroxy-1-(hydroxymethyl)-1- methylethyl]biphenyl-2-sulfonamide


 






256
4′-(2-aminopyrimidin-5-yl)-3′-fluoro- N-methyl-N-[(3S)-piperidin-3- yl]biphenyl-2-sulfomamide


 






257
4′-(2-aminopyrimidin-5-yl)-3′-fluoro- N-methyl-N-[(3R)-piperidin-3- yl]biphenyl-2-suifonamide


 






258
[(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}piperazin-2-yl]methanol


 






259
racemic (cis) 4′-(2-Aminopyrimidin-5- yl)-3′-fluoro-N-[(cis)-2- hydroxycyclohexyl]biphenyl-2- sulfonamide


 






260
racemic (trans) 4′-(2-Aminopyrimidin- 5-yl)-3′-fluoro-N-[(trans)-2- hydroxycyclohexyl]biphenyl-2- sulfonamide


 






261
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxyethyl)-N-(1- methylethyl)biphenyl-2-sulfonamide


 






262
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(trans-4- hydroxycyclohexyl)biphenyl-2- sulfonamide


 






263
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(3S)-2-oxopyrrolidin-3-yl]biphenyl- 2-sulfonamide


 






264
5-{2′-[(1,1-Dioxidothiomorpholin-4- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine


 






265
1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}azetidin- 3-ol trifluoroacetic acid salt


 






266
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(3R)-2-oxopiperidin-3-yl]biphenyl- 2-sulfonamide trifluoroacetic acid salt


 






267
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(3S)-2-oxopiperidin-3-yl]biphenyl- 2-sulfonamide trifluoroacetic acid salt


 






268
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1R)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt


 






269
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N[(R)-1-(hydroxymethyl)-2,2- dimethylpropyl]biphenyl-2- sulfonamide trifluoroacetic acid salt


 






270
4′-2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-1-(hydroxymethyl)-2,2- dimethylpropyl]biphenyl-2- sulfonamide trifiuoroacetic acid salt


 






271
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-1-(hydroxymethyl)-2- methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt


 






272
4′-(2-Aminopyrimidin-5-y)-3′-fluoro- N-(2-hydroxy-2- methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt


 






273
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1R)-1-(hydroxymethyl)-2- methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt


 






274
4′-(2-Aminopyrimidin-5-yl)-N-[(2S)- 2,3-dihydroxypropyl]-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt


 






275
4′-(2-.Aminopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxyethyl)biphenyl-2′ sulfonamide trifluoroacetic acid salt


 






276
[(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt


 






277
[(2S)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- ylisulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt


 






278
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(2R)-2-hydroxypropyl]biphenyl-2- sulfonamide


 






279
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(2S)-2-hydroxypropyl]biphenyl-2- sulfonamide trifluoroacetic acid salt


 






280
4′-(2-.Aminopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxy-1,1- dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt


 






281
5-{2′-[(4-Cyclopropylpiperazin-1- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine trifluoroacetic acid salt


 






282
2-(4-{(4′-[2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperazin- 1-yl)ethanol trifluoroacetic acid salt


 






283
4′-(2-Aminopyrimidin-5-yl)-N- (cyclopropylmethyl)-3′-fluorobiphenyl- 2-sulfonamide trifiuoroacetic acid


 






284
4′-(2-Aminopyrimidin-5-yl)-N- cyclopropyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt


 






285
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-phenylbiphenyl-2-sulfonamide trifluoroacetic acid salt


 






286
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt


 






287
4′-(2-Aminopyrimidin-5-yl)-N-tert- butyl-3′-fluoro-3-methylbiphenyl-2- sulfonamide trifluoroacetic acid salt


 






288
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt


 






289
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1R)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt


 






290
5-[3-Fluoro-2′-(piperazin-1- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine trifluoroacetic acid salt


 






291
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1R)-2,2,2-trifluoro-1- phanylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt


 






292
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-2,2,2-trifluoro-1- phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt


 






293
5-[2′-(tert-Butylsulfonyl)-3- fluorobiphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt


 






294
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(2-methylpropyl)biphenyl-2- sulfonamide trifiuoroacetic acid salt


 






295
4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt


 






296
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(2,2,2-trifluoro-1,1- dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt


 






297
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt


 






298
5-[3-Fluoro-2′-(pyrrolidin-1- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine trifluoroacetic acid salt


 






299
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N,N-dimethylbiphenyl-2-sulfonamide trifluoroacetic acid salt


 






300
4′-(2-Aminopyrimidin-5-yl)-N,N- diethyl-3′-fluorobiphenyl-2- sulfonamide trifiuoroacetic acid salt


 






301
5-[3-Fluoro-2′-(piperidin-1- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine trifluoroacetic acid salt


 






302
4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt


 






303
5-[3-Fluoro-2′-(morpholin-4- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine trifluoroacetic acid salt


 






304
5-[3-Fluoro-2′- (methylsulfonyl)biphenyl-4- yl]pyrimidin-2-amine trifluoroacetic acid salt


 






305
4′-(2-aminopyrimidin-5-yl)-N-(tert- butyl)-3′-fluoro[1,1′-biphenyl]-2- sulfonamide trifluoroacetic acid salt


 






306
4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}piperazin- 2-one trifluoroacetic acid salt


 






307
tert-Butyl N-{[4′-(2-aminopyrimidin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L- alaninate


 






308
N-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-L- alanine


 






309
N-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]pyrrolidine-1- sulfonamide


 






310
N-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]morpholine-4- sulfonamide


 






311
N′-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]-N,N- dimethylsulfamide


 






312
5-(2′-(2-oxa-6-azaspiro[3.3]heptan-6- ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4- yl)pyrimidin-2-amine


 






313
6-((4′-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-2- thia-6-azaspiro[3.3]heptane 2,2- dioxide


 






314
1-((4′-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)azetidine-3-carbonitrile


 






315
1-((4-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3- (trifluoromethyl)azetidin-3-ol


 






316
5-{2′-[(1,1-Dioxidotetrahydro-2H- thiopyran-4-yl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrimidin.-2-amine hydrochloride


 






317
2-(((4′-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)methyl)quinazolin-4(3H)- one


 






318
1-(3-((4′-(2-aminopyrimidin-5-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)propyl)-1H- benzo[d]imidazol-2(3H)-one


 






319
5-(2′-{[3- (Cyclohexylsulfonyl)propyl]sulfonyl}- 3-fluorobiphenyl-4-yl)pyrimidin-2- amine


 






320
5-{3-Fluoro-2′-[(1-methyl-1H- benzimidazol-2-yl)sulfonyl]biphenyl- 4-yl}pyrimidin-2-amine


 






321
5-(2′-{[(3-Cyclopropyl-1,2,4- oxadiazol-5-yl)methyl]sulfonyl}-3- fluorobiphenyl-4-yl)pyrimidin-2-amine


 






322
4′-(2-aminopyrimidin-5-yl)-3′-fuoro-4- (trifluoromethyl)biphenyl-2- sulfonamide


 






323
5-[3-fluoro-2′-(methylsulfonyl)-4′- (trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine


 






324
4-{[4′-(2-aminopyrimidin-5-yl)-3′- fluoro-4-(trifluoromethyl)biphenyl-2- yl]sulfonyl}piperazin-2-one


 






325
4′-(2-aminopyrimidin-5-yl)-3′-fluoro- N-methyl-4-(trifluoromethyl)biphenyl- 2-sulfonamide


 






326
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2- sulfonamide


 






327
4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′- fluoro-4-(trifluoromethyl)biphenyl-2′- sulfonamide


 






328
5-{3-Fluoro-2′-[(4-methylpiperazin-1- yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4- yl}pyrimidin-2-amine


 






329
5-{2′-[(5-Aminopyrimidin-2- yl)sulfanyl)-3-fluorobiphenyl-4- yl)pyrimidin-2-amine formate salt


 






330
5-{2′-[(4-Aminopyrimidin-2- yl)sulfanyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine formate salt


 






331
5-{2′-[(5-Aminopyrimidin-4- yl)sulfanyl]-3-fluorobiphenyl-4- yl)pyrimidin-2-amine formate salt


 






332
5-[3-Fluoro-2′-(pyrimidin-2- ylsulfanyl)biphenyl-4-yl]pyrimidin-2- amine hydrochloride


 






333
5-[3-Fluoro-2′-(pyrazin-2- ylsulfanyl)biphenyl-4-yl]pyrimidin-2- amine hydrochloride


 






334
5-{2′-[(6-Aminopyrimidin-4- yl)sulfanyl)-3-fluorobiphenyl-4- yl}pyrimidin-2-amine formate salt


 






335
4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrimidin- 2-amine formate salt


 






336
5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]- 3-fluorobiphenyl-4-yl}pyrimidin-2- amine formate salt


 






337
5-{2′-[(5-Aminopyrimidin-4- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine hydrochloride


 






338
5-[3-Fluoro-2′-({[2- trimethylsilyl)ethoxy]methyl}sulfonyl) biphenyl-4-yl]pyrimidin-2-amine formate salt


 






339
5-{2′-[(5-Aminopyrimidin-2- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine hydrochloride 


 






340
5-[3-Fluoro-2′-({[2- (trimethylsilyl)ethoxy]methyl}sulfanyl) biphanyl-4-yl]pyrimidin-2-amine


 






341
5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′- biphenyl]-4-yl)pyridin-2-amine


 






342
4′-(6-aminopyridin-3-yl)-N-((tert-butyl)- 3′-fluoro-[1,1′-biphenyl]-2- sulfonamide


 






343
4′-(6-aminopyridin-3-yl)-N,N-diethyl- 3′-fluoro-[1,1′-biphenyl]-2- sulfonamide


 






344
5-(3-fluoro-2′-(pyrrolidin-1-ylsulfonyl)- [1,1′-biphenyl]-4-yl)pyridin-2-amine


 






345
5-(3-fluoro-2′-(piperidin-1-ylsulfonyl)- [1,1′-biphenyl]-4-yl)pyridin-2-amine


 






346
4′-(6-aminopyridin-3-yl)-N-cyclohexyl- 3′-fluoro-[1,1′-biphenyl]-2- sulfonamide


 






347
(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro- N-(1-hydroxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide


 






348
4′-(6-aminopyridin-3-yl)-3′-fluoro-N- isobutyl-[1,1′-biphenyl]-2-sulfonamide


 






349
4′-(6-aminopyridin-3-yl)-3′-fluoro-N- (tert-pentyl)-[1,1′-biphenyl]-2- sulfonamide


 






350
4′-(6-aminopyridin-3-yl)-3′-fluoro-N- (1,1,1-trifluoro-2-methylpropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide


 






351
(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro- N-(2,2,2-trifluoro-1-phenylethyl)-[1,1′- biphenyl]-2-sulfonamide


 






352
(R)-4′-(6-aminopyridin-3-yl)-3-fluoro- N-(1-hydroxypropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide


 






353
4′-(6-aminopyridin-3-yl)-3′-fluoro-N- (1-methylcyclobutyl)-[1,1′-biphenyl]- 2-sulfonamide


 






354
4-((4′-(6-aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2- yl)sulfonyl)thiomorpholine 1,1-dioxide


 






355
(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro- N-(1,1,1-trifluoropropan-2-yl)-[1,1′- biphenyl]-2-sulfonamide


 






356
5-(2′-((1S,4S)-2-oxa-5- azabicyclo[2.2.1]heptan-5-ylsulfonyl)- 3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2- amine


 






357
tert-butyl 3-((4′-(6-aminopyridin-3-yl)- 3′-fluoro-[1,1′-biphenyl]-2- ylsulfonamido)methyl)-3- hydroxyazetidine-1-carboxylate


 






358
4′-(6-aminopyridin-3-yl)-3′-fluoro-N- ((3-hydroxyazetidin-3-yl)methyl)-[1,1′- biphenyl]-2-sulfonamide


 






359
2-(1-(4′-(6-aminopyridin-3-yl)-3′- fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-4-yl)ethanol


 






360
1-((4′-(6-aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2-yl)sulfonyl)piperidin- 4-ol


 






361
(1-((4′-(6-aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2-yl)sulfonyl)piperidin- 4-yl)methanol


 






362
3′-Fluoro-N-[(1S)-2-hydroxy-1- methylethyl]-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2-sulfonamide


 






363
3′-Fluoro-N-[(1R)-2-hydroxy-1- methylethyl]-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2-sulfonamide


 






364
3′-Fluoro-N-[(3S)-2-oxopyrrolidin-3- yl]-4′-(1H-pyrrolo[2,3-b]pyridin-5- yl)biphenyl-2-sulfonamide


 






365
5-[2′-(Cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]-1H-pyrrolo[2,3- b]pyridine


 






366
3′-Fluoro-N-(2-hydroxyethyl)-4′-(1H- pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide


 






367
N-tert-Butyl-3′-fluoro-4′-(1H- pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide


 






368
3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin 5-yl)biphenyl-2-sulfonamide


 






369
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- yl]methanesulfonamide


 






370
3′-Fluoro-N,N-dimethyl-4′-(5H- pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide


 






371
N-tert-Butyl-3′-fluoro-4′-(5H- pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide


 






372
2-[3-Fluoro-2′-(pyrrolidin-1- ylsulfonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine


 






373
N-Diethyl-3′-fluoro-4′-(5H- pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide


 






374
2-[3-Fluoro-2′-(piperidin-1- ylsulfonyl)biphenyl-4-yl)-5H- pyrrolo[2,3-b]pyrazine


 






375
2-[3.-Fluoro-2′-(morpholin-4- ylsulfonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine


 






376
3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)N-N-(2,2,2-trifluoro-1- methylethyl)biphenyl-2-sulfonamide


 






377
2-[3-Fluoro-2′- (methylsulfonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine


 






378
3′-Fluoro-N-[(1R)-2-hydroxy-1- methylethyl]-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- sulfonamide


 






379
3′-Fluoro-N-methyl-4′-(5H- pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide


 






380
3′-Fluoro-N-[(1S)-2-hydroxy-1- methylethyl]4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- sulfonamide


 






381
1-{[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- yl]sulfonyl}piperidin-4-amine


 






382
2-{2′-[(1,1-Dioxidothiomorpholin-4- yl)sulfonyl]-3-fluorobiphenyl-4-yl}-5H- pyrrolo[2,3-b]pyrazine


 






383
2-[3,5-Difiuoro-2′- (methylsulfanyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine


 






384
2-[2′-(Ethylsulfanyl)-3-fluorobiphenyl- 4-yl]-5H-pyrrolo[2,3-b]pyrazine


 






385
7-[3-Fluoro-2′- (methylsulfonyl)biphenyl-4-yl]-3,4- dihydro-2H-pyrido[3,2-b][1,4]oxazine


 






386
7-[3-Fluoro-2′-(piperidin-1- ylsulfonyl)biphenyl-4-yl]-3,4-dihydro- 2H-pyrido[3,2-b][1,4]oxazine


 






387
4′-(3,4-Dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)-3′-fluorobiphenyl- 2-sulfonamide


 






388
4′-(3,4-Dihydro-2H-pyrido[3,2- b]l[1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)- 2-hydroxy-1-methylethyl]biphenyl-2- sulfonamide


 






389
1-{[4′-(3,4-Dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)-3′-fluorobiphenyl- 2-yl]sulfonyl}piperidin-4-amine


 






390
4′-(3,4-Dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1R)- 2-hydroxy-1-methylethyl]biphenyl-2- sulfonamide


 






391
4′-(3,4-Dihydro-2H-pyrido[3,2- b][1,4]oxazin-7-yl)-N,N-diethyl-3′- fluorobiphenyl-2-sulfonamide


 






392
7-{2′-[(1,1-Dioxidothiomorpholin-4- yl)sulfonyl]-3-fluorobiphenyl-4-yl]-3,4- dihydro-2H-pyrido[3,2-b][1,4]oxazine


 






393
N-tert-Butyl-4′-(3,4-dihydro-2H- pyrido[3,2-b][1,4]oxazin-7-yl)-3′- fluorobiphenyl-2-sulfonamide


 






394
2-(2-Fluoro-4-{2-[(1- methylethyl)sulfanyl]-5- (trifluoromethyl)pyridin-3-yl}phenyl)- 5H-pyrrolo[2,3-b]pyrazine


 






395
5-(2-Fluoro-4-{2-[(1- methylethyl)sulfonyl]pyridin-3- yl}phenyl)pyrazin-2-amine


 






396
5-(2-Fluoro-4-{2-[(1- methylethyl)sulfanyl]pyridin-3- yl}phenyl)pyrazin-2-amine


 






397
2-{2-Fluoro-4-[2-(2,2,2- trifluoroethoxy)pyridin-3-yl]phenyl}- 5H-pyrrolo[2,3-b]pyrazine


 






398
2-{2-Fluoro-4-[2-(2- methylpropoxy)pyridin-3-yl]phenyl)- 5H-pyrrolo[2,3-b]pyrazine


 






399
2-{2-Fluoro-4-[2-(1- methylethoxy)pyridin-3-yl]phenyl}- 5H-pyrrolo[2,3-b]pyrazine


 






400
2-{4-[2-(Cyclopropylmethoxy)pyridin- 3-yl]-2-fluorophenyl}-5H-pyrrolo[2,3- b]pyrazine


 






401
5-{2-Fluoro-4-[2-(1- methylethoxy)pyridin-3- yl]phenyl}pyrazin-2-amine


 






402
5-{4-[2-(Cyclopentyloxy)pyridin-3-yl]- 2-fluorophenyl}pyrazin-2-amine


 






403
5-{4-[2-(Cyclohexyloxy)pyridin-3-yl]- 2-fluorophenyl}pyrazin-2-amine


 






404
5-[2-Fluoro-4-(2-methoxypyridin-3- yl)phenyl]pyrazin-2-amine


 






405
5-{4-[2-(Cyclobutyloxy)pyridin-3-yl]-2- fluorophenyl}pyrazin-2-amine


 






406
tert-Butyl 3-[({3-[4-(5-aminopyrazin-2- yl)-3-fluorophenyl]pyridin-2- yl}oxy)methyl]pyrrolidine-1- carboxylate


 






407
5-{2-Fluoro-4-[2-(pyrrolidin-3′- ylmethoxy)pyridin-3- yl]phenyl}pyrazin-2-amine


 






408
5-{2-Fluoro-4-[2-(1- methylethoxy)pyridin-3- yl]phenyl}pyrimidin-2-amine


 






409
5-[4-(2-Aminopyridin-3-yl)-2- fluorophenyl]pyrimidin-2-amine


 






410
4′-(5-amino-6-cyanopyrazin-2-yl)-3′- fluoro-N-[(1R)-2-hydroxy-1- methylethypiphenyl-2-sulfonamide


 






411
3-Amino-6-[2′-(cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazine-2- carbonitrile


 






412
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′- fluoro-N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-sulfonamide


 






413
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′- fluoro-N-(2-hydroxyethyl)biphenyl-2- sulfonamide


 






414
3-Amino-6-{3-fluoro-2′-[(3- oxopiperazin-1-yl)sulfonyl]biphenyl-4- yl}pyrazine-2-carbontrile


 






415
4′-(5-Amine-6-cyanopyrazin-2-yl)-3′- fluoro-N-[(R)-2- hydroxypropyl]biphenyl-2- sulfonamide


 






416
3-Amino-6-[3-fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]pyrazine-2- carbonitrile


 






417
4′-(6-Aminopyridazin-3-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide


 






418
N-tert-Butyl-3′-fluoro-4′-(7H- pyrrolo[2,3-d]pyrimidin-2-yl)biphenyl- 2-sulfonamide


 






419
N-tert-Butyl-3′-fluoro-4′-(1,8- naphthyridin-3-yl)biphenyl-2- sulfonamide


 






420
N-tert-Butyl-3′-fluoro-4′-quinoxalin-6- ylbiphenyl-2-sulfonamide


 






421
N-tert-Butyl-3′-fluoro-4′-(1H-indol-5- yl)biphenyl-2-sulfonamide


 






422
4′-(1H-Benzimidazol-5-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide


 






423
4′-1H-Benzimidazol-5-yl)-3′-fluoro-N- methylbiphenyl-2-sulfonamide


 






424
4′-(1,3-Benzothiazol-5-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide


 






425
N-tert-Butyl-3′-fluoro-4′-(1H- pyrrolo[3,2-b]pyridin-6-yl)biphenyl-2- sulfonamide


 






426
3′-Fluoro-N-methyl-4′-(1H- pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2- sulfonamide


 






427
4′-(5-Aminepyridin-2-yl)-N-tert-butyl- 3′-fluoro-biphenyl-2-sulfonamide


 






428
N-tert-Butyl-4′-(5,6-diaminopyrazin-2- yl)-3′-fluorobiphenyl-2-sulfonamide


 






429
N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3- dihydro-1H-imidazo[4,5-b]pyrazin-5- yl)biphenyl-2-sulfonamide


 






430
4′-(6-Amino-5-fluoropyridin-3-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






431
N-tert-Butyl-4′-(2,3-dihydro-1H- pyrrolo[2,3-b]pyridin-5-yl)-3′- fluorobiphenyl-2-sulfonamide


 






432
N-tert-Butyl-3′-fluoro-4′-(3H- imidazo[4,5-b]pyridin-6-yl)biphenyl-2- sulfonamide


 






433
4′-(5-Amino-6-methoxypyrazin-2-yl)- N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






434
4′-(5-Amino-6-cyanopyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






435
4′-(5-Amino-3-cyanopyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






436
4′-(6-Amino-4-cyanopyridin-3-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






437
4′-(6-amino-2-cyanopyridin-3-yl)-N- (tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2- sulfonamide


 






438
4′-(5-amino-1,3,4-thiadiazol-2-yl)-N- (tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2- sulfonamide


 






439
(R)-4′-(5-amino-1,3,4-thiadiazol-2-yl)- 3-fluoro-N-(1-hydroxypropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide


 






440
4-((4′-(5-amino-1,3,4-thiadiazol-2-yl)- 3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)thiomorpholine 1,1-dioxide


 






441
4′-(5-Amino-6-chloropyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






442
4′-(5-Amino-6-bromopyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






443
6-amino-3-(2′-(cyclopropylsulfonyl)-3- fluoro-[1,1′-biphenyl]-4- yl)picolinonitrile


 






444
N-tert-Butyl-3′-fluoro-4′- [1,2,4]triazolo[4,3-a]pyridin-7- ylbiphenyl-2-sulfonamide


 






445
4′-(5-Amino-6-methylpyrazin-2-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






446
4′-(5-Amino-6-methylpyrazin-2-yl)-3′- fluorobiphenyl-2-sulfonamide


 






447
N-tert-Butyl-3′-fluoro-4′-(1H- imidazo[4,5-b]pyrazin-5-yl)biphenyl- 2-sulfonamide


 






448
N-tert-Butyl-4′-(5,6-diaminopyridin-3- yl)-3′-fluorobiphenyl-2-sulfonamide


 






449
4′-(5-Amino-6-methylpyrazin-2-yl)-3′- fluoro-N-methylbiphenyl-2- sulfonamide


 






450
4′-(6-Amino-5-cyanopyridin-3-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt


 






451
4′-(6-Amino-5-chloropyridin-3-yl)-N- tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt


 






452
4′-[6-Amino-5-(trifluoromethyl)pyridin- 3-yl]-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifiuoroacetic acid salt


 






453
4′-[2-Amino-4- (trifluoromethyl)pyrimidin-5-yl]-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt


 






454
4′-(2-Amino-4-methylpyrimidin-5-yl)- N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide trifluoroacetic acid salt


 






455
N-tert-Butyl-3′-fluoro-4′-[3- (hydroxymethyl)-1H-pyrrolo[2,3- b]pyridin-5-yl]biphenyl-2-sulfonamide


 






456
4′-(7-Amino-1H-indol-5-yl)-3′-fluoro- N-[1- (hydroxymethyl)cyclopentyl]biphenyl- 2-sulfonamide


 






457
3′-Fluoro-4′-[3-(hydroxymethyl)-1H- pyrrolo[2,3-b]pyridin-5-yl]-N- methylbiphenyl-2-sulfonamide


 






458
4′-(7-Amino-1H-indol-5-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide


 






459
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]acetamide


 






460
1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]urea


 






461
5-[2,3-Difluoro-2′- (methylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine


 






462
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 2′,3′-difluorobipnenyl-2-sulfonamide


 






463
N-[4′-(5-Aminopyrazin-2-y)-3′-fluoro- 2′-methylbiphenyl-2- yl]methanesulfonamide


 






464
4′-(5-Aminopyrazin-2-yl)-2′,3′- difluorobiphenyl-2-sulfonamide


 






465
4′-(2-Aminopyrimidin-5-yl)-2′,3′- difluoro-N-methylbiphenyl-2- sulfonamide trifluoroacetic acid salt


 






466
4′-(2-Aminopyrimidin-5-yl)-N-tert- butyl-2′,3′-difluorobipenyl-2- sulfonamide trifluoroacetic acid salt


 






467
5-[2′,3-Difluoro-4′- (trifluoromethoxy)biphenyl-4- yl]pyrazin-2-amine


 






468
5-(2′,3-Difluorobiphenyl-4-yl)pyrazin- 2-amine


 






469
5-(2′-Chloro-3-fluorobiphenyl-4- yl)pyrazin-2-amine


 






470
5-(3-Fluoro-2′-methylbiphenyl-4- yl)pyrazin-2-amine


 






471
5-[2′,3-Difiuoro-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine


 






472
5-[3-Fluoro-2′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine


 






473
5-(3-Fluoro-2′-methoxybiphenyl-4- yl)pyrazin-2-amine


 






474
5-[3-Fluoro-2′- (methylsulfanyl)biphenyl-4-yl]pyrazin- 2-amine


 






475
5-[3-Fluoro-2′- (trifluoromethoxy)biphenyl-4- yl]pyrazin-2-amine


 






476
4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-ol


 






477
5-[3-Fluoro-2′- (phenylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine


 






478
5-(2′,3,6′-Trifluorobiphenyl-4- yl)pyrazin-2-amine


 






479
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]benzenesulfonamide


 






480
5-(2′-Ethyl-3-fluorobiphenyl-4- yl)pyrazin-2-amine


 






481
{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}acetic acid


 






482
5-[3-Fluoro-2′-(1- methylethyl)biphenyl-4-yl]pyrazin-2- amine


 






483
1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]ethanone


 






484
5-[3-Fluoro-2′-(2,2,2- trifluoroethoxy)biphenyl-4-yl]pyrazin- 2-amine


 






485
4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-carboxylic acid


 






486
4′-(5-Aminopyrazin-2′-yl)-3′- fluorobiphenyl-2-carboxamide


 






487
5-[3-Fluoro-2′-(1- methylethoxy)biphenyl-4-yl]pyrazin- 2-amine


 






488
5-{4-[2-(Cyclopropylmethoxy)pyridin- 3-yl]-2-fluorophenyl}pyrazin-2-amine


 






489
2-[3,4′-Difluoro-2′- (methylsulfonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine


 






490
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- methylmethanesulfonmide


 






491
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- yl]ethanesulfonamide


 






492
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2-yl]-N-N- methylmethanesulfonamide


 






493
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2-yl]-N- methylethanesulfonamide


 






494
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- methylethanesulfonamide


 






495
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2-yl]-2- methylpropane-1-sulfonamide


 






496
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- ethylmethanesulfonamide


 






497
N-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N,2- dimethylpropane-1-sulfonamide


 






498
5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]-1H- pyrrolo[2,3-b]pyridine


 






499
5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]pyrimidin-2- amine


 






500
2-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]-5H- pyrrolo[2,3-b]pyrazine


 






501
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-fluorobiphenyl-2-carboxamide


 






502
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′,4-difluorobiphenyl-2-carboxamide


 






503
4′-(5-Aminopyrazin-2-yl)-N,N-diethyl- 3′-fluorobiphenyl-2-carboxamide


 






504
4′-(2-Aminopyrimidin-5-yl)-3-fluoro- N-[(1S)-2,2,2-trifluoro-1- methylethyl]piphenyl-2-carboxamide


 






505
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide


 






506
5-[3-Fluoro-2′-(piperazin-1- ylcarbonyl)biphenyl-4-yl]pyrazin-2- amine


 






507
5-{2′-[(4-Acetylpiperazin-1- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






508
4′-(5-Aminopyrazin-2-yl)-N- cyclohexyl-3′-fluorobiphenyl-2- carboxamide


 






509
5-{2′-[(1,1-Dioxidathiomorpholin-4- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






510
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- methylbiphenyl-2-carboxamide


 






511
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R)-2,2,2-trifluoro-1- methylethyl]biphenyl-2-carboxamide


 






512
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1R)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide


 






513
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- [(1S)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide


 






514
1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl)piperidin-4-ol


 






515
5-{2′-[(4-Aminopiperidin-1- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrazin-2-amine


 






516
5-{2′-[(1,1-Dioxidothiomorpholin-4- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine


 






517
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N-[(1S)-2-hydroxy-1- methylethyl]biphenyl-2-carboxamide


 






518
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro- N[(1R)-2,2,2-trifluoro-1- methylethypiphenyl-2-carboxamide


 






519
4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperazin-2-one


 






520
4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperazin-2-one


 






521
5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine


 






522
5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)-4′- (trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine


 






523
4-{[3′-Fluoro-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2- yl]oxy}pyrimidin-2-amine


 






524
2-{[3′-Fluoro-4′-(1H-pyrrolo[2,3- b]pyridin-5-yl)biphenyl-2- yl]oxy}pyrimidin-4-amine


 






525
5-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]-1H-pyrrolo[2,3- b]pyridine


 






526
5-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]pyrazin-2-amine


 






527
5-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]pyrimidin-2-amine


 






528
2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-4- amine


 






529
5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3- fluorobiphenyl-4-yllpyrimidin-2-amine


 






530
6-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]oxy}methyl)pyridine-2-carbonitrile


 






531
2-({[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]oxy}methyl)pyridine-3-carbonitrile


 






532
2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile


 






533
4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-2- amine


 






534
4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-2- amine


 






535
6-{[4′-(5-Aminopyrazin-2′yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-4′- amine


 






536
5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3- fluorobiphenyl-4-yl}pyrimidin-2-amine


 






537
4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile


 






538
4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile


 






539
5-{2′-[(6-Azetidin-1-ylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine


 






540
5-{2′-[(6-Azetidin-1-ylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine


 






541
5-{3-Fluoro-2′-[(2-methylpyrimidin-4- yl)oxy]biphenyl-4-yl}pyrazin-2-amine


 






542
5-{3-Fluoro-2′-[(2-methylpyrimidin-4- yl)oxy]biphenyl-4-yl}pyrimidin-2- amine


 






543
5-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]-1H- benzimidazole


 






544
6-[3-Fluoro-2′-(pyrimidin-2- yloxy)biphenyl-4-yl]-3H-imidazo[4,5- b]pyridine


 






545
5-{3-Fluoro-2′-[(4-methylpyrimidin-2- yl)oxy]biphenyl-4-yl}pyrazin-2-amine


 






546
5-{3-Fluoro-2′-[(4-methylpyrimidin-2- yl)oxy]biphenyl-4-yl}pyrimidin-2- amine


 






547
5-(3-Fluoro-2′-{(2- (trifluoromethyl)pyrimidin-4- yl]oxy}biphenyl-4-yl)pyrazin-2-amine


 






548
5-(3-Fluoro-2′-{(2- (trifluoromethyl)pyrimidin-4- yl]oxylbiphenyl-4-yl)pyrimidin-2- amine


 






549
5-{3-Fluoro-2′-[(5-methoxypyrimidin- 2-yl)oxy]biphenyl-4-yl}pyrazin-2- amine


 






550
5-{3-Fluoro-2′-[(5-methoxypyrimidin- 2-yl)oxy]biphenyl-4-yl}pyrimidin-2- amine


 






551
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine


 






552
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′- (trifluoromethyl)biphenyl-4- yl]pyrimidin-2-amine


 






553
5-[3-Fluoro-2′-methoxy-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine


 






554
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2-ol


 






555
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-2-amine


 






556
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-4-amine


 






557
5-[3-Fluoro-4′-(trifluoromethyl)-2′-{[2- (trimethylsilyl)ethoxy]methoxy}biphenyl- yl-4-yl]pyrimidin-2-amine


 






558
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2-ol


 






559
5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3- fluoro-4′-(trifluoromethyl)biphenyl-4- yl}pyrimidin-2-amine


 






560
4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluoro-4-(trifluoromethyl)biphenyl-2- yl]oxy}pyrimidin-2-amine


 






561
5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3- fluoro-4′-(trifluoromethyl)biphenyl-4- yl}pyrimidin-2-amine


 






562
5-[3-Fluoro-2′,4′- bis(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine


 






563
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2- carbonitrile


 






564
5-{5-[2-(Pyrimidin-2-yloxy)-4- (trifluoromethyl)phenyl]pyridin-2- yl}pyrimidin-2-amine


 






565
4-{2-[6-(2-Aminopyrimidin-5- yl)pyridin-3-yl]-5- (trifluoromethyl)phenoxy}pyrimidin-2- amine


 






566
5-{5-[2-(Pyrimidin-2- yloxy)phenyl]pyridin-2-yl}pyrimidin-2- amine


 






567
4-{2-[6-(2-Aminopyrimidin-5- yl)pyridin-3-yl]phenoxy}pyrimidin-2- amine


 






568
5-(5-{2-[(4-Aminopyrimidin-2- yl)oxy]phenyl}pyridin-2-yl)pyrimidin- 2-amine


 






569
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-methylbiphenyl-2-sulfonamide


 






570
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-methoxybiphenyl-2-sulfonamide


 






571
4′-(5-Aminopyrazin-2-yl)-N-tert- butylbiphenyl-2-sulfonamide


 






572
4′-(5-Aminopyrazin-2-yl)-N,N- dimethylbiphenyl-2-sulfonamide


 






573
5-[2′-(Morpholin-4- ylsulfonyl)biphenyl-4-yl]pyrazin-2′- amine


 






574
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 2′-fluorobiphenyl-sultonamide


 






575
4′-(5-Aminopyrazin-2-yl)-2′-fluoro- N,N-dimethylbiphenyl-2-sulfonamide


 






576
4′-(2-Amino-1,3-oxazol-4-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide


 






577
4′-(2-Amino-1,3-thiazol-4-yl)-N-tert- butyl-3′-fluorobiphenyl-2-sulfonamide


 






578
4′-(2-Amino-1,3-thiazol-4-yl)-N,N- diethyl-3′-fluorobiphenyl-2- sulfonamide


 






579
4-[3-Fluoro-2′-(pyrrolidin-1- ylsulfonyl)biphenyl-4-yl]-1,3-thiazol-2- amine


 






580
N-tert-Butyl-3′-fluoro-4′-(8- fluoroimidazo[1,2-a]pyridin-2- yl)biphenyl-2-sulfonamide


 






581
4′-(5-Aminoimidazo[1,2-a]pyridin-2- yl)-N-tert-butyl-3′-fluorobiphenyl-2- sulfonamide


 






582
2-[2′-(tert-Butylsulfamoyl)-3- fluorobiphenyl-4-yl]imidazo[1,2- a]pyridine-6-carboxamide


 






583
2-[2′-(tert-Butylsulfamoyl)-3- fluorobiphenyl-4-yl]imidazo[1,2- a]pyridine-6-carboxamide


 






584
N-tert-Butyl-4′-(5-cyanoimidazo[1,2- a]pyridin-2-yl)-3′-fluorobiphenyl-2- sulfonamide


 






585
N-tert-Butyl-4′-(6-cyanoimidazo[1,2- a]pyridin-2-yl)-3′-fluorobiphenyl-2- sulfonamide


 






586
N-tert-Butyl-3′-fluoro-4′-[6- (trifluoromethyl)imidazo[1,2-a]pyridin- 2-yl]biphenyl-2-sulfonamide


 






587
Ethyl 2-[2′-(tert-butylsulfamoyl)-3- fluorobiphenyl-4-yl]imidazo[1,2- a]pyridine-5-carboxylate


 






588
N-tert-Butyl-3-fluoro-4′-(5- methoxyimidazo[1,2-a]pyridin-2- yl)biphenyl-2-sulfonamide


 






589
5-[2′-(Methylsulfonyl)biphenyl-4- yl]pyrazin-2-amine.


 






590
5-[3-Methyl-2′- (methylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine.


 






591
4′-(5-Aminopyrazin-2-yl)-N,N,3′- trimethylbiphenyl-2-sulfonamide.


 






592
4′-(5-Aminopyrazin-2-yl)-3′- hydroxybiphenyl-2-sulfonamide.


 






593
n-[4′-(5-Aminopyrazin-2-yl)biphenyl- 2-yl]methanesulfonamide.


 






594
4′-(5-Aminopyrazin-2-yl)biphenyl-2- sulfonamide.


 






595
N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3- dihydro-1H-indol-5-yl)biphenyl-2- sulfonamide.


 






596
N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl)-3′- fluorobiphenyl-2-sulfonamide.


 






597
4′-(3-Amino-1H-indazol-5-yl)-N-tert- butyl-3′-fluorobiphenyl-2- sulfonamide.


 






598
3-Amino-6-[2′-(tert-butylsulfamoyl)-3- fluorobiphenyl-4-yl]pyrazine-2- carboxylic acid.


 






599
2-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]sulfonyl}acetamide.


 






600
2-{4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-N,N- diethylacetamide.


 






601
5-{3-Fluoro-2′-[(2-morpholin-4-yl-2- oxoethyl)sulfonyl]biphenyl-4- yl}pyrimidin-2-amine.


 






602
5,5′-(3,3′-Difluoro-1,1′:2′,1′′- terphenyl-4,4′′-diyl)dipyrazin-2- amine.


 






603
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2-carboxylic acid.


 






604
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4- (trifluoromethyl)biphenyl-2- carbaldehyde.


 






605
5-[3-Fluoro-2′-(morpholin-4-ylmethyl)- 4′-(trifluoromethyl)biphenyl-4- yl]pyrazin-2-amine.


 






606
5-{2′-[(4-Aminopiperidin-1-yl)methyl]- 3-fluoro-4′-(trifluoromethyl)biphenyl- 4-yl}pyrazin-2-amine.


 






607
2-({[4′-(5-Aminopyrazin-2-yl)-3′- fluoro-4-(trifluoromethyl)biphenyl-2- yl]methyl}amino)ethanol.


 






608
5-{2′-[(4,6-Dimethylpyrimidin-2- yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine.


 






609
5-{2′-[(4,6-Dimethylpyrimidin-2- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine.


 






610
5-(3-Fluoro-2′-{(2- (trifluoromethyl)pyridin-4- yl]oxy}biphenyl-4-yl)pyrazin-2-amine.


 






611
5-(3-Fluore-2′-{[2- (trifluoromethyl)pyridin-4- yl)oxy}biphenyl-4-yl)pyrimidin-2- amine.


 






612
5-(3-Fluoro-2′-{[4- (trifluoromethyl)pyrimidin-2- yl]oxy}biphenyl-4-yl)pyrazin-2-amine.


 






613
5-(3-Fluoro-2′-{[4- (trifluoromethyl)pyrimidin-2- yl]oxy}biphenyl-4-yl)pyrimidin-2- amine.


 






614
2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyrimidin-5- amine.


 






615
5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3- fluorobiphenyl-4-yl}pyrimidin-2- amine.


 






616
2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}-6- methylpyrimidin-4-amine.


 






617
5-{2′-[(4-Amino-6-methylpyrimidin-2- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine.


 






618
6-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile.


 






619
6-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-2- carbonitrile.


 






620
5-{2′-[(5-Aminopyridin-2-yl)oxy]-3- fluorobiphenyl-4-yl}pyrazin-2-amine.


 






621
5-{2′-[(5-Aminopyridin-2-yl)oxy]-3- fluorobiphenyl-4-yl}pyrimidin-2- amine.


 






622
5-{2′-[(6-Amino-2-methylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine.


 






623
6-{[4′-(5-Aminopyrazin-2-yl)-(3′ fluorobiphenyl-2-yl]oxy}-2- methylpyrimidin4-amine.


 






624
5-(3-Fluoro-2′-{[6- (trifluoromethyl)pyridin-2- yl]oxy}biphenyl-4-yl)pyrimidin-2- amine.


 






625
5-(3-Fluoro-2′-{[6- (trifluoromethyl)pyridin-2- yl]oxy}biphenyl-4-yl)pyrazin-2-amine.


 






626
6-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile.


 






627
6-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}pyridine-3- carbonitrile.


 






628
2-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}ethanol.


 






629
2-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}ethanol.


 






630
5-[3-Fluoro-2′-(piperidin-4- yloxy)biphenyl-4-yl]pyrazin-2-amine.


 






631
5-[3-fluoro-2′-(piperidin-4- yloxy)biphenyl-4-yl]pyrimidin-2- amine.


 






632
5-{3-Fluoro-2′-[(3R)-piperidin-3- yloxy]biphenyl-4-yl}pyrazin-2-amine


 






633
5-{3-Fluoro-2′-[(3R)-piperidin-3- yloxy]biphenyl-4-yl}pyrimidin-2- amine.


 






634
5-{3-Fluoro-2′-[(3S)-piperidin-3- yloxy]biphenyl-4-yl}pyrazin-2-amine.


 






635
5-{3-Fluoro-2′-[(3S)-piperidin-3- yloxy]biphenyl-4-yl}pyrimidin-2- amine.


 






636
5-{2′-[(6-Cyclopropylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin- 2-amine.


 






637
5-{2′-[(6-Cyclopropylpyrimidin-4- yl)oxy]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine.


 






638
5-{2′-[(2-Aminopyridin-4-yl)oxy]-3- fluorobiphenyl-4-yl}pyrazin-2-amine.


 






639
5-{2′-[(2-Aminopyridin-4-yl)oxy]-3- fluorobiphenyl-4-yl}pyrimidin-2- amine.


 






640
5-[2′-(2-Aminoethoxy)-3- fluorobiphenyl-4-yl]pyrazin-2-amine.


 






641
5-[2′-(2-Aminoethoxy)-3- fluorobiphenyl-4-yl]pyrimidin-2- amine.


 






642
{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}acetonitrile.


 






643
{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}acetonitrile.


 






644
{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}acetic acid.


 






645
5-{2-Fluoro-4-[2-(piperidin-4- yloxy)pyridin-3-ylphenyl}pyrazin-2- amine.


 






646
5-{2-Fluoro-4-[2-(piperidin-4- yloxy)pyridin-3-yl]phenyl}pyrimidin-2- amine.


 






647
5-(4-{2-[(1,1-Dioxidotetrahydro-2H- thiopyran4-yl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine.


 






648
5-(4-{2-[(1,1-Dioxidotetranydro-2H- thiopyran-4-yl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine.


 






649
2-({3-[4-(2-Aminopyrimidin-5-yl)-3- fluorophenyl]pyridin-2-yl}oxy)ethanol.


 






650
2-({3-[4-(5-Aminopyrazin-2-yl)-3- fluorophenyl]pyridin-2-yl}oxy)ethanol.


 






651
5-(4-{2-[(trans-4- Aminocyclohexyl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine.


 






652
5-(4-{2-[(trans-4- Aminocyclohexyl)oxy]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine formic acid salt


 






653
5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-yloxy)pyridin-3- yl]phenyl}pyrazin-2-amine.


 






654
5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-yloxy)pyridin-3- yl]phenyl}pyrimidin-2-amine


 






655
(2R)-2-({3-[4-(5-Aminopyrazin-2-yl)- 3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol.


 






656
(2R)-2-({3-[4-(2-Aminopyrimidin-5-yl- 3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol.


 






657
(2S)-2-({3-[4-(5-Aminopyrazin-2-yl)- 3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol.


 






658
(2I)-2-({3-[4-(2-Aminopyrimidin-5-yl)- 3-fluorophenyl]pyridin-2- yl}oxy)propan-1-ol


 






659
N-(4′-(6-Aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2- yl)methanesulfonamide


 






660
5-(3-Fluoro-2′-(morpholinosulfonyl)- [1,1′-biphenyl]-4-yl)pyridin-2-amine


 






661
4′-(6.-Aminopyridin-3-yl)-3′-fluoro-N- methyl-[1,1′-biphenyl]-2-sulfonamide


 






662
4′-(6-Aminopyridin-3-yl)-3′-fluoro- [1,1′-biphenyl]-2-sulforiamide trifluoroacetate


 






663
5-(2′-((1S,4S)-2-Oxa-5- azabicyclo[2.2.1]heptan-5-ylsulfonyl)- 3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2- amine


 






664
4′-(6-Aminopyrazin-2-yl)-3′-fluoro-N- ((3-hydroxyazetidin-3-yl)methyl)-[1,1′- biphenyl]-2-sulfonamide


 






665
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N- (1-hydroxy-2-methylpropan-2-yl)- [1,1′-biphenyl]-2-sulfonamide


 






666
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N- ((1S,2S)-1-hydroxy-1-phenylpropan- 2-yl)-N-methyl-[1,1′-biphenyl]-2- sulfonamide


 






667
4′-(6-Amino-5-fluoropyridin-3-yl)-3′- fluoro-N-(1-hydroxy-2-methylpropan- 2-yl)-[1,1′-biphenyl]-2-sulfonamide


 






668
(racemic)-1-((4′-(6-Amino-5- fluoropyridin-3-yl)-3′-fluoro-[1,1′- biphenyl]-2-yl)sulfonyl)piperidin-3-ol


 






669
4′-(6-Amino-5-fluoropyridin-3-yl)-3′- fluoro-N-((1S,2S)-1-hydroxy-1- phenylpropan-2-yl)-N-methyl-[1,1′- biphenyl]-2-sulfonamide


 






670
N-(1-((4′-(6-Amino-5-fluoropyridin-3- yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidin-4-yl)acetamide


 






671
racemic 2-(1-((4′-(6-Amino-5- fluoropyridin-3-yl)-3′-fluoro-[1,1′- biphenyl]-2-yl)sulfonyl)piperidin-3- yl)ethanol.


 






672
racemic 1-(4′-(6-Amino-5- fluoropyridin-3-yl)-3′-fluoro-[1,1′- biphenyl]-2-yl)sulfonyl)piperidin-3- yl)methanol.


 






673
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-[(2R)-2- hydroxypropyl]benzenesulfonamide.


 






674
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-ethyl-5- (trifluoromethyl)benzenesulfonamide.


 






675
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-tert- butylbenzenesulfonamide.


 






676
5-{5-[2-(Morpholin-4-ylmethyl)-4- (trifluoromethyl)phenyl]pyridin-2- yl}pyrimidin-2-amine.


 






677
5-{5-[2-(Morpholin-4- ylcarbonyl)phenyl]pyridin-2- yl}pyrimidin-2-amine.


 






678
5-[5-(2-Methoxyphenyl)pyridin-2- yl]pyrimidin-2-amine.


 






679
5-(5-{2-[(3,3Difluoropiperidin-1- yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt.


 






680
5-(5-{2-[(3,3-Difluoropyrrolidin-1- yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt.


 






681
5-{5-[2-(Azepan-1- ylsulfonyl)phenyl]pyridin-2- yl}pyrimidin-2-amine trifluoroacetic acid salt.


 






682
5-(5-{2-[(4,4-Difluoropiperidin-1- yl)sulfonyl]phenyl}pyridin-2- yl)pyrimidin-2-amine trifluoroacetic acid salt.


 






683
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-ethylbenzenesulfonamide trifluoroacetic acid salt.


 






684
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N- (dicyclopropylmethyl)benzene- sulfonamide  trifluoroacetic acid salt.


 






685
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(1S)-2,2,2-trifluoro-1- methylethyl]benzenesulfonamide trifluoroacetic acid salt.


 






686
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(1R)-2,2,2-trifluoro-1- methylethyl]benzenesulfonamide trifluoroacetic acid salt.


 






687
4-({2-[6-(2-Aminopyrimidin-5- yl)pyridin-3- yl]phenyl}sulfonyl)piperazin-2-one.


 






688
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(2S)-2- hydroxypropyl]benzenesulfonamide.


 






689
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(2R)-2- hydroxypropyl]benzenesulfonamide.


 






690
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-(2-hydroxyethyl)-5- (trifluoromethyl)benzenesulfonamide.


 






691
5-{5-[2- (Cyclopropylsulfonyl)phenyl]pyridin- 2yl}pyrimidin-2-amine trifluoroacetic acid salt.


 






692
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-ethyl-5- (trifluoromethyl)benzenesulfonamide trifluoroacetic acid salt.


 






693
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-tert-butylbenzenesulfonamide.


 






694
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3- yl]-N-[(1R)-2-hydroxy-1- methylethyl]benzenesulfonamide.


 






695
3-Amino-6-{2′-[(4-aminopyrimidin-2- yl)oxy]-3-fluorobiphenyl-4- yl}pyrazine-2-carbonitrile trifluoroacetic acid salt.


 






696
5-(4′-Bromo-2′,3-difluoroblphenyl-4- yl)pyrazin-2-amine.


 






697
5-(4′-Bromo-2′,3-difluorobiphenyl-4- yl)-1H-pyrrolo[2,3-b]pyridine.


 






698
5-(3-fluoro-2-methoxy-4′- (trifluoromethyl)-[1,1′-biphenyl]-4- yl)pyrazin-2-amine.


 






699
5-(2′,3,4′-Trifluorobiphenyl-4- yl)pyrazin-2-amine


 






700
racemic 5-[3-Fluoro-2′- (methylsulfinyl)biphenyl-4-yl]pyrazin- 2-amine


 






701
4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-carbonitrile


 






702
1-(4′-(5-Aminopyrazin-2-yl)- 3′-fluoro-[1,1′-biphenyl]-2- yl)imidazolidin-2-one


 






703
4′-(2-Amino-4- cyanopyrimidin-5-yl)-N-tert-butyl-3′- fluorobiphanyl-2-sulfonamide


 






704
6-Amino-3-{2′-[(1,1- dioxidothiomorpholin-4-yl)sulfonyl]-3- fluorobiphenyl4-yl}pyrazine-2- carbonitrile


 






705
1-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N- methylazetidine-3-carboxamide


 






706
4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-(2- hydroxyethyl)biphenyl-2-sulfonamide


 






707
4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-[(2S)-2- hydroxypropyl]biphenyl-2- sulfonamide


 






708
4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-[(2R)-2- hydroxypropyl]biphenyl-2- sulfonamide


 






709
1-((4′-(2-Aminopyrimidin-5- yl)-3′-fluoro-[1,1′-biphenyl]-2- yl)sulfonyl)piperidine-4-carboxamide


 






710
4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluora-N-[(1R)-2-hydroxy-1- methylethyl]piphenyl-2-sulfonamide


 






711
4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1- methylethypiphenyl-2-sulfonamide


 






712
4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4- (trifluoromethyl)biphenyl-2- sulfonamide


 






713
4′-(5-Amino-3-cyanopyrazin- 2-yl)-N-ethyl-3′-fluoro-4- (trifluoromethyl)-[1,1′-biphenyl]-2- sulfonamide


 






714
4′-(5-Amino-3-cyanopyrazin- 2-yl)-3′-fluoro-N-(3-hydroxy-2,2- dimethylpropyl)biphenyl-2- sulfonamide


 






715
6-Amino-3-{3-fluoro-2′-[(3- oxopiperazin-1-yl)sulfonyl]-4′- (trifluoromethyl)biphenyl-4- yl}pyrazine-2-carbonitrile


 






716
N-(2-{[4′-(2-Aminopyrimidin- 5-yl)-3′-fluorobiphenyl-2- yl]sulfonyl}ethyl)benzamide


 






717
1-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl)- 3,3-dimethylbutan-2-one


 






718
5-[3-Fluoro-2′-(pyrimidin-2- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine


 






719
5-[3-Fluoro-2′-(pyrazin-2- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine


 






720
5-[3-Fluoro-2′-(pyrimidin-4- ylsulfonyl)biphenyl-4-yl]pyrimidin-2- amine


 






721
5-{2′-[(6-Aminopyrimidin-4- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine


 






722
5-{2′-[(4-Aminopyrimidin-2- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine


 






723
5-{2′-[(5-Aminopyrazin-2- yl)sulfonyl]-3-fluorobiphenyl-4′- yl}pyrimidin-2-amine


 






724
4-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-2-amine


 






725
5-{2′-[(6-Aminopyrazin-2- yl)sulfonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine


 






726
6-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-4-amine


 






727
2.-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}pyrimidin-4-amine


 






728
5-{2′- [(Cyclopropylmethyl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrimidin-2-amine


 






729
6-Amino-3-[2′- (cyclopropylsulfonyl)-3- fluorobiphenyl-4-yl]pyrazine-2- carbonitrile


 






730
1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarbonitrile


 






731
1-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarboxamide


 






732
2-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanenitrile


 






733
2-{[4′-(2-Aminopyridin-5- yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanamide


 






734
5--{2′-[(2-Amino-1,1- dimethylethyl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrimidin-2-amine


 






735
2-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanenitrile


 






736
2-{[4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2-yl]sulfonyl}-2- methylpropanamide


 






737
5-{2′-[(2-Amino-1,1- dimethylethyl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrazin-2-amine


 






738
1-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarbonitrile


 






739
1-{[4′-(2-Aminopyrimidin-5- yl)-3′-fluorobiphenyl-2- yl]sulfonyl}cyclopentanecarboxamide


 






740
5-(2′-{[1- (Aminomethyl)cyclopentyl]sulfonyl}- 3-fluorobiphenyl-4-yl)pyrimidin-2- amine


 






741
5-{[4′-(5-Aminopyrazin-2′-yl)-3′- fluorobiphenyl-2-yl]sulfanyl}pyrazin- 2-amine


 






742
5-{2′-[(6-Aminopyrazin-2- yl)sulfanyl]-fluorobiphenyl-4- yl}pyrazin-2-amine


 






743
5-(3-Fluoro-2′-(pyrimidin-4- ylthio)-[1,1′-biphenyl]-4-yl)pyrazin-2- amine


 






744
5-{2′-[(5-Aminopyrazin-2- yl)sulfanyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine


 






745
6-Amino-3-{2′-[(4-aminopyrimidin-2- yl)oxy]-3-fluorobiphenyl-4- yl}pyrazine-2-carbanitrile


 






746
6-Amino-3-[3-fluoro-2′-(pyrimidin-2- yloxy)-4′-(trifluoramethyl)biphenyl-4- yl]pyrazine-2-carbonitrile


 






747
6-Amino-3-[3-fluoro-2′- (pyrimidin-2-yloxy)biphenyl-4- yl]pyrazine-2-carbonitrile


 






748
N-(tert-Butyl)-3′-fluoro-4′-(5- (methylsulfonamido)pyrazin-2-yl)- [1,1′-biphenyl]-2-sulfonamide


 






749
5-{2′-[(Ethylsulfonyl)methyl]-3- fluorobiphenyl-4-yl}pyrazin-2-amine hydrogen chloride salt


 






750
5-{3-Fluoro-2′- [(methylsulfonyl)methyl]biphenyl-4- yl}pyrazin-2-amine


 






751
5-(3-Fluoro-2′-{[(1- methylethyl)sulfonyl]methyl}biphenyl- 4-yl)pyrazin-2-amine


 






752
5-{3-Fluoro-2′-(pyrimidin-2- ylsulfonyl)methyl]biphenyl-4- yl}pyrazin-2-amine


 






753
2-({(4′-(5-Aminopyrazin-2-yl)- 3′-fluorobiphenyl-2- yl]methyl}sulfanyl)pyrimidin-4-amine


 






754
racemic 5-(3-Fluoro-2′-{[2- {trifluoromethyl)morpholin-4- yl]carbonyl}biphenyl-4-yl)pyrazin-2- amine


 






755
1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]carbonyl}azetidin- 3-ol


 






756
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (tetrahydro-2H-pyran-4-yl)biphenyl-2- carboxamide


 






757
5-{2′-[(1,1-Dioxidothiomorpholin-4- yl)carbonyl]-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl}pyrazin- 2-amine


 






758
1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl)morpholin-2-yl)ethanol (diastereomeric mixture).


 






759
1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture).


 






760
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N- (2-hydroxyethyl)biphenyl-2- carboxamide


 






761
4′-(2-4minopyrimidin-5-yl)-3′-fluoro- N-(2-hydroxyethyl)biphenyl-2- carboxamide


 






762
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol


 






763
(cis/trans) 4′-(5-Aminopyrazin-2-yl)- 3′-fluoro-N-(4- hydroxycyclohexyl)biphenyl-2- carboxamide


 






764
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol


 






765
(cis/trans) 4′-(2-Aminopyrimidin-5-yl)- 3′-fluoro-N-(4- hydroxycyclohexyl)biphenyl-2- carboxamide


 






766
racemic 5-(3-Fluoro-2′-{[2- (trifluoromethyl)morpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2- amine


 






767
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol


 






768
(3S)-1-{[4-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}piperidin-3-ol


 






769
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol


 






770
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)- 3′-fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol


 






771
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol


 






772
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]carbonyl}pyrrolidin-3-ol


 






773
5-{2′-[(2,6-Dimethylmorpholin-4- yl)carbonyl]-3-fluorobiphenyl-4- yl)pyrazin-2-amine (diastereoisomeric mixture).


 






774
5-(3-Fluoro-2′-{[(3S)-3- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrazin-2- amine


 






775
5-(3-Fluoro-2′-{[(3R)-3- methylmorpholin-4- yl]carbonyl}biphenyyl-4-yl)pyrazin-2- amine


 






776
5-(3-Fluoro-2′-{[(2S)-2- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrazin-2- amine


 






777
5-(3-Fluoro-2′-{[(2S)-2- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2- amine


 






778
5-(3-Fluoro-2′-{[(3S)-3- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2′- amine


 






779
5-(3-Fluoro-2′-{[(3R)-3- methylmorpholin-4- yl]carbonyl}biphenyl-4-yl)pyrimidin-2- amine


 






780
5-{2′-[(2,6-Dimethylmorpholin-4- yl)carbonyl]-3-fluorobiphenyl-4- yl}pyrimidin-2-amine (diastereoisomeric mixture)


 






781
5-{2-Fluoro-4-[2-(morpholin-4- ylcarbonyl)pyridin-3-yl]phenyl]-1H- pyrrolo[2,3-b]pyridine


 






782
5-{2-Fluoro-4-[2-(morpholin-4- ylcarbonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine


 






783
5-{2-Fluoro-4-[2-(morpholin-4- ylcarbonyl)pyridin-3- yl]phenyl}pyrazin-2-amine


 






784
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-N-tert-butyl-5- (trifluoromethyl)benzamide


 






785
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-N-[(1R)-2-hydroxy-1-methyl- ethyl]-5-(trifluoromethyl)benzamide


 






786
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-N-[(1S)-2-hydroxy-1-methyl- ethyl]-5-(trifluoromethyl)benzamide


 






787
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-5-(trifluoromethyl)-N-[(1R)- 2,2,2-trifluoro-1-methyl- ethyl]enzamide


 






788
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro- phenyl]-5-(trifuoromethyl)-N-[(1S)- 2,2,2-trifluoro-1-methyl- ethyl]enzamide


 






789
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro- phenyl]-5-(trifluoromethyl)-N-(1R)- 2,2,2-trifluoro-1-methyl- ethyl)benzamide


 






790
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-5-(trifiuoromethyl)-N-[(1S)- 2,2,2-trifluoro-1-methyl- ethyl]benzamide


 






791
[2-[4-(2-Aminopyrimidin-5-yl)-3- fluoro-phenyl]phenyl]-(3- hydroxyazetidin-1-yl)methanone


 






792
[2-[4-(2-Aminopyrimidin-5-yl)-3- fluoro-phenyl]phenyl]-[4- (methylamino)-1-piperidyl]methanone


 






793
[2-[4-(2-Aminopyrimidin-5-yl)-3- fluoro-phenyl]-5- (trifluoromethyl)phenyl]-(1,1-dioxo- 1,4-thiazinan-4-yl)methanone


 






794
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro- phenyl]-N-tert-butyl-5- (trifluoromethyl)benzamide


 






795
[2-[4-(5-Aminopyrazin-2-yl)-3-fluoro- phenyl]-5-(trifluoromethyl)phenyl]-(4- hydroxy-1-piperidyl)methanone


 






796
[2-[4-(2-Aminopyrimidin-5-yl)-3- fluoro-phenyl]-5- (trifluoromethyl)phenyl]-(4-hydroxy-1- piperidyl)methanone


 






797
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro- phenyl]-N-tetrahydropyran-4-yl- benzamide


 






798
racemic [2-]4-(5-Aminopyrazin-2-yl)- 3-fluoro-phenyl]phenyl]-[2- (hydroxymethyl)morpholin-4- yl]methanone


 






799
racemic [2-[4-(2-Aminopyrimidin-5- yl)-3-fluoro-phenyl]phenyl]-2- (hydroxymethyl)morpholin-4- yl]methanone


 






800
N-[3-[4-(2-Aminopyrimidin-5-yl)-3- fluorophenyl]pyridin-2-yl}-2,2- dimethylpropanamide


 






801
N-{3-[4-(5-Aminopyrazin-2-yl)-3- fluorophenyl]pyridin-2-yl}-2,2- dimethylpropanamide


 






802
N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3- b]pyridin-5-yl)phenyl]pyridin-2-yl}-2,2- dimethylpropanamide


 






803
racemic 5-(2-Fluoro-4-(2- (pyrrolidin-3-ylsulfonyl)pyridin-3- yl)phenyl)pyrazin-2-amine hydrochloride


 






804
5-(2-Fluoro-4-(2- (pyrrolidin-3- ylsulfonyl)pyridin-3- yl)phenyl)pyrimidin-2-amine formic acid salt.


 






805
5-(4-(2- (Cyclobutylsulfonyl)pyridin-3- yl)-2-fluorophenyl)pyrimidin- 2-amine hydrochloride.


 






806
5-(4-(2- (Cyclobutylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine hydrochloride


 






807
5-(4-(2- (Cyclohexylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidin-2-amine hydrochloride


 






808
5-(4-(2- (Cyclohexylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine hydrochloride


 






809
5-(4-2- (Cyclopentylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidine-2-amine hydrochloride


 






810
5-(4-(2- (Cyclopentylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine hydrochloride


 






811
5-(4-(2-(tert- Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidin-2-amine formic acid salt.


 






812
5-(4-(2-(tert- Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine formic acid salt.


 






813
racemic 5-(4-(2-(sec- Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrimidin-2-amine formate


 






814
racemic 5-(4-(2-(sec- Butylsulfonyl)pyridin-3-yl)-2- fluorophenyl)pyrazin-2-amine formate


 






815
1-((3-(4-(2-Aminopyrimidin-5- yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)piperidin-1-yl)ethanone


 






816
1-((3-(4-(2-Aminopyrazin-5- yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)piperidin-1-yl)ethanone hydrogen chloride salt


 






817
5-(2-Fluoro-4-(2-((3- methoxypropyl)sulfonyl)pyridine-3- yl)phenyl)pyrimidin-2-amine hydrogen chloride salt.


 






818
5-(2-Fluoro-4-(2-((3- methoxypropyl)sulfonyl)pyridine-3- yl)phenyl)pyrazin-2-amine hydrogen chloride salt.


 






819
4-((3-(4-(2-aminopyrimidin-5- yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide


 






820
4-((3-(4-(2-Aminopyrazin-5- yl)-3-fluorophenyl)pyridine-2- yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide


 






821
5-(2-Fluoro-4-(2-((2- morpholinoethyl)sulfonyl)pyridine- 3-yl)phenyl)pyrimidin-2- amine formic acid salt.


 






822
5-(2-Fluoro-4-(2-((2- morpholinoethyl)sulfonyl)pyridine-3- yl)phenyl)pyrazin-2-amine


 






823
5-(2-Fluoro-4-(2- (((tetrahydro-2H-pyran-4- yl)methyl)sulfonyl)pyridine-3- yl)pyrimidin-2-amine formic acid salt.


 






824
5-(2-Fluoro-4-(2- (((tetrahydro-2H-pyran-4- yl)methyl)sulfonyl)pyridine-3- yl)pyrazin-2-amine formic acid salt.


 






825
5-(2-Fluoro-4-{2-[(1- methylethyl)sulfonyl]pyridin-3- yl}phenyl)pyrimidin-2-amine


 






826
5-(2-Fluoro-4-(2- (isopropylsulfonyl)pyridine-3- yl)phenyl)-1H-pyrrolo[2,3-b]pyridine


 






827
5-{2-Fluoro-4-[2-(piperidin-4- ylsulfonyl)pyridin-3- yl]phenyl)pyrimidin-2-amine formic acid salt.


 






828
5-{4-[2-(Cyclopropylsulfonyl)pyridin- 3-yl]-2-fluorophenyl}pyrimidin-2- amine formic acid salt.


 






829
5-{4-[2-(Cyclopropylsulfonyl)pyridin- 3-yl]-2-fluorophenyl}pyrazin-2-amine formic acid salt.


 






830
5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-ylsulfonyl)pyridin-3- yl]phenyl}pyrazin-2-amine hydrochloride


 






831
5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-ylsulfonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine formic acid salt.


 






832
5-{2-Fluoro-4-[2-(piperidin-4- ylsulfonyl)pyridin-3-yl]phenyl}pyrazin- 2-amine hydrochloride


 






833
5-(2,3-Difluorobiphenyl-4-yl)pyrazin- 2-amine.


 






834 
5-(3-Fluoro-2-methoxybiphenyl-4- yl)pyrazin-2-amine.


 






835
5-[3-Fluoro-2-methoxy-2′- (methylsulfonyl)biphenyl-4-yl]pyrazin- 2-amine.


 






836
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl- 3′-fluoro-2′-methoxybiphenyl-2- sulfonamide.


 






837
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 2′-methoxybiphenyl-2- yl]methanesulfonamide.


 






838
5-(3-fluoro-2′-(pyrazin-2-yl-[1,1′- biphenyl]-4-yl)pyrazin-2-amine


 






839
5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4- yl)pyrimidin-2-amine.


 






840
5,5′-(3′-Fluorobiphenyl-2,4′- diyl)dipyrazin-2-amine.


 






841
5-[2′-(5-Aminopyrazin-2-yl)-3- fluorobiphenyl-4-yl]pyrimidin-2- amine.


 






842
5-[2′-(6-Aminopyrazin-2-yl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine.


 






843
5-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrimidin-2- amine.


 






844
5-5′-(3′-Fluorobiphenyl-2,4′- diyl)dipyrimidin-2-amine.


 






845
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 5-(trifluoromethyl)biphenyl-2- yl]pyrimidin-2-amine.


 






846
5-[3-Fluoro-2′-(2-methoxypyrimidin-5- yl)biphenyl-4-yl]pyrazin-2-amine.


 






847
5-[3-Fluoro-2′-(1-methyl-1H-pyrazol- 4,yl)biphenyl-4-yl]pyrazin-2-amine.


 






848
5-(3-Fluoro-2′-pyrimidin-5-ylbiphenyl- 4-yl)pyrazin-2-amine.


 






849
5-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrimidine-2- carbonitrile.


 






850
5-[3-Fluoro-2′-(2-morpholin-4- ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin- 2-amine.


 






851
1-{4-[4-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl)-1H-pyrazol-1-yl}- 2-methylpropan-2-ol.


 






852
5-[3-Fluoro-2′-(1,2,3,6- tetrahydropyridin-4-yl)-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine.


 






853
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro- 4-(trifluoromethyl)biphenyl-2- yl]pyrimidin-2-amine.


 






854
5-{2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]phenyl}pyrimidin-2- amine.


 






855
5-{5-[2-(2-Aminopyrimidin-5- yl)phenyl]pyridin-2-yl}pyrimidin-2- amine.


 






856
5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)- 3-fluorobiphenyl-4-yl]pyrazin-2-amine


 






857
5-[2′-(1,1-Dioxido-1,2-thiazinan-2-yl)- 3-fluorobiphenyl-4-yl]pyrazin-2-amine


 






858
5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)- 3-fluorobiphenyl-4-yl]pyrimidin-2- amine


 






859
5-[2-Fluoro-4-(2-pyrrolidin-1- ylpyridin-3-yl)phenyl]pyrazin-2-amine


 






860
1-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrrolidin-2-one


 






861
5-[2′-(6-Aminopyridin-3-yl)-3- fluorobiphenyl-4-yl]pyrazin-2-amine


 






862
5-[3-Fluoro-2′-(2-piperazin-1- ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin- 2-amine


 






863
6-[4-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyridazin-3-amine


 






864
5-{2′-[1-(2-Aminoethyl)-1H-pyrazol-4- yl]-3-fluorobiphenyl-4-yl]pyrazin-2- amine


 






865
5-[2′-(6-Aminopyridin-3-yl)-3- fluorobiphenyl-4-yl]pyrimidin-2-amine


 






866
5-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]-N- methylpyrimidin-2-amine


 






867
4-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]pyrimidin-2-amine


 






868
4-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]pyrimidin-2-amine


 






869
5-{3-Fluoro-2′-[1-(2-methoxyethyl)- 1H-pyrazol-4-yl]biphenyl-4- yl}pyrazin-2-amine


 






870
5-[3-Fluoro-2′-(1H-pyrazol-4- yl)biphenyl-4-yl]pyrazin-2-amine


 






871
{4-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-1H-pyrazol-1- yl}acetonitrile


 






872
5-[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]-N- methylpyrimidin-2-amine


 






873
5-(3-Fluoro-2′-isothiazol-4-ylbiphenyl- 4-yl)pyrazin-2-amine


 






874
2-{4-[4′-(5-Aminopyrazin-2-yl)-3′- flluoroblphenyl-2-yl-1H-pyrazol-1- yl}ethanol


 






875
{4-[4′-(2-Aminopyrimidin.-5-yl)-3′- fluorobiphenyl-2-yl]-1H-pyrazol- yl}acetonitrile


 






876
5-[3-Fluoro-2′-(1H-pyrazo-4- yl)biphenyl-4-yl]pyrimidin-2-amine


 






877
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-[(1S)-2,2,2- trifluoro-1- methylethyl]penzenesulfonamide as the hydrochloride salt


 






878
5-{5-[2-(Cyclopropylsulfonyl)phenyl]- 3-fluoropyridin-2-yl}pyrimidin-2-amine


 






879
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-[(2S)-2- hydroxypropyl]benzenesulfonamide


 






880
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-[(1S)-2-hydroxy- 1-methylethyl]benzenesulfonamide


 






881
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-a-yl]-N-[(1R)-2-hydroxy- 1-methylethyl]benzenesulfonamide


 






882
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3-yl]-N-(2- hydroxyethyl)benzenesulfonamide.


 






883
2-[6-(2-Aminopyrimidin-5-yl)-5- fluoropyridin-3yl]-N-[(1R)-2,2,2- trifluoro-1- methylethyl]benzenesulfonamide


 






884
5-{2′-[(1,1-Dioxidotetrahydro-2H- thiopyran-4-yl)methoxy]-3- fluorobiphenyl-4-yl}pyrazin-2-amine


 






885
5-{2′-[(1,1-Dioxidotetrahydro-2H- thiopyran-4-yl)oxy]-3-fluorobiphenyl- 4-yl}pyrazin-2-amine


 






886
4-(([4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2- yl]oxy}methyl)benzoic acid


 






887
4-({[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2- yl]oxy}methyl)benzoic acid


 






888
4-{[4′-(5-Aminopyrazin-2-yl)-3′- fluorobiphenyl-2-yl]oxy}benzoic acid


 






889
4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy}benzoic acid


 






890
4-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]oxy)benzamide


 






891
5-{2′-1(trans-4-Aminocyclohexyl)oxy]- 3-fluorobiphenyl-4-yl}pyrazin-2-amine


 






892
5-[2′-Amino-3-fluoro-4′- (trifluoromethyl)biphenyl-4-yl]pyrazin- 2-amine


 






893
5-[2-Fluoro-4-(2-phenylpyridin-3- yl)phenyl]pyrazin-2-amine


 






894
5-[2-Fluoro-4-(2-phenoxypyridin-3- yl)phenyl]pyrazin-2-amine


 






895
5-[2-Fluoro-4-(2-phenoxypyridin-3- yl)phenyl]pyrimidin-2-amine


 






896
5-{2-Fluoro-4-[2-(pyridin-3- yloxy)pyridin-3-yl]phenyl}pyrazin-2- amine


 






897
5-{2-Fluoro-4-[2- (phenylsulfonyl)pyridin-3- yl]phenyl}pyrazin-2-amine


 






898
5-{2-fluoro-4-[2- (phenylsulfonyl)pyridin-3- yl]phenyl}pyrimidin-2-amine


 






899
5-{2-Fluoro-4-[2-(pyridin-3- ylsulfonyl)pyridin-3-yl]phenyl}pyrazin- 2-amine


 






900
5-(2-Fluoro-4-{2-[(1-methylpyrrolidin- 3-yl)sulfonyl]pyridin-3- yl}phenyl)pyrazin-2-amine


 






901
5-(2-Fluoro-4-{2-[(1- methylethyl)sulfonyl]-6- (trifluoromethyl)pyridin-3- yl}phenyl)pyrazin-2-amine


 






902
5-(2-Fluoro-4-{2-[(1- methylethyl)sulfonyl]-6- (trifluoromethyl)pyridin-3- yl}phenyl)pyrimidin-2-amine


 






903
5-(4-{2-[(1-Acetylpiperidin-3- yl)sulfonyl]pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine


 






904
2-[4-({3-[4-(5-Aminopyrazin-2-yl)-3- fluorophenyl]pyridin-2- yl}sulfonyl)pipendin-1-yl]ethanol


 






905
(racemic)-1-[4({3-[4-(5- Aminopyrazin-2-yl)-3- fluorophenyl]pyridin-2- yl}sulfonyl)piperidin-1-yl]propan-2-ol


 






906
5-{2-Fluoro-4-[2-tetrahydro-2H- pyran-4-ylsulfonyl)-6- (trifluoromethyl)pyridin-3- yl]phenyl}pyrazin-2-amine


 






907
5-{2-Fluoro-4-[2-(tetrahydro-2H- pyran-4-ylsulfonyl)-6- (trifluoromethyl)pyridin-3- yl]phenyl}pyrimidin-2-amine


 






908
5-(2-Fluoro-4-(2-{[1- (methylsulfonyl)piperidin-4- yl]sulfonyl}pyridin-3- yl)phenyl]pyrazin-2-amine


 






909
5-(2-Fluoro-4-(2-{[1- (methylsulfonyl)piperidin-4- yl]sulfonyl}pyridin-3- yl)phenyl]pyrimidin-2-amine


 






910
5-(4-{2-[(1-Acetylpiperidin-4- yl)sulfonyl]-6-(trifluoromethyl)pyridin- 3-yl}-2-fluorophenyl)pyrazin-2-amine


 






911
5-(4-{2-[(1-Acetylpiperidin-4- yl)sulfonyl]-6-(trifluoromethyl)pyridin- 3-yl}-2-fluorophenyl)pyrimidin-2- amine


 






912
5-(4-{2-[(1,1-Dioxidotetrahydra-2H- thiopyran-4-yl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}-2- fluorophenyl)pyrazin-2-amine


 






913
5-(4-{2-[(1,1-Dioxidotetrahydro-2H- thiopyran-4-yl)sulfonyl]-6- (trifluoromethyl)pyridin-3-yl}-2- fluorophenyl)pyrimidin-2-amine









C) Synthesis
The invention provides methods of making the disclosed compounds according to traditional organic synthetic methods as well as matrix or combinatorial synthetic methods. Scheme A described suggested synthetic routes. Using the schemes, the guidelines below, and the examples, a person of skill in the art may develop analogous or similar methods for a given compound that is within the invention. These methods are representative of the synthetic schemes, but are not to be construed as limiting the scope of the invention.
Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. Where the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form or as individual enantiomers or diasteromers by either stereospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers or diastereomers by standard techniques, such as the formation of stereoisomeric pairs by salt formation with an optically active base, followed by fractional crystallization and regeneration of the free acid. The compounds may also be resolved by formation of stereoisomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column. It is to be understood that all stereoisomers, racemic and scalemic mixtures, diastereomers, geometric isomers, and enantiomers thereof are encompassed within the scope of the present invention.
Representative compounds of the present invention can be synthesized in accordance with the general synthetic schemes described below and are illustrated more particularly in the specific synthetic examples that follow. The general schemes are offered by way of illustration; the invention should not be construed as being limited by the chemical reactions and conditions expressed. The methods for preparing the various starting materials used in the schemes and examples are well within the skill of persons versed in the art. No attempt has been made to optimize the yields obtained in any of the example reactions. One skilled in the art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.
General: 1H and 13C NMR spectra were measured on a Bruker AC-300 (300 MHz) spectrometer using tetramethylsilane and the deuterated solvent respectively as internal standards. Elemental analyses were obtained by Quantitative Technologies Inc. (Whitehouse, N.J.) and the results were within 0.4% of the calculated values unless otherwise mentioned. Melting points were determined in open capillary tubes with a Mel-Temp II apparatus (Laboratory Devices Inc.) and were uncorrected. Electrospray mass spectra (MS-ESI) were recorded in the positive mode on a Hewlett Packard 59987A spectrometer. High resolution mass spectra (HRMS) were obtained on a Micromass Autospec. E spectrometer by fast atom bombardment (FAB) technique.
Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
Examples of the described synthetic routes include Scheme A-G, Intermediates A-HZ. Examples 1-588 and prophetic Examples 1-247. Compounds analogous to the target compounds of these examples can be made according to similar routes. The disclosed compounds are useful as pharmaceutical agents as described herein.
Abbreviations or acronyms useful herein include:











Abbreviation
Meaning







BOC/boc
tert-butyloxycarbonyl


BOP
benzotriazol-1-yloxy-tris(dimethylamino)phosphonium



hexafluorophosphate


Cpd
compound


DCE
dichloroethane


DCM
dichloromethane


DIPEA
diisopropyl ethyl amine


DMA
N,N-dimethylacetamide


DMAP
N,N-dimethylaminopyridine


DMF
N,N-dimethylformamide


DMSO
dimethyl sulfoxide


DPBS
Dulbecco's phosphate buffered saline


EDC
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide



hydrochloride


ESI
electrospray ionization


Et3N or TEA
triethylamine


EtOAc
ethyl acetate


h/hr/hrs
hour(s)


HATU
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-



b]pyridinium 3-oxid hexafluorophosphate


HOBT
1-hydroxybenzotriazole hydrate


HBTU
O-benzotriazol-1-yloxy-N,N,N′,N′-tetramethyluronium



hexafluorophosphate


I.D.
interior diameter


LG
Leaving group


LiOH
lithium hydroxide


m-CPBA
meta-chloroperoxybenzoic acid


min
minute(s)


MS
mass spectroscopy


NMR
nuclear magnetic resonance spectroscopy


OTf
Triflate


PG
protecting group


RT/rt
room temperature


TBME
tert-butyl methyl ether


THF
tetrahydrofuran


TLC
thin layer chromatography


Tos
p-toluenesulfonyl


dppf
1,1′-Bis(diphenylphosphino)ferrocene









General Guidance Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated more particularly in the schemes that follow. Since the schemes are illustrations, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art. The substituents for compounds of Formula (I) or a form thereof, represented in the schemes below, are as previously defined herein.

Unless otherwise specified, reaction solutions were stirred at room temperature under a N2(g) or Ar(g) atmosphere. When solutions were “concentrated to dryness”, they were concentrated using a rotary evaporator under reduced pressure, when solutions were dried, they are typically dried over a drying agent such as MgSO4 or Na2SO4.
Normal phase flash column chromatography (FCC) was performed on silica gel with RediSep® silica gel columns using ethyl acetate (EtOAc)/hexanes, CH2Cl2/MeOH, CH2Cl2/10% 2 N NH3 in MeOH, CH2Cl2/i-PrOH, and the like as eluent, unless otherwise indicated.
Reverse phase high performance liquid chromatography (HPLC) was performed under the following conditions: 1) Instrument, Shimadzu; Column, Waters XBridge C18 10 μm (250×50 mm), Phenomenex Gemini column 5 μm C18 (150×21.2 mm) or Waters Xterra RP18 OBD 5 μm (100×30 mm); Gradient, 95:5 to 0:100 water (0.05% trifluoroacetic acid (TFA))/CH3CN (0.05% TFA); Flow rate, 30-80 mL/min; Detection, UV at λ=220-254 nM; 2) Instrument, Gilson; Column, Phenomenex LUNA column 5 μm C18 (250×50 mm) or Waters XBridge Prep C18 OBD 5 μm (30×150 mm); Gradient, 95:5 to 0:100 water (0.05% TFA)/CH3CN (0.05% TFA); Flow rate, 30-80 mL/min; Detection, UV at λ=220-254 nM; 3) Instrument. Gilson/Shimadzu: Column, Inertsil ODS-3 column (30×100 mm) or Inertsil ODS-3 (30×50 mm, 5 μm); Gradient, water-acetonitrile with both phases with 0.05% by volume trifluoroacetic acid; 1 min hold at 5% ACN, then 6 min gradient to 99% ACN followed by a hold at that concentration for 3 min. Flow rate, 80 ml/min; heated column at 46° Celsius with detection of UV light at λ=254 nm; and 4) Instrument, Dionex: UVD 170U Diode array detector and ThermoFinnegan Surveyor MSQ plus mass spectrometer for data collection. Waters XBridge C18 5 μm OBD 50×100 mm prep column.
All runs on the Dionex utilized water acetonitrile with 20 mM NH4OH added to the aqueous phase and a flow rate for all gradients was 80 mL/min using four possible gradients: 1) 5-60% MeCN over 12 min, then ramped to 100% MeCN and held for 6.3 min; 2) 30-70% MeCN over 12 min, then ramped to 100% MeCN and held for 6.3 min; 3) 50-80% MeCN over 12 min, then ramped to 100% MeCN and held for 6.3 min; and 4) 60-100% MeCN over 12 min, and then held for 6.3 min. The total run time for all gradient systems was 18.5 min.
Instances where solutions were filtered through a syringe filter, Pall 0.45 μM GHP membrane 13 mm and 25 mm diameter syringe filters were used
Thin-layer chromatography was performed using Merck silica gel 60 F254 2.5 cm×7.5 cm 250 μm or 5.0 cm×10.0 cm 250 m pre-coated silica gel plates. Preparative thin-layer chromatography was performed using EM Science silica gel 60 F254 20 cm×20 cm 0.5 mm pre-coated plates with a 20 cm×4 cm concentrating zone. Microwave reactions were carried out in either a CEM DiscoverTM or a Biotage InitiatorTM or OptimizerTM Microwave at specified temperatures. Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated mass corresponds to the exact mass.
NMR spectra were obtained on either a Bruker model DPX400 (400 MHz), DPX500 (500 MHz), DRX600 (600 MHz) spectrometer. The format of the 1H NMR data below is: chemical shift in ppm down field of the tetramethylsilane reference (multiplicity, coupling constant J in Hz, integration).
Hydrochloride salts were obtained by treating the corresponding free bases with HCl (4 N in dioxane, 2 M in Et2O, or 1.25 N in MeOH) at room temperature with mixtures either concentrated to obtain the HCl salt, or the resulting solid being isolated by filtration. Trifluoroacetic acid salts were obtained by purification of the crude reaction product by preparative reverse phase HPLC, whereby the final products were isolated as either mono-, di- or tri-fluoro acetic acid salts.
Chemical names were generated using ChemDraw Ultra 12.0 (CambridgeSoft Corp., Cambridge, Mass.) or ACD/Name Version 10.01 (Advanced Chemistry).
The compounds of Formula (I), wherein ring A, L, V, W, R, R′, n, R1, R2, R3, and R4 are defined as in Formula (I), may be synthesized as outlined by the general synthetic route illustrated in Scheme A-G.




Referring to Scheme A, compounds of formulae (XI) can be obtained through a series of metal mediated cross coupling reactions starting from compound (XIII). Compounds of formulae (XIV) in which Ar1 can be an amine substituted or des-amino 5-, 6-membered or 5/6- or 6/6-fused aromatic or heteroaromatic nitrogen containing ring system, can be prepared via Pd mediated cross coupling of either an aryl or heteroaryl boronic acid or ester, Ar1—B(OP)2, with intermediates of structure (XIII) in which W is bromo or chloro, Y is an alkyl, hetero-alkyl, aryl, or heteroaryl and Z is H, fluoro, alkyl or heteroalkyl. In instances where W is either bromo or chloro, the boronic acid or ester of compound (XIII) can be formed via palladium catalysis using bis(pinacolato)diboron and KOAc in the presence of [1,1′-bis(diphenylphosphino)ferrocene]-dichloro-palladium(II).CH2Cl2 (Pd(dppf)Cl2.CH2Cl2) or the X-Phos pre-catalyst in solvents such as 1,4-dioxane or DMSO, at temperatures ranging from 0-100° Celsius. Alliteratively, compounds of Formulae (XIII) in which W is B(OP)2 can be cross-coupled with an aryl or heteroaryl halide, Ar1−X where X is either bromo or chloro to obtain compounds of formulae (XII). Preferably, in compounds of formulae (XII), Y is t-butyl, cyclobutyl, trifluoromethoxy, or SF5, Z is H or -fluoro ortho to Ar1, and Ar1 is either amino-pyrazine, amino-pyrimidine, or amino-pyridine alliteratively substituted with or without CN, CH3, OCH3, CF3, Cl, F, OH, and NH2. Preferred solvents for cross coupling reactions include DME, DMSO, 1,4-dioxane, THF, EtOH DMF, water, and toluene or mixtures thereof, in the presence of a base, such as Na2CO3, K2CO3, KOAc, KH2PO4, and K3PO4 using catalysts such as Pd(dppf)Cl2.CH2Cl2, palladium trifluoroacetate and PhP3, chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl)]-palladium(II), 1,1′-bis[di-t-butylphosphino)ferrocene]palladium chloride with temperatures ranging from rt to 100° Celsius.
Compounds of formulae (XI) can be prepared from compounds of formulae (XIII) via sequential (XIII→XIV→XI or XIII→XV→XI) Pd mediated cross-coupling using methods and intermediates, analogous to those described above compounds of formulae (XV) can be obtained via compounds of formulae (XIII), wherein Y is a boronic acid or ester and W is bromo or chloro, Compounds of formulae (XIII) in which Y is the boronic acid or ester can be obtained from the corresponding iodide wherein W is either bromo or chloro. Preferred methods for conversion of the iodo to the corresponding boronic acid or ester are analogous to the methods described above. In some cases, aryl and heteroaryl halides, boronic esters and acids are commercially available or can be prepared by known methods.
Compounds (XIV) in which Y is alkyl or cycloalykyl can be obtained from the corresponding bromide using alkylzinc bromides in solvents such as THF in the presence of palladium acetate and 2-dicyclohexylphosphine-2′,6′-dimethoxy-1,1′-biphenyl at temperatures ranging from rt to 100° Celsius.
In further embodiments, compounds of formulae (XI) containing a pyridine core, where Z is H or -fluoro ortho to Ar1, can be prepared using analogous Pd mediated cross coupling reactions described herein.




Referring to Scheme B, substituted aryl and heteroaryl sulfonamides (XVI) possessing from 0 to 3 G groups, where a G group is alkyl, cycloalkyl, heteroalkyl, CF3, F, Cl, Br, or combinations thereof, and where X is bromo or chloro, can be prepared by addition of various primary and secondary amines to the aryl or heteroaryl sulfonyl chloride in solvents such as CH2Cl2, CH3CN, THF, and DMF in the presences of bases such as pyridine, Et3N and i-Pr2EtNH at temperatures ranging from −20° to 1000 Celsius.
Alliteratively, sulfones (XVI) can be obtained from the corresponding bromo or chloro aryl thiol (XVIII). SN1 substitution in the presence of a strong acid, such as H2SO4, with an appropriately reactive alcohol, such as tert-butanol, provides the desired aryl sulfide. Additionally, one can obtain substituted aryl sulfides via SN2 or SNAr displacement of alkyl or aryl bromide, chloride, and fluorides (aryl only) under basic conditions using bases such as NaH or i-Pr2EtNH and the desired in solvents such as THF, DMSO, and DMF at temperatures ranging from rt to 1000 Celsius. Sulfone (XVI) can then be obtained via oxidation of the sulfide using an appropriate oxidant such as m-CPBA, oxone, or RuCl3/NaIO4.




Referring to Scheme C, sulfonamides of formulae (XIX) can be prepared from an aniline (XX) possessing from 0 to 3 G groups G, where a G group can be a variety of alky, heteroalkyl, F, Cl, Br, CF3, or combinations thereof, and X is bromo, chloro, B(OH)2, or B(OP)2, by treatment with an appropriate sulfonyl chloride on which R is alkyl, cycloalkyl, substituted aryl, substituted heteroaryl or CF3, in a solvent, such as CH2Cl2, in the presence of a base, such as pyridine, at temperatures ranging from 0° to 100° Celsius.




Referring to Scheme D, methanesulfonamides of formulae (XXI) can be prepared by treatment of a substituted (halomethyl)benzene, where X is bromo or chloro and possessing 0 to 3 G groups, which can be a variety of alkyl, cycloalkyl, heteroalkyl, F, Cl, Br, CF3, or combinations thereof, with sodium sulfite to provide the desired arylmethyl sulfonate which can be subsequently treated with phosphorous pentachloride to provide the desired arylmethylsulfonyl chloride (XXIII). Sulfonyl chlorides (XXIII) can then be transformed to the corresponding sulfonamide (XXI) using methods described herein.




Referring to Scheme E, variously substituted amides (XXIV) can be prepared using standard amide coupling reactions. Substituted carboxylic acid (XXV), where X is bromo or chloro, and possessing 0 to 3 G groups, which can be a variety of alkyl, cycloalkyl, heteroalkyl, F, Cl, Br, CF3, or combinations thereof, can be treated with various primary and secondary amines using standard carbodiimide peptide coupling reagents, such as HATU or EDCl, in solvents such as DMF and CH2Cl2, at temperatures ranging from 0-60° Celsius, to provide amide (XXIV).




Referring to Scheme F, phenyl ethers of formulae (XXVI) can be prepared from the corresponding phenol (XXVII), where X is bromo or chloro, and possessing 0 to 3 G groups, which can be a variety of alkyl, cycloalkyl, heteroalkyl, F, Cl, Br, CF3, or combinations thereof, and n=0, 1. Treatment of phenol (XXVII) with appropriately substituted halo aromatic heterocycles, where halo refers to F, Cl, and Br, or halomethyl aromatic heterocycles in which halo refers to Cl or Br, a base, such as Cs2CO3, K2CO3, or Na2CO3, In a polar solvent, such as DMSO, CH3CN, or DMF at temperatures ranging from rt to 100° Celsius, provides ethers (XXVI).




Referring to Scheme G, instances where Ar1 in Scheme A is a 5-, 6-membered, or 5/5-, 5/6-fused heterocyle, compounds of formulae (XXVIII) and (XXX) can be obtained starting from methyl ketone (XXIX). Treatment of the ketone with either urea or thiourea in the presence of I2 in EtOH at temperatures ranging from rt to 80° Celsius results in the corresponding five-membered amino heterocycle (XXVIII). Whereas, treatment of the ketone under analogous conditions with substituted 2-amino pyridines, possessing 0 to 3 G groups, which can be a variety of alkyl, cycloalkyl, heteroalkyl. F, Cl, Br, CF3, or combinations thereof, results in a substituted fused 5/6 heterocycle (XXX).
EXAMPLES
The following examples are offered by way of illustration: the invention should not be construed as being limited by the chemical reactions and conditions expressed.
Intermediate A




Method 1
To a 250 mL round-bottomed flask were added a stirbar, 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (3.07 g, 11.5 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (5.82 g, 22.9 mmol), Pd(dppf)Cl2.CH2Cl2 (512 mg, 0.623 mmol), and KOAc (2.30 g, 23.4 mmol). The flask was then thoroughly sparged with nitrogen and then charged with 1,4-dioxane (114 mL, sparged with N2 for 30 min). The flask was then heated at 80° Celsius for 19.5 hours before cooling to rt, filtering the reaction mixture through Na2SO4 and concentrating the filtrate to dryness. The residue was purified by FCC to give the title compound. MS (ESI): mass calcd. for C16H19BFN3O2, 315.16; m/z found, 316.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.38 (dd, J=2.4, 1.5, 1H), 8.02 (d, J=1.5, 1H), 7.96-7.89 (m, 1H), 7.56 (dd, J=7.7, 1.1, 1H), 7.42 (dd, J=11.8, 1.1, 1H), 6.77 (s, 2H), 1.31 (s, 12H).
Method 2
Step A: 5-(4-Bromo-2-fluorophenyl)pyrazin-2-amine
To a solution of 5-bromopyrazin-2-amine (1.74 g, 10.0 mmol) in 1,4-dioxane (40 mL) were added 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.65 g, 10.5 mmol) and KOAc (1.96 g, 20.0 mmol). The mixture was sparged with N2 several times before adding Pd(dppf)Cl2.CH2Cl2 (0.41 g, 0.5 mmol). The resultant mixture was stirred at 90° Celsius for 60 hours under N2. After cooling to rt, 4-bromo-2-fluoro-1-iodobenzene (4.5 g, 15.0 mmol), K2CO3 (2.76 g, 20.0 mmol) and another portion of Pd(dppf)Cl2.CH2Cl2 (0.41 g, 0.5 mmol) were added. The resultant mixture was sparged with N2 again, and stirred at 80° Celsius for 48 hours under N2. The mixture was then cooled to rt, diluted with THF (30 mL) and filtered. The filtrate was concentrated to dryness and the residue purified by FCC to give 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (0.4 g, 15%). 1H NMR (300 MHz, DMSO-d6) δ 8.33 (s, 1H), 8.01 (s, 1H), 7.82 (m, 1H), 7.63 (dd, J=11.1, 2.1, 1H), 7.50 (dd, J=8.4, 2.1, 1H), 6.75 (s, 2H).
Step B
To a solution of 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (535 mg, 2.0 mmol) in 1,4-dioxane (20 mL) was added 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.1 g, 4.0 mmol) and KOAc (0.39 g, 4.0 mmol). The mixture was sparged by bubbling N2 for 10 min. The mixture was treated with Pd(dppf)Cl2.CH2Cl2 (82 mg, 0.1 mmol) and then stirred at 80° Celsius for 1 hour under N2. After cooling to rt, the reaction mixture was filtered through Na2SO4 and the filtrate concentrated to dryness. The residue was purified by FCC to give the title compound (460 mg, 72%).
Intermediate B




Step A: 6-Amino-3-(4-chloro-2-fluorophenyl)pyrazine-2-carbonitrile
To a 200 mL round-bottomed flask were added a stirbar, 5-amino-3-cyano-2-bromopyrazine (4.09 g, 20.5 mmol), 4-chloro-2-fluorophenylboronic acid (3.90 g, 22.4 mmol), Pd(dppf)Cl2.CH2Cl2 (839 mg, 1.03 mmol) and K2CO3 (8.36 g, 60.5 mmol). The flask was flushed with nitrogen and then charged with toluene (17.5 mL), water (17.5 mL) and DMF (10.5 mL), all of which were sparged with N2. The flask was heated at 80° Celsius for 19 hours before cooling to rt and adding MgSO4 until the mixture was a thick paste. The reaction mixture was then stirred with EtOAc and filtered through a thick pad of celite. The pad was rinsed with EtOAc until the filtrate was colorless. The filtrate was concentrated to dryness and subjected to FCC to give 6-amino-3-(4-chloro-2-fluorophenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C11H6ClFN4, 248.03; m/z found, 249.0 [M+H]+. 1H NMR (500 MHz, DMSO-d) δ 8.22 (s, 1H), 7.67-7.60 (m, 2H), 7.46 (dd, J=8.4, 2.0, 1H), 7.37 (s, 2H).
Step B
To a 200 mL round-bottomed flask were added a stirbar, 6-amino-3-(4-chloro-2-fluorophenyl)pyrazine-2-carbonitrile (1.175 g, 4.73 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.583 g, 6.23 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (194 mg, 0.247 mmol), and KOAc (1.43 g, 14.6 mmol). The flask was fitted with a septum and sparged with nitrogen for 30 min before adding 48 mL of thoroughly N2 sparged THF via syringe. The mixture was then heated at 80° Celsius for 16.5 hours before cooling the mixture to rt and concentrating to dryness. The dark residue was taken up in DCM, filtered through a plug of celite, and concentrated to dryness. The residue was subjected to FCC to give the title compound. 1H NMR (600 MHz, DMSO-d6) δ 8.23 (s, 1H), 7.66-7.58 (m, 2H), 7.53-7.46 (d, J=10.2, 1H), 7.40 (s, 2H), 1.34 (s, 12H).
Intermediate C




Step A: 4-Bromo-2-fluorobenzoyl chloride
A solution of 4-bromo-2-fluorobenzoic acid (10.8 g, 50.0 mmol) in SOCl2 (50 mL) was stirred at 70° Celsius for 1 hour. After cooling to rt, the resulting mixture was concentrated to give 4-bromo-2-fluorobenzoyl chloride as colorless oil, which was used directly in the next step without purification.
Step B: 2-(4-Bromo-2-fluorobenzoyl)-hydrazinecarbothioamide
Hydrazinecarbothioamide (6.8 g, 75 mmol) was added to a solution of 4-bromo-2-fluorobenzoyl chloride (11.8 g, 50.0 mmol) in THF (50 mL) at rt and stirred for 1 hour. The reaction mixture was concentrated to give 2-(4-bromo-2-fluorobenzoyl)-hydrazinecarbothioamide as a white solid, which was used directly in the next step without purification. MS (ESI): mass calcd. for C8H7BFN3OS, 290.95, m/z found, 292.1 [M+H]+.
Step C: 5-(4-Bromo-2-fluorophenyl)-1,3,4-thiadiazol-2-amine
H2SO4 (2 mL) was added to a solution of 2-(4-bromo-2-fluorobenzoyl)-hydrazinecarbothioamide (2.9 g, 10.0 mmol) in pentanoic acid (5 mL) and the resulting mixture was stirred at 110° Celsius for 2 hours. After cooling to rt, the reaction mixture was poured into ice-water (20 mL) and treated with NH3.H2O (15 mL). 5-(4-Bromo-2-fluorophenyl)-1,3,4-thiadiazol-2-amine was then isolated via vacuum filtration and air dried. MS (ESI): mass calcd. for C8H5BFN3OS, 272.94, m/z found, 274.1 [M+H]+.
Step D
To a solution of 5-(4-bromo-2-fluorophenyl)-1,3,4-thiadiazol-2-amine (2.73 g, 10.0 mmol) in 1,4-dioxane (20 mL) were added 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.54 g, 10.0 mmol) and KOAc (1.5 g, 20.0 mmol). The mixture was sparged with N2 for 10 min. Pd(dppf)Cl2.CH2Cl2 (82 mg, 0.1 mmol) was then added, and the mixture, stirred at 80° Celsius for 1 hour under N2. After cooling to rt, the reaction mixture was filtered through a pad of anhydrous Na2SO4 and the filtrate concentrated to dryness. The residue was purified by FCC to give the title compound. MS (ESI): mass calcd. for C14H17N3BO2SBr 321.11, m/z found 322.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.28-8.19 (m, 1H), 7.65 (dd, J=7.8, 1.0, 1H), 7.57 (d, J=11.3, 1H), 5.39 (s, 2H), 1.36 (s, 12H).
Intermediate D




Step A: 4′-Bromo-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-sulfonamide
1-Bromo-2-fluoro-4-iodobenzene (6.30 g, 20.9 mmol) and (2-(N-methyl-sulfamoyl)-phenyl) boronic acid (4.50 g, 20.9 mmol) were added to a 250 mL flask equipped with a stir bar and reflux condenser. 1,4-Dioxane (50 mL) and Na2CO3 (2 M, 50 mL) were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 minutes before Pd(dppf)Cl2.CH2Cl2 (766 mg, 1.05 mmol) was added and the reaction was stirred at 80° Celsius for 15 hours. The reaction was then diluted with 50 mL of water and extracted with ethyl acetate (1×50 mL, 3×100 mL). The combined organic extracts were dried with Na2CO3, filtered and concentrated to dryness. The crude product was purified by FCC to give 4′-bromo-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-sulfonamide. 1H NMR (500 MHz, CDCl3) δ 8.17-8.11 (m, 1H), 7.66-7.59 (m, 2H), 7.59-7.54 (m, 1H), 7.33-7.29 (m, 1H), 7.28-7.23 (m, 1H), 7.20-7.13 (m, 1H), 3.67-3.56 (dd, J=10.1, 4.5, 1H), 2.46-2.43 (d, J=5.3, 3H).
Step B: 3′-Fluoro-N-methyl-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide
4′-Bromo-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-sulfonamide (2.0 g, 5.8 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.95 g, 11.6 mmol) and anhydrous KOAc (1.71 g, 17.4 mmol) and 1,4-dioxane (50 mL) were added to a flask, equipped with a stir bar and reflux condenser. The reaction mixture was sparged with argon for 10 min, before adding Pd(dppf)Cl2.CH2Cl2 (0.425 g, 0.58 mmol) was added. The flask was heated at 80° Celsius for 15 hours before cooling to rt, diluting with ethyl acetate (50 mL), filtering through Na2SO4 and concentrating to dryness. The crude product was purified by FCC to provide the title compound. 1H NMR (400 MHz, CDCl3) δ 8.19-8.12 (dd, J=7.8, 1.4, 1H), 7.87-7.78 (dd, J=7.6, 6.2, 1H), 7.64-7.59 (dd, J=7.5, 1.5, 1H), 7.58-7.51 (m, 1H), 7.35-7.27 (m, 2H), 7.19-7.11 (dd, J=9.6, 1.5, 1H), 3.57-3.45 (d, J=5.5, 1H), 2.41-2.37 (d, J=5.4, 3H), 1.39 (s, 12H).
Intermediate E




The title compound was prepared in a manner similar to that described for Intermediate D using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid in Step A. 1H NMR (400 MHz, CDCl3) δ 8.17 (dd, J=7.9, 1.4, 1H), 7.81 (dd, J=7.6, 6.2, 1H), 7.62-7.53 (m, 1H), 7.53-7.46 (m, 1H), 7.36-7.30 (m, 1H), 7.29-7.27 (m, 1H), 7.19 (dd, J=9.9, 1.5, 1H), 3.61 (s, 1H), 1.39 (s, 12H), 1.04 (s, 9H).
Intermediate F




The title compound was prepared in a manner similar to that described for Intermediate D using 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide in Step A. 1H NMR (500 MHz, CD3OD) δ 8.09-8.03 (dd, J=8.0, 1.3, 1H), 7.76-7.70 (dd, J=7.6, 6.2, 1H), 7.68-7.62 (m, 1H), 7.61-7.54 (dd, J=8.5, 7.1, 1H), 7.37-7.31 (dd, J=7.5, 1.4, 1H), 7.24-7.20 (dd, J=7.6, 1.5, 1H), 7.16-7.11 (dd, J=10.0, 1.5, 1H), 3.48-3.43 (t, J=5.9, 2H), 2.88-2.82 (t, J=5.9, 2H), 1.37 (s, 12H).
Intermediate G




The title compound was prepared using analogous methods described in Intermediate D using 7-amino-5-bromoindole in Step A. MS (ESI): mass calcd. for C20H22BFN2O2, 352.18; m/z found, 353.3 [M+H]+.
Intermediate H




To a solution of 3-amino-6-bromopyrazine-2-carbonitrile (2.00 g, 9.55 mmol) in 1,4-dioxane (48 mL), were added (4-chloro-2-fluorophenyl)boronic acid (1.66 g, 9.55 mmol) and aqueous Na2CO3 (2 M, 24 mL, 48 mmol) and the reaction mixture sparged with N2 gas for 10 min. Pd(dppf)Cl2.CH2Cl2 (0.349 g, 0.477 mmol) was then added and the reaction mixture sparged for an additional 10 min with N2 gas. The reaction vessel was sealed and heated for 3 hours at 80° Celsius. The mixture was cooled to rt, filtered through celite, and the filter cake washed with EtOAc (300 mL). The filtrate was washed with a 1:1 mixture of brine/H2O (2×100 mL). The organic phase was concentrated to dryness and subjected to FCC to give the title compound (1.99 g, 84%). MS (ESI): mass calcd. for C11H6ClFN4, 248.03; m/z found 249.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.67 (d, J=2.0, 1H), 7.83 (m, 1H), 7.25-7.08 (m, 2H), 5.36 (s, 2H).
Intermediate I




To a solution of 3-amino-6-(4-chloro-2-fluorophenyl)pyrazine-2-carbonitrile (0.290 g, 1.17 mmol) in 1,4-dioxane (12 mL), were added (4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (0.370 g, 1.46 mmol) and KOAc (0.343 g, 3.50 mmol). The reaction mixture sparged with N2 gas for 10 min, before adding chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (18 mg, 0.023 mmol) and then sparged for an additional 10 min with N2 gas. The reaction vessel was sealed, heated 3 hours at 80° Celsius and cooled to rt. The mixture was filtered through celite and the filter cake washed with EtOAc (30 mL). The filtrate was concentrated in vacuo onto silica gel and purified via FCC to give the product which was then triturated with hexanes to give 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile (0.25 g, 63%). MS (ESI): mass calcd. for C17H18BFN4O2, 340.15; m/z found 341.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.79 (d, J=1.8, 1H), 7.94 (m, 1H), 7.67 (dd, J=7.7, 1.1, 1H), 7.58 (dd, J=11.8, 1.1, 1H), 5.35 (s, 2H), 1.36 (s, 12H).
Intermediate K




To a 20 mL vial were added a stirbar, 2-bromobenzene-1-sulfonyl chloride (1.053 g, 4.12 mmol), cyclohexylamine (431 mg, 4.34 mmol) and dry pyridine (5 mL). The mixture was stirred for 3 hours before adding it to a separatory funnel containing 1 N HCl and EtOAc. The layers were mixed thoroughly and then separated. The organic layer was then washed with water followed by sat. NaHCO3, dried over MgSO4, filtered and evaporated to dryness to give the title compound. MS (ESI): mass calcd. for C12H16NO2SBr 317.01, m/z found 318.0 [M+H]+; 1H NMR (500 MHz, CDCl3) δ 8.14 (dd, J=7.9, 1.7, 1H), 7.71 (dd, J=7.9, 1.2, 1H), 7.49-7.42 (m, 1H), 7.42-7.35 (m, 1H), 5.05 (d, J=7.7, 1H), 3.19-3.04 (m, 1H), 1.79-1.66 (m, 2H), 1.66-1.57 (m, 2H), 1.52-1.44 (m, 1H), 1.28-1.04 (m, 5H).
Intermediate L




The title compound was prepared using analogous conditions to those described in Intermediate K using cyclopropylamine. 1H NMR (500 MHz, CDCl3) 8.19 (dd, J=7.8, 1.8, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.51-7.45 (m, 1H), 7.44-7.39 (m, 1H), 5.46 (s, 1H), 2.21-2.08 (m, 1H), 0.69-0.60 (m, 2H), 0.60-0.51 (m, 2H).
Intermediate M




The title compound was prepared using analogous conditions to those described in Intermediate K using cyclopentylamine. 1H NMR (500 MHz, DMSO-d6) δ 8.02 (dd, J=7.7, 1.8, 1H), 7.84 (dd, J=7.8, 1.3, 2H), 7.61-7.55 (m, 1H), 7.55-7.50 (m, 1H), 3.51-3.40 (m, 1H), 1.64-1.49 (m, 4H), 1.45-1.30 (m, 4H).
Intermediate N




The title compound was prepared using analogous conditions to those described in Intermediate K using isobutylamine. 1H NMR (500 MHz, CDCl3) δ 8.12 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.9, 1.3, 1H), 7.48-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.18-5.03 (m, 1H), 2.67 (t, J=6.6, 2H), 1.78-1.64 (m, 1H), 0.87 (d, J=6.7, 6H).
Intermediate O




The title compound was prepared using analogous conditions to those described in Intermediate K using 2-phenethylamine. 1H NMR (600 MHz, CDCl3) δ 8.14-8.09 (dd, J=7.9, 1.7, 1H), 7.69-7.63 (dd, J=7.8, 1.2, 1H), 7.47-7.42 (m, 1H), 7.42-7.36 (m, 1H), 7.29-7.24 (m, 2H), 7.24-7.17 (m, 1H), 7.12-7.06 (m, 2H), 5.16-5.00 (t, J=6.1, 1H), 3.23-3.10 (m, 2H), 2.84-2.73 (t, J=7.0, 2H).
Intermediate P




The title compound was prepared using analogous conditions to those described in Intermediate K using cyclopropylmethylamine. 1H NMR (500 MHz, CDCl3) δ 8.18 (dd, J=7.8, 1.7, 1H), 7.70 (dd, J=7.9, 1.2, 1H), 7.50-7.43 (m, 1H), 7.42-7.36 (m, 1H), 5.52 (s, 1H), 1.17-1.09 (m, 3H), 0.89-0.76 (m, 2H), 0.50-0.41 (m, 2H).
Intermediate Q




The title compound was prepared using analogous conditions to those described in Intermediate K using 2,3-dihydro-1H-inden-2-amine. 1H NMR (600 MHz, DMSO-d6) δ 8.34-8.27 (d, J=7.0, 1H), 8.09-8.04 (dd, J=7.7, 1.8, 1H), 7.91-7.85 (dd, J=7.8, 1.3, 1H), 7.64-7.54 (m, 2H), 7.17-7.06 (m, 4H), 4.01-3.92 (m, 1H), 2.98-2.89 (m, 2H), 2.87-2.79 (m, 2H).
Intermediate R




The title compound was prepared using analogous conditions to those described in Intermediate K using racemic 2-amino-1,1,1-trifluoropropane. 1H NMR (500 MHz, CDCl3) 8.10 (dd, J=7.7, 1.9, 1H), 7.74 (dd, J=7.7, 1.4, 1H), 7.49-7.38 (m, 2H), 5.33 (d, J=9.8, 1H), 4.03-3.88 (m, 1H), 1.29 (d, J=7.0, 3H).
Intermediate S




The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-2-amino-1,1,1-trifluoropropane.
Intermediate T




The title compound was prepared using analogous conditions to those described in Intermediate K using racemic (endo)-bicyclo[2.2.1]heptan-2-amine 1H NMR (500 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.8, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.49-7.42 (m, 1H), 7.42-7.37 (m, 1H), 4.98 (d, J=7.1, 1H), 3.17-3.04 (m, 1H), 2.27-2.14 (m, 1H), 2.05 (d, J=3.7, 1H), 1.62-1.50 (m, 1H), 1.45-1.28 (m, 3H), 1.28-1.17 (m, 1H), 1.17-1.08 (m, 1H), 1.05-0.91 (m, 2H).
Intermediate U




The title compound was prepared using analogous conditions to those described in Intermediate K using cyclobutylmethylamine. 1H NMR (500 MHz, CDCl3) δ 8.12 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.36 (m, 1H), 5.04 (d, J=6.0, 1H), 2.89 (dd, J=7.4, 6.1, 2H), 2.45-2.31 (m, 1H), 2.04-1.91 (m, 2H), 1.90-1.71 (m, 2H), 1.64-1.52 (m, 2H).
Intermediate V




The title compound was prepared using analogous conditions to those described in Intermediate K using 1-amino-1-methylcyclobutane. 1H NMR (500 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.70 (dd, J=7.9, 1.3, 1H), 7.47-7.41 (m, 1H), 7.40-7.34 (m, 1H), 5.26 (s, 1H), 2.26-2.13 (m, 2H), 1.86-1.76 (m, 2H), 1.76-1.59 (m, 2H), 1.32 (t, J=0.8, 3H).
Intermediate W




The title compound was prepared using analogous conditions to those described in Intermediate K using 2-methylbutan-2-amine. 1H NMR (500 MHz, DMSO-d6) δ 7.81 (dd, J=7.8, 1.7, 1H), 7.58 (dd, J=7.8, 1.3, 1H), 7.35-7.29 (m, 1H), 7.29-7.24 (m, 1H), 1.24 (q, J=7.4, 2H), 0.80 (s, 6H), 0.52 (t, J=7.4, 3H).
Intermediate X




The title compound was prepared using analogous conditions to those described in Intermediate K using 1,1,1-trifluoro-2-methylpropan-2-amine. 1H NMR (500 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.05 (dd, J=7.7, 1.8, 1H), 7.86 (dd, J=7.7, 1.4, 1H), 7.62-7.57 (m, 1H), 7.57-7.52 (m, 1H), 1.30 (s, 6H).
Intermediate Y




The title compound was prepared using analogous conditions to those described in Intermediate K using (R)-2,2,2-trifluoro-1-phenylethanamine. 1H NMR (600 MHz, DMSO-d6) δ 9.64-9.53 (d, J=10.2, 1H), 8.03-7.91 (dd, J=7.8, 1.7, 1H), 7.68-7.62 (dd, J=7.8, 1.2, 1H), 7.53-7.39 (m, 4H), 7.34-7.23 (m, 3H), 5.25-5.11 (m, 1H).
Intermediate Z




The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-2,2,2-trifluoro-1-phenylethanamine.
Intermediate AA




The title compound was prepared using analogous conditions to those described in Intermediate K using (R)-1-phenylethanamine 1H NMR (600 MHz, DMSO-d6) δ 8.46-8.34 (d, J=8.4, 1H), 7.94-7.83 (dd, J=7.7, 1.9, 1H), 7.74-7.65 (dd, J=7.7, 1.4, 1H), 7.50-7.37 (m, 2H), 7.27-7.07 (m, 5H), 4.42-4.29 (m, 1H), 1.37-1.27 (d, J=7.0, 3H).
Intermediate AB




The title compound was prepared using analogous conditions to those described in Intermediate K using (R)-2,3-dihydro-1H-inden-1-amine. 1H NMR (600 MHz, DMSO-d6) δ 8.47-8.39 (d, J=9.0, 1H), 8.14-8.06 (dd, J=7.7, 1.8, 1H), 7.93-7.87 (dd, J=7.8, 1.3, 1H), 7.64-7.53 (m, 2H), 7.23-7.10 (m, 4H), 4.77-4.64 (m, 1H), 2.91-2.78 (m, 1H), 2.72-2.61 (m, 1H), 2.21-2.10 (m, 1H), 1.91-1.77 (m, 1H).
Intermediate AC




The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-2,3-dihydro-1H-inden-1-amine. NMR spectra as for Intermediate AB.
Intermediate AD




The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-3-amino-1-ethylazepan-2-one. 1H NMR (600 MHz, DMSO-d6) δ 8.04-7.99 (dd, J=7.8, 1.7, 1H), 7.84-7.80 (dd, J=7.9, 1.3, 1H), 7.58-7.53 (m, 2H), 7.53-7.49 (m, 1H), 4.13-4.04 (m, 1H), 3.40-3.31 (m, 1H), 3.30-3.15 (m, 3H), 1.85-1.73 (m, 2H), 1.73-1.63 (m, 1H), 1.62-1.52 (m, 1H), 1.50-1.40 (m, 1H), 1.28-1.16 (m, 1H), 0.96-0.88 (t, J=7.1, 3H).
Intermediate AE




The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-3-aminoazepan-2-one. 1H NMR (600 MHz, DMSO-d6) δ 8.05-8.01 (dd, J=7.8, 1.7, 1H), 7.96-7.91 (m, 1H), 7.85-7.81 (dd, J=7.8, 1.3, 1H), 7.60-7.55 (m, 1H), 7.55-7.50 (m, 1H), 7.47-7.43 (d, J=6.0, 1H), 3.95-3.86 (m, 1H), 3.04-2.93 (m, 2H), 1.89-1.79 (m, 2H), 1.71-1.62 (m, 1H), 1.59-1.44 (m, 2H), 1.20-1.07 (m, 1H).
Intermediate AF




The title compound was prepared using analogous conditions to those described in Intermediate K using (S)-3-amino-1-methylazepan-2-one. MS (ESI): mass calcd. for C13H17BrN2O3S 360.01, m/z found 361.0 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.03-8.00 (dd, J=7.8, 1.8, 1H), 7.84-7.81 (dd, J=7.8, 1.3, 1H), 7.59-7.50 (m, 3H), 4.17-4.07 (m, 1H), 3.48-3.38 (m, 1H), 3.20-3.09 (m, 1H), 2.87-2.79 (s, 3H), 1.92-1.81 (dd, J=14.4, 3.4, 1H), 1.81-1.70 (m, 1H), 1.67-1.52 (m, 2H), 1.52-1.41 (m, 1H), 1.34-1.21 (m, 1H).
Intermediate AG




The title compound was prepared using analogous conditions to those described in Intermediate K using 1,2,2,6,6-pentamethylpiperidin-4-amine. MS (ESI): mass calcd. for C16H25BrN2O2S 388.08, m/z found 389.1 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.07-8.03 (dd. J=7.8, 1.7, 1H), 7.87-7.81 (m, 2H), 7.61-7.56 (m, 1H), 7.56-7.51 (m, 1H), 3.32-3.21 (m, 1H), 2.11-2.02 (s, 3H), 1.46-1.37 (m, 2H), 1.35-1.26 (m, 2H), 1.01-0.92 (s, 6H), 0.83-0.74 (s, 6H).
Intermediate AH




The title compound was prepared using analogous conditions to those described in Intermediate K using aniline. 1H NMR (600 MHz, DMSO-d6) δ 10.68-10.56 (s, 1H), 8.13-8.02 (dd, J=7.9, 1.7, 1H), 7.85-7.75 (dd, J=7.8, 1.3, 1H), 7.62-7.46 (m, 2H), 7.25-7.16 (m, 2H), 7.12-7.04 (m, 2H), 7.02-6.93 (m, 1H).
Intermediate AI




The title compound was prepared using analogous conditions to those described in Intermediate K using 3-aminopyridine. MS (ESI): mass calcd. for C11H9BrN2O2S 311.96, m/z found 312.9 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 11.05-10.87 (s, 1H), 8.40-8.29 (m, 1H), 8.25-8.17 (dd, J=4.7, 1.4, 1H), 8.15-8.06 (dd, J=7.8, 1.8, 1H), 7.93-7.78 (dd, J=7.8, 1.3, 1H), 7.66-7.52 (m, 2H), 7.47-7.44 (dd, J=2.7, 1.4, 1H), 7.32-7.23 (m, 2H).
Intermediate AJ




The title compound was prepared using analogous conditions to those described in Intermediate K using (R)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C9H12NOSBr 292.97, m/z found 294.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.9, 1.3, 1H), 7.48-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.42 (d, J=7.4, 1H), 3.60-3.50 (m, 1H), 3.49-3.40 (m, 1H), 3.38-3.28 (m, 1H), 2.16 (t, J=5.4, 1H), 1.04 (d, J=6.8, 3H).
Intermediate AK




To a 20 mL vial were added a stirbar, 2-bromobenzene-1-sulfonyl chloride (0.995 g, 3.89 mmol), and THF (5 mL). The vial was then charged with EtNH2 in THF (5 mL, 2.0 M). The mixture was stirred for 24 hours before adding it to a separatory funnel containing 1 N HCl and EtOAc. The layers were mixed thoroughly and then separated. The organic layer was then washed with water followed by sat. NaHCO3, dried over MgSO4, filtered and concentrated to dryness to give the crude product. Subjecting the oil to FCC yielded the title compound (580 mg, 56%). 1H NMR (600 MHz, CDCl3) 8.17-8.10 (dd, J=7.8, 1.7, 1H), 7.75-7.69 (dd, J=7.8, 1.2, 1H), 7.48-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.16-4.91 (t, J=6.7, 1H), 3.06-2.87 (m, 2H), 1.19-1.00 (t, J=7.3, 3H).
Intermediate AL




The title compound was prepared using analogous conditions to those described in Intermediate AK using 0.5 M methylamine in 1,4-dioxane. 1H NMR (600 MHz, CDCl3) δ 8.15-8.11 (dd, J=7.8, 1.7, 1H), 7.75-7.70 (dd, J=7.8, 1.3, 1H), 7.49-7.45 (m, 1H), 7.44-7.39 (m, 1H), 5.11-5.00 (d, J=6.6, 1H), 2.66-2.55 (d, J=5.4, 3H).
Intermediate AM




To a 500 mL round-bottomed flask were added a stirbar, (S)-2-aminopropan-1-ol (2.151 g, 28.65 mmol), dry DCM (100 mL), and DIPEA (14.0 mL, 81.2 mmol). The mixture was then treated with 2-bromobenzene-1-sulfonyl chloride (6.981 g, 27.32 mmol) and stirred for 66.5 hours before concentrating to dryness and subjecting the residue to FCC to give the title compound. (7.31 g, 91%).
Intermediate AN




The title compound was prepared using analogous conditions to those described in Intermediate AM using 2-amino-2-methylpropan-1-ol. MS (ESI): mass calcd. for C10H14BrNO3S 306.99, m/z found 330.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.14 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.9, 1.2, 1H), 7.50-7.42 (m, 1H), 7.42-7.35 (m, 1H), 5.33 (s, 1H), 3.46 (d, J=6.3, 2H), 1.11 (s, 6H).
Intermediate AO




The title compound was prepared using analogous conditions to those described in Intermediate AM using (R)-2-amino-3-methylbutan-1-ol. MS (ESI): mass calcd. for C11H16BrNO3S 321.00, m/z found 322.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.15-8.06 (m, 1H), 7.78-7.67 (m, 1H), 7.50-7.42 (m, 1H), 7.42-7.34 (m, 1H), 5.39 (s, 1H), 3.65-3.54 (m, 1H), 3.54-3.43 (m, 1H), 3.11-3.01 (m, 1H), 1.82 (d, J=5.7, 1H), 0.95-0.83 (m, 3H), 0.83-0.73 (m, 3H).
Intermediate AP




The title compound was prepared using analogous conditions to those described in Intermediate AM using (S)-3-aminopiperidin-2-one. MS (ESI): mass calcd. for C11H13BrN2O3S 331.98, m/z found 333.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.08 (dd, J=7.8, 1.8, 1H), 7.71 (dd, J=7.8, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.36 (m, 1H), 6.77 (s, 1H), 6.52-6.41 (m, 1H), 3.61-3.49 (m, 1H), 3.34-3.18 (m, 2H), 2.43-2.32 (m, 1H), 1.96-1.84 (m, 1H), 1.81-1.69 (m, 2H).
Intermediate AQ




To a 20 mL vial were added a stir-bar, trans-4-aminocyclohexanol (683 mg, 4.50 mmol), DMF (5 mL), and DIPEA (2.0 mL, 12 mmol). The mixture was then treated with 2-bromobenzene-1-sulfonyl chloride (1.00 g, 3.93 mmol) and the mixture stirred for 2 hours before subjecting the vial's content to FCC to give the title compound. (978 mg, 74%). MS (ESI): mass calcd. for C12H16BrNO3S 333.00, m/z found 334.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.12 (dd, J=7.8, 1.7, 1H), 7.70 (dd, J=7.8, 1.2, 1H), 7.49-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.10 (d, J=7.5, 1H), 3.62-3.47 (m, 1H), 3.11-3.01 (m, 1H), 2.12 (s, 1H), 1.91-1.75 (m, 4H), 1.31-1.15 (m, 4H).
Intermediate AR




The title compound was prepared using analogous conditions to those described in Intermediate AQ using (S)-pyrrolidin-3-ylmethanol. 1H NMR (600 MHz, CDCl3) δ 8.06 (dd, J=7.9, 1.7, 1H), 7.70 (dd, J=7.9, 1.2, 1H), 7.44-7.38 (m, 1H), 7.38-7.32 (m, 1H), 3.61-3.54 (m, 1H), 3.54-3.45 (m, 3H), 3.39-3.33 (m, 1H), 3.17 (dd, J=9.8, 6.4, 1H), 2.53-2.39 (m, 2H), 2.04-1.94 (m, 1H), 1.74-1.65 (m, 1H).
Intermediate AS




The title compound was prepared using analogous conditions to those described in Intermediate AQ using (R)-pyrrolidin-3-ylmethanol.
Intermediate AT




The title compound was prepared using analogous conditions to those described in Intermediate AQ using (R)-3-aminopiperidin-2-one.
Intermediate AU




To a 20 mL vial were added a stirbar, 3-amino-3-methylbutan-1-ol (428 mg, 4.15 mmol), ACN (5 mL), and DIPEA (2.0 mL, 12 mmol). The mixture was then treated with 2-bromobenzene-1-sulfonyl chloride (994 mg, 3.89 mmol) and stirred for 12.5 hours before concentrating to dryness and subjecting the residue to FCC to give the title compound. (676 mg, 54%). MS (ESI): mass calcd. for C11H16BrNO3S 321.00, m/z found 344.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.15 (dd, J=7.9, 1.7, 1H), 7.70 (dd, J=7.8, 1.2, 1H), 7.46-7.39 (m, 1H), 7.39-7.31 (m, 1H), 6.15 (s, 1H), 3.93-3.81 (m, 2H), 1.76 (t, J=6.0, 2H), 1.20 (s, 6H).
Intermediate AV




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3-(methylamino)piperidine-1-carboxylate. MS (ESI): mass calcd. for C17H25BrN2O4S 432.07, m/z found 455.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.14 (dd, J=7.9, 1.7, 1H), 7.72 (dd, J=7.9, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.06 (s, 2H), 3.67 (s, 1H), 2.85 (s, 3H), 2.72 (s, 1H), 2.47 (s, 1H), 1.86 (d, J=11.8, 1H), 1.75-1.65 (m, 1H), 1.65-1.55 (m, 1H), 1.54-1.46 (m, 1H), 1.38 (s, 9H).
Intermediate AW




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3-(methylamino)piperidine-1-carboxylate.
Intermediate AX




The title compound was prepared using analogous conditions to those described in Intermediate AU using (1S,2R)-1-amino-2,3-dihydro-1H-inden-2-ol. MS (ESI): mass calcd. for C15H14BrNO3S 366.99, m/z found 389.9 [M+Na]4; 1H NMR (600 MHz, CDCl3) δ 8.20 (dd, J=7.7, 1.9, 1H), 7.79 (dd, J=7.8, 1.4, 1H), 7.50-7.42 (m, 2H), 7.24-7.16 (m, 4H), 5.85 (d, J=8.2, 1H), 4.70-4.63 (m, 1H), 4.38-4.31 (m, 1H), 3.09-2.97 (m, 1H), 2.95-2.86 (m, 1H), 2.12 (d, J=5.2, 1H).
Intermediate AY




The title compound was prepared using analogous conditions to those described in Intermediate AU using (1S,2R)-2-amino-1-phenylpropane-1,3-diol. MS (ESI): mass calcd. for C15H16BrNO4S 384.00, m/z found 407.9 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 7.88 (dd, J=7.6, 1.9, 1H), 7.54 (dd, J=7.6, 1.5, 1H), 7.34-7.26 (m, 2H), 7.23-7.19 (m, 2H), 7.17-7.09 (m, 3H), 5.89 (d, J=6.4, 1H), 4.97 (dd, J=4.3, 2.4, 1H), 3.83-3.73 (m, 1H), 3.73-3.64 (m, 1H), 3.48-3.38 (m, 1H), 3.05 (d, J=2.6, 1H), 2.37-2.27 (m, 1H).
Intermediate AZ




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-3-phenylpropan-1-ol. MS (ESI): mass calcd. for C15H16BrNO3S 369.00, m/z found 392.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.07 (dd, J=7.8, 1.7, 1H), 7.62 (dd, J=7.9, 1.2, 1H), 7.45-7.39 (m, 1H), 7.38-7.32 (m, 1H), 7.20-7.10 (m, 3H), 7.05-6.95 (m, 2H), 5.46 (d, J=6.8, 1H), 3.63-3.54 (m, 1H), 3.54-3.43 (m, 2H), 2.88-2.78 (m, 1H), 2.78-2.68 (m, 1H), 2.14-1.97 (m, 1H).
Intermediate BA




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-2-amino-3-phenylpropan-1-ol. 1H NMR (600 MHz, CDCl3) δ 8.10 (dd, J=7.8, 1.8, 1H), 7.71 (dd, J=7.8, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.37 (m, 1H), 7.33-7.28 (m, 2H), 7.28-7.25 (m, 3H), 5.68-5.57 (m, 1H), 4.78 (dd, J=8.7, 3.7, 1H), 3.26-3.15 (m, 1H), 3.04-2.94 (m, 1H), 2.41 (s, 1H).
Intermediate BB




The title compound was prepared using analogous conditions to those described in Intermediate AU using (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol. MS (ESI): mass calcd. for C16H18BrNO3S 383.02, m/z found 406.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.19 (dd, J=7.9, 1.7, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.41-7.36 (m, 1H), 7.34-7.29 (m, 2H), 7.29-7.25 (m, 3H), 4.45 (dd, J=9.4, 3.4, 1H), 3.95-3.85 (m, 1H), 3.05 (d, J=3.4, 1H), 2.98 (s, 3H), 0.97-0.86 (d, J=6.7, 3H).
Intermediate BC




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-1-aminoethane-1,2-diol. MS (ESI): mass calcd. for C9H12BrNO4S 308.97, m/z found 310.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.05 (dd, J=7.8, 1.7, 1H), 7.68 (dd, J=7.9, 1.3, 1H), 7.49-7.40 (m, 1H), 7.40-7.32 (m, 1H), 6.18 (t, J=6.3, 1H), 3.95-3.75 (m, 3H), 3.64 (dd, J=11.8, 3.6, 1H), 3.54 (dd, J 11.6, 6.0, 1H), 3.06-2.97 (m, 1H), 2.97-2.85 (m, 1H).
Intermediate BD




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-3-aminopyrrolidin-2-one. MS (ESI): mass calcd. for C10H11BrN2O3S 317.97, m/z found 318.9 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.14-8.05 (m, 1H), 7.71 (dd, J=7.8, 1.3, 1H), 7.49-7.36 (m, 2H), 7.06 (s, 1H), 6.22 (d, J=4.7, 1H), 3.81-3.68 (m, 1H), 3.41-3.29 (m, 1H), 3.29-3.18 (m, 1H), 2.47-2.34 (m, 1H), 2.12-2.00 (m, 1H).
Intermediate BE




The title compound was prepared using analogous conditions to those described in Intermediate AU using 1-amino-2-methylpropan-2-ol. MS (ESI): mass calcd. for C10H14BrNO3S 306.99, m/z found 290.0 [M−OH]+; 1H NMR (600 MHz, CDCl3) δ 8.11 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.48-7.43 (m, 1H), 7.43-7.38 (m, 1H), 5.53 (t, J=6.0, 1H), 2.79 (d, J=6.6, 2H), 1.22 (s, 6H).
Intermediate BF




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-2-amino-1,1,1-trifluoropropane.
Intermediate BG




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-tert-butyl (pyrrolidin-2-ylmethyl)carbamate. MS (ESI): mass calcd. for C16H23BrN2O4S 418.06, m/z found 319.0 [M-Boc+H]+; 1H NMR (600 MHz, CDCl3) δ 8.10 (dd, J=7.9, 1.7, 1H), 7.73 (dd, J=7.9, 1.3, 1H), 7.46-7.41 (m, 1H), 7.41-7.36 (m, 1H), 4.99 (t, J=6.5, 1H), 4.05-3.95 (m, 1H), 3.50-3.40 (m, 1H), 3.40-3.34 (m, 1H), 3.32-3.17 (m, 2H), 1.98-1.86 (m, 2H), 1.86-1.71 (m, 2H), 1.40 (s, 9H).
Intermediate BH




The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl 4-aminopiperidine-1-carboxylate. MS (ESI): mass calcd. for C16H23BrN2O4S 418.06, m/z found 441.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.38 (m, 1H), 5.15 (d, J=7.5, 1H), 3.86 (s, 2H), 3.32-3.20 (m, 1H), 2.75 (s, 2H), 1.69 (d, J=12.2, 2H), 1.40 (s, 9H), 1.38-1.29 (m, 2H).
Intermediate BI




The title compound was prepared using analogous conditions to those described in Intermediate AU using azetidin-3-ol. MS (ESI): mass calcd. for C9H10BrNO3S 290.96, m/z found 292.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.02 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.44-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.61-4.51 (m, 1H), 4.18-4.10 (m, 2H), 3.97-3.91 (m, 2H), 2.92 (d, J=6.3, 1H).
Intermediate BJ




The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-(1,2-trans)-1R-2-aminocyclohexanol. MS (ESI): mass calcd. for C12H16BrNO3S 333.00, m/z found 334.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.15 (dd, J=7.8, 1.7, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.50-7.44 (m, 1H), 7.44-7.39 (m, 1H), 5.29 (d, J=7.4, 1H), 3.38-3.28 (m, 1H), 2.88-2.77 (m, 1H), 2.58 (d, J=3.0, 1H), 2.04-1.96 (m, 1H), 1.77-1.69 (m, 1H), 1.59-1.51 (m, 1H), 1.27-1.12 (m, 3H), 1.12-1.01 (m, 1H).
Intermediate BK




The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-(1,2-trans)-1R-2-aminocyclohexyl)methanol. MS (ESI): mass calcd. for C13H18BrNO3S 347.02, m/z found 348.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.44-7.38 (m, 1H), 5.19-5.06 (m, 1H), 4.10-4.00 (m, 1H), 3.51-3.41 (m, 1H), 3.08-2.97 (m, 1H), 2.45-2.36 (m, 1H), 1.72-1.66 (m, 1H), 1.66-1.60 (m, 1H), 1.59-1.53 (m, 1H), 1.52-1.46 (m, 1H), 1.41-1.32 (m, 1H), 1.31-1.24 (m, 1H), 1.20-1.07 (m, 2H), 1.05-0.96 (m, 1H).
Intermediate BL




The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-(1,2-cis)-1R-2-aminocyclohexanol. MS (ESI): mass calcd. for C12H16BrNO3S 333.00, m/z found 334.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.38 (m, 1H), 5.52 (d, J=7.7, 1H), 3.80-3.72 (m, 1H), 3.27-3.15 (m, 1H), 1.80 (d, J=4.8, 1H), 1.74-1.63 (m, 1H), 1.63-1.51 (m, 2H), 1.51-1.43 (m, 2H), 1.43-1.36 (m, 1H), 1.36-1.26 (m, 1H), 1.26-1.11 (m, 1H).
Intermediate BM




The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-(1,2-cis)-1R-2-aminocyclohexyl)methanol. MS (ESI): mass calcd. for C13H18BrNO3S 347.02, m/z found 348.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.8, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.44-7.39 (m, 1H), 5.43 (d, J=9.3, 1H), 3.76-3.65 (m, 1H), 3.65-3.54 (m, 1H), 3.45-3.33 (m, 1H), 2.82 (dd, J=8.9, 5.2, 1H), 1.73-1.60 (m, 2H), 1.58-1.51 (m, 1H), 1.42-1.35 (m, 1H), 1.35-1.16 (m, 4H), 1.10-0.97 (m, 1H).
Intermediate BN




The title compound was prepared using analogous conditions to those described in Intermediate AU using 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine. MS (ESI): mass calcd. for C12H12BrN3O2S 340.98, m/z found 341.9 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.15 (dd, J=7.8, 1.7, 1H), 7.71 (dd, J=7.9, 1.2, 1H), 7.47-7.42 (m, 1H), 7.41-7.36 (m, 1H), 7.33 (s, 1H), 4.45 (s, 2H), 3.66 (t, J=5.8, 2H), 2.83 (t, J=5.8, 2H).
Intermediate BO




The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl (azetidin-3-ylmethyl)carbamate. MS (ESI): mass calcd. for C15H21BrN2O4S 404.04, m/z found 349.0 [M-tBu+H]+; 1H NMR (600 MHz, CDCl3) δ 8.04 (dd. J=7.8, 1.8, 1H), 7.73 (dd, J=7.7, 1.3, 1H), 7.44-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.71 (s, 1H), 4.13-4.03 (m, 2H), 3.70 (dd, J=7.9, 5.4, 2H), 3.35-3.22 (m, 2H), 2.78-2.64 (m, 1H), 1.40 (s, 9H).
Intermediate BP




The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl 3-(aminomethyl)azetidine-1-carboxylate. 1H NMR (600 MHz, CDCl3) δ 8.12 (dd. J=7.8, 1.7, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.50-7.45 (m, 1H), 7.45-7.39 (m, 1H), 5.42-5.30 (m, 1H), 3.96-3.85 (m, 2H), 3.52 (d, J=9.3, 2H), 3.17-3.02 (m, 2H), 2.69-2.54 (m, 1H), 1.39 (s, 9H).
Intermediate BQ




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-tert-butyl methyl(pyrrolidin-3-yl)carbamate. MS (ESI): mass calcd. for C16H23BrN2O4S 418.06, m/z found 441.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.08 (dd. J=7.9, 1.8, 1H), 7.73 (dd, J=7.8, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.34 (m, 1H), 4.80 (s, 1H), 3.61 (s, 1H), 3.51 (s, 1H), 3.38-3.30 (m, 1H), 3.19 (dd, J=9.9, 7.4, 1H), 2.73 (s, 3H), 2.12-2.03 (m, 1H), 2.03-1.93 (m, 1H), 1.41 (s, 9H).
Intermediate BR




The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate. MS (ESI): mass calcd. for C16H21BrN2O4S 416.04, m/z found 439.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) 8.10 (dd, J=7.9, 1.8, 1H), 7.73 (dd, J=8.0, 1.2, 1H), 7.46-7.40 (m, 1H), 7.40-7.34 (m, 1H), 4.63-4.39 (m, 2H), 3.59-3.39 (m, 2H), 3.33-3.22 (m, 2H), 1.88-1.76 (m, 2H), 1.42 (d, J=5.0, 9H).
Intermediate BS




The title compound was prepared using analogous conditions to those described in Intermediate AU (1S,4S)-tert-butyl 2,5-diazabicyclo[2.2.]heptane-2-carboxylate.
Intermediate BT




The title compound was prepared using analogous conditions to those described in Intermediate AU using 4-(piperidin-4-yl)-1H-1,2,4-triazol-5(4H)-one. MS (ESI): mass calcd. for C13H15BrN4O3S 386.00, m/z found 387.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 9.63 (s, 1H), 8.10 (dd, J=7.8, 1.8, 1H), 7.75 (dd, J=7.9, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.37 (m, 2H), 4.05-3.97 (m, 3H), 2.97-2.89 (m, 2H), 2.09-2.03 (m, 2H), 1.89-1.79 (m, 2H).
Intermediate BU




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-3-aminopropane-1,2-diol.
Intermediate BV




The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl ((cis)-4-aminocyclohexyl)carbamate. MS (ESI): mass calcd. for C17H25BrN2O4S 432.07, m/z found 455.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.8, 1.2, 1H), 7.48-7.43 (m, 1H), 7.43-7.38 (m, 1H), 5.17 (s, 1H), 4.45 (s, 1H), 3.47 (s, 1H), 3.30-3.20 (m, 1H), 1.66 (s, 2H), 1.60-1.49 (m, 4H), 1.45 (d, J=7.3, 1H), 1.41 (s, 9H).
Intermediate BW




The title compound was prepared using analogous conditions to those described in Intermediate AU using 5-aminopentan-1-ol. MS (ESI): mass calcd. for C11H16BrNO3S 321.00, m/z found 322.0 [M+H]+; 1H NMR (600 MHz, CDCl3) b 8.10 (dd. J=7.8, 1.7, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.48-7.42 (m, 1H), 7.42-7.35 (m, 1H), 5.23 (t, J=6.3, 1H), 3.62-3.50 (m, 2H), 2.93-2.83 (m, 2H), 1.55 (s, 1H), 1.52-1.42 (m, 4H), 1.39-1.29 (m, 2H).
Intermediate BX




The title compound was prepared using analogous conditions to those described in Intermediate AU using 6-aminohexan-1-ol. MS (ESI): mass calcd. for C12H18BrNO3S 335.02, m/z found 336.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.11 (dd, J=7.8, 1.8, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.48-7.42 (m, 1H), 7.42-7.36 (m, 1H), 5.15 (t, J=6.2, 1H), 3.57 (t, J=6.6, 2H), 2.94-2.81 (m, 2H), 1.56-1.35 (m, 5H), 1.33-1.21 (m, 4H).
Intermediate BY




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-indolin-2-ylmethanol. MS (ESI): mass calcd. for C15H14BrNO3S 366.99, m/z found 389.9 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.12 (dd, J=7.9, 1.7, 1H), 7.65 (dd, J=7.9, 1.3, 1H), 7.42-7.36 (m, 1H), 7.36-7.31 (m, 1H), 7.27 (d, J=8.1, 1H), 7.14-7.09 (m, 1H), 7.09-7.04 (m, 1H), 6.98-6.93 (m, 1H), 4.86-4.78 (m, 1H), 3.81-3.68 (m, 2H), 3.28 (dd, J=16.2, 9.6, 1H), 2.88-2.79 (m, 1H), 2.20 (s, 1H).
Intermediate BZ




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-(cyclohexylamino)ethanol. MS (ESI): mass calcd. for C14H20BrNO3S 361.03, m/z found 362.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.14 (dd. J=7.9, 1.7, 1H), 7.71 (dd, J=7.8, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.34 (m, 1H), 3.71 (m, 2H), 3.65-3.57 (m, 1H), 3.47 (t, J=6.1, 2H), 2.22 (t, J=5.9, 1H), 1.80-1.67 (m, 4H), 1.62-1.53 (m, 1H), 1.44-1.32 (m, 2H), 1.27-1.15 (m, 2H), 1.07-0.94 (m, 1H).
Intermediate CA




The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic-azetidine-2-carboxamide. MS (ESI): mass calcd. for C10H11BrN2O3S 319.97, m/z found 319.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.11-8.07 (m, 1H), 7.83-7.79 (m, 1H), 7.53-7.46 (m, 2H), 6.91 (s, 1H), 5.53 (s, 1H), 4.75 (t, J=8.8, 1H), 4.02-3.94 (m, 1H), 3.75-3.67 (m, 1H), 2.49-2.39 (m, 2H).
Intermediate CB




Step A: 1-[(2-Bromophenyl)sulfonyl]-4-{1-[(2-bromophenyl)sulfonyl]-1H-imidazol-4-yl}piperidine
To a 20 mL vial were added a stirbar, 4-(1H-imidazol-4-yl)piperidine.HCl (696 mg, 3.71 mmol), ACN (5 mL), and DIPEA (2.0 mL, 12 mmol). The mixture was then treated with 2-bromobenzene-1-sulfonyl chloride (900 mg, 3.52 mmol) and the mixture was stirred for 15.5 hours before concentrating to dryness and subjecting the residue to FCC to give the title compound (950 mg, 92%). MS (ESI): mass calcd. for C20H19Br2N3O4S2 586.92 m/z found 587.9 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.20 (dd, J=7.9, 1.8, 1H), 8.08 (dd, J=7.8, 1.7, 1H), 8.06 (d, J=1.3, 1H), 7.75 (dd, J=7.7, 1.3, 1H), 7.72 (dd, J=7.9, 1.2, 1H), 7.58-7.53 (m, 1H), 7.53-7.49 (m, 1H), 7.45-7.40 (m, 1H), 7.39-7.34 (m, 1H), 6.93-6.91 (m, 1H), 3.90-3.82 (m, 2H), 2.93-2.83 (m, 2H), 2.68-2.59 (m, 1H), 2.02 (dd, J=13.9, 3.0, 2H), 1.70-1.59 (m, 2H).
Step B
To a 20 mL vial containing 1-[(2-bromophenyl)sulfonyl]-4-{1-[(2-bromophenyl)-sulfonyl]-1H-imidazol-4-yl}piperidine (884 mg, 1.50 mmol) were added a stirbar and DMSO (10 mL). Once the DMSO solution was homogeneous, LiOH (3 mL, 1.0 M) was added slowly. After 30 min the reaction mixture was diluted with EtOAc, washed with water (×4) and brine (×1), dried over MgSO4, filtered and concentrated to dryness to give the title compound (522 mg, 94%). MS (ESI): mass calcd. for C14H16BrN3O2S 369.01 m/z found 370.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.08 (dd, J=7.9, 1.7, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.62 (s, 1H), 7.45-7.41 (m, 1H), 7.40-7.35 (m, 1H), 6.76 (s, 1H), 3.88 (d, J=12.8, 1H), 2.90 (m, 2H), 2.76-2.69 (m, 1H), 2.09-2.01 (m, 2H), 1.77-1.67 (m, 2H).
Intermediate CC




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl piperidin-3-ylcarbamate. MS (ESI): mass calcd. for C16H23BrN2O4S 418.06 m/z found 441.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.10-8.06 (m, 1H), 7.73 (dd, J=7.7, 1.3, 1H), 7.46-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.88 (d, J=8.5, 1H), 3.77 (s, 1H), 3.44 (s, 1H), 3.28 (d, J=11.8, 1H), 3.23-3.03 (m, 2H), 1.85-1.55 (m, 4H), 1.39 (s, 9H).
Intermediate CD




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2,2′-azanediyldiethanol. MS (ESI): mass calcd. for C10H14BrNO4S 322.98 m/z found 324.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.10-8.05 (m, 1H), 7.74 (dd, J=7.8, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.37 (m, 1H), 3.83 (dd, J=7.3, 3.8, 4H), 3.48 (t, J=5.0, 4H), 3.38 (s, 2H).
Intermediate CE




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3-methylpiperazine-1-carboxylate. MS (ESI): mass calcd. for C16H23BrN2O4S 418.06 m/z found 319.0 [M-Boc+H]+; 1H NMR (600 MHz, CDCl3) δ 8.14 (dd, J=7.8, 1.8, 1H), 7.72 (dd, J=7.8, 1.3, 1H), 7.45-7.40 (m, 1H), 7.40-7.35 (m, 1H), 4.16-3.73 (m, 3H), 3.63-3.42 (m, 1H), 3.32-3.22 (m, 1H), 3.17-2.68 (m, 2H), 1.42 (s, 9H), 1.25-1.09 (m, 3H).
Intermediate CF




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-tert-butyl 3-methylpiperazine-1-carboxylate.
Intermediate CG




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-(isopropylamino)ethanol. MS (ESI): mass calcd. for C11H16BrNO3S 321.00 m/z found 322.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.15 (dd. J=7.9, 1.7, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.46-7.41 (m, 1H), 7.39-7.34 (m, 1H), 4.01 (hept, J=6.7, 1H), 3.74 (m, 2H), 3.47 (t, J=6.1, 2H), 2.27 (t, J=5.8, 1H), 1.13 (d, J=6.8, 6H).
Intermediate CH




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate. MS (ESI): mass calcd. for C16H23BrN2O5S 434.05 m/z found 335.0 [M-Boc+H]+; 1H NMR (600 MHz, CDCl3) δ 8.16 (dd, J=7.8, 1.8, 1H), 7.73 (dd, J=7.9, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.37 (m, 1H), 4.32-3.43 (m, 6H), 3.27-3.15 (m, 1H), 3.15-2.66 (m, 3H), 1.44 (s, 9H).
Intermediate CI




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-amino-2-methylpropane-1,3-diol. 1H NMR (600 MHz, CDCl3) δ 8.14 (dd, J=7.8, 1.7, 1H), 7.73 (dd, J=7.9, 1.3, 1H), 7.48-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.93 (s, 1H), 3.72-3.56 (m, 4H), 2.53-2.44 (m, 2H), 0.93 (s, 3H).
Intermediate CJ




The title compound was prepared using analogous conditions to those described in Intermediate AU using endo-3-azabicyclo[3.1.0]hexan-6-amine. MS (ESI): mass calcd. for C11H13BrN2O2S 315.99 m/z found 317.0 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 7.97 (dd, J=7.7, 1.9, 1H), 7.88 (dd, J=7.7, 1.4, 1H), 7.62-7.58 (m, 1H), 7.58-7.54 (m, 1H), 3.42-3.38 (m, 2H), 3.37-3.29 (m, 4H), 2.02 (t, J=2.2, 1H), 1.46-1.41 (m, 2H).
Intermediate CK




The title compound was prepared using analogous conditions to those described in Intermediate AU using tert-butyl(2-aminoethyl)carbamate. 1H NMR (600 MHz, CDCl3) δ 8.10 (dd, J=7.7, 1.7, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.47-7.43 (m, 1H), 7.43-7.37 (m, 1H), 5.66 (t, J=5.8, 1H), 4.86 (s, 1H), 3.21 (t, J=5.8, 2H), 3.03-2.95 (m, 2H), 1.40 (s, 9H).
Intermediate CL




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-3-methylbutan-1-ol. 1H NMR (600 MHz, CDCl3) δ 8.11 (dd, J=7.8, 1.7, 1H), 7.72 (dd, J=7.9, 1.2, 1H), 7.47-7.42 (m, 1H), 7.41-7.36 (m, 1H), 5.35 (d, J=8.6, 1H), 3.63-3.54 (m, 1H), 3.54-3.43 (m, 1H), 3.11-3.01 (m, 1H), 1.88-1.75 (m, 2H), 0.86 (d, J=6.9, 3H), 0.80 (d, J=6.8, 3H).
Intermediate CM




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-3,3-dimethylbutan-1-ol. MS (ESI): mass calcd. for C12H18BrNO3S 335.02 m/z found 336.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.09 (dd, J=7.9, 1.7, 1H), 7.71 (dd, J=7.9, 1.3, 1H), 7.46-7.41 (m, 1H), 7.40-7.35 (m, 1H), 5.40 (d, J=9.4, 1H), 3.66-3.55 (m, 2H), 3.11-3.01 (m, 1H), 1.81 (t, J=5.6, 1H), 0.85 (s, 9H).
Intermediate CN




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-2-amino-3,3-dimethylbutan-1-ol.
Intermediate CO




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-aminobutan-1-ol. MS (ESI): mass calcd. for C10H14BrNO3S 306.99 m/z found 308.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.11 (dd. J=7.8, 1.7, 1H), 7.72 (dd, J=7.9, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.37 (m, 1H), 5.41 (d, J=7.9, 1H), 3.59-3.46 (m, 2H), 3.19-3.10 (m, 1H), 2.15-1.99 (m, 1H), 1.56-1.38 (m, 2H), 0.78 (t, J=7.5, 3H).
Intermediate CP




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3-aminopyrrolidine-1-carboxylate. MS (ESI): mass calcd. for C15H21BrN2O4S 404.04 m/z found 427.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.17-8.11 (m, 1H), 7.77-7.69 (m, 1H), 7.51-7.45 (m, 1H), 7.45-7.39 (m, 1H), 5.38-5.29 (m, 1H), 3.87-3.75 (m, 1H), 3.46-3.32 (m, 2H), 3.32-3.21 (m, 1H), 3.16-3.05 (m, 1H), 2.05-1.68 (m, 2H), 1.39 (s, 9H).
Intermediate CQ




The title compound was prepared using analogous conditions to those described in Intermediate AU using (1S,2S)-1-amino-2,3-dihydro-1H-inden-2-ol. MS (ESI): mass calcd. for C15H14BrNO3S 366.99 m/z found 390.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.21 (dd, J=7.7, 1.8, 1H), 7.80 (dd, J=7.8, 1.3, 1H), 7.52-7.47 (m, 1H), 7.47-7.43 (m, 1H), 7.25-7.21 (m, 1H), 7.21-7.13 (m, 3H), 5.61 (d, J=6.8, 1H), 4.58-4.47 (m, 1H), 4.44-4.37 (m, 1H), 3.26 (dd, J=15.9, 7.7, 1H), 3.13 (d. J=2.7, 1H), 2.84-2.73 (m, 1H).
Intermediate CR




The title compound was prepared using analogous conditions to those described in Intermediate AU using (1R,2R)-1-amino-2,3-dihydro-1H-inden-2-ol.
Intermediate CS




The title compound was prepared using analogous conditions to those described in Intermediate AU using (1R,2S)-1-amino-2,3-dihydro-1H-inden-2-ol.
Intermediate CT




The title compound was prepared using analogous conditions to those described in Intermediate AU using N-cyclopropyltetrahydro-2H-pyran-4-amine. MS (ESI): mass calcd. for C14H18BrNO3S 359.02 m/z found 392.0 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.16 (dd, J=7.9, 1.7, 1H), 7.69 (dd, J=7.9, 1.2, 1H), 7.47-7.40 (m, 1H), 7.40-7.34 (m, 1H), 4.40-4.30 (m, 1H), 4.05-3.96 (m, 2H), 3.52-3.39 (m, 2H), 2.34-2.25 (m, 1H), 2.16-2.06 (m, 2H), 1.85-1.75 (m, 2H), 0.64-0.56 (m, 2H), 0.54-0.46 (m, 2H).
Intermediate CU




The title compound was prepared using analogous conditions to those described in Intermediate AU using racemic morpholin-2-ylmethanol. MS (ESI): mass calcd. for C11H14BrNO4S 334.98 m/z found 357.9 [M+Na]+; 1H NMR (600 MHz, CDCl3) δ 8.06 (dd, J=7.8, 1.8, 1H), 7.74 (dd, J=7.8, 1.3, 1H), 7.47-7.42 (m, 1H), 7.42-7.36 (m, 1H), 3.93 (m, 1H), 3.70-3.58 (m, 5H), 3.58-3.51 (m, 1H), 2.94 (m, 1H), 2.77 (m, 1H), 1.96-1.83 (m, 1H).
Intermediate CV




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-aminopyrazine. MS (ESI): mass calcd. for C10H8BrN3O2S 312.95 m/z found 313.9 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 11.94 (s, 1H), 8.34 (s, 1H), 8.25-8.16 (m, 2H), 8.11 (dd, J=2.7, 1.5, 1H), 7.81 (dd, J=7.9, 1.2, 1H), 7.68-7.59 (m, 1H), 7.59-7.51 (m, 1H).
Intermediate CW




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-4-methylpentanamide. MS (ESI): mass calcd. for C12H17BrN2O3S 348.01 m/z found 349.0 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.01 (dd, J=7.7, 1.8, 1H), 7.92 (d, J=8.3, 1H), 7.82 (dd, J=7.8, 1.3, 1H), 7.58-7.49 (m, 2H), 7.24 (d, J=2.3, 1H), 6.97 (d, J=2.2, 1H), 3.67-3.56 (m, 1H), 1.65-1.53 (m, 1H), 1.51-1.40 (m, 1H), 1.35-1.25 (m, 1H), 0.79 (d, J=6.6, 3H), 0.61 (d, J=6.5, 3H).
Intermediate CX




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-aminoacetamide. MS (ESI): mass calcd. for C8H9BrN2O3S 291.95 m/z found 293.0 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.00 (dd, J=7.7, 1.8, 1H), 7.88 (s, 1H), 7.84 (dd, J=7.8, 1.3, 1H), 7.59-7.54 (m, 1H), 7.54-7.50 (m, 1H), 7.27 (s, 1H), 7.13 (s, 1H), 3.51 (s, 2H).
Intermediate CY




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-amino-3-phenylpropanamide. MS (ESI): mass calcd. for C15H15BrN2O3S 382.00 m/z found 382.9 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 7.95 (d, J=8.8, 1H), 7.71-7.65 (m, 2H), 7.44-7.35 (m, 3H), 7.20-7.12 (m, 5H), 7.06 (d, J=2.2, 1H), 3.93 (m, 1H), 2.91 (dd, J=13.7, 4.9, 1H), 2.77 (dd, J=13.7, 9.4, 1H).
Intermediate CZ




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-2-aminopropanamide. MS (ESI): mass calcd. for C9H11BrN2O3S 305.97 m/z found 307.0 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.01 (dd, J=7.7, 1.8, 1H), 7.86 (d, J=5.2, 1H), 7.84 (dd, J=7.7, 1.3, 1H), 7.60-7.55 (m, 1H), 7.55-7.50 (m, 1H), 7.24 (s, 1H), 7.07 (s, 1H), 3.78-3.69 (m, 1H), 1.17 (d, J=7.1, 3H).
Intermediate DA




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 3,4-diamino-4-oxobutanoate. MS (ESI): mass calcd. for C14H19BrN2O5S 406.02 m/z found 429.0 [M+Na]+; 1H NMR (600 MHz, DMSO-d6) δ 8.04-7.99 (m, 2H), 7.80 (dd, J=7.7, 1.3, 1H), 7.58-7.53 (m, 1H), 7.53-7.49 (m, 1H), 7.24 (s, 1H), 7.16 (s, 1H), 4.00 (m, 1H), 2.56-2.51 (m, 1H), 2.45-2.39 (m, 1H), 1.32 (s, 9H).
Intermediate DB




The title compound was prepared using analogous conditions to those described in Intermediate AU using (R)-2-amino-2-phenylacetamide. MS (ESI): mass calcd. for C14H13BrN2O3S 367.98 m/z found 369.0 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.20 (d, J=8.8, 1H), 7.91-7.86 (m, 1H), 7.76-7.71 (m, 1H), 7.58 (d, J=2.0, 1H), 7.49-7.43 (m, 2H), 7.35-7.29 (m, 2H), 7.26-7.20 (m, 4H), 4.94 (d, J=8.8, 1H).
Intermediate DC




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl-2-amino-3-methylbutanoate. 1H NMR (600 MHz, DMSO-d6) δ 8.24 (d, J=9.6, 1H), 8.00 (dd, J=7.8, 1.7, 1H), 7.82 (dd, J=7.9, 1.3, 1H), 7.58-7.54 (m, 1H), 7.54-7.48 (m, 1H), 3.45 (dd, J=9.5, 7.1, 1H), 1.97 (h, J=6.8, 1H), 1.22 (s, 9H), 0.87 (d, J=6.7, 3H), 0.82 (d, J=6.8, 3H).
Intermediate DD




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-tert-butyl 2-aminopropanoate. MS (ESI): mass calcd. for C13H18BrNO4S 363.01 m/z found 386.0 [M+Na]+; 1H NMR (600 MHz, DMSO-d6) δ 8.36 (d, J=8.6, 1H), 7.99 (dd, J=7.8, 1.8, 1H), 7.83 (dd, J=7.8, 1.3, 1H), 7.58-7.53 (m, 1H), 7.53-7.49 (m, 1H), 3.87-3.78 (m, 1H), 1.30-1.21 (m, 12H).
Intermediate DE




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-pyrrolidine-3-carboxamide. MS (ESI): mass calcd. for C11H13BrN2O3S 331.98, m/z found 333.0 [M+H]+; 1H NMR (500 MHz, DMSO-d6) δ 8.05-7.97 (dd, J=7.7, 1.9, 1H), 7.92-7.85 (dd, J=7.7, 1.5, 1H), 7.64-7.53 (m, 2H), 7.43 (s, 1H), 6.96 (s, 1H), 3.57-3.50 (dd, J=9.5, 8.0, 1H), 3.46-3.39 (m, 1H), 3.37-3.27 (m, 2H), 3.02-2.94 (p, J=7.8, 1H), 2.12-2.02 (m, 1H), 2.02-1.91 (m, 1H).
Intermediate DF




The title compound was prepared using analogous conditions to those described in Intermediate AU using piperidine-4-carboxamide. MS (ESI): mass calcd. for C12H15BrN2O3S 346.00, m/z found 347.0 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.03-7.97 (dd, J=7.8, 1.8, 1H), 7.91-7.86 (dd, J=7.8, 1.3, 1H), 7.63-7.53 (m, 2H), 7.28 (s, 1H), 6.82 (s, 1H), 3.72-3.62 (m, 2H), 2.83-2.73 (m, 2H), 2.27-2.17 (m, 1H), 1.79-1.70 (m, 2H), 1.57-1.44 (m, 2H).
Intermediate DG




The title compound was prepared using analogous conditions to those described in Intermediate AU using 3-(trifluoromethyl)azetidin-3-ol. MS (ESI): mass calcd. for C10H9BrF3NO3S 358.94; m/z found 359.9 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.03-8.00 (m, 1H), 7.94-7.91 (dd, J=7.4, 1.7, 1H), 7.65-7.58 (m, 3H), 4.20-4.15 (m, 2H), 4.09-4.04 (m, 2H).
Intermediate DH




The title compound was prepared using analogous conditions to those described in Intermediate AU using N-methylazetidine-3-carboxamide. MS (ESI): mass calcd. for C11H13BrN2O3S 331.98; m/z found 333.0 [M+H]+; 1H NMR (600 MHz, CDCl3) δ 8.09-8.04 (dd, J=7.8, 1.8, 1H), 7.79-7.74 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.44-7.37 (m, 1H), 5.72 (s, 1H), 4.25-4.13 (m, 4H), 3.29-3.16 (m, 1H), 2.89-2.77 (d, J=4.8, 3H).
Intermediate DI




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-oxa-6-azaspiro[3.3]heptane. MS (ESI): mass calcd. for C11H12BrNO3S 316.97; m/z found 317.9 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.00-7.96 (m, 1H), 7.91-7.88 (m, 1H), 7.63-7.56 (m, 2H), 4.62 (s, 4H), 4.11 (s, 4H).
Intermediate DJ




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-thia-6-azaspiro[3.3]heptane 2,2-dioxide. MS (ESI): mass calcd. for C11H12BrNO4S2 364.94; m/z found 365.9 [M+H]+; 1H NMR (600 MHz, DMSO-d6) δ 8.02-7.98 (m, 1H), 7.93-7.89 (m, 1H), 7.64-7.58 (m, 2H), 4.46 (s, 4H), 4.17 (s, 4H).
Intermediate DL




To a solution of 2-bromoaniline (344 mg, 2.0 mmol) in pyridine (5 mL) was slowly added ethyl-sulfonyl chloride (257 mg, 2.0 mmol) at rt and the mixture was stirred at rt for 16 hours. The pyridine was removed under reduced pressure and resulting residue diluted with water (30 mL) and extracted with DCM (10 mL×2). The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by FCC to give the title compound (240 mg, 45%). MS (ESI): mass calcd. for C8H10BrNO2S 262.96 m/z found 264.1 [M+H]+. 1H NMR (300 MHz, CDCl3) 7.71 (dd, J=4.8, 1.5, 1H), 7.59 (dd, J=4.8, 1.5, 1H), 7.32-7.28 (m, 1H), 7.08-7.05 (m, 1H), 6.77 (bs, 1H), 3.14 (q, J=7.2, 2H), 1.41 (t, J=7.5, 3H).
Intermediate DM




The title compound was prepared using analogous conditions described for Intermediate DL utilizing n-propylsulfonyl chloride. MS (ESI): mass calcd. for C9H12BrNO2S, 276.98; m/z found, 278.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 7.70 (dd, J=4.8, 1.5, 1H), 7.59 (dd, J=4.8, 1.5, 1H), 7.32-7.28 (m, 1H), 7.08-7.05 (m, 1H), 6.72 (br s, 1H), 3.15-2.94 (m, 2H), 1.93-1.73 (m, 2H), 1.00 (t, J=7.4, 3H).
Intermediate DN




The title compound was prepared using analogous conditions described for Intermediate DL utilizing iso-butylsulfonyl chloride. MS (ESI): mass calcd. for C10H14BrNO2S, 290.99; m/z found, 292.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 7.69 (dd, J=4.8, 1.5, 1H), 7.59 (dd, J=4.8, 1.5, 1H), 7.32-7.28 (m, 1H), 7.08-7.05 (m, 1H), 6.77 (br s, 1H), 2.99 (d, J=4.2, 2H), 2.38-2.25 (m, 1H), 1.07 (d, J=6.9, 6H).
Intermediate DO




Step A: Sodium (2-bromophenyl)methanesulfonate
A mixture of 1-bromo-2-(bromomethyl)benzene (20 g, 0.08 mol) and Na2SO3 (15 g, 0.12 mol) in methanol/H2O (100 mL/100 mL) was stirred at 85° Celsius for 2.5 hours, concentrated to dryness and dried to give sodium (2-bromophenyl)methanesulfonate (34 g, crude). 1H NMR (300 MHz, DMSO-d6) δ 7.54 (m, 2H), 7.27 (m, 1H), 7.12 (m, 1H), 3.91 (s, 2H).
Step B: (2-Bromophenyl)methanesulfonyl chloride
To a suspension of crude sodium (2-bromophenyl)methanesulfonate (34 g) in toluene (500 mL) was added PCl5 (34 g, 0.16 mol). The resulting mixture was stirred at 100° Celsius for 4 hours before concentrating to dryness and pouring the residue onto crushed ice (150 g), stirring for 5 min, and extracting with DCM (3×50 mL). The combined organic extracts were dried over MgSO4, filtered and concentrated to dryness to give (2-bromophenyl)methanesulfonyl chloride (16.8 g, 77%). 1H NMR (300 MHz, DMSO-d6) δ 7.62-7.45 (m, 2H), 7.29 (m, 1H), 7.18-7.01 (m, 1H), 3.97 (s, 2H).
Step C
To a solution of (2-bromophenyl)methanesulfonyl chloride (2 g, 7 mmol) in THF (15 mL) was added CH3NH2/H2O (25%, 2 g, 20 mmol) at 0° Celsius. The resulting mixture was warmed up to rt, stirred for 16 hours, concentrated to dryness and purified by HPLC to give the title compound (0.8 g, 41%). MS (ESI): mass calcd. for C8H8BrO2S, 262.96; m/z found, 264.0 [M+H]+; 1H NMR (300 MHz, CDCl3) δ 7.65-7.54 (m, 2H), 7.35 (m, 1H), 7.22 (dd, J=7.6, 1.7, 1H), 4.53 (s, 2H), 4.10 (s, 1H), 2.72 (s, 3H).
Intermediate DP




The title compound was prepared using analogous conditions described for Intermediate DO utilizing ethylamine. MS (ESI): mass calcd. for C9H12BrNO2S, 276.98; m/z found, 277.9 [M+H]+; 1H NMR (300 MHz, CD3OD) δ 7.64 (dd, J=8.0, 1.0, 1H), 7.57 (dd, J=7.6, 1.6, 1H), 7.37 (m, 1H), 7.25 (m, 1H), 4.54 (s, 2H), 3.03 (q, J=7.2, 2H), 1.12 (t, J=7.2, 3H).
Intermediate DQ




The title compound was prepared using analogous conditions described for Intermediate DO utilizing ethanolamine. MS (ESI): mass calcd. for C9H12BrNO3S, 292.97; m/z found, 294.0 [M+H]+; 1H NMR (300 MHz, CDCl3) δ 7.69-7.52 (m, 2H), 7.35 (m, 1H), 7.26-7.19 (m, 1H), 4.77 (t, J=6, 1H), 4.56 (s, 2H), 3.65 (t, J=6, 2H), 3.12 (t, J=6, 2H), 2.13 (br s, 1H).
Intermediate DR




The title compound was prepared using analogous conditions described for Intermediate DO utilizing (S)-3-amino-2-propanol. The product was isolated as a x. MS (ESI): mass calcd. for C7H4BrF3O2S, 306.99; m/z found, 307.9 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 7.69-7.52 (m, 2H), 7.35 (m, 1H), 7.29-7.20 (m, 1H), 4.67 (s, 1H), 3.96-3.76 (m, 1H), 3.17-2.96 (m, 1H), 2.95-2.74 (m, 1H), 1.90-1.63 (m, 2H), 1.15 (d, J=6.3, 3H).
Intermediate DS




The title compound was prepared using analogous conditions described for Intermediate DO utilizing (R)-3-amino-2-propanol.
Intermediate DT




The title compound was prepared using analogous conditions described for Intermediate DO using ammonia. 1H NMR (300 MHz, DMSO-d6) δ 7.65 (d, J=7.9, 1H), 7.52 (dd, J=7.6, 1.6, 1H), 7.41 (m, 1H), 7.28 (m, 1H), 7.04 (s, 2H), 4.46 (s, 2H).
Intermediate DU




The title compound was prepared using analogous conditions described for Intermediate DO utilizing piperazin-2-one. The product was isolated as a white solid. MS (ESI): mass calcd. for C11H13BrN2O3S, 331.98; m/z found, 333.0 [M+H]+; 1H NMR (300 MHz, CDCl3) δ 7.68-7.57 (m, 2H), 7.37 (m, 1H), 7.29-7.21 (m, 1H), 6.93 (s, 1H), 4.55 (s, 2H), 3.90 (s, J=18.1, 2H), 3.43-3.17 (m, 4H).
Intermediate DV




The title compound was prepared using analogous conditions described for Intermediate DO utilizing trans-4-aminocyclohexanol. The product was isolated as a white solid. MS (ESI): mass calcd. for C7H4BrF3O2S, 347.02; m/z found, 348.0 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 7.70-7.56 (m, 2H), 7.37 (m, 1H), 7.26 (m, 1H), 4.55 (s, 2H), 3.54-3.42 (m, 1H), 3.10-2.93 (m, 1H), 2.05-1.82 (m, 4H), 1.40-1.16 (m, 4H).
Intermediate DW




The title compound was prepared using analogous conditions described for Intermediate DO utilizing tert-butyl piperazine-1-carboxylate. The product was isolated as a white solid. MS (ESI): mass calcd. for C17H25BrN2O4S, 432.07; m/z found, 454.9 [M+Na]+. 1H NMR (300 MHz, DMSO-d6) δ 7.67 (dd, J=7.9, 1.2, 1H), 7.52 (dd, J=7.7, 1.7, 1H), 7.41 (m, 1H), 7.36-7.26 (m, 1H), 6.92 (d, J=7.8, 1H), 4.51 (s, 2H), 3.50 (d, J=12.2, 2H), 3.45-3.35 (m, 1H), 2.92 (t, J=11.3, 2H), 1.77 (d, J=12.5, 2H), 1.45-1.30 (m, 11H).
Intermediate DX




Step A: 1-(2-Bromobenzylsulfonyl)piperidin-4-amine.HCl
A mixture of tert-butyl (1-((2-bromobenzyl)sulfonyl)piperidin-4-yl)carbamate (500 mg, 1.15 mmol) in HCl methanol (6 N, 20 mL) was stirred at rt for 24 hours, and then concentrated to dryness to give 1-(2-bromobenzylsulfonyl)piperidin-4-amine.HCl (400 mg, 94%), which was directly used for next step without any further purification. MS (ESI): mass calcd. for C14H19BrN2O3S, 332.02; m/z found, 332.9 [M+H]+.
Step B
To a mixture of 1-(2-bromobenzylsulfonyl)piperidin-4-amine.HCl (200 mg, 0.54 mmol) and Et3N (164 mg, 1.62 mmol) in dry DCM (20 mL) was added acetyl chloride (85 mg, 1.1 mmol) drop-wise at rt. The reaction mixture was stirred at rt for 2 hours before concentrating to dryness and purifying the residue by HPLC to give the title compound (180 mg, 89%). MS (ESI): mass calcd. for C14H19BrN2O3S, 374.03; m/z found, 374.8 [M+H]+.
Intermediate DY




To a mixture of 1-(2-bromobenzylsulfonyl)piperidin-4-amine.HCl (200 mg, 0.54 mmol) and Et3N (164 mg, 1.62 mmol) in dry THF (20 mL) was added (COCl2)3 (160 mg, 0.54 mmol) at rt. The reaction mixture was stirred at rt for 1 hour, and then a solution of NH3 in THF (4 N, 10 mL) was added drop-wise. The resulting mixture was stirred at rt for 5 hours, concentrated to dryness and purified by HPLC to give the title compound (140 mg, 69%). MS (ESI): mass calcd. for C13H18BrN3O3S, 375.03; m/z found, 376.0 [M+H]+.
Intermediate DZ




The title compound was prepared using analogous conditions described for Intermediate DO utilizing 3-hydroxyazetidine. The product was isolated as a white solid. MS (ESI): mass calcd. for C7H4BrF3O2S, 304.97; m/z found 306.0 [M+H]+; 1H NMR (300 MHz, CDCl3) δ 7.59 (dd, J=17.3, 7.8, 2H), 7.33 (m, 1H), 7.24-7.17 (m, 1H), 4.61-4.37 (m, 3H), 4.04-3.90 (m, 2H), 3.87-3.75 (m, 2H), 2.13 (br s, 1H).
Intermediate EA




To a 50 mL round-bottomed flask were added a stirbar, water (3.5 mL) and H2SO4 (5.0 mL, 18 M). The flask was then cooled to approximately −10° Celsius and treated with t-BuOH (0.70 mL, 7.5 mmol) followed by 2-bromo-thiophenol (0.60 mL, 5.0 mmol) (drop-wise over three minutes). The resulting mixture was stirred for 24 hours with gradual warming to rt. The reaction mixture was then added to a separatory funnel containing Et2O and sat. NaHCO3. The layers were mixed thoroughly and then separated. The organic layer was washed with 1 N NaOH, dried over MgSO4, filtered and concentrated to dryness. The resulting residue was subjected to FCC gave the title compound (686 mg, 56%). 1H NMR (500 MHz, DMSO-d6) δ 7.75 (dd, J=7.8, 1.4, 1H), 7.68 (dd, J=7.6, 1.6, 1H), 7.43-7.37 (m, 1H), 7.36-7.29 (m, 1H), 1.28 (s, 9H).
Intermediate EB




To a 20 mL vial containing 411 mg (1.43 mmol) 2-bromophenyl)(tert-butyl)sulfane were added DCM (6.0 mL) and a stirbar. The vial was cooled to 0° Celsius and then charged with m-CPBA (77%, 922 mg, 4.43 mmol). The resultant mixture was stirred for 22 hours with gradual warming to rt. The mixture was diluted with EtOAc, washed with aq Na2S2O3 followed by 1 N NaOH, dried over MgSO4, filtered and concentrated to dryness. The residue was subjected to FCC to give the title compound (304 mg, 77%). 1H NMR (500 MHz, CDCl3) δ 8.09-8.02 (dd, J=7.9, 1.8, 1H), 7.79-7.74 (dd, J=7.9, 1.3, 1H), 7.50-7.45 (m, 1H), 7.45-7.39 (m, 1H), 1.42-1.37 (s, 9H).
Intermediate EC




Step A: (2-Bromophenyl)(3-(methylthio)propyl)sulfane
To a solution of 1-bromo-3-chloropropane (1.2 mL, 12.0 mmol), DIPEA (2.1 mL, 12.0 mmol) in DCM (50 mL) was added 2-bromobenzenethiol (1.08 mL, 6.0 mmol) at 5° Celsius. The reaction mixture was warmed to rt and stirred for 4 hours. The reaction mixture was concentrated to dryness and the residue dissolved in ethanol (50 mL) and treated with NaSCH3 (1.26 g, 18.0 mmol). The resulting mixture was stirred at rt for 18 h. The ethanol was then removed under reduced pressure and the residue taken up in DCM (100 mL) and washed with water (3×20 mL). The organic phase was dried over Na2SO4, filtered and concentrated to dryness to give (2-bromophenyl)(3-(methylthio)propyl)sulfane (2.3 g, crude).
Step B
The procedure to make 1-bromo-2-(3-(methylsulfonyl)propylsulfonyl)benzene is analogous to the one used to make Intermediate EB utilizing (2-bromophenyl)(3-(methylthio)propyl)sulfane. MS (ESI): mass calcd. for C10H13BrO4S2, 339.94; m/z found, 340.9 [M+H]+; 1H NMR (300 MHz, CDCl3) δ 8.19-8.12 (m, 1H), 7.83-7.75 (m, 1H), 7.59-7.46 (m, 2H), 3.65 (t, J=7.1, 2H), 3.34-3.23 (m, 2H), 2.94 (s, 3H), 2.43-2.30 (m, 2H).
Intermediate ED




To a suspension of NaH (135 mg, 3.40 mmol, 60% in mineral oil) in anhydrous DMF (5 mL) was added 2-bromobenzenethiol (580 mg, 3.10 mmol) drop-wise at rt. After the resultant mixture was stirred at 20° Celsius for 10 min, bromoethane (670 mg, 6.10 mmol) was slowly added into the mixture. The reaction mixture was stirred at 30° Celsius for 14 hours in an oil bath. The reaction was diluted with water (60 mL) and extracted with petroleum ether (20 mL×2). The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated to dryness. The residue was dissolved in a mixture of methanol (10 mL) and water (15 mL) then treated with oxone (10 g, 15 mmol) portion-wise. The reaction mixture was stirred at 80° Celsius for 16 hours. The mixture was cooled to rt and the methanol removed. The remaining aqueous mixture was further diluted with water (50 mL) and extracted with DCM (20 mL×2). The combined organic extracts were washed with brine, dried over Na2SO4, filtered, concentrated to dryness and purified by FCC to give the title compound (570 mg, 75%). 1H NMR (300 MHz, CDCl3) δ 8.18-8.12 (m, 1H), 7.76 (dd, J=7.8, 1.5, 1H), 7.52-7.43 (m, 2H), 3.46 (q, J=7.5, 2H), 1.26 (t, J=7.5, 3H).
Intermediate EE




The title compound was prepared using analogous conditions described for Intermediate ED utilizing 1-bromopropane. MS (ESI): mass calcd. for C9H11BrO2S, 261.97; m/z found, 263.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ8.15 (dd, J=7.8, 2.1, 1H), 7.78-7.74 (m, 1H), 7.54-7.42 (m, 2H), 3.45-3.37 (m, 2H), 1.80-1.67 (m, 2H), 1.02 (t. J=7.5, 3H).
Intermediate EF




The title compound was prepared using analogous conditions described for Intermediate ED utilizing 1-bromohexane. MS (ESI): mass calcd. for C12H17BrO2S, 304.01; m/z found, 305.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.20-8.12 (m, 1H), 7.82-7.73 (m, 1H), 7.58-7.44 (m, 2H), 3.49-3.38 (m, 2H), 1.77-1.63 (m, 2H), 1.43-1.24 (m, 6H), 0.86 (t, J=6.6, 3H).
Intermediate EG




The title compound was prepared using analogous conditions described for Intermediate ED utilizing isopropyl bromide. MS (ESI): mass calcd. for C9H11BrO2S, 261.97; m/z found, 263.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.14-8.10 (m, 1H), 7.77-7.72 (m, 1H), 7.50-7.43 (m, 2H), 3.93-3.83 (m, 1H), 1.30 (d, J=6.9, 6H).
Intermediate EH




The title compound was prepared using analogous conditions described for Intermediate ED utilizing isobutyl bromide. MS (ESI): mass calcd. for C10H13BrO2S, 275.98; m/z found, 277.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.19-8.14 (m, 1H), 7.78-7.73 (m, 1H), 7.55-7.42 (m, 2H), 3.34 (d, J=6.6, 2H), 2.30-2.19 (m, 1H), 1.07 (d, J=6.6, 6H).
Intermediate EI




The title compound was prepared using analogous conditions described for Intermediate ED utilizing bromocyclopropane. MS (ESI): mass calcd. for C9H9BrO2S, 259.95; m/z found, 261.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.11-8.04 (m, 1H), 7.76 (dd, J=7.8, 1.5, 1H), 7.52-7.43 (m, 2H), 3.22-3.14 (m, 1H), 1.36-1.31 (m, 2H), 1.08-1.03 (m, 2H).
Intermediate EJ




The title compound was prepared using analogous conditions described for Intermediate ED utilizing bromocyclobutane. MS (ESI): mass calcd. for C10H11BrO2S, 273.97; m/z found, 275.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.13 (dd, J=7.8, 2.1, 1H), 7.73 (dd, J=7.8, 1.5, 1H), 7.53-7.38 (m, 2H), 4.46 (p, J=8.1, 1H), 2.65-2.46 (m, 2H), 2.25-2.12 (m, 2H), 2.08-1.98 (m, 2H).
Intermediate EK




The title compound was prepared using analogous conditions described for Intermediate ED utilizing bromocyclopentane. MS (ESI): mass calcd. for C11H13BrO2S, 287.98; m/z found, 289.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.20-8.10 (m, 1H), 7.80-7.72 (m, 1H), 7.58-7.39 (m, 2H), 4.27-4.12 (m, 1H), 2.12-1.97 (m, 2H), 1.93-1.75 (m, 4H), 1.70-1.57 (m, 2H).
Intermediate EL




The title compound was prepared using analogous conditions described for Intermediate ED utilizing trifluoroiodomethane. MS (ESI): mass calcd. for C7H4BrF3O2S, 287.91; m/z found, 289.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.15-8.07 (m, 1H), 7.80-7.72 (m, 1H), 7.52-7.43 (m, 2H).
Intermediate EM




To a solution of 2-aminophenylboronic acid hydrochloride (347 mg, 2.0 mmol) in pyridine (5 mL) was slowly added chlorosulfonylisopropane (300 mg, 2.1 mmol). The mixture was stirred below 20° Celsius for 14 hours, concentrated to dryness and the residue purified by FCC to give the title compound (280 mg, 57% yield). 1H NMR (300 MHz, D2O+DMSO-d6) δ 8.57-8.55 (m, 1H), 7.82-7.79 (m, 1H), 7.49-7.46 (m, 1H), 7.40-7.37 (m, 2H), 7.08-7.05 (m, 1H), 3.31-3.27 (m, 1H), 1.26 (d, J=6.9, 6H).
Intermediate EN




A solution of 2-bromobenzene-1-sulfonyl chloride (0.300 g, 1.17 mmol) and 3,3-difluoropyrrolidine hydrochloride (0.169 g, 1.17 mmol) in pyridine (5 mL) was stirred for 16 hours at 60° Celsius. The reaction was then cooled to rt, diluted with EtOAc (25 mL), washed with 1 N HCl (2×25 mL), and brine (50 mL). The organic layer was isolated, dried over MgSO4, filtered and concentrated to dryness to yield the title compound (0.335 g, 86%), The product was used without further purification. 1H NMR (500 MHz, CDCl3) δ 8.13-8.09 (m, 1H), 7.80-7.76 (m, 1H), 7.50-7.41 (m, 2H), 3.74 (t, J=12.8, 2H), 3.67 (t, J=7.2, 2H), 2.44-2.35 (m, 2H).
Intermediate EO




The title compound was prepared in a manner similar to that described in Intermediate EN using 4,4-difluoropiperidine. 1H NMR (500 MHz, CDCl3) δ 8.13-8.11 (m, 1H), 7.78-7.75 (m, 1H), 7.50-7.45 (m, 1H), 7.44-7.39 (m, 1H), 3.53-3.44 (m, 4H), 2.12-2.03 (m, 4H).
Intermediate EP




The title compound was prepared in a manner similar to that described in Intermediate EN using piperazine.
Intermediate EQ




The title compound was prepared in a manner similar to that described in Intermediate EN using 3,3-difluoropiperidine. 1H NMR (500 MHz, CDCl3) δ 8.14-8.11 (m, 1H), 7.77-7.74 (m, 1H), 7.49-7.44 (m, 1H), 7.44-7.39 (m, 1H), 3.54 (t, J=11.2, 2H), 3.32 (t, J=5.5, 2H), 2.04-1.94 (m, 2H), 1.91-1.85 (m, 2H).
Intermediate ER




The title compound was prepared in a manner similar to that described in Intermediate EN using 3,3-difluoroazetidine. 1H NMR (500 MHz, CDCl3) 8.11-8.06 (m, 1H), 7.80-7.76 (m, 1H), 7.50-7.42 (m, 2H), 4.42 (t, J=12.1, 4H).

Intermediate ES




The title compound was prepared in a manner similar to that described in Intermediate EN using azepane.
Intermediate ET




The title compound was prepared in a manner similar to that described in Intermediate EN using 4-(trifluoromethyl)piperidin-4-ol.
Intermediate EU




A solution of 2-bromobenzene-1-sulfonyl chloride (50 mg, 0.20 mmol), tert-butyl piperidin-4-ylcarbamate (49 mg, 0.25 mmol), and diisopropylethyl amine (0.101 mL, 0.59 mmol) in CH2Cl2 was stirred for 90 min at rt. The reaction mixture was then concentrated to dryness to give the title compound in quantitative yield. The product was used without further purification.
Intermediate EV




The title compound was prepared in a manner similar to that described in Intermediate EU using racemic tert-butyl piperidin-3-ylcarbamate. 1H NMR (400 MHz, CDCl3) δ 8.12-8.09 (m, 1H), 7.77-7.74 (m, 1H), 7.48-7.38 (m, 2H), 4.91 (d, J=8.0, 1H), 3.79 (s, 1H), 3.45 (s, 1H), 3.32 (d, J=12.4, 1H), 3.23-3.07 (m, 2H), 1.86-1.59 (m, 4H), 1.45 (s, 9H).
Intermediate EW




A solution of racemic tert-butyl (1-((2-bromophenyl)sulfonyl)piperidin-3-yl)carbamate (82 mg, 0.20 mmol) in CH2Cl2 (5 mL) was treated with 2 N HCl/Et2O (1 mL, 2 mmol) and stirred 16 hours at rt. The reaction mixture was then concentrated to dryness to give the title compound in quantitative yield. The product was used without further purification.
Intermediate EX




The title compound was prepared in a manner similar to that described in Intermediate EW using tert-butyl (1-((2-bromophenyl)sulfonyl)piperidin-4-yl)carbamate.
Intermediate EY




The title compound was prepared in a manner similar to that described in Intermediate EU using 1-(methylsulfonyl)piperazine.
Intermediate EZ




The title compound was prepared in a manner similar to that described in Intermediate EU using 1-(piperazin-1-yl)ethanone.
Intermediate FA




The title compound was prepared in a manner similar to that described in Intermediate EU using cyclopropyl(piperazin-1-yl)methanone.
Intermediate FB




The title compound was prepared in a manner similar to that described in Intermediate EU using 2-(piperazin-1-yl)ethanol.
Intermediate FC




The title compound was prepared in a manner similar to that described in Intermediate EU using 1-cyclopropylpiperazine.
Intermediate FD




The title compound was prepared in a manner similar to that described in Intermediate EU using racemic-octahydropyrrolo[1,2-a]pyrazine.
Intermediate FE




The title compound was prepared in a manner similar to that described in Intermediate EU using piperazin-2-one.
Intermediate FF




The title compound was prepared in a manner similar to that described in Intermediate EU using racemic-piperidine-3-carbonitrile.
Intermediate FG




The title compound was prepared in a manner similar to that described in Intermediate EU using piperidine-4-carbonitrile.
Intermediate FH




The title compound was prepared in a manner similar to that described in Intermediate EU using 1-methylpiperazine.
Intermediate FI




A solution of 2-bromobenzene-1-sulfonyl chloride (0.500 g, 1.96 mmol), 4-acetamidopiperidine (0.335 g, 2.45 mmol), and diisopropylethyl amine (1.0 mL, 5.8 mmol) in CH2Cl2 (5 mL) was stirred for 15 min at rt. The reaction mixture was then washed with 1 N HCl (2×5 mL) followed by brine (10 mL). The organic layer was isolated, dried over MgSO4, filtered, and concentrated to dryness to give the title compound (0.672 g, 95%). The product was used without further purification. 1H NMR (400 MHz, CDCl3) δ 8.09-8.05 (m, 1H), 7.77-7.74 (m, 1H), 7.49-7.38 (m, 2H), 6.08 (d, J=8.0, 1H), 3.87-3.79 (m, 2H), 2.93-2.85 (m, 2H), 2.00-1.93 (m, 5H), 1.59-1.51 (m, 3H).
Intermediate FJ




The title compound was prepared in a manner similar to that described in Intermediate FI using piperidin-4-ol. 1H NMR (400 MHz, CDCl3) δ 8.11-8.07 (m, 1H), 7.77-7.73 (m, 1H), 7.48-7.36 (m, 2H), 3.92-3.84 (m, 1H), 3.65-3.55 (m, 2H), 3.18-3.11 (m, 2H), 1.99-1.88 (m, 2H), 1.69-1.59 (m, 2H).
Intermediate FK




The title compound was prepared in a manner similar to that described in Intermediate FI using piperidin-4-ylmethanol. 1H NMR (400 MHz, CDCl3) δ 8.11-8.07 (m, 1H), 7.76-7.73 (m, 1H), 7.47-7.36 (m, 2H), 3.90-3.84 (m, 2H), 3.50 (d, J=6.4, 2H), 2.82-2.73 (m, 2H), 1.79-1.84 (m, 2H), 1.67-1.56 (m, 1H), 1.37-1.24 (m, 2H).
Intermediate FL




The title compound was prepared in a manner similar to that described in Intermediate FI using 2-(piperidin-4-yl)ethanol. 1H NMR (400 MHz, CDCl3) δ 8.10-8.06 (m, 1H), 7.76-7.72 (m, 1H), 7.47-7.36 (m, 2H), 3.86-3.79 (m, 2H), 3.68 (t, J=6.3, 2H), 2.80-2.72 (m, 2H), 1.78-1.71 (m, 2H), 1.56-1.51 (m, 3H), 1.37-1.23 (m, 2H).
Intermediate FM




The title compound was prepared in a manner similar to that described in Intermediate FI using racemic piperidin-3-ol. 1H NMR (400 MHz, CDCl3) δ 8.13-8.09 (m, 1H), 7.77-7.73 (m, 1H), 7.50-7.37 (m, 2H), 3.89-3.82 (m, 1H), 3.57-3.51 (m, 1H), 3.40-3.32 (m, 1H), 3.24-3.16 (m, 1H), 3.06-3.00 (m, 1H), 2.16 (s, 1H), 1.94-1.80 (m, 2H), 1.70-1.50 (m, 2H).
Intermediate FN




The title compound was prepared in a manner similar to that described in Intermediate FI using racemic piperidin-3-ylmethanol. 1H NMR (400 MHz, CDCl3) δ 8.11-8.07 (m, 1H), 7.76-7.72 (m, 1H), 7.47-7.36 (m, 2H), 3.76-3.51 (m, 4H), 3.02-2.94 (m, 1H), 2.83-2.75 (m, 1H), 1.94-1.84 (m, 1H), 1.82-1.71 (m, 3H), 1.67-1.57 (m, 1H), 1.29-1.17 (m, 1H).
Intermediate FO




The title compound was prepared in a manner similar to that described in Intermediate FI using racemic 2-(piperidin-3-yl)ethanol. 1H NMR (400 MHz, CDCl3) δ 8.10-8.06 (m, 1H), 7.76-7.72 (m, 1H), 7.47-7.36 (m, 2H), 3.72-3.62 (m, 4H), 2.88-2.80 (m, 1H), 2.60-2.53 (m, 1H), 1.89-1.39 (m, 7H), 1.16-1.03 (m, 1H).
Intermediate FP




The title compound was prepared in a manner similar to that described in Intermediate FI using thiomorpholine 1,1-dioxide. 1H NMR (400 MHz, CDCl3) δ 8.17-8.11 (m, 1H), 7.81-7.76 (m, 1H), 7.53-7.43 (m, 2H), 3.92-3.86 (m, 4H), 3.24-3.13 (m, 4H).
Intermediate FQ




The title compound was prepared in a manner similar to that described in Intermediate FI using (1S,2S)-2-amino-1-phenylpropane-1,3-diol.
Intermediate FR




The title compound was prepared in a manner similar to that described in Intermediate FI using (S)-2-amino-4-methylpentan-1-ol.
Intermediate FS




The title compound was prepared in a manner similar to that described in Intermediate FI using 3-aminopropan-1-ol
Intermediate FT




The title compound was prepared in a manner similar to that described in Intermediate FI using (S)-2-amino-2-phenylethanol.
Intermediate FU




The title compound was prepared in a manner similar to that described in Intermediate FI using (R)-2-amino-2-phenylethanol
Intermediate FV




The title compound was prepared in a manner similar to that described in Intermediate FI using (1R,2S)-2-amino-1-phenylpropan-1-ol.
Intermediate FW




The title compound was prepared in a manner similar to that described in Intermediate FI using (2S,3S)-2-amino-3-methylpentan-1-ol.
Intermediate FX




The title compound was prepared in a manner similar to that described in Intermediate FI using (1R,2R)-2-aminocyclohexanol.
Intermediate FY




The title compound was prepared in a manner similar to that described in Intermediate FI using (1S,2R)-2-aminocyclohexanol
Intermediate FZ




The title compound was prepared in a manner similar to that described in Intermediate FI using (R)-2-aminobutan-1-ol.
Intermediate GA




A solution of 2-bromobenzene-1-sulfonyl chloride (100 mg, 0.39 mmol), 2,6-dimethylpiperazine (56 mg, 0.49 mmol), and diisopropylethyl amine (0.202 mL, 1.17 mmol) in CH2Cl2 (2.5 mL) was allowed to stir for 15 min at rt. The reaction mixture was then directly subjected to FCC purification to give the title compound (0.105 g, 81%). 1H NMR (600 MHz, CDCl3) δ 8.09-8.07 (m, 1H), 7.76-7.73 (m, 1H), 7.47-7.44 (m, 1H), 7.43-7.37 (m, 1H), 3.70-3.66 (m, 2H), 2.97-2.91 (m, 2H), 2.38-2.33 (m, 2H), 1.06-1.04 (m, 6H).
Intermediate GB




The title compound was prepared in a manner similar to that described in Intermediate EU using N-methylpiperidin-4-amine.
Intermediate GC




The title compound was prepared in a manner similar to that described in Intermediate EU using N,N-dimethylpiperidin-4-amine.
Intermediate GD




The title compound was prepared using analogous conditions to those described in Intermediate AM using cycloleucinol. 1H NMR (500 MHz, CDCl3) δ 8.16 (dd, J=7.8, 1.8, 1H), 7.75 (dd, J=7.9, 1.3, 1H), 7.51-7.45 (m, 1H), 7.44-7.39 (m, 1H), 5.25 (s, 1H), 4.23 (s, 1H), 3.59 (d. J=6.4, 2H), 2.36 (t, J=6.5, 1H), 1.90-1.78 (m, 1H), 1.77-1.60 (m, 4H), 1.56-1.49 (m, 2H).
Intermediate GE




The title compound was prepared using analogous conditions to those described in Intermediate AM using 3-phenyl-3-pyrrolidinol. 1H NMR (500 MHz, CDCl3) δ 8.17 (dd, J=7.8, 1.8, 1H), 7.77 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 3H), 7.43-7.34 (m, 3H), 7.34-7.27 (m, 1H), 3.82-3.75 (m, 3H), 3.71 (d, J=10.8, 1H), 2.46-2.37 (m, 1H), 2.29-2.23 (m, 1H), 2.15 (s, 1H).
Intermediate GF




The title compound was prepared using analogous conditions to those described in Intermediate AM using (R)-3-hydroxypyrrolidine. 1H NMR (500 MHz, CDCl3) δ 8.13 (dd, J=7.8, 1.7, 1H), 7.75 (dd, J=7.8, 1.3, 1H), 7.48-7.42 (m, 1H), 7.39 (m, 1H), 4.57-4.47 (m, 1H), 3.63-3.51 (m, 3H), 3.48-3.40 (m, 1H), 2.14-2.04 (m, 1H), 2.04-1.94 (m, 1H), 1.94-1.84 (m, 1H).
Intermediate GG




The title compound was prepared using analogous conditions to those described in Intermediate AM using (S)-3-hydroxypyrrolidine. 1H NMR (500 MHz, CDCl3) δ 8.12 (dd, J=7.8, 1.7, 1H), 7.75 (dd, J=7.8, 1.3, 1H), 7.45 (m, 1H), 7.39 (m, 1H), 4.56-4.46 (m, 1H), 3.65-3.50 (m, 3H), 3.44 (m, 1H), 2.13-2.03 (m, 1H), 2.03-1.87 (m, 2H).
Intermediate GH




The title compound was prepared using analogous conditions to those described in Intermediate AM using (racemic)-[1,3′-bipyrrolidin]-4′-ol. 1H NMR (500 MHz, CDCl3) δ 8.12 (dd, J=7.8, 1.8, 1H), 7.75 (dd, J=7.8, 1.3, 1H), 7.48-7.34 (m, 2H), 4.42-4.29 (m, 1H), 3.74 (m, 2H), 3.36 (m, 2H), 2.83 (dd, J=10.9, 6.3, 1H), 2.70-2.43 (m, 4H), 1.83-1.66 (m, 4H).
Intermediate GI




The title compound was prepared using analogous conditions to those described in Intermediate AM using Racemic-4-morpholinopyrrolidin-3-ol. 1H NMR (500 MHz, CDCl3) δ 8.11 (dd, J=7.8, 1.8, 1H), 7.76 (dd, J=7.8, 1.3, 1H), 7.49-7.44 (m, 1H), 7.44-7.38 (m, 1H), 4.35 (t, J=7.4, 1H), 3.78-3.70 (m, 2H), 3.70-3.67 (m, 4H), 3.35-3.26 (m, 2H), 2.89 (m, 1H), 2.65-2.56 (m, 2H), 2.52-2.44 (m, 2H).
Intermediate GJ




The title compound was prepared using analogous conditions to those described in Intermediate AM using Racemic-4-(4-methylpiperazin-1-yl)pyrrolidin-3-ol. 1H NMR (500 MHz, CDCl3) δ 8.10 (dd, J=7.8, 1.8, 1H), 7.76 (dd, J=7.8, 1.3, 1H), 7.51-7.37 (m, 2H), 4.37 (dd, J=12.1, 5.8, 1H), 3.81-3.65 (m, 2H), 3.29 (m, 2H), 2.99 (dd, J=13.1, 7.3, 1H), 2.91-2.57 (m, 8H), 2.45 (s, 3H).
Intermediate GK




The title compound was prepared using analogous conditions to those described in Intermediate EU using 2-bromobenzene-1-sulfonyl chloride and piperazin-2-one. MS (ESI): mass calcd. for C10H11BrN2O3S, 317.96; m/z found, 319.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.12 (s, 1H), 8.09-8.00 (m, 1H), 7.93-7.89 (m, 1H), 7.62 (m, 2H), 3.79 (s, 2H), 3.50-3.43 (m, 2H), 3.18 (m, 2H).
Intermediate GL




The title compound was prepared in a manner similar to that described for Intermediate EU using 2-aminoethanol. 1H NMR (500 MHz, CDCl3) δ 8.17-8.11 (dd, J=7.8, 1.8, 1H), 7.79-7.72 (dd. J=7.8, 1.3, 1H), 7.52-7.46 (m, 1H), 7.46-7.40 (m, 1H), 5.79-5.66 (t, J=5.7, 1H), 3.73-3.65 (dd, J=5.6, 4.6, 2H), 3.13-3.03 (m, 2H), 2.14 (s, 1H).
Intermediate GM




The title compound was prepared in a manner similar to that described for Intermediate EU using (R)-pyrrolidin-2-ylmethanol. 1H NMR (500 MHz, CDCl3) δ 8.25-8.04 (m, 1H), 7.86-7.70 (m, 1H), 7.54-7.45 (m, 1H), 7.45-7.39 (m, 1H), 4.11-3.96 (m, 1H), 3.75-3.57 (m, 2H), 3.58-3.46 (dd, J=10.8, 4.5, 1H), 3.46-3.36 (m, 1H), 2.91-2.39 (m, 1H), 2.14-1.85 (m, 3H), 1.85-1.74 (dd, J=10.7, 5.3, 1H).
Intermediate GN




The title compound was prepared in a manner similar to that described for Intermediate EU using (S)-pyrrolidin-2-ylmethanol. 1H NMR (500 MHz, CDCl3) δ 8.18-8.07 (dd, J=7.9, 1.8, 1H), 7.81-7.70 (dd, J=7.9, 1.3, 1H), 7.52-7.45 (m, 1H), 7.45-7.38 (m, 1H), 4.08-3.92 (m, 1H), 3.70-3.56 (m, 2H), 3.55-3.45 (m, 1H), 3.45-3.35 (m, 1H), 2.76-2.67 (t. J=6.1, 1H), 2.03-1.87 (m, 3H), 1.84-1.74 (m, 1H).
Intermediate GO




The title compound was prepared in a manner similar to that described for Intermediate EU using (R)-1-aminopropan-2-ol. 1H NMR (500 MHz, CDCl3) δ 8.17-8.09 (dd, J=7.8, 1.8, 1H), 7.81-7.71 (dd, J=7.8, 1.3, 1H), 7.51-7.46 (m, 1H), 7.46-7.40 (m, 1H), 5.65-5.60 (t, J=6.1, 1H), 3.98-3.81 (m, 1H), 3.08-2.96 (m, 1H), 2.85-2.58 (m, 1H), 2.04-2.02 (d, J=4.3, 1H), 1.18-1.14 (d, J=6.3, 3H).
Intermediate GP




The title compound was prepared in a manner similar to that described for Intermediate EU using (S)-1-aminopropan-2-ol. 1H NMR (500 MHz, CDCl3) δ 8.21-8.04 (dd, J=7.8, 1.8, 1H), 7.78-7.72 (dd, J=7.8, 1.3, 1H), 7.53-7.46 (m, 1H), 7.46-7.38 (m, 1H), 5.71-5.54 (d, J=5.9, 1H), 3.97-3.84 (m, 1H), 3.07-2.96 (m, 1H), 2.80-2.69 (m, 1H), 2.03-1.95 (d, J=4.4, 1H), 1.19-1.07 (d, J=6.3, 3H).
Intermediate GQ




The title compound was prepared in a manner similar to that described for Intermediate EU using 1-(aminomethyl)cyclohexanol. 1H NMR (500 MHz, CDCl3) δ 8.17-8.09 (dd. J=7.8, 1.8, 1H), 7.78-7.70 (dd, J=7.8, 1.3, 1H), 7.51-7.45 (m, 1H), 7.45-7.39 (m, 1H), 5.56-5.45 (t, J=6.3, 1H), 3.71 (s, 1H), 2.89-2.77 (d, J=6.4, 2H), 1.60-1.28 (m, 10H).
Intermediate GR




The title compound was prepared in a manner similar to that described for Intermediate EU using (S)-tert-butyl pyrrolidin-3-ylcarbamate. 1H NMR (500 MHz, CDCl3) δ 8.17-8.06 (dd, J=7.8, 1.8, 1H), 7.81-7.67 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.37 (m, 1H), 4.73 (s, 1H), 4.25 (s, 1H), 3.65-3.51 (d, J=8.8, 2H), 3.51-3.43 (m, 1H), 3.37-3.20 (dd, J=10.0, 3.8, 1H), 2.33-2.12 (m, 1H), 1.98-1.81 (dd, J=12.8, 6.9, 1H), 1.43 (s, 9H).
Intermediate GS




The title compound was prepared in a manner similar to that described for Intermediate EU using (R)-tert-butyl pyrrolidin-3-ylcarbamate. 1H NMR (500 MHz, CDCl3) δ 8.15-8.10 (dd, J=7.8, 1.8, 1H), 7.79-7.73 (dd, J=7.8, 1.3, 1H), 7.49-7.43 (m, 1H), 7.43-7.37 (m, 1H), 4.73 (s, 1H), 4.25 (s, 1H), 3.65-3.52 (m, 2H), 3.51-3.43 (m, 1H), 3.34-3.22 (m, 1H), 2.25-2.13 (m, 1H), 1.95-1.82 (dd, J=12.6, 7.0, 1H), 1.43 (s, 9H).
Intermediate GT




The title compound was prepared in a manner similar to that described for Intermediate EU using 2-(piperazin-1-yl)pyrazine. 1H NMR (500 MHz, CDCl3) δ 8.16-8.09 (m, 2H), 8.07-8.02 (dd, J=2.6, 1.5, 1H), 7.90-7.87 (d, J=2.6, 1H), 7.78-7.74 (dd, J=7.9, 1.3, 1H), 7.51-7.45 (m, 1H), 7.44-7.37 (m, 1H), 3.74-3.58 (m, 4H), 3.48-3.38 (m, 4H).
Intermediate GU




The title compound was prepared in a manner similar to that described for Intermediate EU using 2-(piperazin-1-yl)pyrimidine. 1H NMR (500 MHz, CDCl3) δ 8.33-8.27 (d, J=4.7, 2H), 8.15-8.06 (dd, J=7.9, 1.7, 1H), 7.78-7.71 (dd, J=7.9, 1.3, 1H), 7.50-7.43 (m, 1H), 7.43-7.36 (m, 1H), 6.57-6.43 (t, J=4.7, 1H), 3.98-3.78 (m, 4H), 3.42-3.31 (m, 4H).
Intermediate GV




The title compound was prepared in a manner similar to that described for Intermediate EU using methylamine and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. 1H NMR (500 MHz, CDCl3) δ 8.46-8.29 (d, J=2.4, 1H), 7.99-7.79 (d, J=8.3, 1H), 7.79-7.59 (dd. J=8.3, 2.3, 1H), 5.20-5.01 (d, J=6.4, 1H), 2.80-2.56 (d, J=5.3, 3H).
Intermediate GW




The title compound was prepared in a manner similar to that described for Intermediate EU using ethylamine and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. 1H NMR (500 MHz, CDCl3) δ 8.43-8.38 (m, 1H), 7.93-7.86 (dd, J=8.3, 0.9, 1H), 7.70-7.62 (m, 1H), 5.08 (s, 1H), 3.11-2.96 (m, 2H), 1.19-1.09 (t, J=7.2, 3H).
Intermediate GX




The title compound was prepared in a manner similar to that described for Intermediate EU using 2-aminoethanol and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. 1H NMR (500 MHz, CD3OD) δ 8.35-8.30 (m, 1H), 8.07-7.98 (dd, J=8.2, 0.9, 1H), 7.82-7.76 (m, 1H), 3.59-3.50 (t, J=5.9, 2H), 3.10-3.02 (t, J=5.9, 2H).
Intermediate GY




The title compound was prepared in a manner similar to that described for Intermediate EU using 1-methylpiperazine and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. 1H NMR (500 MHz, CDCl3) δ 8.37-8.28 (d, J=2.2, 1H), 7.98-7.86 (d, J=8.2, 1H), 7.73-7.59 (d, J=8.2, 1H), 3.45-3.31 (t, J=5.0, 4H), 2.60-2.42 (t, J=4.9, 4H), 2.40-2.20 (d, J=1.5, 3H).
Intermediate GZ




The title compound was prepared in a manner similar to that described for Intermediate EU using piperazin-2-one and 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride. 1H NMR (400 MHz, CDCl3) δ 8.43-8.35 (d, J=2.3, 1H), 7.99-7.89 (d, J=8.2, 1H), 7.77-7.65 (dd, J=8.3, 2.3, 2H), 6.95 (s, 2H), 3.99 (s, 3H), 3.73-3.58 (t, J=5.3, 3H), 3.51-3.42 (m, 3H), 1.36-1.04 (m, 1H).
Intermediate HA




To a 500 mL round-bottomed flask were added 5-bromo-2-aminopyrimidine (4.0 g, 23 mmol), 4-chloro-2-fluorophenylboronic acid (3.9 g, 23 mmol), palladium(II)trifluoroacetate (240 mg, 0.72 mmol), and triphenylphoshine (373 mg, 1.40 mmol). The reaction vessel was fitted with a rubber septum, sparged with nitrogen and then charged with sparged toluene (75 mL), ethanol (75 mL), and a 2M solution of sodium carbonate (42 mL, 84 mmol) (solvents were sparged individually nitrogen gas for 30 minutes). The resulting mixture was stirred vigorously and heated at 50° Celsius. After 12 hours, the mixture was cooled to rt and treated with 100 mL of water. The precipitate was isolated via vacuum filtration, and the filtrate extracted with EtOAC. The EtOAc solution was dried, filtered and concentrated to dryness. The resultant solids were recrystallized from IPA (80 mL) to afford title compound (3.8 g, 74%). MS (ESI): mass calcd. for C10H7ClFN3, 223.03; m/z found, 224.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.44 (d, J=1.4, 2H), 7.59 (m, 1H), 7.54 (dd, J=10.7, 2.1, 1H), 7.37 (dd, J=8.3, 2.1, 1H), 6.94 (s, 2H).
Intermediate HB




Nitrogen sparged 1,4-dioxane (80 mL) was added to a 250 mL round-bottomed flask containing 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.1 g, 8.4 mmol), 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine (1.5 g, 6.7 mmol), chloro(2-dicyclohexyl-phosphino-2′,4′,6′-triisopropyl-1-1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (X-Phos pre-catalyst) (0.1 g, 0.13 mmol), and potassium acetate (1.9 g, 20 mmol). The reaction mixture was heated at 80° Celsius for 4 hours before cooling to rt, concentrating to dryness, and the residue subjected to FCC to provide the title compound (1.8 g, 83%). MS (ESI): mass calcd. for C16H19BFN3O2, 315.15; m/z found, 316.4 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.53 (d, J=1.3 Hz, 2H), 7.64 (dd. J=7.6, 1.0 Hz, 1H), 7.58 (dd, J=11.0, 0.9 Hz, 1H), 7.38 (m, 1H), 5.23 (s, 2H), 1.36 (s, 12H).
Example 1




Method 1
To a 100 mL round-bottomed flask were added a stirbar, 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine, (3.639 g, 13.57 mmol) (2-(methylsulfonyl)-phenyl)boronic acid (4.076 g, 20.38 mmol), Pd(dppf)Cl2.CH2Cl2 (1.136 g, 1.391 mmol) and K2CO3 (5.663 g, 40.97 mmol). The flask was flushed with nitrogen and then charged with 56.0 mL thoroughly sparged (1 hour of bubbling N2) DMSO. The flask was heated at 80° Celsius for 5.25 hours before cooling to room temperature, diluting the reaction mixture with EtOAc and filtering the mixture through a pad of celite. The filtrate was washed twice with 1 N NaOH and the organic layer dried over MgSO4. Filtering and concentrating the filtrate to dryness gave the crude product. The soluble portion of the residue was then subjected to FCC to give the title compound. (3.80 g, 81%).
Method 2
Step A: 5-(4-Chloro-2-fluorophenyl)pyrazin-2-amine
To a nitrogen flushed flask containing 4-chloro-2-fluorobenzene boronic acid (40.0 g, 229 mmol), 2-amino-5-bromopyrazine (39.9 g, 229 mmol), palladium(II) trifluoroacetate (1.5 g, 4.6 mmol), and triphenylphosphine (2.4 g, 9.2 mmol) were added sparged toluene (750 mL), ethanol (750 mL), and 2 M Na2CO3(aq) (418 mL, 836 mmol). The mixture was stirred and heated at 50° Celsius for 15 hours and then cooled to rt. Water (750 mL) was added and the layers were separated. The aqueous layer was washed with ethyl acetate (750 mL). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated to dryness to give 55.4 g of crude product. The crude solid was crystallized from toluene (450 mL) to provide the title compound (40.0 g, 78%). MS (ESI): mass calcd. for C10H7ClFN3, 223.03; m/z found, 224.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.34 (dd, J=2.6, 1.5, 1H), 8.03 (d, J=1.6, 1H), 7.89 (m, 1H), 7.52 (dd, J=11.3, 2.1, 1H), 7.38 (dd, J=8.5, 2.1, 1H), 6.79 (s, 2H).
Step B: 5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine
To a nitrogen sparged flask containing 5-(4-chloro-2-fluorophenyl)pyrazin-2-amine (34.0 g, 152 mmol), 2-methylsulfonylphenylboronic acid (38.0 g, 190 mmol), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (2.39 g, 3.0 mmol) were added sparged THF (300 mL) and K3PO4(aq) (608 mL, 0.5 M). The mixture was stirred for 15 hours at rt and then concentrated under reduced pressure to remove the THF. The remaining portion was treated with toluene (325 mL) and THF (25 mL). The biphasic slurry was stirred for 20 h at rt and then filtered and the isolated solid washed with water (150 mL) and toluene (150 mL). The filter cake was dried to provide the title compound (47.1 g, 90%). MS (ESI): mass calcd. for C17H14FN3O2S, 343.08; m/z found, 344.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.41 (dd, J=2.4, 1.5, 1H), 8.12 (dd, J=7.9, 1.4, 1H), 8.04 (d, J=1.5, 1H), 7.93 (m, 1H), 7.80 (m, 1H), 7.72 (m, 1H), 7.48 (dd, J=7.6, 1.4, 1H), 7.37 (dd, J=12.3, 1.7, 1H), 7.32 (dd, J=8.1, 1.7, 1H), 6.76 (s, 2H), 2.95 (s, 3H).
Example 2




The title compound was prepared using analogous conditions to those described in Example 1 using (2-(methylsulfonamido)phenyl)boronic acid. MS (ESI): mass calcd. for C17H15FN4O2S, 358.09; m/z found, 359.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 9.11 (s, 1H), 8.40 (dd, J=2.3, 1.4, 1H), 8.04 (d, J=1.5, 1H), 7.97-7.89 (m, 1H), 7.50-7.34 (m, 6H), 6.71 (s, 2H), 2.84 (s, 3H).
Example 3




The title compound was prepared using analogous conditions to those described in Example 1 using 2-(methylsulfonyl)phenylboronic acid and 5-(4-bromo-2-fluorophenyl)-6-cyanopyrazin-2-amine. MS (ESI): mass calcd. for C18H13FN4O2S, 368.07; m/z found, 369.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.26 (s, 1H), 8.13 (dd, J=8.0, 1.4, 1H), 7.84-7.77 (m, 1H), 7.76-7.70 (m, 1H), 7.69-7.62 (m, 1H), 7.51 (dd, J=7.6, 1.4, 1H), 7.46 (dd, J=11.0, 1.6, 1H), 7.42-7.35 (m, 3H), 2.97 (s, 3H).
Example 4




The title compound was prepared using analogous conditions to those described in Example 1 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (500 MHz, DMSO-de) δ 8.39 (dd. J=2.2, 1.4, 1H), 8.09-8.02 (m, 2H), 7.93-7.87 (m, 1H), 7.68-7.63 (m, 1H), 7.63-7.57 (m, 1H), 7.38 (dd, J=7.5, 1.4, 1H), 7.33-7.26 (m, 2H), 6.94 (s, 1H), 6.71 (s, 2H), 1.02 (s, 9H).
Example 5




Method 1
To a 50 mL round-bottomed flask were added 1.071 g (2.67 mmol) 4′-(5-aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, a stirbar and 20 mL TFA. The mixture was heated at 50° Celsius for 2 hours and then carefully and slowly added to 300 mL rapidly stirring sat. NaHCO3. The resulting mixture was stirred for 30 min and then the solid was isolated via vacuum filtration. The solid was washed with 200 mL deionized water, air dried and then further dried under high vacuum with gentle heating to give the title compound (751 mg, 82%).
Method 2
Step A: 4′-(5-Aminopyrazin-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide
To a nitrogen flushed flask containing 5-(4-chloro-2-fluorophenyl)pyrazin-2-amine (82.8 g, 370 mmol), (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid (100.0 g, 388.9 mmol), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (5.83 g, 7.41 mmol) were added N2 sparged THF (926 mL) and sparged 0.5 M K3PO4(aq) (1.65 L, 825 mmol). The mixture was stirred for 15 hours at room temperature. The layers were separated and the organic layer was washed with 600 mL brine, dried over MgSO4, filtered, and concentrated to dryness to give a solid residue. The solid was dissolved in 900 mL DMA, stirred with 60 g activated charcoal at 80° Celsius for 2 hours, and then stirred at room temperature for an additional 16 hours. The charcoal was removed by filtration and then washed with 150 mL DMA. The combined filtrates were treated three times with fresh Silicycle brand SiliaMetS Thiol Pd Scavenger (30 g, 15 g, 7.5 g) in DMA at 80° Celsius for 8 hours to 16 hours. Upon cooling to rt the scavenger was filtered off and the filtrate was concentrated to dryness. The resulting solid was triturated in toluene (1.2 L) at 90° Celsius for 2 hours. Upon cooling to rt the solid was collected by filtration and washed twice with toluene (700 mL) and twice with hexanes (700 mL) yielding the title compound (120.0 g, 80.9%). MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.42-8.37 (m, 1H), 8.10-8.02 (m, 2H), 7.95-7.86 (m, 1H), 7.70-7.63 (m, 1H), 7.63-7.58 (m, 1H), 7.41-7.35 (m, 1H), 7.35-7.26 (m, 2H), 7.00-6.92 (s, 1H), 6.79-6.66 (s, 2H), 1.10-0.95 (s, 9H).
Step B: 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide
A solution of 4′-(5-aminopyrazin-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (130.0 g, 298.0 mmol), anisole (97.4 mL, 894.0 mmol), and TFA (228.0 mL, 2.98 mol) was stirred at 60° Celsius for 16 hours. The reaction was cooled to rt, concentrated to dryness, and partitioned between 600 mL H2O and 600 mL acetone. 750 mL sat. NaHCO3(aq), was added over 30 min. The resulting precipitate was isolated via filtration and rinsed with 300 mL H2O then 300 mL acetone. The precipitate was triturated with 1.5 L acetone at 50° Celsius for 16 hours. After cooling to room temperature the solid was collected by filtration and rinsed twice with 250 mL acetone then dried in a vacuum oven at 50° Celsius for 16 hours yielding the title compound (74.3 g, 72.4%). MS (ESI): mass calcd. for C16H13FN4O2S, 344.07; m/z found, 345.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.44-8.36 (s, 1H), 8.10-8.02 (m, 2H), 7.92-7.85 (m, 1H), 7.69-7.59 (m, 2H), 7.43-7.35 (m, 3H), 7.35-7.27 (m, 2H), 6.77-6.69 (s, 2H). Elemental analysis: calcd. for C16H13FN4O2S, C, 55.80; H, 3.81; N, 16.27; measured: C, 55.43; H, 3.54; N, 16.22.
Example 6




To a 5 mL microwave vial were added a stirbar, 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (54 mg, 0.17 mmol), 2-bromo-N-cyclohexylbenzenesulfonamide (58 mg, 0.18 mmol), Pd(dppf)Cl2.CH2Cl2 (10 mg, 0.013 mmol), and K2CO3 (80 mg, 0.58 mmol). The vial was capped and flushed with nitrogen before adding 1 mL N2 sparged DMSO and heating at 80° Celsius for 20 hours. The vial was cooled to rt and the reaction mixture subjected to FCC purification to give the title compound (45 mg, 62%). MS (ESI): mass calcd. for C22H23FN4O2S, 426.15; m/z found, 427.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.43-8.35 (m, 1H), 8.05-8.03 (d, J=1.4, 1H), 8.03-7.99 (dd, J=7.9, 1.4, 1H), 7.92-7.84 (m, 1H), 7.70-7.64 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.37 (m, 2H), 7.32-7.24 (m, 2H), 6.72 (s, 2H), 2.85-2.72 (m, 1H), 1.69-1.52 (m, 5H), 1.48-1.39 (m, 1H), 1.19-0.93 (m, 5H).
Example 7




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(2-methylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.42-8.37 (m, 1H), 8.05-8.01 (d, J=1.5, 1H), 7.95-7.91 (dd, J=7.9, 1.3, 1H), 7.91-7.86 (m, 1H), 7.70-7.65 (m, 1H), 7.64-7.59 (m, 1H), 7.55-7.49 (m, 1H), 7.44-7.40 (dd, J=7.5, 1.4, 1H), 7.33-7.26 (m, 2H), 6.73 (s, 2H), 2.55-2.51 (m, 2H), 1.65-1.54 (m, 1H), 0.81-0.75 (d, J=6.7, 6H).
Example 8




The title compound was prepared using analogous conditions to those described in Example 6 utilizing racemic 2-bromo-N-(2,2,2-trifluoro-1-methylethyl)-benzenesulfonamide. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.54-8.47 (d, J=8.9, 1H), 8.43-8.36 (m, 1H), 8.09-8.00 (m, 2H), 7.93-7.86 (m, 1H), 7.73-7.68 (m, 1H), 7.68-7.61 (m, 1H), 7.44-7.39 (dd, J=7.5, 1.4, 1H), 7.30-7.21 (m, 2H), 6.73 (s, 2H), 3.96-3.83 (m, 1H), 1.19-1.10 (d, J=6.9, 3H).
Example 9




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(cyclobutylmethyl)benzenesulfonamide. MS (ESI): mass calcd. for C21H21FN4O2S, 412.14; m/z found, 413.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.41-8.36 (dd, J=2.2, 1.4, 1H), 8.06-8.01 (d, J=1.5, 1H), 7.97-7.91 (dd, J=7.9, 1.4, 1H), 7.91-7.85 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.59 (m, 1H), 7.52-7.47 (m, 1H), 7.44-7.39 (dd. J=7.5, 1.4, 1H), 7.33-7.24 (m, 2H), 6.73 (s, 2H), 2.79-2.69 (dd, J=7.2, 5.8, 2H), 2.35-2.24 (m, 1H), 1.93-1.82 (m, 2H), 1.81-1.67 (m, 2H), 1.59-1.50 (m, 2H).
Example 10




The title compound was prepared using analogous conditions to those described in Example 6 utilizing racemic (endo)-N-Bicyclo[2.2.1]hept-2-yl-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C23H23FN4O2S, 438.15; m/z found, 439.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.42-8.36 (m, 1H), 8.06-8.01 (d, J=1.5, 1H), 7.99-7.94 (dd, J=7.9, 1.3, 1H), 7.91-7.85 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.60 (m, 1H), 7.43-7.39 (dd, J=7.5, 1.4, 1H), 7.39-7.34 (d, J=6.9, 1H), 7.30-7.22 (m, 2H), 6.73 (s, 2H), 2.83-2.74 (m, 1H), 2.12-2.06 (m, 1H), 1.97-1.92 (m, 1H), 1.47-1.37 (m, 2H), 1.34-1.21 (m, 3H), 1.01-0.77 (m, 4H).
Example 11




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(1-methylcyclobutyl)benzenesulfonamide. MS (ESI): mass calcd. for C21H21FN4O2S, 412.14; m/z found, 413.1 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.52 (s, 1H), 8.26 (s, 1H), 8.16-8.11 (dd, J=7.9, 1.3, 1H), 8.11-8.05 (m, 1H), 7.62-7.58 (m, 1H), 7.56-7.51 (m, 1H), 7.40-7.37 (dd, J=8.1, 1.7, 1H), 7.34-7.28 (m, 2H), 4.37 (s, 1H), 2.13-2.00 (m, 2H), 1.82-1.73 (m, 2H), 1.69-1.59 (m, 2H), 1.24 (s, 3H).
Example 12




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(1,1-dimethylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O2S, 414.15; m/z found, 415.1 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.56 (s, 1H), 8.28 (s, 1H), 8.18-8.13 (dd, J=7.9, 1.3, 1H), 8.12-8.06 (m, 1H), 7.62-7.56 (m, 1H), 7.55-7.49 (m, 1H), 7.44-7.39 (dd, J=8.1, 1.7, 1H), 7.35-7.28 (m, 2H), 3.90 (s, 1H), 1.50-1.39 (q, J=7.4, 2H), 1.01 (s, 6H), 0.78-0.68 (t, J=7.4, 3H).
Example 13




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(2,2,2-trifluoro-1,1-dimethylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H18F4N4O2S, 454.11; m/z found, 455.1 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.54 (s, 1H), 8.27 (s, 1H), 8.15-8.10 (dd, J=8.0, 1.3, 1H), 8.10-8.04 (m, 1H), 7.66-7.59 (m, 1H), 7.57-7.52 (m, 1H), 7.40-7.27 (m, 3H), 4.49 (s, 1H), 1.33 (s, 6H).
Example 14




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-cyclopentylbenzenesulfonamide. MS (ESI): mass calcd. for C21H21FN4O2S, 412.14; m/z found, 413.1 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.46 (s, 1H), 8.21 (s, 1H), 8.14-8.10 (dd, J=8.0, 1.4, 1H), 8.10-8.04 (m, 1H), 7.64-7.59 (m, 1H), 7.57-7.51 (m, 1H), 7.38-7.25 (m, 3H), 4.42-4.25 (d, J=6.6, 1H), 3.49-3.35 (m, 1H), 1.80-1.66 (m, 2H), 1.63-1.48 (m, 2H), 1.48-1.38 (m, 2H), 1.35-1.19 (m, 2H).
Example 15




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-methylbenzenesulfonamide. MS (ESI): mass calcd. for C17H15FN4O2S, 358.09; m/z found, 359.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.32 (s, 2H), 8.07-8.01 (dd, J=7.9, 1.4, 1H), 7.99-7.94 (m, 1H), 7.71-7.64 (m, 1H), 7.63-7.57 (m, 1H), 7.43-7.37 (dd, J=7.5, 1.4, 1H), 7.35-7.26 (m, 2H), 2.45 (s, 3H).
Example 16




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-ethylbenzenesulfonamide. MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 373.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37 (s, 1H), 8.30 (s, 1H), 8.10-8.01 (dd, J=8.0, 1.5, 1H), 8.01-7.93 (m, 1H), 7.70-7.62 (m, 1H), 7.62-7.54 (m, 1H), 7.42-7.36 (dd, J=7.6, 1.5, 1H), 7.35-7.25 (m, 2H), 2.91-2.74 (q, J=7.2, 2H), 1.08-0.93 (t, J=7.2, 3H).
Example 17




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(2-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C24H21FN4O2S, 448.14; m/z found, 449.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.35 (s, 1H), 8.14 (s, 1H), 8.10-8.05 (dd, J=7.9, 1.3, 1H), 7.99-7.91 (m, 1H), 7.63-7.57 (m, 1H), 7.57-7.49 (m, 1H), 7.31-7.26 (dd, J=7.5, 1.4, 1H), 7.23-7.17 (m, 2H), 7.17-7.09 (m, 3H), 7.05-6.98 (m, 2H), 4.82-4.67 (m, 1H), 3.15-3.00 (m, 2H), 2.75-2.65 (t, J=7.1, 2H).
Example 18




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1R)-2,2,2-trifluoro-1-phenylethyl]-benzenesulfonamide. MS (ESI): mass calcd. for C24H18F4N4O2S, 502.08; m/z found, 503.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.37-8.31 (s, 1H), 8.23-8.18 (dd, J=8.0, 1.4, 1H), 7.99-7.93 (d, J=1.6, 1H), 7.87-7.80 (m, 1H), 7.63-7.57 (m, 1H), 7.55-7.49 (m, 1H), 7.36-7.31 (d, J=7.4, 1H), 7.30-7.25 (m, 2H), 7.23-7.18 (d, J=7.6, 1H), 7.20-7.10 (m, 2H), 7.11-7.02 (m, 2H), 5.04-4.93 (s, 2H), 4.84-4.72 (m, 1H).
Example 19




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1S)-2,2,2-trifluoro-1-phenylethyl]-benzenesulfonamide.
Example 20




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.21-8.12 (m, 2H), 7.92-7.85 (s, 1H), 7.85-7.79 (m, 1H), 7.62-7.55 (m, 1H), 7.54-7.47 (m, 1H), 7.43-7.36 (d, J=8.0, 1H), 7.33-7.27 (dd, J=7.5, 1.4, 1H), 7.19-7.07 (d, J=12.6, 1H), 5.45-5.13 (s, 2H), 4.04-3.90 (m, 1H), 1.31-1.22 (d, J=7.0, 3H).
Example 21




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(2,3-dihydro-1H-inden-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C25H21FN4O2S, 460.14; m/z found, 461.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.44-8.39 (m, 1H), 8.24-8.18 (dd, J=8.0, 1.4, 1H), 8.05-8.00 (d, J=1.5, 1H), 7.91-7.84 (m, 1H), 7.65-7.58 (m, 1H), 7.58-7.51 (m, 1H), 7.34-7.29 (dd, J=7.5, 1.4, 1H), 7.27-7.21 (m, 1H), 7.15-7.04 (m, 5H), 4.89-4.74 (s, 2H), 4.74-4.61 (d, J=6.6, 1H), 4.00-3.89 (m, 1H), 3.06-2.92 (dd, J=15.9, 6.9, 2H), 2.70-2.58 (dd, J=15.9, 5.6, 2H).
Example 22




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1S)-2,3-dihydro-1H-inden-1-yl]benzenesulfonamide. MS (ESI): mass calcd. for C25H21FN4O2S, 460.14; m/z found, 461.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.30-8.24 (dd, J=7.9, 1.4, 1H), 8.24-8.19 (m, 1H), 8.00-7.95 (d, J=1.5, 1H), 7.85-7.78 (m, 1H), 7.65-7.58 (m, 1H), 7.58-7.52 (m, 1H), 7.34-7.27 (dd, J=7.5, 1.4, 1H), 7.23-7.18 (d, J=7.7, 1H), 7.18-7.12 (dd, J=4.9, 1.1, 2H), 7.07-6.98 (m, 2H), 6.96-6.88 (d, J=7.6, 1H), 5.05-4.90 (d, J=8.7, 1H), 4.87-4.79 (s, 2H), 4.79-4.71 (m, 1H), 2.86-2.74 (m, 1H), 2.74-2.60 (m, 1H), 2.28-2.16 (m, 1H), 1.79-1.64 (m, 1H).
Example 23




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1R)-2,3-dihydro-1H-inden-1-yl]benzenesulfonamide.
Example 24




The title compound was prepared using analogous conditions to those described in Example 6 using 2-bromo-N-[(1R)-1-phenylethyl]benzenesulfonamide. MS (ESI): mass calcd. for C24H21FN4O2S, 448.14; m/z found, 449.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.44-8.37 (d, J=1.4, 1H), 8.19-8.12 (m, 1H), 8.10-8.03 (dd, J=8.0, 1.3, 1H), 7.97-7.89 (m, 1H), 7.61-7.53 (m, 1H), 7.52-7.45 (m, 1H), 7.22-7.15 (m, 4H), 7.12-7.00 (s, 1H), 6.97-6.91 (m, 2H), 6.89-6.78 (s, 1H), 4.68-4.51 (d, J=7.0, 1H), 4.39-4.25 (m, 1H), 1.45-1.33 (d, J=6.9, 3H).
Example 25




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.28 (m, 2H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.01-7.93 (m, 1H), 7.71-7.63 (m, 1H), 7.62-7.55 (m, 1H), 7.43-7.37 (dd, J=7.6, 1.4, 1H), 7.37-7.30 (m, 2H), 3.42-3.37 (m, 1H), 3.30-3.25 (dd, J=10.9, 6.3, 1H), 3.24-3.16 (m, 1H), 1.04-0.98 (d, J=6.6, 3H).
Example 26




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-phenylbenzenesulfonamide. MS (ESI): mass calcd. for C22H17FN4O2S, 420.11; m/z found, 421.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 10.12 (s, 1H), 8.45-8.37 (m, 1H), 8.13-8.06 (d, J=1.5, 1H), 8.06-8.00 (dd, J=8.0, 1.4, 1H), 7.92-7.84 (t, J=8.3, 1H), 7.70-7.63 (m, 1H), 7.63-7.57 (m, 1H), 7.39-7.32 (dd, J=7.6, 1.4, 1H), 7.24-7.16 (dd, J=8.5, 7.3, 2H), 7.12 (s, 1H), 7.11-7.08 (dd, J=4.1, 1.6, 1H), 7.01-6.96 (m, 1H), 6.95-6.89 (m, 2H).
Example 27




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(3S)-1-ethyl-2-oxoazepan-3-yl]benzenesulfonamide. MS (ESI): mass calcd. for C24H26FN5O3S, 483.17; m/z found, 484.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.39-8.33 (d, J=1.4, 1H), 8.25-8.20 (d, J=1.4, 1H), 8.10-8.05 (m, 1H), 8.05-8.00 (dd, J=8.0, 1.3, 1H), 7.61-7.55 (m, 1H), 7.53-7.47 (m, 1H), 7.43-7.38 (dd, J=8.1, 1.7, 1H), 7.34-7.30 (dd, J=7.5, 1.4, 1H), 7.30-7.25 (dd, J=12.3, 1.7, 1H), 6.02-5.93 (d, J=5.5, 1H), 3.91-3.83 (m, 1H), 3.45-3.20 (m, 3H), 3.18-3.10 (m, 1H), 2.04-1.94 (m, 1H), 1.92-1.81 (m, 1H), 1.81-1.70 (m, 1H), 1.66-1.53 (m, 1H), 1.52-1.42 (m, 1H), 1.34-1.21 (m, 1H), 1.09-0.99 (t, J=7.2, 3H).
Example 28




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(3S)-2-oxoazepan-3-yl]benzenesulfonamide. MS (ESI): mass calcd. for C22H22FN5O3S, 455.14; m/z found, 456.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.46-8.33 (s, 1H), 8.24-8.14 (s, 1H), 8.10-8.00 (m, 2H), 7.63-7.56 (m, 1H), 7.56-7.48 (m, 1H), 7.41-7.35 (dd, J=8.0, 1.7, 1H), 7.35-7.29 (dd, J=7.4, 1.4, 1H), 7.29-7.25 (d, J=1.8, 1H), 7.00-6.82 (s, 1H), 5.88-5.71 (d, J=6.0, 1H), 3.89-3.73 (d, J=9.4, 1H), 3.24-3.11 (m, 1H), 3.11-2.97 (m, 1H), 2.09-1.98 (d, J=12.5, 1H), 1.98-1.85 (d, J=13.2, 1H), 1.81-1.67 (m, 1H), 1.64-1.44 (m, 2H), 1.37-1.21 (m, 1H).
Example 29




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(3S)-1-methyl-2-oxoazepan-3-yl]benzenesulfonamide. MS (ESI): mass calcd. for C23H24FN5O3S, 469.16; m/z found, 470.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.44-8.38 (d, J=1.3, 1H), 8.22 (s, 1H), 8.10-8.05 (m, 1H), 8.05-8.00 (dd, J=7.9, 1.3, 1H), 7.63-7.56 (m, 1H), 7.54-7.47 (m, 1H), 7.43-7.37 (dd, J=8.1, 1.5, 1H), 7.34-7.29 (dd, J=7.6, 1.4, 1H), 7.28-7.24 (m, 1H), 6.00-5.85 (d, J=5.6, 1H), 3.98-3.86 (d, J=11.4, 1H), 3.39-3.28 (dd, J=15.2, 11.4, 1H), 3.16-3.05 (dd, J=15.3, 5.1, 1H), 2.95 (s, 3H), 2.04-1.93 (dd, J=17.1, 4.1, 1H), 1.91-1.81 (m, 1H), 1.77-1.66 (m, 1H), 1.65-1.53 (m, 1H), 1.53-1.42 (m, 1H), 1.38-1.26 (m, 1H).
Example 30




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)benzenesulfonamide. MS (ESI): mass calcd. for C26H32FN5O2S, 497.23; m/z found, 498.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.35 (d, J=1.4, 1H), 8.35-8.30 (m, 1H), 8.18-8.13 (dd, J=8.0, 1.3, 1H), 8.05-7.99 (m, 1H), 7.73-7.67 (m, 1H), 7.65-7.59 (m, 1H), 7.45-7.40 (dd, J=7.6, 1.3, 1H), 7.39-7.36 (m, 1H), 7.36-7.32 (dd, J=2.9, 1.5, 1H), 3.49-3.39 (m, 1H), 2.75 (s, 3H), 1.95-1.87 (m, 2H), 1.75-1.64 (m, 2H), 1.38 (s, 6H), 1.30 (s, 6H).
Example 31




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-pyridin-3-ylbenzenesulfonamide. MS (ESI): mass calcd. for C21H16FN5O2S, 421.10; m/z found, 422.1 [M+H]+. 1H NMR (600 MHz. CD3OD) δ 8.38-8.34 (d, J=1.5, 1H), 8.34-8.30 (m, 2H), 8.29-8.23 (m, 2H), 7.91-7.85 (m, 1H), 7.83-7.79 (m, 1H), 7.75-7.71 (m, 1H), 7.71-7.68 (dd, J=8.6, 5.4, 1H), 7.68-7.64 (m, 1H), 7.41-7.37 (dd, J=7.6, 1.3, 1H), 7.20-7.15 (dd, J=12.1, 1.7, 1H), 7.15-7.12 (dd, J=8.0, 1.7, 1H).
Example 32




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-N-[(1S)-2-hydroxy-1-methylethyl]benzenesulfonamide.
Example 33




To a solution of tert-butanol (13 mg, 0.18 mmol) in DCM (5 mL) was added chlorosulfonylisocyanate (25 mg, 0.18 mmol) at 0° Celsius. The resulting solution containing N-(tert-butoxycarbonyl)sulfamoyl chloride was added to a reaction flask containing 5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazin-2-amine (50 mg, 0.18 mmol) and triethylamine (36 mg, 0.36 mmol) in anhydrous DCM (10 mL) at 0° Celsius. The mixture was warmed to rt, stirred 2 hours, then concentrated to dryness, re-dissolved in TFA/DCM (5 mL/5 mL), stirred at rt for 1 hour, and concentrated to dryness. The residue was diluted with water (10 mL) and saturated NaHCO3(aq) (10 mL), extracted with DCM (10 mL×3) and the combined organic extracts washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by HPLC to give the title compound (10 mg, 16%). MS (ESI): mass calcd. for C16H14FN5O2S, 359.09; m/z found, 360.0 [M+H]+; 1H NMR (300 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.33 (s, 1H), 8.04 (d, J=1.3, 1H), 7.91 (m, 1H), 7.63 (d, J=7.8, 1H), 7.44-7.22 (m, 4H), 7.24 (m, 1H), 7.05 (s, 2H), 6.70 (s, 2H).
Example 34




To a solution of 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (309 mg, 1.15 mmol) in DMSO (5 mL) was added K2CO3 (317 mg, 2.3 mmol). The mixture was sparged with N2 several times. Pd(PPh3)4 (66 mg, 0.058 mmol) and (2-(1-methylethylsulfonamido)-phenyl)boronic acid (280 mg, 1.15 mmol) were added and the resultant mixture sparged with N2. The mixture was heated at 80° Celsius for 14 hours before cooling to rt and diluting with water (70 mL). The precipitate was collected, rinsed with water, air dried, and then purified by HPLC to give the title compound (40 mg, 9%). MS (ESI): mass calcd. for C19H19FN4O2S, 386.12; m/z found, 387.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.72 (s, 1H), 8.25 (d, J=1.2, 1H), 8.16 (m, 1H), 7.50 (d, J=7.8, 1H), 7.47-7.34 (m, 5H), 3.15-3.03 (m, 1H), 1.23 (d, J=6.8, 6H).
Example 35




The title compound was prepared using analogous conditions to those described in Example 34 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(2-bromophenyl)ethanesulfonamide. MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 372.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.08 (s, 1H), 8.43-8.36 (m, 1H), 8.04 (d, J=1.0, 1H), 7.93 (m, 1H), 7.46-7.28 (m, 6H), 6.72 (s, 2H), 2.91 (q, J=7.4, 2H), 1.07 (t, J=7.3, 3H).
Example 36




The title compound was prepared using analogous conditions to those described in Example 34 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-bromo-2-(propylsulfonyl)benzene. MS (ESI): mass calcd. for C19H19FN4O2S, 386.12; m/z found, 387.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (s, 1H), 8.38 (s, 1H), 8.04 (d, J=1.3, 1H), 7.93 (m, 1H), 7.42-7.35 (m, 6H), 6.71 (s, 2H), 2.87-2.74 (m, 2H), 1.59-1.44 (m, 2H), 0.81 (t, J=7.4, 3H).
Example 37




The title compound was prepared using analogous conditions to those described in Example 34 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(2-bromophenyl)isobutylsulfonamide. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 8.14 (s, 1H), 7.96 (m, 1H), 7.49 (d, J=7.0, 1H), 7.45-7.30 (m, 5H), 2.77 (d, J=6.5, 2H), 2.15-2.02 (m, 1H), 0.97 (d, J=6.7, 6H).
Example 38




Step A: 2-(di-tert-Butyloxycarbonyl)amino-5-(4-bromo-2-fluorophenyl)pyrazine
2-Amino-5-(4-bromo-2-fluorophenyl)pyrazine (3.0 g, 11 mmol) was dissolved in pyridine (40 mL), and then slowly treated with (Boc)2O (6.8 g, 34 mmol) at rt. The mixture was stirred at rt for 18 hours, concentrated to dryness and purified by FCC to give 2-(di-tert-butyloxycarbonyl)amino-5-(4-bromo-2-fluorophenyl)pyrazine (3.6 g, 68%) as a white solid. MS (ESI): mass calcd. for C20H23FBrN3O4S, 467.09; m/z found, 468.0 [M+H]+.
Step B: 2-(di-tert-Butyloxycarbonyl)amino-5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazine
To a solution of 2-(di-tert-butyloxycarbonyl)amino-5-(4-bromo-2-fluorophenyl)-pyrazine (232 mg, 0.5 mmol) and 2-aminophenylboronic acid hydrochloride (174 mg, 1.0 mmol) in 1,4-dioxane/H2O (10 mL/0.5 mL) was added Na2CO3 (232 mg, 2.0 mmol). The mixture was sparged with N2 several times. Pd(PPh3)4 (29 mg, 0.025 mmol) was added and the resulted mixture was stirred at 80° Celsius for 14 hours under N2. After cooling to rt, the mixture was diluted with water (50 mL) and extracted with DCM (15 mL×3). The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated to dryness to give 2-(di-tert-butyloxycarbonyl)amino-5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazine, which was directly used in next step without any further purification. MS (ESI): mass calcd. for C26H29FN4O4S, 480.22; m/z found, 481.0 [M+H]+.
Step C
To a solution of 2-(di-tert-butyloxycarbonyl)amino-5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazine (280 mg crude, 0.5 mmol) in pyridine (5 mL) was slowly added cyclopropane-sulfonyl chloride (105 mg, 0.75 mmol) at rt. The resultant mixture was stirred at 60° Celsius for 16 hours. The mixture was concentrated to dryness, the residue diluted with 40 mL of water and extracted with DCM (10 mL×2). The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by FCC to give 230 mg of impure product. The solid was dissolved in HCl (4 N) in EtOH (5 mL) and stirred at rt for 1 hour, then concentrated to dryness. The residue was purified by HPLC to give the title compound (55 mg, 37% yield). MS (ESI): mass calcd. for C19H17FN4O4S, 384.11; m/z found, 385.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 9.14 (s, 1H), 8.39 (s, 1H), 8.05 (d, J=1.3, 1H), 7.92 (m, 1H), 7.51 (d, J=7.8, 1H), 7.48-7.34 (m, 5H), 6.81 (s, 2H), 2.48-2.42 (m, 1H), 0.89-0.75 (m, 4H).
Example 39




The title compound was prepared using analogous conditions to those described in Example 38 utilizing hexane-1-sulfonyl chloride. MS (ESI): mass calcd. for C22H25FN4O2S, 428.17; m/z found, 429.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.13 (s, 1H), 8.40 (s, 1H), 8.04 (d, J=1.1, 1H), 7.96 (m, 1H), 7.48-7.34 (m, 6H), 6.73 (s, 2H), 2.77-2.63 (m, 2H), 1.41-1.33 (m, 2H), 1.16-0.95 (m, 6H), 0.72 (t, J=6.9, 3H).
Example 40




The title compound was prepared using analogous conditions to those described in Example 38 utilizing cyclobutanesulfonyl chloride. MS (ESI): mass calcd. for C20H19FN4O2S, 398.12; m/z found, 399.0 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 9.07 (s, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 7.92 (m, 1H), 7.47-7.31 (m, 6H), 6.71 (s, 2H), 3.66 (p, J=7.7, 1H), 2.21-2.08 (m, 2H), 2.03-1.92 (m, 2H), 1.86-1.70 (m, 2H).
Example 41




Trifluoromethanesulfonic anhydride (263 mg, 0.95 mmol) was added drop-wise to a solution consisting of 2-(di-tert-butyloxycarbonyl)amino-5-(2′-amino-3-fluorobiphenyl-4-yl)pyrazine (300 mg, 0.62 mmol) and Et3N (190 mg, 1.86 mmol) and DCM (10 mL), at rt. The resulting mixture was stirred at rt for 16 hours, then quenched with sat. NaHCO3 (20 mL), diluted with water (40 mL), and extracted with DCM (15 mL×3). The combined organic fractions were washed with brine, dried over Na2SO4 and concentrated to dryness. The solid was dissolved in 4 N HCl in EtOH (10 mL) and stirred at rt for 1 hour, concentrated to dryness and purified by HPLC to give the title compound. MS (ESI): mass calcd. for C1H12F4N4O2S, 412.06; m/z found, 413.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1H), 8.06 (s, 1H), 7.96 (m, 1H), 7.56-7.45 (m, 3H), 7.44-7.32 (m, 3H), 6.77 (s, 2H).
Example 42




To a 20 mL vial were 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (50 mg, 0.19 mmol), (2-(N,N-dimethylsulfamoyl)phenyl)boronic acid, K2CO3 (43 mg, 0.19 mmol), and Pd(dppf)Cl2.CH2Cl2 (8 mg, 0.009 mmol), and a stir-bar. The vial was sealed with a teflon lined cap and sparged with N2. The vial was then charged with freshly sparged DMSO (2 mL) and then stirred 16 hours at 80° Celsius. The reaction mixture was then cooled to rt, filtered, and purified by HPLC to give the title compound (36 mg, 40%). MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 373.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.33 (s, 2H), 8.06-7.96 (m, 2H), 7.72-7.67 (m, 1H), 7.64-7.59 (m, 1H), 7.43-7.39 (m, 1H), 7.32-7.26 (m, 2H), 2.49 (s, 6H).
Example 43




The title compound was prepared in a manner similar to that described in Example 42 using 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2-(piperidin-1-ylsulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C21H21FN4O2S, 412.14; m/z found, 413.3 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.40-8.30 (m, 2H), 8.10-8.06 (m, 1H), 7.98 (m, 1H), 7.79-7.73 (m, 1H), 7.71-7.64 (m, 1H), 7.62-7.56 (m, 1H), 7.43-7.39 (m, 1H), 7.34-7.28 (m, 1H), 2.86 (d, J=5.3, 4H), 1.50-1.38 (m, 6H).
Example 44




The title compound was prepared in a manner similar to that described in Example 42 using 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2-(morpholinosulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 8.31 (s, 1H), 8.13-8.09 (m, 1H), 7.99 (m, 1H), 7.75-7.69 (m, 1H), 7.65-7.60 (m, 1H), 7.46-7.43 (m, 1H), 7.37-7.31 (m, 2H), 3.54-3.46 (m, 4H), 2.91-2.84 (m, 4H).
Example 45




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C20H19FN4O4S2, 462.08: m/z found, 463.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.62-8.60 (m, 1H), 8.16-8.14 (m, 1H), 8.13-8.12 (m, 1H), 8.05 (t, J=8.1 Hz, 1H), 7.69-7.65 (m, 1H), 7.59-7.54 (m, 1H), 7.39-7.36 (m, 1H), 7.25-7.21 (m, 2H), 4.81 (s, 2H), 3.36-3.30 (m, 4H), 3.02-2.98 (m, 4H).
Example 46




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)piperazine. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.39 (m, 1H), 8.21-8.13 (m, 2H), 8.01-7.95 (m, 1H), 7.79-7.74 (m, 1H), 7.69-7.63 (m, 1H), 7.50-7.46 (m, 1H), 7.37-7.30 (m, 2H), 3.14-3.08 (m, 4H), 3.06-2.99 (m, 4H).
Example 47




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N,N-diethylbenzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.29 (d, J=1.4, 1H), 8.08-8.04 (m, 1H), 8.0-7.94 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.36 (m, 1H), 7.32-7.25 (m, 2H), 2.96 (q, J=7.1, 4H), 1.00 (t, J=7.1, 6H).
Example 48




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)pyrrolidine. MS (ESI): mass calcd. for C20H19FN4O2S, 398.12; m/z found, 399.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 8.28 (d, J=1.4, 1H), 8.12-8.08 (m, 1H), 8.0-7.94 (m, 1H), 7.71-7.65 (m, 2H), 7.62-7.56 (m, 1H), 7.42-7.39 (m, 1H), 7.34-7.27 (m, 2H), 2.94 (t, J=6.7, 4H), 1.81-1.69 (m, 4H).
Example 49




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4,4-difluoropiperidine. MS (ESI): mass calcd. for C21H19F3N4O2S, 448.12: m/z found, 449.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.35 (s, 1H), 8.27 (d, J=1.4, 1H), 8.12 (d, J=8.0, 1H), 7.98 (m, 1H), 7.75-7.67 (m, 1H), 7.63 (m, 1H), 7.43 (d, J=7.6, 1H), 7.32 (d, J=10.6, 2H), 3.02-2.93 (m, 4H), 1.90-1.73 (m, 4H).
Example 50




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoropiperidine. MS (ESI): mass calcd. for C21H19F3N4O2S, 448.12; m/z found, 449.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.35-8.27 (m, 2H), 8.12-8.05 (m, 1H), 8.01-7.94 (m, 1H), 7.74-7.67 (m, 1H), 7.65-7.58 (m, 1H), 7.44-7.38 (m, 1H), 7.32-7.24 (m, 2H), 3.04-2.96 (m, 2H), 2.95-2.88 (m, 2H), 1.96-1.82 (m, 2H), 1.69-1.61 (m, 2H).
Example 51




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoropyrrolidine. MS (ESI): mass calcd. for C20H17F3N4O2S, 434.10; m/z found, 435.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.35 (d, J=1.3, 1H), 8.27 (d, J=1.4, 1H), 8.11 (d, J=7.9, 1H), 7.99 (m, 1H), 7.77-7.69 (m, 1H), 7.67-7.59 (m, 1H), 7.47-7.40 (m, 1H), 7.34-7.25 (m, 2H), 3.23 (t, J=12.9, 2H), 3.14 (t, J=7.3, 2H), 2.28-2.14 (m, 2H).
Example 52




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoroazetidine. MS (ESI): mass calcd. for C19H15F3N4O2S, 420.09; m/z found, 421.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37-8.26 (m, 2H), 8.14-8.07 (m, 1H), 8.02-7.95 (m, 1H), 7.77-7.69 (m, 1H), 7.66-7.57 (m, 1H), 7.48-7.40 (m, 1H), 7.35-7.24 (m, 2H), 4.02-3.92 (m, 4H).
Example 53




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)azepane. MS (ESI): mass calcd. for C22H23FN4O2S, 426.15; m/z found, 427.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.21 (s, 1H), 8.02 (d, J=7.9, 1H), 7.96 (t, J=8.2, 1H), 7.66 (m, 1H), 7.60-7.55 (m, 1H), 7.38 (d, J=6.5, 1H), 7.31-7.24 (m, 2H), 1.63-1.52 (m, 12H).
Example 54




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-methylpiperazine. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.2 [M+H]+. 1H NMR (400 MHz. CD3OD) δ 8.37 (m, 1H), 8.23 (d, J=1.4, 1H), 8.16-8.12 (m, 1H), 8.02-7.96 (m, 1H), 7.78-7.73 (m, 1H), 7.68-7.62 (m, 1H), 7.48-7.45 (m, 1H), 7.34 (s, 1H), 7.32-7.30 (m, 1H), 3.61-3.33 (m, 4H), 3.01-2.70 (m, 7H).
Example 55




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-(trifluoromethyl)piperidin-4-d. MS (ESI): mass calcd. for C22H20F4N4O3S, 496.12; m/z found, 497.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 8.23 (d, J=1.1, 1H), 8.15-8.11 (m, 1H), 7.94 (m, 1H), 7.75-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.45-7.41 (m, 1H), 7.35-7.27 (m, 2H), 3.29-3.22 (m, 2H), 2.79-2.64 (m, 2H), 1.65-1.48 (m, 4H).
Example 56




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-(methylsulfonyl)piperazine. MS (ESI): mass calcd. for C21H22FN5O4S2, 491.11; m/z found, 492.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.23 (s, 1H), 8.13 (d, J=7.0, 1H), 7.97 (m, 1H), 7.77-7.71 (m, 1H), 7.67-7.61 (m, 1H), 7.46 (d, J=6.4, 1H), 7.39-7.32 (m, 2H), 3.03-2.94 (m, 8H), 2.78 (s, 3H).
Example 57




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluor-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)ethanone. MS (ESI): mass calcd. for C22H22FN5O3S, 455.14; m/z found, 456.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.34 (d, J=6.0, 2H), 8.11-8.08 (m, 1H), 8.00 (m, 1H), 7.75-7.70 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.41 (m, 1H), 7.37-7.29 (m, 2H), 3.43-3.34 (m, 4H), 2.96-2.81 (m, 4H), 2.02 (s, 3H).
Example 58




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (4-((2-bromophenyl)sulfonyl)piperazin-1-yl)(cyclopropyl)-methanone. MS (ESI): mass calcd. for C24H24FN5O3S, 481.16: m/z found, 482.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.63-8.59 (m, 1H), 8.16-8.10 (m, 2H), 8.00 (m, 1H), 7.67-7.62 (m, 1H), 7.58-7.53 (m, 1H), 7.39-7.36 (m, 1H), 7.32-7.30 (m, 1H), 7.28 (s, 1H), 4.76 (s, 2H), 3.48 (s, 4H), 2.94-2.82 (m, 4H), 1.63-1.54 (m, 1H), 0.97-0.89 (m, 2H), 0.79-0.70 (m, 2H).
Example 59




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)ethanol. MS (ESI): mass calcd. for C22H24FN5O3S, 457.16; m/z found, 458.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (m, 1H), 8.21 (d, J=1.5, 1H), 8.16-8.13 (m, 1H), 7.98 (m, 1H), 7.79-7.73 (m, 1H), 7.68-7.63 (m, 1H), 7.49-7.45 (m, 1H), 7.36-7.30 (m, 2H), 3.86-3.78 (m, 2H), 3.66-3.32 (m, 4H), 3.24-3.20 (m, 2H), 3.15-2.72 (m, 4H).
Example 60




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-cyclopropylpiperazine. MS (ESI): mass calcd. for C23H24FN5O2S, 453.16; m/z found, 454.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.40 (s, 1H), 8.18-8.12 (m, 2H), 7.97 (m, 1H), 7.79-7.74 (m, 1H), 7.68-7.63 (m, 1H), 7.49-7.46 (m, 1H), 7.34-7.30 (m, 2H), 3.28-2.98 (d, J=1.6, 8H), 2.82-2.75 (m, 1H), 0.96-0.85 (m, 4H).
Example 61




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic 2-((2-bromophenyl)sulfonyl)octahydropyrrolo[1,2-a]pyrazine. MS (ESI): mass calcd. for C23H24FN5O2S, 453.16; m/z found, 454.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (d, J=1.4, 1H), 8.24 (d, J=1.4, 1H), 8.17-8.13 (m, 1H), 7.99 (m, 1H), 7.78-7.73 (m, 1H), 7.68-7.63 (m, 1H), 7.48-7.45 (m, 1H), 7.36-7.30 (m, 2H), 3.89-3.35 (m, 4H), 3.26-2.53 (m, 6H), 2.18-1.97 (m, 3H).
Example 62




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and Racemic-1-((2-bromophenyl)sulfonyl)-3,5-dimethylpiperazine. MS (ESI): mass calcd. for C22H24FN5O2S, 441.16; m/z found, 442.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.24 (d, J=1.4, 1H), 8.17-8.14 (m, 1H), 7.99 (m, 1H), 7.79-7.73 (m, 1H), 7.68-7.63 (m, 1H), 7.49-7.46 (m, 1H), 7.37-7.32 (m, 2H), 3.49-3.42 (m, 2H), 3.14-3.01 (m, 2H), 2.47-2.39 (m, 2H), 1.17 (d, J=6.6, 6H).
Example 63




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic 1-((2-bromophenyl)sulfonyl)piperidine-3-carbonitrile. MS (ESI): mass calcd. for C22H20FN5O2S, 437.13; m/z found, 438.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.35 (s, 1H), 8.29 (d, J=1.1, 1H), 8.11-8.07 (m, 1H), 7.98 (m, 1H), 7.74-7.68 (m, 1H), 7.65-7.60 (m, 1H), 7.44-7.40 (m, 1H), 7.36-7.30 (m, 2H), 3.06-3.02 (m, 2H), 2.90-2.86 (m, 2H), 2.80-2.74 (m, 1H), 1.89-1.80 (m, 1H), 1.77-1.61 (m, 2H), 1.53-1.42 (m, 1H).
Example 64




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)piperidine-4-carbonitrile. MS (ESI): mass calcd. for C22H20FN5O2S, 437.13; m/z found, 438.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.35 (s, 1H), 8.29 (d, J=1.1, 1H), 8.12-8.09 (m, 1H), 7.99 (m, 1H), 7.74-7.69 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.42 (m, 1H), 7.34 (s, 1H), 7.32-7.30 (m, 1H), 3.10-3.02 (m, 2H), 2.86-2.73 (m, 3H), 1.82-1.73 (m, 2H), 1.64-1.53 (m, 2H).
Example 65




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)piperidin-4-amine. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.25-8.23 (d. J=1.4, 1H), 8.11-8.08 (m, 1H), 7.96 (m, 1H), 7.74-7.69 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.41 (m, 1H), 7.32-7.29 (m, 1H), 7.28 (s, 1H), 3.47-3.40 (m, 2H), 3.18-3.08 (m, 1H), 2.57-2.43 (m, 2H), 1.91-1.84 (m, 2H), 1.51-1.39 (m, 2H).
Example 66




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 4-((2-bromophenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.27 (d, J=1.4, 1H), 8.17-8.13 (m, 1H), 7.98 (m, 1H), 7.77-7.72 (m, 1H), 7.67-7.62 (m, 1H), 7.47-7.43 (m, 1H), 7.34-7.26 (m, 2H), 3.39 (s, 2H), 3.14 (s, 4H).
Example 67




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)piperidin-4-ol. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36-8.31 (m, 2H), 8.10-8.06 (m, 1H), 7.99 (m, 1H), 7.73-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (m, 1H), 7.34-7.28 (m, 2H), 3.66-3.55 (m, 1H), 3.20-3.08 (m, 2H), 2.71-2.61 (m, 2H), 1.72-1.63 (m, 2H), 1.39-1.26 (m, 2H).
Example 68




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (1-((2-bromophenyl)sulfonyl)piperidin-4-yl)methanol. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36-8.29 (m, 2H), 8.11-8.07 (m, 1H), 7.98 (m, 1H), 7.74-7.67 (m, 1H), 7.64-7.59 (m, 1H), 7.44-7.41 (m, 1H), 7.36-7.29 (m, 2H), 3.40-3.32 (m, 4H), 2.46-2.36 (m, 2H), 1.59 (d, J=10.5, 2H), 1.48-1.36 (m, 1H), 1.01-0.89 (m, 2H).
Example 69




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)ethanol. MS (ESI): mass calcd. for C23H25FN4O3S, 456.16; m/z found, 457.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 1H), 8.31 (d, J=1.2, 1H), 8.10-8.07 (m, 1H), 7.98 (m, 1H), 7.73-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.41 (m, 1H), 7.34 (s, 1H), 7.32-7.30 (m, 1H), 3.56-3.48 (m, 2H), 3.32 (d, J=4.5, 2H), 2.45-2.36 (m, 2H), 1.61-1.54 (m, 2H), 1.46-1.34 (m, 3H), 1.01-0.87 (m, 2H).
Example 70




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic-1-((2-bromophenyl)sulfonyl)piperidin-3-ol. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 1H), 8.31 (d, J=1.4, 1H), 8.11-8.06 (m, 1H), 8.01-7.96 (m, 1H), 7.73-7.68 (m, 1H), 7.64-7.59 (m, 1H), 7.44-7.40 (m, 1H), 7.34-7.32 (m, 1H), 7.31-7.29 (m, 1H), 3.44-3.35 (m, 1H), 3.27-3.21 (m, 1H), 3.15-3.06 (m, 1H), 2.48-2.38 (m, 1H), 2.27-2.21 (m, 1H), 1.88-1.79 (m, 1H), 1.68-1.59 (m, 1H), 1.41-1.28 (m, 1H), 1.26-1.15 (m, 1H).
Example 71




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic-2-(1-((2-bromophenyl)sulfonyl)piperidin-3-yl)ethanol. MS (ESI): mass calcd. for C23H25FN4O3S, 456.16; m/z found, 457.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36-8.31 (m, 2H), 8.10-8.05 (m, 1H), 8.01-7.95 (m, 1H), 7.73-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (m, 1H), 7.36-7.29 (m, 2H), 3.52-3.40 (m, 2H), 3.26-3.16 (m, 2H), 2.48-2.36 (m, 1H), 2.14-2.08 (m, 1H), 1.77-1.67 (m, 1H), 1.62-1.53 (m, 1H), 1.49-1.37 (m, 1H), 1.36-1.25 (m, 3H), 1.02-0.89 (m, 1H).
Example 72




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-N-methylpiperidin-4-amine. MS (ESI): mass calcd. for C22H24FN5O2S, 441.16; m/z found, 442.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.21 (d, J=1.4, 1H), 8.12-8.09 (m, 1H), 7.96 (m, 1H), 7.75-7.70 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.41 (m, 1H), 7.32-7.30 (m, 1H), 7.28 (s, 1H), 3.49-3.42 (m, 2H), 3.10-3.01 (m, 1H), 2.63 (s, 3H), 2.54-2.42 (m, 2H), 2.00-1.92 (m, 2H), 1.47-1.35 (m, 2H).
Example 73




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)-N,N-dimethylpiperidin-4-amine. MS (ESI): mass calcd. for C23H26FN5O2S, 455.18; m/z found, 456.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (m, 1H), 8.20 (d, J=1.5, 1H), 8.14-8.10 (m, 1H), 7.99-7.94 (m, 1H), 7.76-7.71 (m, 1H), 7.66-7.61 (m, 1H), 7.47-7.43 (m, 1H), 7.36-7.30 (m, 2H), 3.52-3.45 (m, 2H), 3.26-3.16 (m, 1H), 2.78 (s, 6H), 2.55-2.44 (m, 2H), 1.93 (d, J=11.6, 2H), 1.48-1.36 (m, 2H).
Example 74




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic-1-((2-bromophenyl)sulfonyl)piperidin-3-amine. MS (ESI): mass calcd. for C26H30FN5O4S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.45 (s, 1H), 8.33 (s, 1H), 8.11-8.07 (m, 1H), 8.03 (m, 1H), 7.76-7.70 (m, 1H), 7.67-7.62 (m, 1H), 7.46-7.42 (m, 1H), 7.36-7.29 (m, 2H), 3.40-3.41 (m, 1H), 3.13-3.02 (m, 2H), 2.66-2.60 (m, 2H), 2.01-1.92 (m, 1H), 1.78-1.67 (m, 1H), 1.55-1.42 (m, 2H).
Example 75




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)acetamide. MS (ESI): mass calcd. for C23H24FN5O3S, 469.16; m/z found, 470.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.41-8.38 (m, 1H), 8.08 (d, J=1.4, 1H), 8.01-7.97 (m, 1H), 7.90 (m, 1H), 7.80 (d, J=7.6, 1H), 7.77-7.72 (m, 1H), 7.68-7.63 (m, 1H), 7.46-7.42 (m, 1H), 7.33-7.24 (m, 2H), 3.61-3.50 (m, 1H), 3.26-3.18 (m, 2H), 2.59-2.52 (m, 2H), 1.76 (s, 3H), 1.67-1.59 (m, 2H), 1.27-1.15 (m, 2H).
Example 76




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic (1-((2-bromophenyl)sulfonyl)piperidin-3-yl)methanol. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.33 (d, J=8.7, 2H), 8.10-8.06 (m, 1H), 7.96 (m, 1H), 7.73-7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (m, 1H), 7.36-7.29 (m, 2H), 3.43-3.32 (m, 2H), 3.27-3.16 (m, 2H), 2.43-2.34 (m, 1H), 2.22-2.14 (m, 1H), 1.68-1.54 (m, 2H), 1.53-1.42 (m, 1H), 1.35-1.21 (m, 1H), 1.03-0.91 (m, 1H).
Example 77




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic tert-butyl (1-((2-bromophenyl)sulfonyl)piperidin-3-yl)carbamate. MS (ESI): mass calcd. for C26H30FN5O4S, 527.20: m/z found, 528.3 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.34 (d, J=9.1, 2H), 8.10-8.07 (m, 1H), 8.00 (m, 1H), 7.73-7.68 (m, 1H), 7.64-7.59 (m, 1H), 7.44-7.40 (m, 1H), 7.35-7.29 (m, 2H), 3.30-3.20 (m, 2H), 3.15-3.06 (m, 1H), 2.51-2.40 (m, 1H), 2.30-2.21 (m, 1H), 1.79-1.70 (m, 1H), 1.65-1.56 (m, 1H), 1.39-1.28 (m, 10H), 1.26-1.14 (m, 1H).
Example 78




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((1S,2S)-1,3-dihydroxy-1-phenylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C25H23FN4O4S, 494.14; m/z found, 495.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.45 (d. J=1.4, 1H), 8.10 (s, 1H), 7.87-7.80 (m, 2H), 7.55 (t, J=7.5, 1H), 7.43-7.36 (m, 2H), 7.30-7.14 (m, 8H), 4.89 (d, J=4.0, 1H), 3.65-3.57 (m, 1H), 3.36 (d, J=1.4, 2H).
Example 79




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (S)-2-bromo-N-(1-hydroxy-4-methylpentan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H25FN4O3S, 444.16; m/z found, 445.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.33 (s, 1H), 8.29 (d, J=1.4, 1H), 8.16-8.12 (m, 1H), 7.98-7.92 (m, 1H), 7.68-7.63 (m, 1H), 7.60-7.55 (m, 1H), 7.40-7.28 (m, 3H), 3.41-3.34 (m, 1H), 3.29-3.22 (m, 2H), 1.59-1.47 (m, 1H), 1.35-1.17 (m, 2H), 0.81 (d, J=6.7, 3H), 0.73 (d, J=6.5, 3H).
Example 80




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-(3-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (d, J=1.2, 1H), 8.30 (s, 1H), 8.08-8.03 (m, 1H), 8.01-7.96 (m, 1H), 7.70-7.63 (m, 1H), 7.62-7.56 (m, 1H), 7.42-7.32 (m, 1H), 7.36-7.28 (m, 2H), 3.51 (t, J=6.2, 2H), 2.88 (t, J=7.0, 2H), 1.65-1.54 (m, 2H).
Example 81




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (S)-2-bromo-N-(2-hydroxy-1-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C24H21FN4O3S, 464.13; m/z found, 465.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.30 (m, 2H), 8.05-8.01 (m, 1H), 7.85 (t, J=8.2, 1H), 7.61-7.56 (m, 1H), 7.50-7.44 (m, 1H), 7.26-7.19 (m, 4H), 7.10-6.97 (m, 4H), 4.20 (t, J=6.6, 1H), 3.69-3.58 (m, 2H).
Example 82




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (R)-2-bromo-N-(2-hydroxy-1-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C24H21FN4O3S, 464.13; m/z found, 465.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36-8.32 (m, 1H), 8.07-8.01 (m, 2H), 7.75 (t, J=8.2, 1H), 7.60-7.54 (m, 1H), 7.49-7.44 (m, 1H), 7.25-7.18 (m, 4H), 7.07-7.00 (m, 3H), 6.98-6.92 (m, 1H), 4.19 (t, J=6.6, 1H), 3.69-3.58 (m, 2H).
Example 83




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C25H23FN4O3S, 478.15; m/z found, 479.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.12-8.05 (m, 2H), 7.89-7.83 (m, 1H), 7.67-7.62 (m, 1H), 7.59-7.54 (m, 1H), 7.37-7.34 (m, 1H), 7.27-7.12 (m, 7H), 4.60 (t, J=4.4, 1H), 3.42-3.34 (m, 1H), 0.91-0.84 (m, 3H).
Example 84




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((2S,3S)-1-hydroxy-3-methylpentan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H25FN4O3S, 444.16; m/z found, 445.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.16-8.13 (m, 1H), 8.06 (d, J=1.4, 1H), 7.86 (m, 1H), 7.67-7.62 (m, 1H), 7.58-7.53 (m, 1H), 7.39-7.28 (m, 3H), 3.46-3.35 (m, 2H), 3.13 (q, J=5.4, 1H), 1.60-1.49 (m, 1H), 1.48-1.36 (m, 1H), 1.07-0.93 (m, 1H), 0.84-0.74 (m, 6H).
Example 85




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((1R,2R)-2-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37-8.30 (m, 2H), 8.21-8.16 (m, 1H), 7.97 (m, 1H), 7.68-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.40-7.32 (m, 3H), 3.26-3.18 (m, 1H), 2.87-2.79 (m, 1H), 1.94-1.77 (m, 2H), 1.67-1.50 (m, 2H), 1.26-1.09 (m, 4H).
Example 86




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (R)-2-bromo-N-(1-hydroxybutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.32 (m, 2H), 8.16-8.12 (m, 1H), 7.96 (m, 1H), 7.68-7.63 (m, 1H), 7.60-7.55 (m, 1H), 7.40-7.30 (m, 3H), 3.43-3.35 (m, 1H), 3.33 (d, J=5.9, 1H), 3.12-3.05 (m, 1H), 1.60-1.48 (m, 1H), 1.42-1.28 (m, 1H), 0.79 (t, J=7.4, 3H).
Example 87




The title compound was prepared in a manner similar to that described in Example 448 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-((1R,2S)-2-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.33 (s, 2H), 8.15-8.11 (m, 1H), 7.98 (m, 1H), 7.69-7.64 (m, 1H), 7.61-7.56 (m, 1H), 7.42-7.32 (m, 3H), 3.70-3.63 (m, 1H), 3.09-3.03 (m, 1H), 1.70-1.61 (m, 1H), 1.60-1.44 (m, 3H), 1.42-1.24 (m, 3H), 1.22-1.10 (m, 1H).
Example 88




5-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (40 mg, 0.13 mmol) and 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide (53 mg, 0.19 mmol) were added to a 5 mL sealable vial equipped with a stir bar. 1,4-Dioxane (0.7 mL) and Na2CO3 (0.3 mL, 2 M) were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 min before adding Pd(dppf)Cl2.CH2Cl2 (5 mg, 0.006 mmol) and heating the mixture heated 15 hours at 80° Celsius. The reaction was cooled to rt, diluted with 2 mL of ethylacetate, 2 mL of water and extracted with of ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na2SO4 and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C18H17FN4O3S, 388.10; m/z found, 389.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.37 (dd, J=2.2, 1.5, 1H), 8.11-8.06 (m, 2H), 7.93-7.86 (m, 1H), 7.70-7.64 (m, 1H), 7.62-7.56 (m, 1H), 7.44-7.38 (dd, J=7.6, 1.3, 1H), 7.35-7.27 (m, 2H), 3.49-3.44 (t, J=5.9, 2H), 2.90-2.84 (t, J=5.9, 2H).
Example 89




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-cyclopropylbenzenesulfonamide. MS (ESI): mass calcd. for C19H17FN4O2S, 384.11; m/z found, 385.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.31 (d, J=1.6, 1H), 8.26-8.18 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.0, 1.3, 1H), 7.97-7.89 (m, 1H), 7.73-7.66 (m, 1H), 7.65-7.57 (m, 1H), 7.46-7.37 (dd, J=7.6, 1.4, 1H), 7.33-7.23 (m, 3H), 2.22-2.13 (m, 1H), 0.50-0.43 (m, 2H), 0.41-0.34 (m, 2H).
Example 90




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(cyclopropylmethyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H19FN4O2S, 398.12; m/z found, 399.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.33 (m, 1H), 8.15-8.10 (dd, J=8.0, 1.3, 1H), 8.09-8.06 (d, J=1.5, 1H), 7.91-7.82 (m, 1H), 7.70-7.63 (m, 1H), 7.61-7.53 (m, 1H), 7.40-7.35 (dd, J=7.6, 1.4, 1H), 7.25 (s, 1H), 7.24-7.21 (m, 1H), 1.21 (m, 3H), 0.50-0.46 (m, 2H), 0.39-0.28 (m, 2H).
Example 91




The title compound was prepared in a manner similar to that described in Example 88 using (R)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)methanol. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.34 (m, 1H), 8.24-8.19 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.0, 1.3, 1H), 7.98-7.91 (m, 1H), 7.73-7.66 (m, 1H), 7.65-7.57 (m, 1H), 7.46-7.39 (dd, J=7.6, 1.3, 1H), 7.33-7.32 (m, 1H), 7.32-7.27 (dd, J=6.0, 1.6, 1H), 3.52-3.45 (m, 1H), 3.41-3.34 (dd, J=11.0, 3.9, 1H), 3.24-3.13 (m, 1H), 3.02-2.89 (m, 2H), 1.88-1.73 (m, 3H), 1.71-1.62 (dd, J=6.9, 4.6, 1H).
Example 92




The title compound was prepared in a manner similar to that described in Example 88 using (R)-1-((2-bromophenyl)sulfonyl)pyrrolidin-3-amine, followed by removal of the Boc group with trifluoroacetic acid in dichloromethane at rt. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.44-8.29 (m, 1H), 8.17-8.13 (d, J=1.5, 1H), 8.13-8.09 (dd, J=8.0, 1.3, 1H), 7.99-7.88 (m, 1H), 7.79-7.69 (m, 1H), 7.69-7.59 (m, 1H), 7.50-7.42 (dd, J=7.6, 1.4, 1H), 7.32 (s, 1H), 7.31-7.29 (dd, J=2.9, 1.5, 1H), 3.77-3.60 (m, 1H), 3.29-3.25 (m, 1H), 3.21-3.12 (dd. J=10.9, 6.7, 1H), 3.12-3.01 (dd, J=10.9, 5.0, 1H), 2.98-2.86 (m, 1H), 2.23-2.12 (m, 1H), 1.94-1.78 (m, 1H).
Example 93




The title compound was prepared in a manner similar to that described in Example 88 using (S)-1-((2-bromophenyl)sulfonyl)pyrrolidin-3-amine, followed by removal of the Boc group with trifluoroacetic acid in dichloromethane at rt. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.35 (m, 1H), 8.16-8.13 (d, J=1.4, 1H), 8.13-8.09 (dd, J=8.0, 1.3, 1H), 7.98-7.90 (m, 1H), 7.77-7.71 (m, 1H), 7.68-7.60 (m, 1H), 7.47-7.43 (dd, J=7.5, 1.3, 1H), 7.34-7.31 (m, 1H), 7.31-7.29 (q, J=1.5, 1H), 3.73-3.63 (p, J=6.1, 1H), 3.29-3.23 (m, 1H), 3.19-3.13 (dd, J=10.8, 6.7, 1H), 3.10-3.03 (dd, J=10.9, 5.0, 1H), 2.98-2.85 (m, 1H), 2.25-2.11 (m, 1H), 1.93-1.80 (m, 1H).
Example 94




The title compound was prepared in a manner similar to that described in Example 88 using (R)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)-methan-amine. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.38 (m, 1H), 8.16-8.13 (dd, J=8.1, 1.3, 1H), 8.13-8.12 (d, J=1.5, 1H), 7.94-7.89 (m, 1H), 7.78-7.73 (m, 1H), 7.69-7.63 (m, 1H), 7.48-7.45 (dd, J=7.6, 1.3, 1H), 7.36-7.30 (m, 2H), 3.71-3.62 (m, 1H), 3.15-3.08 (m, 1H), 3.05-2.98 (m, 1H), 2.86-2.74 (m, 2H), 1.92-1.76 (m, 2H), 1.73-1.62 (m, 2H).
Example 95




The title compound was prepared in a manner similar to that described in Example 88 using (S)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)methanol. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37-8.34 (m, 1H), 8.24-8.22 (d, J=1.4, 1H), 8.13-8.09 (dd, J=8.0, 1.3, 1H), 7.98-7.93 (m, 1H), 7.73-7.67 (m, 1H), 7.63-7.59 (m, 1H), 7.44-7.40 (dd, J=7.6, 1.3, 1H), 7.34-7.32 (m, 1H), 7.32-7.30 (dd, J=5.9, 1.6, 1H), 3.52-3.45 (dd, J=7.6, 4.0, 1H), 3.40-3.34 (m, 1H), 3.22-3.11 (dd, J=10.8, 7.9, 1H), 3.02-2.87 (m, 2H), 1.90-1.72 (m, 3H), 1.71-1.62 (dd, J=6.7, 4.5, 1H).
Example 96




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(methylsulfonyl)benzenesulfonamide. MS (ESI): mass calcd. for C17H15FN4O4S2, 422.05; m/z found, 423.0 [M+H]+. 1H NMR (500 MHz, acetone-d6) δ 8.56 (s, 1H), 8.25-8.18 (dd, J=7.9, 1.4, 1H), 8.16 (s, 1H), 7.90-7.84 (m, 1H), 7.64-7.57 (m, 1H), 7.57-7.50 (m, 1H), 7.46-7.40 (dd, J=8.2, 1.6, 1H), 7.38-7.31 (d, J=13.3, 1H), 7.31-7.26 (dd, J=7.4, 1.4, 1H), 2.96 (s, 3H).
Example 97




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37 (s, 1H), 8.27-8.19 (m, 1H), 8.11-8.03 (dd, J=8.0, 1.3, 1H), 7.99-7.91 (m, 1H), 7.72-7.64 (m, 1H), 7.64-7.55 (m, 1H), 7.45-7.38 (d, J=7.5, 1H), 7.37-7.27 (m, 2H), 3.74-3.61 (m, 1H), 2.80-2.72 (m, 1H), 2.72-2.64 (m, 1H), 1.10-0.99 (d, J=6.2, 3H).
Example 98




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.35 (m, 1H), 8.21-8.17 (d, J=1.5, 1H), 8.10-8.04 (dd, J=8.0, 1.3, 1H), 7.96-7.91 (m, 1H), 7.71-7.65 (m, 1H), 7.62-7.57 (m, 1H), 7.44-7.39 (dd, J=7.5, 1.3, 1H), 7.36-7.29 (m, 2H), 3.73-3.60 (m, 1H), 2.77-2.72 (m, 1H), 2.71-2.65 (m, 1H), 1.08-1.03 (d, J=6.3, 3H).
Example 99




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1-hydroxycyclohexyl)methyl)-benzenesulfonamide. MS (ESI): mass calcd. for C23H25FN4O3S, 456.16; m/z found, 457.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.44-8.37 (dd, J=2.2, 1.5, 1H), 8.10-8.04 (m, 2H), 7.96-7.87 (m, 1H), 7.71-7.64 (m, 1H), 7.63-7.56 (m, 1H), 7.46-7.39 (dd, J=7.6, 1.4, 1H), 7.37-7.28 (m, 2H), 2.67 (s, 2H), 1.61-1.22 (m, 10H).
Example 100




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.35 (m, 1H), 8.18-8.13 (m, 2H), 7.97-7.90 (m, 1H), 7.69-7.63 (m, 1H), 7.60-7.54 (m, 1H), 7.41-7.38 (dd, J=7.7, 1.4, 1H), 7.38-7.33 (m, 2H), 3.27 (s, 2H), 1.01 (s, 6H).
Example 101




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.38 (dd, J=2.2, 1.4, 1H), 8.10-8.07 (d, J=1.5, 1H), 8.07-8.03 (dd, J=7.9, 1.0, 1H), 7.93-7.88 (m, 1H), 7.70-7.64 (m, 1H), 7.62-7.57 (m, 1H), 7.44-7.40 (dd, J=7.5, 1.2, 1H), 7.36-7.28 (m, 2H), 2.67 (s, 2H), 1.09 (s, 6H).
Example 102




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(4-hydroxy-2-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.36 (m, 1H), 8.18-8.16 (d, J=1.5, 1H), 8.16-8.12 (dd, J=8.0, 1.3, 1H), 7.96-7.89 (m, 1H), 7.68-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.42-7.37 (dd, J=7.6, 1.4, 1H), 7.37-7.35 (m, 1H), 7.35-7.32 (dd. J=3.9, 1.6, 1H), 3.61-3.53 (t, J=6.7, 2H), 1.67-1.62 (t, J=6.7, 2H), 1.08 (s, 6H).
Example 103




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(3-hydroxy-2,2-dimethylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.35 (m, 1H), 8.10-8.06 (d, J=1.5, 1H), 8.05-8.02 (dd, J=8.0, 1.3, 1H), 7.95-7.85 (m, 1H), 7.71-7.63 (m, 1H), 7.63-7.54 (m, 1H), 7.45-7.39 (dd, J=7.6, 1.3, 1H), 7.38-7.28 (m, 2H), 3.19 (s, 2H), 2.62 (s, 2H), 0.77 (s, 6H).
Example 104




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(2,3-dihydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O4S, 418.11; m/z found, 419.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.33 (m, 1H), 8.27-8.23 (d, J=1.4, 1H), 8.11-8.05 (dd, J=8.0, 1.3, 1H), 7.99-7.93 (m, 1H), 7.72-7.64 (m, 1H), 7.63-7.57 (m, 1H), 7.44-7.39 (dd, J=7.6, 1.4, 1H), 7.38-7.29 (m, 2H), 3.62-3.53 (m, 1H), 3.43-3.39 (m, 2H), 2.97-2.90 (dd, J=13.2, 4.8, 1H), 2.79-2.71 (dd, J=13.2, 7.0, 1H).
Example 105




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2,3-dihydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O4S, 418.11; m/z found, 419.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.32 (m, 1H), 8.29-8.22 (d, J=1.4, 1H), 8.11-8.05 (dd, J=8.0, 1.3, 1H), 8.00-7.91 (m, 1H), 7.72-7.64 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (dd, J=7.6, 1.3, 1H), 7.37-7.29 (m, 2H), 3.61-3.52 (m, 1H), 3.43-3.39 (m, 2H), 2.97-2.90 (dd, J=13.1, 4.8, 1H), 2.80-2.72 (dd, J=13.1, 7.0, 1H).
Example 106




The title compound was prepared in a manner similar to that described in Example 88 using (trans)-1-((2-bromophenyl)sulfonyl)pyrrolidine-3,4-diol. MS (ESI): mass calcd. for C20H19FN4O4S, 430.11; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.34 (m, 1H), 8.24-8.20 (d, J=1.5 Hz, 1H), 8.15-8.08 (dd. J=8.0, 1.3 Hz, 1H), 7.97-7.88 (m, 1H), 7.70-7.64 (td, J=7.5, 1.4 Hz, 1H), 7.62-7.54 (td, J=7.7, 1.4 Hz, 1H), 7.47-7.38 (dd, J=7.6, 1.3 Hz, 1H), 7.34-7.31 (dd, J=8.0, 1.7 Hz, 1H), 7.31-7.27 (dd, J=12.3, 1.7 Hz, 1H), 4.00-3.97 (m, 2H), 3.29-3.27 (m, 2H), 3.07-3.03 (m, 2H).
Example 107




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(2-oxopyrrolidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.38 (dd, J=2.2, 1.4, 1H), 8.26-8.22 (dd, J=8.2, 1.3, 1H), 8.08-8.06 (d, J=1.5, 1H), 7.91-7.84 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.38 (dd, J=7.6, 1.3, 1H), 7.38-7.32 (m, 2H), 3.88-3.81 (dd, J=10.3, 8.3, 1H), 3.28-3.22 (m, 1H), 3.22-3.15 (m, 1H), 2.38-2.30 (m, 1H), 1.96-1.86 (m, 1H).
Example 108




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(2-oxopiperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H20FN5O3S, 441.13; m/z found, 442.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37 (s, 1H), 8.25-8.15 (m, 2H), 7.97-7.88 (m, 1H), 7.71-7.62 (m, 1H), 7.62-7.54 (m, 1H), 7.42-7.30 (m, 3H), 3.67-3.57 (dd, J=10.4, 5.8, 1H), 3.22-3.17 (m, 2H), 2.19-2.07 (d, J=10.6, 1H), 1.90-1.79 (m, 1H), 1.78-1.64 (m, 2H).
Example 109




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.37 (dd, J=2.2, 1.4, 1H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.91-7.84 (m, 1H), 7.68-7.61 (m, 1H), 7.60-7.53 (m, 1H), 7.39-7.35 (dd, J=7.7, 1.4, 1H), 7.36-7.28 (m, 2H), 3.45-3.39 (m, 1H), 3.38-3.33 (m, 1H), 3.10-3.03 (m, 1H), 1.89-1.75 (m, 1H), 0.86-0.75 (dd, J=6.9, 4.4, 6H).
Example 110




The title compound was prepared in a manner similar to that described in Example 88 using trans-2-bromo-N-(4-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.34 (m, 1H), 8.22-8.17 (d, J=1.5, 1H), 8.14-8.08 (dd, J=7.9, 1.3, 1H), 7.96-7.90 (m, 1H), 7.69-7.64 (m, 1H), 7.62-7.56 (m, 1H), 7.43-7.38 (dd, J=7.7, 1.3, 1H), 7.35-7.28 (m, 2H), 3.43-3.36 (m, 1H), 2.89-2.77 (m, 1H), 1.87-1.77 (m, 2H), 1.77-1.68 (dd, J=8.3, 4.0, 2H), 1.27-1.05 (m, 4H).
Example 111




The title compound was prepared in a manner similar to that described in Example 88 using (R)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-3-yl)methanol. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37 (s, 1H), 8.22-8.19 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.1, 1.3, 1H), 7.97-7.93 (m, 1H), 7.75-7.66 (m, 1H), 7.65-7.57 (m, 1H), 7.45-7.39 (dd, J=7.6, 1.3, 1H), 7.37-7.25 (m, 2H), 3.42-3.36 (m, 1H), 3.09-3.03 (dd, J=9.5, 7.5, 1H), 3.03-2.97 (m, 1H), 2.95-2.85 (m, 1H), 2.75-2.64 (dd, J=9.6, 7.2, 1H), 2.29-2.17 (m, 1H), 1.86-1.76 (m, 1H), 1.54-1.41 (m, 1H).
Example 112




The title compound was prepared in a manner similar to that described in Example 88 using (S)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-3-yl)methanol. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.32 (m, 1H), 8.24-8.17 (d, J=1.5, 1H), 8.12-8.07 (dd, J=8.0, 1.3, 1H), 7.99-7.93 (m, 1H), 7.72-7.66 (m, 1H), 7.64-7.58 (m, 1H), 7.44-7.40 (dd, J=7.5, 1.3, 1H), 7.35-7.26 (m, 2H), 3.43-3.36 (m, 1H), 3.33-3.28 (m, 1H), 3.08-3.03 (dd, J=9.6, 7.6, 1H), 3.03-2.98 (m, 1H), 2.94-2.86 (m, 1H), 2.74-2.65 (dd, J=9.6, 7.1, 1H), 2.30-2.13 (m, 1H), 1.87-1.74 (m, 1H), 1.56-1.41 (m, 1H).
Example 113




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2-oxopiperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H20FN5O3S, 441.13; m/z found, 442.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37-8.34 (m, 1H), 8.26-8.19 (m, 2H), 7.97-7.91 (m, 1H), 7.69-7.64 (m, 1H), 7.62-7.54 (m, 1H), 7.42-7.34 (m, 3H), 3.67-3.58 (dd, J=10.4, 5.9, 1H), 3.22-3.16 (m, 2H), 2.19-2.10 (m, 1H), 1.88-1.80 (m, 1H), 1.78-1.64 (m, 2H).




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-methyl-N-(piperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C2H24FN5O2S, 441.16; m/z found, 442.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.37 (m, 1H), 8.20-8.16 (dd, J=8.1, 1.3, 1H), 8.16-8.14 (d, J=1.5, 1H), 8.00-7.92 (m, 1H), 7.78-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.48-7.43 (dd, J=7.6, 1.3, 1H), 7.37-7.35 (m, 1H), 7.35-7.32 (dd, J=7.0, 1.7, 1H), 3.64-3.53 (m, 1H), 3.23-3.17 (d, J=12.8, 1H), 3.06-3.00 (t, J=5.9, 1H), 3.00-2.93 (m, 1H), 2.78-2.70 (m, 1H), 2.42 (s, 3H), 1.92-1.81 (dd, J=16.5, 3.2, 1H), 1.68-1.57 (m, 1H), 1.57-1.44 (m, 1H), 1.44-1.33 (d, J=12.3, 1H).
Example 115




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-methyl-N-(piperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H24FN5O2S, 441.16; m/z found, 442.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.36 (m, 1H), 8.21-8.15 (dd, J=8.1, 1.3, 1H), 8.14-8.09 (d, J=1.5, 1H), 7.99-7.90 (m, 1H), 7.78-7.72 (m, 1H), 7.67-7.61 (m, 1H), 7.49-7.43 (dd, J=7.6, 1.3, 1H), 7.36-7.35 (m, 1H), 7.35-7.32 (dd, J=7.1, 1.7, 1H), 3.64-3.52 (m, 1H), 3.22-3.17 (d, J=13.2, 1H), 3.05-3.00 (m, 1H), 3.00-2.93 (m, 1H), 2.79-2.69 (m, 1H), 2.42 (s, 3H), 1.93-1.82 (m, 1H), 1.67-1.56 (m, 1H), 1.56-1.45 (m, 1H), 1.43-1.34 (m, 1H).
Example 116




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxy-3-phenylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C25H23FN4O3S, 478.15; m/z found, 479.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.35 (m, 1H), 8.10-8.05 (d, J=1.5, 1H), 7.99-7.95 (dd, J=8.0, 1.3, 1H), 7.86-7.79 (t, J=8.1, 1H), 7.63-7.57 (m, 1H), 7.51-7.45 (m, 1H), 7.31-7.26 (dd, J=7.6, 1.3, 1H), 7.19-7.07 (m, 5H), 7.08-7.02 (dd, J=8.0, 1.5, 2H), 3.49-3.41 (m, 2H), 3.41-3.34 (m, 1H), 2.92-2.82 (dd, J=13.9, 6.3, 1H), 2.68-2.59 (dd, J=13.9, 6.8, 1H).
Example 117




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2-hydroxy-2-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C24H21FN4O3S, 464.13; m/z found, 465.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.33 (m, 1H), 8.11-8.03 (m, 2H), 7.90-7.82 (t, J=8.2, 1H), 7.70-7.63 (m, 1H), 7.61-7.54 (m, 1H), 7.42-7.36 (dd, J=7.6, 1.3, 1H), 7.30-7.16 (m, 7H), 4.60-4.53 (dd, J=7.9, 4.8, 1H), 2.98-2.92 (m, 1H), 2.92-2.86 (m, 1H).
Example 118




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylbenzenesulfonamide. MS (ESI): mass calcd. for C26H25FN4O3S, 492.16; m/z found, 493.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.35 (m, 1H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.10-8.07 (d, J=1.5, 1H), 7.92-7.84 (t, J=8.0, 1H), 7.68-7.61 (m, 1H), 7.60-7.54 (m, 1H), 7.40-7.35 (dd, J=7.6, 1.4, 1H), 7.33-7.20 (m, 7H), 4.57-4.43 (d, J=8.4, 1H), 3.91-3.79 (m, 1H), 2.49 (s, 3H), 0.75-0.62 (d, J=6.8, 3H).
Example 119




The title compound was prepared in a manner similar to that described in Example 88 using 1-((2-bromophenyl)sulfonyl)azetidin-3-ol. MS (ESI): mass calcd. for C19H17FN4O3S, 400.10; m/z found, 401.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.29 (m, 1H), 8.22-8.17 (d, J=1.4, 1H), 8.10-8.05 (dd, J=8.0, 1.3, 1H), 7.97-7.91 (m, 1H), 7.75-7.67 (m, 1H), 7.64-7.56 (m, 1H), 7.46-7.40 (dd, J=7.5, 1.3, 1H), 7.36-7.27 (m, 2H), 4.37-4.25 (m, 1H), 3.70-3.60 (m, 2H), 3.60-3.53 (m, 2H).
Example 120




The title compound was prepared in a manner similar to that described in Example 88 using racemic-(trans)-2-bromo-N-(2-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37 (s, 1H), 8.21-8.16 (m, 2H), 7.95-7.90 (m, 1H), 7.68-7.62 (m, 1H), 7.60-7.55 (m, 1H), 7.40-7.36 (dd, J=7.6, 1.3, 1H), 7.36-7.35 (m, 1H), 7.35-7.32 (dd, J=6.2, 1.6, 1H), 3.25-3.19 (m, 1H), 2.86-2.79 (m, 1H), 1.94-1.86 (m, 1H), 1.85-1.77 (m, 1H), 1.66-1.58 (m, 1H), 1.58-1.51 (m, 1H), 1.26-1.09 (m, 4H).
Example 121




The title compound was prepared in a manner similar to that described in Example 88 using racemic (trans)-2-bromo-N-(2-(hydroxymethyl)cyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C23H25FN4O3S, 456.16; m/z found, 457.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.34 (m, 1H), 8.20-8.14 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.1, 1.3, 1H), 7.97-7.88 (m, 1H), 7.70-7.63 (m, 1H), 7.63-7.55 (m, 1H), 7.43-7.36 (dd, J=7.7, 1.4, 1H), 7.35-7.25 (m, 2H), 3.61-3.52 (dd, J=11.1, 3.7, 1H), 3.43-3.36 (dd, J=11.0, 6.4, 1H), 2.92-2.79 (m, 1H), 1.86-1.80 (m, 1H), 1.66-1.53 (m, 3H), 1.34-1.26 (m, 1H), 1.18-1.03 (m, 4H).
Example 122




The title compound was prepared in a manner similar to that described in Example 88 using racemic cis-2-bromo-N-(2-(hydroxymethyl)cyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C23H25FN4O3S, 456.16; m/z found, 457.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.37 (m, 1H), 8.16-8.10 (dd, J=8.0, 1.3, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.92-7.85 (m, 1H), 7.70-7.63 (m, 1H), 7.62-7.55 (m, 1H), 7.43-7.37 (dd, J=7.5, 1.4, 1H), 7.34-7.26 (m, 2H), 3.58-3.51 (dd, J=11.1, 7.1, 1H), 3.47-3.39 (m, 1H), 3.38-3.33 (m, 1H), 1.69-1.59 (m, 1H), 1.58-1.50 (m, 1H), 1.47-1.16 (m, 7H).
Example 123




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(piperidin-4-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.37 (m, 1H), 8.16-8.10 (m, 2H), 7.95-7.89 (m, 1H), 7.74-7.66 (m, 1H), 7.64-7.56 (m, 1H), 7.46-7.40 (dd, J=7.7, 1.3, 1H), 7.38-7.29 (m, 2H), 3.30-3.22 (m, 2H), 3.21-3.14 (m, 1H), 2.98-2.89 (m, 2H), 1.98-1.85 (dd, J=14.6, 3.9, 2H), 1.65-1.48 (m, 2H).
Example 124




The title compound was prepared in a manner similar to that described in Example 88 using (1-((2-bromophenyl)sulfonyl)azetidin-3-yl)methanamine. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.37 (m, 1H), 8.14-8.11 (d, J=1.5, 1H), 8.11-8.07 (dd, J=8.0, 1.3, 1H), 7.97-7.90 (m, 1H), 7.76-7.70 (m, 1H), 7.65-7.57 (m, 1H), 7.52-7.42 (dd, J=7.7, 1.3, 1H), 7.39-7.25 (m, 2H), 3.81-3.67 (t, J=8.1, 2H), 3.42-3.36 (dd, J=8.1, 5.5, 2H), 3.07-3.00 (d, J=7.5, 2H), 2.72-2.59 (m, 1H).
Example 125




The title compound was prepared in a manner similar to that described in Example 88 using N-(azetidin-3-ylmethyl)-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.37 (m, 1H), 8.17-8.12 (d, J=1.5, 1H), 8.09-8.05 (dd, J=8.0, 1.3, 1H), 7.97-7.88 (m, 1H), 7.73-7.66 (m, 1H), 7.65-7.58 (m, 1H), 7.47-7.41 (dd, J=7.6, 1.4, 1H), 7.36-7.28 (m, 2H), 4.02-3.95 (dd, J=11.2, 7.7, 2H), 3.91-3.78 (dd, J=11.3, 6.1, 2H), 3.04-2.91 (m, 3H).
Example 126




The title compound was prepared in a manner similar to that described in Example 88 using (R)-1-((2-bromophenyl)sulfonyl)-N-methylpyrrolidin-3-amine. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.44-8.35 (m, 1H), 8.15-8.08 (m, 2H), 7.98-7.91 (m, 1H), 7.78-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.48-7.43 (dd, J=7.7, 1.3, 1H), 7.34-7.27 (m, 2H), 3.69-3.57 (m, 1H), 3.29-3.23 (m, 1H), 3.22-3.16 (m, 1H), 3.16-3.11 (m, 1H), 2.99-2.85 (m, 1H), 2.65 (s, 3H), 2.28-2.14 (m, 1H), 1.99-1.87 (m, 1H).
Example 127




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.38 (dd, J=2.1, 1.5, 1H), 8.13-8.09 (dd, J=8.1, 1.3, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.90-7.85 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.36 (dd, J=7.7, 1.4, 1H), 7.30-7.27 (dd, J=8.0, 1.7, 1H), 7.27-7.22 (dd, J=12.3, 1.7, 1H), 3.91-3.79 (m, 1H), 1.24-1.16 (d, J=7.0, 3H).
Example 128




The title compound was prepared in a manner similar to that described in Example 88 using 5-((2-bromophenyl)sulfonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]-pyridine. MS (ESI): mass calcd. for C22H19FN6O2S, 450.13; m/z found, 451.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.35 (m, 1H), 8.21-8.14 (dd, J=8.1, 1.3, 1H), 8.11-8.07 (d, J=1.5, 1H), 7.85-7.79 (m, 1H), 7.76-7.68 (m, 1H), 7.65-7.59 (m, 1H), 7.45-7.37 (dd, J=7.5, 1.4, 1H), 7.31-7.14 (m, 3H), 4.02-3.88 (m, 2H), 3.28-3.22 (t, J=5.9, 2H), 2.59-2.48 (t, J=5.9, 2H).
Example 129




The title compound was prepared in a manner similar to that described in Example 88 using 4-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)-1H-1,2,4-triazol-5(4H)-one. MS (ESI): mass calcd. for C23H22FN7O3S, 495.15; m/z found, 496.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.35 (m, 1H), 8.24-8.22 (d, J=1.5, 1H), 8.15-8.11 (dd, J=8.1, 1.3, 1H), 8.01-7.96 (m, 1H), 7.78 (s, 1H), 7.76-7.70 (m, 1H), 7.66-7.60 (m, 1H), 7.48-7.43 (dd, J=7.6, 1.3, 1H), 7.41-7.33 (m, 2H), 3.88-3.76 (m, 1H), 3.51-3.42 (m, 2H), 2.64-2.53 (m, 2H), 1.88-1.79 (d, J=12.3, 2H), 1.68-1.50 (m, 2H).
Example 130




The title compound was prepared in a manner similar to that described in Example 88 using (1R,4R)-2-((2-bromophenyl)sulfonyl)-2,5-diazabicyclo[2.2.1]heptane. MS (ESI): mass calcd. for C21H20FN5O2S, 425.13; m/z found, 426.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.38 (m, 1H), 8.19-8.14 (dd, J=8.1, 1.3, 1H), 8.14-8.10 (d, J=1.5, 1H), 7.99-7.91 (m, 1H), 7.79-7.72 (m, 1H), 7.68-7.60 (m, 1H), 7.51-7.43 (dd, J=7.6, 1.3, 1H), 7.38-7.35 (m, 1H), 7.33 (s, 1H), 4.32 (s, 1H), 4.05 (s, 1H), 3.38-3.33 (m, 1H), 3.30-3.25 (m, 1H), 3.21-3.14 (dd, J=11.6, 2.2, 1H), 3.04-2.98 (dd, J=11.0, 2.6, 1H), 1.85-1.72 (m, 2H).
Example 131




The title compound was prepared in a manner similar to that described in Example 88 using (1S,4S)-2-((2-bromophenyl)sulfonyl)-2,5-diazabicyclo[2.2.1]heptane. MS (ESI): mass calcd. for C21H20FN5O2S, 425.13; m/z found, 426.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.36 (m, 1H), 8.17-8.14 (m, 2H), 8.00-7.92 (m, 1H), 7.79-7.72 (m, 1H), 7.68-7.61 (m, 1H), 7.49-7.45 (dd, J=7.6, 1.3, 1H), 7.39-7.35 (m, 1H), 7.34 (s, 1H), 4.38-4.28 (m1H), 4.05 (s, 1H), 3.38-3.32 (dd, J=11.6, 1.7, 1H), 3.30-3.26 (m, 1H), 3.23-3.12 (dd, J=11.6, 2.2, 1H), 3.08-2.95 (dd, J=11.0, 2.6, 1H), 1.85-1.74 (m, 2H).
Example 132




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(5-hydroxypentyl)benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.44-8.38 (m, 1H), 8.10-8.07 (d, J=1.5, 1H), 8.07-8.04 (dd, J=8.0, 1.3, 1H), 7.92-7.87 (m, 1H), 7.68-7.64 (m, 1H), 7.62-7.55 (m, 1H), 7.43-7.38 (dd, J=7.6, 1.4, 1H), 7.33-7.27 (m, 2H), 3.49-3.45 (t, J=6.6, 2H), 2.78-2.73 (t, J=7.1, 2H), 1.48-1.41 (m, 2H), 1.41-1.34 (m, 2H), 1.31-1.21 (m, 2H).
Example 133




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(6-hydroxyhexyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H25FN4O3S, 444.16; m/z found, 445.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.38 (m, 1H), 8.09-8.08 (d, J=1.5, 1H), 8.08-8.04 (dd, J=7.9, 1.3, 1H), 7.94-7.85 (m, 1H), 7.70-7.63 (m, 1H), 7.62-7.56 (m, 1H), 7.43-7.37 (dd, J=7.7, 1.4, 1H), 7.33-7.26 (m, 2H), 3.51-3.46 (t, J=6.6, 2H), 2.78-2.72 (t, J=7.1, 2H), 1.51-1.41 (m, 2H), 1.42-1.33 (p, J=7.2, 2H), 1.33-1.16 (m, 4H).
Example 134




The title compound was prepared in a manner similar to that described in Example 88 using (cis)-N-(4-aminocyclohexyl)-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C22H24FN5O2S, 441.16; m/z found, 442.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.36 (m, 1H), 8.19-8.14 (m, 1H), 8.13-8.07 (dd, J=8.0, 1.3, 1H), 7.97-7.91 (m, 1H), 7.73-7.67 (m, 1H), 7.65-7.58 (m, 1H), 7.46-7.41 (dd, J=7.5, 1.3, 1H), 7.35-7.33 (m, 1H), 7.33-7.31 (dd, J=6.2, 1.6, 1H), 3.15-3.00 (m, 2H), 1.80-1.69 (m, 4H), 1.68-1.57 (m, 2H), 1.58-1.48 (m, 2H).
Example 135




The title compound was prepared in a manner similar to that described in Example 88 using (S)-(1-((2-bromophenyl)sulfonyl)indolin-2-yl)methanol. MS (ESI): mass calcd. for C25H21FN4O3S, 476.13; m/z found, 477.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36-8.33 (m, 1H), 8.22-8.20 (d, J=1.5, 1H), 8.19-8.14 (dd, J=8.0, 1.3, 1H), 7.85-7.79 (m, 1H), 7.69-7.63 (m, 1H), 7.61-7.56 (m, 1H), 7.32-7.28 (dd, J=7.5, 1.4, 1H), 7.11-7.06 (m, 2H), 7.01-6.95 (dd, J=12.2, 1.7, 1H), 6.91-6.80 (m, 3H), 3.85-3.74 (m, 1H), 3.67-3.58 (dd, J=10.9, 4.2, 1H), 3.40-3.33 (dd, J=11.0, 7.8, 1H), 2.89-2.72 (m, 2H).
Example 136




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-cyclohexyl-N-(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C24H27FN4O3S, 470.18; m/z found, 471.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.40-8.34 (m, 1H), 8.21-8.18 (d, J=1.5, 1H), 8.16-8.12 (dd, J=8.0, 1.4, 1H), 7.99-7.92 (m, 1H), 7.72-7.65 (m, 1H), 7.63-7.56 (m, 1H), 7.42-7.38 (dd, J=7.6, 1.4, 1H), 7.35-7.32 (m, 1H), 7.32-7.28 (dd, J=5.5, 1.6, 1H), 3.43-3.34 (dd, J=8.0, 6.9, 2H), 3.19-3.09 (m, 1H), 2.95-2.87 (dd, J=8.0, 6.9, 2H), 1.73-1.58 (d, J=12.6, 2H), 1.58-1.40 (m, 3H), 1.38-1.23 (m, 2H), 1.17-0.93 (m, 3H).
Example 137




The title compound was prepared in a manner similar to that described in Example 88 using (S)-1-((2-bromophenyl)sulfonyl)piperidin-3-amine. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.41-8.37 (m, 1H), 8.18-8.14 (d, J=1.5, 1H), 8.14-8.08 (dd, J=8.0, 1.3, 1H), 7.97-7.90 (m, 1H), 7.79-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.49-7.42 (dd, J=7.6, 1.4, 1H), 7.33-7.31 (m, 1H), 7.31-7.28 (dd, J=5.2, 1.6, 1H), 3.37-3.32 (m, 1H), 3.10-2.98 (m, 2H), 2.73-2.62 (m, 1H), 2.62-2.50 (dd, J=12.7, 8.9, 1H), 2.00-1.88 (m, 1H), 1.81-1.66 (m, 1H), 1.59-1.33 (m, 2H).
Example 138




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N,N-bis(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O4S, 432.13; m/z found, 433.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37-8.33 (m, 1H), 8.30-8.25 (d, J=1.4, 1H), 8.10-8.05 (dd, J=7.9, 1.3, 1H), 8.01-7.94 (m, 1H), 7.72-7.65 (m, 1H), 7.65-7.56 (m, 1H), 7.43-7.38 (dd, J=7.6, 1.4, 1H), 7.34-7.33 (m, 1H), 7.32-7.29 (dd, J=5.2, 1.6, 1H), 3.57-3.49 (t, J=6.0, 4H), 3.09-3.01 (t, J=6.0, 4H).
Example 139




The title compound was prepared in a manner similar to that described in Example 88 using racemic 1-((2-bromophenyl)sulfonyl)azetidine-2-carboxamide. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.38 (m, 1H), 8.19-8.13 (m, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.93-7.87 (m, 1H), 7.79-7.73 (m, 1H), 7.68-7.61 (m, 1H), 7.49-7.43 (dd, J=7.6, 1.3, 1H), 7.38-7.31 (m, 2H), 4.57-4.49 (dd, J=9.5, 7.8, 1H), 3.80-3.68 (m, 1H), 2.39-2.28 (m, 1H), 2.26-2.15 (m, 1H). (one proton obscured under methanol signal)
Example 140




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-cyclopropyl-N-(tetrahydro-2H-pyran-4-yl)-benzenesulfonamide. MS (ESI): mass calcd. for C24H25FN4O3S, 468.16; m/z found, 469.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.33 (m, 1H), 8.20-8.17 (dd, J=8.0, 1.3, 1H), 8.16-8.15 (d, J=1.5, 1H), 7.95-7.90 (m, 1H), 7.74-7.68 (m, 1H), 7.66-7.59 (m, 1H), 7.44-7.39 (dd, J=7.6, 1.3, 1H), 7.35-7.27 (m, 2H), 3.83-3.75 (dd, J=11.4, 4.3, 2H), 3.52-3.43 (m, 1H), 3.20-3.11 (m, 2H), 2.25-2.17 (m, 1H), 1.93-1.81 (m, 2H), 1.26-1.19 (d, J=12.0, 2H), 0.54-0.47 (m, 2H), 0.31-0.26 (dd, J=4.0, 2.3, 2H).
Example 141




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxyethyl)-N-isopropylbenzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.36 (m, 1H), 8.21-8.17 (d, J=1.5, 1H), 8.14-8.10 (dd, J=8.0, 1.3, 1H), 8.00-7.91 (m, 1H), 7.72-7.66 (m, 1H), 7.63-7.56 (m, 1H), 7.44-7.38 (dd, J=7.5, 1.3, 1H), 7.36-7.27 (m, 2H), 3.69-3.55 (m, 1H), 3.43-3.37 (dd, J=7.8, 6.9, 2H), 2.92-2.84 (t, J=7.3, 2H), 1.01-0.97 (d, J=6.7, 6H).
Example 142




The title compound was prepared in a manner similar to that described in Example 88 using racemic (4-((2-bromophenyl)sulfonyl)morpholin-2-yl)methanol. MS (ESI): mass calcd. for C21H21FN4O4S, 444.13; m/z found, 445.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.34 (m, 1H), 8.24-8.18 (d, J=1.4, 1H), 8.14-8.07 (dd, J=8.0, 1.3, 1H), 7.98-7.92 (m, 1H), 7.76-7.69 (m, 1H), 7.69-7.60 (m, 1H), 7.49-7.43 (dd, J=7.6, 1.3, 1H), 7.35 (s, 1H), 7.34-7.31 (dd, J=3.6, 1.5, 1H), 3.78-3.70 (dd, J=11.3, 3.0, 1H), 3.45-3.39 (m, 1H), 3.38-3.33 (m, 1H), 3.29-3.25 (m, 1H), 3.22-3.16 (m, 2H), 3.12-3.04 (d, J=12.3, 1H), 2.62-2.49 (m, 1H), 2.45-2.31 (m, 1H).
Example 143




The title compound was prepared in a manner similar to that described in Example 88 using endo-3-((2-bromophenyl)sulfonyl)-3-azabicyclo[3.1.0]hexan-6-amine. MS (ESI): mass calcd. for C21H20FN5O2S, 425.13: m/z found, 426.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.38 (m, 1H), 8.16-8.14 (d, J=1.5, 1H), 8.11-8.06 (dd, J=8.1, 1.3, 1H), 7.98-7.91 (m, 1H), 7.75-7.69 (m, 1H), 7.65-7.59 (m, 1H), 7.46-7.42 (dd, J=7.7, 1.3, 1H), 7.35-7.28 (m, 2H), 3.28 (s, 1H), 2.99-2.90 (m, 2H), 2.25-2.16 (t, J=2.3, 1H), 1.90-1.80 (m, 2H).
Example 144




The title compound was prepared in a manner similar to that described in Example 88 using (S)-1-((2-bromophenyl)sulfonyl)-2-methylpiperazine. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz. CD3OD) δ 8.43-8.37 (m, 1H), 8.23-8.17 (dd, J=8.0, 1.3, 1H), 8.15-8.10 (d, J=1.5, 1H), 8.01-7.91 (m, 1H), 7.80-7.73 (m, 1H), 7.69-7.60 (m, 1H), 7.53-7.46 (dd, J=7.7, 1.3, 1H), 7.44-7.35 (d, J=9.9, 2H), 3.93-3.80 (m 1H), 3.23-3.15 (m, 1H), 3.15-3.03 (m, 3H), 2.79-2.63 (m, 2H), 1.21-1.14 (d, J=7.1, 3H).
Example 145




The title compound was prepared in a manner similar to that described in Example 88 using (R)-1-((2-bromophenyl)sulfonyl)-2-methylpiperazine. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.38 (m, 1H), 8.23-8.16 (dd, J=8.1, 1.3, 1H), 8.16-8.12 (d, J=1.5, 1H), 8.01-7.95 (m, 1H), 7.80-7.73 (m, 1H), 7.68-7.62 (m, 1H), 7.52-7.45 (dd, J=7.6, 1.3, 1H), 7.44-7.36 (m, 2H), 3.95-3.79 (dd, J=7.1, 4.4, 1H), 3.23-3.15 (m, 1H), 3.15-3.03 (m, 3H), 2.79-2.64 (m, 2H), 1.19-1.15 (d, J=7.1, 3H).
Example 146




The title compound was prepared in a manner similar to that described in Example 88 using (R)-(1-((2-bromophenyl)sulfonyl)piperazin-2-yl)methanol. MS (ESI): mass calcd. for C21H22FN5O3S, 443.14; m/z found, 444.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.37 (m, 1H), 8.24-8.17 (dd, J=8.0, 1.3, 1H), 8.16-8.11 (d, J=1.5, 1H), 8.01-7.94 (m, 1H), 7.82-7.74 (m, 1H), 7.69-7.61 (m, 1H), 7.53-7.46 (dd, J=7.7, 1.3, 1H), 7.41 (s, 1H), 7.40-7.36 (dd, J=4.3, 1.6, 1H), 3.79-3.64 (m, 3H), 3.49-3.43 (m, 1H), 3.43-3.35 (m, 1H), 3.29-3.25 (d, J=3.7, 1H), 3.21-3.11 (m, 1H), 2.81-2.70 (m, 1H), 2.70-2.62 (dd, J=13.1, 4.7, 1H).
Example 147




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(1,3-dihydroxy-2-methylpropan-2-yl)-benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O4S, 432.13; m/z found, 433.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.37 (dd, J=2.2, 1.5, 1H), 8.20-8.14 (dd, J=8.0, 1.3, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.93-7.84 (m, 1H), 7.69-7.63 (m, 1H), 7.60-7.54 (m, 1H), 7.42-7.38 (dd, J=7.5, 1.3, 1H), 7.38-7.32 (m, 2H), 3.45-3.39 (m, 2H), 3.39-3.33 (m, 2H), 0.97 (s, 3H).
Example 148




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.38 (d, J=1.7, 1H), 8.15-8.12 (dd, J=8.0, 1.3, 1H), 8.09-8.06 (d, J=1.5, 1H), 7.90-7.84 (m, 1H), 7.67-7.61 (m, 1H), 7.60-7.54 (m, 1H), 7.39-7.35 (dd, J=7.6, 1.4, 1H), 7.35-7.29 (m, 2H), 3.46-3.39 (m, 1H), 3.39-3.33 (m, 1H), 3.09-3.02 (q, J=5.5, 1H), 1.90-1.75 (m, 1H), 0.83-0.76 (dd, J=6.9, 4.4, 6H).
Example 149




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H25FN4O3S, 444.16; m/z found, 445.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.35 (dd, J=2.2, 1.5, 1H), 8.16-8.11 (dd, J=8.1, 1.3, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.93-7.83 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 1H), 7.37-7.35 (dd, J=3.3, 1.6, 1H), 7.35-7.31 (m, 2H), 3.55-3.49 (m, 1H), 3.49-3.43 (m, 1H), 3.11-3.04 (dd, J=5.9, 4.2, 1H), 0.82 (s, 9H).
Example 150




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H25FN4O3S, 444.16; m/z found, 445.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.37 (m, 1H), 8.15-8.11 (dd, J=8.0, 1.3, 1H), 8.09-8.05 (d, J=1.5, 1H), 7.92-7.86 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 1H), 7.38-7.35 (dd, J=3.3, 1.5, 1H), 7.35-7.31 (m, 2H), 3.55-3.49 (m, 1H), 3.49-3.42 (m, 1H), 3.10-3.04 (dd, J=5.9, 4.2, 1H), 0.82 (s, 9H).
Example 151




The title compound was prepared in a manner similar to that described in Example 88 using tert-butyl-(2-(2-bromophenylsulfonamido)ethyl)carbamate. MS (ESI): mass calcd. for C23H26FN5O4S, 487.17; m/z found, 488.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.57-8.54 (m, 1H), 8.18-8.13 (dd, J=8.0, 1.4, 1H), 8.11-8.08 (d, J=1.5, 1H), 8.05-7.98 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 1H), 7.37-7.33 (m, 2H), 7.32-7.29 (dd, J=11.8, 1.7, 1H), 4.78 (s, 3H), 4.46 (s, 1H), 3.17-3.04 (d, J=5.9, 2H), 2.97-2.77 (m, 2H), 1.38 (s, 9H).
Example 152




The title compound was prepared in a manner similar to that described in Example 88 using N-(2-aminoethyl)-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C18H18FN5O2S, 387.12; m/z found, 388.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.38 (d, J=1.7, 1H), 8.15-8.11 (d, J=1.5, 1H), 8.10-8.06 (dd, J=8.0, 1.3, 1H), 7.98-7.91 (m, 1H), 7.74-7.69 (m, 1H), 7.65-7.59 (m, 1H), 7.47-7.43 (dd, J=7.6, 1.3, 1H), 7.33-7.32 (dd, J=4.1, 1.8, 1H), 7.31-7.29 (dd, J=8.2, 1.6, 1H), 3.05-2.98 (t, J=5.9, 2H), 2.97-2.92 (m, 2H).
Example 153




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxybutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.35 (d, J=1.6, 1H), 8.23-8.17 (d, J=1.5, 1H), 8.17-8.10 (dd, J=8.0, 1.3, 1H), 7.97-7.88 (m, 1H), 7.69-7.61 (m, 1H), 7.61-7.55 (m, 1H), 7.41-7.36 (dd, J=7.5, 1.4, 1H), 7.36-7.28 (m, 2H), 3.43-3.36 (m, 1H), 3.34-3.31 (m, 1H), 3.12-3.05 (m, 1H), 1.60-1.46 (m, 1H), 1.42-1.28 (m, 1H), 0.85-0.72 (t, J=7.4, 3H).
Example 154




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(pyrrolidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.37 (m, 1H), 8.15-8.10 (m, 2H), 7.96-7.90 (m, 1H), 7.75-7.69 (m, 1H), 7.66-7.60 (m, 1H), 7.45 (dd, J=7.6, 1.3 Hz, 1H), 7.33 (s, 1H), 7.31 (dd, J=3.7, 1.6 Hz, 1H), 3.74-3.60 (m, 1H), 3.33-3.32 (m, 1H), 3.28-3.26 (m, 1H), 3.25-3.18 (m, 1H), 3.11 (dd, J=12.3, 5.4 Hz, 1H), 2.17-2.04 (m, 1H), 1.85-1.73 (m, 1H).
Example 155




The title compound was prepared in a manner similar to that described in Example 88 using N-(2-(2-bromophenylsulfonamido)ethyl)acetamide. MS (ESI): mass calcd. for C20H20FN5O3S, 429.13; m/z found, 430.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.33 (m, 1H), 8.28-8.25 (d, J=1.4, 1H), 8.09-8.03 (dd, J=8.0, 1.3, 1H), 8.00-7.93 (m, 1H), 7.70-7.65 (dd, J=7.5, 1.4, 1H), 7.63-7.56 (m, 1H), 7.43-7.39 (dd, J=7.5, 1.4, 1H), 7.36-7.28 (m, 2H), 3.19-3.12 (t, J=6.3, 2H), 2.89-2.83 (t, J=6.3, 2H), 1.86 (s, 3H).
Example 156




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-(2-bromophenylsulfonamido)propanoic acid. MS (ESI): mass calcd. for C19H17FN4O4S, 416.10; m/z found, 417.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.34 (m, 1H), 8.23-8.20 (d, J=1.4, 1H), 8.13-8.08 (dd, J=8.0, 1.3, 1H), 7.96-7.89 (m, 1H), 7.69-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.39-7.36 (dd, J=7.6, 1.3, 1H), 7.36-7.34 (dd, J=8.0, 1.7, 1H), 7.34-7.30 (dd, J=12.3, 1.7, 1H), 3.77-3.66 (q, J=7.2, 1H), 1.33-1.25 (d, J=7.2, 3H).
Example 157




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-ureidoethyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN6O3S, 430.12; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.32 (m, 1H), 8.29 (s, 1H), 8.09-8.03 (dd, J=8.0, 1.3, 1H), 8.01-7.93 (m, 1H), 7.73-7.64 (m, 1H), 7.64-7.55 (m, 1H), 7.45-7.38 (dd, J=7.6, 1.4, 1H), 7.37-7.28 (m, 2H), 3.15-3.04 (t, J=6.2, 2H), 2.87-2.78 (t, J=6.2, 2H).
Example 158




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)benzenesulfonamide. MS (ESI): mass calcd. for C25H21FN4O3S, 476.13; m/z found, 477.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.34 (m, 1H), 8.29-8.24 (dd, J=8.0, 1.3, 1H), 8.07-8.05 (d, J=1.5, 1H), 7.84-7.79 (m, 1H), 7.71-7.66 (m, 1H), 7.63-7.58 (m, 1H), 7.42-7.37 (dd, J=7.6, 1.3, 1H), 7.31-7.23 (m, 2H), 7.21-7.13 (m, 2H), 7.12-7.07 (m, 1H), 7.03-6.97 (m, 1H), 4.49-4.45 (d, J=5.3, 1H), 4.28-4.22 (m, 1H), 3.19-3.11 (dd, J=15.8, 6.7, 1H), 2.70-2.64 (dd, J=15.8, 5.9, 1H).
Example 159




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1R,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)benzenesulfonamide. MS (ESI): mass calcd. for C25H21FN4O3S, 476.13; m/z found, 477.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.34 (m, 1H), 8.29-8.25 (dd, J=8.1, 1.3, 1H), 8.07-8.04 (d, J=1.5, 1H), 7.86-7.78 (m, 1H), 7.73-7.65 (m, 1H), 7.65-7.57 (m, 1H), 7.44-7.36 (dd, J=7.6, 1.3, 1H), 7.32-7.23 (m, 2H), 7.22-7.12 (m, 2H), 7.12-7.06 (m, 1H), 7.02-6.95 (d, J=7.6, 1H), 4.51-4.43 (d, J=5.4, 1H), 4.30-4.21 (m, 1H), 3.20-3.10 (dd, J=15.9, 6.7, 1H), 2.72-2.58 (dd, J=15.8, 6.0, 1H).
Example 160




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)benzenesulfonamide. MS (ESI): mass calcd. for C25H21FN4O3S, 476.13; m/z found, 477.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.33 (m, 1H), 8.27-8.22 (dd. J=8.0, 1.3, 1H), 8.08-8.04 (d, J=1.5, 1H), 7.88-7.80 (m, 1H), 7.72-7.67 (m, 1H), 7.65-7.58 (m, 1H), 7.42-7.37 (dd. J=7.7, 1.4, 1H), 7.31-7.26 (dd, J=8.0, 1.7, 1H), 7.26-7.21 (dd, J=12.2, 1.7, 1H), 7.20-7.16 (dd, J=4.7, 1.2, 2H), 7.12-7.05 (m, 1H), 7.06-7.01 (m, 1H), 4.64-4.56 (dd, J=5.1, 1.0, 1H), 4.30-4.24 (m, 1H), 3.01-2.93 (dd, J=16.2, 5.2, 1H), 2.80-2.72 (dd, J=16.2, 2.6, 1H).
Example 161




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)benzenesulfonamide. MS (ESI): mass calcd. for C25H21FN4O3S, 476.13; m/z found, 477.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.32 (m, 1H), 8.28-8.21 (dd, J=8.0, 1.3, 1H), 8.09-8.02 (d, J=1.5, 1H), 7.88-7.79 (m, 1H), 7.73-7.66 (m, 1H), 7.65-7.57 (m, 1H), 7.42-7.38 (dd, J=7.6, 1.4, 1H), 7.30-7.26 (dd, J=8.0, 1.7, 1H), 7.26-7.21 (dd, J=12.2, 1.7, 1H), 7.20-7.16 (dd, J=4.7, 1.2, 2H), 7.11-7.05 (m, 1H), 7.06-7.01 (m, 1H), 4.62-4.55 (d, J=5.3, 1H), 4.30-4.21 (m, 1H), 3.04-2.92 (dd, J=16.2, 5.2, 1H), 2.81-2.72 (dd, J=16.1, 2.6, 1H).
Example 162




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-((1S,2S)-2-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]4. 1H NMR (500 MHz, CD3OD) δ 8.36 (s, 1H), 8.26-8.22 (d, J=1.5, 2H), 8.22-8.15 (dd, J=8.0, 1.3, 2H), 7.97-7.90 (m, 2H), 7.69-7.62 (m, 2H), 7.61-7.54 (m, 2H), 7.41-7.32 (m, 5H), 3.25-3.18 (m, 1H), 2.88-2.77 (m, 2H), 1.96-1.84 (m, 2H), 1.85-1.77 (m, 2H), 1.68-1.59 (m, 2H), 1.59-1.49 (m, 2H), 1.25-1.18 (m, 4H), 1.18-1.11 (m, 3H).
Example 163




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(6-(trifluoromethyl)pyridin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H15F4N5O2S, 489.09; m/z found, 490.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.38 (m, 1H), 8.29-8.24 (dd, J=8.0, 1.4, 1H), 8.11-8.08 (d, J=1.5, 1H), 8.08-8.06 (d, J=2.6, 1H), 7.87-7.80 (m, 1H), 7.72-7.67 (m, 1H), 7.67-7.61 (m, 1H), 7.58-7.52 (d, J=8.7, 1H), 7.46-7.42 (dd, J=8.7, 2.5, 1H), 7.38-7.33 (dd, J=7.5, 1.4, 1H), 7.16-7.10 (dd, J=12.1, 1.7, 1H), 7.10-7.05 (dd, J=8.0, 1.7, 1H).
Example 164




The title compound was prepared in a manner similar to that described in Example 88 using 1-((2-bromophenyl)sulfonyl)-4-(1H-imidazol-4-yl)piperidine. MS (ESI): mass calcd. for C24H23FN6O2S, 478.16; m/z found, 479.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.83-8.76 (d, J=1.4, 1H), 8.39-8.33 (m, 1H), 8.16-8.08 (m, 2H), 7.98-7.85 (m, 1H), 7.75-7.68 (m, 1H), 7.65-7.60 (m, 1H), 7.48-7.41 (dd, J=7.5, 1.3, 1H), 7.34 (s, 1H), 7.32-7.31 (m, 1H), 7.30-7.26 (d, J=1.2, 1H), 3.48-3.39 (d, J=13.3, 2H), 2.84-2.69 (m, 1H), 2.64-2.48 (m, 2H), 1.93-1.80 (d, J=12.9, 2H), 1.52-1.33 (m, 2H).
Example 165




The title compound was prepared in a manner similar to that described in Example 88 using N-((4-amino-2-methylpyrimidin-5-yl)methyl)-2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C22H20FN7O2S, 465.14; m/z found, 466.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.36 (s, 1H), 8.26-8.18 (d, J=1.4, 1H), 8.12-8.06 (d, J=7.9, 1H), 7.98-7.92 (m, 1H), 7.90 (s, 1H), 7.76-7.69 (m, 1H), 7.68-7.59 (m, 1H), 7.48-7.41 (dd, J=7.6, 1.4, 1H), 7.39-7.29 (m, 2H), 3.88 (s, 2H), 2.50 (s, 3H).
Example 166




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H19FN6O4S, 482.12; m/z found, 483.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.36 (m, 1H), 8.28-8.20 (d, J=8.0, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.84-7.77 (m, 1H), 7.66-7.52 (m, 3H), 7.34-7.29 (d, J=7.3, 1H), 7.14-7.05 (m, 2H), 3.75 (s, 3H), 3.60 (s, 3H).
Example 167




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(5-methylpyrazin-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H17FN6O2S, 436.11; m/z found, 437.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.37 (m, 1H), 8.25-8.21 (dd, J=8.1, 1.0, 1H), 8.10-8.07 (d, J=1.5, 1H), 7.94-7.85 (m, 2H), 7.82-7.76 (m, 1H), 7.67-7.60 (m, 1H), 7.61-7.54 (m, 1H), 7.34-7.27 (m, 1H), 7.15-7.05 (m, 2H), 2.23 (s, 3H).
Example 168




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-(2-bromophenylsulfonamido)-4-methylpentanamide. MS (ESI): mass calcd. for C22H24FN5O3S, 457.16; m/z found, 458.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.37 (m, 1H), 8.13-8.09 (dd, J=8.0, 1.3, 1H), 8.09-8.06 (d, J=1.5, 1H), 7.90-7.85 (m, 1H), 7.69-7.62 (m, 1H), 7.59-7.53 (m, 1H), 7.40-7.36 (dd, J=7.6, 1.3, 1H), 7.36-7.29 (m, 2H), 3.79-3.73 (dd, J=9.1, 5.7, 1H), 1.72-1.54 (m, 1H), 1.51-1.34 (m, 2H), 0.88-0.84 (d, J=6.6, 3H), 0.81-0.78 (d, J=6.6, 3H).
Example 169




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-cyanoethyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H16FN5O2S, 397.10; m/z found, 398.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.34 (m, 1H), 8.21-8.17 (d, J=1.5, 1H), 8.09-8.06 (dd, J=8.0, 1.3, 1H), 7.96-7.90 (m, 1H), 7.72-7.66 (m, 1H), 7.64-7.57 (m, 1H), 7.43-7.39 (dd, J=7.7, 1.4, 1H), 7.37-7.27 (m, 2H), 3.09-3.02 (t, J=6.6, 2H), 2.56-2.50 (t, J=6.6, 2H).
Example 170




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(1-cyanopropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H18FN5O2S, 411.12; m/z found, 412.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.36 (m, 1H), 8.17-8.14 (d, J=1.4, 1H), 8.14-8.10 (dd, J=8.0, 1.3, 1H), 7.96-7.87 (m, 1H), 7.72-7.65 (m, 1H), 7.63-7.56 (m, 1H), 7.44-7.38 (dd, J=7.7, 1.4, 1H), 7.37-7.29 (m, 2H), 3.47-3.39 (dd, J=12.3, 6.1, 1H), 2.61-2.46 (m, 2H), 1.18-1.11 (d, J=6.7, 3H).
Example 171




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-cyanopropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H18FN5O2S, 411.12; m/z found, 412.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.38 (dd, J=2.2, 1.5, 1H), 8.16-8.09 (dd, J=8.0, 1.3, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.93-7.86 (m, 1H), 7.71-7.65 (m, 1H), 7.64-7.56 (m, 1H), 7.45-7.38 (dd, J=7.5, 1.3, 1H), 7.37-7.28 (m, 2H), 3.51-3.37 (m, 1H), 2.64-2.45 (m, 2H), 1.18-1.11 (d, J=6.7, 3H).
Example 172




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-cyanoethyl)-N-cyclopropylbenzenesulfonamide. MS (ESI): mass calcd. for C22H20FN5O2S, 437.13; m/z found, 438.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.34 (d, J=1.6, 1H), 8.23-8.18 (d, J=1.4, 1H), 8.18-8.13 (dd, J=8.0, 1.3, 1H), 8.00-7.92 (m, 1H), 7.76-7.71 (m, 1H), 7.68-7.60 (m, 1H), 7.43-7.38 (dd, J=7.6, 1.3, 1H), 7.22 (s, 1H), 7.21-7.19 (dd, J=4.4, 1.5, 1H), 3.02-2.95 (t, J=6.7, 2H), 2.62-2.55 (t, J=6.7, 2H), 2.52-2.35 (m, 1H), 0.63-0.52 (m, 2H), 0.42-0.34 (m, 2H).
Example 173




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(3-methyloxetan-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38 (s, 1H), 8.17 (s, 1H), 8.14-8.08 (d, J=8.0, 1H), 7.97-7.88 (m, 1H), 7.73-7.65 (m, 1H), 7.65-7.55 (m, 1H), 7.47-7.38 (d, J=7.6, 1H), 7.37-7.25 (m, 2H), 4.57-4.49 (d, J=6.3, 2H), 4.20-4.13 (d, J=6.2, 2H), 1.46 (s, 3H).
Example 174




The title compound was prepared in a manner similar to that described in Example 88 using 3-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)propanenitrile. MS (ESI): mass calcd. for C23H23FN6O2S, 466.16; m/z found, 467.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40-8.38 (m, 1H), 8.15-8.11 (m, 2H), 8.00-7.92 (m, 1H), 7.78-7.70 (m, 1H), 7.67-7.60 (m, 1H), 7.49-7.43 (dd, J=7.6, 1.3, 1H), 7.34-7.32 (d, J=0.9, 1H), 7.32-7.30 (dd. J=3.7, 1.6, 1H), 3.13-3.07 (t, J=7.1, 2H), 3.07-3.02 (t. J=4.7, 4H), 2.87-2.81 (d, J=4.8, 4H), 2.81-2.76 (t, J=7.0, 2H).
Example 175




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-bromo-N-(1-methoxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.37 (m, 1H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.91-7.86 (m, 1H), 7.70-7.62 (m, 1H), 7.61-7.53 (m, 1H), 7.42-7.36 (dd, J=7.5, 1.4, 1H), 7.35-7.26 (m, 2H), 3.37-3.31 (m, 1H), 3.22-3.18 (m, 1H), 3.17 (s, 3H), 3.15-3.10 (m, 1H), 1.06-1.00 (d, J=6.7, 3H).
Example 176




The title compound was prepared in a manner similar to that described in Example 88 using 2-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)pyrazine. MS (ESI): mass calcd. for C24H22FN7O2S, 491.15; m/z found, 492.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.32 (m, 1H), 8.23-8.17 (d, J=1.4, 1H), 8.16-8.10 (m, 2H), 8.09-8.05 (m, 1H), 7.97-7.90 (m, 1H), 7.80-7.76 (d, J=2.7, 1H), 7.75-7.70 (m, 1H), 7.67-7.60 (m, 1H), 7.47-7.42 (dd. J=7.6, 1.3, 1H), 7.36-7.33 (dd, J=5.1, 1.6, 1H), 7.33 (s, 1H), 3.53-3.39 (t, J=5.1, 4H), 3.02-2.95 (t, J=5.1, 4H).
Example 177




The title compound was prepared in a manner similar to that described in Example 88 using 2-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)pyrimidine. MS (ESI): mass calcd. for C24H22FN7O2S, 491.15; m/z found, 492.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39 (s, 1H), 8.29-8.23 (d, J=4.7, 2H), 8.16-8.10 (d, J=8.0, 1H), 8.08 (s, 1H), 7.95-7.87 (m, 1H), 7.76-7.68 (m, 1H), 7.66-7.57 (m, 1H), 7.50-7.42 (d, J=7.5, 1H), 7.34-7.32 (d, J=3.6, 1H), 7.31 (s, 1H), 6.68-6.51 (t, J=4.8, 1H), 3.73-3.56 (t, J=5.0, 4H), 2.97-2.85 (t, J=4.9, 4H).
Example 178




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromoaniline. MS (ESI): mass calcd. for C16H13FN4, 280.11; m/z found, 281.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.02 (s, 1H), 7.91 (m, 1H), 7.31 (d, J=12.7, 2H), 7.04 (d, J=7.3, 2H), 6.82-6.58 (m, 4H), 4.94 (s, 2H).
Example 179




The title compound was prepared in a manner similar to that described in Example 584 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromo-N-(1-(hydroxymethyl)-cyclopentyl)benzenesulfonamide in Step B. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.39 (s, 1H), 8.18 (d, J=7.3, 1H), 8.08 (m, 1H), 7.66-7.60 (m, 1H), 7.58-7.52 (m, 1H), 7.43 (dd, J=8.1, 1.8, 1H), 7.38-7.32 (m, 2H), 4.12 (s, 1H), 3.49 (s, 2H), 1.64-1.39 (m, 8H).
Example 180




The title compound was prepared in a manner similar to that described in Example 584 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and racemic 1-((2-bromophenyl)sulfonyl)-3-phenylpyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C26H23FN4O3S, 490.15; m/z found, 491.2 [M+H]4. 1H NMR (500 MHz, CDCl3) δ 8.57 (s, 1H), 8.20 (d, J=9.2, 1H), 8.11 (d, J=1.5, 1H), 8.00 (t, J=8.1, 1H), 7.61 (dd, J=7.5, 6.2, 1H), 7.53 (m, 1H), 7.40-7.34 (m, 3H), 7.34-7.28 (m, 5H), 4.68 (s, 2H), 3.41-3.23 (m, 4H), 3.18 (d, J=10.8, 1H), 2.21-2.11 (m, 1H), 2.10-2.01 (m, 1H).
Example 181




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(2-bromophenyl)pyrrolidine-1-sulfonamide in Step B. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.40 (dd, J=5.4, 1.4, 2H), 8.14 (m, 1H), 7.61 (dd, J=8.3, 1.1, 1H), 7.42-7.35 (m, 1H), 7.32 (dd, J=8.0, 1.7, 1H), 7.23 (dd, J=3.6, 1.6, 1H), 7.22-7.15 (m, 1H), 6.44 (s, 1H), 3.33-3.25 (m, 4H), 1.87 (dd, J=7.0, 0.9, 4H).
Example 182




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl) N,N-dimethylsulfonamide in Step B. MS (ESI): mass calcd. for C18H18FN5O2S, 387.12; m/z found, 388.3 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.60 (dd, J=2.3, 1.4, 1H), 8.12 (d, J=1.5, 1H), 8.07 (m, 1H), 7.61 (dd, J=8.3, 1.1, 1H), 7.40-7.34 (m, 1H), 7.29-7.26 (m, 1H), 7.25-7.24 (m, 1H), 7.21-7.16 (m, 2H), 6.42 (s, 1H), 4.72 (s, 2H), 2.79 (s, 6H).
Example 183




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl)morpholine-4-sulfonamide. MS (ESI): mass calcd. for C20H20FN5O3S, 429.13; m/z found, 430.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.34 (d, J=1.4, 1H), 8.14 (m, 1H), 7.63 (d, J=8.0, 1H), 7.43-7.35 (m, 1H), 7.31 (dd, J=8.0, 1.7, 1H), 7.24-7.19 (m, 2H), 6.39 (s, 1H), 3.67 (dd, J=5.8, 3.7, 4H), 3.23-3.14 (m, 4H).
Example 184




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and (S)-1-((2-bromophenyl)sulfonyl)pyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.44 (d, J=1.3, 1H), 8.33 (d, J=1.5, 1H), 8.13 (dd, J=7.9, 1.3, 1H), 8.07 (m, 1H), 7.62 (m, 1H), 7.58-7.52 (m, 1H), 7.41-7.29 (m, 3H), 4.44-4.36 (m, 1H), 3.23-3.15 (m, 3H), 3.07-2.99 (m, 1H), 1.98-1.88 (m, 1H), 1.88-1.78 (m, 1H).
Example 185




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and (R)-1-((2-bromophenyl)sulfonyl)pyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.43 (d, J=1.4, 1H), 8.33 (d, J=1.5, 1H), 8.13 (dd, J=7.7, 1.3, 1H), 8.07 (m, 1H), 7.62 (m, 1H), 7.55 (m, 1H), 1.98-1.88 (m, 1H), 7.42-7.29 (m, 3H), 3.24-3.15 (m, 3H), 3.04 (t, J=1.5, 1H), 1.86 (s, 1H), 4.44-4.35 (m, 1H).
Example 186




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and Racemic-1′-((2-bromophenyl)sulfonyl)-[1,3′-bipyrrolidin]-4′-ol in Step B. MS (ESI): mass calcd. for C24H26FN5O3S, 483.17; m/z found, 484.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.60-8.57 (m, 1H), 8.15 (d, J=6.8, 1H), 8.11 (d, J=1.5, 1H), 7.97 (m, 1H), 7.61 (dd, J=7.5, 6.1, 1H), 7.55-7.49 (m, 1H), 7.38-7.28 (m, 3H), 4.68 (s, 2H), 4.18-4.12 (m, 1H), 3.30 (dd, J=10.5, 6.2, 1H), 3.23 (dd, J=10.1, 6.8, 1H), 2.95 (dd, J=10.0, 6.4, 1H), 2.88 (dd, J=10.4, 4.4, 1H), 2.63-2.57 (m, 1H), 2.52-2.38 (m, 5H), 1.74-1.67 (m, 4H).
Example 187




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and Racemic-1-((2-bromophenyl)sulfonyl)-4-morpholinopyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C24H26FN5O4S, 499.17; m/z found, 500.3 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.41 (s, 1H), 8.32 (s, 1H), 8.13-8.09 (m, 1H), 7.99 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.56 (m, 1H), 7.38 (dd, J=7.5, 1.3, 1H), 7.35-7.30 (m, 2H), 4.72-4.63 (m, 2H), 3.94-3.85 (m, 3H), 3.40-3.25 (m, 3H), 3.22-3.10 (m, 3H), 3.05-2.94 (m, 2H), 2.92-2.84 (m, 2H), 2.08-2.02 (m, 2H).
Example 188




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and Racemic-1-((2-bromophenyl)sulfonyl)-4-(4-methylpiperazin-1-yl)pyrrolidin-3-ol in Step B. MS (ESI): mass calcd. for C25H29FN6O3S, 512.20; m/z found, 513.3 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 6.90-6.87 (m, 1H), 6.63-6.57 (m, 2H), 6.45-6.40 (m, 1H), 6.23-6.17 (m, 1H), 6.12-6.07 (m, 1H), 5.95-5.89 (m, 1H), 5.83-5.76 (m, 2H), 2.58-2.50 (m, 1H), 2.46 (s, 2H), 1.84-1.81 (m, 2H), 1.77-1.72 (m, 2H), 1.63-1.58 (m, 1H), 1.32 (s, 3H), 1.31-1.26 (m, 1H), 1.23-1.13 (m, 3H),
Example 189




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-trifluorothiomethylbromobenzene. MS (ESI): mass calcd. for C17H11F4N3S, 365.06; m/z found, 366.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.46-8.37 (m, 1H), 8.09 (d, J=1.3, 1H), 7.93 (m, 1H), 7.87 (d, J=7.7, 1H), 7.69-7.60 (m, 1H), 7.55-7.50 (m, 2H), 7.28-7.17 (m, 2H).
Example 190




The title compound was prepared using analogous conditions to those described in The title compound was prepared using analogous conditions to those described in Example 6 utilizing (2-bromophenyl)(tert-butyl)sulfane. MS (ESI): mass calcd. for C20H20FN3S, 353.14; m/z found, 354.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.44-8.36 (m, 1H), 8.10-8.03 (d, J=1.5, 1H), 7.93-7.86 (m, 1H), 7.73-7.65 (dd, J=7.8, 1.4, 1H), 7.56-7.49 (m, 1H), 7.49-7.41 (m, 2H), 7.34-7.25 (m, 2H), 1.99 (s, 1H), 1.02 (s, 9H).
Example 191




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl)ethane-1-sulfonamide. MS (ESI): mass calcd. for C18H16FN3O2S, 357.09; m/z found, 358.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.48-8.36 (m, 1H), 8.16 (dd, J=7.9, 1.3, 1H), 8.09 (d, J=1.4, 1H), 7.94 (m, 1H), 7.78 (m, 1H), 7.68 (m, 1H), 7.48 (dd, J=7.5, 1.3, 1H), 7.34 (s, 1H), 7.31 (d, J=2.4, 1H), 2.84 (q, J=7.4, 2H), 1.06 (t, J=7.4, 3H).
Example 192




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(propylsulfonyl)benzene. MS (ESI): mass calcd. for C19H18FN3O2S, 371.11; m/z found, 372.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.14 (d, J=1.2, 1H), 8.08 (dd, J=7.8, 1.1, 1H), 7.95 (m, 1H), 7.81 (m, 1H), 7.72 (m, 1H), 7.48 (dd, J=7.4, 1.1, 1H), 7.38 (dd, J=12.4, 1.4, 1H), 7.32 (dd, J=8.0, 1.6, 1H), 2.94-2.81 (m, 2H), 1.49-1.32 (m, 2H), 0.79 (t, J=7.4, 3H).
Example 193




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(isobutylsulfonyl)benzene. MS (ESI): mass calcd. for C20H20FN3O2S, 385.13; m/z found, 386.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.12 (dd, J=7.9, 1.1, 1H), 8.05 (d, J=1.4, 1H), 7.96 (m, 1H), 7.81 (m, 1H), 7.73 (m, 1H), 7.49 (dd, J=7.5, 1.0, 1H), 7.37 (dd, J=12.4, 1.5, 1H), 7.32 (dd. J=8.0, 1.6, 1H), 6.76 (s, 2H), 2.81 (d, J=6.4, 2H), 1.85-1.75 (m, 1H), 0.82 (d, J=6.7, 6H).
Example 194




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 1-bromo-2-(tert-butylsulfonyl)benzene. MS (ESI): mass calcd. for C20H20FN3O2S, 385.13; m/z found, 386.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.51-8.44 (d, J=1.4, 1H), 8.27-8.20 (d, J=1.4, 1H), 8.10-8.04 (dd, J=8.0, 1.4, 1H), 8.04-7.98 (m, 1H), 7.70-7.63 (m, 1H), 7.62-7.55 (m, 1H), 7.36-7.30 (dd, J=7.6, 1.4, 1H), 7.29-7.25 (dd, J=8.1, 1.7, 1H), 7.22-7.17 (dd, J=12.3, 1.7, 1H), 1.23-1.11 (s, 9H).
Example 195




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(cyclopentylsulfonyl)benzene MS (ESI): mass calcd. for C21H2FN3O2S, 397.13; m/z found, 398.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.65 (d, J=1.3, 1H), 8.30 (d, J=1.3, 1H), 8.19 (dd, J=7.9, 1.2, 1H), 8.14 (m, 1H), 7.79 (m, 1H), 7.71 (m, 1H), 7.48 (dd, J=7.5, 1.2, 1H), 7.42 (s, 1H), 7.41-7.38 (m, 1H), 3.23-3.15 (m, 1H), 1.92-1.81 (m, 2H), 1.77-1.63 (m, 4H), 1.60-1.51 (m, 2H).
Example 196




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(cyclobutylsulfonyl)benzene. MS (ESI): mass calcd. for C20H18FN3O2S, 383.11; m/z found, 384.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.44 (s, 1H), 8.17 (dd, J=7.9, 1.1, 1H), 8.13 (d, J=1.4, 1H), 7.96 (m, 1H), 7.77 (m, 1H), 7.68 (m, 1H), 7.46 (dd, J=7.6, 1.1, 1H), 7.34 (s, 1H), 7.31 (dd, J=6.4, 1.5, 1H), 3.65-3.53 (m, 1H), 2.39-2.26 (m, 2H), 2.08-1.98 (m, 2H), 1.98-1.87 (m, 2H).
Example 197




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C19H16FN3O2S, 369.09; m/z found, 370.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.55-8.49 (m, 1H), 8.33 (s, 1H), 8.13 (dd, J=8.0, 1.2, 1H), 8.11-8.05 (m, 1H), 7.77 (m, 1H), 7.68 (m, 1H), 7.48 (dd, J=7.6, 1.1, 1H), 7.43-7.36 (m, 2H), 2.35-2.26 (m, 1H), 1.04-0.91 (m, 4H).
Example 198




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(hexylsulfonyl)benzene MS (ESI): mass calcd. for C22H24FN3O2S, 413.16; m/z found, 414.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.66 (s, 1H), 8.31 (s, 1H), 8.21-8.13 (m, 2H), 7.81 (m, 1H), 7.72 (m, 1H), 7.49 (dd, J=7.6, 1.2, 1H), 7.43 (dd, J=3.6, 1.4, 1H), 7.40 (s, 1H), 2.89-2.80 (m, 2H), 1.50 (m, 2H), 1.31-1.11 (m, 6H), 0.85 (t, J=7.1, 3H).
Example 199




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(isopropylsulfonyl)benzene. MS (ESI): mass calcd. for C19H18FN3O2S, 371.11; m/z found, 372.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.42 (s, 1H), 8.15 (dd, J=8.0, 1.1, 1H), 8.09 (d, J=1.4, 1H), 7.93 (m, 1H), 7.78 (m, 1H), 7.68 (m, 1H), 7.51-7.44 (m, 1H), 7.37-7.28 (m, 2H), 2.90-2.77 (m, 1H), 1.09 (d, J=6.8, 6H).
Example 200




The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenyl)thio)acetamide. MS (ESI): mass calcd. for C18H15FN4OS, 354.10; m/z found, 355.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.36 (dd, J=2.2, 1.4, 1H), 8.10-8.06 (d, J=1.5, 1H), 7.93-7.87 (m, 1H), 7.53-7.48 (m, 1H), 7.39-7.34 (m, 1H), 7.33-7.25 (m, 4H), 3.52 (s, 2H).
Example 201




The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenyl)thio)-N,N-diethylacetamide. MS (ESI): mass calcd. for C22H23FN4OS, 410.16; m/z found, 411.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.42-8.35 (d, J=1.9, 1H), 8.12-8.06 (d, J=1.5, 1H), 7.94-7.86 (m, 1H), 7.63-7.55 (dd, J=7.1, 2.1, 1H), 7.41-7.23 (m, 5H), 3.62 (s, 2H), 3.31-3.26 (m, 4H), 1.13-1.08 (t, J=7.1, 3H), 1.07-1.03 (t, J=7.1, 3H).
Example 202




The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenyl)thio)-1-morpholinoethanone. MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 425.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.39 (m, 1H), 8.10-8.08 (d, J=1.5, 1H), 7.95-7.89 (m, 1H), 7.68-7.61 (m, 1H), 7.41-7.34 (m, 2H), 7.34-7.29 (m, 2H), 7.29-7.25 (dd, J=12.2, 1.7, 1H), 3.66 (s, 2H), 3.58-3.53 (t, J=4.9, 2H), 3.54-3.49 (t, J=4.8, 2H), 3.49-3.44 (m, 2H), 3.40-3.35 (t, J=4.8, 2H).
Example 203




The title compound was prepared in a manner similar to that described in Example 88 using racemic 5-(((2-bromophenyl)thio)methyl)oxazolidin-2-one. MS (ESI): mass calcd. for C20H17FN4O2S, 396.11; m/z found, 397.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.37 (m, 1H), 8.09-8.07 (d, J=1.5, 1H), 7.94-7.88 (m, 1H), 7.65-7.59 (m, 1H), 7.43-7.37 (m, 1H), 7.37-7.29 (m, 3H), 7.28-7.23 (dd, J=12.2, 1.7, 1H), 4.68-4.54 (m, 1H), 3.56-3.48 (t, J=8.8, 1H), 3.29-3.22 (dd, J=9.2, 6.4, 1H), 3.20-3.13 (m, 1H), 3.07-3.01 (m, 1H).
Example 204




The title compound was prepared in a manner similar to that described in Example 88 using N-(2-((2-bromophenyl)thio)ethyl)benzamide. MS (ESI): mass calcd. for C25H21FN4OS, 444.14; m/z found, 445.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.32 (m, 1H), 8.09-8.03 (d, J=1.4, 1H), 7.89-7.83 (t, J=8.1, 1H), 7.73-7.67 (m, 2H), 7.67-7.63 (d, J=7.9, 1H), 7.52-7.45 (m, 1H), 7.44-7.34 (m, 3H), 7.30-7.26 (m, 3H), 7.26-7.21 (dd, J=12.4, 1.7, 1H), 3.53-3.46 (t. J=7.0, 2H), 3.11-3.03 (t, J=7.0, 2H).
Example 205




The title compound was prepared in a manner similar to that described in Example 88 using (2-bromophenyl)(4-(methylsulfonyl)benzyl)sulfane. MS (ESI): mass calcd. for C24H20FN3O2S2, 465.10; m/z found, 466.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.35 (m, 1H), 8.12-8.04 (d, J=1.5, 1H), 7.87-7.81 (m, 1H), 7.79-7.73 (m, 2H), 7.59-7.48 (m, 1H), 7.39-7.30 (m, 4H), 7.29-7.24 (m, 1H), 7.18-7.12 (dd, J=8.0, 1.7, 1H), 7.11-7.03 (dd, J=12.3, 1.7, 1H), 4.04 (s, 2H), 3.08 (s, 3H).
Example 206




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C17H12F4N4O2S, 412.06; m/z found, 413.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41 (s, 1H), 8.38 (s, 1H), 8.22-8.16 (m, 1H), 8.01-7.92 (m, 2H), 7.63-7.58 (d, J=8.0, 1H), 7.40-7.30 (m, 2H).
Example 207




The title compound was prepared in a manner similar to that described in Example 88 using 1-bromo-2-(methylsulfonyl)-4-(trifluoromethyl)benzene and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H13F4N3O2S, 411.07; m/z found, 412.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.45-8.44 (d, J=2.0, 1H), 8.43 (s, 1H), 8.10-8.09 (d, J=1.5, 1H), 8.09-8.06 (dd, J=7.8, 1.7, 1H), 8.02-7.97 (m, 1H), 7.71-7.68 (d, J=7.9, 1H), 7.41-7.39 (m, 1H), 7.39-7.37 (m, 1H), 2.88 (s, 3H).
Example 208




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-methyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H14F4N4O2S, 426.08; m/z found, 427.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.36 (m, 1H), 8.34-8.27 (d, J=1.9, 1H), 8.21-8.14 (d, J=1.4, 1H), 8.02-7.92 (m, 2H), 7.66-7.61 (d, J=7.9, 1H), 7.35 (s, 1H), 7.34-7.32 (dd, J=4.3, 1.6, 1H), 2.46 (s, 3H).
Example 209




The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromo-5-(trifluoromethyl)phenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C21H17F4N5O3S, 495.10; m/z found, 496.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.37 (m, 2H), 8.24-8.21 (d, J=1.4, 1H), 8.08-8.04 (dd, J=8.0, 1.8, 1H), 8.04-7.99 (m, 1H), 7.69-7.65 (d, J=7.9, 1H), 7.38-7.35 (m, 1H), 7.35-7.32 (dd, J=5.8, 1.6, 1H), 3.38 (s, 2H), 3.15 (s, 4H).
Example 210




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H16F4N4O3S, 456.09; m/z found, 457.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.39 (m, 1H), 8.36 (s, 1H), 8.16-8.13 (d, J=1.5, 1H), 7.99-7.93 (m, 2H), 7.64-7.61 (d, J=8.0, 1H), 7.38-7.36 (m, 1H), 7.36-7.33 (dd, J=5.0, 1.6, 1H), 3.49-3.45 (t, J=5.9, 2H), 2.93-2.86 (t, J=5.8, 2H).
Example 211




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.37 (m, 1H), 8.34-8.31 (m, 1H), 8.20-8.16 (d, J=1.5, 1H), 8.01-7.94 (m, 2H), 7.65-7.59 (d, J=7.9, 1H), 7.37-7.34 (m, 1H), 7.34-7.31 (dd, J=2.9, 1.5, 1H), 2.88-2.76 (q, J=7.2, 2H), 1.07-0.94 (t, J=7.2, 3H).
Example 212




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H21F4N5O2S, 495.14; m/z found, 496.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.44-8.41 (m, 1H), 8.41-8.38 (d, J=2.0, 1H), 8.13-8.10 (d, J=1.5, 1H), 8.10-8.06 (m, 1H), 8.05-7.97 (m, 1H), 7.73-7.60 (d, J=8.0, 1H), 7.39-7.37 (dd, J=6.6, 1.6, 1H), 7.37-7.35 (dd, J=2.8, 1.7, 1H), 2.85 (s, 3H), 3.93-2.45 (br m, 8H).
Example 213




Step A: Ethyl 3-(2-bromophenylthio)propanoate
A mixture of 2-bromobenzenethiol (6 g, 30 mmol), ethyl 3-chloropropanoate (13 g, 96 mmol), K2CO3 (8.8 g, 64 mmol) and acetone (150 mL) was refluxed for 15 h. The reaction mixture was filtered and the filter cake washed with acetone (50 mL). The filtrate was concentrated to dryness and subjected to FCC to give ethyl 3-(2-bromophenylthio)propanoate (7 g, 78%). MS (ESI): mass calcd. for C11H13O2S, 287.98; m/z found, 288.8 [M+H]+.
Step B: Ethyl 3-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylthio) propanoate
A mixture of ethyl 3-(2-bromophenylthio)propanoate (7 g, 24 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (7.6 g, 24 mmol), Pd(dppf)Cl2.CH2Cl2 (378 mg, 0.52 mmol) and Na2CO3 (5 g, 48 mmol) in dioxane/water (20 mL/5 mL) was stirred at 80° Celsius for 5 hours under N2, then poured into water (60 mL) and extracted with EtOAc (50 mL×3). The combined organic extracts were dried over Na2SO4, filtered, concentrated to dryness and purified by FCC to give ethyl 3-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylthio) propanoate (7.7 g, 80%) as a white solid. MS (ESI): mass calcd. for C21H20FN3O2S, 397.13; m/z found, 397.9 [M+H]+.
Step C: 4′-(5-Aminopyrazin-2-yl)-5′-fluorobiphenyl-2-thiol
To a solution consisting of ethyl 3-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylthio) propanoate (7.7 g, 19.4 mmol) and THF (60 mL) was added t-BuOK (4.3 g, 38.8 mmol) and the mixture stirred for 1 hour at rt. The reaction mixture was poured into water (100 mL) and the system brought to a pH=5-6 with 1 M HCl. The mixture was, extracted with EtOAc (80 mL×3) and the combined extracts dried over Na2SO4, filtered and concentrated to dryness to give 4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-thiol (4.6 g, 80%). MS (ESI): mass calcd. for C16H12FN3S, 297.07; m/z found, 298.0 [M+H]+.
Step D
To a solution of 4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-thiol (400 mg, 1.34 mmol) and 2-chloropyrimidine (167 mg, 1.47 mmol) in DMF (8 mL) were added DIPEA (345 mg, 2.68 mmol) and Ph3P (351 mg, 1.34 mmol) and the resultant mixture heated at 80° Celsius for 1 hour under a N2 atmosphere for 15 h. The mixture was cooled to rt, concentrated to dryness and the residue subjected to FCC to give the title compound (350 mg, 68%). MS (ESI): mass calcd. for C20H14FN5S.HCl, 375.10; m/z found, 376.0 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.42 (d, J=4.9, 2H), 8.33-8.28 (m, 1H), 8.03 (d, J=1.4, 1H), 7.79-7.69 (m, 2H), 7.60-7.53 (m, 1H), 7.51-7.43 (m, 2H), 7.21 (dd, J=8.0, 1.7, 1H), 7.15 (dd, J=12.3, 1.6, 1H), 7.06 (m, 1H).
Example 214




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-chloropyrimidine. MS (ESI): mass calcd. for C20H14FN5S, 375.10; m/z found, 375.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.84 (d, J=1.1, 1H), 8.46 (d, J=1.4, 2H), 8.44 (d, J=5.6, 1H), 7.81-7.75 (m, 1H), 7.73-7.65 (m, 1H), 7.62-7.51 (m, 3H), 7.30 (dd, J 20=11.8, 1.6, 1H), 7.24 (dd, J=7.9, 1.7, 1H), 6.96 (dd, J=5.6, 1.3, 1H), 6.90 (s, 2H).
Example 215




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-amino-6-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 391.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.29-8.25 (m, 3H), 7.94 (m 1H), 7.82 (d, J=7.4, 1H), 7.74 (m, 1H), 7.67-7.58 (m, 2H), 7.34-7.23 (m, 2H), 5.94 (s, 1H).
Example 216




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 390.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.31 (m, 1H), 8.16 (s, 1H), 7.88 (m, 1H), 7.83-7.75 (m, 2H), 7.71-7.63 (m, 1H), 7.58-7.52 (m, 2H), 7.32-7.21 (m, 2H), 6.37 (d, J=7.2, 1H).
Example 217




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 5-amino-4-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11: m/z found, 391.0 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.35-8.30 (m, 1H), 8.22 (s, 1H), 8.02 (d, J=1.4, 1H), 7.90 (s, 1H), 7.80 (m, 1H), 7.59-7.54 (m, 2H), 7.52-7.44 (m, 2H), 7.24 (dd, J=6.5, 1.6, 1H), 7.21 (m, 1H).
Example 218




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 2-chloropyrazine. MS (ESI): mass calcd. for C20H14FN5S, 375.10; m/z found, 375.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.26-8.24 (m, 3H), 8.18 (d, J=2.6, 1H), 8.08 (d, J=1.4, 1H), 7.84 (m, 1H), 7.77-7.69 (m, 1H), 7.64-7.55 (m, 1H), 7.55-7.46 (m, 2H), 7.27-7.14 (m, 2H).
Example 219




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 5-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 391.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.24 (s, 1H), 7.95 (s, 2H), 7.88 (m, 1H), 7.65-7.59 (m, 1H), 7.53-7.38 (m, 3H), 7.27-7.16 (m, 2H).
Example 220




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)-N-methylmethanesulfonamide. MS (ESI): mass calcd. for C16H17FN4O2S, 372.11; m/z found, 373.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 1H), 8.25 (s, 1H), 7.99 (m, 1H), 7.68-7.60 (m, 1H), 7.50-7.40 (m, 2H), 7.39-7.31 (m, 3H), 4.36 (s, 2H), 2.49 (s, 3H).
Example 221




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)-N-(2-hydroxyethyl)methanesulfonamide. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (d, J=1.2, 1H), 8.31 (s, 1H), 8.02 (m, 1H), 7.70-7.63 (m, 1H), 7.49-7.40 (m, 2H), 7.40-7.30 (m, 3H), 4.40 (s, 2H), 3.51 (t, J=5.9, 2H), 2.95 (t, J=5.9, 2H), 2.66 (s, 1H).
Example 222




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-((2-bromobenzyl)sulfonyl)azetidin-3-ol. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 414.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.43-8.38 (m, 1H), 8.08 (d, J=1.5, 1H), 7.95 (m, 1H), 7.68-7.60 (m, 1H), 7.49-7.41 (m, 2H), 7.39-7.28 (m, 3H), 4.45-4.36 (m, 3H), 3.79-3.70 (m, 2H), 3.67-3.59 (m, 2H).
Example 223




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 4-((2-bromobenzyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C21H20FN5O3S, 441.13; m/z found, 441.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.41 (s, 1H), 8.08 (d, J=1.3, 1H), 7.96 (m, 1H), 7.70-7.62 (m, 1H), 7.52-7.28 (m, 5H), 4.48 (s, 2H), 3.63 (s, 2H), 3.25 (s, 4H).
Example 224




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and(S)-1-(2-bromophenyl)-N-(1-hydroxypropan-2-yl)methanesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 416.9 [M+H]+. 1H NMR (400 MHz, DMSO-d) 8.43-8.36 (m, 1H), 8.03 (d, J=1.5, 1H), 7.92 (m, 1H), 7.70-7.59 (m, 1H), 7.47-7.28 (m, 5H), 7.12 (d, J=6.6, 1H), 6.71 (s, 2H), 4.75 (t, J=5.4, 1H), 4.35 (q, J=14.1, 2H), 3.31-3.11 (m, 3H), 1.01 (d, J=6.2, 3H).
Example 225




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and (R)-1-(2-bromophenyl)-N-(1-hydroxypropan-2-yl)methanesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.48; m/z found, 417.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.32 (d, J=3.7, 2H), 7.99 (m, 1H), 7.77-7.66 (m, 1H), 7.50-7.39 (m, 2H), 7.39-7.28 (m, 3H), 4.41 (q, J=13.9, 2H), 3.49-3.33 (m, 3H), 1.11 (d, J=6.3, 3H).
Example 226




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and trans-1-(2-bromophenyl)-N-((trans)-4-hydroxycyclohexyl)-methane-sulfonamide. MS (ESI): mass calcd. for C23H25FN4O3S.HCO2H, 456.16; m/z found, 457.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.40 (s, 1H), 8.08 (d, J=1.3, 1H), 7.94 (m, 1H), 7.72-7.63 (m, 1H), 7.47-7.38 (m, 1H), 7.38-7.27 (m, 3H), 4.36 (s, 2H), 3.42 (s, 1H), 2.97 (s, 1H), 1.84 (d, J=9.0, 4H), 1.38-1.10 (m, 4H).
Example 227




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (S)-1-(2-bromophenyl)-N-(2-hydroxypropyl)-methane-sulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.67 (s, 1H), 8.28-8.23 (m, 1H), 8.13 (m, 1H), 7.70-7.62 (m, 1H), 7.49-7.30 (m, 5H), 4.40 (s, 2H), 3.77-3.65 (m, 1H), 2.80 (d. J=5.9, 2H), 1.09 (d, J=6.3, 3H).
Example 228




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and (R)-1-(2-bromophenyl)-N-(2-hydroxypropyl)methane-sulfonamide.
Example 229




Step A: tert-Butyl 1-((4′-(5-aminopyrazin-2-yl-5′-fluorobiphenyl-2-yl)methylsulfonyl)-piperidin-4-ylcarbamate
A mixture of tert-butyl (1-((2-bromobenzyl)sulfonyl)piperidin-4-yl)carbamate (200 mg, 0.46 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (175 mg, 0.55 mmol), Pd(dppf)Cl2.CH2Cl2 (34 mg, 0.046 mmol) and Na2CO3 (150 mg, 1.36 mmol) in dry DMF (15 mL) was stirred at 130° Celsius under N2. After 5 hours, the solvent was removed under vacuum and the residue was subjected to FCC purification to give tert-butyl 1-((4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methylsulfonyl)piperidin-4-ylcarbamate (190 mg, 76%). MS (ESI): mass calcd. for C27H32FN5O2S, 541.22; m/z found, 542.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.95 (s, 1H), 7.78-7.29 (m, 7H), 6.87 (d, J=5.2, 1H), 6.73 (s, 2H), 4.34 (s, 2H), 3.45-3.33 (m, 3H), 2.85-2.75 (m, 2H), 1.72 (d, J=12.4, 2H), 1.45-1.30 (m, 11H).
Step B
A mixture of tert-butyl 1-((4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methylsulfonyl)piperidin-4-ylcarbamate (190 mg, 0.35 mmol) in HCl (20 mL, 6 N in methanol) was stirred at rt for 24 hours. The solvent was removed under reduced pressure and the residue purified by HPLC to give the title compound (80 mg HCl salt, 61%). MS (ESI): mass calcd. for C22H24FN5O2S, 441.16; m/z found, 442.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.10 (br, 4H), 7.95 (m, 1H), 7.64-7.55 (m, 1H), 7.52-7.32 (m, 4H), 4.80 (br, 4H), 4.37 (s, 2H), 3.50 (d, J=13.0, 2H), 3.10 (s, 1H), 2.76 (t. J=12.6, 2H), 1.91 (d. J=11.0, 3H), 1.58-1.41 (m, 2H).
Example 230




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and (2-bromophenyl)methanesulfonamide. MS (ESI): mass calcd. for C17H15FN4O2S, 358.09; m/z found, 359.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.12 (s, 1H), 7.92 (m, 1H), 7.66-7.56 (m, 1H), 7.38 (m, 5H), 6.98 (s, 2H), 4.31 (s, 2H).
Example 231




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)-N-ethylmethanesulfonamide. MS (ESI): mass calcd. for C19H19FN4O2S, 386.12; m/z found, 387.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.39 (s, 1H), 8.08 (d, J=1.4, 1H), 7.93 (m, 1H), 7.71-7.61 (m, 1H), 7.49-7.27 (m, 5H), 4.36 (s, 2H), 2.85 (q, J=7.2, 2H), 1.06 (t, J=7.2, 3H).
Example 232




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(1-((2-bromobenzyl)sulfonyl)piperidin-4-yl)urea. MS (ESI): mass calcd. for C23H25FN6O3S, 484.17; m/z found, 485.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.16 (s, 1H), 7.96 (t, J=8.2, 1H), 7.66-7.28 (m, 6H), 4.35 (s, 2H), 3.41-3.32 (m, 2H), 2.85-2.70 (m, 2H), 1.83-1.70 (m, 2H), 1.33-1.19 (m, 2H).
Example 233




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and N-(1-((2-bromobenzyl)sulfonyl)piperidin-4-yl)acetamide. MS (ESI): mass calcd. for C24H26FN5O3S, 483.17; m/z found, 484.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.03 (d, J=1.3, 1H), 7.95 (m, 1H), 7.81 (d, J=7.3, 1H), 7.64-7.55 (m, 1H), 7.50-7.31 (m, 5H), 6.73 (s, 2H), 4.35 (s, 2H), 3.71-3.56 (m, 1H), 3.39 (d, J=11.6, 2H), 2.79 (t, J=10.8, 2H), 1.82-1.67 (m, 5H), 1.41-1.24 (m, 3H).
Example 234




Step A: (4′-(5-Aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methanol
A mixture of 2-(hydroxymethyl)phenylboronic acid (1 g, 7 mmol), 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine (1.76 g, 6.6 mmol), Pd(dppf)Cl2.CH2Cl2 (483 mg, 0.66 mmol) and Na2CO3 (2.1 g, 20 mmol) in DMF (50 mL) was stirred at 110° Celsius overnight under N2. The solution was concentrated to dryness and the residue purified by FCC to give (4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methanol (1.2 g, 62%). 1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.02 (d, J=1.4, 1H), 7.90 (m, 1H), 7.57 (d, J=7.4, 1H), 7.49-7.26 (m, 5H), 6.69 (s, 2H), 5.20 (t, J=5.3, 1H), 4.44 (d, J=5.3, 2H).
Step B: 5-(6′-(Chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine
A mixture of (4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methanol (1.8 g, 6.1 mmol) and SOCl2 (6 mL) in DCM (20 mL) was stirred at 70° Celsius for 4 hours. The reaction mixture was cooled to rt and concentrated to dryness to give 5-(6′-(chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine (1.86 g, 98%). 1H NMR (300 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.04 (s, 1H), 7.96 (m, 1H), 7.66-7.57 (m, 1H), 7.51-7.42 (m, 2H), 7.40-7.30 (m, 3H), 6.89-6.62 (br s, 2H), 4.73 (s, 2H).
Step C: S-(4′-(5-Aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate
A mixture of 5-(6′-(chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine (1.86 g, 5.94 mmol) and KSAc (0.81 g, 7.1 mmol) in 1,4-dioxane/H2O (30 mL/6 mL) was stirred at rt for 2 hours. Then the solvent was removed under vacuum and the residue purified by FCC to give S-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate (1.42 g, 68%). MS (ESI): mass calcd. for C19H18FN3OS, 353.10; m/z found, 353.9 [M+H]+.
Step D
To a solution of S-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate (100 mg, 0.28 mmol) in CH3OH (30 mL) were added Ph3P (147 mg, 0.56 mmol) and K2CO3 (78 mg, 0.56 mmol) followed by drop-wise addition of bromoethane (60 mg, 0.56 mmol). After 16 hours, the mixture was concentrated to dryness and the residue was purified by prep-TLC and followed by HPLC to give the title compound (70 mg HCOOH salt, 73%). MS (ESI): mass calcd. for C19H18FN3S, 339.12; m/z found, 340.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (m, 1H), 8.07 (d, J=1.5, 1H), 7.89 (m, 1H), 7.48-7.40 (m, 1H), 7.37-7.21 (m, 5H), 3.71 (s, 2H), 2.42 (q, J=7.4, 2H), 1.13 (t, J=7.4, 3H).
Example 235




The title compound was prepared using analogous conditions to those described in Example 234 utilizing iodomethane. MS (ESI): mass calcd. for C18H16FN3S, 325.10; m/z found, 326.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.45 (s, 1H), 8.30 (d, J=1.0, 1H), 8.04 (m, 1H), 7.49-7.24 (m, 6H), 3.68 (s, 2H).
The title
Example 236




The title compound was prepared using analogous conditions to those described in Example 234 utilizing 2-iodopropane. MS (ESI): mass calcd. for C20H20FN3S, 353.14; m/z found, 354.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.66 (s, 1H), 8.23 (d, J=1.2, 1H), 8.12 (m, 1H), 7.48-7.23 (m, 6H), 3.73 (s, 2H), 2.84-2.71 (m, 1H), 1.16 (d, J=6.7, 6H).
Example 237




The title compound was prepared using analogous conditions to those described in Example 234 utilizing 4-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C18H16FN3S, 404.12; m/z found, 404.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.77-8.68 (m, 1H), 8.21 (d, J=1.3, 1H), 8.10 (m, 1H), 7.79 (d, J=6.9, 1H), 7.63-7.55 (m, 1H), 7.45-7.22 (m, 5H), 6.73 (d, J=6.8, 1H), 4.57 (s, 2H).
Example 238




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 4-amino-6-chloropyrimidine. MS (ESI): mass calcd. for C21H17FN6S, 404.12; m/z found, 405.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.78-8.68 (m, 1H), 8.38 (d, J=0.6, 1H), 8.26 (d, J=1.3, 1H), 8.16 (m, 1H), 7.66-7.57 (m, 1H), 7.50-7.44 (m, 2H), 7.42-7.31 (m, 3H), 6.58 (d, J=3.4, 1H), 4.51 (s, 2H).
Example 239




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 3-chloropyrazine. MS (ESI): mass calcd. for C21H16FN5S, 389.11; m/z found, 390.1 [M+H]4. 1H NMR (400 MHz. CD3OD) δ 9.33-9.24 (m, 1H), 8.74 (s, 1H), 8.31-8.20 (m, 2H), 8.14 (m, 2H), 7.72-7.64 (m, 1H), 7.50-7.33 (m, 5H), 4.63 (s, 2H).
Example 240




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 3-chloropyrazine. MS (ESI): mass calcd. for C21H17FN6S, 404.12; m/z found, 405.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.70-8.63 (m, 1H), 8.28 (d, J=1.1, 1H), 8.12 (m, 1H), 7.65-7.57 (m, 2H), 7.46-7.41 (m, 2H), 7.39 (dd, J=8.1, 1.6, 1H), 7.36-7.30 (m, 3H), 4.43 (s, 2H).
Example 241




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 4-((2-bromophenyl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C21H20FN3O4S2, 461.09; m/z found, 462.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.07-8.04 (m, 2H), 7.92 (m, 1H), 7.84 (m, 1H), 7.75 (m, 1H), 7.49 (dd, J=7.5, 1.0, 1H), 7.38-7.31 (m, 1H), 7.29 (dd, J=8.0, 1.6, 1H), 6.74 (s, 2H), 3.25-3.06 (m, 5H), 2.16-2.04 (m, 2H), 2.02-1.86 (m, 2H).
Example 242




The title compound was prepared using analogous conditions to those described in Example 234 utilizing 2-amino-4-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 391.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39-8.32 (m, 1H), 8.01 (d, J=1.5, 1H), 7.94 (d, J=6.1, 1H), 7.85 (m, 1H), 7.76 (d, J=7.8, 1H), 7.71-7.65 (m, 1H), 7.62-7.53 (m, 2H), 7.35-7.24 (m, 2H), 6.88 (s, 2H), 6.18 (d, J=6.4, 1H).
Example 243




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 4-chloropyrimidine. MS (ESI): mass calcd. for C18H16FN3S, 389.11; m/z found, 390.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.70 (d, J=1.4, 1H), 8.53 (d, J=4.9, 2H), 8.20 (d, J=1.3, 1H), 8.10 (m, 1H), 7.65-7.55 (m, 1H), 7.39-7.25 (m, 5H), 7.13 (m, 1H), 4.46 (s, 2H).
Example 244




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl)-pyrazin-2-amine and (2-(((2-bromophenyl)thio)methoxy)ethyl)trimethylsilane. MS (ESI): mass calcd. for C22H26FN3OSSi, 427.16; m/z found, 428.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.43-8.36 (m, 1H), 8.07 (d, J=1.5, 1H), 7.89 (m, 1H), 7.73 (dd, J=6.7, 1.4, 1H), 7.40-7.17 (m, 5H), 4.90 (s, 2H), 3.64-3.50 (m, 2H), 0.91-0.78 (m, 2H). 0.04 (s, 9H).
Example 245




The title compound was prepared using analogous conditions to those described in Example Example 244 utilizing 5-[3-fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl-biphenyl-4-yl]-pyrazin-2-amine. MS (ESI): mass calcd. for C22H26FN3O3SSi, 459.14; m/z found, 459.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.44-8.39 (m, 1H), 8.18 (dd, J=8.0, 1.3, 1H), 8.08 (d, J=1.4, 1H), 7.94 (m, 1H), 7.80-7.75 (m, 1H), 7.72-7.65 (m, 1H), 7.47 (dd, J=7.5, 1.4, 1H), 7.31 (dd, J=3.6, 1.7, 1H), 7.28 (dd, J=7.7, 1.5, 1H), 4.34 (s, 2H), 3.77-3.68 (m, 2H), 0.85-0.75 (m, 2H), 0.08 (s, 9H).
Example 246




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 1-bromo-2-((3-(methylsulfonyl)propyl)sulfonyl)benzene. MS (ESI): mass calcd. for C20H20FN3O4S2, 449.53; m/z found, 450.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.69 (d, J=1.3, 1H), 8.25 (d, J=1.3, 1H), 8.18 (dd, J=7.9, 1.3, 1H), 8.12 (m, 1H), 7.81 (m, 1H), 7.71 (m, 1H), 7.48 (dd, J=7.4, 1.3, 1H), 7.44-7.34 (m, 2H), 3.20-3.09 (m, 4H), 2.89 (s, 3H), 2.12-1.96 (m, 2H).
Example 247




Step A: (R)-tert-Butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl-3-methylpiperazine-1-carboxylate
The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (R)-tert-butyl 4-((2-bromophenyl)sulfonyl)-3-methypiperazine-1-carboxylate. MS (ESI): mass calcd. for C26H30FN5O4S, 527.20; m/z found, 528.2 [M+H]+.
Step B
The title compound was prepared by dissolving (R)-tert-butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-methylpiperazine-1-carboxylate (42 mg, 0.08 mmol) in a 50/50 mixture of DCM/TFA (1 mL) and allowing it to stir at rt for 2 h. The reaction mixture was concentrated to dryness and the residue subjected to HPLC purification to give the title compound (29 mg, 85%). MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J=1.4, 2H), 8.16 (dd, J=8.0, 1.4, 1H), 7.65-7.58 (m, 1H), 7.56-7.49 (m, 1H), 7.48-7.39 (m, 1H), 7.38-7.31 (m, 3H), 5.18 (s, 2H), 3.64-3.52 (m, 1H), 2.99-2.87 (m, 2H), 2.81-2.69 (m, 1H), 2.61-2.41 (m, 4H), 1.18 (d, J=6.8, 3H).
Example 248




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-phenyl)pyrimidin-2-amine and (S)-2-bromo-N-(1-hydroxybutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.47 (d, J=1.3, 2H), 8.18 (dd, J=7.9, 1.4, 1H), 7.67-7.57 (m, 1H), 7.59-7.49 (m, 1H), 7.42-7.30 (m, 4H), 5.39 (s, 2H), 5.07 (d, J=8.0, 1H), 3.55-3.38 (m, 2H), 3.25-3.11 (m, 1H), 1.93 (s, 1H), 1.54-1.29 (m, 2H), 0.80 (t, J=7.4, 3H).
Example 249




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phenyl)pyrimidin-2-amine and 2-bromo-N-(2-cyanoethyl)-N-cyclopropylbenzenesulfonamide. MS (ESI): mass calcd. for C22H20FN5O2S, 437.13; m/z found, 438.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J=1.4, 2H), 8.17 (dd, J=7.9, 1.3, 1H), 7.71-7.62 (m, 1H), 7.62-7.52 (m, 1H), 7.49-7.40 (m, 1H), 7.33 (dd, J=7.5, 1.4, 1H), 7.20 (dd, J=8.0, 1.7, 1H), 7.14 (dd, J=11.1, 1.7, 1H), 5.20 (s, 2H), 3.02 (t, J=7.0, 2H), 2.59-2.41 (m, 3H), 0.65-0.55 (m, 2H), 0.39-0.28 (m, 2H).
Example 250




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phenyl)pyrimidin-2-amine and 2-bromo-N-(2-cyanoethyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H16FN5O2S, 397.10; m/z found, 398.1 [M+H]+. 1H NMR (400 MHz, CDCl3) 8.50 (d, J=1.4, 2H), 8.18 (dd, J=7.9, 1.4, 1H), 7.70-7.64 (m, 1H), 7.62-7.55 (m, 1H), 7.49-7.42 (m, 1H), 7.40-7.32 (m, 3H), 5.36 (s, 2H), 5.24 (t, J=6.5, 1H), 3.07 (m, 2H), 2.50 (t, J=6.5, 2H).
Example 251




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phenyl)pyrimidin-2-amine and 2-bromo-N-(3-hydroxy-2,2-dimethylpropyl)-benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J=1.4, 2H), 8.12 (dd, J=7.8, 1.5, 1H), 7.62-7.55 (m, 1H), 7.55-7.48 (m, 1H), 7.48-7.38 (m, 1H), 7.38-7.27 (m, 3H), 5.08 (s, 2H), 4.23 (t, J=6.6, 1H), 3.33-3.21 (m, 2H), 2.61 (d, J=6.8, 2H), 1.40 (s, 6H).
Example 252




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phenyl)pyrimidin-2-amine and racemic (4-((2-bromophenyl)sulfonyl)morpholin-2-yl)methanol. MS (ESI): mass calcd. for C21H21FN4O4S, 444.13; m/z found, 445.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J=1.4, 2H), 8.10 (dd, J=7.9, 1.4, 1H), 7.70-7.60 (m, 1H), 7.60-7.52 (m, 1H), 7.47-7.35 (m, 2H), 7.33-7.26 (m, 2H), 5.22 (s, 2H), 3.86-3.76 (m, 1H), 3.63-3.51 (m, 1H), 3.51-3.29 (m, 3H), 3.24-3.09 (m, 2H), 2.64-2.52 (m, 1H), 2.45 (dd, J=12.4, 10.5, 1H), 1.95 (s, 1H).
Example 253




Step A: (S-tert-Butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl-3-methylpiperazine-1-carboxylate
The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-tert-butyl 4-((2-bromophenyl)sulfonyl)-3-methypiperazine-1-carboxylate. MS (ESI): mass calcd. for C26H30FN5O4S, 527.20: m/z found, 528.2 [M+H]+.
Step B
The title compound was prepared as described in the preparation of Example 252 using (S)-tert-butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-methylpiperazine-1-carboxylate. MS (ESI): mass calcd. for C21H22FN5O2S, 427.15; m/z found, 428.1 [M+H]+. 1H NMR (400 MHz, CDCl3) b 8.56 (d, J=1.4, 2H), 8.16 (dd, J=7.9, 1.3, 1H), 7.65-7.58 (m, 1H), 7.56-7.49 (m, 1H), 7.48-7.39 (m, 1H), 7.38-7.31 (m, 3H), 5.16 (s, 2H), 3.64-3.51 (m, 1H), 3.02-2.86 (m, 2H), 2.81-2.70 (m, 1H), 2.63-2.41 (m, 4H), 1.18 (d, J=6.8, 3H).
Example 254




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C19H16FN3O2S, 369.10; m/z found, 370.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J=1.5, 2H), 8.14 (dd, J=7.9, 1.5, 1H), 7.70-7.63 (m, 1H), 7.62-7.54 (m, 1H), 7.45 (m, 1H), 7.41-7.28 (m, 3H), 5.23 (s, 2H), 2.19-2.06 (m, 1H), 1.16-1.07 (m, 2H), 0.93-0.81 (m, 2H).
Example 255




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-bromo-N-(1,3-dihydroxy-2-methylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O4S, 432.13; m/z found, 433.1 [M+H]+.
Example 256




Step A: (S)-tert-Butyl 3-(4′-2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-ylsulfonamido)piperidine-1-carboxylate
The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-tert-butyl 3-(2-bromo-N-methylphenylsulfonamido)-piperidine-1-carboxylate yielding 41 mg (48%) of the title compound after HPLC purification. MS (ESI): mass calcd. for C27H32FN5O4S, 541.21; m/z found, 542.1 [M+H]+.
Step B
The title compound was prepared as described in the preparation of Example 247 using (S)-tert-butyl 3-(4′-2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-ylsulfonamido)piperidine-1-carboxylate. The crude product was purified by HPLC to give the title compound (35 mg, 91%). MS (ESI): mass calcd. for C22H24FN5O2S, 441.16; m/z found, 442.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J=1.4, 2H), 8.14 (dd, J=7.9, 1.4, 1H), 7.65-7.57 (m, 1H), 7.56-7.49 (m, 1H), 7.48-7.38 (m, 1H), 7.37-7.24 (m, 3H), 5.19 (s, 2H), 3.43-3.24 (m, 1H), 2.96-2.74 (m, 2H), 2.51 (t, J=11.3, 1H), 2.42 (s, 4H), 2.38-2.27 (m, 1H), 1.78-1.21 (m, 4H).
Example 257




Step A: R)-tert-Butyl 3-(4′-2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-ylsulfonamido)piperidine-1-carboxylate
The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (R)-tert-butyl 3-(2-bromo-N-methylphenylsulfonamido)piperidine-1-carboxylate. MS (ESI): mass calcd. for C27H32FN5O4S, 541.21; m/z found, 542.2 [M+H]+.
Step B
The title compound was prepared as described in the preparation of Example 247 using (R)-tert-butyl 3-(4′-2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-ylsulfonamido)piperidine-1-carboxylate. MS (ESI): mass calcd. for C22H24FN5O2S, 441.16; m/z found, 442.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J=1.4, 2H), 8.14 (dd, J=8.0, 1.4, 1H), 7.65-7.57 (m, 1H), 7.56-7.49 (m, 1H), 7.47-7.36 (m, 1H), 7.37-7.25 (m, 3H), 5.18 (s, 2H), 3.42-3.26 (m, 1H), 2.93-2.73 (m, 2H), 2.57-2.46 (m, 1H), 2.42 (s, 3H), 2.38-2.27 (m, 2H), 1.73-1.23 (m, 4H).
Example 258




Step A: (R)-tert-Butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-(hydroxymethyl)piperazine-1-carboxylate
The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (R)-tert-butyl 4-((2-bromophenyl)sulfonyl)-3-hydroxymethy)piperazine-1-carboxylate. MS (ESI): mass calcd. for C26H30FN5O5S, 543.20; m/z found, 544.2 [M+H]+.
Step B
The title compound was prepared as described in the preparation of Example 247 using (R)-tert-butyl 4-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-(hydroxymethyl)piperazine-1-carboxylate. MS (ESI): mass calcd. for C21H22FN5O3S, 443.14; m/z found, 444.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J=1.4, 2H), 8.18 (dd, J=8.0, 1.3, 1H), 7.66-7.59 (m, 1H), 7.57-7.49 (m, 1H), 7.47-7.40 (m, 1H), 7.39-7.31 (m, 3H), 5.19 (s, 2H), 3.94-3.77 (m, 2H), 3.52-3.39 (m, 1H), 3.34-3.18 (m, 1H), 3.17-2.99 (m, 2H), 2.88-2.77 (m, 1H), 2.65-2.46 (m, 2H), 1.65 (br s, 2H).
Example 259




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and racemic 2-bromo-N-((cis)-2-hydroxycyclohexyl)-benzenesulfonamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.51 (d, J=1.3, 2H), 8.17 (dd, J=8.0, 1.4, 1H), 7.64-7.59 (m, 1H), 7.57-7.51 (m, 1H), 7.44-7.31 (m, 4H), 5.30 (s, 2H), 4.83 (d, J 20=7.7, 1H), 3.78 (s, 1H), 3.20-3.11 (m, 1H), 1.72-1.65 (m, 1H), 1.57-1.10 (m, 8H).
Example 260




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-bromo-N-((trans)-2-hydroxycylohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.51 (d, J=1.3, 2H), 8.17 (dd, J=8.0, 1.4, 1H), 7.64-7.59 (m, 1H), 7.57-7.51 (m, 1H), 7.44-7.31 (m, 4H), 5.30 (s, 2H), 4.83 (d, J=7.7, 1H), 3.78 (s, 1H), 3.20-3.11 (m, 1H), 1.72-1.65 (m, 1H), 1.57-1.10 (m, 8H).
Example 261




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-bromo-N-(2-hydroxyethyl)-N-isopropylbenzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.56 (d. J=1.4, 2H), 8.10 (dd. J=8.0, 1.4, 1H), 7.65-7.57 (m, 1H), 7.58-7.49 (m, 1H), 7.49-7.38 (m, 1H), 7.37-7.28 (m, 3H), 5.22 (s, 2H), 3.72 (p, J=6.7, 1H), 3.65-3.50 (m, 2H), 2.99 (t, J=6.0, 2H), 2.19 (d, J=7.0, 1H), 1.04 (d, J=6.7, 6H).
Example 262




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and trans-2-bromo-N-4-hydroxycyclohexyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.15; m/z found, 443.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.22-8.15 (m, 1H), 7.67-7.60 (m, 1H), 7.59-7.51 (m, 1H), 7.48-7.39 (m, 1H), 7.39-7.31 (m, 3H), 5.26 (s, 2H), 4.11 (d, J=7.1, 1H), 3.60-3.43 (m, 1H), 3.10-2.94 (m, 1H), 1.93-1.73 (m, 4H), 1.38 (d, J=4.4, 1H), 1.34-1.00 (m, 5H).
Example 263




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-2-bromo-N-(2-oxopyrrolidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.51 (dd, J=2.2, 1.3, 2H), 8.18 (dd, J=7.9, 1.3, 1H), 7.67-7.60 (m, 1H), 7.58-7.51 (m, 1H), 7.45-7.31 (m, 4H), 6.05 (d, J=9.3, 1H), 5.51 (dd, J=9.8, 3.3, 1H), 5.35 (d, J=3.1, 2H), 3.67-3.55 (m, 1H), 3.39-3.19 (m, 2H), 2.65-2.50 (m, 1H), 2.16-1.99 (m, 1H).
Example 264




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C20H19FN4O4S2. 462.08; m/z found, 463.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.78 (d, J=0.9, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.75 (m, 1H), 7.71-7.62 (m, 2H), 7.44 (dd, J=7.6, 1.1, 1H), 7.40-7.31 (m, 2H), 3.34 (dd, J=7.8, 3.2, 4H), 3.04-2.99 (m, 4H).
Example 265




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)azetidin-3-ol. MS (ESI): mass calcd. for C19H17FN4O3S, 400.10; m/z found, 401.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.79 (d, J=0.7, 2H), 8.08 (dd, J=8.0, 1.1, 1H), 7.72 (m, 1H), 7.68-7.55 (m, 2H), 7.47-7.38 (m, 1H), 7.36 (dd, J=8.3, 1.5, 2H), 4.36 (m, 1H), 3.76-3.64 (m, 2H), 3.60-3.53 (m, 2H).
Example 266




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(2-oxopiperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H20FN5O3S, 441.13; m/z found, 442.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.71 (d, J=0.7, 2H), 8.24 (dd, J=8.0, 1.2, 1H), 7.67 (m, 1H), 7.58 (m, 2H), 7.42 (s, 1H), 7.41-7.39 (m, 1H), 7.38 (dd, J=7.6, 1.2, 1H), 3.63 (dd, J=10.5, 5.8, 1H), 3.20 (dd, J=8.9, 5.1, 2H), 2.17 (m, 1H), 1.89-1.80 (m, 1H), 1.78-1.64 (m, 2H).
Example 267




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(2-oxopiperidin-3-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H20FN5O3S, 441.13; m/z found, 442.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.74 (d, J=0.8, 2H), 8.24 (dd, J=8.0, 1.1, 1H), 7.67 (m, 1H), 7.62-7.54 (m, 2H), 7.42 (s, 1H), 7.42-7.40 (m, 1H), 7.38 (dd, J=7.6, 1.2, 1H), 3.64 (dd, J=10.5, 5.8, 1H), 3.20 (dd, J=8.7, 5.0, 2H), 2.17 (m, 1H), 1.89-1.80 (m, 1H), 1.80-1.65 (m, 2H).
Example 268




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.0 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.64 (d, J=0.9, 2H), 8.10 (dd, J=8.0, 1.1, 1H), 7.67 (m, 1H), 7.59 (m, 1H), 7.55 (m, 1H), 7.37 (dd, J=7.6, 1.2, 1H), 7.33-7.24 (m, 2H), 3.86 (m, 1H), 1.22 (m, 3H).
Example 269




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H25FN4O3S, 444.16; m/z found, 445.2 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.68 (d, J=1.0, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.62 (m, 1H), 7.58-7.49 (m, 2H), 7.42-7.35 (m, 2H), 7.35-7.29 (m, 1H), 3.50 (m, 2H), 3.06 (dd, J=5.8, 4.3, 1H), 0.84 (s, 9H).
Example 270




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(1-hydroxy-3,3-dimethylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H25FN4O3S, 444.16; m/z found, 445.2 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.69 (d, J=1.0, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.63 (m, 1H), 7.59-7.47 (m, 2H), 7.41-7.36 (m, 2H), 7.33 (m, 1H), 3.50 (m, 2H), 3.06 (dd, J=5.9, 4.2, 1H), 0.84 (s, 9H).
Example 271




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.71 (d, J=0.9, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.66-7.61 (m, 1H), 7.60-7.54 (m, 2H), 7.36 (m, 3H), 3.47-3.38 (m, 1H), 3.38-3.32 (m, 1H), 3.06 (q, J=5.5, 1H), 1.84 (m, 1H), 0.83-0.78 (m, 6H).
Example 272




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.1 [M+H]4. 1H NMR (600 MHz. CD3OD) δ 8.75 (d, J=1.0 Hz, 2H), 8.04 (dd, J=8.0, 1.3 Hz, 1H), 7.70-7.65 (m, 1H), 7.64-7.58 (m, 2H), 7.41 (dd, J=7.6, 1.3 Hz, 1H), 7.39-7.35 (m, 2H), 2.71 (s, 2H), 1.11 (s, 6H).
Example 273




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(1-hydroxy-3-methylbutan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.71 (d, J=0.9, 2H), 8.15 (dd, J=8.0, 1.1, 1H), 7.66-7.61 (m, 1H), 7.60-7.54 (m, 2H), 7.36 (m, 3H), 3.47-3.38 (m, 1H), 3.38-3.32 (m, 1H), 3.06 (q, J=5.5, 1H), 1.84 (m, 1H), 0.83-0.78 (m, 6H).
Example 274




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(2,3-dihydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O4S, 418.11; m/z found, 419.1 [M+H]+.
Example 275




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H17FN4O3S, 388.10; m/z found, 389.1 [M+H]4. 1H NMR (600 MHz, CD3OD) δ 8.75 (d, J=0.9, 2H), 8.07 (m, 1H), 7.71-7.66 (m, 1H), 7.63-7.59 (m, 2H), 7.40 (dd, J=7.6, 1.1, 1H), 7.37 (m, 2H), 3.49 (t, J=5.9, 2H), 2.90 (t, J=5.9, 2H).
Example 276




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)methanol. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.1 [M+H]+. 1H NMR (600 MHz, CD3OD) G 8.70 (d, J=1.0, 2H), 8.10 (dd, J=8.0, 1.2, 1H), 7.70 (m, 1H), 7.64-7.61 (m, 1H), 7.59 (dd, J=10.9, 5.4, 1H), 7.41 (dd, J=7.6, 1.2, 1H), 7.37-7.32 (m, 2H), 3.50 (m, 1H), 3.37 (dd, J=10.8, 3.9, 1H), 3.21-3.15 (m, 1H), 3.03-2.95 (m, 2H), 1.88-1.75 (m, 3H), 1.73-1.66 (m, 1H).
Example 277




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-(1-((2-bromophenyl)sulfonyl)pyrrolidin-2-yl)methanol. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.70 (d, J=1.0, 2H), 8.10 (dd, J=8.0, 1.2, 1H), 7.70 (m, 1H), 7.64-7.61 (m, 1H), 7.59 (dd, J=10.9, 5.4, 1H), 7.41 (dd, J=7.6, 1.2, 1H), 7.37-7.32 (m, 2H), 3.50 (m, 1H), 3.37 (dd, J=10.8, 3.9, 1H), 3.21-3.15 (m, 1H), 3.03-2.95 (m, 2H), 1.88-1.75 (m, 3H), 1.73-1.66 (m, 1H).
Example 278




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.60 (d, J=1.2 Hz, 2H), 8.06 (dd, J=8.0, 1.3 Hz, 1H), 7.71-7.65 (m, 1H), 7.63-7.58 (m, 1H), 7.58-7.51 (m, 1H), 7.41 (dd, J=7.5, 1.4 Hz, 1H), 7.35 (s, 1H), 7.34-7.30 (m, 1H), 3.74-3.63 (m, 1H), 2.76 (dd, J=13.1, 5.0 Hz, 1H), 2.69 (dd, J=13.0, 6.8 Hz, 1H), 1.06 (d, J=6.3 Hz, 3H).
Example 279




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.60 (d, J=1.2 Hz, 2H), 8.06 (dd, J=8.0, 1.3 Hz, 1H), 7.71-7.65 (m, 1H), 7.63-7.58 (m, 1H), 7.58-7.51 (m, 1H), 7.41 (dd, J=7.5, 1.4 Hz, 1H), 7.35 (s, 1H), 7.34-7.30 (m, 1H), 3.74-3.63 (m, 1H), 2.76 (dd, J=13.1, 5.0 Hz, 1H), 2.69 (dd, J=13.0, 6.8 Hz, 1H), 1.06 (d, J=6.3 Hz, 3H)
Example 280




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O3S, 416.13; m/z found, 417.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.69 (s, 2H), 8.16 (dd, J=8.0, 1.2, 1H), 7.66 (m, 1H), 7.61-7.55 (m, 2H), 7.38 (dd, J=7.8, 1.3, 3H), 3.27 (s, 2H), 1.03 (s, 6H).
Example 281




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-4-cyclopropylpiperazine. MS (ESI): mass calcd. for C23H24FN5O2S, 453.16; m/z found, 454.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.75 (d, J=0.6, 2H), 8.13 (dd, J=8.0, 1.2, 1H), 7.79-7.74 (m, 1H), 7.69-7.59 (m, 2H), 7.45 (dd, J=7.6, 1.2, 1H), 7.37-7.32 (m, 2H), 3.59-3.33 (m, 4H), 3.28-3.00 (m, 4H), 2.82 (m, 1H), 1.00-0.86 (m, 4H).
Example 282




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-(4-((2-bromophenyl)sulfonyl)piperazin-1-yl)ethanol. MS (ESI): mass calcd. for C22H24FN5O3S, 457.16; m/z found, 458.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.72 (s, 2H), 8.13 (dd, J=8.0, 1.2, 1H), 7.77 (m, 1H), 7.71-7.59 (m, 2H), 7.46 (dd, J=7.6, 1.2, 1H), 7.39-7.33 (m, 2H), 3.85-3.80 (m, 2H), 3.68-3.33 (m, 4H), 3.26-3.22 (m, 2H), 3.17-2.81 (m, 4H).
Example 283




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(cyclopropylmethyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H19FN4O2S, 398.12; m/z found, 399.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.67 (s, 2H), 8.10 (dd, J=8.0, 1.4 Hz, 1H), 7.70-7.65 (m, 1H), 7.65-7.53 (m, 2H), 7.39-7.35 (m, 1H), 7.31-7.25 (m, 2H), 1.22 (s, 3H), 0.52-0.48 (m, 2H), 0.38-0.33 (m, 2H).
Example 284




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-cyclopropylbenzenesulfonamide. MS (ESI): mass calcd. for C19H17FN4O2S, 384.10; m/z found, 385.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.68 (d, J=1.0, 2H), 8.11 (dd, J=8.0, 1.2, 1H), 7.69 (m, 1H), 7.62 (m, 1H), 7.56 (m, 1H), 7.40 (dd, J=7.6, 1.2, 1H), 7.35-7.22 (m, 2H), 2.20 (m, 1H), 0.55-0.34 (m, 4H).
Example 285




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-phenylbenzenesulfonamide. MS (ESI): mass calcd. for C22H17FN4O2S, 420.10; m/z found, 421.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.66 (s, 1H), 8.14 (d, J=7.8, 1H), 7.57 (m, 3H), 7.33 (m, 2H), 7.12 (m, 4H), 7.02-6.75 (m, 3H).
Example 286




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C19H19FN4O3S, 402.11; m/z found, 403.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.59 (d, J=1.3, 2H), 8.07 (dd, J=7.9, 1.4, 1H), 7.68 (td, J=7.5, 1.4, 1H), 7.65-7.58 (m, 2H), 7.39 (dd, J=7.5, 1.4, 1H), 7.35 (dd, J=11.8, 1.8, 1H), 7.29 (dd, J=7.9, 1.8, 1H), 7.25 (d, J=7.5, 1H), 3.30 (dd, J=10.3, 4.9, 1H), 3.14-3.09 (m, 1H), 3.09-3.01 (m, 1H), 0.96 (d. J=6.5, 3H).
Example 287




To a 6 mL microwave vial the following were added 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine (60 mg, 0.19 mmol), N-(tert-butyl)-2-chloro-6-methylbenzenesulfonamide (62 mg, 0.24 mmol), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1-1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (3 mg, 0.004 mmol). The vial was flushed with nitrogen and charged with N2 sparged THF (0.3 mL) and N2 sparged K3PO4 (0.8 mL, 0.5 M). The resulting biphasic mixture was stirred at rt for 1 h and at 45° C. for 1 h. The resulting mixture was concentrated to dryness and the resulting residue was purified by HPLC to provide the title compound. MS (ESI): mass calcd. for C21H23FN4O2S, 414.15: m/z found, 415.1 [M+H]+.
Example 288




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-methylbenzenesulfonamide. MS (ESI): mass calcd. for C17H15FN4O2S, 358.09; m/z found, 359.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.59 (s, 2H), 7.93 (dd, J=7.8, 1.4, 1H), 7.70 (td, J=7.5, 1.4, 1H), 7.67-7.58 (m, 2H), 7.42 (dd, J=7.5, 1.5, 1H), 7.34 (dd, J=11.8, 1.8, 1H), 7.31-7.26 (m, 4H), 2.41 (d, J=4.8, 3H).
Example 289




Method 1
The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide.
Method 2
A mixture of 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine (30.0 g, 95.2 mmol), K3PO4 (70.7 g, 333 mmol), (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide (28.0 g, 95.2 mmol), PdCl2(dppf).CH2Cl2 (0.70 g, 0.95 mmol), acetonitrile (476 mL), and water (190 mL) was sparged with N2 and stirred at 75° Celsius for 26 hours. After filtration, water was added and the reaction mixture was cooled to rt. Solid precipitate was collected by vacuum filtration and dried in a vacuum oven at 70° Celsius (24.0 g, 63%). The solid was recrystallized from EtOH and treated successively with activated charcoal and silica-supported thiol to remove residual Pd and afford the title compound (21.6 g, 57%). MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.52 (d, J=1.4, 2H), 8.12-7.99 (m, 1H), 7.73-7.65 (m, 1H), 7.65-7.53 (m, 2H), 7.39 (dd, J=7.5, 1.4, 1H), 7.36-7.31 (m, 1H), 7.28 (dd, J=7.9, 1.8, 1H), 7.23 (d, J=7.5, 1H), 6.92 (s, 2H), 4.75-4.67 (m, 1H), 3.33-3.27 (m, 1H), 3.16-3.01 (m, 2H), 0.96 (d, J=6.4, 3H). Chiral HPLC: Chiralpak IC 4.6×250 mm column, 30% EtOH+0.2% TEA, 70% CO2, 2 mL/min, retention time 22.4 min, ee>99%.
Example 290




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)piperazine. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.63 (s, 2H), 8.54 (d, J=1.0, 2H), 8.08-8.04 (m, 1H), 7.81 (m, 1H), 7.74-7.68 (m, 1H), 7.61 (m, 1H), 7.50 (d, J=7.6, 1H), 7.36 (dd, J=11.6, 1.5, 1H), 7.29 (dd, J=7.9, 1.7, 1H), 7.05 (s, 2H), 3.04-2.86 (m, 8H).
Example 291




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (R)-2-bromo-N-(2,2,2-trifluoro-1-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C24H18F4N4O2S, 502.11; m/z found, 503.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 9.28 (d, J=10.1, 1H), 8.54 (d, J=1.2, 2H), 7.88 (dd, J=8.1, 1.1, 1H), 7.59 (m, 1H), 7.53 (t, J=8.3, 1H), 7.46-7.40 (m, 3H), 7.41-7.30 (m, 3H), 7.27 (dd, J=7.6, 1.2, 1H), 7.12-6.97 (m, 4H), 5.14-4.96 (m, 1H).
Example 292




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(2,2,2-trifluoro-1-phenylethyl)benzenesulfonamide. MS (ESI): mass calcd. for C24H18F4N4O2S, 502.11; m/z found, 503.1 [M+H]+. 1H NMR (600 MHz, DMSO-d) δ 9.29 (d, J=10.1, 1H), 8.59 (s, 2H), 7.88 (dd, J=8.0, 1.0, 1H), 7.60 (m, 1H), 7.54 (t, J=8.2, 1H), 7.47-7.42 (m, 3H), 7.38-7.31 (m, 3H), 7.27 (dd, J=7.6, 1.0, 1H), 7.11-7.04 (m, 2H), 5.11-5.03 (m, 1H).
Example 293




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 1-bromo-2-(tert-butylsulfonyl)benzene. MS (ESI): mass calcd. for C20H20FN3O2S, 385.12; m/z found, 386.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.57 (d, J=0.8, 2H), 8.03 (dd, J=8.0, 1.2, 1H), 7.81 (m, 1H), 7.72 (m, 1H), 7.56 (m, 1H), 7.41 (dd, J=7.6, 1.2, 1H), 7.32 (dd, J=11.9, 1.6, 1H), 7.25 (dd, J=7.9, 1.7, 1H), 7.14 (s, 2H), 1.08 (s, 9H).
Example 294




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-isobutylbenzenesulfonamide. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.53 (s, 2H), 7.94 (dd, J=7.9, 1.0, 1H), 7.68 (m, 1H), 7.65-7.57 (m, 2H), 7.52 (m, 1H), 7.41 (dd, J=7.5, 1.1, 1H), 7.33 (dd, J=11.8, 1.4, 1H), 7.29 (dd, J=7.9, 1.6, 1H), 7.03 (s, 2H), 2.53 (t, J=6.4, 2H), 1.60 (m, 1H), 0.79 (d, J=6.7, 6H).
Example 295




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-ethylbenzenesulfonamide. MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 373.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.57 (d, J=1.3, 2H), 7.96 (dd, J=7.9, 1.4, 1H), 7.69 (td, J=7.5, 1.4, 1H), 7.66-7.58 (m, 2H), 7.44-7.40 (m, 2H), 7.34 (dd, J=11.8, 1.8, 1H), 7.29 (dd, J=7.9, 1.7, 1H), 7.18 (s, 2H), 2.77 (qd, J=7.2, 5.6, 2H), 0.97 (t. J=7.2, 3H).
Example 296




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-bromo-N-(1,1,1-trifluoro-2-methylpropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H18F4N4O2S, 454.11; m/z found, 455.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.65 (s, 2H), 8.12 (dd, J=8.0, 1.1, 1H), 7.67 (m, 1H), 7.60 (m, 1H), 7.55 (m, 1H), 7.39 (dd, J=7.5, 1.2, 1H), 7.32 (dd, J=6.0, 4.7, 2H), 1.29 (s, 6H).
Example 297




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and (S)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.71 (s, 2H), 8.10 (d, J=7.9, 1H), 7.68 (m, 1H), 7.63-7.53 (m, 2H), 7.40-7.34 (m, 1H), 7.33-7.26 (m, 2H), 3.87 (m, 1H), 1.23 (d, J=7.0, 3H).
Example 298




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C20H19FN4O2S, 398.12; m/z found, 399.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.54 (d. J=1.2, 2H), 7.98 (dd. J=7.9, 1.1, 1H), 7.73 (m, 1H), 7.67-7.59 (m, 2H), 7.43 (dd, J=7.5, 1.1, 1H), 7.34 (dd, J=11.8, 1.6, 1H), 7.28 (dd. J=7.9, 1.7, 1H), 7.05 (s, 2H), 2.88 (t, J=6.7, 4H), 1.76-1.60 (m, 4H).
Example 299




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(N,N-dimethyl-sulfamoyl)phenyl)boronic acid MS (ESI): mass calcd. for C18H17FN4O2S, 372.10; m/z found, 373.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.56 (d, J=1.1, 2H), 7.95 (dd, J=7.9, 1.2, 1H), 7.73 (m, 1H), 7.66 (m, 1H), 7.61 (m, 1H), 7.43 (dd, J=7.5, 1.2, 1H), 7.32 (dd, J=11.8, 1.6, 1H), 7.26 (dd, J=7.9, 1.7, 1H), 2.50 (s, 6H).
Example 300




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(N,N-diethyl-sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.54 (d, J=1.3, 2H), 7.96 (dd, J=8.0, 1.2, 1H), 7.71 (m, 1H), 7.63 (m, 2H), 7.41 (dd, J=7.5, 1.2, 1H), 7.30 (m, 1H), 7.26 (m, 1H), 7.04 (s, 2H), 2.93 (q, J=7.1, 4H), 0.94 (t, J=7.1, 6H).
Example 301




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(piperidin-1-ylsulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C21H21FN4O2S, 412.14; m/z found, 413.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.54 (d, J=1.2, 2H), 7.99 (dd, J=8.0, 1.2, 1H), 7.73 (m, 1H), 7.69-7.57 (m, 2H), 7.44 (dd, J=7.6, 1.2, 1H), 7.33 (m, 1H), 7.27 (dd, J=7.9, 1.7, 1H), 7.05 (s, 2H), 2.84-2.74 (m, 4H), 1.43-1.25 (m, 6H).
Example 302




Trifluoroacetic acid (1 mL) was added to neat 4′-(2-aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (52 mg, 0.13 mmol). After 4 hours, the resulting solution was concentrated to dryness and purified by HPLC to provide the title compound (33 mg, 59%) as a clear glassy solid. MS (ESI): mass calcd. for C16H13FN4O2S, 344.07; m/z found, 345.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.54 (d, J=1.3, 2H), 8.05 (dd, J=7.8, 1.4, 1H), 7.70-7.56 (m, 3H), 7.40-7.28 (m, 5H), 7.03 (s, 2H).
Example 303




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(morpholino-sulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.56 (d, J=1.3, 2H), 8.02 (dd, J=8.0, 1.2, 1H), 7.77 (m, 1H), 7.68 (m, 1H), 7.62 (m, 1H), 7.46 (dd, J=7.6, 1.2, 1H), 7.38 (dd, J=11.8, 1.6, 1H), 7.31 (dd, J=7.9, 1.7, 1H), 3.46-3.37 (m, 4H), 2.83-2.73 (m, 4H).
Example 304




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(methyl-sulfonyl)phenyl)boronic acid. MS (ESI): mass calcd. for C17H14FN3O2S, 343.08; m/z found, 344.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J=1.3, 2H), 8.12 (dd, J=8.0, 1.2, 1H), 7.80 (m, 1H), 7.72 (m, 1H), 7.65 (m, 1H), 7.46 (dd, J=7.5, 1.2, 1H), 7.40 (dd, J=11.7, 1.7, 1H), 7.33 (dd, J=7.9, 1.7, 1H), 2.96 (s, 3H).
Example 305




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(4-chloro-2-fluorophenyl)pyrimidin-2-amine and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.55 (s, 2H), 8.06 (dd, J=7.9, 1.3, 1H), 7.66 (m, 1H), 7.63-7.57 (m, 2H), 7.38 (dd, J=7.5, 1.2, 1H), 7.33 (dd, J=11.9, 1.5, 1H), 7.28 (dd, J=7.9, 1.6, 1H), 6.99-6.88 (m, 1H), 1.03 (s, 9H).
Example 306




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 4-((2-bromophenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 7.22 (d, J=0.7, 2H), 6.61 (m, 1H), 6.22 (m, 1H), 6.12 (m, 1H), 6.07 (dd, J=11.3, 4.9, 1H), 5.92 (dd, J=7.6, 1.2, 1H), 5.82 (t, J=1.8, 1H), 5.80 (dd, J=5.4, 1.4, 1H), 1.81 (s, 2H), 1.63 (m, 4H).
Example 307




The title compound was prepared using analogous conditions to those described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (S)-tert-butyl 2-(2-bromophenylsulfonamido)propanoate. MS (ESI): mass calcd. for C23H25FN4O4S, 472.16; m/z found, 473.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.65 (d, J=1.1, 2H), 8.08 (dd, J=8.0, 1.2, 1H), 7.66 (m, 1H), 7.61-7.49 (m, 2H), 7.37 (m, 3H), 3.66 (q, J=7.2, 1H), 1.34 (s, 9H), 1.26 (d, J=7.2, 3H).
Example 308




Trifluoroacetic acid (0.5 mL) was added to a solution of tert-butyl N-{[4′-(2-aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L-alaninate (80 mg, 0.17 mmol) in DCM (1 mL) at rt. After 2 hours, the solution was concentrated to dryness and purified by HPLC to afford the title compound (70 mg, 89%). MS (ESI): mass calcd. for C19H17FN4O4S, 416.10; m/z found, 417.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.72 (s, 2H), 8.10 (dd, J=8.0, 1.2, 1H), 7.66 (m, 1H), 7.61-7.53 (m, 2H), 7.37 (m, 3H), 3.73 (q, J=7.2, 1H), 1.31 (d, J=7.2, 3H).
Example 309




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and N-(2-bromophenyl)pyrrolidine-1-sulfonamide MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.4 [M+H]+. 1H NMR (500 MHz, CDCl3) 8.63 (s, 2H), 7.59 (d, J=8.4, 1H), 7.50 (m, 1H), 7.39 (m, 1H), 7.32-7.29 (m, 2H), 7.24-7.22 (m, 1H), 7.22-7.15 (m, 1H), 6.87-6.79 (m, 2H), 6.36 (s, 1H), 3.37-3.26 (m, 4H), 1.94-1.83 (m, 4H).
Example 310




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and N-(2-bromophenyl)morpholine-4-sulfonamide. MS (ESI): mass calcd. for C20H20FN5O3S, 429.13; m/z found, 430.4 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.63 (d, J=1.2, 2H), 7.70-7.54 (m, 2H), 7.48-7.25 (m, 5H), 3.70-3.55 (m, 4H), 3.05 (dd, J=5.7, 3.8, 4H).
Example 311




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and N-(2-bromophenyl)-N,N-dimethylsulfonamide. MS (ESI): mass calcd. for C18H18FN5O2S, 387.12; m/z found, 388.3 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.57 (d, J=1.4, 2H), 7.61-7.55 (m, 1H), 7.50 (m, 1H), 7.42-7.35 (m, 1H), 7.24-7.21 (m, 1H), 7.21-7.17 (m, 2H), 6.36 (s, 1H), 5.17 (s, 2H), 2.82 (s, 6H).
Example 312




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 6-((2-bromophenyl)sulfonyl)-2-oxa-6-azaspiro[3.3]heptanes and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H19FN4O3S, 426.12; m/z found, 426.9 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.53 (s, 2H), 8.05-7.96 (d, J=7.9, 1H), 7.78-7.71 (m, 1H), 7.68-7.58 (m, 2H), 7.47-7.41 (d, J=7.5, 1H), 7.35-7.28 (m, 1H), 7.28-7.23 (m, 1H), 6.90 (s, 2H), 4.51 (d, J=1.3, 4H), 3.71 (d, J=1.4, 4H).
Example 313




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 6-((2-bromophenyl)sulfonyl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H19FN4O4S2, 474.08; m/z found, 474.8 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.56-8.50 (d, J=1.4, 2H), 8.05-7.99 (dd, J=8.0, 1.3, 1H), 7.80-7.73 (m, 1H), 7.69-7.60 (m, 2H), 7.48-7.43 (dd, J=7.6, 1.3, 1H), 7.38-7.32 (dd, J=11.8, 1.8, 1H), 7.31-7.26 (dd, J=7.9, 1.7, 1H), 6.90 (s, 2H), 4.32 (s, 4H), 3.76 (s, 4H).
Example 314




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 1-((2-bromophenyl)sulfonyl)azetidine-3-carbonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H16FN5O2S, 409.10; m/z found, 409.9 [M+H]+. 1H NMR (500 MHz, DMSO-d) δ 8.52 (s, 2H), 8.08-8.00 (d, J=8.0, 1H), 7.83-7.75 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.51-7.43 (d, J=7.5, 1H), 7.38-7.31 (d, J=11.7, 1H), 7.31-7.26 (m, 1H), 6.89 (s, 2H), 3.96-3.87 (m, 2H), 3.68-3.59 (m, 3H).
Example 315




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 1-((2-bromophenyl)sulfonyl)-3-(trifluoromethyl)azetidin-3-ol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H16F4N4O3S, 468.09; m/z found, 469.0 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.53-8.47 (d, J=1.4, 2H), 8.06-8.01 (dd, J=8.0, 1.3, 1H), 7.81-7.76 (m, 1H), 7.70-7.65 (m, 1H), 7.64-7.58 (m, 1H), 7.51-7.45 (m, 2H), 7.35-7.29 (dd, J=11.7, 1.8, 1H), 7.28-7.24 (dd, J=7.8, 1.7, 1H), 6.94 (s, 2H), 3.81-3.76 (d, J=9.3, 2H), 3.71-3.66 (m, 2H)
Example 316




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 4-((2-bromophenyl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C21H20FN3O4S2, 461.09; m/z found, 461.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.55 (s, 2H), 8.06 (d, J=7.9, 1H), 7.85 (m, 1H), 7.76 (m, 1H), 7.61 (m, 1H), 7.49 (d, J=7.5, 1H), 7.37 (d, J=11.6, 1H), 7.30 (d, J=8.0, 1H), 6.94 (s, 2H), 3.26-3.07 (m, 5H), 2.12-2.09 (m, 2H), 2.01-1.86 (m, 2H).
Example 317




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 2-(((2-bromophenyl)sulfonyl)methyl)quinazolin-4(3H)-one. MS (ESI): mass calcd. for C25H18FN5O3S, 487.11; m/z found, 487.9 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.60-8.43 (d, J=1.4, 2H), 8.12-8.02 (dd, J=8.0, 1.5, 1H), 7.96-7.89 (dd, J=8.0, 1.3, 1H), 7.84-7.71 (m, 2H), 7.66-7.42 (m, 4H), 7.42-7.22 (m, 3H), 6.91 (s, 2H), 4.37 (s, 2H).
Example 318




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine and 1-(3-((2-bromophenyl)sulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one. MS (ESI): mass calcd. for C26H22FN5O3S, 503.14; m/z found, 503.9 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 10.85 (s, 1H), 8.45 (s, 2H), 8.12-8.03 (d, J=7.8, 1H), 7.83-7.75 (m, 1H), 7.75-7.66 (m, 1H), 7.45-7.30 (m, 2H), 7.27-7.19 (d, J=11.5, 1H), 7.09-6.88 (m, 6H), 3.79-3.72 (t, J=6.5, 2H), 2.97-2.88 (dd, J=9.7, 6.3, 2H), 1.79-1.68 (m, 2H).
Example 319




The title compound was prepared in a manner similar to that described in Example 88 using 1-bromo-2-((3-(cyclohexylsulfonyl)propyl)sulfonyl)benzene and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C25H28FN3O4S2, 517.15; m/z found, 518.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.59-8.51 (d, J=1.4, 2H), 8.20-8.14 (dd, J=8.0, 1.3, 1H), 7.82-7.76 (m, 1H), 7.72-7.67 (m, 1H), 7.59-7.52 (m, 1H), 7.51-7.46 (dd, J=7.7, 1.3, 1H), 7.38-7.31 (m, 2H), 3.16-3.08 (t, J=7.5, 2H), 3.08-3.01 (t, J=7.3, 2H), 2.94-2.82 (m, 1H), 2.07-1.97 (m, 4H), 1.91-1.80 (m, 2H), 1.79-1.62 (d, J=13.0, 1H), 1.48-1.35 (m, 2H), 1.35-1.25 (m, 2H), 1.24-1.12 (m, 1H).
Example 320




The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenyl)sulfonyl)-1-methyl-1H-benzo[d]imidazole and 5-(2-fluor-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C24H18FN5O2S, 459.12; m/z found, 460.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 7.03-6.96 (dd, J=7.8, 1.5, 1H), 6.88-6.86 (d, J=1.4, 2H), 6.43-6.28 (m, 1.5, 2H), 6.15-6.09 (d, J=8.2, 1H), 6.08-5.99 (m, 2H), 5.97-5.86 (m, 2H), 5.64-5.53 (m, 1H), 5.34-5.30 (dd, J=7.8, 1.7, 1H), 5.30-5.23 (dd, J=11.3, 1.7, 1H), 2.22 (s, 3H).
Example 321




The title compound was prepared in a manner similar to that described in Example 88 using 5-(((2-bromophenyl)sulfonyl)methyl)-3-cyclopropyl-1,2,4-oxadiazole and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine. MS (ESI): mass calcd. for C22H18FN5O3S, 451.11: m/z found, 452.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.56 (s, 1H), 7.98-7.94 (m, 1H), 7.85-7.77 (dd, J=8.2, 6.9, 1H), 7.67-7.61 (m, 1H), 7.61-7.57 (m, 1H), 7.52-7.46 (d, J=7.6, 1H), 7.39-7.35 (dd, J=7.9, 1.6, 1H), 7.35-7.31 (m, 1H), 2.05-1.94 (m, 1H), 1.04-0.94 (m, 1H), 0.79-0.72 (m, 1H).
Example 322




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-5-(trifluoromethyl)benzenesulfonamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C17H12F4N4O2S, 412.06; m/z found, 413.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.56-8.53 (d, J=1.4, 2H), 8.43-8.40 (m, 1H), 7.98-7.92 (d, J=7.7, 1H), 7.63-7.58 (d, J=8.0, 1H), 7.58-7.52 (m, 1H), 7.37-7.35 (m, 1H), 7.35-7.32 (m, 1H).
Example 323




The title compound was prepared in a manner similar to that described in Example 88 using 1-bromo-2-(methylsulfonyl)-4-(trifluoromethyl)benzene and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H13F4N3O2S, 411.07; m/z found, 412.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.61-8.51 (d, J=1.4, 2H), 8.44 (s, 1H), 8.11-8.05 (d, J=7.5, 1H), 7.72-7.66 (d, J=8.0, 1H), 7.66-7.59 (m, 1H), 7.45-7.35 (m, 2H), 2.89 (s, 3H).
Example 324




The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromo-5-(trifluoromethyl)phenyl)-sulfonyl)-piperazin-2-one and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine. MS (ESI): mass calcd. for C21H17F4N5O3S, 495.10; m/z found, 496.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.70-8.61 (d, J=1.2, 2H), 8.40 (s, 1H), 8.10-8.03 (d, J=7.7, 1H), 7.71-7.64 (d, J=7.9, 1H), 7.64-7.58 (m, 1H), 7.39-7.37 (m, 1H), 7.36 (s, 1H), 3.34 (s, 2H), 3.22-3.17 (m, 2H), 3.17-3.12 (m, 2H).
Example 325




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-methyl-5-(trifluoromethyl)benzenesulfonamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H14F4N4O2S, 426.08; m/z found, 427.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.57-8.52 (d, J=1.4, 2H), 8.33-8.27 (m, 1H), 8.02-7.94 (m, 1H), 7.66-7.60 (d, J=7.9, 1H), 7.60-7.52 (m, 1H), 7.38-7.31 (m, 2H), 2.46 (s, 3H).
Example 326




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine. MS (ESI): mass calcd. for C19H16F4N4O3S, 456.09; m/z found, 457.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.57-8.53 (d, J=1.4, 2H), 8.38-8.35 (m, 1H), 8.00-7.96 (dd, J=8.1, 1.5, 1H), 7.63-7.60 (d, J=8.0, 1H), 7.59-7.54 (m, 1H), 7.38-7.36 (dd, J=6.1, 1.6, 1H), 7.36-7.34 (m, 1H), 3.51-3.45 (t, J=5.9, 2H), 2.95-2.86 (t, J=5.9, 2H).
Example 327




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.56-8.53 (d, J=1.4, 2H), 8.34-8.31 (m, 1H), 7.99-7.95 (m, 1H), 7.63-7.59 (d, J=8.0, 1H), 7.59-7.53 (m, 1H), 7.36-7.34 (dd, J=7.1, 1.6, 1H), 7.34-7.32 (m, 1H), 2.97-2.71 (q, J=7.2, 2H), 1.15-0.84 (t, J=7.2, 3H).
Example 328




The title compound was prepared in a manner similar to that described in Example 88 using 1-((2-bromo-5-(trifluoromethyl)phenyl)sulfonyl)-4-methylpiperazine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H21F4N5O2S, 495.14; m/z found, 496.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.63-8.61 (d, J=1.4, 2H), 8.40-8.37 (d, J=1.4, 1H), 8.10-8.05 (m, 1H), 7.70-7.67 (d, J=8.0, 1H), 7.67-7.63 (m, 1H), 7.46-7.30 (m, 2H), 2.86 (s, 3H), 3.83-2.53 (br m, 8H).
Example 329




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 5-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 391.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.4, 2H), 7.95 (s, 2H), 7.66-7.59 (m, 1H), 7.55-7.48 (m, 2H), 7.46-7.41 (m, 2H), 7.27-7.20 (m, 2H), 6.89 (s, 2H), 5.45 (s, 2H).
Example 330




The title compound was prepared using analogous conditions to those described in Example 213 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 390.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.4, 2H), 7.80 (d, J=5.8, 1H), 7.73-7.66 (m, 1H), 7.57-7.50 (m, 2H), 7.48-7.44 (m, 2H), 7.32-7.23 (m, 2H), 6.90-6.88 (m, 4H), 6.11 (d, J=5.8, 1H).
Example 331




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 5-amino-4-chloropyrimidine. MS (ESI): mass calcd. for C20H5FN6S, 390.11; m/z found, 391.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J=1.4, 2H), 8.16 (s, 1H), 7.92 (s, 1H), 7.59-7.49 (m, 3H), 7.49-7.44 (m, 2H), 7.30-7.20 (m, 2H), 6.89 (s, 2H), 5.44 (s, 2H).
Example 332




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and and 2-chloropyrimidine. MS (ESI): mass calcd. for C20H14FN5S, 375.10; m/z found, 375.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.66 (s, 2H), 8.56 (d, J=4.9, 2H), 7.79-7.73 (m, 1H), 7.63-7.56 (m, 2H), 7.55-7.48 (m, 2H), 7.33-7.24 (m, 2H), 7.21 (m, 1H), 6.23 (s, 2H).
Example 333




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 2-chloropyrazine. MS (ESI): mass calcd. for C2H14FN5S, 375.10; m/z found, 375.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.70-8.57 (m, 2H), 8.41 (dd, J=2.5, 1.6, 1H), 8.35 (d, J=2.6, 1H), 8.27 (d. J=1.5, 1H), 7.72 (dd. J=8.0, 1.2, 1H), 7.64-7.57 (m, 2H), 7.56-7.50 (m, 2H), 7.34 (d, J=11.8, 1H), 7.27 (d, J=8.0, 1H), 6.01 (s, 2H).
Example 334




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 4-amino-6-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 390.9 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.48 (d, J=1.4, 2H), 8.06 (s, 1H), 7.77-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.60-7.52 (m, 3H), 7.29 (dd, J=11.9, 1.5, 1H), 7.25 (dd, J=7.9, 1.7, 1H), 6.88 (s, 2H), 6.78 (s, 2H), 5.78 (d, J=0.9, 1H).
Example 335




The title compound was prepared using analogous conditions to those described in Example 213 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 2-amino-4-chloropyrimidine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 390.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.3, 2H), 7.90 (d, J=5.3, 1H), 7.78-7.71 (m, 1H), 7.68-7.61 (m, 1H), 7.59-7.51 (m, 3H), 7.30 (dd. J=11.8, 1.6, 1H), 7.25 (dd, J=7.9, 1.7, 1H), 6.89 (s, 2H), 6.64 (s, 2H), 5.86 (d, J=5.3, 1H).
Example 336




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-thiol and 2-amino-6-chloropyrazine. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 391.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.3, 2H), 7.67-7.60 (m, 1H), 7.59-7.51 (m, 3H), 7.49-7.46 (m, 2H), 7.31 (dd, J=11.9, 1.5, 1H), 7.26 (dd, J=7.9, 1.7, 1H), 7.18 (s, 1H), 6.90 (s, 2H), 6.57 (s, 2H).
Example 337




To a solution of 5-{2′-[(5-aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}-pyrimidin-2-amine (200 mg, 0.51 mmol) in MeCN/DCM/H2O (5 mL/5 mL/5 mL) were added NaIO4 (326 mg, 1.50 mmol) and RuCl3 (16 mg, 0.075 mmol). The reaction mixture was stirred at rt for 10 hours then poured into water (50 mL) and extracted with EtOAc (30 mL×3). The combined organic extracts were concentrated and purified by HPLC to give the title compound as a white solid. MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.57 (s, 2H), 8.30-8.25 (m, 2H), 8.22 (s, 1H), 7.83 (m, 1H), 7.77 (m, 1H), 7.44-7.33 (m, 2H), 6.88 (d, J=9.5, 2H), 6.29 (s, 2H).
Example 338




The title compound was prepared using analogous conditions to those described in Example 337 utilizing 5-[3-fluoro-2′-({[2-(trimethylsilyl)-ethoxy]methyl}-sulfanyl)-biphenyl-4-yl]pyrimidin-2-amine. MS (ESI): mass calcd. for C22H26FN3O3SSi, 459.14; m/z found, 460.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.63 (s, 2H), 8.19 (dd, J=7.9, 1.4, 1H), 7.79 (m, 1H), 7.70 (m, 1H), 7.59 (m, 1H), 7.46 (dd, J=7.5, 1.3, 1H), 7.34-7.31 (m, 2H), 4.36 (s, 2H), 3.80-3.68 (m, 2H), 0.87-0.76 (m, 2H), 0.08 (s, 9H).
Example 339




The title compound was prepared using analogous conditions to those described in Example 337 utilizing 5-{2′-[(5-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.83 (s, 2H), 8.34 (dd, J=7.7, 1.5, 1H), 7.94 (s, 2H), 7.79-7.69 (m, 2H), 7.44 (m, 1H), 7.34 (dd, J=7.3, 1.4, 1H), 6.93 (dd, J=7.9, 1.6, 1H), 6.88 (dd, J=11.5, 1.5, 1H).
Example 340




The title compound was prepared using analogous conditions to those described in Example 6 utilizing utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (2-(((2-bromophenyl)thio)methoxy)ethyl)trimethylsilane. MS (ESI): mass calcd. for C22H26FN3OSSi, 427.16; m/z found, 428.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.47 (d, J=1.4, 2H), 7.69 (dd, J=7.7, 1.1, 1H), 7.44 (m, 1H), 7.34-7.15 (m, 5H), 4.86 (s, 2H), 3.60-3.47 (m, 2H), 0.88-0.76 (m, 2H), 0.06 (s, 9H)
Example 341




Step A: 5-(4-Chloro-2-fluorophenyl)pyridin-2-amine
Solid 4-chloro-2-fluorobenzeneboronic acid (10.0 g, 57.4 mmol), 2-amino-5-bromopyridine (9.92 g, 57.4 mmol), palladium (II) trifluoroacetate (0.381 g, 1.15 mmol), and triphenylphosphine (0.602 g, 2.29 mmol) were combined in a 1 L flask under nitrogen, then toluene (150 mL), EtOH (150 mL), and 2 M Na2CO3 (100 mL) were added. The mixture was sparged with nitrogen for 30 min using a gas dispersion tube, then heated at 80° Celsius for 20 hours with vigorous stirring. The mixture was cooled to rt, diluted with EtOAc (200 mL), and transferred to a separatory funnel. The aqueous phase was removed, and the organic phase washed with brine. The combined aqueous phases were extracted with an equal volume of EtOAc, and the combined organic phases were dried and concentrated to dryness. The residue was subjected to FCC to provide 5-(4-chloro-2-fluorophenyl)pyridin-2-amine (9.10 g, 71%). MS (Cl): mass calcd. for C11H8CFN2, 222.04; m/z found, 223.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.54-8.22 (s, 2H), 8.22-8.18 (d, J=2.1, 1H), 8.15-8.10 (m, 1H), 7.68-7.58 (m, 2H), 7.48-7.38 (m, 1H), 7.16-7.06 (d, J=9.3, 1H).
Step B: 5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine
5-(4-Chloro-2-fluorophenyl)pyridin-2-amine (100 mg, 0.449 mmol), 2-(methylsulfonyl)phenylboronic acid (112 mg, 0.561 mmol), and chloro(2-dicyclohexyl-phosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl)]palladium(II) (33 mg, 0.045 mmol) were placed in a sealable reaction tube under nitrogen. THF (2 mL, sparged with nitrogen) and K3PO4 (2 mL, 0.5 M sparged with nitrogen) were added, and the reaction vessel was sealed and heated at 60° Celsius for 16 hours with vigorous stirring. The mixture was cooled to rt, diluted with EtOAc, and washed with 2 M K2CO3, then dried and concentrated to dryness. The residue was subjected to FCC to provide the title compound (45 mg, 29%). MS (Cl): mass calcd. for C18H15FN2O2S, 342.08; m/z found, 343.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.38-8.31 (s, 1H), 8.29-8.22 (m, 1H), 7.77-7.71 (m, 1H), 7.71-7.65 (m, 1H), 7.64-7.57 (m, 1H), 7.52-7.45 (m, 1H). 7.42-7.37 (m, 1H), 7.36-7.27 (m, 2H), 6.64-6.59 (m, 1H), 4.66-4.51 (s, 2H), 2.81-2.69 (s, 2H).
Example 342




The title compound was prepared in a manner similar to that described in Example 341, using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C21H22FN3O2S, 399.14; m/z found, 400.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.22-8.13 (s, 1H), 8.10-8.03 (d, J=7.8, 1H), 7.67-7.57 (m, 3H), 7.53-7.48 (m, 1H), 7.40-7.36 (d, J=7.4, 1H), 7.31-7.22 (m, 2H), 6.94-6.89 (s, 1H), 6.60-6.52 (d, J=8.6, 1H), 6.24-6.11 (s, 2H), 1.07-0.99 (s, 9H).
Example 343




The title compound was prepared in a manner similar to that described in Example 341, using (2-(N,N-diethylsulfamoyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C21H22FN3O2S, 399.14; m/z found, 400.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.28-8.22 (d, J=1.9, 1H), 8.18-8.12 (d, J=9.3, 1H), 8.12-7.88 (m, 1H), 7.76-7.69 (m, 1H), 7.68-7.59 (m, 2H), 7.43-7.38 (dd, J=7.5, 1.1, 1H), 7.37-7.32 (m, 1H), 7.32-7.27 (m, 1H), 7.09-7.04 (d, J=9.2, 1H), 2.99-2.90 (m, 3H), 1.00-0.90 (m, 4H).
The title compound was prepared in a manner similar to that described in
Example 344




The title compound was prepared in a manner similar to that described in Example 341, using (2-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C21H20FN3O2S, 397.13; m/z found, 398.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.37-8.11 (m, 4H), 8.01-7.95 (m, 1H), 7.77-7.71 (m, 1H), 7.69-7.61 (m, 2H), 7.44-7.36 (m, 2H), 7.35-7.30 (m, 1H), 7.15-7.10 (d, J=9.3, 1H), 2.99-2.80 (m, 4H), 1.77-1.62 (m, 4H).
Example 345




The title compound was prepared in a manner similar to that described in Example 341, using (2-(piperidin-1-ylsulfonyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C22H22FN3O2S, 411.14; m/z found, 412.2 [M+H]+. 1H NMR (500 MHz, DMSO-d) δ 8.47-8.16 (m, 4H), 8.02-7.96 (m, 1H), 7.79-7.72 (m, 1H), 7.71-7.60 (m, 2H), 7.46-7.36 (m, 2H), 7.35-7.29 (m, 1H), 7.16-7.11 (d, J=9.3, 1H), 2.86-2.74 (m, 4H), 1.45-1.27 (m, 6H).
Example 346




Step A: (4-(6-Aminopyridin-3-yl)-3-fluorophenyl)boronic acid
5-(4-Chloro-2-fluorophenyl)pyridin-2-amine (2.0 g, 9.0 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (2.9 g, 11.0 mmol), chloro(2-dicyclohexyl-phosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (0.14 g, 0.18 mmol), and KOAc (2.7 g, 27 mmol) were combined in a sealable reaction vessel under nitrogen, and then treated with anhydrous 1,4-dioxane (100 mL, sparged with nitrogen). The vessel was sealed and then heated at 80° Celsius for 16 hours. The mixture was cooled to rt, HCl (1 m, 50 mL) was added and the mixture stirred for 20 min. The mixture was then diluted with EtOAc (200 mL) and the aqueous phase was collected. The organic phase was extracted with 1 M HCl (2×75 mL). The combined aqueous phases were cooled in an icebath and the pH was adjusted to ca. 7 using solid sodium bicarbonate. The resulting precipitate was collected by filtration, washed well with water, and dried to provide the title compound (2.1 g, 98%). MS (Cl): mass calcd. for C11H10BFN2O2, 232.08; m/z found, 233.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.29-8.20 (s, 2H), 8.18-8.13 (s, 1H), 7.80-7.72 (m, 1H), 7.69-7.63 (m, 1H), 7.63-7.57 (m, 1H), 7.51-7.44 (m, 1H), 6.84-6.57 (m, 3H).
Step B: 4′-(6-Aminopyridin-3-yl)-N-cyclohexyl-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide
A mixture of (4-(6-aminopyridin-3-yl)-3-fluorophenyl)boronic acid (75 mg, 0.32 mmol), 2-bromo-N-cyclohexylbenzenesulfonamide (0.11 g, 0.36 mmol), 1,1′-bis[di-tert-butylphosphino)ferrocene]palladium(II) chloride (11 mg, 0.016 mmol), K2CO3 (2 M, 1.6 mL, sparged with nitrogen) and THF (2 mL, sparged with nitrogen) were combined in a sealed vessel under nitrogen. The mixture was vigorously stirred at rt for 16 hours, then diluted with EtOAc. The aqueous phase was removed and the organic layer was dried and concentrated. The residue was subjected to FCC to provide the title compound (15 mg, 11%). MS (Cl): mass calcd. for C23H24FN3O2S, 425.16; m/z found, 426.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.20-8.14 (s, 1H), 8.05-7.96 (m, 1H), 7.70-7.57 (m, 3H), 7.55-7.47 (m, 1H), 7.44-7.35 (m, 2H), 7.30-7.20 (m, 2H), 6.59-6.52 (d, J=8.6, 1H), 6.23-6.11 (s, 2H), 2.83-2.69 (d, J=7.4, 1H), 1.68-1.52 (m, 4H), 1.49-1.38 (s, 1H), 1.19-0.92 (m, 6H).
Example 347




A mixture of (4-(6-aminopyridin-3-yl)-3-fluorophenyl)boronic acid (100 mg, 0.43 mmol), (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide (160 mg, 0.54 mmol), Pd(dppf)Cl2.CH2Cl2 (18 mg, 0.022 mmol), K2CO3 (340 mg, 2.4 mmol), and DMSO (3 mL) was sparged with nitrogen, then the reaction vessel was sealed and heated at 80° Celsius for 16 hours. The mixture was cooled to rt, then filtered, and subjected to HPLC purification to provide the title compound. MS (Cl): mass calcd. for C20H20FN3O3S, 401.12; m/z found, 402.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.31-7.93 (m, 5H), 7.72-7.57 (m, 3H), 7.42-7.25 (m, 4H), 7.11-7.04 (d, J=9.2, 1H), 3.34-3.25 (s, 1H), 3.18-3.00 (m, 2H), 1.00-0.91 (d, J=6.5, 3H).
Example 348




The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-iso-butylbenzenesulfonamide. MS (Cl): mass calcd. for C21H22FN3O2S, 399.14; m/z found, 400.0 [M+H]+. 1H NMR (500 MHz, DMSO-d5) δ 8.26-8.19 (d, J=2.1, 1H), 8.18-8.11 (d, J=9.2, 1H), 8.08-7.79 (m, 3H), 7.72-7.53 (m, 4H), 7.43-7.30 (m, 3H), 7.08-7.00 (d, J=9.2, 1H), 2.57-2.52 (m, 2H), 1.66-1.56 (m, 1H), 0.82-0.75 (d, J=6.7, 6H).
Example 349




The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-(tert-pentyl)benzenesulfonamide. MS (Cl): mass calcd. for C22H24FN3O2S, 413.16; m/z found, 414.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.23-8.19 (d, J=2.0, 1H), 8.19-8.11 (d, J=9.0, 1H), 8.10-8.05 (m, 1H), 8.05-7.79 (s, 2H), 7.69-7.57 (m, 3H), 7.40-7.29 (m, 3H), 7.09-7.02 (d, J=9.2, 1H), 6.98-6.91 (s, 1H), 1.48-1.36 (m, 2H), 1.04-0.91 (s, 6H), 0.79-0.67 (m, 3H).
Example 350




The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-(1,1,1-trifluoro-2-methylpropan-2-yl)benzenesulfonamide. MS (Cl): mass calcd. for C21H19F4N3O2S, 453.11; m/z found, 454.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.28-8.19 (m, 2H), 8.17-8.11 (d, J=9.1, 1H), 8.07-8.02 (m, 1H), 8.03-7.80 (s, 2H), 7.74-7.65 (m, 2H), 7.64-7.58 (m, 1H), 7.43-7.39 (m, 1H), 7.38-7.32 (m, 1H), 7.32-7.28 (dd, J=7.9, 1.7, 1H), 7.07-7.00 (d, J=9.2, 1H), 1.29-1.17 (s, 6H).
Example 351




The title compound was prepared in a manner similar to that described in Example 347 using (S)-2-bromo-N-(2,2,2-trifluoro-1-phenylethyl)benzenesulfonamide. MS (Cl): mass calcd. for C25H19F4N3O2S, 501.11; m/z found, 502.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 9.32-9.24 (d, J=10.1, 1H), 8.24-8.20 (d, J=2.1, 1H), 8.20-8.11 (d, J=9.2, 1H), 8.11-7.90 (s, 2H), 7.90-7.85 (m, 1H), 7.64-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.49-7.40 (m, 3H), 7.40-7.31 (m, 3H), 7.29-7.24 (dd, J=7.6, 1.2, 1H), 7.15-7.03 (m, 3H), 5.22-4.90 (m, 1H).
Example 352




The title compound was prepared in a manner similar to that described in Example 347 using (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (Cl): mass calcd. for C20H20FN3O3S, 401.12; m/z found, 402.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.26-8.20 (d, J=2.1, 1H), 8.19-8.11 (d, J=9.2, 1H), 8.09-8.05 (m, 1H), 8.05-7.84 (s, 2H), 7.72-7.58 (m, 3H), 7.41-7.35 (m, 2H), 7.35-7.27 (m, 2H), 7.08-7.02 (d, J=9.2, 1H), 5.05-4.29 (m, 1H), 3.34-3.27 (dd, J=10.3, 5.0, 1H), 3.14-3.02 (m, 2H), 1.00-0.93 (d, J=6.5, 3H).
Example 353




The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-(1-methylcyclobutyl)benzenesulfonamide. MS (Cl): mass calcd. for C22H22FN3O2S, 411.14; m/z found, 412.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.24-8.20 (s, 1H), 8.20-8.15 (d, J=9.5, 1H), 8.15-7.90 (m, 3H), 7.70-7.58 (m, 3H), 7.55-7.51 (s, 1H), 7.41-7.28 (m, 3H), 7.10-7.05 (d. J=9.2, 1H), 2.15-2.05 (m, 2H), 1.71-1.51 (m, 4H), 1.26-1.18 (s, 3H).
Example 354




The title compound was prepared in a manner similar to that described in Example 347 using 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (Cl): mass calcd. for C21H20FN3O4S2, 461.09; m/z found, 462.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.27-8.21 (d, J=2.0, 1H), 8.20-8.14 (d, J=9.1, 1H), 8.13-7.88 (m, 3H), 7.82-7.76 (m, 1H), 7.72-7.62 (m, 2H), 7.48-7.39 (m, 2H), 7.37-7.31 (m, 1H), 7.10-7.02 (d, J=9.2, 1H), 3.12-3.04 (m, 4H), 3.34-3.26 (m, 4H).
Example 355




The title compound was prepared in a manner similar to that described in Example 347 using (S)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (Cl): mass calcd. for C20H17F4N3O2S, 439.10; m/z found, 440.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.56-8.49 (d, J=8.9, 1H), 8.26-8.20 (s, 1H), 8.20-8.12 (d, J=9.5, 1H), 8.09-7.82 (m, 3H), 7.74-7.59 (m, 3H), 7.42-7.37 (m, 1H), 7.36-7.27 (m, 2H), 7.09-7.01 (d, J=9.1, 1H), 3.98-3.86 (m, 1H), 1.22-1.11 (d, J=7.0, 3H).
Example 356




The title compound was prepared in a manner similar to that described in Example 347 using (1S,4S)-5-((2-bromophenyl)sulfonyl)-2-oxa-5-azabicyclo[2.2.1]heptane. MS (Cl): mass calcd. for C22H20FN3O3S, 425.12; m/z found, 426.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.27-8.23 (d, J=2.0, 1H), 8.20-8.15 (d, J=9.2, 1H), 8.15-7.89 (m, 3H), 7.79-7.74 (m, 1H), 7.70-7.62 (m, 2H), 7.47-7.38 (m, 2H), 7.37-7.32 (m, 1H), 7.10-7.03 (d, J=9.2, 1H), 4.53-4.47 (s, 1H), 4.01-3.96 (s, 1H), 3.63-3.30 (m, 2H), 2.99-2.87 (m, 2H), 1.72-1.61 (d, J=10.0, 1H), 1.47-1.36 (m, 1H).
Example 357




The title compound was prepared in a manner similar to that described in Example 347 using tert-butyl 3-((2-bromophenylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate. MS (Cl): mass calcd. for C26H29FN4O5S, 528.18; m/z found, 529.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.26-8.21 (d, J=2.0, 1H), 8.20-8.13 (d, J=9.4, 1H), 8.11-7.86 (m, 3H), 7.86-7.80 (m, 1H), 7.74-7.67 (m, 1H), 7.67-7.58 (m, 2H), 7.44-7.31 (m, 3H), 7.09-7.02 (d, J=9.1, 1H), 3.79-3.73 (m, 2H), 3.55-3.52 (m, 2H), 2.93-2.86 (d, J=6.5, 2H), 1.40-1.28 (s, 9H).
Example 358




A mixture of tert-butyl 3-((2-bromophenylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate (15 mg, 0.028 mmol), TFA (1 mL), and MeOH (1 mL) was maintained at rt for 2 hours, then concentrated to dryness. The residue was purified by HPLC to provide the title compound (8.0 mg, 52%) MS (Cl): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.84-8.70 (s, 1H), 8.68-8.52 (s, 1H), 8.26-8.19 (d, J=2.1, 1H), 8.13-8.03 (d, J=7.4, 1H), 8.01-7.94 (m, 1H), 7.94-7.88 (m, 1H), 7.74-7.71 (m, 1H), 7.69-7.65 (m, 1H), 7.63-7.59 (m, 1H), 7.48-7.42 (m, 1H), 7.42-7.31 (m, 2H), 7.05-6.91 (d, J=8.8, 1H), 6.33-6.17 (s, 1H), 3.94-3.87 (m, 2H), 3.76-3.69 (m, 2H), 3.05-3.00 (d, J=6.5, 2H).
Example 359




The title compound was prepared in a manner similar to that described in Example 347 using 2-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)ethanol. MS (Cl): mass calcd. for C24H26FN3O3S, 455.17; m/z found, 456.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.24-8.20 (d, J=2.2, 1H), 8.17-8.09 (d, J=9.1, 1H), 8.02-7.98 (m, 1H), 3.37-3.36 (m, 5H), 7.97-7.78 (s, 2H), 7.77-7.73 (m, 1H), 7.69-7.64 (m, 1H), 7.64-7.59 (m, 1H), 7.44-7.41 (m, 1H), 7.41-7.35 (m, 1H), 7.34-7.30 (dd, J=7.9, 1.7, 1H), 7.07-6.99 (d, J=9.2, 1H), 3.40-3.34 (m, 3H), 3.25-3.21 (d, J=12.3, 2H), 2.43-2.34 (m, 2H), 1.59-1.50 (d, J=10.7, 2H), 1.45-1.31 (s, 1H), 1.31-1.20 (m, 2H), 0.89-0.78 (m, 2H).
Example 360




The title compound was prepared in a manner similar to that described in Example 347 using 1-((2-bromophenyl)sulfonyl)piperidin-4-ol. MS (Cl): mass calcd. for C22H22FN3O3S, 427.14; m/z found, 428.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.26-8.22 (d, J=2.0, 1H), 8.19-8.15 (d, J=9.4, 1H), 8.14-7.92 (m, 3H), 7.78-7.73 (m, 1H), 7.69-7.65 (m, 1H), 7.65-7.60 (m, 1H), 7.45-7.40 (dd, J=7.6, 1.2, 1H), 7.40-7.35 (m, 1H), 7.33-7.28 (m, 1H), 7.09-7.04 (d, J=9.2, 1H), 3.54-3.52 (m, 2H), 3.09-3.01 (m, 2H), 2.69-2.61 (m, 2H), 1.64-1.53 (m, 2H), 1.28-1.17 (m, 2H).
Example 361




The title compound was prepared in a manner similar to that described in Example 347 using (1-((2-bromophenyl)sulfonyl)piperidin-4-yl)methanol. MS (Cl): mass calcd. for C23H24FN3O3S, 441.15; m/z found, 442.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.26-7.94 (m, 5H), 7.78-7.72 (m, 1H), 7.70-7.60 (m, 2H), 7.45-7.36 (m, 2H), 7.34-7.30 (dd, J=8.0, 1.6, 1H), 7.10-7.04 (d, J=9.2, 1H), 3.29-3.24 (d, J=12.4, 2H), 3.19-3.14 (d, J=6.3, 2H), 2.45-2.36 (m, 2H), 1.60-1.52 (d, J=10.7, 2H), 1.41-1.29 (s, 1H), 0.94-0.78 (m, 2H).
Example 362




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H20FN3O3S, 425.12; m/z found, 426.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 9.57 (s, 1H), 8.29-8.22 (m, 2H), 7.95-7.85 (m, 1H), 7.69-7.61 (m, 1H), 7.61-7.53 (m, 1H), 7.42-7.33 (m, 4H), 7.29 (d, J=7.8, 1H), 6.54-6.49 (m, 1H), 5.92 (d, J=6.7, 1H), 3.64-3.51 (m, 1H), 3.47-3.34 (m, 2H), 2.34 (s, 1H), 1.03 (d, J=6.5, 3H).
Example 363




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H20FN3O3S, 425.12; m/z found, 426.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.65 (s, 1H), 8.30-8.19 (m, 2H), 7.93-7.84 (m, 1H), 7.69-7.61 (m, 1H), 7.61-7.53 (m, 1H), 7.44-7.31 (m, 4H), 7.27 (d, J=7.8, 1H), 6.56-7.47 (m, 1H), 6.07 (d, J=6.5, 1H), 3.57 (t, J=7.0, 1H), 3.49-3.32 (m, 2H), 2.41 (s, 1H), 1.04 (d, J=6.4, 3H).
Example 364




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C23H19FN4O3S, 450.12; m/z found, 451.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 9.35 (s), 9.23 (s), 8.51-8.42 (m), 8.41-8.31 (m), 8.24-8.17 (m), 8.13-8.00 (m), 7.68-7.61 (m), 7.59-7.49 (m), 7.46-7.38 (m), 7.38-7.29 (m), 6.57-6.51 (m), 6.38 (s), 6.13 (s), 6.05 (s), 5.68 (s), 3.69-3.57 (m), 3.40-3.18 (m), 2.61-2.48 (m), 2.25-1.96 (m).
Example 365




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C22H17FN2O2S, 392.10; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.26 (s, 1H), 8.62-8.52 (m, 1H), 8.24-8.12 (m, 2H), 7.71-7.63 (m, 1H), 7.62-7.53 (m, 2H), 7.45-7.31 (m, 4H), 6.64-6.55 (m, 1H), 2.19-2.08 (m, 1H), 1.18-1.08 (m, 2H), 0.93-0.82 (m, 2H).
Example 366




The title compound was prepared in a manner similar to that described in Example 88 using 5-bromo-1H-pyrrolo[2,3-b]pyridine and 3′-fluoro-N-(2-hydroxyethyl)-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C21H18FN3O3S, 411.11; m/z found, 412.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.44-8.41 (m, 1H), 8.24-8.21 (m, 1H), 8.14-8.05 (dd, J=8.0, 1.3, 1H), 7.71-7.64 (m, 1H), 7.63-7.55 (m, 2H), 7.46-7.44 (d, J=3.5, 1H), 7.44-7.41 (dd, J=7.6, 1.2, 1H), 7.36-7.34 (dd, J=3.8, 1.7, 1H), 7.34-7.31 (dd, J=7.3, 1.4, 1H), 6.59-6.55 (d, J=3.5, 1H), 3.52-3.47 (t, J=5.9, 2H), 2.92-2.87 (t. J=5.9, 2H).
Example 367




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-1H-pyrrolo[2,3-b]pyridine. MS (ESI): mass calcd. for C23H22FN3O2S, 423.14; m/z found, 424.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.56-8.45 (m, 2H), 8.18-8.11 (dd, J=8.0, 1.3, 1H), 7.70-7.61 (m, 2H), 7.61-7.55 (m, 3H), 7.44-7.35 (m, 3H), 6.76-6.69 (d, J=3.5, 1H), 1.09 (s, 9H).
Example 368




The title compound was prepared by forming N-tert-butyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide then removing the tert-butyl group by dissolving the crude N-tert-butyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide in 1 mL of trifluoroacetic acid and heating it at 60° Celsius for 2 hours, after which time the reaction was cooled, concentrated to dryness and purified using FCC. MS (ESI): mass calcd. for C19H14FN3O2S, 367.08; m/z found, 368.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43 (s, 1H), 8.26-8.22 (m, 1H), 8.17-8.12 (dd, J=8.0, 1.3, 1H), 7.69-7.62 (m, 1H), 7.62-7.55 (m, 2H), 7.47-7.44 (d, J=3.5, 1H), 7.44-7.40 (dd, J=7.6, 1.4, 1H), 7.38-7.30 (m, 2H), 6.60-6.56 (d, J=3.5, 1H).
Example 369




Step A: 2-(4-Bromo-2-fluorphenyl)-5H-pyrrolo[2,3-b]pyrazine
To a 150 mL screw-cap vessel under nitrogen was added 5-bromo-4,7-diazaindole (1.0 g, 5.05 mmol), 4-bromo-2-fluorophenyl boronic acid (1.33 g, 6.06 mmol), Pd(dppf)Cl2.CH2Cl2 (0.2 g, 0.24 mmol), K2CO3 (2.09 g, 15.2 mmol), 1,4-dioxane (35 mL) and water (13 mL). The mixture was sparged with nitrogen for 10 minutes, the vessel capped and the reaction heated at 95° Celsius for 24 hours. The reaction was then cooled to rt, diluted with ethyl acetate (200 mL) and washed with water (1×100 mL) and brine (1×100 mL). The organic layer was dried with Na2SO4 and evaporated to dryness. The crude product was purified by HPLC giving the title compound (515 mg, 35%). MS (ESI): mass calcd. for C12H7BrFN2, 290.98; m/z found, 292.0 [M+H]+.
Step B
To a mixture of 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine (50 mg, 0.17 mmol), N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-methane-sulfonamide (61 mg, 0.21 mmol) and Pd(dppf)Cl2.CH2Cl2 (6.7 mg, 0.009 mmol) in a microwave vial were added acetonitrile (2.0 mL) and sat. NaHCO3 (2.0 mL). The vial was sparged with nitrogen for 5 min then heated at 110° Celsius for 90 min via microwave irradiation. After cooling to rt, the reaction mixture was diluted with ethyl acetate (50 mL), washed with water (25 mL) and brine (25 mL), dried (Na2SO4) and concentrated to dryness. The crude product was purified by HPLC giving the title compound (45 mg, 69%). MS (ESI): mass calcd. for C19H15FN4O2S, 382.09; m/z found, 383.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 10.38 (s, 1H), 8.78 (d, J=2.7, 1H), 8.20-8.12 (m, 1H), 7.71-7.64 (m, 2H), 7.48-7.39 (m, 1H), 7.37-7.31 (m, 2H), 7.28-7.21 (m, 2H), 6.91 (s, 1H), 6.81-6.75 (m, 1H), 2.93 (s, 3H).
Example 370




The title compound was prepared using methods analogous to those described in Example 369 using N,N-dimethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide in Step B. MS (ESI): mass calcd. for C20H17FN4O2S, 396.11; m/z found, 397.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 10.57 (s, 1H), 8.79 (d, J=2.6, 1H), 8.15-8.04 (m, 2H), 7.69-7.59 (m, 2H), 7.58-7.51 (m, 1H), 7.41-7.31 (m, 3H), 6.81-6.74 (m, 1H), 2.48 (s, 6H).
Example 371




The title compound was prepared using methods analogous to those described in Example 369 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 425.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.69 (d, J=2.6, 1H), 8.13-8.04 (m, 1H), 8.03-7.93 (m, 2H), 7.74-7.55 (m, 2H), 7.47-7.32 (m, 3H), 7.02 (s, 1H), 6.73 (d, J=3.6, 1H), 1.04 (s, 9H).
Example 372




The title compound was prepared using methods analogous to those described in Example 369 using (2-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C22H19FN4O2S, 422.12; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.22 (br s, 1H), 8.83 (d, J=2.5, 1H), 8.24 (d, J=2.5, 1H), 8.19-8.13 (m, 1H), 8.14-8.07 (m, 1H), 7.96-7.90 (m, 1H), 7.72-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.57-7.49 (m, 1H), 7.49-7.30 (m, 1H), 6.88-6.79 (m, 1H), 3.02-2.90 (m, 3H), 1.77-1.66 (m, 3H), 1.59 (s, 2H).
Example 373




The title compound was prepared using methods analogous to those described in Example 369 using (2-(N,N-diethylsulfamoyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 425.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.23 (s, 1H), 8.83 (d, J=2.5, 1H), 8.15-8.05 (m, 2H), 7.71-7.66 (m, 1H), 7.63-7.56 (m, 1H), 7.55-7.48 (m, 1H), 7.39-7.30 (m, 3H), 6.86-6.82 (m, 1H), 3.03-2.88 (m, 4H), 1.00 (t, J=7.15, 6H).
Example 374




The title compound was prepared using methods analogous to those described in Example 369 using (2-(piperidin-1-ylsulfonyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C23H21FN4O2S, 436.14; m/z found, 437.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.20 (s, 1H), 8.83 (d, J=2.5, 1H), 8.18-8.03 (m, 2H), 7.71-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.41-7.32 (m, 3H), 6.87-6.82 (m, 1H), 2.93-2.81 (m, 4H), 1.46-1.36 (m, 6H).
Example 375




The title compound was prepared using methods analogous to those described in Example 369 using (2-(morphilinosulfonyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C22H19FN4O3S, 438.12; m/z found, 439.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 10.69 (s, 1H), 8.79 (d, J=2.6, 1H), 8.17-8.06 (m, 2H), 7.71-7.61 (m, 2H), 7.61-7.53 (m, 1H), 7.44-7.33 (m, 3H), 6.80-6.74 (m, 1H), 3.54-3.45 (m, 4H), 2.94-2.83 (m, 4H).
Example 376




To a mixture of 2-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5H-pyrrolo[2,3-b]pyrazine (32 mg, 0.09 mmol), racemic 2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide (38 mg, 0.11 mmol) and Pd(dppf)Cl2.CH2Cl2 (6 mg, 0.007 mmol) in a microwave vial were added acetonitrile (2.0 mL) and sat. NaHCO3 (2.0 mL). The mixture was sparged with nitrogen for 5 min and then the vial capped and heated at 110° Celsius for 90 min. After cooling, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (25 mL) and brine (25 mL). The organic layer was dried (Na2SO4) and concentrated to dryness. The crude product was purified by HPLC to give the title compound (28 mg, 64%). MS (ESI): mass calcd. C21H16F4N4O2S, 464.09; m/z found, 465.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 8.47 (s, 1H), 8.27-8.17 (m, 1H), 7.75-7.41 (m, 5H), 7.40-7.32 (m, 2H), 7.20 (d, J=12.6, 1H), 6.74-6.67 (m, 1H), 4.12-3.94 (m, 1H), 1.39-1.19 (m, 3H).
Example 377




Step A: 2-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine
The title compound was prepared using methods analogous to those described in Example 369 using (2-(methylthio)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C19H14FN3S., 335.09; m/z found, 336.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.81 (d, J=2.5, 1H), 8.11-8.01 (m, 1H), 7.69-7.63 (m, 1H), 7.44-7.19 (m, 6H), 6.87-6.82 (m, 1H), 2.41 (s, 3H).
Step B
To a 10 mL round bottomed flask under nitrogen at rt were added 2-[3-fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine (32 mg, 0.07 mmol), m-CPBA (0.33 mg, 0.19 mmol) and DCM (1 mL). The mixture was stirred at rt for 2 hours. An additional 0.5 equivalents of mCPBA was added at this time and the reaction stirred an additional 1 hour. The reaction was then poured into sat. NaHCO3 and extracted with DCM (×2). The solvent was then removed and the crude product purified by HPLC to give the title compound (12 mg, 35%). MS (ESI): mass calcd. for C19H14FN3O2S, 481.08; m/z found, 368.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 8.82 (s, 1H), 8.27 (d, J=8.0, 1H), 8.18-8.09 (m, 1H), 7.77-7.67 (m, 2H), 7.66-7.57 (m, 1H), 7.48-7.36 (m, 3H), 6.89-6.83 (m, 1H), 2.76 (s, 3H).
Example 378




The title compound was prepared using methods analogous to those described in Example 376 using (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. C21H19FN4O3S, 426.12; m/z found, 427.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.40 (s, 1H), 8.74 (d, J=2.7, 1H), 8.60 (s, 1H), 8.29-8.20 (m, 1H), 7.83-7.74 (m, 1H), 7.71-7.62 (m, 2H), 7.61-7.50 (m, 1H), 7.47-7.36 (m, 2H), 7.35-7.16 (m, 1H), 5.50 (s, 1H), 3.65-3.49 (m, 1H), 3.48-3.28 (m, 2H), 2.16-1.94 (m, 1H), 1.04 (d, J=6.6, 3H).
Example 379




The title compound was prepared using methods analogous to those described in Example 376 using 2-bromo-N-methylbenzenesulfonamide. MS (ESI): mass calcd. C19H15FN4O2S, 382.09; m/z found, 383.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.35 (s, 1H), 8.67 (d, J=2.2, 1H), 8.29-8.18 (m, 1H), 8.03-7.83 (m, 1H), 7.71-7.55 (m, 3H), 7.47-7.29 (m, 3H), 6.83-6.73 (m, 1H), 4.85 (s, 1H), 2.56 (d, J=5.2, 3H).
Example 380




The title compound was prepared using methods analogous to those described in Example 376 using (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. C21H19FN4O3S, 426.12; m/z found, 427.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.40 (s, 1H), 8.74 (d, J=2.7, 1H), 8.60 (s, 1H), 8.29-8.20 (m, 1H), 7.83-7.74 (m, 1H), 7.71-7.62 (m, 2H), 7.61-7.50 (m, 1H), 7.47-7.36 (m, 2H), 7.35-7.16 (m, 1H), 5.50 (s, 1H), 3.65-3.49 (m, 1H), 3.48-3.28 (m, 2H), 2.16-1.94 (m, 1H), 1.04 (d, J=6.6, 3H).
Example 381




Step A: tert-Butyl (1-((3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)-[1,1′-biphenyl]-2-yl)-sulfonyl)piperidin-4-yl)carbamate
The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and tert-butyl (1-((2-bromophenyl)sulfonyl)piperidin-4-yl)carbamate. MS (ESI): mass calcd. for C28H30FN5O4S, 551.20; m/z found, 552.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 8.81 (d. J=2.4, 1H), 8.18-8.04 (m, 2H), 7.69-7.59 (m, 2H), 7.60-7.48 (m, 1H), 7.48-7.30 (m, 4H), 6.85 (dd, J=3.7, 1.9, 1H), 4.44 (d, J=8.2, 1H), 3.79 (d, J=13.2, 1H), 3.49-3.27 (m, 3H), 2.91 (t, J=11.7, 1H), 2.47 (t, J=12.2, 2H), 1.98 (d, J=13.4, 1H), 1.79 (d, J=11.8, 2H), 1.42 (d, J=9.5, 12H), 1.31-1.10 (m, 3H).
Step B
The title compound was prepared as described in the preparation of Example 247 using tert-butyl (1-((3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-yl)carbamate. MS (ESI): mass calcd. for C23H22FN5O2S, 451.15; m/z found, 452.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.66 (s, 1H), 8.82 (d, J=2.5, 1H), 8.20-8.04 (m, 2H), 7.69 (d, J=3.7, 1H), 7.66-7.59 (m, 1H), 7.58-7.51 (m, 1H), 7.42-7.32 (m, 3H), 6.83 (d, J=3.7, 1H), 3.43-3.30 (m, 2H), 2.70-2.59 (m, 1H), 2.55-2.40 (m, 2H), 1.75-1.65 (m, 2H), 1.56 (br s, 2H), 1.24-1.07 (m, 2H).
Example 382




The title compound was prepared using methods analogous to those described in Example 376 using 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C22H19FN4O4S2, 486.08; m/z found, 487.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.19 (s, 1H), 8.83 (d, J=2.5, 1H), 8.22-8.11 (m, 2H), 7.75-7.65 (m, 2H), 7.64-7.55 (m, 1H), 7.43-7.37 (m, 1H), 7.34-7.21 (m, 2H), 6.88-6.80 (m, 1H), 3.45-3.26 (m, 4H), 3.09-2.94 (m, 4H).
Example 383




The title compound was prepared using methods analogous to those described in Example 369 using (5-fluoro-2-(methylthio)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C19H13F2N3S, 353.08; m/z found, 354.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.98 (s, 1H), 8.82 (d, J=2.6, 1H), 8.14-8.05 (m, 1H), 7.70-7.63 (m, 1H), 7.41-7.28 (m, 3H), 7.13-7.01 (m, 2H), 6.87-6.80 (m, 1H), 2.36 (s, 3H).
Example 384




The title compound was prepared using methods analogous to those described in Example 369 using (2-(ethylthio)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C20H16FN3S, 349.10: m/z found, 350.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.12 (s, 1H), 8.83 (d, J=2.6, 1H), 8.11-8.02 (m, 1H), 7.69-7.63 (m, 1H), 7.44-7.21 (m, 6H), 6.86-6.81 (m, 1H), 2.85 (q, J=7.4, 2H), 1.26 (t, J=7.4, 3H).
Example 385




The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 1-bromo-2-(methylsulfonyl)benzene. MS (ESI): mass calcd. for C20H17FN2O3S, 384.09; m/z found, 385.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.27-8.24 (m, 1H), 7.99-7.93 (m, 1H), 7.71-7.65 (m, 1H), 7.63-7.57 (m, 1H), 7.47 (m, 1H), 7.41-7.38 (m, 1H), 7.33-7.27 (m, 3H), 4.32-4.24 (m, 2H), 3.67-3.59 (m, 2H), 2.76 (s, 3H).
Example 386




The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 1-((2-bromophenyl)sulfonyl)piperidine. MS (ESI): mass calcd. for C24H24FN3O3S, 453.15; m/z found, 454.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.07-8.03 (m, 1H), 7.82 (d, J=1.0, 1H), 7.73-7.67 (m, 2H), 7.65-7.55 (m, 2H), 7.42-7.39 (m, 1H), 7.36-7.30 (m, 2H), 4.41-4.32 (m, 2H), 3.74-3.71 (m, 2H), 2.91-2.79 (m, 4H), 1.49-1.37 (m, 6H).
Example 387




The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 2-bromobenzenesulfonamide. MS (ESI): mass calcd. for C19H16FN3O3S, 385.09; m/z found, 386.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.14-8.11 (m, 1H), 7.80 (d, J=1.0, 1H), 7.73-7.71 (m, 1H), 7.68-7.62 (m, 1H), 7.61-7.52 (m, 2H), 7.39-7.31 (m, 3H), 4.40-4.34 (m, 2H), 3.75-3.69 (m, 2H).
Example 388




The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H22FN3O4S, 443.13; m/z found, 444.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.15-8.12 (m, 1H), 7.80 (m, 1H), 7.72 (d, J=1.3, 1H), 7.69-7.64 (m, 1H), 7.62-7.52 (m, 2H), 7.40-7.33 (m, 3H), 4.37 (t, J=4.6, 2H), 3.76-3.69 (m, 2H), 3.43-3.36 (m, 1H), 3.30-3.26 (m, 1H), 3.24-3.16 (m, 1H), 1.04-1.01 (m, 3H).
Example 389




The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 1-((2-bromophenyl)sulfonyl)piperidin-4-amine. MS (ESI): mass calcd. for C24H25FN4O3S, 468.16; m/z found, 469.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.09-8.05 (m, 1H), 7.83 (d, J=1.1, 1H), 7.75-7.68 (m, 2H), 7.66-7.55 (m, 2H), 7.43-7.39 (m, 1H), 7.34-7.26 (m, 2H), 4.39-4.35 (m, 2H), 3.76-3.68 (m, 2H), 3.47 (d, J=13.4, 2H), 3.21-3.11 (m, 1H), 2.60-2.50 (m, 2H), 1.96-1.87 (m, 2H), 1.56-1.43 (m, 2H).
Example 390




The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C22H22FN3O4S, 443.13; m/z found, 444.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.16-8.10 (m, 1H), 7.82-7.79 (m, 1H), 7.74-7.71 (m, 1H), 7.70-7.64 (m, 1H), 7.61-7.57 (m, 1H), 7.54-7.46 (m, 1H), 7.40-7.33 (m, 3H), 4.40-4.36 (m, 2H), 3.75-3.69 (m, 2H), 3.48-3.33 (m, 2H), 3.24-3.16 (m, 1H), 1.05-1.01 (m, 3H).
Example 391




The title compound was prepared in a manner similar to that described in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine and 2-bromo-N,N-diethylbenzenesulfonamide. MS (ESI): mass calcd. for C23H24FN3O3S, 441.15; m/z found, 442.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.03-8.00 (m, 1H), 7.82 (d, J=1.0, 1H), 7.73-7.65 (m, 2H), 7.62-7.55 (m, 2H), 7.40-7.36 (m, 1H), 7.31 (s, 1H), 7.30-7.28 (m, 1H), 4.39-4.35 (m, 2H), 3.74-3.70 (m, 2H), 2.99 (q, J=7.1, 4H), 1.01 (t. J=7.1, 6H).
Example 392




Step A: 7-(4-Chloro-2-fluorophenyl-3,4-dihydro-2H-pyrido[3,2-b][1.4]oxazine
Prepared in a manner similar to that found in Example 1 using of 7-bromo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine with (4-chloro-2-fluorophenyl)boronic acid. 1H NMR (400 MHz, CDCl3) δ 7.84 (m, 1H), 7.35-7.28 (m, 1H), 7.20-7.14 (m, 3H), 4.29-4.25 (m, 2H), 3.64-3.58 (m, 2H).
Step B: 7-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine
Into a 100 mL flask were added 7-(4-chloro-2-fluorophenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (1.25 g, 4.72 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.5 g, 5.9 mmol), KOAc (1.39 g, 14.2 mmol). Chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II), 186 g, 0.236 mmol), and a stir bar. The flask was sealed with a rubber septum and sparged with N2. The flask was charged with freshly sparged 1,4-dioxane (25 mL) and heated at 80° Celsius for 16 hours. The reaction was cooled to rt and concentrated to dryness. The crude product was purified by FCC to give 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (1.208 g, 71%). 1H NMR (500 MHz, CDCl3) δ 7.86-7.84 (m, 1H), 7.61-7.59 (m, 1H), 7.56-7.53 (m, 1H), 7.38 (m, 1H), 7.27-7.24 (m, 1H), 4.27-4.22 (m, 2H), 3.61-3.58 (m, 2H), 2.09 (s, 1H), 1.35 (s, 12H).
Step C
7-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-3,4-dihydro-2H-pyrido[3,2-b]-b][1,4]oxazine. Prepared in a manner similar to that found in Example 444 using 7-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)phenyl)-3,4-dihydro-2H-pyrido[3,2-b]-b][1,4]oxazine with 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C23H22FN3O5S2, 503.10; m/z found, 504.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.16-8.13 (m, 1H), 7.85-7.83 (m, 1H), 7.78-7.72 (m, 2H), 7.69-7.60 (m, 2H), 7.45-7.41 (m, 1H), 7.37-7.30 (m, 2H), 4.41-4.35 (m, 2H), 3.76-3.68 (m, 2H), 3.38-3.33 (m, 4H), 3.06-2.98 (m, 4H).
Example 393




The title compound was prepared in a manner similar to that described in Example 444 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 7-bromo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine. MS (ESI): mass calcd. for C23H24FN3O3S, 441.15; m/z found, 442.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.15-8.12 (m, 1H), 7.80 (d, J=0.9, 1H), 7.72-7.69 (m, 1H), 7.68-7.62 (m, 1H), 7.60-7.54 (m, 2H), 7.39-7.33 (m, 3H), 4.42-4.33 (m, 2H), 3.75-3.69 (m, 2H), 1.09 (s, 9H).
Example 394




The title compound was prepared using methods analogous to those described in Example 369 using (2-(isopropylthio)-5-(trifluoromethyl)pyridine-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C21H16F4N4S, 432.10; m/z found, 433.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.12 (s, 1H), 8.83 (d, J=2.6, 1H), 8.74-8.68 (m, 1H), 8.19-8.10 (m, 1H), 7.71-7.66 (m, 1H), 7.62 (d, J=1.9, 1H), 7.42-7.37 (m, 1H), 7.33 (dd, J=1.7, 11.52, 1H), 6.87-6.82 (m, 1H), 4.19-4.03 (m, 1H), 1.40 (d, J=6.8, 6H).
Example 395




Step A: 3-Bromo-2-(isopropylthio)pyridine
3-Bromopyridine-2-thiol (500 mg, 2.63 mmol) was added drop-wise to a suspension of sodium hydride in mineral oil (60%, 126 mg, 3.16 mmol) in DMF (5.0 mL) at 0° Celsius. The mixture was then stirred at 0° Celsius for 30 min followed by removal of the ice bath and stirring at rt for an additional 30 min. 2-Iodopropane (537 mg, 3.16 mmol) was then added and the reaction stirred at 60° Celsius for 18 hours. The reaction was cooled to rt, carefully diluted with water (100 mL), and extracted with ethyl acetate (2×100 mL). The combined organic extracts were dried with Na2SO4, filtered and concentrated to dryness. The crude product was purified by FCC giving 453 mg (74%) of the target thioether. MS (ESI): mass calcd. for C8H10BrNS, 230.97; m/z found, 232.1 [M+H]+.
Step B: 3-Bromo-2-(isopropylsulfonyl)pyridine
3-Bromo-2-(isopropylthio)pyridine (100 mg, 0.43 mmol) was dissolved in DCM (6.0 mL) and m-CPBA (198 mg, 1.15 mmol) added. The reaction was stirred for 1.5 hours, and then treated with additional m-CPBA (100 mg, 0.058 mmol). Once complete conversion was achieved, the mixture was poured into sat. NaHCO3 (50 mL) and extracted with DCM (2×50 mL). The combined extracts were concentrated to dryness and the crude product (112 mg, 98%) was used in next step without further purification.
Step C
The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 3-bromo-2-(isopropylsulfonyl)pyridine yielding 52 mg (88%) of the title compound. MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 373.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.69 (dd, J=4.6, 1.7, 1H), 8.60 (dd, J=2.1, 1.5, 1H), 8.10 (d, J=1.5, 1H), 8.08-7.98 (m, 1H), 7.81 (dd, J=7.8, 1.6, 1H), 7.58 (dd, J=7.8, 4.6, 1H), 7.38 (dd, J=8.0, 1.8, 1H), 7.32 (dd, J=11.7, 1.7, 1H), 4.71 (s, 2H), 4.19 (hept, J=6.8, 1H), 1.31 (d, J=6.9, 6H).
Example 396




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 3-bromo-2-(isopropylthio)pyridine. MS (ESI): mass calcd. for C18H17FN4S, 340.12; m/z found, 341.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.62-8.57 (m, 1H), 8.49-8.43 (m, 1H), 8.12 (d, J=1.5, 1H), 8.04-7.93 (m, 1H), 7.45-7.39 (m, 1H), 7.34-7.30 (m, 1H), 7.29-7.22 (m, 1H), 7.11-7.03 (m, 1H), 4.69 (s, 2H), 4.17-4.00 (m, 1H), 1.37 (d, J=6.8, 6H).
Example 397




The title compound was prepared using methods analogous to those described in Example 369 using (2-((2,2,2-trifluoroethoxy)pyridine-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C19H12F4N4O, 388.09; m/z found, 389.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.10 (s, 1H), 8.83 (d, J=2.5, 1H), 8.21-8.16 (m, 1H), 8.16-8.07 (m, 1H), 7.82-7.76 (m, 1H), 7.71-7.64 (m, 1H), 7.57-7.52 (m, 1H), 7.51-7.44 (m, 1H), 7.16-7.09 (m, 1H), 6.87-6.82 (m, 1H), 4.95-4.79 (m, 2H).
Example 398




The title compound was prepared using methods analogous to those described in Example 369 using (2-isobutoxypyridin-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C21H19FN4O, 362.15; m/z found, 363.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.26 (s, 1H), 8.84 (d, J=2.5, 1H), 8.23-8.15 (m, 1H), 8.14-8.04 (m, 1H), 7.74-7.65 (m, 2H), 7.59-7.48 (m, 2H), 7.03-6.96 (m, 1H), 6.88-6.81 (m, 1H), 4.17 (d, J=6.6, 2H), 2.33-1.99 (m, 1H), 1.02 (d, J=6.7, 6H).
Example 399




The title compound was prepared using methods analogous to those described in Example 369 using (2-isopropoxypyridin-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C20H17FN4O, 348.14; m/z found, 349.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 8.83 (d, J=2.5, 1H), 8.17 (dd, J=1.9, 4.9, 1H), 8.11-8.01 (m, 1H), 7.72-7.64 (m, 2H), 7.57-7.46 (m, 2H), 6.96 (dd, J=5.0, 7.3, 1H), 6.87-6.80 (m, 1H), 5.52-5.37 (m, 1H), 1.38 (d, J=6.2, 6H).
Example 400




The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclopropylmethoxy)pyridin-3-yl)boronic acid in Step B. MS (ESI): mass calcd. for C21H17FN4O, 360.14; m/z found, 361.1 [M+H]+. 1H NMR (400 MHz, CDCl3) G 9.28 (s, 1H), 8.83 (d, J=2.5, 1H), 8.19-8.14 (m, 1H), 8.13-8.04 (m, 1H), 7.74-7.64 (m, 2H), 7.61-7.53 (m, 2H), 6.99 (dd, J=5.0, 7.4, 1H), 6.84 (dd, J=1.9, 3.7, 1H), 4.25 (d, J=7.0, 2H), 1.39-1.23 (m, 1H), 0.67-0.57 (m, 2H), 0.41-0.31 (m, 2H).
Example 401




The title compound was prepared using methods analogous to those described in Example 369 using (2-isopropoxypyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C18H17FN4O, 324.14; m/z found, 325.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.63-8.57 (m, 1H), 8.18-8.13 (m, 1H), 8.12 (d, J=1.4, 1H), 7.99-7.90 (m, 1H), 7.69-7.62 (m, 1H), 7.58-7.41 (m, 2H), 6.98-6.91 (m, 1H), 5.49-5.35 (m, 1H), 4.68 (s, 2H), 1.37 (d, J=6.2, 6H).
Example 402




The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclopentyloxy)pyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C20H19FN4O, 350.15; m/z found, 351.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.62-8.58 (m, 1H), 8.19-8.15 (m, 1H), 8.12 (d, J=1.5, 1H), 8.00-7.90 (m, 1H), 7.69-7.63 (m, 1H), 7.48-7.40 (m, 2H), 6.98-6.92 (m, 1H), 5.59-5.50 (m, 1H), 4.68 (s, 2H), 2.03-1.89 (m, 2H), 1.89-1.70 (m, 4H), 1.71-1.55 (m, 2H).
Example 403




The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclohexyloxy)pyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.64-8.57 (m, 1H), 8.18-8.10 (m, 2H), 8.00-7.92 (m, 1H), 7.70-7.63 (m, 1H), 7.52-7.43 (m, 2H), 6.94 (dd, J=5.0, 7.4, 1H), 5.26-5.16 (m, 1H), 4.66 (s, 2H), 2.05-1.91 (m, 2H), 1.82-1.68 (m, 2H), 1.66-1.24 (m, 6H).
Example 404




The title compound was prepared using methods analogous to those described in Example 369 using (2-(methoxy)pyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C16H13FN4O, 296.11; m/z found, 297.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.62-8.56 (m, 1H), 8.19 (dd, J=1.9, 5.0, 1H), 8.12 (d, J=1.5, 1H), 8.01-7.94 (m, 1H), 7.70-7.65 (m, 1H), 7.48-7.41 (m, 2H), 7.00 (dd, J=5.0, 7.31, 1H), 4.66 (s, 2H), 4.00 (s, 3H).
Example 405




The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclobutoxy)pyridin-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C19H17FN4O, 336.14; m/z found, 337.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.63-8.57 (m, 1H), 8.17-8.10 (m, 2H), 8.01-7.92 (m, 1H), 7.66 (dd, J=1.9, 7.4, 1H), 7.52-7.43 (m, 2H), 7.00-6.93 (m, 1H), 5.38-5.22 (m, 1H), 4.67 (s, 2H), 2.57-2.37 (m, 2H), 2.26-2.05 (m, 2H), 1.90-1.61 (m, 2H).
Example 406




The title compound was prepared using methods analogous to those described in Example 369 using tert-butyl 3-(((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-yl)oxy)methyl)pyrrolidine-1-carboxylate and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C25H28FN5O3, 465.22; m/z found, 466.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.63-8.58 (m, 1H), 8.18-8.09 (m, 2H), 8.03-7.94 (m, 1H), 7.73-7.64 (m, 1H), 7.48-7.36 (m, 2H), 7.05-6.96 (m, 1H), 4.70 (s, 2H), 4.47-4.22 (m, 2H), 3.68-3.26 (m, 3H), 3.25-3.09 (m, 1H), 2.77-2.60 (m, 1H), 2.14-1.98 (m, 1H), 1.84-1.68 (m, 1H), 1.44 (s, 9H).
Example 407




Step A: Tert-butyl 3-(((3-(4-(5-aminopyrazin-2-yl)-3-fluorophenyl)pyridine-2-yl)oxy)methyl)pyrrolidine-1-carboxylate
The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and tert-butyl 3-(((3-bromopyridin-2-yl)oxy)methyl)pyrrolidine-1-carboxylate yielding the title compound (47 mg, 54%). MS (ESI): mass calcd. for C25H28FN5O3, 465.22; m/z found, 466.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.63-8.58 (m, 1H), 8.18-8.09 (m, 2H), 8.03-7.94 (m, 1H), 7.73-7.64 (m, 1H), 7.48-7.36 (m, 2H), 7.05-6.96 (m, 1H), 4.70 (s, 2H), 4.47-4.22 (m, 2H), 3.68-3.26 (m, 3H), 3.25-3.09 (m, 1H), 2.77-2.60 (m, 1H), 2.14-1.98 (m, 1H), 1.84-1.68 (m, 1H), 1.44 (s, 9H).
Step B
The title compound was prepared as described in the preparation of Example 249 using tert-butyl 3-(((3-(4-(5-aminopyrazin-2-yl)-3-fluorophenyl)pyridine-2-yl)oxy)methyl)pyrrolidine-1-carboxylate to give the title compound (15 mg, 41%). MS (ESI): mass calcd. for C20H20FN5O, 365.17; m/z found, 366.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.63-8.57 (m, 1H), 8.20-8.13 (m, 1H), 8.12 (d, J=1.5, 1H), 8.02-7.93 (m, 1H), 7.72-7.65 (m, 1H), 7.49-7.38 (m, 2H), 7.03-6.96 (m, 1H), 4.69 (s, 2H), 4.40-4.20 (m, 2H), 3.09 (dd, J=11.2, 7.7, 1H), 3.04-2.83 (m, 2H), 2.76 (dd, J=11.2, 6.1, 1H), 2.66-2.49 (m, 1H), 2.06-1.89 (m, 1H), 1.61-1.49 (m, 2H).
Example 408




To a microwave vial the following were added 5-(4-chloro-2-fluorophenyl)-pyrimidin-2-amine (50 mg, 0.22 mmol), (2-isopropoxypyridin-3-yl)boronic acid (51 mg, 0.28 mmol) and X-Phos precatalyst (4 mg, 0.005 mmol). The vial was flushed with nitrogen and then THF (0.5 mL) and 0.5 M K3PO4 (0.9 mL) were added. Both THF and the K3PO4 solution were sparged separately for 30 min prior to use. The resulting biphasic mixture was stirred at rt overnight. The reaction mixture was then poured into sat. NaHCO3 (50 mL) and extracted with ethyl acetate (2×50 mL). The combined organic extracts were washed with water (1×50 mL) and brine (1×50 mL), dried (Na2SO4) and concentrated to dryness. The crude product was purified by HPLC to give the title compound (35 mg, 48%). MS (ESI): mass calcd. for C18H17FN4O, 324.14; m/z found, 325.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J=1.4, 2H), 8.21-8.13 (m, 1H), 7.68-7.60 (m, 1H), 7.50-7.36 (m, 3H), 6.99-6.91 (m, 1H), 5.51-5.37 (m, 1H), 5.15 (s, 2H), 1.38 (d, J=6.2, 6H).
Example 409




The title compound was prepared in a manner similar to that described in Example 88 using 3-bromopyridin-2-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C15H12FN5, 281.11; m/z found, 282.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.64-8.54 (m, 1H), 8.00-7.89 (m, 1H), 7.74-7.64 (m, 1H), 7.46-7.36 (m, 1H), 7.09-7.03 (m, 1H).
Example 410




The title compound was prepared in manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (400 MHz. CD3OD) δ8.73 (d, J=2.1, 1H), 8.16 (dd. J=7.9, 1.4, 1H), 7.93 (m, 1H), 7.69 (m, 1H), 7.60 (m, 1H), 7.45-7.28 (m, 3H), 3.47-3.36 (m, 1H), 3.34-3.18 (m, 2H), 1.03 (d. J=6.6, 3H).
Example 411




The title compound was prepared in manner similar to that described in Example 88 using 1-bromo-2-(cyclopropylsulfonyl)benzene and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C20H15FN4O2S, 394.09; m/z found, 395.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.84 (d, J=1.8, 1H), 8.14 (dd, J=8.0, 1.4, 1H), 8.01 (m, 1H), 7.66 (m, 1H), 7.58 (m, 1H), 7.39-7.35 (m, 3H), 5.34 (s, 2H), 2.13-2.05 (m, 1H), 1.13-1.06 (m, 2H), 0.88-0.82 (m, 2H).
Example 412




The title compound was prepared in manner similar to that described in Example 88 using (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.78 (d, J=1.6, 1H), 8.18 (dd, J=7.9, 1.4, 1H), 8.01 (m, 1H), 7.63 (m, 1H), 7.56 (m, 1H), 7.40-7.32 (m, 3H), 5.43 (s, 2H), 4.46-4.36 (m, 1H), 3.55-3.46 (m, 1H), 3.43-3.28 (m, 2H), 1.76 (t, J=5.7, 1H), 0.99 (d, J=6.6, 3H).
Example 413




The title compound was prepared in manner similar to that described in Example 88 using 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C19H16FN5O3S, 413.10; m/z found, 414.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.81 (d, J=1.8, 1H), 8.17 (dd, J=8.0, 1.4, 1H), 8.02 (m, 1H), 7.64 (m, 1H), 7.56 (m, 1H), 7.40-7.31 (m, 3H), 5.38 (s, 2H), 4.35 (s, 1H), 3.64-3.58 (m, 2H), 2.95-2.87 (m, 2H), 1.64 (t, J=5.2, 1H).
Example 414




The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromophenyl)sulfonyl)piperazin-2-one and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C21H17FN6O3S, 452.11; m/z found, 453.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.65 (d. J=2.1, 1H), 8.05 (dd. J=8.1, 1.3, 1H), 7.85 (m, 1H), 7.65 (m, 1H), 7.55 (m, 1H), 7.36 (dd, J=7.6, 1.3, 1H), 7.26-7.17 (m, 2H), 3.29 (s, 2H), 3.04 (s, 4H).
Example 415




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.75 (d, J=2.1, 1H), 8.09 (dd, J=8.0, 1.3, 1H), 7.95 (m, 1H), 7.70 (m, 1H), 7.62 (m, 1H), 7.43 (dd, J=7.6, 1.4, 1H), 7.39-7.31 (m, 2H), 3.74-3.62 (m, 1H), 2.80-2.67 (m, 2H), 1.07 (d, J=6.3, 3H).
Example 416




The title compound was prepared in a manner similar to that described in Example 88 using (2-bromophenyl)(morpholino)methanone and 3-amino-6-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile. MS (ESI): mass calcd. for C22H18FN5O2, 403.14; m/z found, 404.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 7.45 (d, J=2.1, 1H), 6.71 (m, 1H), 6.32-6.21 (m, 3H), 6.17-6.10 (m, 2H), 6.07 (dd, J=12.4, 1.8, 1H), 2.40-2.22 (m, 3H), 2.13-2.03 (m, 2H), 1.86-1.77 (m, 1H), 1.62-1.49 (m, 2H).
Example 417




The title compound was prepared in a manner similar to that described in Example 444 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 6-chloropyridazin-3-amine. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.26-8.22 (m, 1H), 8.16-8.13 (m, 1H), 7.91-7.85 (m, 1H), 7.69-7.64 (m, 1H), 7.63-7.56 (m, 2H), 7.44-7.37 (m, 3H), 1.09 (s, 9H).
Example 418




The title compound was prepared in a manner similar to that described in Example 444 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 2-bromo-7H-pyrrolo[2,3-d]pyrimidine. MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 425.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.31 (s, 1H), 8.82 (s, 1H), 8.15 (m, 1H), 7.90 (d, J=3.6, 1H), 7.68 (d, J=7.5, 1H), 7.63 (d, J=6.3, 1H), 7.50 (s, 1H), 7.42 (d, J=7.1, 1H), 7.02 (d, J=3.6, 1H), 6.66 (d, J=3.6, 1H), 1.12 (s, 9H).
Example 419




The title compound was prepared in a manner similar to that described in Example 444 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 3-bromo-1,8-naphthyridine. MS (ESI): mass calcd. for C24H22FN3O2S, 435.14; m/z found, 436.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.46 (s, 1H), 9.23 (s, 1H), 8.89 (s, 1H), 8.85 (d, J=7.2, 1H), 8.18-8.14 (m, 1H), 7.94-7.90 (m, 1H), 7.80 (m, 1H), 7.70-7.65 (m, 1H), 7.62-7.57 (m, 1H), 7.49-7.40 (m, 3H), 1.11 (s, 9H).
Example 420




Step A: 4′-Bromo-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide
1-Bromo-2-fluoro-4-iodobenzene (117 mg, 0.389 mmol) and (2-(N-(tert-butyl)sulfamoyl)phenyl) boronic acid (100 mg, 0.389 mmol) were added to a 5 mL sealable vial equipped with a stir bar. 1,4-Dioxane (1 mL) and 2 M Na2CO3 (1 mL) solution were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 min then Pd(dppf)Cl2.CH2Cl2 (14 mg, 0.019 mmol) was added. The mixture was then stirred for 15 hours at 80° Celsius under an argon atmosphere. The reaction was diluted with 2 mL of ethyl acetate and 2 mL of water and the aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na2SO4 and concentrated to dryness. The crude product was purified by FCC to give the title compound. 1H NMR (500 MHz, CDCl3) δ 8.20-8.15 (dd, J=7.9, 1.4, 1H), 7.64-7.59 (dd, J=8.2, 7.1, 1H), 7.60-7.55 (m, 1H), 7.54-7.49 (m, 1H), 7.31-7.27 (m, 2H), 7.21-7.16 (dd, J=8.5, 2.2, 1H), 3.65 (s, 1H), 1.07 (s, 9H).
Step B: N-tert-Butyl-3′-fluoro-4′-quinoxalin-6-ylbiphenyl-2-sulfonamide
4′-Bromo-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (30 mg, 0.078 mmol) and 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline (12 mg, 0.085 mmol) were added to a 5 mL sealable vial equipped with a stir bar. Dioxane (0.2 mL) and 2 M Na2CO3 (0.2 mL) were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 min then Pd(dppf)Cl2.CH2Cl2 (3 mg, 0.004 mmol) was added, and the mixture heated for 15 hours at 80° Celsius under an argon atmosphere. The reaction was diluted with 2 mL of ethyl acetate and 2 mL of water and the aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na2SO4 and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C24H22FN3O2S, 435.14; m/z found, 436.4 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.93-8.91 (d, J=1.8, 1H), 8.91-8.89 (d, J=1.8, 1H), 8.37-8.34 (m, 1H), 8.24-8.22 (m, 1H), 8.22-8.20 (m, 1H), 8.09-8.04 (m, 1H), 7.71-7.66 (m, 1H), 7.65-7.59 (m, 1H), 7.58-7.52 (m, 1H), 7.51-7.44 (dd, J=7.9, 1.8, 1H), 7.44-7.40 (dd, J=11.3, 1.7, 1H), 7.40-7.36 (dd, J=7.5, 1.4, 1H), 3.74 (s, 1H), 1.10 (s, 9H).
Example 421




The title compound was prepared in a manner similar to that described in Example 420 using tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate in Step B. After work up, the Boc group was then removed by treatment with trifluoroacetic acid (0.3 mL) in dichloromethane (1 mL) at rt followed by concentration and purification by HPLC to give the title compound. MS (ESI): mass calcd. for C24H23FN2O2S, 422.15; m/z found, 423.3 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.27 (s, 1H), 8.23-8.17 (dd, J=8.0, 1.3, 1H), 7.91-7.85 (m, 1H), 7.63-7.56 (m, 2H), 7.55-7.49 (m, 2H), 7.48-7.43 (m, 1H), 7.42-7.36 (m, 2H), 7.36-7.31 (dd, J=11.3, 1.8, 1H), 7.31-7.27 (dd, J=3.2, 2.4, 1H), 6.67-6.61 (m, 1H), 3.72 (s, 1H), 1.06 (s, 9H).
Example 422




The title compound was prepared in a manner similar to that described in Example 420 using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole in Step B. MS (ESI): mass calcd. for C23H22FN3O2S, 423.14; m/z found, 424.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 9.32-9.21 (d, J=6.0, 1H), 8.18-8.12 (dd, J=8.0, 1.3, 1H), 8.04 (s, 1H), 7.96-7.89 (m, 1H), 7.89-7.82 (m, 1H), 7.69-7.55 (m, 3H), 7.45-7.33 (m, 3H), 1.11 (s, 9H).
Example 423




The title compound was prepared in a manner similar to that described in Example 420 using (2-(N-methylsulfamoyl)phenyl)boronic acid in Step A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazole in Step B. MS (ESI): mass calcd. for C20H16FN3O2S, 381.09; m/z found, 382.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 9.35 (s, 1H), 8.06 (s, 1H), 8.05-8.03 (dd, J=8.0, 1.3, 1H), 7.96-7.92 (m, 1H), 7.91-7.86 (m, 1H), 7.72-7.67 (m, 1H), 7.65-7.60 (m, 2H), 7.46-7.43 (dd, J=7.5, 1.4, 1H), 7.38-7.32 (m, 2H), 2.50 (s, 3H).
Example 424




The title compound was prepared in a manner similar to that described in Example 420 using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzo[d]thiazole in Step B. MS (ESI): mass calcd. for C23H21FN2O2S2, 440.10; m/z found, 441.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 9.07 (s, 1H), 8.39-8.35 (m, 1H), 8.24-8.19 (dd, J=8.0, 1.3, 1H), 8.10-8.05 (dd, J=8.4, 0.6, 1H), 7.75-7.69 (m, 1H), 7.65-7.62 (m, 1H), 7.62-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.45-7.42 (dd, J=7.8, 1.8, 1H), 7.41-7.38 (dd, J=4.1, 1.5, 1H), 7.38-7.36 (d, J=1.6, 1H), 3.73 (s, 1H), 1.08 (s, 9H).
Example 425




The title compound was prepared in a manner similar to that described in Example 420 using 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine in Step B. MS (ESI): mass calcd. for C23H22FN3O2S, 423.14; m/z found, 424.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.87-8.81 (m, 1H), 8.77-8.70 (d, J=1.5, 1H), 8.20-8.17 (d, J=3.3, 1H), 8.17-8.12 (dd, J=8.0, 1.3, 1H), 7.78-7.71 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.47-7.44 (dd, J=4.9, 1.5, 1H), 7.44 (s, 1H), 7.43-7.40 (dd, J=7.5, 1.4, 1H), 6.95-6.89 (dd, J=3.2, 0.9, 1H), 1.12 (s, 9H).
Example 426




The title compound was prepared in a manner similar to that described in Example 420 using (2-(N-methylsulfamoyl)phenyl)boronic acid in Step A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine in Step B. MS (ESI): mass calcd. for C20H16FN3O2S, 381.09; m/z found, 382.1 [M+H]4. 1H NMR (500 MHz, CD3OD) δ 8.49 (s, 1H), 8.46-8.37 (m, 1H), 8.13-7.97 (dd, J=7.9, 1.3, 1H), 7.74-7.66 (m, 1H), 7.66-7.57 (m, 2H), 7.57-7.52 (d, J=3.5, 1H), 7.46-7.40 (dd, J=7.7, 1.4, 1H), 7.38-7.30 (m, 2H), 6.72-6.63 (d, J=3.5, 1H), 2.48 (s, 3H).
Example 427




N-(tert-Butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide (37 mg, 0.085 mmol) and 6-bromopyridin-3-amine (22 mg, 0.13 mmol) were added to a 5 mL sealable vial equipped with a stir bar. 1,4-Dioxane (0.2 mL) and 2 M Na2CO3 (0.2 mL) were added. Argon was bubbled through the solvent while it was rapidly stirred for 10 min then Pd(dppf)Cl2.CH2Cl2 (3 mg, 0.004 mmol) was added, and the mixture stirred for 15 hours at 80° Celsius under an argon atmosphere. The reaction was diluted with 2 mL of ethyl acetate and 2 mL of water and the aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na2SO4 and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C21H22FN3O2S, 399.14; m/z found, 400.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.66 (s, 1H), 8.25-8.16 (dd, J=8.0, 1.4, 1H), 7.83-7.76 (dd, J=8.8, 1.7, 1H), 7.77-7.68 (m, 1H), 7.66-7.58 (m, 1H), 7.58-7.48 (m, 2H), 7.46-7.39 (m, 2H), 7.37-7.30 (dd, J=7.4, 1.5, 1H), 4.31 (s, 1H), 1.09 (s, 9H).
Example 428




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromopyrazine-2,3-diamine. MS (ESI): mass calcd. for C20H22FN5O2S, 415.15; m/z found, 416.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.11-8.06 (m, 1H), 7.66 (s, 1H), 7.66-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.40-7.35 (dd, J=7.5, 1.4, 1H), 7.35-7.34 (m, 1H), 7.34-7.31 (dd, J=7.7, 1.6, 1H), 1.07 (s, 9H).
Example 429




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-1H-imidazo[4,5-b]pyrazin-2(3H)-one. MS (ESI): mass calcd. for C21H20FN5O3S, 441.13; m/z found, 442.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.45-8.39 (d, J=1.7, 1H), 8.17-8.10 (m, 1H), 8.06-7.98 (m, 1H), 7.70-7.60 (m, 1H), 7.60-7.52 (m, 1H), 7.42-7.38 (dd, J=7.4, 1.3, 1H), 7.38-7.33 (m, 2H), 1.07 (s, 9H).
Example 430




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-3-fluoropyridin-2-amine. MS (ESI): mass calcd. for C21H21F2N3O2S, 417.13; m/z found, 418.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.16-8.11 (dd, J=8.0, 1.3, 1H), 8.04-7.97 (m, 2H), 7.69-7.62 (m, 1H), 7.61-7.53 (m, 2H), 7.39-7.32 (m, 3H), 1.24-0.86 (s, 9H).
Example 431




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine. MS (ESI): mass calcd. for C23H24FN3O2S, 425.16; m/z found, 426.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.18-8.06 (dd, J=7.9, 1.3, 1H), 7.95-7.85 (m, 1H), 7.76 (s, 1H), 7.68-7.62 (m, 1H), 7.61-7.49 (m, 2H), 7.43-7.30 (m, 3H), 4.03-3.92 (dd, J=8.8, 7.8, 2H), 3.37-3.32 (m, 2H), 1.10 (s, 9H).
Example 432




The title compound was prepared in a manner similar to that described in Example 427 using 6-bromo-3H-imidazo[4,5-b]pyridine. MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 425.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.92 (s, 1H), 8.84-8.74 (m, 1H), 8.40 (s, 1H), 8.21-8.08 (dd, J=8.1, 1.3, 1H), 7.70-7.63 (m, 2H), 7.62-7.55 (m, 1H), 7.46-7.36 (m, 3H), 1.10 (s, 9H).
Example 433




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-3-methoxypyrazin-2-amine. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.18-8.10 (m, 2H), 7.95 (s, 1H), 7.68-7.62 (m, 1H), 7.60-7.54 (m, 1H), 7.40-7.35 (m, 2H), 7.35-7.32 (dd, J=12.9, 1.6, 1H), 4.19 (s, 3H), 1.07 (s, 9H).
Example 434




The title compound was prepared in a manner similar to that described in Example 427 using 3-amino-6-bromopyrazine-2-carbonitrile. MS (ESI): mass calcd. for C21H20FN5O2S, 425.13; m/z found, 426.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.76-8.69 (d, J=2.1, 1H), 8.18-8.10 (dd, J=8.0, 1.3, 1H), 7.96-7.89 (m, 1H), 7.68-7.62 (m, 1H), 7.61-7.53 (m, 1H), 7.40-7.37 (dd, J=7.6, 1.4, 1H), 7.37-7.36 (m, 1H), 7.36-7.33 (dd, J=4.4, 1.6, 1H), 1.07 (s, 9H).
Example 435




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 6-amino-3-(4-bromo-2-fluorophenyl)pyrazine-2-carbonitrile and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C21H20FN5O2S, 425.13; m/z found, 426.1 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.25 (s, 1H), 8.19 (dd, J=8.0, 1.4, 1H), 7.64-7.56 (m, 2H), 7.54-7.49 (m, 1H), 7.47 (dd, J=7.9, 1.7, 1H), 7.40-7.33 (m, 2H), 1.04 (s, 9H).
Example 436




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-amino-5-(4-bromo-2-fluorophenyl)pyridine-4-carbonitrile and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 425.1 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.18 (d, J=7.8, 1H), 8.01 (s, 1H), 7.64-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.46-7.28 (m, 4H), 3.91 (s, 1H), 1.04 (s, 9H).
Example 437




The title compound was prepared using analogous conditions to those described in Example 6 utilizing N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 6-amino-3-bromo-2-cyanopyridine. MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 424.9 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.11-8.04 (d, J=7.9, 1H), 7.71-7.64 (m, 1H), 7.64-7.58 (m, 2H), 7.54-7.48 (m, 1H), 7.45-7.36 (dd, J=19.2, 9.2, 2H), 7.36-7.30 (dd, J=7.9, 1.6, 1H), 6.89-6.83 (d, J=8.7, 1H), 6.83-6.75 (d, J=10.0, 3H), 1.03 (s, 9H).
Example 438




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-thiadiazol-2-amine and 2-bromo-N-(tert-butyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H19FN4O2S2, 406.09; m/z found, 407.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.20-8.10 (m, 2H), 7.69-7.56 (m, 2H), 7.46-7.36 (m, 3H), 1.08 (s, 9H).
Example 439




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-thiadiazol-2-amine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C17H17FN4O3S2, 408.07; m/z found, 409.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.15-8.12 (m, 2H), 7.68 (m, 1H), 7.61 (m, 1H), 7.44-7.38 (m, 3H), 3.42-3.38 (m, 1H), 3.30-3.25 (m, 1H), 3.22-3.18 (m, 1H), 1.02 (d, J=6.6, 3H).
Example 440




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-thiadiazol-2-amine and 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C18H17FN4O4S2, 468.04; m/z found, 469.0 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.19 (m, 1H), 8.15 (dd, J=8.0, 1.1, 1H), 7.76 (m, 1H), 7.67 (m, 1H), 7.45 (dd, J=7.6, 1.2, 1H), 7.39 (dd, J=11.9, 1.4, 1H), 7.36 (dd, J=8.1, 1.6, 1H), 3.42-3.33 (m, 4H), 3.09-3.02 (m, 4H).
Example 441




To a 25 mL round-bottomed flask were added a stirbar, 52 mg (0.13 mmol) 4′-(5-aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide, 27 mg (0.20 mmol) N-chlorosuccinamide, and dry DMF (2.0 mL). The flask was sparged with nitrogen and heated at 60° Celsius for 18 hours before cooling to rt and subjecting the reaction mixture (after syringe filtration) to HPLC purification to give the title compound (29.6 mg, 52%). MS (ESI): mass calcd. for C20H20ClFN4O2S, 434.10; m/z found, 435.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.44 (d, J=2.0, 1H), 8.06 (dd, J=8.1, 1.5, 1H), 7.85 (dd, J=9.4, 6.8, 1H), 7.70-7.64 (m, 1H), 7.64-7.57 (m, 1H), 7.43-7.27 (m, 3H), 7.13 (s, 2H), 6.98 (d, J=3.7, 1H), 1.02 (s, 9H).
Example 442




To a 25 mL round-bottomed flask were added a stirbar, (55 mg, 14 mmol) 4′-(5-aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide (32 mg, 0.18 mmol) NBS, and dry DMF (2.0 mL). The flask was sparged with nitrogen and stirred at rt for 18 hours before subjecting the reaction mixture (after syringe filtration) to HPLC purification to give the title compound (46 mg, 70%). MS (ESI): mass calcd. for C20H20BrFN4O2S, 479.05; m/z found, 479.0 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.45 (d, J=1.8, 1H), 8.06 (dd, J=7.9, 1.4, 1H), 7.88-7.81 (m, 1H), 7.69-7.64 (m, 1H), 7.64-7.58 (m, 1H), 7.37 (dd, J=7.6, 1.4, 1H), 7.35-7.29 (m, 2H), 7.05 (s, 2H), 6.98 (s, 1H), 1.02 (s, 9H).
Example 443




The title compound was prepared using analogous conditions to those described in Example 6 2-(2′-(cyclopropylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and 6-amino-3-bromo-2-cyanopyridine. MS (ESI): mass calcd. for C21H16FN3O2S, 393.09; m/z found, 393.9 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.07 (d, J=7.9, 1H), 7.71-7.64 (m, 1H), 7.64-7.58 (m, 2H), 7.54-7.48 (m, 1H), 7.40 (dd, J=19.2, 9.2, 2H), 7.33 (dd, J=7.9, 1.6, 1H), 6.86 (d, J=8.7, 1H), 6.79 (d, J=10.0, 3H), 1.03 (s, 9H).
Example 444




To a 20 mL vial were added N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide (45 mg, 0.10 mmol), 7-bromo-[1,2,4]triazolo[4,3-a]pyridine (21 mg, 0.10 mmol) K2CO3 (29 mg, 0.21 mmol), Pd(dppf)Cl2.CH2Cl2 (4 mg, 0.005 mmol), and a stir bar. The vial was sealed with a teflon lined cap and the vial sparged with N2. The vial was then charged with freshly sparged DMSO (2 mL) and stirred for 16 hours at 80° Celsius. The reaction mixture was then cooled to rt, filtered, and purified by HPLC to give the title compound (30 mg, 53%). MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 425.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.40 (s, 1H), 8.79 (s, 1H), 8.20-8.11 (m, 2H), 7.77 (m, 1H), 7.70-7.57 (m, 3H), 7.47-7.38 (m, 3H), 1.10 (s, 9H).
Example 445




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-3-methylpyrazin-2-amine. MS (ESI): mass calcd. for C21H23FN4O2S, 414.15; m/z found, 415.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.31-8.24 (m, 1H), 8.17-8.12 (dd, J=8.2, 1.3, 1H), 7.97-7.91 (m, 1H), 7.68-7.61 (m, 1H), 7.59-7.53 (m, 1H), 7.43-7.36 (dd, J=7.5, 1.3, 1H), 7.36-7.28 (m, 2H), 2.59-2.35 (m, 3H), 1.06 (s, 9H).
Example 446




The title compound was prepared by forming 4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide then removing the tert-butyl group by dissolving the crude 4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide in 1 mL of trifluoroacetic acid and heating it to 60° Celsius for 2 hours, after which time the reaction was cooled to rt, concentrated to dryness and purified using FCC. MS (ESI): mass calcd. for C17H15FN4O2S, 358.09; m/z found, 359.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.22 (s, 1H), 8.16-8.10 (dd, J=7.7, 1.3, 1H), 8.03-7.97 (m, 1H), 7.68-7.62 (m, 1H), 7.61-7.54 (m, 1H), 7.41-7.37 (dd, J=7.7, 1.4, 1H), 7.36-7.33 (dd, J=8.0, 1.7, 1H), 7.33-7.29 (dd, J=12.3, 1.6, 1H), 2.66-2.43 (m, 3H).
Example 447




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-1H-imidazo[4,5-b]pyrazine. MS (ESI): mass calcd. for C21H20FN5O2S, 425.13; m/z found, 426.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 9.06-8.88 (d, J=2.1, 1H), 8.80 (s, 1H), 8.18-8.11 (dd, J=8.1, 1.3, 1H), 8.13-8.04 (m, 1H), 7.71-7.64 (m, 1H), 7.63-7.54 (m, 1H), 7.48-7.39 (m, 3H), 1.09 (s, 9H).
Example 448




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromopyridine-2,3-diamine. MS (ESI): mass calcd. for C21H23FN4O2S, 414.15; m/z found, 415.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.18-8.06 (m, 1H), 7.69-7.62 (m, 1H), 7.61-7.56 (m, 1H), 7.56-7.50 (m, 2H), 7.47-7.42 (m, 1H), 7.40-7.30 (m, 3H), 1.104 (s, 9H).
Example 449




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-3-methylpyrazin-2-amine and 3′-fluoro-N-methyl-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 373.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.27 (s, 1H), 8.09-8.00 (d, J=7.9, 1H), 7.96-7.87 (m, 1H), 7.71-7.63 (m, 1H), 7.63-7.55 (m, 1H), 7.44-7.38 (d, J=7.5, 1H), 7.34-7.21 (m, 2H), 2.46 (s, 3H), 2.44 (s, 3H).
Example 450




The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 2-amino-5-bromonicotinonitrile. MS (ESI): mass calcd. for C22H21FN4O2S, 424.14; m/z found, 425.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.49-8.44 (m, 1H), 8.12 (d, J=1.8, 1H), 8.06 (dd, J=7.9, 1.3, 1H), 7.66 (m, 1H), 7.63-7.56 (m, 2H), 7.38 (dd, J=7.5, 1.3, 1H), 7.33 (dd, J=11.9, 1.6, 1H), 7.27 (dd, J=7.9, 1.7, 1H), 7.18 (s, 2H), 6.90 (s, 1H), 1.03 (s, 9H).
Example 451




The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 5-bromo-3-chloropyridin-2-amine. MS (ESI): mass calcd. for C21H21ClFN3O2S, 433.10; m/z found, 434.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.20 (s, 1H), 8.06 (dd, J=7.9, 1.2, 1H), 7.85 (s, 1H), 7.66 (m, 1H), 7.62-7.54 (m, 2H), 7.37 (m, 1H), 7.31 (dd, J=11.9, 1.6, 1H), 7.26 (dd, J=7.9, 1.7, 1H), 6.89 (s, 1H), 6.62 (s, 2H), 1.03 (s, 9H).
Example 452




The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 5-bromo-3-(trifluoromethyl)pyridin-2-amine. MS (ESI): mass calcd. for C22H21F4N3O2S, 467.13; m/z found, 468.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.47 (s, 1H), 8.07 (dd, J=7.9, 1.2, 1H), 7.96 (s, 1H), 7.66 (m, 1H), 7.63-7.55 (m, 2H), 7.38 (dd, J=7.5, 1.3, 1H), 7.33 (dd, J=11.9, 1.6, 1H), 7.27 (dd, J=7.9, 1.7, 1H), 6.88 (s, 1H), 6.76 (s, 2H), 1.02 (s, 9H).
Example 453




The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 5-bromo-4-(trifluoromethyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H20F4N4O2S, 468.12; m/z found, 469.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.45 (s, 1H), 8.07 (dd, J=7.8, 1.4, 1H), 7.67 (m, 1H), 7.62 (m, 1H), 7.53 (s, 2H), 7.45-7.38 (m, 2H), 7.37-7.29 (m, 2H), 6.74 (s, 1H), 1.01 (s, 9H).
Example 454




The title compound was prepared using analogous conditions to those described in Example 1 using N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide and 5-bromo-4-methylpyrimidin-2-amine. MS (ESI): mass calcd. for C21H23FN4O2S, 414.15; m/z found, 415.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.17 (s, 1H), 8.08 (dd, J=8.0, 1.2, 1H), 7.67 (m, 1H), 7.64-7.58 (m, 1H), 7.43-7.38 (m, 2H), 7.36 (dd, J=10.9, 1.6, 1H), 7.30 (dd, J=7.8, 1.7, 1H), 7.13 (s, 2H), 6.86 (s, 1H), 2.25 (d, J=0.8, 3H), 1.00 (s, 9H).
Intermediate HC




Step A: 5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde
Hexamethylenetetramine (1.08 g, 7.61 mmol) was added to a solution of 5-bromo-1H-pyrrolo[2,3-b]pyridine (1 g, 5 mol) in HOAc (6.34 mL). The mixture was heated at 100° Celsius for 6 hours. The reaction mixture was then cooled to rt and diluted with water. The mixture was extracted with EtOAc, dried (Na2SO4), filtered and concentrated to dryness. The residue was purified by FCC to provide the title compound (379 mg, 33%). 1H NMR (500 MHz, CDCl3) δ 10.02 (s, 1H), 8.77 (d, J=2.2, 1H), 8.48 (d, J=2.2, 1H), 7.99 (d, J=2.7, 1H).
Step B
The title compound was prepared using analogous conditions to those described in Example 88 using 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde and 3′-fluoro-N-methyl-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C21H16FN3O3S, 409.09; m/z found, 410.2 [M+H]+.
Intermediate HD




The title compound was prepared using analogous conditions to those described in Example 88 using 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde and N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C24H22FN3O3S, 451.14; m/z found, 452.2 [M+H]+.
Intermediate HE




The title compound was prepared using analogous conditions to those described in Example 88 using 5-bromo-7-nitroindole and N-(tert-butyl)-3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-sulfonamide. 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 8.27-8.18 (m, 2H), 7.65-7.58 (m, 2H), 7.58-7.50 (m, 1H), 7.50-7.35 (m, 4H), 6.83-6.77 (m, 1H), 1.17-1.03 (m, 9H).
Example 455




The title compound was prepared using similar methods to those described in Example 457 using N-(tert-butyl)-3′-fluoro-4′-(3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-[1,1′-biphenyl]-2-sulfonamide. MS (ESI): mass calcd. for C24H24FN3O3S, 453.15; m/z found, 454.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 8.26-8.20 (m, 2H), 7.63-7.58 (m, 1H), 7.56-7.48 (m, 3H), 7.44-7.39 (m, 1H), 7.39-7.34 (m, 3H), 4.92 (s, 2H), 1.11 (d, J=12.1, 9H).
Example 456




The title compound was prepared in a manner similar to that described in Example 571 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-indol-7-amine and 2-bromo-N-(1-(hydroxymethyl)-cyclopentyl)benzenesulfonamide in Step B. MS (ESI): mass calcd. for C26H26FN3O3S, 479.17; m/z found, 480.3 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.18 (dd, J=8.1, 1.4, 1H), 8.13 (s, 1H), 7.65-7.50 (m, 3H), 7.42 (s, 1H), 7.41-7.31 (m, 3H), 6.87 (m, 1H), 6.61 (dd, J=3.1, 2.0, 1H), 4.05 (s, 1H), 3.48 (s, 2H), 1.50-1.34 (m, 4H), 1.37-1.22 (m, 2H), 0.93-0.73 (m, 2H).
Example 457




NaBH4 (4.45 mg, 0.13 mmol) was added to 3′-fluoro-4′-(3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide (18 mg, 0.044 mmol) in MeOH (0.52 mL). The mixture was stirred at rt for 1 h and then concentrated to dryness. The residue was subjected to FCC purification to give the title compound. MS (ESI): mass calcd. for C21H18FN3O3S, 411.11; m/z found, 412.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 9.36 (s, 1H), 8.34 (s, 1H), 8.23 (dd, J=7.9, 1.2, 1H), 8.12 (s, 1H), 7.68-7.61 (m, 1H), 7.61-7.54 (m, 1H), 7.42-7.30 (m, 5H), 5.21 (s, 1H), 4.88 (s, 2H), 2.52 (dd, J=13.9, 5.3, 3H).
Example 458




Zn dust (123 mg, 1.88 mmol) was added to a solution of N-(tert-butyl)-3′-fluoro-4′-(7-nitro-1H-indol-5-yl)-[1,1′-biphenyl]-2-sulfonamide (23 mg, 0.19 mmol) and NH4Cl (101 mg, 1.88 mmol) in water (0.75 mL) and acetone (3.76 mL). The mixture was stirred at rt for 1 hour and then filtered through Celite. The resulting filtrate was concentrated to dryness and then taken up in water and extracted with EtOAc. The organic extract was dried (Na2SO4), filtered and concentrated to dryness to give the title compound (23 mg, 28%). MS (ESI): mass calcd. for C24H24FN3O2S, 437.16: m/z found, 438.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.20 (dd, J=8.0, 1.3, 1H), 8.17-8.10 (m, 1H), 7.63-7.56 (m, 2H), 7.54-7.48 (m, 1H), 7.42 (s, 1H), 7.38 (dd, J=7.8, 1.7, 2H), 7.32 (dd, J=11.4, 1.8, 1H), 6.86 (m, 1H), 6.62 (dd, J=3.2, 2.0, 1H), 3.78-3.68 (m, 2H), 1.05 (s, 9H).
Example 459




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl)acetamide. MS (ESI): mass calcd. for C18H15FN4O, 322.12; m/z found, 322.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1H), 8.38 (s, 1H), 8.02 (s, 1H), 7.91 (m, 1H), 7.53-7.21 (m, 6H), 6.73 (s, 2H), 1.92 (s, 3H).
Example 460




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)urea. MS (ESI): mass calcd. for C17H14FN5O, 323.12; m/z found, 323.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.02 (s, 1H), 7.95 (m, 1H), 7.86 (d, J=8.9, 1H), 7.56 (s, 1H), 7.36-7.19 (m, 4H), 7.08 (m, 1H), 6.73 (s, 2H), 6.01 (s, 2H).
Intermediate HF




A mixture of (4-bromo-2,3-difluorophenyl)boronic acid (400 mg, 1.69 mmol) and 5-bromopyrazin-2-amine (588 mg, 3.38 mmol was suspended in EtOH (5.6 ml) and toluene (5.7 mL) The resulting mixture was treated with aqueous Na2CO3 (2.0 N, 4.2 mL, 8.45 mmol). The resulting mixture was then sparged with nitrogen through the mixture for 10 min, and then Pd(PPh3)4 (98 mg, 0.085 mmol) was added. The reaction vessel was sealed and heated at 80° Celsius for 17 hours. The reaction mixture was cooled to rt and then partitioned between saturated aqueous NH4Cl and EtOAc. The organic layer was dried over MgSO4 and concentrated to dryness. The residue was suspended in DCM and the solid isolated by filtration to afford the title compound (160 mg, 33%), which was used without further purification. MS (ESI): mass calcd. for C10H6BrF2N3. 284.97; m/z found, 286.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.01 (d, J=1.2, 1H), 7.68-7.56 (m, 2H), 6.87 (s, 2H).
Example 461




Nitrogen sparged DMSO (0.73 ml) was added to a mixture of 5-(4-bromo-2,3-difluorophenyl)pyrazin-2-amine (50 mg, 0.18 mmol), (2-(methylsulfonyl)phenyl)boronic acid (35 mg, 0.18 mmol), K2CO3 (73 mg, 0.532 mmol) and PdCl2(dppf).CH2Cl2 (13 mg, 0.018 mmol) and heated at 80° Celsius for 2.5 hours. The mixture was cooled to rt and partitioned between sat. NaHCO3 and EtOAc. The organic layer was isolated, dried over MgSO4, and concentrated to dryness. Purification by FCC afforded the title compound (26 mg, 41%). MS (ESI): mass calcd. for C17H13F2N3O2S, 361.07; m/z found, 362.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.44-8.41 (m, 1H), 8.14 (dd, J=7.9, 1.4, 1H), 8.04 (d, J=1.5, 1H), 7.84 (m, 1H), 7.78 (m, 1H), 7.75-7.66 (m, 1H), 7.53 (dd, J=7.5, 1.3, 1H), 7.30 (dd, J=11.6, 4.9, 1H), 6.85 (s, 2H), 3.06 (s, 3H).
Example 462




The title compound was prepared by methods analogous to Example 461 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C20H20F2N4O2S, 418.13; m/z found, 419.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.36 (s, 1H), 8.25 (dd, J=7.9, 1.3, 1H), 7.94 (d, J=1.4, 1H), 7.71-7.66 (m, 1H), 7.60 (m, 1H), 7.55 (m, 1H), 7.34 (dd, J=7.4, 1.1, 1H), 7.33-7.28 (m, 1H), 5.47 (s, 1H), 5.19 (s, 2H), 1.20 (s, 9H).
Example 463




Step A: 5-(4-chloro-2-fluoro-3-methylphenyl)pyrazin-2-amine
The title compound was prepared by methods analogous to Intermediate HF using (4-chloro-2-fluoro-3-methylphenyl)boronic acid. MS (ESI): mass calcd. for C11H9ClFN3, 237.05; m/z found, 238.0 [M+H]+.
Step B
To a mixture of 5-(4-chloro-2-fluoro-3-methylphenyl)pyrazin-2-amine (75 mg, 0.32 mmol), (2-(methylsulfonamido)phenyl)boronic acid (85 mg, 0.39 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (5.0 mg, 0.006 mmol) in a sealed tube flushed with N2 were added N2 sparged K3PO4 (1.26 ml, 0.5 N) followed by N2 sparged THF (0.63 ml). The reaction mixture was stirred at rt for 18 hours. The reaction mixture was then partitioned between EtOAc and brine. The organic layer was isolated, dried over MgSO4, filtered and concentrated to dryness. Purification by FCC afforded the title compound (100 mg, 85%). MS (ESI): mass calcd. for C18H17FN4O2S, 372.10; m/z found, 373.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.81 (s, 1H), 8.39-8.35 (m, 1H), 8.02 (d, J=1.5, 1H), 7.70 (m, 1H), 7.47 (dd, J=8.1, 1.0, 1H), 7.45-7.39 (m, 1H), 7.29 (m, 1H), 7.21 (dd, J=7.6, 1.5, 1H), 7.07 (d, J=8.0, 1H), 6.67 (s, 2H), 2.87 (s, 3H), 2.01 (d, J=2.5, 3H).
Example 464




A suspension of 4′-(5-aminopyrazin-2-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-sulfonamide (168 mg, 0.40 mmol) in TFA (3 mL) was heated at 50° Celsius for 3 hours. The reaction was then cooled to rt and carefully partitioned between NaHCO3 and EtOAc. The organic layer was isolated, dried over MgSO4, and concentrated to dryness. Purification by FCC afforded the title compound (140 mg, 96%). MS (ESI): mass calcd. for C16H12F2N4O2S, 362.06; m/z found, 363.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.12-8.01 (m, 2H), 7.72-7.61 (m, 3H), 7.45-7.36 (m, 3H), 7.19 (m, 1H), 6.81 (s, 2H).
Intermediate HG




The title compound was prepared using analogous conditions to those described in 5-(4-chloro-2-fluorophenyl)pyrazin-2-amine using (4-bromo-2,3-difluorophenyl)boronic acid and 5-bromopyrimidin-2-amine. MS (ESI): mass calcd. for C10H6BrF2N3, 284.97; m/z found, 286.0 [M+H]+.
Example 465




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(4-bromo-2,3-difluorophenyl)pyrimidin-2-amine and (2-(N-methylsulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C17H14F2N4O2S, 376.08; m/z found, 377.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.56 (s, 2H), 7.98 (dd, J=7.7, 1.6, 1H), 7.72 (m, 2H), 7.45 (dd, J=7.3, 1.6, 1H), 7.41 (m, 1H), 7.35 (m, 1H), 7.19 (m, 1H), 7.12 (s, 2H), 2.40 (d, J=4.9, 3H).
Example 466




The title compound was prepared using analogous conditions to those described in Example 1 using 5-(4-bromo-2,3-difluorophenyl)pyrimidin-2-amine and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C20H20F2N4O2S, 418.13; m/z found, 419.1 [M+H]+. 1H NMR (600 MHz, CD3OD) δ 8.63 (d, J=0.9, 2H), 8.15 (dd, J=7.9, 1.2, 1H), 7.67 (m, 1H), 7.63-7.58 (m, 1H), 7.38 (dd, J=7.5, 1.3, 1H), 7.35-7.29 (m, 1H), 7.27-7.18 (m, 1H), 1.13 (s, 9H).
Example 467




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-fluoro-4-(trifluoromethoxy)bromobenzene. MS (ESI): mass calcd. for C17H10F5N3O, 367.07; m/z found, 368.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.03-7.96 (m, 2H), 7.78 (m, 1H), 7.56-7.49 (m, 3H), 7.37 (d, J=8.2, 1H), 6.75 (s, 2H).
Example 468




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromofluorobenzene. MS (ESI): mass calcd. for C16H11F2N3, 283.09; m/z found, 284.1 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.63-8.54 (m, 1H), 8.13 (d, J=1.4, 1H), 8.00 (m, 1H), 7.52-7.31 (m, 4H), 7.24-7.12 (m, 2H), 4.72 (s, 2H).
Example 469




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromochlorobenzene. MS (ESI): mass calcd. for C16H11ClFN3, 299.06; m/z found, 300.1 [M+H]+. 1H NMR (600 MHz, CDCl3) δ 8.60 (s, 1H), 8.12 (s, 1H), 7.98 (m, 1H), 7.54-7.44 (m, 1H), 7.41-7.23 (m, 5H), 4.68 (s, 2H).
Example 470




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromotoluene. MS (ESI): mass calcd. for C17H14FN3, 279.12; m/z found, 280.1 [M+H]+. 1H NMR (400 MHz, CDCl3) 8.59 (s, 1H), 8.12 (s, 1H), 7.95 (m, 1H), 7.28-7.12 (m, 6H), 4.66 (s, 2H), 2.32 (s, 3H).
Example 471




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-fluoro-4-(trifluoromethyl)bromobenzene. MS (ESI): mass calcd. for C17H10F5N3, 351.08; m/z found, 351.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.11-7.97 (m, 2H), 7.90-7.83 (m, 2H), 7.71 (d, J=8.1, 1H), 7.61-7.54 (m, 2H), 6.78 (s, 2H).
Example 472




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-trifluoromethylbromobenzene. MS (ESI): mass calcd. for C17H11F4N3, 333.09; m/z found, 334.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.40 (s, 1H), 8.09 (s, 1H), 7.91 (m, 1H), 7.81 (d, J=7.6, 1H), 7.69 (m, 1H), 7.59 (m, 1H), 7.44 (d, J=7.8, 1H), 7.23 (d, J=8.7, 1H), 7.17 (d, J=11.8, 1H).
Example 473




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-methoxybromobenzene. MS (ESI): mass calcd. for C17H14FN3O, 295.11; m/z found, 296.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 8.08 (s, 1H), 7.85 (m, 1H), 7.45-7.29 (m, 4H), 7.14-7.00 (m, 2H), 3.84 (s, 3H).
Example 474




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-thiomethylbromobenzene. MS (ESI): mass calcd. for C17H14FN3S, 311.09; m/z found, 312.0 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.37 (s, 1H), 8.02 (d, J=1.2, 1H), 7.90 (m, 1H), 7.44-7.32 (m, 2H), 7.30 (s, 1H), 7.27-7.18 (m, 3H), 6.71 (s, 2H), 2.40 (s, 3H).
Example 475




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(trifluoromethoxy)bromobenzene. MS (ESI): mass calcd. for C17H11F4N3O, 349.08; m/z found, 350.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.02 (s, 1H), 7.96 (m, 1H), 7.65-7.47 (m, 4H), 7.42 (d, J=5.1, 1H), 7.39 (s, 1H), 6.73 (s, 2H).
Example 476




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromophenol. MS (ESI): mass calcd. for C16H12FN3O, 281.10; m/z found, 282.0 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 9.72 (s, 1H), 8.36 (s, 1H), 8.01 (d, J=1.4, 1H), 7.87 (m, 1H), 7.49 (dd, J=4.4, 1.3, 1H), 7.45 (s, 1H), 7.34 (dd, J=7.4, 1.3, 1H), 7.19 (m, 1H), 6.95 (d, J=7.3, 1H), 6.89 (m, 1H), 6.68 (s, 2H).
Example 477




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-bromo-2-(phenylsulfonyl)benzene. MS (ESI): mass calcd. for C22H16FN3O2S, 405.09; m/z found, 406.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.29 (dd, J=6.7, 2.5, 1H), 8.03 (d, J=1.4, 1H), 7.80-7.66 (m, 3H), 7.58 (m, 1H), 7.41-7.28 (m, 5H), 6.84 (dd, J=8.0, 1.6, 1H), 6.78-6.66 (m, 3H).
Example 478




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2,6-difluorobromobenzene. MS (ESI): mass calcd. for C16H10F3N3, 301.08; m/z found, 302.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.02 (s, 1H), 7.97 (m, 1H), 7.56-7.47 (m, 1H), 7.43 (d, J=12.5, 1H), 7.37 (d, J=7.9, 1H), 7.25 (m, 2H), 6.76 (s, 2H).
Example 479




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and N-(2-bromophenyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H17FN4O2S, 420.11; m/z found, 421.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.73 (s, 1H), 8.38 (s, 1H), 8.04 (s, 1H), 7.85-7.75 (m, 1H), 7.59-7.46 (m, 5H), 7.29-7.10 (m, 6H), 6.71 (s, 2H).
Example 480




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-ethylbromobenzene. MS (ESI): mass calcd. for C18H16FN3, 293.13; m/z found, 294.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.03 (d, J=1.3, 1H), 7.92 (m, 1H), 7.36 (d, J=3.9, 2H), 7.32-7.19 (m, 4H), 6.71 (s, 2H), 2.60 (q, J=7.5, 2H), 1.06 (t, J=7.5, 3H).
Example 481




Step A: Methyl 2-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)oxy)acetate
To a solution consisting of 4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ol Example 476 (50 mg, 0.18 mmol) and DMF (1 mL) was added Cs2CO3 (116 mg, 0.36 mmol). The mixture was stirred at rt for 30 min. Methyl 2-bromoacetate (30 mg, 0.19 mmol) was added and the resultant mixture stirred at rt for 1 hour and then poured into 15 mL of water. The precipitate was collected and washed with water and air dried to give methyl 2-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)oxy)acetate (50 mg, 72%). MS (ESI): mass calcd. for C19H16FN3O3, 353.12; m/z found, 354.0 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.03 (s, 1H), 7.93 (m, 1H), 7.57 (d, J=13.0, 1H), 7.54 (d, J=9.2, 1H), 7.50 (d, J=7.4, 1H), 7.34 (m, 1H), 7.10-7.02 (m, 2H), 6.70 (s, 2H), 4.89 (s, 2H), 3.71 (s, 3H).
Step B
To a solution of methyl 2-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yloxy)acetate (50 mg, 0.14 mmol) in THF (2 mL) were added LiOH.H2O (63 mg, 1.5 mmol) and H2O (2 mL). The mixture was stirred at rt for 14 hours. The THF was removed under reduced pressure, and the residue diluted with 15 mL of water, washed with DCM (5 mL×2), and then acidified with 1 N HCl to pH=7. The precipitate was collected and washed with water and dried under high vacuum to give the title compound (40 mg, 95% yield). MS (ESI): mass calcd. for C18H14FN3O3, 339.10; m/z found, 340.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 13.02 (s, 1H), 8.36 (s, 1H), 8.01 (s, 1H), 7.88 (m, 1H), 7.55 (d, J=13.0, 1H), 7.48 (d, J=9.2, 1H), 7.40 (d, J=7.4, 1H), 7.33 (m, 1H), 7.08-7.00 (m, 2H), 6.69 (s, 2H), 4.76 (s, 2H).
Example 482




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-isopropylbromobenzene. MS (ESI): mass calcd. for C19H18FN3, 307.15; m/z found, 308.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.91 (m, 1H), 7.49-7.34 (m, 2H), 7.27-7.17 (m, 4H), 6.71 (s, 2H), 3.06-2.97 (m, 1H), 1.14 (d, J=6.8, 6H).
Example 483




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2-acetylphenyl)boronic acid. MS (ESI): mass calcd. for C18H14FN3O, 307.11; m/z found, 307.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.03 (d. J=1.2, 1H), 7.91 (m, 1H), 7.69 (d, J=7.5, 1H), 7.61 (m, 1H), 7.53 (d, J=7.5, 1H), 7.48 (d, J=8.2, 1H), 7.26 (d, J=12.4, 1H), 7.19 (dd, J=8.0, 1.3, 1H), 6.75 (s, 2H), 2.31 (s, 3H).
Example 484




The title compound was prepared using analogous conditions to those described in Example 1 utilizing what 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(2,2,2-trifluoroethoxy)bromobenzene. MS (ESI): mass calcd. for C18H13F4N3O, 363.10; m/z found, 363.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.91 (m, 1H), 7.56-7.34 (m, 4H), 7.25 (d, J=8.0, 1H), 7.16 (m, 1H), 6.71 (s, 2H), 4.82 (q. J=8.8, 2H).
Example 485




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromobenzoic acid. MS (ESI): mass calcd. for C17H12FN3O2, 309.09; m/z found, 310.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.88 (s, 1H), 8.36 (s, 1H), 8.02 (s, 1H), 7.87 (m, 1H), 7.76 (d, J=7.5, 1H), 7.60 (m, 1H), 7.50 (d, J=7.2, 1H), 7.44 (d, J=8.2, 1H), 7.25 (d, J=5.1, 1H), 7.22 (s, 1H), 6.70 (s, 2H).
Example 486




The title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromobenzamide. MS (ESI): mass calcd. for C17H13FN4O, 308.11; m/z found, 309.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.01 (s, 1H), 7.86 (m, 1H), 7.75 (s, 1H), 7.55-7.26 (m, 7H), 6.70 (s, 2H).
Example 487




The title compound was prepared using methods analogous to those described in Example 369 3 using (2-isopropoxyphenyl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C19H18FN3O, 323.14; m/z found, 324.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.63-8.57 (m, 1H), 8.12 (d, J=1.4, 1H), 7.97-7.87 (m, 1H), 7.48-7.42 (m, 1.5H), 7.42-7.34 (m, 1.5H), 7.34-7.28 (m, 1H), 7.07-6.97 (m, 2H), 4.65 (s, 2H), 4.59-4.44 (m, 1H), 1.29 (d, J=6.1, 6H).
Example 488




The title compound was prepared using methods analogous to those described in Example 369 using (2-(cyclopropylmethoxy)pyridin-3-yl)boronic and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C19H17FN4O, 336.14; m/z found, 337.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.64-8.59 (m, 1H), 8.17-8.09 (m, 2H), 8.02-7.93 (m, 1H), 7.72-7.66 (m, 1H), 7.54-7.48 (m, 2H), 7.01-6.95 (m, 1H), 4.67 (s, 2H), 4.24 (d, J=7.0, 2H), 1.37-1.22 (m, 1H), 0.66-0.54 (m, 2H), 0.42-0.31 (m, 2H).
Example 489




The title compound was prepared using methods analogous to those described in Step B of Example 377 using 2-[3,4′-difluoro-2′-(methylthio)-[1,1′-biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. for C19H13F2N3O2S, 385.07; m/z found, 386.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.48 (s, 1H), 8.82 (s, 1H), 8.27 (d, J=8.0, 1H), 8.18-8.09 (m, 1H), 7.77-7.67 (m, 2H), 7.66-7.57 (m, 1H), 7.48-7.36 (m, 2H), 6.89-6.83 (m, 1H), 2.76 (s, 3H).
Example 490




Step A: N-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide
To a solution of 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1 g, 5 mmol) in pyridine (20 mL) was added methanesulfonyl chloride (627 mg, 5.5 mmol) and the mixture stirred at rt for 24 hours. The solvent was then removed under reduced pressure, and the resulting residue redissolved in DCM (200 mL), washed with 1 N HCl (1×100 mL) and 20% NaHCO3 (1×100 mL). The organic layer was then isolated, dried (Na2SO4) and concentrated to dryness. The crude product was purified by crystallization from DCM/hexanes to give the title compound (700 mg, 52%). 1H NMR (400 MHz, CDCl3) δ 8.43 (s, 1H), 7.82-7.77 (m, 1H), 7.59 (d, J=8.2, 1H), 7.51-7.43 (m, 1H), 7.17-7.10 (m, 1H), 2.95 (s, 3H), 1.37 (s, 12H).
Step B: —N-Methyl-N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-methane-sulfonamide
To a round bottom flask under nitrogen were added N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide (250 mg, 0.84 mmol), K2CO3 (140 mg, 1.01 mmol) and acetone (5.0 mL). Iodomethane (0.06 mL, 1 mmol) was then added to the mixture dropwise and the reaction stirred for 18 hours at rt. The reaction was then diluted with ethyl acetate (100 mL), washed with water (2×) and brine (1×), dried (Na2SO4) and concentrated to dryness. The crude product was purified by FCC providing the title compound (230 mg, 88%). 1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J=7.3, 1.8, 1H), 7.51-7.43 (m, 1H), 7.40-7.29 (m, 2H), 3.32 (s, 3H), 2.93 (s, 3H), 1.36 (s, 12H).
Step C
The title compound was prepared using methods analogous to those described in Example 369 using N-methyl-N-(2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 373.1 [M+H]+. 1H NMR (400 MHz, CDCl3) 8.61-8.58 (m, 1H), 8.12 (d, J=1.5, 1H), 7.47-7.39 (m, 5H), 7.37-7.31 (m, 1H), 7.30-7.23 (m, 1H), 4.75 (s, 2H), 3.17 (s, 3H), 2.76 (s, 3H).
Example 491




Step A: N-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide
The title compound was prepared using methods analogous to those described in Step A of Example 490 using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline for 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline and ethanesulfonyl chloride. 1H NMR (400 MHz, CDCl3) δ 8.52 (s, 1H), 7.82-7.74 (m, 1H), 7.64 (d, J=8.3, 1H), 7.49-7.41 (m, 1H), 7.14-7.06 (m, 1H), 3.12 (q, J=7.4, 2H), 1.37 (s, 12H), 1.32 (t, J=7.4, 3H).
Step B
The title compound was prepared using methods analogous to those described in Step C of Example 490 using N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide and 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. for C20H17FN4O2S, 396.11; m/z found, 397.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.16 (s, 1H), 8.78 (d, J=2.6, 1H), 8.20-8.11 (m, 2H), 7.75-7.66 (m, 2H), 7.47-7.37 (m, 1H), 7.36-7.28 (m, 2H), 7.27-7.20 (m, 1H), 6.87-6.79 (m, 1H), 6.59 (s, 1H), 3.11 (q, J=7.4, 2H), 1.33-1.18 (m, 3H).
Example 492




The title compound was prepared using methods analogous to those described in Step C of Example 490 using 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. C20H17FN4O2S, 396.11; m/z found, 397.1 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.69 (d, J=2.6, 1H), 8.05-7.99 (m, 1H), 7.97 (d, J=3.6, 1H), 7.67-7.61 (m, 1H), 7.57-7.48 (m, 3H), 7.46-7.39 (m, 2H), 6.72 (d, J=3.6, 1H), 4.75 (s, 1H), 3.14 (s, 3H), 2.99 (s, 3H).
Example 493




The title compound was prepared using methods analogous to those described in Step C of Example 490 using 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. C21H19FN4O2S, 410.12: m/z found, 411.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 11.04 (s, 1H), 8.77 (d, J=2.7, 1H), 8.13-8.05 (m, 1H), 7.70-7.63 (m, 1H), 7.53-7.42 (m, 4H), 7.40-7.30 (m, 2H), 6.78-6.71 (m, 1H), 3.17 (s, 3H), 2.99-2.88 (m, 2H), 1.27 (t, J=7.4, 3H).
Example 494




The title compound was prepared using methods analogous to those described in Example 369 using N-methyl-N-(2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. C19H19FN4O2S, 386.12; m/z found, 387.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.63-8.57 (m, 1H), 8.13-8.09 (d, J=1.5, 1H), 8.04-7.95 (m, 1H), 7.72-7.62 (m, 0.75H), 7.59-7.51 (m, 0.25H), 7.50-7.39 (m, 3.75H), 7.37-7.32 (m, 1H), 7.31-7.28 (m, 0.25H), 4.69 (s, 2H), 3.16 (s, 3H), 2.89 (q, J=7.4, 2H), 1.25 (t, J=7.4, 3H).
Example 495




Step A: N-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methylpropanesulfonamide
The title compound was prepared using methods analogous to those described in Step B of Example 490 using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline and isobutylsulfonyl chloride. 1H NMR (400 MHz, CDCl3) δ 8.48 (s, 1H), 7.81-7.75 (m, 1H), 7.63-7.58 (m, 1H), 7.49-7.41 (m, 1H), 7.14-7.06 (m, 1H), 2.96 (d, J=10.1, 2H), 2.39-2.19 (m, 1H), 1.37 (s, 12H), 1.11-0.99 (m, 6H).
Step B
The title compound was prepared using methods analogous to those described in Step C of Example 490 using N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isobutylsulfonamide and 2-(4-bromo-2-fluorophenyl)-5H-pyrrolo[2,3-b]pyrazine. MS (ESI): mass calcd. C22H21FN4O2S, 424.14; m/z found, 425.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.09 (s, 1H), 8.78 (d, J=2.6, 1H), 8.20-8.11 (m, 1H), 7.73-7.65 (m, 2H), 7.46-7.37 (m, 1H), 7.34-7.29 (m, 2H), 7.26-7.19 (m, 2H), 6.87-6.79 (m, 1H), 6.59 (s, 1H), 2.97 (d, J=6.6, 2H), 2.31-2.13 (m, 1H), 1.05 (d, J=6.7, 6H).
Example 496




Step A: —N-Ethyl-N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methane-sulfonamide
The title compound was prepared using methods analogous to those described in Step B of Example 490 using iodoethane. 1H NMR (400 MHz, CDCl3) δ 7.87-7.82 (m, 1H), 7.50-7.44 (m, 1H), 7.40-7.31 (m, 2H), 3.72 (q, J=7.1, 2H), 2.93 (s, 3H), 1.35 (s, 12H), 1.21-1.10 (m, 3H).
Step B
The title compound was prepared using methods analogous to those described in Step B of Example 369 by using N-ethyl-N-(2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine. MS (ESI): mass calcd. C19H19FN4O2S.C2HF3O2, 386.12; m/z found, 387.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.44 (d, J=1.2, 1H), 8.33 (d, J=1.2, 1H), 8.14-8.04 (m, 1H), 7.51-7.33 (m, 6H), 3.46 (s, 2H), 2.95 (s, 3H), 1.05 (t, J=7.2, 3H).
Example 497




Step A: —N-Methyl-N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methylpropanesulfonamide
The title compound was prepared using methods analogous to those described in Step B of Example 490 using N-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methylpropanesulfonamide. 1H NMR (400 MHz, CDCl3) δ 7.83-7.78 (m, 1H), 7.49-7.43 (m, 1H), 7.38-7.29 (m, 2H), 3.30 (s, 3H), 2.97-2.91 (m, 2H), 2.38-2.23 (m, 1H), 1.36 (s, 12H), 1.12-1.04 (m, 6H).
Step B
The title compound was prepared using methods analogous to those described in Step B of Example 369 using N-methyl-N-(2-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-methylpropanesulfonamide and 5-(4-bromo-2-fluoro-phenyl)pyrazin-2-amine yielding the title compound after purification by HPLC (32 mg, 41%). MS (ESI): mass calcd. C21H23FN4O2S, 414.15; m/z found, 415.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.59 (s, 1H), 8.11 (d, J=1.3, 1H), 8.04-7.94 (m, 1H), 7.47-7.37 (m, 4H), 7.36-7.31 (m, 1H), 7.30-7.24 (m, 1H), 4.69 (s, 2H), 3.13 (s, 3H), 2.70 (d, J=6.6, 2H), 2.26-2.11 (m, 1H), 1.00 (d, J=6.7, 6H).
Example 498




The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and (2-bromophenyl)(morpholino)methanone. MS (ESI): mass calcd. for C24H20FN3O2, 401.15; m/z found, 402.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.16 (s, 1H), 8.58-8.48 (m, 1H), 8.21-8.13 (m, 1H), 7.61-7.30 (m, 8H), 6.63-6.57 (m, 1H), 3.78-3.56 (m, 3H), 3.48-3.33 (m, 2H), 3.14-3.00 (m, 1H), 2.94-2.75 (m, 2H).
Example 499




The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (2-bromophenyl)(morpholino)methanone. MS (ESI): mass calcd. for C21H19FN4O2, 378.15; m/z found, 379.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.56 (d, J=1.4, 2H), 7.54-7.41 (m, 5H), 7.36 (dd. J=8.0, 1.8, 1H), 7.32 (dd, J=11.5, 1.8, 1H), 5.20 (s, 2H), 3.74-3.58 (m, 3H), 3.49-3.30 (m, 2H), 3.15-3.01 (m, 1H), 2.94-2.77 (m, 2H).
Example 500




The title compound was prepared using methods analogous to those described in Example 369 using (2-bromophenyl)(morpholino)methanone. MS (ESI): mass calcd. for C23H19FN4O2, 402.15; m/z found, 403.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.12 (s, 1H), 8.82 (d, J=2.5, 1H), 8.19-8.09 (m, 1H), 7.71-7.65 (m, 1H), 7.55-7.34 (m, 6H), 6.87-6.80 (m, 1H), 3.74-3.57 (m, 3H), 3.51-3.30 (m, 2H), 3.15-3.01 (m, 1H), 2.97-2.77 (m, 2H).
Example 501




The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N-(tert-butyl)benzamide. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.55-8.50 (m, 1H), 8.13 (d, J=1.4, 1H), 8.04-7.95 (m, 1H), 7.64-7.58 (m, 1H), 7.51-7.44 (m, 1H), 7.43-7.37 (m, 2H), 7.36-7.31 (m, 1H), 7.29-7.22 (m, 1H), 5.69 (s, 1H), 5.45 (s, 2H), 2.65-2.54 (m, 1H), 1.24 (m, 9H).
Example 502




The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromo-N-(tert-butyl)-5-fluorobenzamide. MS (ESI): mass calcd. for C21H20F2N4O, 382.16; m/z found, 383.2 [M+H]+.
Example 503




The title compound was prepared using methods analogous to those described in Example 369 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-bromo-N,N-diethylbenzamide. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.59-8.54 (m, 1H), 8.11 (d, J=1.5, 1H), 8.00-7.90 (m, 1H), 7.50-7.36 (m, 5H), 7.36-7.29 (m, 1H), 4.69 (s, 2H), 3.87-3.69 (m, 1H), 3.17-2.92 (m, 2H), 2.85-2.66 (m, 1H), 0.99 (t, J=7.1, 3H), 0.81 (t, J=7.1, 3H).
Example 504




Step A: Methyl 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylate
A mixture of methyl 2-bromobenzoate (155 mg, 0.72 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (250 mg, 0.79 mmol), Pd(dppf)Cl2.CH2Cl2 (31 mg, 0.036 mmol) and K2CO3 (2 mL, 2 N) in 1,4-dioxane (10 mL) was stirred at 60° Celsius under N2 for 3 hours. The solvent was removed and the crude product was purified by FCC to afford the desired product (218 mg, 93%). MS (ESI): mass calcd. for C18H14FN3O2, 323.11; m/z found, 323.9 [M+H]+.
Step B: 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid
A solution of methyl 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylate (218 mg, 0.67 mmol) in NaOH (8 mL, 2 N) and THF (8 mL) was stirred at 80° Celsius for 48 hours, and then concentrated to dryness. The residue was acidified with 2 N HCl. The precipitate was collected by filtration and washed with water several times, and dried in vacuo to afford the desired product (220 mg, 106%). The crude product was used without further purification. MS (ESI): mass calcd. for C17H12FN3O2, 309.09; m/z found, 309.9 [M+H]+.
Step C:
To a solution of DIPEA (47 mg, 0.36 mmol) in DMF (2 mL) were added 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid (75 mg, 0.24 mmol), (S)-1,1,1-trifluoropropan-2-amine (30 mg, 0.27 mmol) and HATU (110 mg, 0.290 mmol). The reaction mixture was stirred at rt overnight. The solvent was removed and the residue was purified by FCC to afford the title compound (41 mg, 41%). MS (ESI): mass calcd. for C20H16F4N4O, 404.13; m/z found, 404.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.87 (d, J=8.9, 1H), 8.44 (d, J=1.4, 2H), 7.58-7.50 (m, 2H), 7.49-7.40 (m, 3H), 7.26-7.19 (m, 2H), 6.86 (s, 2H), 4.60 (dd, J=15.7, 7.8, 1H), 1.15 (d, J=7.0, 3H).
Example 505




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid. MS (ESI): mass calcd. for C20H16F4N4O, 404.13; m/z found, 405.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.91 (d, J=8.9, 1H), 8.46-8.28 (m, 1H), 8.01 (d, J=1.4, 1H), 7.90-7.80 (m, 1H), 7.57-7.52 (m, 1H), 7.50-7.41 (m, 3H), 7.28-7.20 (m, 2H), 6.69 (s, 2H), 4.66-4.57 (m, 1H), 1.16 (d, J=7.0, 3H).
Example 506




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and piperazine. MS (ESI): mass calcd. for C21H20FN5O, 377.17; m/z found, 378.2 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.64-8.56 (m, 1H), 8.11 (d, J=1.5, 1H), 8.04-7.93 (m, 1H), 7.53-7.40 (m, 4H), 7.37 (dd, J=8.1, 1.8, 1H), 7.30 (dd, J=12.2, 1.7, 1H), 4.77 (s, 2H), 3.72 (d, J=25.1, 2H), 3.14 (s, 1H), 2.92 (s, 2H), 2.65 (s, 2H), 2.05 (s, 1H).
Example 507




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid for and 1-(piperazin-1-yl)ethanone. MS (ESI): mass calcd. for C23H22FN5O2, 419.18; m/z found, 420.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.65-8.56 (m, 1H), 8.11 (d, J=1.5, 1H), 8.02 (dd, J=10.4, 5.8, 1H), 7.55-7.41 (m, 4H), 7.42-7.32 (m, 1H), 7.34-7.28 (m, 1H), 4.71 (s, 2H), 3.65 (s, 2H), 3.51-2.93 (m, 4H), 2.79 (s, 2H), 1.99 (d, 3H).
Example 508




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and cyclohexanamine. MS (ESI): mass calcd. for C23H23FN4O, 390.19; m/z found, 391.4 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.60-8.53 (m, 1H), 8.11 (d, J=1.5, 1H), 8.03-7.93 (m, 1H), 7.74-7.62 (m, 1H), 7.54-7.37 (m, 3H), 7.32 (dd, J=8.0, 1.7, 1H), 7.30-7.20 (m, 1H), 5.24 (d, J=8.3, 1H), 4.72 (s, 2H), 3.93-3.73 (m, 1H), 1.78-1.67 (m, 2H), 1.61-1.44 (m, 3H), 1.39-1.27 (m, 2H), 1.14-0.98 (m, 1H), 0.97-0.81 (m, 2H).
Example 509




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C21H19FN4O3S, 426.12; m/z found, 427.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.60 (s, 1H), 8.11 (s, 1H), 8.11-8.02 (m, 1H), 7.58-7.47 (m, 3H), 7.43 (d, J=7.5, 1H), 7.37 (dd, J=8.1, 1.8, 1H), 7.32 (dd, J=12.1, 1.7, 1H), 4.74 (s, 2H), 4.23 (s, 1H), 4.05 (s, 1H), 3.57-3.48 (m, 1H), 3.38 (s, 1H), 3.01 (s, 1H), 2.85 (s, 1H), 2.62 (s, 1H), 2.05 (s, 1H).
Example 510




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and methylamine. MS (ESI): mass calcd. for C18H15FN4O, 322.12; m/z found, 323.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (dd, J=2.3, 1.6, 1H), 8.15 (d, J=4.7, 1H), 8.00 (d, J=1.5, 1H), 7.84 (d, J=8.1, 1H), 7.52-7.41 (m, 4H), 7.27 (s, 1H), 7.24 (dd, J=5.5, 1.7, 1H), 6.68 (s, 2H), 2.59 (d, J=4.6, 3H).
Example 511




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and (R)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C20H16F4N4O, 404.13: m/z found, 405.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.91 (d, J=8.8, 1H) 8.34 (s, 1H), 8.01 (d, J=1.2, 1H), 7.90-7.80 (m, 1H), 7.58-7.40 (m, 4H), 7.29-7.18 (m, 2H), 6.69 (s, 2H), 4.68-4.56 (m, 1H), 1.16 (d, J=7.0, 3H).
Example 512




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and (R)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C20H19FN4O2, 366.15; m/z found, 367.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.15-7.97 (m, 2H), 7.94-7.82 (m, 1H), 7.55-7.39 (m, 4H), 7.37-7.26 (m, 2H), 6.71 (s, 2H), 4.64 (s, 1H), 3.92-3.73 (m, 1H), 3.26-3.10 (m, 2H), 0.98 (d, J=6.1, 3H).
Example 513




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and (S)-2-aminopropan-1-ol for (S)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C20H19FN4O2, 366.15; m/z found, 367.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.05 (d, J=5.1, 2H), 7.93-7.83 (m, 1H), 7.54-7.43 (m, 3H), 7.37-7.28 (m, 2H), 6.72 (s, 2H), 4.66 (t, J=5.6, 1H), 3.82 (d, J=7.0, 1H), 3.35 (s, 1H), 3.16 (d, J=10.4, 2H), 0.98 (d, J=6.6, 3H).
Example 514




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and piperidin-4-ol. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.1 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.54 (d, J=13.9), 8.11-8.05 (m), 7.98-7.83 (m), 7.47-7.27 (m), 6.72 (s), 4.68 (s), 4.24-4.05 (m), 3.76-3.53 (m), 3.27-3.18 (m), 2.91-2.80 (m), 2.62-2.51 (m), 1.82 (m), 1.69 (m), 1.51-1.45 (m), 1.26-1.18 (m), 0.48-0.41 (m).
Example 515




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-carboxylic acid and piperidin-4-amine. MS (ESI): mass calcd. for C22H22FN5O, 391.18; m/z found, 392.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.99 (s, 1H), 7.88 (s, 1H), 7.48 (d, J=14.8, 3H), 7.35-7.20 (m, 3H), 6.69 (s, 2H), 4.31 (s, 1H), 3.08-2.50 (m, 6H), 1.75 (t, J=80.9, 2H), 1.38-0.86 (m, 2H).
Example 516




The title compound was prepared using methods analogous to those described in Step C of Example 504 using thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C21H19FN4O3S, 426.12; m/z found, 426.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.43 (s, 2H), 7.63 (s, 1H), 7.52 (d, J=20.5, 4H), 7.30 (dd, J=16.9, 9.9, 2H), 6.89 (s, 2H), 3.97 (s, 1H), 3.84 (s, 1H), 3.46 (s, 1H), 3.32 (s, 1H), 3.02 (s, 1H), 2.85 (s, 1H), 2.47 (s, 1H), 2.11 (s, 1H).
Example 517




The title compound was prepared using methods analogous to those described in Step C of Example 504 using (S)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C20H19FN4O2, 366.15; m/z found, 366.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (s, 2H), 8.00 (d, J=8.1, 1H), 7.62-7.50 (m, 1H), 7.48 (d, J=4.1, 1H), 7.43 (d, J=7.3, 3H), 7.34-7.23 (m, 2H), 6.88 (s, 2H), 4.61 (s, 1H), 3.87-3.75 (m, 1H), 3.38 (s, 1H), 3.14 (s, 1H), 0.96 (d, J=6.6, 3H).
Example 518




The title compound was prepared using methods analogous to those described in Step C of Example 504 using (R)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C20H16F4N4O, 404.13; m/z found, 404.9 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.52 (d, J=1.0, 2H), 7.68 (dd, J=7.6, 1.4, 1H), 7.60-7.49 (m, 1H), 7.48-7.38 (m, 3H), 7.28-7.25 (m, 1H), 7.22 (dd, J=11.1, 1.7, 1H), 5.39 (d, J=9.6, 1H), 5.18 (s, 2H), 4.73 (m, 1H), 1.12 (d, J=7.0, 3H).
Example 519




The title compound was prepared using methods analogous to those described in Step C of Example 504 using 4′-(2-aminopyrazin-5-yl)-3′-fluoro-[1, l-biphenyl]-2-carboxylic acid and piperazin-2-one. MS (ESI): mass calcd. for C21H18FN5O2, 391.14; m/z found, 392.1 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.58-8.55 (m), 8.50-8.40 (m), 8.10 (d, J=1.5), 8.04-7.98 (m), 7.56-7.41 (m), 7.37-7.27 (m), 6.75 (s), 6.43 (s), 5.06 (s), 4.83 (s), 4.45 (d, J=19.2), 4.05-3.95 (m), 3.72-3.46 (m), 3.27 (s), 3.14 (s), 2.97 (s), 2.67 (s).
Example 520




The title compound was prepared using methods analogous to those described in Step C of Example 504 using piperazin-2-one. MS (ESI): mass calcd. for C21H18FN5O2, 391.14; m/z found, 391.9 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.47 (d, J=1.2), 8.41 (d, J=1.2), 7.49-7.34 (m), 7.29-7.19 (m), 6.68 (s), 6.35 (s), 5.45 (s), 5.25 (s), 4.38 (d, J=18.7), 4.03 (s), 3.59-3.50 (m), 3.31-2.88 (m), 2.64 (s).
Intermediate HH




2-Bromo-5-(trifluoromethyl)benzoic acid (200 mg, 0.74 mmol) was dissolved in DMF (4.65 mL) and HATU (424 mg, 1.12 mmol) added to the resultant mixture at rt. The solution was stirred for 10 min then treated with N,N-diisopropylethylamine (0.51 mL, 3.0 mmol) and morpholine (0.096 mL, 1.1 mmol). The reaction was stirred for 15 hours then quenched by the addition of saturated NH4Cl (5 mL) and EtOAc (5 mL). The aqueous phase was extracted with ethyl acetate (3×10 mL) and the combined organic extracts washed with brine, dried over Na2SO4 and concentrated to dryness. The crude product was purified by FCC to give the title compound. 1H NMR (500 MHz, CDCl3) δ 7.76-7.71 (m, 1H), 7.55-7.49 (m, 2H), 3.92-3.86 (m, 1H), 3.83-3.69 (m, 4H), 3.66-3.58 (m, 1H), 3.32-3.24 (m, 1H), 3.25-3.17 (m, 1H).
Example 521




The title compound was prepared in a manner similar to that described in Example 88 using (2-bromo-5-(trifluoromethyl)phenyl)(morpholino)-methanone. MS (ESI): mass calcd. for C22H18F4N4O2, 446.14; m/z found, 447.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40 (s, 1H), 8.18 (s, 1H), 8.10-8.01 (m, 1H), 7.90-7.82 (d, J=7.9, 1H), 7.78-7.69 (m, 2H), 7.47-7.35 (m, 2H), 3.72-3.60 (dd, J=10.0, 4.2, 2H), 3.58-3.49 (m, 1H), 3.44-3.36 (m, 1H), 3.15-3.04 (m, 1H), 2.90-2.80 (dd, J=13.4, 5.2, 1H), 2.80-2.72 (m, 1H).
Example 522




The title compound was prepared in a manner similar to that described in Example 88 using (2-bromo-5-(trifluoromethyl)phenyl)(morpholino)methanone and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H18F4N4O2, 446.14; m/z found, 447.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.65-8.58 (d, J=1.3, 2H), 7.91-7.85 (dd, J=8.3, 1.9, 1H), 7.78-7.76 (m, 1H), 7.76-7.73 (d, J=8.1, 1H), 7.71-7.63 (m, 1H), 7.46-7.43 (dd, J=2.7, 1.8, 1H), 7.43-7.41 (dd, J=6.2, 1.7, 1H), 3.72-3.60 (m, 2H), 3.60-3.52 (m, 1H), 3.46-3.39 (m, 1H), 3.37-3.33 (m, 1H), 3.16-3.09 (m, 1H), 2.92-2.77 (m, 2H).
Example 523




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 4-(2-bromophenoxy)pyrimidin-2-amine. MS (ESI): mass calcd. for C23H16FN5O, 397.13; m/z found, 398.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.30 (s, 1H), 8.55-8.45 (m, 1H), 8.18-8.08 (m, 1H), 8.07 (d, J=5.7, 1H), 7.55-7.28 (m, 8H), 7.22 (dd, J=8.0, 1.4, 1H), 6.08 (d, J=5.7, 1H), 4.95 (s, 2H).
Example 524




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 2-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C23H16FN5O, 397.13; m/z found, 398.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.94 (s, 1H), 8.47 (s, 1H), 8.11 (d, J=2.1, 1H), 7.96 (d, J=5.7, 1H), 7.54-7.30 (m, 9H), 6.07 (d, J=5.7, 1H), 4.96-4.85 (m, 2H).
Example 525




The title compound was prepared using methods analogous to those described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 2-(2-bromophenoxy)pyrimidine. MS (ESI): mass calcd. for C23H15FN4O, 382.12: m/z found, 383.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.24 (s, 1H), 8.51-8.42 (m, 3H), 8.14-8.05 (m, 1H), 7.57-7.28 (m, 8H), 6.99-6.89 (m, 1H), 6.55 (dd, J=3.6, 1.8, 1H).
Intermediate HI




To a 48 mL pressure tube containing a stirbar were added 2-chloropyrimidine (1.69 g, 14.7 mmol), 2-bromophenol (1.63 mL, 14.0 mmol), Cs2CO3 (5.49 g, 16.8 mmol) and DMSO (30 mL). The vial was sealed and heated at 120° Celsius for 15 hours. The reaction was then diluted with 100 mL of ethyl acetate and extracted with brine (2×50 mL). The organic layer was isolated, dried and concentrated to dryness to provide the crude product which was subsequently purified FCC to provide the title compound. 1H NMR (500 MHz, CDCl3) δ 8.57 (s, 1H), 8.56 (s, 1H), 7.72-7.60 (dd, J=8.0, 1.6, 1H), 7.45-7.34 (m, 1H), 7.32-7.23 (m, 1H), 7.23-7.11 (m, 1H), 7.10-7.01 (t, J=4.8, 1H).
Intermediate HJ




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloropyrimidin-4-amine. 1H NMR (500 MHz, CDCl3) δ 8.04-7.94 (d, J=5.7, 1H), 7.66-7.58 (dd, J=8.0, 1.5, 1H), 7.41-7.30 (m, 1H), 7.30-7.20 (m, 1H), 7.18-7.05 (m, 1H), 6.20-6.09 (d, J=5.7, 1H), 5.19 (s, 2H).
Intermediate HK




The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloropyrimidin-2-amine. 1H NMR (500 MHz, CDCl3) δ 8.15-8.12 (d, J=5.6, 1H), 7.65-7.61 (dd, J=8.0, 1.6, 1H), 7.37-7.32 (m, 1H), 7.20-7.16 (dd, J=8.1, 1.5, 1H), 7.16-7.09 (m, 1H), 6.19-6.14 (d, J=5.7, 1H), 5.21 (s, 2H).
Intermediate HL




The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloropyrimidin-4-amine. 1H NMR (500 MHz, DMSO-d) δ 7.95 (d, J=0.8, 1H), 7.67-7.62 (m, 1H), 7.38 (m, 1H), 7.20-7.14 (m, 2H), 6.75 (s, 2H), 5.77 (d, J=0.9, 1H).
Intermediate HM




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-4-methylpyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 8.44 (d, J=5.1, 1H), 7.72 (dd, J=8.0, 1.6, 1H), 7.49-7.43 (m, 1H), 7.34 (dd, J=8.0, 1.6, 1H), 7.26-7.20 (m, 1H), 7.17-7.14 (m, 1H), 2.41 (s, 3H).
Intermediate HN




The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloro-2-methylpyrimidine. 1H NMR (500 MHz, CDCl3) δ 8.47 (d, J=5.8, 1H), 7.64 (dd, J=8.0, 1.5, 1H), 7.42-7.33 (m, 1H), 7.23-7.10 (m, 2H), 6.64 (d, J=5.7, 1H), 2.55 (s, 3H).
Intermediate HO




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloronicotinonitrile. 1H NMR (500 MHz, CDCl3) δ 8.32-8.21 (dd, J=5.0, 1.9, 1H), 8.09-7.95 (dd, J=7.6, 1.9, 1H), 7.68-7.60 (dd, J=8.0, 1.5, 1H), 7.45-7.36 (m, 1H), 7.29-7.23 (dd, J=8.1, 1.5, 1H), 7.21-7.16 (m, 1H), 7.15-7.09 (dd, J=7.6, 5.0, 1H).
Intermediate HP




The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloropicolinonitrile. 1H NMR (500 MHz, DMSO-d6) δ 8.60-8.55 (m, 1H), 7.82-7.77 (m, 1H), 7.73-7.66 (m, 1H), 7.51 (m, 1H), 7.42-7.36 (m, 1H), 7.34-7.27 (m, 1H), 7.11-7.06 (m, 1H).
Intermediate HQ




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-5-methoxypyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 8.41 (d, J=0.6, 2H), 7.73 (d, J=8.0, 1H), 7.46 (m, 1H), 7.33 (d, J=8.1, 1H), 7.23 (m, 1H), 3.87 (d, J=0.5, 3H).
Intermediate HR




The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloro-2-(trifluoromethyl)pyrimidine. 1H NMR (500 MHz, DMSO-d) δ 8.92 (d, J=5.8, 1H), 7.76 (dd, J=8.0, 1.5, 1H), 7.53-7.40 (m, 3H), 7.29 (m, 1H).
Intermediate HS




The title compound was prepared in a manner similar to that described for Intermediate HI using 4-(azetidin-1-yl)-6-chloropyrimidine. 1H NMR (400 MHz, DMSO-d6) δ 8.10 (d, J=0.8, 1H), 7.70 (dd, J=8.0, 1.5, 1H), 7.43 (m, 1H), 7.30-7.18 (m, 2H), 5.84 (d, J=0.8, 1H), 4.06-3.97 (m, 4H), 2.41-2.30 (m, 2H).
Intermediate HT




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-bromo-5-(trifluoromethyl)phenol. 1H NMR (500 MHz, CDCl3) δ 8.62-8.49 (d, J=4.8, 2H), 7.82-7.75 (dd, J=8.4, 0.9, 1H), 7.54-7.51 (d, J=2.0, 1H), 7.44-7.40 (m, 1H), 7.13-7.08 (m, 1H).
Intermediate HU




To a sealable 4 mL vial, containing 6-(chloromethyl)picolinonitrile (100 mg, 0.66 mmol) and 2-bromophenol (113 mg, 0.66 mmol), were added Cs2CO3 (320 mg, 0.98 mmol) and acetonitrile (1.7 mL). The vial was then heated at 80° Celsius for 15 hours. The reaction was then diluted with ethyl acetate, filtered through a celite plug and concentrated to dryness. The material was used without further purification. 1H NMR (500 MHz, CDCl3) δ 8.02-7.93 (m, 1H), 7.93-7.85 (m, 1H), 7.65-7.59 (dd, J=7.7, 1.1, 1H), 7.58-7.53 (dd, J=7.9, 1.6, 1H), 7.29-7.22 (m, 1H), 6.93-6.90 (dd, J=8.3, 1.3, 1H), 6.90-6.86 (m, 1H), 5.23 (s, 2H).
Intermediate HV




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-(chloromethyl)nicotinonitrile. 1H NMR (500 MHz, CDCl3) δ 8.83-8.74 (dd, J=4.9, 1.7, 1H), 8.02-7.97 (dd, J=7.9, 1.7, 1H), 7.57-7.49 (dd, J=7.9, 1.6, 1H), 7.42-7.35 (dd, J=7.9, 4.9, 1H), 7.27-7.20 (m, 1H), 7.08-7.01 (dd. J=8.2, 1.3, 1H), 6.91-6.83 (m, 1H), 5.37 (s, 2H).
Example 526




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidine. MS (ESI): mass calcd. for C20H14FN5O, 359.12; m/z found, 360.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.56 (d, J=4.8, 2H), 8.35-8.30 (m, 1H), 7.99 (d, J=1.5, 1H), 7.82 (m, 1H), 7.58 (dd, J=7.6, 1.7, 1H), 7.52-7.46 (m, 1H), 7.42-7.28 (m, 4H), 7.17 (t, J=4.8, 1H), 6.70 (s, 2H).
Example 527




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H14FN5O, 359.12; m/z found, 360.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.58 (d, J=4.8, 2H), 8.43 (d, J=1.4, 2H), 7.58-7.46 (m, 3H), 7.42-7.27 (m, 4H), 7.20 (t, J=4.8, 1H), 6.88 (s, 2H).
Example 528




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C20H15FN6O, 374.13; m/z found, 375.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.35-8.28 (dd, J=2.1, 1.5, 1H), 8.08-8.00 (d, J=1.5, 1H), 7.84-7.77 (m, 1H), 7.77-7.71 (d, J=5.9, 1H), 7.52-7.47 (dd, J=7.6, 1.7, 1H), 7.46-7.40 (m, 1H), 7.38-7.32 (m, 2H), 7.32-7.27 (dd, J=12.6, 1.7, 1H), 7.23-7.16 (dd, J=8.1, 1.2, 1H), 6.11-6.09 (d, J=5.9, 1H).
Example 529




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-4-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H15FN6O, 374.13; m/z found, 375.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.49-8.43 (d, J=1.4, 2H), 7.79-7.72 (d, J=5.9, 1H), 7.51-7.47 (dd, J=7.6, 1.7, 1H), 7.47-7.41 (m, 2H), 7.39-7.28 (m, 3H), 7.22-7.17 (dd, J=8.1, 1.2, 1H), 6.16-6.05 (d, J=5.9, 1H).
Example 530




The title compound was prepared in a manner similar to that described in Example 88 using 6-((2-bromophenoxy)methyl)picolinonitrile. MS (ESI): mass calcd. for C23H16FN5O, 397.13; m/z found, 398.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.29 (d, J=1.5, 1H), 8.24 (s, 1H), 8.01-7.90 (m, 2H), 7.83-7.73 (m, 1H), 7.72-7.64 (dd, J=8.2, 1.0, 1H), 7.52-7.48 (dd, J=8.1, 1.6, 1H), 7.48-7.44 (m, 1H), 7.44-7.40 (dd, J=7.6, 1.7, 1H), 7.40-7.34 (m, 1H), 7.19-7.15 (dd. J=8.3, 1.1, 1H), 7.14-7.07 (m, 1H), 5.26 (s, 2H).
Example 531




The title compound was prepared in a manner similar to that described in Example 88 using 2-((2-bromophenoxy)methyl)nicotinonitrile. MS (ESI): mass calcd. for C23H16FN5O, 397.13; m/z found, 398.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.80-8.73 (dd, J=5.0, 1.7, 1H), 8.32-8.27 (m, 1H), 8.24-8.22 (d, J=1.4, 1H), 8.22-8.15 (dd, J=7.9, 1.7, 1H), 7.89-7.82 (m, 1H), 7.57-7.49 (dd, J=7.9, 5.0, 1H), 7.45 (s, 1H), 7.44-7.42 (dd, J=4.4, 1.6, 1H), 7.41-7.35 (m, 2H), 7.26-7.22 (dd, J=8.2, 1.0, 1H), 7.14-7.09 (m, 1H), 5.34 (s, 2H).
Example 532




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)nicotinonitrile. MS (ESI): mass calcd. for C22H14FN5O, 383.12; m/z found, 384.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.28-8.25 (m, 1H), 8.22-8.18 (d, J=1.4, 1H), 8.17-8.13 (dd. J=5.0, 1.9, 1H), 8.10-8.04 (dd, J=7.6, 1.9, 1H), 7.89-7.82 (m, 1H), 7.57-7.53 (dd, J=7.6, 1.7, 1H), 7.53-7.47 (m, 1H), 7.45-7.41 (m, 1H), 7.41-7.37 (dd, J=8.1, 1.7, 1H), 7.34-7.28 (m, 2H), 7.12-7.04 (dd, J=7.6, 5.0, 1H).
Example 533




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H15FN6O, 374.13; m/z found, 375.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.35-8.29 (m, 1H), 8.12-8.07 (d, J=1.5, 1H), 8.05-8.00 (d, J=7.0, 1H), 7.92-7.85 (m, 1H), 7.59-7.55 (dd, J=7.5, 1.8, 1H), 7.55-7.49 (m, 1H), 7.49-7.43 (m, 1H), 7.36-7.33 (dd, J=8.1, 1.7, 1H), 7.33-7.31 (dd, J=8.0, 1.3, 1H), 7.31-7.27 (dd, J=12.5, 1.7, 1H), 6.72-6.42 (d, J=7.0, 1H).
Example 534




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyrimidin-2-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H15FN6O, 374.13; m/z found, 375.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.46 (s, 2H), 7.98-7.94 (d, J=5.8, 1H), 7.53-7.49 (d, J=7.6, 1H), 7.49-7.42 (m, 2H), 7.41-7.36 (m, 1H), 7.36-7.32 (d, J=8.2, 1H), 7.32-7.27 (m, 1H), 7.26-7.14 (d, J=8.0, 1H), 6.13-6.04 (d, J=5.8, 1H).
Example 535




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C20H15FN6O, 374.13; m/z found, 375.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.24 (s, 1H), 7.97 (d, J=1.4, 1H), 7.90 (s, 1H), 7.74 (m, 1H), 7.50 (dd, J=7.6, 1.7, 1H), 7.42 (m, 1H), 7.36-7.29 (m, 2H), 7.28-7.22 (m, 1H), 7.13 (d, J=8.1, 1H), 6.65 (s, 2H), 6.52 (s, 2H), 5.67 (s, 1H).
Example 536




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)pyrimidin-4-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H15FN6O, 374.13; m/z found, 375.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.38 (s, 2H), 7.92 (s, 1H), 7.47 (m, 2H), 7.40 (d, J=6.4, 1H), 7.36-7.23 (m, 3H), 7.11 (d, J=7.7, 1H), 6.68 (br, 4H), 5.68 (s, 1H).
Example 537




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)picolinonitrile. MS (ESI): mass calcd. for C22H14FN5O, 383.12; m/z found, 384.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.47 (d, J=5.1, 1H), 8.29 (s, 1H), 7.96 (s, 1H), 7.81 (s, 1H), 7.66-7.56 (m, 2H), 7.48 (dd, J=20.1, 7.3, 2H), 7.39-7.20 (m, 3H), 7.07 (s, 1H), 6.68 (s, 2H).
Example 538




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)picolinonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H14FN5O, 383.12; m/z found, 384.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.50 (d, J=5.7, 1H), 8.40 (d, J=1.3, 2H), 7.61 (dd, J=7.9, 2.0, 2H), 7.53 (dd, J=11.1, 5.0, 2H), 7.48-7.42 (m, 1H), 7.36 (dd, J=12.1, 1.5, 1H), 7.31 (dd, J=11.5, 5.0, 2H), 7.11 (dd, J=5.7, 2.5, 1H), 6.86 (s, 2H).
Example 539




The title compound was prepared in a manner similar to that described in Example 88 using 4-(azetidin-1-yl)-6-(2-bromophenoxy)pyrimidine. MS (ESI): mass calcd. for C23H19FN6O, 414.16; m/z found, 415.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39-8.31 (m, 1H), 8.08 (d, J=0.9, 1H), 8.02 (d, J=1.5, 1H), 7.85 (m, 1H), 7.55 (dd, J=7.6, 1.7, 1H), 7.51-7.42 (m, 1H), 7.40-7.29 (m, 3H), 7.18 (dd, J=8.0, 1.2, 1H), 6.71 (s, 2H), 5.71 (d, J=0.9, 1H), 3.96 (t, J=7.5, 4H), 2.39-2.24 (m, 2H).
Example 540




The title compound was prepared in a manner similar to that described in Example 88 using 4-(azetidin-1-yl)-6-(2-bromophenoxy)pyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C23H19FN6O, 414.16; m/z found, 415.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J=1.5, 2H), 8.11 (d, J=0.9, 1H), 7.60-7.52 (m, 2H), 7.50-7.41 (m, 1H), 7.41-7.31 (m, 3H), 7.17 (dd, J=8.1, 1.2, 1H), 6.89 (s, 2H), 5.73 (d, J=0.9, 1H), 3.98 (t, J=7.5, 4H), 2.41-2.27 (m, 2H).
Example 541




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-methylpyrimidine. MS (ESI): mass calcd. for C21H16FN5O, 373.13; m/z found, 374.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.53 (s, 1H), 8.35 (d, J=5.8, 1H), 8.08 (d, J=1.3, 1H), 7.87 (m, 1H), 7.51 (dd, J=7.5, 1.9, 1H), 7.45 (m, 1H), 7.38 (dd, J=7.8, 6.9, 1H), 7.33 (dd, J=7.9, 1.6, 1H), 7.26 (m, 1H), 7.21 (d, J=8.1, 1H), 6.49 (d, J=5.8, 1H), 4.73 (s, 2H), 2.51 (s, 3H).
Example 542




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-methylpyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H16FN5O, 373.13; m/z found, 374.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.50 (s, 2H), 8.38 (d, J=5.8, 1H), 7.53-7.28 (m, 6H), 7.21 (d, J=7.9, 1H), 6.51 (d, J=5.7, 1H), 5.30 (s, 2H), 2.52 (s, 3H).
Example 543




The title compound was prepared in a manner similar to that described in Example 88 using 5-bromo-1H-benzo[d]imidazole and 2-((3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-yl)oxy)pyrimidine. MS (ESI): mass calcd. for C23H15FN4O, 382.12; m/z found, 383.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 9.31 (s, 1H), 8.52-8.45 (d, J=4.9, 2H), 7.95 (s, 1H), 7.92-7.87 (d, J=8.6, 1H), 7.79-7.70 (d, J=8.6, 1H), 7.59-7.55 (dd, J=7.7, 1.7, 1H), 7.55-7.47 (m, 2H), 7.45-7.39 (m, 2H), 7.38-7.32 (dd, J=12.0, 1.7, 1H), 7.30-7.23 (dd, J=8.1, 1.2, 1H), 7.13-7.08 (t, J=4.8, 1H).
Example 544




The title compound was prepared in a manner similar to that described in Example 88 using 6-bromo-3H-imidazo[4,5-b]pyridine and 2-((3′-fluoro-4′-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1′-biphenyl]-2-yl)oxy)pyrimidine. MS (ESI): mass calcd. for C22H14FN5O, 383.12; m/z found, 384.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.55-8.52 (m, 1H), 8.51-8.47 (d, J=4.9, 2H), 8.43 (s, 1H), 8.19-8.14 (t, J=1.7, 1H), 7.59-7.55 (dd, J=7.7, 1.8, 1H), 7.55-7.47 (m, 2H), 7.46-7.40 (m, 2H), 7.39-7.33 (dd, J=11.9, 1.7, 1H), 7.30-7.25 (dd, J=8.0, 1.2, 1H).
Example 545




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4-methylpyrimidine. MS (ESI): mass calcd. for C21H16FN5O, 373.13; m/z found, 374.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.37 (d, J=5.1, 1H), 8.32 (d, J=1.6, 1H), 8.00 (d, J=1.6, 1H), 7.82 (m, 1H), 7.56 (dd, J=7.5, 1.7, 1H), 7.51-7.44 (m, 1H), 7.41-7.24 (m, 4H), 7.05 (d, J=5.1, 1H), 6.70 (s, 2H), 2.34 (s, 3H).
Example 546




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4-methylpyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H16FN5O, 373.13; m/z found, 374.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.44 (s, 2H), 8.39 (d. J=5.1, 1H), 7.57-7.44 (m, 3H), 7.41-7.31 (m, 3H), 7.25 (d, J=7.2, 1H), 7.07 (d, J=4.9, 1H), 6.89 (s, 2H), 2.35 (s, 3H).
Example 547




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. for C21H13F4N5O, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.76 (d, J=5.8, 1H), 8.29-8.24 (m, 1H), 7.95 (d, J=1.5, 1H), 7.78 (m, 1H), 7.58 (dd, J=7.5, 1.8, 1H), 7.54-7.48 (m, 1H), 7.45 (m, 1H), 7.39 (dd, J=8.0, 1.3, 1H), 7.27 (m, 3H), 6.66 (s, 2H).
Example 548




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-(trifluoromethyl)pyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H13F4N5O, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.78 (d, J=5.7, 1H), 8.37 (m, 2H), 7.57 (dd, J=7.5, 1.8, 1H), 7.48 (m, 3H), 7.39 (dd, J=8.0, 1.3, 1H), 7.33-7.22 (m, 3H), 6.85 (s, 2H).
Example 549




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-5-methoxypyrimidine. MS (ESI): mass calcd. for C21H16FN5O2, 389.13; m/z found, 390.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.45 (s, 1H), 8.35 (s, 1H), 7.55 (m, 2H), 7.46 (m, 1H), 7.42-7.32 (m, 3H), 7.22 (d, J=8.0, 1H), 6.89 (s, 2H), 3.83 (s, 3H).
Example 550




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-5-methoxypyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H16FN5O2, 389.13; m/z found, 390.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.30-8.26 (m, 3H), 7.96 (d, J=1.5, 1H), 7.78 (m, 1H), 7.52 (dd, J=7.6, 1.7, 1H), 7.46-7.39 (m, 1H), 7.37-7.26 (m, 3H), 7.19 (dd, J=8.1, 1.2, 1H), 6.66 (s, 2H), 3.76 (d, J=1.9, 3H).
Example 551




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidine. MS (ESI): mass calcd. for C21H13F4N5O, 427.11; m/z found, 428.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.49 (s, 1H), 8.48 (s, 1H), 8.30-8.27 (d, J=1.7, 1H), 8.13-8.10 (d, J=1.4, 1H), 7.89-7.84 (m, 1H), 7.77-7.73 (m, 1H), 7.73-7.68 (m, 1H), 7.63-7.59 (d, J=2.0, 1H), 7.42-7.38 (dd, J=8.1, 1.7, 1H), 7.37-7.33 (dd, J=12.4, 1.7, 1H), 7.14-7.07 (t, J=4.9, 1H).
Example 552




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidine. MS (ESI): mass calcd. for C21H13F4N5O, 427.11; m/z found, 428.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.50 (s, 1H), 8.49 (s, 1H), 8.45-8.43 (d, J=1.4, 2H), 7.76-7.73 (m, 1H), 7.73-7.69 (m, 1H), 7.62-7.60 (d, J=1.6, 1H), 7.49-7.44 (m, 1H), 7.41-7.38 (m, 1H), 7.38-7.34 (dd, J=11.9, 1.7, 1H), 7.14-7.11 (t, J=4.8, 1H).
Example 553




The title compound was prepared in a manner similar to that described in Example 88 using 1-bromo-2-methoxy-4-(trifluoromethyl)benzene. MS (ESI): mass calcd. for C18H13F4N3O, 363.10; m/z found, 364.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39-8.37 (m, 1H), 8.11-8.08 (d, J=1.5, 1H), 7.93-7.87 (m, 1H), 7.55-7.52 (m, 1H), 7.45-7.37 (m, 2H), 7.36-7.31 (m, 2H), 3.90 (s, 3H).
Example 554




To a stirred solution of 5-[3-fluoro-2′-methoxy-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine (370 mg, 1.02 mmol) in dry dichloromethane (9.8 mL) at −78° Celsius, was added a boron tribromide in dichloromethane (3.1 mL, 1 M). The flask was slowly warmed to rt and stirred overnight. The reaction was poured into sat. NH4Cl and the pH adjusted to 8 with saturated NaHCO3. The resultant mixture was extracted with DCM (3×30 mL) and the combined extracts dried over Na2SO4, filtered and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C17H11F4N3O, 349.08; m/z found, 350.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.35 (m, 1H), 8.17-8.10 (d, J=1.5, 1H), 7.99-7.88 (m, 1H), 7.56-7.46 (m, 3H), 7.22-7.19 (m, 1H), 7.19-7.17 (d, J=1.7, 1H).
Example 555




To a 5 mL vial were added a stir bar, 4′-(5-aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol (40 mg, 0.12 mmol), 4-chloropyrimidin-2-amine (17.8 mg, 0.14 mmol), DMSO (1 mL) and Cs2CO3 (52 mg, 0.16 mmol). The vial was flushed with nitrogen and heated for 15 hours at 120° Celsius. The reaction was diluted with 5 mL of ethyl acetate and 5 mL of brine. The aqueous layer was then extracted with ethyl acetate (3×10 mL), the combined organic extracts dried over Na2SO4, and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C21H14F4N6O, 442.12; m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.34 (s, 1H), 8.09-8.07 (d, J=1.4, 1H), 8.07-8.05 (d, J=7.0, 1H), 7.96-7.88 (m, 1H), 7.82-7.74 (d, J=1.6, 2H), 7.71 (s, 1H), 7.41-7.37 (dd, J=8.1, 1.7, 1H), 7.37-7.32 (dd, J=12.4, 1.7, 1H), 6.64-6.56 (d, J=7.0, 1H).
Example 556




The title compound was prepared in a manner similar to that described in Example 555 using 2-chloropyrimidin-4-amine. MS (ESI): mass calcd. for C21H14F4N6O, 442.12; m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.32 (m, 1H), 8.10-8.04 (d, J=1.5, 1H), 7.98-7.90 (m, 1H), 7.89-7.84 (d, J=6.9, 1H), 7.78 (s, 3H), 7.40-7.37 (dd, J=8.1, 1.8, 1H), 7.37-7.33 (dd, J=12.4, 1.7, 1H), 6.36-6.26 (d, J=6.9, 1H).
Example 557




The title compound was prepared in a manner similar to that described in Example 88 using (2-((2-bromo-5-(trifluoromethyl)phenoxy)methoxy)ethyl)trimethylsilane and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrimidin-2-amine. MS (ESI): mass calcd. for C23H25F4N3O2Si, 479.17; m/z found, 480.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.55-8.48 (m, 2H), 7.60-7.51 (m, 3H), 7.48-7.36 (m, 3H), 5.33-5.29 (d, J=1.0, 2H), 3.73-3.66 (m, 2H), 0.93-0.84 (t, J=8.0, 2H), −0.03-−0.07 (m, 9H).
Example 558




To a stirred solution of 5-[3-fluoro-4′-(trifluoromethyl)-2′-{[2-(trimethylsilyl)ethoxy]-methoxy}-biphenyl-4-yl]pyrimidin-2-amine in 14 mL of THF were added water (1.40 mL), acetic acid (1.40 mL) and hydrochloric acid (0.43 mL, 6 N). The reaction was stirred overnight at 65° Celsius, before diluting with ethyl acetate (20 mL) and water (20 mL). The aqueous layer was extracted with ethyl acetate (3×30 mL) and the combined organic extracts dried over Na2SO4, and concentrated to dryness. The crude product was purified by FCC to provide the title compound. MS (ESI): mass calcd. for C17H11F4N3O, 349.08; m/z found, 350.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.61 (s, 2H), 7.61-7.48 (m, 4H), 7.23-7.19 (dd, J=8.3, 1.8, 1H), 7.19-7.17 (d, J=1.6, 1H).
Example 559




The title compound was prepared in a manner similar to that described in Example 555 using 2-chloropyrimidin-4-amine and 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol. MS (ESI): mass calcd. for C21H14F4N6O, 442.12; m/z found, 443.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.46 (s, 2H), 7.80-7.74 (m, 1H), 7.74-7.67 (m, 1H), 7.67-7.62 (m, 1H), 7.52 (s, 1H), 7.51-7.44 (m, 1H), 7.44-7.31 (dd, J=17.9, 10.0, 2H), 6.20-6.08 (dd, J=6.0, 1.4, 1H).
Example 560




The title compound was prepared in a manner similar to that described in Example 555 using 4-chloropyrimidin-2-amine and 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol. MS (ESI): mass calcd. for C21H14F4N6O, 442.12; m/z found, 443.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.51-8.43 (d, J=1.3, 2H), 8.06-7.94 (d, J=5.7, 1H), 7.72-7.69 (m, 1H), 7.69-7.66 (m, 1H), 7.55 (s, 1H), 7.52-7.47 (m, 1H), 7.39-7.31 (m, 2H), 6.31-6.03 (d, J=5.7, 1H).
Example 561




The title compound was prepared in a manner similar to that described in Example 555 using 6-chloropyrimidin-4-amine and 4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol. MS (ESI): mass calcd. for C21H14F4N6O, 442.12; m/z found, 443.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.60-8.54 (d, J=1.3, 2H), 8.11-8.07 (d, J=0.9, 1H), 7.82-7.69 (m, 2H), 7.60 (s, 1H), 7.59-7.52 (m, 1H), 7.47-7.36 (m, 2H), 5.95-5.88 (d, J=0.9, 1H).
Example 562




The title compound was prepared in a manner similar to that described in Example 88 using 1-((2-bromo-5-(trifluoromethyl)phenyl)sulfonyl)-4-methylpiperazine. MS (ESI): mass calcd. for C18H10F7N3, 401.08: m/z found, 402.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.43-8.39 (m, 1H), 8.11-8.07 (m, 2H), 8.04-8.00 (d, J=8.2, 1H), 7.99-7.93 (m, 1H), 7.71-7.65 (d, J=8.0, 1H), 7.29-7.25 (d, J=8.2, 1H), 7.25-7.20 (d, J=11.6, 1H).
Example 563




The title compound was prepared in a manner similar to that described in Example 88 using 2-bromo-5-(trifluoromethyl)benzonitrile. MS (ESI): mass calcd. for C18H10F4N4, 358.08; m/z found, 359.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.45 (s, 1H), 8.23 (s, 1H), 8.11-8.08 (m, 1H), 8.08-8.03 (m, 2H), 7.91-7.84 (d, J=8.2, 1H), 7.58-7.49 (m, 2H).
Intermediate HW




The title compound was prepared using conditions analogous to those described in Example 1 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid and 1-(4-bromo-2-fluorophenyl)ethanone. 1H NMR (500 MHz, CDCl3) δ 8.19 (dd, J=7.9, 1.3, 1H), 7.95 (m, 1H), 7.63-7.57 (m, 1H), 7.57-7.52 (m, 1H), 7.38-7.30 (m, 2H), 7.28 (dd, J=7.5, 1.3, 1H), 2.70 (d, J=4.9, 3H), 1.05 (m, 9H).
Intermediate HX




The title compound was prepared using conditions analogous to those described in Example 1 using (4-acetyl-3-fluorophenyl)boronic acid and 2-bromo-N,N-diethylbenzenesulfonamide. MS (ESI): mass calcd. for C18H20FNO3S, 349.11; m/z found, 350.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.05 (dd, J=7.9, 1.2, 1H), 7.92 (m, 1H), 7.61-7.56 (m, 1H), 7.55-7.49 (m, 1H), 7.29-7.27 (m, 2H), 7.25-7.24 (m, 1H), 2.95 (q, J=7.1, 4H), 2.69 (d, J=4.9, 3H), 1.01 (t, J=7.1, 6H).
Intermediate HY




The title compound was prepared using conditions analogous to those described in Example 1 using (4-acetyl-3-fluorophenyl)boronic acid and 1-(2-bromo-phenylsulfonyl)pyrrolidine. MS (ESI): mass calcd. for C18H18FNO3S, 347.10; m/z found, 348.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.10 (dd, J=7.9, 1.3, 1H), 7.95-7.89 (m, 1H), 7.63-7.58 (m, 1H), 7.58-7.51 (m, 1H), 7.30-7.27 (m, 2H), 7.26-7.25 (m, 1H), 2.98-2.90 (m, 4H), 2.69 (d, J=4.9, 3H), 1.76-1.67 (m, 4H).
Example 564




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H13F3N6O, 410.11; m/z found, 411.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.98 (s, 2H), 8.73 (d, J=2.3, 1H), 8.50 (d, J=4.8, 2H), 8.04 (dd, J=8.3, 2.4, 1H), 7.85 (d, J=8.4, 1H), 7.81-7.72 (m, 2H), 7.66 (d, J=1.7, 1H), 7.13 (t, J=4.8, 1H).
Example 565




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidin-2-amine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H14F3N7O, 425.12; m/z found, 426.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.89 (s, 2H), 8.67 (dd, J=2.3, 0.8, 1H), 7.99 (d, J=5.6, 1H), 7.95 (dd, J=8.3, 2.3, 1H), 7.81 (dd. J=8.2, 0.9, 1H), 7.76-7.69 (m, 2H), 7.59 (s, 1H), 6.18 (d. J=5.8, 1H).
Example 566




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H14N6O, 342.12; m/z found, 343.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.97 (s, 2H), 8.70 (dd, J=2.3, 0.8, 1H), 8.48 (d, J=4.8, 2H), 8.06 (dd, J=8.3, 2.3, 1H), 7.85 (dd, J=8.3, 0.9, 1H), 7.58 (dd, J=7.6, 1.8, 1H), 7.56-7.50 (m, 1H), 7.48-7.41 (m, 1H), 7.30 (dd. J=8.0, 1.2, 1H), 7.10 (t, J=4.8, 1H).
Example 567




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyrimidin-2-amine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H15N7O, 357.13; m/z found, 358.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.91 (s, 2H), 8.68-8.59 (m, 1H), 8.03 (dd, J=6.9, 0.9, 1H), 7.97-7.89 (m, 1H), 7.83 (d, J=8.3, 1H), 7.60-7.53 (m, 2H), 7.52-7.44 (m, 1H), 7.35 (d, J=7.9, 1H), 6.53 (dd, J=6.9, 0.9, 1H).
Example 568




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-4-amine and 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H5N7O, 357.13; m/z found, 358.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.86 (s, 2H), 8.64 (dd, J=2.3, 0.8, 1H), 7.95 (dd, J=8.3, 2.3, 1H), 7.78-7.72 (m, 2H), 7.53-7.45 (m, 2H), 7.38 (m, 1H), 7.23 (dd, J=8.1, 1.2, 1H), 6.11 (d, J=5.9, 1H).
Example 569




The title compound was prepared in a manner similar to that described in Example 571 using (4-bromo-2-methylphenyl)boronic acid in Step A. MS (ESI): mass calcd. for C21H24N4O2S, 396.16; m/z found, 397.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.21-8.17 (dd, J=8.0, 1.3, 1H), 8.13-8.07 (m, 2H), 7.61-7.54 (m, 1H), 7.52-7.47 (m, 1H), 7.47-7.39 (m, 3H), 7.36-7.31 (dd, J=7.5, 1.4, 1H), 4.82 (s, 2H), 4.16-4.09 (m, 1H), 2.41 (s, 3H), 1.05 (s, 9H).
Example 570




The title compound was prepared in a manner similar to that described in Example 571 using (4-bromo-2-methoxyphenyl)boronic acid in Step A. MS (ESI): mass calcd. for C21H24N4O3S, 412.16; m/z found, 413.3 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.51-8.45 (d, J=1.6, 1H), 8.21-8.16 (d, J=1.5, 1H), 8.16-8.11 (dd, J=8.0, 1.3, 1H), 7.84-7.78 (d, J=7.9, 1H), 7.67-7.61 (m, 1H), 7.58-7.54 (m, 1H), 7.45-7.38 (dd, J=7.6, 1.4, 1H), 7.32-7.25 (d, J=1.6, 1H), 7.15-7.09 (dd, J=7.9, 1.6, 1H), 3.92 (s, 3H), 1.04 (s, 9H).
Example 571




Step A: 5-(4-Bromophenyl)pyrazin-2-amine
(4-Bromophenyl)boronic acid (100 mg, 0.498 mmol) and 5-bromopyrazin-2-amine (173 mg, 0.996 mmol) were added to a 5 mL sealable vial equipped with a stir bar. To this vial was added toluene (1.5 mL), ethanol (1.5 mL) and K2CO3 (0.7 mL, 2 M). The solvent was sparged with argon for 10 min before adding Pd(PPh3)4 (17 mg, 0.004 mmol), the vial sealed and the mixture stirred at 50° Celsius for 15 hours. The reaction was cooled to rt and then diluted with ethyl acetate (50 mL) and water (50 mL) and the layers separated. The aqueous layer was further extracted with ethyl acetate (3×50 mL). The combined organic extracts were dried with Na2SO4 and concentrated to dryness. The crude material was purified FCC to give 5-(4-bromophenyl)pyrazin-2-amine. 1H NMR (500 MHz, CDCl3) δ 8.52-8.31 (d, J=1.5, 1H), 8.08-7.95 (d, J=1.6, 1H), 7.86-7.71 (d, J=8.4, 2H), 7.63-7.49 (d, J=8.6, 2H), 4.70 (s, 2H).
Step B: 4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide
To a 5 mL sealable vial equipped with a stir bar were added 5-(4-bromophenyl)pyrazin-2-amine (40 mg, 0.16 mmol), (2-(N-(tert-butyl)sulfamoyl)phenyl)-boronic acid (62 mg, 0.24 mmol), K2CO3 (66 mg, 0.48 mmol) and Pd(dppf)Cl2.CH2Cl2 (12 mg, 0.016 mmol). The vial was then sealed, evacuated, backfilled with argon and charged with argon sparged DMSO (0.64 mL). The vial was heated at 70° Celsius for 15 hours. The reaction mixture was cooled to rt diluted with ethyl acetate (2 mL) and water (2 mL), the layers separated and the aqueous layer further extracted with ethyl acetate (3×10 mL). The combined organic extracts were then dried with Na2SO4 and concentrated to dryness. The crude product was purified by HPLC to give the title compound. MS (ESI): mass calcd. for C20H22N4O2S, 382.15; m/z found, 383.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.48-8.39 (d, J=1.5, 1H), 8.23-8.18 (dd, J=8.0, 1.4, 1H), 8.18-8.15 (d, J=1.4, 1H), 7.99-7.95 (d, J=8.4, 1H), 7.65-7.61 (m, 2H), 7.61-7.55 (m, 1H), 7.55-7.46 (m, 1H), 7.38-7.31 (dd, J=7.5, 1.4, 1H), 3.70 (s, 1H), 1.25 (s, 1H), 1.03 (s, 9H).
Example 572




The title compound was prepared in a manner similar to that described in Example 571 using (2-(N,N-dimethylsulfamoyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C18H18N4O2S, 354.12; m/z found, 355.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.60-8.32 (d, J=1.5, 1H), 8.09-8.05 (dd, J=8.0, 1.4, 1H), 8.05-8.02 (d, J=1.5, 1H), 7.95-7.86 (m, 2H), 7.72-7.62 (m, 1H), 7.61-7.53 (m, 1H), 7.48-7.41 (m, 2H), 7.41-7.35 (dd, J=7.6, 1.4, 1H), 2.40 (s, 6H).
Example 573




The title compound was prepared in a manner similar to that described in Example 571 using (2-(morpholinosulfonyl)phenyl)boronic acid in in Step B. MS (ESI): mass calcd. for C20H20N4O3S, 396.13; m/z found, 397.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.60-8.55 (d, J=1.4, 1H), 8.05-8.00 (dd, J=8.0, 1.3, 1H), 8.00-7.94 (m, 3H), 7.78-7.73 (m, 1H), 7.69-7.62 (m, 1H), 7.49-7.39 (m, 3H), 6.61 (s, 2H), 2.76-2.68 (t. J=4.7, 3H).
Example 574




The title compound was prepared in a manner similar to that described in Example 571 using (4-bromo-3-fluorophenyl)boronic acid in Step A. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.50-8.43 (d, J=1.5, 1H), 8.18-8.12 (dd, J=8.0, 1.4, 1H), 8.05-8.02 (d, J=1.5, 1H), 7.74-7.67 (m, 2H), 7.66-7.61 (m, 1H), 7.60-7.53 (m, 1H), 7.47-7.39 (m, 1H), 7.39-7.32 (dd, J=7.5, 1.5, 1H), 1.11 (s, 9H).
Example 575




The title compound was prepared in a manner similar to that described in Example 571 using (4-bromo-3-fluorophenyl)boronic acid in Step A and using (2-(N,N-dimethylsulfamoyl)phenyl)boronic acid in Step B. MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 373.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.51-8.41 (d, J=1.5, 1H), 8.10-8.06 (dd, J=8.0, 1.4, 1H), 8.06-8.02 (d, J=1.5, 1H), 7.75-7.67 (m, 3H), 7.67-7.59 (m, 1H), 7.43-7.39 (m, 1H), 7.39-7.34 (m, 1H), 2.49 (s, 6H).
The title
Example 576




Step A: 4-(4-Bromo-2-fluorophenyl)oxazol-2-amine
A solution of 2-bromo-1-(4-bromo-2-fluorophenyl)ethanone (53 mg, 0.18 mmol) and urea (10.6 mg, 0.18 mmol) in CH3CN (0.7 mL) was heated at 80° Celsius for 18 hours. The mixture was cooled to rt and made basic with NaOH (2 N). The resulting solution was extracted with EtOAc and the extract was dried (Na2SO4), filtered, and concentrated to dryness. The residue was purified using FCC to give 4-(4-bromo-2-fluorophenyl)oxazol-2-amine (37 mg, 82%). MS (ESI): mass calcd. for C9H6BrFN2O, 255.96; m/z found, 257.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 7.78 (m, 1H), 7.58 (d, J=4.3, 1H), 7.36-7.32 (m, 1H), 7.28 (dd, J=10.5, 1.9, 1H), 4.60 (s, 2H).
Step B
The title compound was prepared using methods described in Example 427 using 4-(4-bromo-2-fluorophenyl)oxazol-2-amine and (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C19H20FN3O3S, 389.12; m/z found, 390.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.18 (dd, J=7.9, 1.4, 1H), 7.98 (m, 1H), 7.66 (d, J=4.2, 1H), 7.57 (m, 1H), 7.54-7.48 (m, 1H), 7.38-7.30 (m, 3H), 4.63 (s, 2H), 3.64 (s, 1H), 1.03 (s, 9H).
Example 577




A solution of 4′-acetyl-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide (100 mg, 0.29 mmol), iodine (94.6 mg, 0.37 mmol), thiourea (44.01, 0.57 mmol) in EtOH (1.1 mL) was heated at 100 Celcius for 48 h. The reaction mixture was cooled to rt and the precipitate collected by filtration thus providing the title compound. MS (ESI): mass calcd. for C19H20FN3O2S2, 405.10; m/z found, 406.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.71 (s, 2H), 8.19 (d, J=7.9, 1H), 7.94 (m, 1H), 7.59 (m, 1H), 7.54 (dd, J=11.6, 3.8, 1H), 7.44 (dd, J=12.1, 1.6, 1H), 7.38 (dd, J=8.1, 1.7, 1H), 7.33 (dd, J=7.5, 1.3, 1H), 6.96 (d, J=1.3, 1H), 1.08 (s, 9H).
Example 578




The title compound was prepared using methods analogous to those described in Example 577 using 4′-acetyl-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide. MS (ESI): mass calcd. for C19H20FN3O2S2, 405.10; m/z found, 406.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.64 (s, 2H), 8.06 (dd, J=7.9, 1.2, 1H), 7.93 (m, 1H), 7.59 (td, J=7.5, 1.4, 1H), 7.52 (m, 1H), 7.39-7.28 (m, 3H), 6.95 (d, J=1.1, 1H), 2.97 (q, J=7.2, 4H), 1.02 (t, J=7.1, 6H).
Example 579




The title compound was prepared using methods analogous to those described in Example 577 using 1-[3-fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]ethanone. MS (ESI): mass calcd. for C19H18FN3O2S2, 403.08; m/z found, 404.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.11 (d, J=6.7, 1H), 7.91 (m, 1H), 7.61 (td, J=7.5, 1.4, 1H), 7.54 (m, 1H), 7.41-7.28 (m, 3H), 6.94 (d, J=1.2, 1H), 2.95 (t, J=6.7, 4H), 1.85-1.64 (m, 4H).
Example 580




The title compound was prepared using methods analogous to those described in Example 577 using 3-fluoropyridin-2-amine. MS (ESI): mass calcd. for C23H21F2N3O2S, 441.13; m/z found, 442.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.60-8.51 (m, 1H), 8.51-8.45 (m, 2H), 8.20 (d, J=6.6, 1H), 7.68-7.53 (m, 3H), 7.53-7.48 (m, 2H), 7.38 (d, J=7.6, 2H), 1.16-1.08 (m, 9H).
Example 581




The title compound was prepared using methods analogous to those described in Example 577 using pyridine-2,3-diamine. MS (ESI): mass calcd. for C23H23FN4O2S, 438.15; m/z found, 439.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.19-8.11 (m, 2H), 7.99-7.95 (m, 1H), 7.61 (dd, J=8.1, 6.8, 1H), 7.55 (m, 1H), 7.38-7.32 (m, 3H), 7.20-7.12 (m, 2H), 6.36 (d, J=8.5, 1H), 1.13 (s, 9H).
Example 582




The title compound was prepared using methods analogous to those described in Example 577 using 6-aminonicotinamide. MS (ESI): mass calcd. for C24H23FN4O3S, 466.15; m/z found, 467.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.91 (s, 1H), 8.24 (d, J=6.5, 1H), 8.14-8.03 (m, 2H), 7.93-7.84 (m, 2H), 7.64-7.52 (m, 3H), 7.49-7.42 (m, 1H), 7.35 (d, J=11.7, 1H), 6.49-6.40 (m, 1H), 1.28-1.20 (m, 9H).
Example 583




The title compound was prepared using methods analogous to those described in Example 577 using 6-aminonicotinamide. MS (ESI): mass calcd. for C24H23FN4O3S, 466.15; m/z found, 467.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.91 (s, 1H), 8.24 (d, J=6.5, 1H), 8.14-8.03 (m, 2H), 7.93-7.84 (m, 2H), 7.64-7.52 (m, 3H), 7.49-7.42 (m, 1H), 7.35 (d, J=11.7, 1H), 6.49-6.40 (m, 1H), 1.28-1.20 (m, 9H).
Example 584




The title compound was prepared using methods analogous to those described in Example 577 using 2-amino-4-cyanopyridine. MS (ESI): mass calcd. for C24H21FN4O2S, 448.14; m/z found, 449.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.38-8.33 (m, 2H), 8.32-8.25 (m, 2H), 8.20 (dd, J=8.0, 1.2, 1H), 7.61 (m, 1H), 7.54 (td, J=7.8, 1.4, 1H), 7.51-7.45 (m, 1H), 7.42 (dd, J=8.0, 1.7, 1H), 7.35 (dd, J=7.5, 1.3, 1H), 7.16 (dd, J=7.0, 1.6, 1H), 1.07 (s, 9H).
Example 585




The title compound was prepared using methods analogous to those described in Example 577 using 2-amino-5-cyanopyridine. MS (ESI): mass calcd. for C24H21FN4O2S, 448.14; m/z found, 449.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.70 (s, 1H), 8.28 (m, 1H), 8.25-8.19 (m, 2H), 8.14 (d, J=9.4, 1H), 7.61 (m, 1H), 7.58-7.52 (m, 2H), 7.51-7.47 (m, 1H), 7.43 (dd, J=8.0, 1.7, 1H), 7.35 (dd, J=7.5, 1.3, 1H), 1.07 (s, 9H).
Example 586




The title compound was prepared using methods analogous to those described in Example 577 using 2-amino-5-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C24H21F4N3O2S, 491.13; m/z found, 492.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.68 (s, 1H), 8.31 (dd, J=16.6, 8.7, 2H), 8.25 (d, J=2.8, 1H), 8.20 (dd, J=8.0, 1.2, 1H), 7.72-7.66 (m, 1H), 7.65-7.59 (m, 1H), 7.59-7.49 (m, 2H), 7.43 (dd, J=8.0, 1.7, 1H), 7.35 (dd, J=7.5, 1.2, 1H), 1.05 (m, 9H).
Example 587




The title compound was prepared using methods analogous to those described in Example 577 using 2-aminonicotinic acid. The ethyl ester was formed as a result of carrying out the reaction in EtOH. MS (ESI): mass calcd. for C26H26FN3O4S, 495.16; m/z found, 496.3 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.62-8.55 (m, 1H), 8.36 (d, J=6.5, 1H), 8.23-8.18 (m, 2H), 8.01 (d. J=7.3, 1H), 7.62-7.55 (m, 1H), 7.55-7.49 (m, 1H), 7.44-7.33 (m, 3H), 6.91 (m, 1H), 4.54 (dd, J=14.2, 7.1, 2H), 1.51 (t, J=7.2, 3H), 1.03 (s, 9H).
Example 588




Step A: 2-(4-Bromo-2-fluorophenyl)-5-methoxyimidazo[1,2-a]pyridine
A solution of 2-bromo-1-(4-bromo-2-fluorophenyl)ethanone (100 mg, 0.34 mmol) and 2-amino-3-methoxypyridine (42 mg, 0.34 mmol) in EtOH (0.8 mL) was heated at 90° Celsius for 24 hours. The reaction mixture was cooled to rt and diluted with water. The resultant precipitate was collected by filtration to provide 2-(4-bromo-2-fluorophenyl)-5-methoxyimidazo[1,2-a]pyridine (35 mg, 32%) which was used without further purification.
Step B
The title compound was prepared using methods analogous to those described in Example 88 using 2-(4-bromo-2-fluorophenyl)-5-methoxyimidazo[1,2-a]pyridine and 2-(tert-butylamino)sulfonylphenylboronic acid. MS (ESI): mass calcd. for C24H24FN3O3S, 453.15; m/z found, 454.4 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.58 (m, 1H), 8.19 (dd, J=8.0, 1.4, 1H), 8.10 (d, J=3.9, 1H), 7.81 (dd, J=6.7, 0.9, 1H), 7.60-7.55 (m, 1H), 7.54-7.48 (m, 1H), 7.43 (dd, J=12.1, 1.7, 1H), 7.38-7.32 (m, 2H), 6.73 (dd, J=7.6, 6.7, 1H), 6.50 (d, J=7.6, 1H), 4.07 (s, 3H), 3.68 (s, 1H), 1.02 (s, 9H).
Intermediate HZ




5-Bromopyrazin-2-amine (173 mg, 0.99 mmol) and (4-bromophenyl)boronic acid (100 mg, 0.490 mmol) were placed in a sealable vial followed by toluene (1.5 mL), ethanol (1.5 mL), and K2CO3 (0.7 mL, 2 M). The resultant mixture was then sparged with argon for 10 minutes before adding tetrakis(triphenylphosphine)palladium(0) (17 mg, 0.15 mmol), and heating at 50° Celsius. Reaction progress was monitored by LCMS. Once the reaction was complete, the reaction mixture was cooled to rt, diluted with EtOAc, filtered through Celite, and the resultant filtrate concentrated to dryness. The crude product was purified by FCC to provide the title compound. 1H NMR (500 MHz, CDCl3) δ 8.52-8.31 (d, J=1.5, 1H), 8.08-7.95 (d, J=1.6, 1H), 7.86-7.71 (d, J=8.4, 2H), 7.63-7.49 (d, J=8.6, 2H), 4.81-4.61 (s, 2H).
Intermediate IA




The title compound was prepared in a manner similar to that described for Intermediate HZ using (4-bromo-2-methylphenyl)boronic acid. 1H NMR (500 MHz, CD3OD) δ 8.01-7.97 (m, 2H), 7.47 (dd, J=1.9, 0.9, 1H), 7.43-7.38 (m, 1H), 7.23 (d, J=8.2, 1H), 2.31 (s, 3H).
Intermediate IB




The title compound was prepared in a manner similar to that described Intermediate HZ using (4-bromo-2-methoxyphenyl)boronic acid.
Example 589




5-(4-Bromophenyl)pyrazin-2-amine (51 mg, 0.20 mmol), (2-(methylsulfonyl)phenyl) boronic acid (61 mg, 0.31 mmol), K2CO3 (85 mg, 0.61 mmol) and Pd(dppf)Cl2.CH2Cl2 (15 mg, 0.020 mmol) were weighed into a sealable vial containing a stir-bar. The vial was sealed and evacuated before backfilling with argon and adding deoxygenated DMSO (0.8 mL). The vial was heated at 70° Celsius for 3 hours by which point the starting material had been consumed. The vial was cooler to rt, diluted with MeOH (1 mL), filtered with a syringe filter, and the filtrate subjected to HPLC purification to provide the title compound. MS (ESI): mass calcd. for C17H15N3O2S, 325.39; m/z found, 326.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.32 (dd, J=8.1, 1.4, 2H), 8.26 (dd, J=8.0, 1.4, 1H), 8.00-7.90 (m, 2H), 7.74-7.64 (m, 1H), 7.64-7.56 (m, 3H), 7.41 (dd, J=7.5, 1.4, 1H), 2.70 (s, 3H).
Example 590




The title compound was prepared in a manner similar to that described in Example 589 using 5-(4-bromo-2-methylphenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C18H17N3O2S, 339.42; m/z found, 340.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.25 (dd, J=8.0, 1.4, 1H), 8.20 (d, J=1.5, 1H), 8.11 (d, J=1.6, 1H), 7.70-7.63 (m, 1H), 7.60-7.54 (m, 1H), 7.49-7.45 (m, 1H), 7.43-7.36 (m, 3H), 4.75 (s, 2H), 2.71 (s, 3H), 2.45 (s, 3H).
Example 591




The title compound was prepared in a manner similar to that described in Example 589 using 5-(4-bromo-2-methylphenyl)pyrazin-2-amine and (2-(N,N-dimethylsulfamoyl)phenyl)boronic acid. MS (ESI): mass calcd. for C19H20N4O2S, 368.46; m/z found, 369.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.16 (d, J=1.5, 1H), 8.12 (dd, J=8.0, 1.3, 1H), 8.10 (d, J=1.5, 1H), 7.60-7.55 (m, 1H), 7.52-7.47 (m, 1H), 7.43 (d, J=7.8, 1H), 7.35-7.29 (m, 3H), 4.77 (s, 2H), 2.44 (s, 3H), 2.42 (s, 6H).
Example 592




The title compound was prepared in a manner similar to that described in Example 589 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid and 5-(4-bromo-2-methoxyphenyl)pyrazin-2-amine. After the coupling, the tert-butyl group and methyl group were removed by treating a solution consisting of 4′-(5-aminopyrazin-2-yl)-N-(tert-butyl)-3′-methoxy-[1,1′-biphenyl]-2-sulfonamide (48 mg, 0.12 mmol) and DCM (2 mL), with BBr3 (0.14 mL, 1 M in DCM) at −78° Celsius. The reaction mixture was warmed to room temperature. After the starting material was consumed the reaction mixture was poured into saturated NH4Cl (10 mL) and extracted with DCM (3×10 mL). The combined organic extracts were dried with sodium sulfate, filtered, and concentrated to dryness. The resultant residue was subjected to HPLC purification to provide the title compound. MS (ESI): mass calcd. for C16H14N4O3S, 342.38; m/z found, 343.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.71 (s, 1H), 8.18 (dd, J=7.9, 1.4, 1H), 7.93 (d, J=1.4, 1H), 7.80 (d, J=8.2, 1H), 7.64-7.57 (m, 1H), 7.57-7.48 (m, 1H), 7.39 (dd, J=7.6, 1.3, 1H), 7.12 (dd, J=8.1, 1.9, 1H), 7.09-7.03 (m, 1H), 4.38 (s, 2H).
Example 593




The title compound was prepared in a manner similar to that described in Example 589 using (2-(methylsulfonamido)phenyl)boronic acid. MS (ESI): mass calcd. for C17H16N4O2S, 340.41; m/z found, 341.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J=1.4, 1H), 8.26 (d, J=1.5, 1H), 8.03-7.94 (m, 2H), 7.67 (dd, J=8.2, 1.1, 1H), 7.46 (d, J=8.3, 2H), 7.45-7.40 (m, 1H), 7.33-7.29 (m, 1H), 7.26-7.23 (m, 1H), 6.49 (s, 1H), 2.93 (s, 3H).
Example 594




The title compound was prepared in a manner similar to that described in Example 589 using (2-sulfamoylphenyl)boronic acid. MS (ESI): mass calcd. for C16H14N4O2S, 326.38; m/z found, 327.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.40 (d. J=1.5, 1H), 8.22 (d, J=1.4, 1H), 8.13 (dd, J=8.0, 1.3, 1H), 7.93 (d, J=8.3, 2H), 7.67-7.59 (m, 1H), 7.59-7.50 (m, 3H), 7.37 (dd, J=7.6, 1.4, 1H).
Example 595




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromoindolin-2-one. MS (ESI): mass calcd. for C24H23FN2O3S, 438.52; m/z found, 439.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.20 (dd, J=7.9, 1.4, 1H), 8.09 (s, 1H), 7.63-7.56 (m, 1H), 7.56-7.50 (m, 1H), 7.50-7.41 (m, 3H), 7.39-7.36 (m, 1H), 7.35 (dd, J=7.6, 1.4, 1H), 7.32 (dd, J=11.4, 1.8, 1H), 6.97 (d, J=7.9, 1H), 3.90 (s, 1H), 3.61 (s, 2H), 1.08 (s, 9H).
Example 596




The title compound was prepared in a manner similar to that described in Example 427 using 6-bromoquinazoline-2,4(1H, 3H)-dione. MS (ESI): mass calcd. for C24H22FN3O4S, 467.52; m/z found, 468.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.30-8.21 (m, 1H), 8.14 (dd, J=8.1, 1.4, 1H), 7.97-7.88 (m, 1H), 7.68-7.62 (m, 1H), 7.62-7.52 (m, 2H), 7.40 (dd, J=7.6, 1.4, 1H), 7.36 (s, 1H), 7.35-7.32 (m, 1H), 7.29 (d, J=8.5, 1H), 1.08 (s, 9H).
Example 597




The title compound was prepared in a manner similar to that described in Example 427 using 5-bromo-1H-indazol-3-amine. MS (ESI): mass calcd. for C23H23FN4O2S, 438.53; m/z found, 439.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.15 (dd, J=8.0, 1.3, 1H), 8.11 (s, 1H), 7.80 (d, J=8.6, 1H), 7.69-7.63 (m, 1H), 7.63-7.55 (m, 2H), 7.49 (dd, J=8.8, 0.9, 1H), 7.40 (dd, J=7.6, 1.4, 1H), 7.37-7.35 (m, 1H), 7.34 (dd, J=6.0, 1.6, 1H), 1.10 (s, 9H).
Example 598




The title compound was prepared in a manner similar to that described in Example 427 using 3-amino-6-bromopyrazine-2-carboxylic acid. MS (ESI): mass calcd. for C21H21FN4O4S, 444.49; m/z found, 445.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.50 (s, 1H), 8.13 (dd, J=8.0, 1.3, 1H), 7.89 (s, 1H), 7.65 (td, J=7.5, 1.4, 1H), 7.56 (td, J=7.8, 1.4, 1H), 7.43 (d, J=7.4, 1H), 7.37-7.22 (m, 2H), 1.07 (s, 8H).
Intermediate IC




Step A: 2-((2-Bromophenyl)thio)acetamide
To a 20 mL vial were added a stir-bar 2-chloroacetamide (783 mg, 8.37 mmol) 2-bromothiophenol (1.00 mL, 8.32 mmol) N,N-diisopropylethyl amine (1.5 ml, 8.7 mmol), and dry THF (5 mL). The reaction mixture was stirred for 4 days before concentrating and subjecting the crude product to FCC to afford the title compound. 1H NMR (600 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.60 (dd, J=7.9, 1.4, 1H), 7.41-7.30 (m, 2H), 7.25 (s, 1H), 7.13-7.06 (m, 1H), 3.69 (s, 2H).
Step B: 2-((2-Bromophenyl)sulfonyl)acetamide
To a 40 mL vial were added 2-((2-bromophenyl)thio)acetamide (1.00 g, 4.06 mmol), Oxone (7.51 g, 12.2 mmol), methanol (12 mL) and water (15 mL). The reaction mixture was stirred for 21 hours at which point it was diluted with ethyl acetate (25 mL) and washed with aqueous Na2S2O3 (25 mL). The organic and water layers were separated and the aqueous phase further extracted with ethyl acetate (3×25 mL). The combined organic extracts were dried over magnesium sulfate, filtered, and concentrated to dryness. The crude product was subjected to FCC to provide the title compound. 1H NMR (600 MHz, DMSO-d6) δ 8.04-7.95 (m, 1H), 7.93-7.87 (m, 1H), 7.72 (s, 1H), 7.68-7.60 (m, 2H), 7.39 (s, 1H), 4.41 (s, 2H).
Intermediate ID




The title compound was prepared in a manner similar to that described for 2-((2-bromophenyl)sulfonyl)acetamide using 2-chloro-N,N-diethylacetamide in Step A. 1H NMR (600 MHz, DMSO-d6) δ 8.01-7.97 (m, 1H), 7.91-7.87 (m, 1H), 7.66-7.60 (m, 2H), 4.75 (s, 2H), 3.47-3.39 (q, J=7.1, 2H), 3.25-3.14 (q, J=7.0, 2H), 1.18-1.09 (t, J=7.1, 3H), 0.99-0.87 (t, J=7.0, 3H).
Intermediate IE




The title compound was prepared in a manner similar to that described for 2-((2-bromophenyl)sulfonyl)acetamide using 2-chloro-1-morpholinoethanone in Step A. 1H NMR (600 MHz, DMSO-d6) δ 8.06-8.01 (m, 1H), 7.93-7.88 (m, 1H), 7.68-7.60 (m, 2H), 4.84 (s, 2H), 3.63-3.55 (m, 4H), 3.53-3.48 (dd, J=5.6, 4.0, 2H), 3.42-3.37 (d, J=5.2, 2H).
Example 599




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)acetamide. MS (ESI): mass calcd. for C18H15FN4O3S, 386.41; m/z found, 387.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.55 (d, J=1.4, 2H), 8.15 (dd, J=7.9, 1.2, 1H), 7.80-7.72 (m, 1H), 7.69-7.61 (m, 1H), 7.59-7.53 (m, 1H), 7.43 (dd, J=7.5, 1.3, 1H), 7.39-7.30 (m, 2H).
Example 600




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)-N,N-diethylacetamide. MS (ESI): mass calcd. for C22H23FN4O3S, 442.52; m/z found, 443.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.55 (d, J=1.4, 2H), 8.13 (dd, J=8.0, 1.3, 1H), 7.81-7.73 (m, 1H), 7.71-7.63 (m, 1H), 7.62-7.55 (m, 1H), 7.44 (dd, J=7.6, 1.3, 1H), 7.39 (dd, J=4.5, 1.7, 1H), 7.37 (dd, J=8.0, 1.3, 1H), 3.29-3.27 (m, 4H), 1.07 (t, J=7.2, 3H), 1.04 (t, J=7.2, 3H).
Example 601




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)-1-morpholinoethanone. MS (ESI): mass calcd. for C22H21FN4O4S, 456.5; m/z found, 457.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.55 (d, J=1.4, 2H), 8.15 (dd, J=7.7, 1.3, 1H), 7.83-7.72 (m, 1H), 7.72-7.63 (m, 1H), 7.58 (dd, J=8.5, 7.7, 1H), 7.45 (dd, J=7.2, 1.2, 1H), 7.42-7.31 (m, 2H), 3.67-3.55 (m, 4H), 3.48 (t, J=4.8, 2H), 3.39 (t, J=4.8, 2H).
Example 602




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 1-bromo-2-iodobenzene. MS (ESI): mass calcd. for C26H18F2N6, 452.47; m/z found, 453.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.35-8.30 (m, 2H), 8.02 (d, J=1.6, 2H), 7.78-7.70 (m, 2H), 7.49 (s, 4H), 7.07 (dd, J=8.1, 1.7, 2H), 7.04 (dd, J=12.4, 1.7, 2H).
Example 603




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-5-(trifluoromethyl)benzoic acid. MS (ESI): mass calcd. for C18H11F4N3O2, 377.3; m/z found, 378.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.39 (s, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 8.00-7.84 (m, 2H), 7.65 (d, J=8.0, 1H), 7.28 (d, J=8.1, 1H), 7.24 (d, J=12.6, 1H).
Example 604




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 2-bromo-5-(trifluoromethyl)benzaldehyde. MS (ESI): mass calcd. for C18H11F4N3O, 361.3; m/z found, 362.1 [M+H]+. The title compound can exist as either the aldehyde or the hydrate (gem-diol). Hydrate: 1H NMR (400 MHz, CD3OD) δ 8.39 (s, 1H), 8.15 (d, J=1.5, 1H), 8.10-8.02 (m, 2H), 7.70 (d, J=7.7, 1H), 7.49 (d, J=8.0, 1H), 7.36-7.27 (m, 2H), 5.47 (s, 1H). Aldehyde: 1H NMR (400 MHz, CD3OD) δ 10.04 (s, 1H), 8.43 (s, 1H), 8.39 (s, 1H), 8.26 (s, 1H), 8.02-7.94 (m, 2H), 7.77 (d, J=8.2, 1H), 7.44-7.36 (m, 2H).
Intermediate IF




2-Bromo-5-(trifluoromethyl)benzaldehyde (266 mg, 1.05 mmol) and morpholine (0.10 mL, 1.2 mmol) were dissolved in DCM (2 mL), stirred for 20 minutes, and then treated with NaBH4 (79 mg, 2.1 mmol). The reaction was stirred overnight at rt, after which time, the reaction was quenched by the slow addition of water (10 mL). The aqueous layer was further extracted with DCM (3×10 mL), dried over sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by FCC to provide the title compound. 1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.67 (d, J=8.3, 1H), 7.37 (d, J=8.3, 1H), 3.80-3.69 (m, 4H), 3.63 (d, J=1.7, 2H), 2.59-2.49 (m, 4H).
Intermediate IG




The title compound was prepared using analogous conditions to those described in Intermediate IF utilizing tert-butyl piperidin-4-ylcarbamate. 1H NMR (500 MHz, CDCl3) δ 7.82 (s, 1H), 7.71-7.59 (m, 1H), 7.41 (d, J=8.3, 1H), 4.80 (s, 2H) 4.44 (s, 1H), 3.52 (s, 1H), 3.14-2.89 (m, 2H), 2.65 (t, J=12.0, 2H), 1.93 (d, J=12.0, 2H), 1.45 (s, 9H), 1.36-1.16 (m, 2H).
Example 605




The title compound was prepared using analogous conditions to those described in Example 6 utilizing 4-(2-bromo-5-(trifluoromethyl)benzyl)morpholine. MS (ESI): mass calcd. for C22H20F4N4O, 432.42; m/z found, 433.0 [M+H]+. 1H NMR (400 MHz, MeOD) δ 8.43 (s, 1H), 8.21-8.11 (m, 2H), 8.11-8.04 (m, 1H), 7.90 (dd, J=8.2, 1.8, 1H), 7.67 (d, J=8.1, 1H), 7.40-7.27 (m, 2H), 4.54 (s, 2H), 3.78 (s, 4H), 3.07 (s, 4H).
Example 606




The title compound was prepared using analogous conditions to those described in Example 6 utilizing tert-butyl (1-(2-bromo-5-(trifluoromethyl)benzyl)piperidin-4-yl)carbamate, followed by removal of the Boc group.
Removal of Boc group: To a stirred solution of tert-butyl (1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)methyl)piperidin-4-yl)carbamate (83 mg, 0.15 mmol) in DCM (2.4 mL) was added TFA (0.64 mL, 8.4 mmol) at room temperature. When the reaction had gone to completion, as followed by LCMS, the stir-bar was removed and the reaction mixture concentrated to dryness and the resultant residue subjected to HPLC purification to provide the title compound. MS (ESI): mass calcd. for C23H23F4N5, 445.47; m/z found, 446.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.44-8.40 (m, 1H), 8.13 (d, J=1.5, 1H), 8.10-8.08 (m, 1H), 8.08-8.03 (m, 1H), 7.87 (d, J=8.2, 1H), 7.65 (d, J=8.1, 1H), 7.35 (dd, J=11.8, 1.7, 1H), 7.31 (dd, J=8.0, 1.7, 1H), 4.41 (s, 2H), 3.42-3.35 (m, 2H), 3.29-3.26 (m, 1H), 2.82-2.69 (m, 2H), 2.14-2.06 (m, 2H), 1.87-1.72 (m, 2H).
Example 607




The title compound was prepared using analogous conditions to those described in Intermediate IF using 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxylic acid and ethanolamine. MS (ESI): mass calcd. for C20H18F4N4O, 406.39; m/z found, 407.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.41 (s, 1H), 8.18 (s, 1H), 8.12-8.01 (m, 2H), 7.86 (dd, J=8.1, 1.7, 1H), 7.65 (d, J=8.1, 1H), 7.34 (dd, J=3.5, 1.6, 1H), 7.33-7.31 (m, 1H), 4.38 (s, 2H), 3.78-3.63 (m, 2H), 3.09-3.00 (m, 2H).
Intermediate IH




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-4,6-dimethylpyrimidine. 1H NMR (400 MHz, DMSO-d6) δ 7.72 (dd, J=8.0, 1.4, 1H), 7.48-7.41 (m, 1H), 7.31 (dd, J=8.0, 1.6, 1H), 7.25-7.19 (m, 1H), 7.02 (s, 1H), 2.32 (s, 6H).
Intermediate ZZ




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-6-methylpyrimidin-4-amine. 1H NMR (400 MHz, DMSO-d6) δ 7.63 (dd, J=8.0, 1.6, 1H), 7.40-7.34 (m, 1H), 7.21 (dd, J=8.0, 1.6, 1H), 7.15-7.09 (m, 1H), 6.83 (s, 2H), 5.99 (s, 1H), 2.07 (s, 3H).
Intermediate II




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-4-(trifluoromethyl)pyrimidine. 1H NMR (400 MHz, DMSO-d) δ 9.03 (d, J=4.9, 1H), 7.86-7.73 (m, 2H), 7.55-7.42 (m, 2H), 7.32-7.24 (m, 1H).
Intermediate IJ




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloropyrimidin-5-amine. 1H NMR (400 MHz, DMSO-d6) δ d 7.98-7.94 (m, 2H), 7.71-7.66 (m, 1H), 7.45-7.37 (m, 1H), 7.24-7.20 (m, 1H), 7.17-7.12 (m, 1H), 5.22 (s, 2H).
Intermediate IK




The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloro-2-methylpyrimidin-4-amine. 1H NMR (400 MHz, DMSO-d6) δ 7.64 (dd, J=8.3, 1.5, 1H), 7.47-7.33 (m, 1H), 7.17 (ddd, J=7.2, 3.8, 1.3, 2H), 6.54 (s, 2H), 5.46 (s, 1H), 2.14 (s, 3H).
Intermediate IL




The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloro-6-cyclopropylpyrimidine. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (s, 1H), 7.81-7.64 (m, 1H), 7.47-7.41 (m, 1H), 7.36-7.28 (m, 1H), 7.26-7.21 (m, 1H), 7.14-7.09 (m, 1H), 2.16-2.08 (m, 1H), 1.06-0.99 (m, 4H).
Intermediate IM




The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloropicolinonitrile. 1H NMR (400 MHz, DMSO-d6) δ 8.13 (dd, J=8.5, 7.3, 1H), 7.82 (dd, J=7.3, 0.7, 1H), 7.77 (dd, J=8.0, 1.5, 1H), 7.53-7.47 (m, 2H), 7.38 (dd, J=8.1, 1.6, 1H), 7.32-7.25 (m, 1H).
Intermediate IN




The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloronicotinonitrile. 1H NMR (400 MHz, DMSO-d6) δ 8.71-8.56 (m, 1H), 8.39-8.34 (m, 1H), 7.78-7.74 (m, 1H), 7.51-7.46 (m, 1H), 7.39-7.33 (m, 2H), 7.30-7.24 (m, 1H).
Intermediate IO




The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloro-2-(trifluoromethyl)pyridine. 1H NMR (400 MHz, DMSO-d6) δ 8.60 (d, J=5.7, 1H), 7.80 (dd, J=8.0, 1.5, 1H), 7.55-7.48 (m, 1H), 7.43-7.36 (m, 2H), 7.31 (m 1H), 7.03 (dd, J=5.7, 2.4, 1H).
Intermediate IP




The title compound was prepared in a manner similar to that described for Intermediate HI using 2-chloro-6-(trifluoromethyl)pyridine. 1H NMR (400 MHz, DMSO-d6) 8.18-8.12 (m, 1H), 7.80-7.74 (m, 1H), 7.65 (d, J=7.4, 1H), 7.51-7.46 (m, 1H), 7.40-7.35 (m, 2H), 7.29-7.24 (m, 1H).
Intermediate IQ




The title compound was prepared in a manner similar to that described for Intermediate HI using 4-chloropyridin-2-amine. 1H NMR (400 MHz, DMSO-d6) δ 8.14 (s, 1H), 7.82-7.72 (m, 2H), 7.50-7.41 (m, 1H), 7.29-7.18 (m, 2H), 6.11 (dd, J=5.9, 2.3, 1H), 6.02 (s, 2H), 5.73 (d, J=2.3, 1H).
Intermediate IR




The title compound was prepared in a manner similar to that described for Intermediate HI using 6-chloropyridin-3-amine. 1H NMR (400 MHz, DMSO-d) δ 7.63 (dd, J=8.0, 1.6, 1H), 7.40-7.34 (m, 1H), 7.21 (dd, J=8.0, 1.6, 1H), 7.15-7.09 (m, 1H), 6.83 (s, 2H), 5.99 (s, 1H), 2.07 (s, 3H).
Example 608




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4,6-dimethylpyrimidine. MS (ESI): mass calcd. for C22H18FN5O, 387.15; m/z found, 388.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.28 (s, 1H), 7.96 (s, 1H), 7.78 (m, 1H), 7.50 (d, J=7.6, 1H), 7.42 (m 1H), 7.35-7.23 (m, 3H), 7.19 (d, J=7.8, 1H), 6.88 (s, 1H), 6.66 (s, 2H), 2.22 (s, 6H).
Example 609




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4,6-dimethylpyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H18FN5O, 387.15; m/z found, 388.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ d 8.40 (s, 2H), 7.52-7.46 (m, 2H), 7.44-7.39 (m, 1H), 7.35-7.25 (m, 3H), 7.18 (d, J=8.0, 1H), 6.90 (s, 1H), 6.85 (s, 2H), 2.24 (s, 6H).
Example 610




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C22H14F4N4O, 426.11; m/z found, 426.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, J=5.7, 1H), 8.30-8.25 (m, 1H), 7.96 (d, J=1.5, 1H), 7.81 (m, 1H), 7.64 (dd, J=7.6, 1.8, 1H), 7.50 (m, 2H), 7.39-7.29 (m, 4H), 7.04 (dd, J=5.7, 2.4, 1H), 6.68 (s, 2H).
Example 611




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-2-(trifluoromethyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H14F4N4O, 426.11; m/z found, 426.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, J=5.7, 1H), 8.38 (d, J=1.5, 2H), 7.62 (dd, J=7.6, 1.8, 1H), 7.56-7.42 (m, 3H), 7.38-7.30 (m, 4H), 7.04 (dd, J=5.6, 2.4, 1H), 6.84 (s, 2H).
Example 612




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4-(trifluoromethyl)pyrimidine. MS (ESI): mass calcd. for C21H13F4N5O, 427.11; m/z found, 428.0 [M+H]+. 1H NMR (400 MHz, DMSO): δ 8.91 (d, J=4.9, 1H), 8.34-8.28 (m, 1H), 8.00 (d, J=1.4, 1H), 7.82 (m, 1H), 7.67 (d, J=4.9, 1H), 7.61-7.58 (m, 1H), 7.55-7.50 (m, 1H), 7.47-7.39 (m, 2H), 7.34-7.29 (m, 2H), 6.70 (s, 2H).
Example 613




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-4-(trifluoromethyl)pyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H13F4N5O, 427.11; m/z found, 428.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.93 (d, J=4.9, 1H), 8.41 (d, J=1.4, 2H), 7.69 (d, J=4.9, 1H), 7.60-7.57 (m, 1H), 7.55-7.50 (m, 2H), 7.46-7.38 (m, 2H), 7.35-7.29 (m, 2H), 6.88 (s, 2H).
Example 614




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-5-amine. MS (ESI): mass calcd. for C2H15FN6O, 374.13; m/z found, 375.0 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.35-8.31 (m, 1H), 8.01 (m, 1H), 7.92-7.89 (m, 2H), 7.83 (m, 1H), 7.53 (dd, J=7.6, 1.7, 1H), 7.44-7.26 (m, 4H), 7.13 (dd, J=8.1, 1.2, 1H), 6.68 (s, 2H), 5.16 (s, 2H).
Example 615




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)pyrimidin-5-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H15FN6O, 374.13; m/z found, 374.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.45 (d, J=1.5, 2H), 7.95-7.90 (m, 2H), 7.57-7.50 (m, 2H), 7.44-7.39 (m, 1H), 7.38-7.37 (m, 1H), 7.36-7.34 (m, 1H), 7.33-7.28 (m, 1H), 7.11 (dd, J=8.1, 1.2, 1H), 6.86 (s, 2H), 5.19 (s, 2H).
Example 616




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-6-methylpyrimidin-4-amine. MS (ESI): mass calcd. for C21H17FN6O, 388.15; m/z found, 389.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.98 (s, 1H), 7.82 (m, 1H), 7.47 (d, J=7.6, 1H), 7.42-7.25 (m, 4H), 7.13 (d, J=8.0, 1H), 6.80 (s, 2H), 6.66 (s, 2H), 5.92 (s, 1H), 2.03 (s, 3H).
Example 617




The title compound was prepared in a manner similar to that described in Example 88 2-(2-bromophenoxy)-6-methylpyrimidin-4-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H17FN6O, 388.15; m/z found, 389.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.43 (d, J=1.2, 2H), 7.53 (t, J=8.2, 1H), 7.49-7.44 (m, 1H), 7.41-7.36 (m, 1H), 7.34 (s, 1H), 7.33-7.30 (m, 1H), 7.29-7.25 (m, 1H), 7.12 (d, J=8.0, 1H), 6.85 (s, 2H), 6.82 (s, 2H), 5.94 (s, 1H), 2.04 (s, 3H).
Example 618




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)picolinonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H14FN5O, 383.12; m/z found, 383.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (d, J=1.4, 2H), 7.99 (dd, J=8.5, 7.4, 1H), 7.71-7.67 (m, 1H), 7.56 (dd, J=7.6, 1.7, 1H), 7.55-7.46 (m, 2H), 7.42-7.37 (m, 1H), 7.35-7.25 (m, 4H), 6.85 (s, 2H).
Example 619




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)picolinonitrile. MS (ESI): mass calcd. for C22H14FN5O, 383.12; m/z found, 383.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.30-8.27 (m, 1H), 8.00-7.94 (m, 2H), 7.83-7.77 (m, 1H), 7.68-7.64 (m, 1H), 7.57 (dd, J=7.6, 1.7, 1H), 7.52-7.45 (m, 1H), 7.43-7.36 (m, 1H), 7.34-7.32 (m, 1H), 7.32-7.27 (m, 3H), 6.67 (s, 2H).
Example 620




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)pyridin-3-amine. MS (ESI): mass calcd. for C21H16FN5O, 373.14; m/z found, 373.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.98 (d, J=1.2, 1H), 7.83 (m, 1H), 7.51-7.45 (m, 2H), 7.42-7.31 (m, 3H), 7.23-7.18 (m, 1H), 7.03-6.99 (m, 1H), 6.94-6.90 (m, 1H), 6.71 (d, J=8.6, 1H), 6.66 (s, 2H), 5.01 (s, 2H).
Example 621




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)pyridin-3-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H16FN5O, 373.14; m/z found, 373.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.44 (s, 2H), 7.53 (m, 1H), 7.50-7.45 (m, 2H), 7.44-7.38 (m, 2H), 7.36-7.30 (m, 1H), 7.20 (t, J=7.4, 1H), 7.06-7.00 (m, 1H), 6.91 (d, J=8.0, 1H), 6.85 (s, 2H), 6.72 (d, J=8.6, 1H), 5.03 (s, 2H).
Example 622




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)-2-methylpyrimidin-4-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H17FN6O, 388.14; m/z found, 389.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.45 (d, J=1.4, 2H), 7.54 (dd, J=7.6, 1.7, 1H), 7.50-7.42 (m, 2H), 7.42-7.29 (m, 3H), 7.20 (dd, J=8.0, 1.2, 1H), 5.43-5.31 (m, 1H), 2.25 (s, 3H).
Example 623




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)-2-methylpyrimidin-4-amine. MS (ESI): mass calcd. for C21H17FN6O, 388.14; m/z found, 389.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.31 (dd, J=2.1, 1.6, 1H), 8.02 (d, J=1.5, 1H), 7.81 (m, 1H), 7.55 (dd, J=7.5, 1.8, 1H), 7.49-7.44 (m, 1H), 7.42-7.33 (m, 3H), 7.30 (dd, J=12.6, 1.7, 1H), 7.21 (dd, J=8.0, 1.2, 1H), 5.39 (s, 1H), 2.25 (s, 3H).
Example 624




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-6-(trifluoromethyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H14F4N4O, 426.11; m/z found, 427.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 2H), 8.04 (m, 1H), 7.59-7.48 (m, 4H), 7.41 (m, 1H), 7.35-7.24 (m, 4H), 6.89 (s, 2H).
Example 625




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C22H14F4N4O, 426.11; m/z found, 427.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.33-8.27 (m, 1H), 8.05-7.98 (m, 2H), 7.81 (m, 1H), 7.62-7.56 (m, 1H), 7.54-7.47 (m, 2H), 7.44-7.38 (m, 1H), 7.35-7.23 (m, 4H), 6.70 (s, 2H).
Example 626




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)nicotinonitrile. MS (ESI): mass calcd. for C22H14FN5O, 383.12; m/z found, 384.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.57 (dd, J=2.3, 0.8, 1H), 8.34-8.31 (m, 1H), 8.24 (dd, J=8.8, 2.3, 1H), 7.99 (d, J=1.4, 1H), 7.83 (m, 1H), 7.60 (dd, J=7.6, 1.6, 1H), 7.53-7.47 (m, 1H), 7.45-7.40 (m, 1H), 7.35-7.28 (m, 3H), 7.19 (dd, J=8.6, 0.6, 1H), 6.70 (s, 2H).
Example 627




The title compound was prepared in a manner similar to that described in Example 88 using 6-(2-bromophenoxy)nicotinonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H14FN5O, 383.12; m/z found, 384.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.60 (dd, J=2.3, 0.8, 1H), 8.44 (d, J=1.6, 2H), 8.26 (dd, J=8.6, 2.3, 1H), 7.59 (dd, J=7.6, 1.8, 1H), 7.56-7.48 (m, 2H), 7.45-7.39 (m, 1H), 7.36-7.27 (m, 3H), 7.21 (dd, J=8.7, 0.7, 1H), 6.89 (s, 2H).
Example 628




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)ethanol. MS (ESI): mass calcd. for C18H16FN3O2, 325.12; m/z found, 326.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.00 (d, J=1.2, 1H), 7.86 (m, 1H), 7.55-7.45 (m, 2H), 7.40-7.36 (m, 1H), 7.35-7.29 (m, 1H), 7.11 (d, J=8.2, 1H), 7.02 (m, 1H), 6.66 (s, 2H), 4.81 (s, 1H), 4.04 (t, J=5.0, 2H), 3.73-3.63 (m, 2H).
Example 629




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)ethanol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H16FN3O2, 325.12; m/z found, 326.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (d, J=1.0, 2H), 7.57-7.51 (m, 2H), 7.48-7.44 (m, 1H), 7.38-7.30 (m, 2H), 7.12 (d. J=8.4, 1H), 7.02 (m, 1H), 6.90 (s, 2H), 4.05 (t, J=5.0, 2H), 3.68 (t, J=5.0, 2H).
Example 630




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)piperidine. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.29 (s, 1H), 8.01 (s, 1H), 7.89 (m, 1H), 7.46-7.31 (m, 4H), 7.19 (d, J=8.2, 1H), 7.05 (m, 1H), 6.68 (s, 2H), 4.68-4.59 (m, 1H), 2.97-2.87 (m, 4H), 2.07-1.93 (m, 2H), 1.82-1.54 (m, 2H).
Example 631




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)piperidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (s, 2H), 8.29 (s, 1H), 7.56 (m, 1H), 7.46-7.31 (m, 4H), 7.20 (d, J=8.4, 1H), 7.05 (m, 1H), 6.86 (s, 2H), 4.62-4.66 (m, 1H), 2.91-2.93 (m, 4H), 2.07-1.96 (m, 2H), 1.77-1.65 (m, 2H).
Example 632




The title compound was prepared in a manner similar to that described in Example 88 using (R)-3-(2-bromophenoxy)piperidine. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.38 (dd, J=2.1, 1.6, 1H), 8.08 (d, J=1.5, 1H), 7.94-7.90 (m, 1H), 7.48-7.37 (m, 4H), 7.23-7.13 (m, 2H), 4.52-4.40 (m, 1H), 3.30-3.24 (m, 2H), 3.20-3.06 (m, 2H), 2.01-1.69 (m, 4H).
Example 633




The title compound was prepared in a manner similar to that described in Example 88 using (R)-3-(2-bromophenoxy)piperidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.48-8.45 (m, 2H), 7.60-7.48 (m, 2H), 7.46-7.34 (m, 3H), 7.23 (d, J=8.0, 1H), 7.13-7.06 (m, 1H), 6.87 (s, 2H), 4.68-4.56 (m, 1H), 3.35-3.30 (m, 1H), 3.11-2.99 (m, 2H), 2.98-2.89 (m, 1H), 2.03-1.93 (m, 1H), 1.88-1.77 (m, 1H), 1.72-1.58 (m, 2H).
Example 634




The title compound was prepared in a manner similar to that described in Example 88 using (S)-3-(2-bromophenoxy)piperidine. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.02 (s, 1H), 7.91-7.87 (m, 1H), 7.52-7.45 (m, 2H), 7.42 (d, J=7.4, 1H), 7.36 (d, J=7.1, 1H), 7.22 (d, J=8.3, 1H), 7.12-7.08 (m, 1H), 6.69 (s, 2H), 4.57 (br m, 1H), 3.09-3.04 (m, 3H), 2.98-2.92 (m, 1H), 2.02-1.90 (m, 1H), 1.87-1.75 (m, 1H), 1.70-1.58 (m, 2H).
Example 635




The title compound was prepared in a manner similar to that described in Example 88 using (S)-3-(2-bromophenoxy)piperidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H21FN4O, 364.17; m/z found, 365.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.48 (s, 2H), 7.59-7.48 (m, 2H), 7.44 (d, J=8.1, 1H), 7.40-7.35 (m, 2H), 7.24 (d, J=8.3, 1H), 7.11-7.07 (m, 1H), 6.87 (s, 2H), 4.73-4.53 (m, 1H), 3.38-3.30 (m, 1H), 3.12-2.86 (m, 3H), 2.04-1.94 (m, 1H), 1.80-1.71 (m, 2H), 1.65-1.54 (m, 1H).
Example 636




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-6-cyclopropylpyrimidine. MS (ESI): mass calcd. for C23H18FN5O, 399.15; m/z found, 399.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.43 (s, 1H), 8.30 (s, 1H), 7.97 (s, 1H), 7.81 (m, 1H), 7.58-7.54 (m, 1H), 7.49-7.43 (m, 1H), 7.41-7.35 (m, 1H), 7.33-7.23 (m, 3H), 6.98 (s, 1H), 6.68 (s, 2H), 2.09-2.01 (m, 1H), 1.02-0.89 (m, 4H).
Example 637




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)-6-cyclopropylpyrimidine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C23H18FN5O, 399.15; m/z found, 399.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.45 (s, 1H), 8.42 (s, 2H), 7.56-7.50 (m, 2H), 7.48-7.43 (m, 1H), 7.41-7.36 (m, 1H), 7.33-7.23 (m, 3H), 6.99 (s, 1H), 6.86 (s, 2H), 2.09-2.01 (m, 1H), 1.02-0.92 (m, 4H).
Example 638




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyridin-2-amine. MS (ESI): mass calcd. for C21H16FN5O, 373.13; m/z found, 374.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36-8.30 (m, 1H), 7.99 (d, J=1.4, 1H), 7.90-7.82 (m, 1H), 7.76 (d. J=6.5, 1H), 7.63 (dd, J=7.7, 1.7, 1H), 7.57-7.48 (m, 1H), 7.46-7.40 (m, 1H), 7.39-7.31 (m, 2H), 7.27 (d, J=8.0, 1H), 6.70 (s, 2H), 6.55 (s, 2H), 6.23 (dd, J=6.4, 2.2, 1H), 5.86 (d, J=2.3, 1H).
Example 639




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)pyridin-2-amine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H16FN5O, 373.13; m/z found, 374.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.44 (s, 2H), 7.77 (d, J=6.3, 1H), 7.65-7.48 (m, 3H), 7.45-7.32 (m, 3H), 7.25 (d, J=8.0, 1H), 6.88 (s, 2H), 6.52 (s, 2H), 6.23 (dd, J=6.3, 2.2, 1H), 5.87 (d, J=2.2, 1H).
Example 640




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)ethanamine. MS (ESI): mass calcd. for C18H17FN4O, 324.14; m/z found, 325.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.31 (s, 1H), 8.01 (d, J=1.3, 1H), 7.90-7.86 (m, 1H), 7.50-7.45 (m, 2H), 7.41-7.33 (m, 2H), 7.14 (d, J=8.1, 1H), 7.08-7.05 (m, 1H), 6.67 (s, 2H), 4.10 (t, J=5.4, 2H), 3.01 (t, J=5.4, 2H).
Example 641




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)ethanamine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H17FN4O, 324.14; m/z found, 325.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=0.9, 2H), 8.29 (s, 1H), 7.58-7.54 (m, 1H), 7.53-7.49 (m, 1H), 7.45 (dd, J=8.0, 1.4, 1H), 7.39-7.34 (m, 2H), 7.15 (d, J=8.1, 1H), 7.09-7.05 (m, 1H), 6.86 (s, 2H), 4.13 (t J=5.4, 2H), 3.05 (t, J=5.4, 2H).
Example 642




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)acetonitrile. MS (ESI): mass calcd. for C18H13FN4O, 320.11; m/z found, 320.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.40-8.33 (m, 1H), 8.01 (d, J=1.4, 1H), 7.91-7.87 (m, 1H), 7.45-7.39 (m, 3H), 7.37 (s, 1H), 7.30-7.24 (m, 1H), 7.18-7.15 (m, 1H), 6.68 (s, 2H), 5.18 (s, 2H).
Example 643




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)acetonitrile and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H13FN4O, 320.11; m/z found, 320.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.5, 2H), 7.60-7.56 (m, 1H), 7.46-7.34 (m, 4H), 7.26 (d. J=8.0, 1H), 7.18-7.14 (m, 1H), 6.87 (s, 2H), 5.18 (s, 2H).
Example 644




The title compound was prepared in a manner similar to that described in Example 88 using 2-(2-bromophenoxy)acetic acid and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H14FN3O3, 339.10; m/z found, 339.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J=1.4, 2H), 7.71 (d, J=13.3, 1H), 7.51 (d, J=5.7, 2H), 7.29 (dd, J=7.5, 1.7, 1H), 7.25-7.17 (m, 1H), 6.92-6.89 (m, 1H), 6.88-6.80 (m, 3H), 4.14 (s, 2H).
Intermediate IS




Step A: tert-Butyl 4-((3-bromopyridin-2-yl)oxy)piperidine-1-carboxylate
A suspension of 2-bromophenol (2.0 g, 10 mmol), tert-butyl 4-hydroxypiperidine-1-carboxylate (2.09 g, 10.4 mmol), and cesium carbonate (6.8 g, 21 mmol) in dimethylsulfoxide (10 mL) was heated at 130° Celsius overnight. The reaction mixture was then cooled to rt, diluted with water (20 mL), and extracted with ethyl acetate (3×20 mL). The combined organic extracts were washed with water (3×10 mL) and dried over anhydrous magnesium sulfate. The solvent was removed in vacuo, and the residue purified by FCC to provide the title compound.
Step B: 3-Bromo-2-(piperidin-4-yloxy)pyridine
To a solution of tert-butyl 4-((3-bromopyridin-2-yl)oxy)piperidine-1-carboxylate in MeOH (10 mL) was added HCl (2 mL, 1 N). The reaction mixture was stirred at rt for 2 h before adjusting the pH to  ̃9 with NH4OH. The mixture was then concentrated to dryness and the crude product purified by FCC to provide the title compound. 1H NMR (400 MHz, DMSO-d6) δ 8.17 (dd, J=4.8, 1.7, 1H), 8.06 (dd, J=7.7, 1.7, 1H), 6.98 (dd, J=7.7, 4.9, 1H), 5.31 (m, 1H), 3.18-3.07 (m, 4H), 2.22-2.05 (m, 2H), 1.92 (m, 2H).
Intermediate IT




Step A: 3-Bromo-2-((tetrahydro-2H-thiopyran-4-yl)oxy)pyridine
To a 100 mL reaction tube, equipped with a reflux condenser and under a nitrogen atmosphere, was added a solution consisting of tetrahydro-2H-thiopyran-4-ol (1.04 g, 8.78 mmol) in DMF (2 mL). The mixture was cooled to the 0° Celsius, and then treated with NaH (0.540 g, 60% dispersion in mineral oil, 13.5 mmol). When the addition was complete, the reaction was warmed to rt and stirred 30 min before adding 3-bromo-2-chloropyridine (1.3 g, 6.8 mmol), and heating at 130° Celsius for 10 hours. The reaction mixture was cooled to rt and carefully quenched with H2O, concentrated to remove the solvent, and extracted with water (20 mL) and EtOAc (3×20 mL). The combined organic extracts were dried over Na2SO4, filtered, and concentrated to dryness. The crude material was purified by FCC to provide the title compound.
Step B: 4-((3-Bromopyridin-2-yl)oxy)tetrahydro-2H-thiopyran 1,1-dioxide
To a 100 mL round-bottomed flask, was added a solution, consisting of 3-bromo-2-(tetrahydro-2H-thiopyran-4-yloxy)pyridine (1.6 g, 5.8 mmol) and DCM (25 mL), under a nitrogen atmosphere. The mixture was cooled to the 0° Celsius and m-CPBA (3.63 g, 14.6 mmol, 77%) was added in portions. When the addition was complete, the reaction was warmed to rt and stirred for 3 h. The reaction was quenched by adding H2O (10 mL) and the organic layer isolated. The aqueous phase was extracted with DCM (3×20 mL) and the combined organic extracts were washed with saturated NaHCO3, dried over sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by FCC to provide the title compound. 1H NMR (400 MHz, DMSO-d6) δ 8.17 (dd, J=4.9, 1.6, 1H), 8.07 (dd, J=7.8, 1.6, 1H), 6.99 (dd, J=7.7, 4.9, 1H), 5.43-5.36 (m, 1H), 3.23-3.19 (m, 2H), 3.15 (dd, J=14.3, 7.3, 2H), 2.31-2.25 (m, 4H).
Intermediate IU




Sodium hydride (1.6 g, 42 mmol) was added to cooled (ice-water bath) ethane-1,2-diol (5 mL) and the resulting mixture stirred at rt for 30 min before adding 3-bromo-2-chloropyridine (2.0 g, 100 mmol). The mixture was then heated at 130° Celsius under a N2 atmosphere overnight before cooling to rt and subjecting the reaction mixture to FCC purification to afford the title compound. 1H NMR (400 MHz, CDCl3) δ 8.05 (dd, J=4.9, 1.7, 1H), 7.82 (dd, J=7.6, 1.7, 1H), 6.80 (dd, J=7.6, 4.9, 1H), 4.54-4.50 (m, 2H), 3.97 (dd, J=8.8, 5.5, 2H), 3.18 (t, J=5.8, 1H).
Intermediate IV




To a cooled (0° C.) 150 mL reaction tube equipped with reflux condenser and under a nitrogen atmosphere, were added trans-4-aminocyclohexanol (2.0 g, 17 mmol), NaH (2.08 g, 60% dispersion in mineral oil, 52.1 mmol), and DMF (25 mL) to give a colorless solution. After stirring for 1 h, 3-bromo-2-chloropyridine (3.34 g, 17.4 mmol) was added to the mixture And the resulting mixture heated at 60° Celsius for 5 h. After the starting material was consumed, the reaction was cooled to room temperature and quenched with H2O (2 mL). The reaction mixture was concentrated to dryness and the resultant residue purified by FCC to provide the title compound. 1H NMR (400 MHz, DMSO-d6) δ 8.11 (dd, J=4.8, 1.6, 1H), 7.98 (dd, J=7.7, 1.6, 1H), 6.89 (dd, J=7.7, 4.8, 1H), 4.92 (dd, J=9.4, 5.2, 1H), 2.98 (s, 1H), 2.05 (m, 2H), 1.95 (m, 2H), 1.53-1.38 (m, 4H)
Intermediate IW




The title compound was prepared in a manner similar to that described in Step A for the synthesis of 4-((3-bromopyridin-2-yl)oxy)tetrahydro-2H-thiopyran1,1-dioxide using tetrahydro-2H-pyran-4-ol. 1H NMR (400 MHz, DMSO-d) 68.11 (dd, J=4.8, 1.7, 1H), 7.99 (dd, J=7.7, 1.7, 1H), 6.90 (dd, J=7.7, 4.8, 1H), 5.22 (m, 1H), 3.86-3.77 (m, 2H), 3.49 (m, 2H), 1.95 (m, 2H), 1.61 (m, 2H).
Intermediate IX




Step A: (R)-2-((1-(Benzyloxy)propan-2-yl)oxy)-3-bromopyridine
To a stirred solution of (R)-1-(benzyloxy)propan-2-ol (2.0 g, 12 mmol) in dry DMF (5 mL) was added NaH (1.5 g, 36 mmol) at 0 Celsius. The reaction mixture was then stirred for 30 min before adding 3-bromo-2-chloropyridine (2.3 g, 12 mmol) and stirring continued for another 4 h. The reaction was quenched by slow addition of water (10 mL) and the resultant mixture extracted with ethyl acetate (3×10 mL). The combined organic extracts were dried over Na2SO4, filtered, concentrated to dryness, and the crude product purified by FCC to provide the title compound.
Step B: (R)-2-((3-Bromopyridin-2-yl)oxy)propan-1-ol
To a stirred solution of (R)-2-((1-(benzyloxy)propan-2-yl)oxy)-3-bromopyridine (2.4 g, 7.5 mmol) in dry DCM (10 mL) was added BBr3 (7.5 mL, 22 mmol, 3 M in DCM) at −78 Celsius in a drop-wise manner and stirring continued for 3 h. The reaction mixture was warmed to rt and the pH adjusted to  ̃7-8 with sat. NaHCO3 (30 mL). The mixture was extracted with DCM (2×10 mL), and the combined extracts dried over Na2SO4, filtered, concentrated to dryness. The crude product was purified by FCC to provide the title compound. 1H NMR (400 MHz, CDCl3) δ 8.05-7.99 (m, 1H), 7.84-7.75 (m, 1H), 6.83-6.71 (m, 1H), 5.25-5.12 (m, 1H), 3.78 (d, J=5.1, 2H), 3.29 (s, 1H), 1.37 (d, J=6.4, 3H).
Intermediate IY




The title compound was prepared in a manner similar to that described for (R)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol using (S)-1-(benzyloxy)propan-2-ol. 1H NMR (400 MHz, CDCl3) δ 8.07-7.97 (m, 1H), 7.79 (m, 1H), 6.76 (m, 1H), 5.26-5.12 (m, 1H), 3.77 (t, J=6.1, 2H), 3.35 (s, 1H), 1.36 (d, J=6.3, 3H).
Example 645




The title compound was prepared in a manner similar to that described in Example 88 using 3-bromo-2-(piperidin-4-yloxy)pyridine. MS (ESI): mass calcd. for C20H20FN5O, 365.17; m/z found, 366.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (dd, J=2.3, 1.5, 1H), 8.20 (dd, J=4.9, 1.9, 1H), 8.04 (d, J=1.5, 1H), 8.00-7.88 (m, 2H), 7.60-7.52 (m, 2H), 7.15 (dd, J=7.4, 4.9, 1H), 6.73 (s, 2H), 5.45-5.32 (m, 1H), 3.11 (t, J=5.9, 4H), 2.23-2.06 (m, 2H), 2.04-1.83 (m, 2H).
Example 646




The title compound was prepared in a manner similar to that described in Example 88 using 3-bromo-2-(piperidin-4-yloxy)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H20FN5O, 365.17; m/z found, 366.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, J=1.5, 2H), 8.20 (dd, J=4.9, 1.9, 1H), 7.89 (dd, J=7.4, 1.9, 1H), 7.68-7.51 (m, 3H), 7.14 (dd, J=7.4, 4.9, 1H), 6.90 (s, 2H), 5.36 (s, 1H), 3.06 (d, J=11.3, 4H), 2.13 (s, 2H), 1.86 (s, 2H).
Example 647




The title compound was prepared in a manner similar to that described in Example 88 using 4-((3-bromopyridin-2-yl)oxy)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.21 (dd, J=4.8, 1.6, 1H), 8.04 (s, 1H), 7.99-7.88 (m, 2H), 7.61-7.51 (m, 2H), 7.16 (dd, J=7.4, 5.0, 1H), 6.71 (s, 2H), 5.49-5.38 (m, 1H), 3.21-3.15 (m, 2H), 3.10-2.99 (m, 2H), 2.30 (d, J=5.1, 4H).
Example 648




The title compound was prepared in a manner similar to that described in Example 88 using 4-((3-bromopyridin-2-yl)oxy)tetrahydro-2H-thiopyran 1,1-dioxide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 8.51 (d, J=1.3, 2H), 8.21 (dd, J=4.9, 1.8, 1H), 7.90 (dd, J=7.4, 1.8, 1H), 7.64 (m, 1H), 7.58 (dd, J=12.4, 1.5, 1H), 7.53 (dd, J=8.0, 1.7, 1H), 7.16 (dd, J=7.4, 4.9, 1H), 6.89 (s, 2H), 5.42 (dd, J=6.3, 3.0, 1H), 3.21 (dd, J=14.5, 8.0, 2H), 3.09-3.01 (m, 2H), 2.34-2.24 (m, 4H).
Example 649




The title compound was prepared in a manner similar to that described in Example 88 using 2-((3-bromopyridin-2-yl)oxy)ethanol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C17H15FN4O2, 326.12; m/z found, 326.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.3, 2H), 8.15 (dd, J=4.9, 1.8, 1H), 7.84 (dd, J=7.4, 1.8, 1H), 7.65-7.52 (m, 3H), 7.08 (dd. J=7.4, 5.0, 1H), 6.87 (s, 2H), 4.80 (s, 1H), 4.40-4.32 (m, 2H), 3.70 (t, J=5.0, 2H).
Example 650




The title compound was prepared in a manner similar to that described in Example 88 using 2-((3-bromopyridin-2-yl)oxy)ethanol. MS (ESI): mass calcd. for C17H15FN4O2, 326.12; m/z found, 327.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J=1.6, 1H), 8.15 (dd, J=4.9, 1.8, 1H), 8.00 (d, J=1.4, 1H), 7.93-7.83 (m, 2H), 7.58 (m, 2H), 7.08 (dd, J=7.4, 4.9, 1H), 6.68 (s, 2H), 4.80 (s, 1H), 4.39-4.34 (m, 2H), 3.70 (d, J=4.5, 2H).
Example 651




The title compound was prepared in a manner similar to that described in Example 88 using trans-4-((3-bromopyridin-2-yl)oxy)cyclohexanamine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H22FN5O, 379.18; m/z found, 380.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.1, 2H), 8.15 (dd, J=4.9, 1.7, 1H), 7.81 (dd. J=7.4, 1.7, 1H), 7.53 (m, 3H), 7.05 (dd, J=7.4, 5.0, 1H), 6.87 (s, 2H), 5.02 (m, 1H), 2.63 (m, 1H), 2.05 (m, 2H), 1.77 (m, 2H), 1.39 (m, 2H), 1.18 (m, 4H).
Example 652




The title compound was prepared in a manner similar to that described in Example 88 using trans-4-((3-bromopyridin-2-yl)oxy)cyclohexanamine. MS (ESI): mass calcd. for C21H22FN5O, 379.18; m/z found, 380.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.36 (d, J=1.9, 1H), 8.15 (dd, J=4.9, 1.8, 1H), 8.00 (d, J=1.4, 1H), 7.88 (m, 1H), 7.83 (dd, J=7.4, 1.9, 1H), 7.53-7.49 (m, 1H), 7.48 (s, 1H), 7.06 (dd, J=7.4, 4.9, 1H), 6.70 (s, 2H), 5.02 (m, 1H), 2.89 (s, 1H), 2.10 (m, 2H), 1.89 (m, 2H), 1.45-1.33 (m, 4H).
Example 653




The title compound was prepared in a manner similar to that described in Example 88 using 3-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridine. MS (ESI): mass calcd. for C20H19FN4O2, 366.15; m/z found, 367.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.38-8.31 (m, 1H), 8.15 (dd. J=4.9, 1.9, 1H), 8.00 (d. J=1.5, 1H), 7.94-7.83 (m, 2H), 7.57-7.48 (m, 2H), 7.07 (dd, J=7.4, 4.9, 1H), 6.68 (s, 2H), 5.38-5.23 (m, 1H), 3.83-3.68 (m, 2H), 3.50 (m, 2H), 1.98 (d, J=7.5, 2H), 1.71-1.54 (m, 2H).
Example 654




The title compound was prepared in a manner similar to that described in Example 88 using 3-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H19FN4O2, 366.15; m/z found, 367.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 8.47 (d, J=1.5, 2H), 8.15 (dd, J=4.9, 1.9, 1H), 7.84 (dd, J=7.4, 1.9, 1H), 7.64-7.48 (m, 3H), 7.07 (dd, J=7.4, 4.9, 1H), 6.86 (s, 2H), 5.30 (m, 1H), 3.81-3.72 (m, 2H), 3.49 (m, 2H), 1.98 (m, 2H), 1.70-1.55 (m, 2H).
Example 655




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol. MS (ESI): mass calcd. for C18H17FN4O2, 340.13; m/z found, 341.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.41-8.35 (m, 1H), 8.17 (dd, J=4.9, 1.8, 1H), 8.03 (d, J=1.4, 1H), 7.94-7.84 (m, 2H), 7.66-7.55 (m, 2H), 7.09 (dd, J=7.4, 4.9, 1H), 6.71 (s, 2H), 5.35-5.23 (m, 1H), 4.86 (t, J=5.4, 1H), 3.62-3.51 (m, 2H), 1.25 (d, J=6.3, 3H).
Example 656




The title compound was prepared in a manner similar to that described in Example 88 using (R)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H17FN4O2, 340.13; m/z found, 340.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 8.50 (d, J=1.4, 2H), 8.17 (dd, J=4.9, 1.9, 1H), 7.85 (dd, J=7.4, 1.9, 1H), 7.67-7.54 (m, 3H), 7.09 (dd, J=7.4, 4.9, 1H), 6.89 (s, 2H), 5.35-5.23 (m, 1H), 4.86 (t, J=5.4, 1H), 3.62-3.51 (m, 2H), 1.25 (d, J=6.3, 3H).
Example 657




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol. MS (ESI): mass calcd. for C18H17FN4O2, 340.13; m/z found, 341.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.38-8.32 (m, 1H), 8.14 (dd. J=4.9, 1.9, 1H), 8.00 (d, J=1.5, 1H), 7.91-7.80 (m, 2H), 7.64-7.52 (m, 2H), 7.05 (dd, J=7.4, 4.9, 1H), 6.68 (s, 2H), 5.32-5.22 (m, 1H), 4.82 (t, J=5.3, 1H), 3.58-3.48 (m, 2H), 1.22 (d, J=6.3, 3H).
Example 658




The title compound was prepared in a manner similar to that described in Example 88 using (S)-2-((3-bromopyridin-2-yl)oxy)propan-1-ol and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C18H17FN4O2, 340.13; m/z found, 341.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 8.47 (d, J=1.2, 2H), 8.14 (dd, J=4.9, 1.8, 1H), 7.82 (dd, J=7.4, 1.8, 1H), 7.64-7.52 (m, 3H), 7.05 (dd, J=7.4, 4.9, 1H), 6.86 (s, 2H), 5.34-5.21 (m, 1H), 4.83 (s, 1H), 3.58-3.47 (m, 2H), 1.22 (d, J=6.3, 3H).
Example 659




The title compound was prepared in a manner similar to that described in Example 341 using (2-(methylsulfonamido)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C18H16FN3O2S, 357.09; m/z found, 358.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 14.69-13.78 (m, 1H), 9.21-9.14 (s, 1H), 8.52-8.10 (m, 5H), 7.72-7.63 (m, 1H), 7.52-7.36 (m, 10H), 7.18-7.10 (d, J=9.3, 1H), 2.90-2.80 (s, 3H).
Example 660




The title compound was prepared in a manner similar to that described in Example 341 using (2-(morpholinosulfonyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C21H20FN3O3S, 413.12; m/z found, 414.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.20-8.13 (s, 1H), 8.05-7.98 (m, 1H), 7.81-7.73 (m, 1H), 7.70-7.60 (m, 3H), 7.57-7.50 (m, 1H), 7.49-7.45 (dd, J=7.6, 1.2, 1H), 7.36-7.29 (dd, J=12.0, 1.6, 1H), 7.29-7.24 (m, 1H), 6.59-6.52 (d, J=8.5, 1H), 6.26-6.14 (s, 2H), 3.44-3.36 (m, 5H), 2.82-2.72 (m, 5H).
Example 661




The title compound was prepared in a manner similar to that described in Example 341 using (2-(N-methylsulfamoyl)phenyl)boronic acid in Step B. MS (Cl): mass calcd. for C18H16FN3O2S, 357.09; m/z found, 358.0 [M+H]+. 1H NMR (500 MHz, acetone-d6) δ 8.29-8.20 (s, 1H), 7.73-7.28 (m, 9H), 6.72-6.65 (m, 1H), 5.74-5.53 (d, J=8.2, 2H), 3.01-2.93 (s, 3H).
Example 662




A mixture of 4′-(6-aminopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (55 mg, 0.14 mmol) and TFA (1 mL) was heated to 50° Celsius for 1.5 h. The mixture was cooled to rt and diluted with ether (10 mL. The resulting precipitate was collected via filtration and dried to provide the title compound. MS (Cl): mass calcd. for C17H14FN3O2S, 343.08; m/z found, 344.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.29-7.90 (m, 4H), 7.70-7.58 (m, 4H), 7.46-7.30 (m, 6H), 7.14-7.04 (d, J=9.2, 1H).
Example 663




The title compound was prepared in a manner similar to that described in Example 347 using (1S,4S)-5-((2-bromophenyl)sulfonyl-2-oxa-5-azabicyclo[2.2.1]heptane. MS (Cl): mass calcd. for C21H19FN4O3S, 426.12; m/z found, 427.0 [M+H]+. 1H NMR (500 MHz, DMSO-d) δ 8.20-8.13 (s, 1H), 8.05-7.98 (m, 1H), 7.81-7.73 (m, 1H), 7.70-7.60 (m, 3H), 7.57-7.50 (m, 1H), 7.49-7.45 (dd, J=7.6, 1.2, 1H), 7.36-7.29 (dd, J=12.0, 1.6, 1H), 7.29-7.24 (m, 1H), 6.59-6.52 (d, J=8.5, 1H), 6.26-6.14 (s, 2H), 3.44-3.36 (m, 5H), 2.82-2.72 (m, 5H).
Example 664




The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-((3-hydroxyazetidin-3-yl)methyl)benzenesulfonamide. MS (Cl): mass calcd. for C20H20FN5O3S, 429.13; m/z found, 430.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.79-8.64 (s, 1H), 8.63-8.51 (s, 1H), 8.43-8.37 (m, 1H), 8.06-8.02 (d, J=1.5, 1H), 8.00-7.94 (m, 1H), 7.94-7.87 (m, 1H), 7.84-7.77 (m, 1H), 7.75-7.69 (m, 1H), 7.69-7.63 (m, 1H), 7.49-7.43 (m, 1H), 7.36-7.27 (m, 2H), 6.89-6.55 (s, 2H), 6.36-6.08 (s, 1H), 3.93-3.88 (m, 2H), 3.72-3.70 (m, 2H), 3.04-2.97 (d, J=6.5, 2H).
Example 665




The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide. MS (Cl): mass calcd. for C21H22FN3O3S, 415.14; m/z found, 418.0 (off) [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.30-7.97 (m, 5H), 7.71-7.57 (m, 3H), 7.42-7.29 (m, 3H), 7.12-7.06 (d, J=9.2, 1H), 6.70-6.63 (s, 1H), 3.20-3.13 (s, 2H), 1.00-0.92 (s, 6H).
Example 666




The title compound was prepared in a manner similar to that described in Example 347 using 2-bromo-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylbenzenesulfonamide. MS (Cl): mass calcd. for C21H22FN3O3S, 494.17; m/z found, 494.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.27-8.21 (d, J=9.5, 1H), 8.17-8.10 (m, 2H), 7.72-7.65 (m, 1H), 7.65-7.54 (m, 2H), 7.41-7.34 (m, 3H), 7.33-7.24 (m, 5H), 7.19-7.12 (d, J=9.3, 1H), 4.57-4.49 (d, J=8.4, 1H), 3.97-3.86 (m, 1H), 2.63-2.52 (s, 3H), 0.94-0.61 (d, J=6.9, 3H).
Example 667




Step A: (4-(6-Amino-5-fluoropyridin-3-yl)-3-fluorophenyl)boronic acid
A mixture of 4-chloro-2-fluorophenylboronic acid (820 mg, 4.70 mmol), 2-amino-3-fluoro-5-bromopyrazine (900 mg, 4.70 mmol), palladium trifluoroacetate (31 mg, 0.094 mmol), triphenylphosphine (49 mg, 0.19 mmol), toluene (15 mL), EtOH (15 mL), and Na2CO3 (9 mL, 2 M) was deoxygenated by sparging with nitrogen. The mixture was then heated at 50° Celsius while stirring for 16 h. The mixture was then cooled to rt and diluted with EtOAc. The mixture was filtered and the filtrate transferred to a separatory funnel. The organic phase was isolated, and the aqueous phase extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, concentrated to dryness, and subjected to FCC to give 5-(4-chloro-2-fluorophenyl)-3-fluoropyridin-2-amine (980 mg). This material was combined with bis(pinacolato)diboron (1.03 g, 4.94 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl)]palladium(II) (62 mg, 0.079 mmol) and anhydrous potassium acetate (1.06 g, 11.8 mmol) in a sealable vessel under nitrogen. Deoxygenated 1,4-dioxane (150 mL) was added, and the reaction vessel sealed and heated at 60° Celsius for 16 h. The mixture was cooled to rt, diluted with EtOAc, and filtered through a pad of silica gel, and concentrated to give a brown residue. This material was taken up in HCl (40 mL, 1 M) and MeOH (ca. 5 mL), and any insoluble material was removed by filtration. The resulting solution was treated with solid NaHCO3 to achieve pH 7. The precipitate was collected and dried to give 4-(6-amino-5-fluoropyridin-3-yl)-3-fluorophenyl)boronic acid (968 mg, 84%). MS (Cl): mass calcd. for C11H9BF2N2O2, 250.01; m/z found, 252.0 [M+H]+.
Step B: 4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide, trifluoroacetate salt
A mixture of 4-(6-amino-5-fluoropyridin-3-yl)-3-fluorophenyl)boronic acid (80 mg, 0.32 mmol), 2-bromo-N-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide (118 mg, 0.380 mmol), Pd(dppf)Cl2.CH2Cl2 (12 mg, 0.016 mmol), K2CO3 (0.80 mL, 1.6 mmol, 2 M), and 1,4-dioxane (2 mL) was deoxygenated by sparging with nitrogen for 10 min, then heated at 80° Celsius for 16 h. The mixture was filtered using a syringe filter and directly subjected to HPLC purification to provide the title compound (74 mg, 42%). MS (Cl): mass calcd. for C21H21F2N3O3S, 433.13; m/z found, 435.0 [M+H]+. 1H NMR (500 MHz, DMSO-do) δ 8.13-8.04 (m, 2H), 7.80-7.73 (d, J=12.3, 1H), 7.69-7.64 (m, 1H), 7.64-7.56 (m, 2H), 7.40-7.36 (m, 1H), 7.36-7.31 (m, 1H), 7.31-7.26 (m, 1H), 6.62-6.55 (s, 1H), 3.19-3.11 (s, 2H), 1.01-0.87 (s, 6H).
Example 668




The title compound was prepared in a manner similar to that described in Example 676 using (racemic)-1-((2-bromophenyl)sulfonyl)piperidin-3-ol in Step B. MS (Cl): mass calcd. for C22H21F2N3O3S, 445.13; m/z found, 448.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.11-8.06 (m, 1H), 8.06-7.98 (m, 2H), 7.74-7.68 (m, 1H), 7.66-7.55 (m, 2H), 7.44-7.39 (m, 1H), 7.36-7.29 (m, 2H), 3.45-3.36 (m, 1H), 1.71-1.62 (m, 1H), 3.30-3.23 (m, 1H), 3.17-3.09 (d, J=12.7, 1H), 2.52-2.42 (m, 1H), 2.30-2.21 (dd, J=12.0, 9.1, 1H), 1.91-1.81 (m, 1H), 1.43-1.31 (m, 1H), 1.28-1.17 (m, 1H).
Example 669




The title compound was prepared in a manner similar to that described in Example 676 using 2-bromo-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylbenzenesulfonamide in Step B. MS (Cl): mass calcd. for C27H25F2N3O3S, 509.16; m/z found, 510.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.15-8.09 (m, 1H), 8.04-7.95 (m, 2H), 7.69-7.63 (m, 1H), 7.62-7.52 (m, 2H), 7.38-7.22 (m, 8H), 4.55-4.45 (d, J=8.4, 1H), 3.95-3.81 (m, 1H), 2.59-2.49 (s, 3H), 0.79-0.70 (d, J=6.9, 3H).
Example 670




The title compound was prepared in a manner similar to that described in Example 676 using N-(1-((2-bromophenyl)sulfonyl)piperidin-4-yl)acetamide in Step B. MS (Cl): mass calcd. for C24H24F2N4O3S, 486.15; m/z found, 487.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.11-8.01 (m, 3H), 7.74-7.67 (m, 1H), 7.65-7.57 (m, 2H), 7.43-7.38 (m, 1H), 7.36-7.28 (m, 2H), 3.68-3.57 (m, 1H), 3.38-3.32 (d, J=13.1, 2H), 2.58-2.48 (m, 2H), 1.90-1.86 (s, 3H), 1.78-1.69 (m, 2H), 1.38-1.25 (m, 2H).
Example 671




The title compound was prepared in a manner similar to that described in Example 676 using racemic 2-(1-((2-bromophenyl)sulfonyl)piperidin-3-yl)ethanol in Step B. MS (Cl): mass calcd. for C24H25F2N3O3S, 473.16; m/z found, 474.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.12-7.99 (m, 3H), 7.73-7.67 (m, 1H), 7.65-7.55 (m, 2H), 7.43-7.38 (m, 1H), 7.38-7.30 (m, 2H), 3.51-3.45 (m, 2H), 3.28-3.21 (m, 2H), 2.48-2.40 (m, 1H), 2.18-2.10 (m, 1H), 1.78-1.69 (m, 1H), 1.65-1.55 (m, 1H), 1.54-1.43 (m, 1H), 1.42-1.27 (m, 3H), 1.04-0.89 (m, 1H).
Example 672




The title compound was prepared in a manner similar to that described in Example 676 using racemic 2-(1-((2-bromophenyl)sulfonyl)piperidin-3-yl)methanol in Step B. MS (Cl): mass calcd. for C23H23F2N3O3S, 459.14; m/z found, 460.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.11-8.00 (m, 3H), 7.73-7.68 (m, 1H), 7.66-7.55 (m, 2H), 7.45-7.30 (m, 3H), 3.45-3.39 (m, 1H), 3.38-3.34 (dd, J=11.0, 5.2, 1H), 3.29-3.24 (d, J=11.7, 1H), 3.24-3.18 (dd, J=11.0, 7.7, 1H), 2.47-2.38 (m, 1H), 2.23-2.14 (m, 1H), 1.68-1.56 (m, 2H), 1.55-1.43 (m, 1H), 1.39-1.26 (m, 1H), 1.04-0.92 (m, 1H).
Example 673




The title compound was prepared in a manner similar to that described in Example 427 using (6-(2-aminopyrimidin-5-yl)-5-fluoropyridin-3-yl)boronic acid and (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H18FN5O3S, 403.11; m/z found, 404.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 9.02 (d, J=0.8, 2H), 8.52-8.47 (m, 1H), 8.09 (dd, J=7.9, 1.4, 1H), 7.81 (dd, J=11.9, 1.8, 1H), 7.72 (m, 1H), 7.66 (m, 1H), 7.46 (dd, J=7.5, 1.4, 1H), 3.74-3.59 (m, 1H), 2.84-2.66 (m, 2H), 1.06 (d, J=6.3, 3H).
Example 674




The title compound was prepared in a manner similar to that described in Example 427 using (6-(2-aminopyrimidin-5-yl)-5-fluoropyridin-3-yl)boronic acid and 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H15F4N5O2S, 441.09; m/z found, 442.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.94 (d, J=1.1, 2H), 8.51-8.46 (m, 1H), 8.37-8.31 (m, 1H), 8.03 (dd, J=8.1, 1.9, 1H), 7.81 (dd, J=11.9, 1.8, 1H), 7.68 (d, J=7.9, 1H), 2.86 (q, J=7.3, 2H), 1.02 (t, J=7.2, 3H).
Example 675




The title compound was prepared in a manner similar to that described in Example 427 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid and 5-(5-chloro-3-fluoropyridin-2-yl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H20FN5O2S, 401.13; m/z found, 402.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.97 (d, J=1.1, 2H), 8.50-8.44 (m, 1H), 8.17 (dd, J=8.0, 1.3, 1H), 7.79 (dd, J=12.0, 1.8, 1H), 7.70 (m, 1H), 7.63 (m, 1H), 7.43 (dd, J=7.5, 1.5, 1H), 1.09 (s, 9H).
Example 676




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 4-(2-bromo-5-(trifluoromethyl)benzyl)morpholine. MS (ESI): mass calcd. for C21H20F3N5O, 415.16; m/z found, 416.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.96 (s, 2H), 8.67 (dd, J=2.3, 0.9, 1H), 7.97 (dd, J=8.2, 2.3, 1H), 7.89 (dd, J=8.2, 0.9, 1H), 7.86-7.84 (m, 1H), 7.72-7.65 (m, 1H), 7.52 (d, J=7.9, 1H), 3.63-3.58 (m, 4H), 3.54-3.48 (m, 2H), 2.41-2.28 (m, 4H).
Example 677




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (2-bromophenyl)(morpholino)methanone. MS (ESI): mass calcd. for C20H19N5O2, 361.15; m/z found, 362.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.96 (s, 2H), 8.69-8.64 (m, 1H), 7.95-7.87 (m, 2H), 7.64-7.59 (m, 1H), 7.58-7.51 (m, 2H), 7.49-7.42 (m, 1H), 3.69-3.54 (m, 3H), 3.48-3.33 (m, 2H), 3.20-3.07 (m, 1H), 2.97-2.80 (m, 2H).
Example 678




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-bromo-2-methoxybenzene. MS (ESI): mass calcd. for C16H14N4O. C2HF3O2, 278.12; m/z found, 279.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.00 (s, 2H), 8.81 (d, J=2.2, 1H), 8.28 (dd, J=8.4, 2.2, 1H), 8.02 (d, J=8.4, 1H), 7.48-7.41 (m, 2H), 7.16 (d, J=8.4, 1H), 7.11 (m, 1H), 3.87 (s, 3H).
Example 679




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoropiperidine. MS (ESI): mass calcd. for C20H19F2N5O2S, 431.12; m/z found, 432.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.06 (s, 2H), 8.62 (dd, J=2.1, 1.1, 1H), 8.12 (dd, J=8.0, 1.3, 1H), 8.00-7.91 (m, 2H), 7.77 (m, 1H), 7.68 (m, 1H), 7.46 (dd, J=7.6, 1.4, 1H), 3.07 (t, J=11.3, 2H), 2.98-2.90 (m, 2H), 1.99-1.80 (m, 2H), 1.70-1.55 (m, 2H).




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-difluoropyrrolidine. MS (ESI): mass calcd. for C19H17F2N5O2S, 417.11; m/z found, 418.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.06 (s, 2H), 8.63 (m, 1H), 8.13 (dd, J=8.0, 1.3, 1H), 7.99-7.92 (m, 2H), 7.78 (m, 1H), 7.69 (m, 1H), 7.48 (dd, J=7.6, 1.4, 1H), 3.30-3.25 (m, 2H), 3.18 (t, J=7.3, 2H), 2.35-2.06 (m, 2H).
Example 681




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)azepane. MS (ESI): mass calcd. for C21H23N5O2S, 409.16; m/z found, 410.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.05 (s, 2H), 8.62 (m, 1H), 8.01 (dd. J=7.8, 1.4, 1H), 7.98-7.92 (m, 2H), 7.71 (m, 1H), 7.64 (m, 1H), 7.43 (dd, J=7.5, 1.4, 1H), 3.01-2.91 (m, 4H), 1.65-1.51 (m, 8H).
Example 682




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-4,4-difluoropiperidine. MS (ESI): mass calcd. for C20H19F2N5O2S, 431.12: m/z found, 432.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.08 (s, 2H), 8.63 (m, 1H), 8.13 (dd, J=8.0, 1.3, 1H), 7.96 (d, J=2.0, 2H), 7.77 (m, 1H), 7.68 (m, 1H), 7.47 (dd, J=7.5, 1.4, 1H), 3.09-2.95 (m, 4H), 1.97-1.71 (m, 4H).
Example 683




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-ethylbenzenesulfonamide. MS (ESI): mass calcd. for C1H17N5O2S, 355.11; m/z found, 356.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.06 (s, 2H), 8.66 (dd, J=2.3, 0.9, 1H), 8.08 (dd, J=7.9, 1.4, 1H), 8.05 (dd, J=8.3, 2.3, 1H), 7.97 (dd, J=8.3, 0.9, 1H), 7.72 (m, 1H), 7.65 (m, 1H), 7.44 (dd, J=7.5, 1.4, 1H), 2.86 (q, J=7.2, 2H), 1.02 (t, J=7.2, 3H).
Example 684




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-(dicyclopropylmethyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H23N5O2S, 421.16; m/z found, 422.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.65 (dd, J=2.3, 0.8, 1H), 8.16 (dd, J=7.9, 1.3, 1H), 8.03 (dd, J=8.3, 2.3, 1H), 7.93 (dd, J=8.3, 0.8, 1H), 7.70 (td, J=7.5, 1.4, 1H), 7.61 (m, 1H), 7.40 (dd. J=7.5, 1.3, 1H), 2.07 (t, J=8.3, 1H), 0.89-0.75 (m, 2H), 0.49-0.36 (m, 2H), 0.30-0.13 (m, 4H), 0.00-−0.09 (m, 2H).
Example 685




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,55-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (S)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C18H16F3N5O2S C18H16F3N5O2S, 423.10; m/z found, 424.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 9.06 (s, 2H), 8.64 (dd, J=2.2, 0.9, 1H), 8.15 (dd, J=8.0, 1.3, 1H), 8.04 (dd, J=8.2, 2.2, 1H), 7.99 (dd, J=8.2, 0.9, 1H), 7.73 (m, 1H), 7.66 (m, 1H), 7.43 (dd, J=7.6, 1.3, 1H), 3.96-3.71 (m, 1H), 1.23 (d, J=7.0, 3H).
Example 686




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (R)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C18H16F3N5O2S C18H16F3N5O2S, 423.10; m/z found, 424.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 9.05 (d, J=0.9, 2H), 8.63 (m, 1H), 8.15 (dd, J=8.0, 1.3, 1H), 8.03-7.99 (m, 1H), 7.97 (m, 1H), 7.73 (m, 1H), 7.65 (m, 1H), 7.42 (dd, J=7.5, 1.3, 1H), 3.91-3.81 (m, 1H), 1.23 (d, J=7.0, 3H).
Example 687




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 4-((2-bromophenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C19H18N6O3S, 410.12; m/z found, 411.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.97 (s, 2H), 8.60 (dd, J=2.2, 0.9, 1H), 8.18 (dd, J=8.0, 1.3, 1H), 7.91 (dd, J=8.2, 2.2, 1H), 7.87 (dd, J=8.2, 1.0, 1H), 7.80 (m, 1H), 7.70 (m, 1H), 7.50 (dd, J=7.5, 1.3, 1H), 3.42 (s, 2H), 3.15 (s, 4H).
Example 688




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (S)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H19N5O3S, 385.12; m/z found, 386.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.92 (s, 2H), 8.61-8.57 (m, 1H), 8.09 (d, J=8.0, 1H), 7.91 (dd, J=8.2, 2.3, 1H), 7.82 (d, J=8.2, 1H), 7.70 (m, 1H), 7.62 (m, 1H), 7.41 (d, J=6.8, 1H), 3.70-3.61 (m, 1H), 2.79-2.66 (m, 2H), 1.04 (d, J=6.3, 3H).
Example 689




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (R)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H19N5O3S, 385.12; m/z found, 386.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.92 (s, 2H), 8.60 (dd, J=2.3, 0.8, 1H), 8.09 (dd, J=8.0, 1.3, 1H), 7.91 (dd, J=8.2, 2.3, 1H), 7.82 (dd, J=8.2, 0.9, 1H), 7.70 (m, 1H), 7.62 (m, 1H), 7.41 (dd, J=7.6, 1.4, 1H), 3.70-3.59 (m, 1H), 2.79-2.67 (m, 2H), 1.04 (d, J=6.3, 3H).
Example 690




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H16F3N5O3S, 439.09; m/z found, 440.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.96 (s, 2H), 8.64 (d, J=1.7, 1H), 8.39 (s, 1H), 8.01 (d, J=8.0, 1H), 7.95 (dd, J=8.2, 2.3, 1H), 7.87 (d, J=8.3, 1H), 7.64 (d, J=8.0, 1H), 3.46 (t, J=5.9, 2H), 2.91 (t, J=5.9, 2H).
Example 691




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C18H16N4O2S, 352.10; m/z found, 353.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 7.80 (s, 2H), 7.41-7.36 (m, 1H), 6.86 (dd, J=8.0, 1.2, 1H), 6.74-6.70 (m, 1H), 6.69-6.64 (m, 1H), 6.50 (m, 1H), 6.42 (m, 1H), 6.20 (dd, J=7.5, 1.2, 1H), 1.08-0.98 (m, 1H), −0.28-−0.39 (m, 4H).
Example 692




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H16F3N5O2S, 423.10; m/z found, 424.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.95 (s, 2H), 8.62 (d, J=2.0, 1H), 8.35 (s, 1H), 8.01 (d, J=9.9, 1H), 7.93 (dd, J=8.2, 2.3, 1H), 7.87 (d, J=8.2, 1H), 7.64 (d, J=7.9, 1H), 2.84 (q, J=7.2, 2H), 1.01 (t, J=7.2, 3H).
Example 693




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-bromo-N-(tert-butyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H21N5O2S, 383.14; m/z found, 384.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.96 (s, 2H), 8.62 (dd, J=2.3, 0.9, 1H), 8.34 (d, J=1.8, 1H), 8.01 (dd, J=8.0, 1.6, 1H), 7.94 (dd, J=8.2, 2.3, 1H), 7.87 (dd, J=8.2, 0.9, 1H), 7.65 (d, J=7.9, 1H), 2.84 (q, J=7.2, 2H), 1.01 (t, J=7.2, 3H).
Example 694




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C18H19N5O3S, 385.12; m/z found, 386.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.92 (s, 2H), 8.66-8.56 (m, 1H), 8.19 (dd, J=8.0, 1.4, 1H), 7.95 (dd, J=8.2, 2.3, 1H), 7.83 (dd, J=8.2, 0.9, 1H), 7.72 (m, 1H), 7.64 (m, 1H), 7.43 (dd, J=7.5, 1.4, 1H), 3.43-3.16 (m, 4H), 1.03 (d, J=6.6, 3H).
Example 695




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 2-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C21H14FN7O, 399.12; m/z found, 400.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.73-8.70 (m, 1H), 7.89-7.81 (m, 2H), 7.51-7.43 (m, 2H), 7.41-7.35 (m, 4H), 7.23 (m, 1H).
Example 696




The title compound was prepared in a manner similar to that described for Intermediate D with DME as a solvent, heating at 100° Celsius for 16 hours and using 2-amino-5-bromopyrazine and 4-bromo-2-fluorobenzeneboronic acid. MS (ESI): mass calcd. for C16H10BrF2N3, 361.00; m/z found, 362.0, 364.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.47 (s, 1H), 8.30 (d, J=1.4, 1H), 8.12-8.02 (m, 1H), 7.49-7.32 (m, 5H), 6.37-5.94 (m, 1H), 6.15 (s, 2H).
Example 697




The title compound was prepared in a manner similar to that described for Intermediate HF heating at 90° Celsius for 16 hours and using 5-bromo-1H-pyrrolo[2,3-b]pyridine and 4-bromo-2-fluorobenzeneboronic acid. MS (ESI): mass calcd. for C19H11BrF2N2, 384.01; m/z found, 385.0, 387.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 12.29 (s, 1H), 8.47 (s, 2H), 7.60-7.50 (m, 2H), 7.50-7.34 (m, 5H), 6.73 (s, 1H).
Example 698




The title compound was prepared in a manner similar to that described for Example 850 using 5-(4-bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine and 4-(trifluoromethyl)phenylboronic acid. MS (ESI): mass calcd. for C18H13F4N3O, 363.10; m/z found, 363.9 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.61-8.56 (m, 1H), 8.12 (d, J=1.5, 1H), 7.72-7.66 (m, 4H), 7.22 (dd, J=8.3, 1.4, 1H), 7.28-7.24 (m, 1H), 4.73 (s, 2H), 3.77 (d. J=1.2, 3H).
Example 699




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2,4-difluorophenyl)boronic acid. MS (ESI): mass calcd. for C16H10F3N3, 301.08; m/z found, 302.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.43-8.35 (m, 1H), 8.03 (d. J=1.4, 1H), 7.97 (m, 1H), 7.73-7.65 (m, 1H), 7.54-7.35 (m, 3H), 7.26-7.20 (m, 1H), 6.74 (s, 2H).
Example 700




The title compound was prepared using conditions analogous to those used to make Intermediate EB utilizing 5-(3-fluoro-2′-(methylsulfinyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine. MS (ESI): mass calcd. for C17H14FN3OS, 327.08; m/z found, 328.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1H), 8.10-7.89 (m, 3H), 7.79-7.58 (m, 2H), 7.51-7.28 (m, 3H), 6.75 (s, 2H), 2.49 (s, 3H).
Example 701




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine and (2-cyanophenyl)boronic acid. MS (ESI): mass calcd. for C17H11FN4, 290.10; m/z found, 291.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.05-7.98 (m, 3H), 7.83 (m, 1H), 7.71 (d, J=7.6, 1H), 7.66-7.47 (m, 3H), 6.77 (s, 2H).
Intermediate IZ




To a solution of imidazolidin-2-one (86 mg, 1.0 mmol) in 1,4-dioxane (5 mL) was added Cs2CO3 (651 mg, 2.00 mmol) and Pd(OAc)2 (15 mg, 0.050 mmol). The mixture was purged with N2 several times. XantPhos (43 mg, 0.075 mmol) and 1-bromo-2-iodobenzene 4 (280 mg, 1.00 mmol) were added and the reaction mixture was stirred at 100° Celsius for 14 hours under an N2 atmosphere. After cooling to rt, the mixture was concentrated to dryness and the residue purified by FCC to give the title compound (60 mg, 25% yield). MS (ESI): mass calcd. for C9H9N2OBr 239.99, m/z found 240.1 [M+H]+; 1H NMR (300 MHz, CDCl3) δ7.65-7.61 (m, 1H), 7.38-7.34 (m, 2H), 7.25-7.19 (m, 1H), 3.94-3.89 (m, 2H), 3.66-3.61 (m, 2H).
Example 702




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluor-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)imidazolidin-2-one. MS (ESI): mass calcd. for C19H16FN5O, 349.13; m/z found, 350.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.41 (s, 1H), 8.10 (s, 1H), 7.94 (m, 1H), 7.81-7.77 (m, 1H), 7.51-7.46 (m, 5H), 3.51 (t, J=6.2, 2H), 3.37 (t, J=6.2, 2H).
Example 703




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing (2′-(N-(tert-butyl)sulfamoyl)-3-fluoro-[1,1′-biphenyl]-4-yl)boronic acid and 2-amino-5-bromo-4-cyanopyrimidine. MS (ESI): mass calcd. for C21H20FN5O2S, 327.08; m/z found, 328.1 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.64-8.59 (m, 1H), 8.07 (dd, J=7.9, 1.4, 1H), 7.71-7.65 (m, 1H), 7.65-7.59 (m, 2H), 7.57 (s, 2H), 7.45-7.39 (m, 2H), 7.36 (dd, J=7.8, 1.7, 1H), 6.89 (s, 1H), 1.02 (s, 9H).
Example 704




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 4-((2-bromophenyl)sulfonyl)thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C21H18FN5O4S2, 487.08: m/z found, 488.1 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.26 (s, 1H), 8.08 (dd, J=8.0, 1.3, 1H), 7.83-7.77 (m, 1H), 7.73-7.68 (m, 1H), 7.68-7.63 (m, 1H), 7.51 (dd, J=7.6, 1.3, 1H), 7.44 (dd, J=10.9, 1.7, 1H), 7.40 (s, 2H), 7.35 (dd, J=7.9, 1.6, 1H), 3.31-3.23 (m, 4H), 3.11-3.04 (m, 4H).
Example 705




The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-N-methylazetidine-3-carboxamide. MS (ESI): mass calcd. for C21H20FN5O3S, 441.13; m/z found, 441.9 [M+H]+. 1H NMR (500 MHz, DMSO-δ6) δ 8.52 (s, 2H), 8.02 (d, J=7.9, 1H), 7.84 (d, J=4.8, 1H), 7.79-7.72 (m, 1H), 7.69-7.63 (m, 1H), 7.61-7.55 (m, 1H), 7.45 (d, J=7.5, 1H), 7.33 (d, J=11.7, 1H), 7.27 (d, J=7.8, 1H), 6.89 (s, 2H), 3.70 (t, J=7.0, 2H), 3.63 (t, J=8.0, 2H), 3.19-3.08 (m, 1H), 2.56 (d, J=4.4, 3H).
Example 706




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C19H16FN5O3S, 413.10; m/z found, 414.0 [M+H]+. 1H NMR (500 MHz, DMSO-δ6) δ 8.26 (s, 1H), 7.99 (dd, J=7.9, 1.4, 1H), 7.72-7.59 (m, 3H), 7.47-7.41 (m, 2H), 7.41-7.31 (m, 4H), 4.70-4.64 (t, J=5.5, 1H), 3.45-3.27 (m, 2H), 2.85-2.78 (m, 2H).
Example 707




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and S-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H18FN5O3S, 427.11; m/z found, 428.0 [M+H]+. 1H NMR (500 MHz, DMSO-δ6) δ 8.26 (s, 1H), 7.97 (dd, J=7.9, 1.4, 1H), 7.72-7.59 (m, 3H), 7.49-7.43 (m, 2H), 7.41-7.33 (m, 4H), 4.71 (d, J=4.7, 1H), 3.61-3.53 (m, 1H), 3.17 (d, J=5.3, 1H), 2.73-2.59 (m, 2H), 0.98 (d, J=6.2, 3H).
Example 708




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and R-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. Characterization data were identical to the enantiomer (Example X).
Example 709




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)piperidine-4-carboxamide. MS (ESI): mass calcd. for C22H22FN5O3S, 455.14; m/z found, 455.9 [M+H]+. 1H NMR (500 MHz, DMSO-δ6) δ 8.51 (d, J=1.4, 2H), 8.02 (dd, J=8.0, 1.3, 1H), 7.78-7.71 (m, 1H), 7.69-7.63 (m, 1H), 7.61-7.54 (m, 1H), 7.45 (dd, J=7.6, 1.4, 1H), 7.32 (dd, J=11.8, 1.7, 1H), 7.26 (dd, J=7.9, 1.8, 1H), 7.17 (s, 1H), 6.88 (s, 2H), 6.73 (s, 1H), 3.26-3.19 (m, 2H), 2.47-2.38 (m, 2H), 2.13-2.02 (m, 1H), 1.59 (dd, J=13.9, 3.8, 2H), 1.31-1.17 (m, 2H).
Example 710




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and R-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C20H18FN5O3S, 426.11; m/z found, 427.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.22 (s, 1H), 8.15 (dd, J=8.0, 1.4, 1H), 7.72-7.64 (m, 1H), 7.64-7.56 (m, 2H), 7.46-7.33 (m, 3H), 3.46-3.36 (m, 1H), 3.30-3.25 (m, 1H), 3.25-3.14 (m, 1H), 1.02 (d, J=6.6, 3H).
Example 711




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and S-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. Characterization data were identical to the enantiomer (Example X).
Example 712




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-bromo-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H15F4N5O3S, 481.08; m/z found, 482.1 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.35-8.31 (m, 1H), 8.26 (s, 1H), 8.10-8.05 (m, 1H), 7.91-7.86 (m, 1H), 7.71 (d, J=7.9, 1H), 7.68-7.63 (m, 1H), 7.46 (dd, J=10.9, 1.7, 1H), 7.43-7.36 (m, 3H), 4.75 (t, J=5.4, 1H), 3.40-3.33 (m, 2H), 2.88-2.78 (m, 2H).
Example 713




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-bromo-N-ethyl-5-(trifluoromethyl)benzenesulfonamide. MS (ESI): mass calcd. for C20H15F4N5O2S, 465.09; m/z found, 465.8 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.26 (s, 2H), 8.11-8.07 (m, 1H), 7.87-7.81 (m, 1H), 7.72 (d, J=7.9, 1H), 7.69-7.63 (m, 1H), 7.45 (dd, J=10.8, 1.7, 1H), 7.43-7.36 (m, 3H), 2.78 (qd, J=7.2, 5.5, 2H), 0.97 (t, J=7.2, 3H).
Example 714




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-bromo-N-(3-hydroxy-2,2-dimethylpropyl)benzenesulfonamide. MS (ESI): mass calcd. for C22H22FN5OS, 455.14; m/z found, 456.0 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.26 (s, 1H), 7.93 (dd, J=7.8, 1.5, 1H), 7.72-7.60 (m, 3H), 7.47 (dd, J=7.4, 1.5, 1H), 7.43-7.34 (m, 5H), 4.49 (t, J=5.4, 1H), 3.08 (d, J=5.4, 2H), 2.62 (d, J=6.5, 2H), 0.73 (s, 6H).
Example 715




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 4-((2-bromo-5-(trifluoromethyl)phenyl)sulfonyl)piperazin-2-one. MS (ESI): mass calcd. for C22H16F4N6O3S, 520.09; m/z found, 520.8 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.29 (d, J=1.9, 1H), 8.26 (s, 1H), 8.19 (dd, J=8.2, 1.9, 1H), 8.07-8.01 (m, 1H), 7.77 (d, J=7.9, 1H), 7.70-7.64 (m, 1H), 7.49 (dd, J=10.8, 1.7, 1H), 7.44-7.36 (m, 3H), 3.39 (s, 2H), 3.07-2.96 (m, 4H).
Example 716




The title compound was prepared using conditions analogous to those used to make Example 337 utilizing N-(2-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)thio)ethyl)benzamide. MS (ESI): mass calcd. for C25H21FN4O3S, 476.13; m/z found, 477.0 [M+H]+. 1H NMR (600 MHz, DMSO) δ 8.52-8.46 (m, 3H), 8.11 (dd. J=7.8, 1.4, 1H), 7.74-7.68 (m, 1H), 7.68-7.61 (m, 3H), 7.61-7.56 (m, 1H), 7.52-7.47 (m, 1H), 7.43-7.38 (m, 3H), 7.36 (dd, J=11.7, 1.7, 1H), 7.30 (dd, J=7.9, 1.7, 1H), 6.93 (s, 2H), 3.47-3.40 (m, 2H), 3.30-3.24 (t, J=6.7, 2H).
Example 717




The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)-3,3-dimethylbutan-2-one. MS (ESI): mass calcd. for C22H22FN3O3S, 427.14; m/z found, 428.0 [M+H]+. 1H NMR (600 MHz, DMSO-d6) δ 8.51 (d, J=1.5, 2H), 8.09 (dd, J=8.0, 1.3, 1H), 7.82-7.76 (m, 1H), 7.75-7.69 (m, 1H), 7.68-7.62 (m, 1H), 7.44 (dd, J=7.6, 1.3, 1H), 7.39-7.34 (dd, J=11.6, 1.8, 1H), 7.29 (dd, J=7.9, 1.7, 1H), 6.96 (s, 2H), 4.44 (s, 2H), 0.94 (s, 9H).
Example 718




Step A: Ethyl 3-(4′-(2-aminopyrimidin-5-yl)-5′-fluorobiphenyl-2-ylthio)propanoate
A mixture of ethyl 3-((2-bromophenyl)thio)propanoate (5.8 g, 20 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine (6.95 g, 22.1 mmol), Pd(dppf)Cl2.CH2Cl2 (1.7 g, 2.0 mmol), Na2CO3 (4.25 g, 40.1 mmol) and 1,4-dioxane/water (80 mL/10 mL) was stirred at 90° C. overnight under N2. The reaction mixture was cooled to rt, filtered, and the filtrate concentrated to dryness. The resultant residue was subjected to FCC to give the title compound (6.5 g, 82%). MS (ESI): mass calcd. for C21H20FN3O2S, 397.13; m/z found, 397.9 [M+H]+.
Step B: 4′-(2-Aminopyrimidin-5-yl)-5′-fluorobiphenyl-2-thiol
To a solution of ethyl 3-(4′-(2-aminopyrimidin-5-yl)-5′-fluorobiphenyl-2-ylthio)propanoate (6.5 g, 16 mmol) in THF (70 mL) was added t-BuOK (3.68 g, 32.8 mmol) under a N2 atmosphere. After stirring for 10 min, methanol (5 mL) was added and the resulting mixture purified by FCC to give the title compound (4.8 g, 16 mmol, 98%). MS (ESI): mass calcd. for C16H12FN3S, 297.07; m/z found, 298.1 [M+H]+.
Step C: 5-(3-Fluoro-6′-(pyrimidin-2-ylthio)biphenyl-4-yl)pyrimidin-2-amine
A solution of 4′-(2-aminopyrimidin-5-yl)-5′-fluorobiphenyl-2-thiol (300 mg, 1.00 mmol), 2-chloropyrimidine (229 mg, 2.00 mmol), PPh3 (262 mg, 1.00 mmol) and TEA (0.38 mL) in DMF (10 mL) was stirred at 120° C. under a N2 atmosphere over-night. The reaction mixture was then cooled to rt, concentrated to dryness, and the residue subjected to FCC purification to give the title compound (170 mg, 45%). MS (ESI): mass calcd. for C20H14FN5S, 375.10; m/z found, 375.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.66 (s, 2H), 8.56 (d, J=4.9, 2H), 7.79-7.73 (m, 1H), 7.63-7.56 (m, 2H), 7.55-7.48 (m, 2H), 7.33-7.24 (m, 2H), 7.21 (t, J=4.9, 1H), 6.23 (s, 2H).
Step D: 5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine
To a rt solution of 5-(3-fluoro-6′-(pyrimidin-2-ylthio)biphenyl-4-yl)pyrimidin-2-amine (100 mg, 0.270 mmol), NaIO4 (170 mg, 0.810 mmol) in CH3CN/DCM/H2O (5 mL/5 mL/5 mL) was added RuCl3 (6 mg, 0.03 mmol). The resultant mixture was stirred for 3 h before diluting with saturated NaHCO3 (15 mL). The organic solvent was removed in vacuo, and the resultant solid isolated by filtration. The filter cake was washed with water, dried under vacuum and then subjected to HPLC purification to give the title compound (12 mg, 11%). MS (ESI): mass calcd. for C20H14FN5O2S, 407.09; m/z found, 408.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.87 (d, J=4.8, 2H), 8.42 (s, 2H), 8.33 (d, J=7.6, 1H), 7.86 (m, 1H), 7.80 (t, J=7.6, 1H), 7.74 (m, 1H), 7.43 (d, J=7.1, 1H), 7.30 (m, 1H), 6.93 (s, 2H), 6.80 (d, J=11.7, 1H), 6.75 (d, J=8.0, 1H).
Example 719




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H14FN5O2S, 407.09; m/z found, 408.1 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.88 (d, J=2.3, 1H), 8.71 (dd, J=2.3, 1.5, 1H), 8.55 (d, J=1.3, 1H), 8.44 (d, J=1.4, 2H), 8.35 (dd, J=7.8, 1.4, 1H), 7.85 (m, 1H), 7.81 (m, 1H), 7.41 (dd, J=7.4, 1.3, 1H), 7.34 (m, 1H), 6.95 (s, 2H), 6.80 (dd, J=7.9, 1.7, 1H), 6.75 (dd. J=11.4, 1.6, 1H).
Example 720




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H14FN5O2S, 407.09; m/z found, 408.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J=1.3, 1H), 8.96 (d, J=5.1, 1H), 8.57 (s, 2H), 8.35 (dd, J=7.8, 1.3, 1H), 7.88 (m, 1H), 7.83 (m, 1H), 7.58 (dd, J=5.1, 1.3, 1H), 7.44 (dd, J=7.4, 1.2, 1H), 7.36 (m, 1H), 6.86-6.81 (m, 2H).
Example 721




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, DMSO-d5) δ 8.64 (s, 2H), 8.27-8.25 (m, 2H), 7.83 (m, 1H), 7.78 (m, 1H), 7.56-7.35 (m, 4H), 6.97-6.87 (m, 2H), 6.45 (s, 1H).
Example 722




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (s, 2H), 8.22 (d, J=7.7, 1H), 7.98 (d, J=5.8, 1H), 7.80 (m, 1H), 7.74 (m, 1H), 7.53 (s, 2H), 7.41 (d, J=7.3, 1H), 7.36 (m, 1H), 7.01 (s, 2H), 6.89-6.84 (m, 2H), 6.43 (d, J=5.9, 1H).
Example 723




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.88 (s, 2H), 8.34 (dd, J=7.8, 1.5, 1H), 7.88 (d, J=1.2, 1H), 7.79-7.68 (m, 3H), 7.51 (m, 1H), 7.34 (dd, J=7.3, 1.4, 1H), 7.04 (dd, J=7.9, 1.6, 1H), 6.98 (dd, J=11.4, 1.5, 1H).
Example 724




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.43 (s, 2H), 8.28 (d, J=4.8, 1H), 8.24 (d, J=7.6, 1H), 7.86-7.79 (m, 1H), 7.76 (m, 1H), 7.43 (d, J=6.1, 1H), 7.36 (m, 1H), 7.25 (s, 2H), 6.98-6.83 (m, 4H), 6.50 (d, J=4.8, 1H).
Example 725




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.84 (s, 2H), 8.36 (dd, J=7.8, 1.3, 1H), 7.96 (s, 1H), 7.80 (m, 1H), 7.75 (m, 1H), 7.61 (s, 1H), 7.47 (m, 1H), 7.38 (dd, J=7.4, 1.2, 1H), 7.03 (dd, J=7.9, 1.6, 1H), 6.96 (dd, J=11.4, 1.5, 1H).
Example 726




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.25-8.22 (m, 2H), 8.02 (s, 1H), 7.85-7.71 (m, 2H), 7.65 (m, 1H), 7.42-7.39 (m, 3H), 6.88 (s, 1H), 6.84 (d, J=7.2, 1H), 6.47 (s, 1H).
Example 727




The title compound was prepared using conditions analogous to those used to make Example 718. MS (ESI): mass calcd. for C20H15FN6O2S, 422.10; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 8.20 (d, J=7.2, 1H), 8.02 (s, 1H), 7.97 (d, J=5.7, 1H), 7.83-7.61 (m, 3H), 7.51 (s, 2H), 7.41 (d, J=7.5, 1H), 6.89-6.82 (m, 2H), 6.43 (d, J=5.9, 1H).
Example 728




The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-bromo-2-((cyclopropylmethyl)sulfonyl)benzene. MS (ESI): mass calcd. for C2H18FN3O2S, 383.11; m/z found, 384.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.53 (d, J=1.5, 2H), 8.11 (dd, J=7.9, 1.2, 1H), 7.80 (m, 1H), 7.72 (m, 1H), 7.62 (m, 1H), 7.46 (dd, J=7.6, 1.1, 1H), 7.37 (dd, J=11.8, 1.7, 1H), 7.28 (dd, J=7.9, 1.7, 1H), 6.93 (s, 2H), 2.91 (d, J=7.2, 2H), 0.78-0.69 (m, 1H), 0.45-0.37 (m, 2H), 0.13-0.05 (m, 2H).
Example 729




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C20H15FN4O2S, 394.09; m/z found, 395.0 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.26 (s, 1H), 8.07 (dd, J=8.0, 1.3, 1H), 7.82-7.77 (m, 1H), 7.74-7.69 (m, 1H), 7.66-7.62 (m, 1H), 7.52 (dd, J=7.6, 1.3, 1H), 7.44 (dd, J=10.8, 1.7, 1H), 7.41-7.36 (m, 3H), 2.47-2.41 (m, 1H), 0.99-0.91 (m, 2H), 0.90-0.83 (m, 2H).
Intermediate JA




Step A: 2-(2-Bromophenylthio)acetonitrile
A mixture of 2-bromobenzenethiol (6.3 mL, 53 mmol), K2CO3 (13.8 g, 100 mmol) and 2-chloroacetonitrile (3.2 mL, 50 mmol) in DMF (50 mL) was stirred at 25° C. for 6 h, poured into water (700 mL), and extracted with petroleum ether (300 mL) followed by DCM (2×200 mL). The combined DCM extracts were concentrated to dryness, and re-dissolved in petroleum ether/ethyl acetate (10:1, 600 mL). The organic solution was washed with water (250 mL) and brine (250 mL), dried over Na2SO4, filtered and concentrated to dryness to give the title compound (11 g, 85%). 1H NMR (300 MHz, CDCl3) δ 7.67 (dd, J=7.8, 1.5, 1H), 7.60 (dd, J=7.8, 1.5, 1H), 7.41 (m, 1H), 7.25 (m, 1H), 3.68 (s, 2H).
Step B: 2-(2-Bromophenylsulfonyl)acetonitrile
A mixture of 2-(2-bromophenylthio)acetonitrile (10.8 g, 47.4 mmol), NaIO4 (30.4 g, 142 mmol) and RuCl3 (4 mg) in DCM/ACN/H2O (1:1:1, 300 mL) was stirred at rt for 18 h, and then filtered. The filtrate was diluted with water (600 mL), extracted with DCM (3×200 mL). The combined organic extracts were washed with brine (200 mL), dried over Na2SO4, filtered through a pad of silica gel, and concentrated to dryness to give the title compound (10.4 g, 84%). 1HNMR (400 MHz, CDCl3) δ 8.30-8.24 (m, 1H), 7.88-7.82 (m, 1H), 7.11-7.62 (m, 2H), 4.48 (s, 2H).
Step C: 1-((2-Bromophenyl)sulfonyl)cyclopentanecarbonitrile
A mixture of 2-(2-bromophenylsulfonyl)acetonitrile (4.4 g, 17 mmol), tetrabutylammonium bromide (0.82 g, 2.6 mmol), 1,4-dibromobutane (3.85 g, 17.8 mmol) and NaOH (14 mL, 5 N) in DCM (30 mL) was stirred at rt for 5 h, before diluting with DCM (200 mL), washing with water (2×80 mL) and brine (60 mL), drying over Na2SO4, filtering, and concentrating to dryness. The residue was treated with IPA (20 mL) and sonicated before isolating the title compound (2.2 g) via vacuum filtration. The filtrate was concentrated to dryness and the resultant residue subjected to FCC to give additional title compound. MS (ESI): mass calcd. for C12H12BrFN3O2S, 312.98; m/z found, 314.0 [M+H]+. 1HNMR (300 MHz, CDCl3) δ 8.28 (dd, J=7.5, 1.5, 1H), 7.85 (dd, J=7.5, 1.5, 1H), 7.62-7.51 (m, 2H), 2.80-2.68 (m, 2H), 2.34-2.22 (m, 2H), 2.02-1.81 (m, 4H).
Intermediate JB




The title compound was prepared using conditions analogous to those used to make 1-((2-bromophenyl)sulfonyl)cyclopentanecarbonitrile utilizing Mel in Step A.
Intermediate JC




A 30% H2O2 solution (1.6 mL) was added drop-wise at rt to a mixture of 1-(2-bromophenylsulfonyl)cyclopentanecarbonitrile (1.6 g, 5.1 mmol), K2CO3 (2.1 g, 15 mmol), and DMSO (5 mL). The mixture was stirred for 30 min before diluting with water (40 mL) and isolating the precipitate via vacuum filtration. The precipitate was washed with water and air-dried to give the title compound (1.5 g, 89%). MS (ESI): mass calcd. for C12H19NO3S, 330.99; m/z found, 331.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.99-7.95 (m, 1H), 7.89-7.84 (m, 1H), 7.64-7.51 (m, 4H), 2.41-2.25 (m, 4H), 1.78-1.66 (m, 2H), 1.58-1.45 (m, 2H).
Intermediate JD




The title compound was prepared using conditions analogous to those used to make 1-(2-bromophenylsulfonyl)cyclopentanecarboxamide starting with 2-((2-bromophenyl)sulfonyl)-2-methylpropanenitrile.
Example 730




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-((2-bromophenyl)sulfonyl)cyclopentanecarbonitrile. MS (ESI): mass calcd. for C22H19FN4O2S, 422.12; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.40 (s, 1H), 8.21 (dd, J=8.0, 1.0, 1H), 8.03 (d, J=1.4, 1H), 7.92 (m, 1H), 7.88-7.80 (m, 2H), 7.53 (d, J=7.6, 1H), 7.35 (dd, J=12.3, 1.5, 1H), 7.29 (dd, J=8.0, 1.6, 1H), 6.74 (s, 2H), 2.21-2.04 (m, 4H), 1.71-1.67 (m, 4H).
Example 731




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenylsulfonyl)cyclopentanecarboxamide. MS (ESI): mass calcd. for C22H21FN4O3S, 440.13; m/z found, 441.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.05 (s, 1H), 7.98 (d, J=7.8, 1H), 7.86 (m, 1H), 7.76 (m, 1H), 7.65 (m, 1H), 7.46 (s, 1H), 7.37 (d, J=7.4, 2H), 7.26-7.23 (m, 2H), 6.77 (s, 2H), 2.20 (s, 2H), 2.05-1.88 (m, 2H), 1.56 (s, 2H), 1.43 (s, 2H).
Example 732




The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropanenitrile. MS (ESI): mass calcd. for C20H17FN4O2S, 396.11; m/z found, 397.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 2H), 8.19 (d, J=7.9, 1H), 7.94 (m, 1H), 7.84 (m, 1H), 7.59 (m, 1H), 7.52 (d, J=7.5, 1H), 7.40 (dd, J=11.8, 1.1, 1H), 7.31 (dd, J=7.9, 1.4, 1H), 1.51 (s, 6H).
Example 733




The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropanamide. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.68 (s, 2H), 7.97 (d, J=7.9, 1H), 7.79 (m, 1H), 7.68 (m, 1H), 7.58 (m, 1H), 7.41 (s, 1H), 7.36 (d, J=7.5, 1H), 7.32-7.29 (m, 2H), 7.26 (d, J=7.9, 1H), 1.32 (s, 6H).
Example 734




Step A: 2-(2-Bromophenylsulfonyl)-2-methylpropan-1-amine
BH3.THF (4 mL, 1 M in THF) was added drop-wise to a solution of 2-((2-bromophenyl)sulfonyl)-2-methylpropanenitrile (258 mg, 1.00 mmol) in THF (1 mL) at rt. The mixture was refluxed for 4 hours and then cooled to rt. Aqueous HCl (5 mL, 6 N) was added and stirring continued for an additional 1 hour. The mixture was basified to pH=9 by addition of NaOH (6 N), diluted with water (20 mL), and extracted with DCM (3×20 mL). The combined extracts were washed with water (2×30 mL) and brine (60 mL), dried over Na2SO4, filtered, and concentrated to dryness to give the crude title compound (203 mg, 70%), which was used in the subsequent step without further purification. MS (ESI): mass calcd. for C10H14NO2S, 290.99; m/z found, 292.1 [M+H]+.
Step B: tert-Butyl 2-(2-bromophenylsulfonyl)-2-methylpropylcarbamate
A mixture of 2-(2-bromophenylsulfonyl)-2-methylpropan-1-amine (203 mg, 0.700 mmol) and di-tert-butyl dicarbonate (152 mg, 0.700 mmol) in MeOH (10 mL) was stirred at 50° C. for 6 hours, cooled to rt, and then concentrated to dryness. The resulting residue was subjected to FCC purification to give the title compound (180 mg, 65%). MS (ESI): mass calcd. for C15H22NO4S, 391.05; m/z found, 291.8 [M-Boc+H]+. 1H NMR (400 MHz, CDCl3) δ 8.05 (dd, J=7.8, 1.7, 1H), 7.80 (dd, J=7.7, 1.0, 1H), 7.56-7.50 (m, 1H), 7.52-7.42 (m, 1H), 5.51 (s, 1H), 3.52 (d, J=6.4, 2H), 1.45 (s, 9H), 1.37 (s, 6H).
Step C: tert-Butyl 2-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylsulfonyl)-2-methylpropyl carbamate
A mixture of K2CO (55 mg, 0.40 mmol) and dry DMF (5 mL) was sparged with N2 for 2 minutes and then treated with tert-butyl 2-(2-bromophenylsulfonyl)-2-methylpropylcarbamate (78 mg, 0.20 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (66 mg, 0.21 mmol), t-BuXphos (14 mg, 0.020 mmol) and Pd2(dba)3 (18 mg, 0.020 mmol). The resulting mixture was purged with N2 several times, and then stirred at 80° C. overnight. The reaction mixture was cooled to rt, diluted with EtOAc (20 mL), and filtered. The filtrate was concentrated to dryness and subjected to FCC to give the title compound (52 mg, 52%). MS (ESI): mass calcd. for C25H29N4O4S, 500.19; m/z found, 501.1 [M+H]+.
Step D: 5-(6′-(1-Amino-2-methylpropan-2-ylsulfonyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine
To a solution of tert-butyl 2-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-ylsulfonyl)-2-methylpropyl carbamate (52 mg, 0.10 mmol) in DCM (5 mL) was added TFA (2 mL). The resulting mixture was stirred at rt overnight then concentrated to dryness. The residue was basified to pH ̃7-8 by addition of saturated NaHCO3. The resulting mixture was diluted with water (30 mL), extracted with DCM (3×10 mL), and the combined extracts washed with brine (20 mL), concentrated to dryness, and the resultant crude product purified by HPLC to give the title compound. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.88 (s, 2H), 8.18 (d. J=7.9, 1H), 7.90-7.86 (m, 1H), 7.80-7.76 (m, 1H), 7.68-7.64 (m, 1H), 7.50 (d, J=7.6, 1H), 7.40 (d, J=3.1, 1H), 7.38 (s, 1H), 3.18 (s, 2H), 1.22 (s, 6H).
Example 735




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluor-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropanenitrile. MS (ESI): mass calcd. for C20H17FN4O2S, 396.11; m/z found, 397.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.18 (d, J=8.0, 1H), 8.12 (d, J=1.2, 1H), 7.94 (m, 1H), 7.88-7.82 (m, 2H), 7.54 (d, J=7.6, 1H), 7.37 (dd, J=12.4, 1.4, 1H), 7.29 (dd, J=8.1, 1.6, 1H), 1.50 (s, 6H).
Example 736




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropanamide. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.16 (d, J=1.2, 1H), 7.96 (dd, J=8.0, 0.9, 1H), 7.85 (m, 1H), 7.78 (m, 1H), 7.72-7.64 (m, 1H), 7.44 (s, 1H), 7.37 (dd, J=7.6, 0.9, 1H), 7.34 (s, 1H), 7.27 (dd, J=6.4, 1.3, 1H), 7.24 (s, 1H), 1.31 (s, 6H).
Example 737




The title compound was prepared using conditions analogous to those used to make Example 6 using -(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-((2-bromophenyl)sulfonyl)-2-methylpropan-1-amine. MS (ESI): mass calcd. for C20H21FN4O2S, 400.14; m/z found, 401.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.40 (s, 1H), 8.11 (d, J=6.9, 1H), 8.08 (d, J=1.4, 1H), 7.89-7.85 (m, 1H), 7.82-7.78 (m, 1H), 7.72-7.68 (m, 1H), 7.47 (d, J=6.5, 1H), 7.30-7.26 (m, 2H), 2.77 (s, 2H), 1.12 (s, 6H).
Example 738




The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-((2-bromophenyl)sulfonyl)cyclopentanecarbonitrile. MS (ESI): mass calcd. for C22H19FN4O2S, 422.12; m/z found, 423.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 2H), 8.21 (d, J=8.0, 1H), 7.91 (m, 1H), 7.86-7.79 (m, 1H), 7.57 (m, 1H), 7.52 (d, J=7.6, 1H), 7.37 (dd, J=11.8, 1.4, 1H), 7.29 (dd, J=8.0, 1.6, 1H), 6.92 (s, 2H), 2.22-2.07 (m, 4H), 1.72-1.68 (m, 4H).
Example 739




The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 1-(2-bromophenylsulfonyl)cyclopentanecarboxamide. MS (ESI): mass calcd. for C22H21FN4O3S, 440.13; m/z found, 441.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 2H), 7.98 (d, J=7.7, 1H), 7.75 (m, 1H), 7.65 (m, 1H), 7.54 (m, 1H), 7.42 (s, 1H), 7.36-7.34 (m, 2H), 7.28-7.22 (m, 2H), 6.93 (s, 2H), 2.27-2.16 (m, 2H), 2.04-1.91 (m, 2H), 1.57 (s, 2H), 1.49-1.35 (m, 2H).
Example 740




The title compound was prepared using conditions analogous to those used to make Example 6 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and (1-((2-bromophenyl)sulfonyl)cyclopentyl)methanamine. MS (ESI): mass calcd. for C22H23FN5O2S, 426.15; m/z found, 427.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.54 (d, J=1.3, 2H), 8.20 (dd, J=7.9, 1.2, 1H), 7.83 (m, 1H), 7.73 (m, 1H), 7.57-7.46 (m, 2H), 7.35-7.32 (m, 2H), 2.92 (s, 2H), 2.13-1.99 (m, 2H), 1.65-1.42 (m, 6H).
Example 741




The title compound was prepared using conditions analogous to those used to make Example 718, Steps A-C using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine in Step A and 2-amino-5-chloropyrazine in Step C. MS (ESI): mass calcd. for C19H16FN5O3S, 390.11; m/z found, 391.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.05 (s, 1H), 7.94-7.86 (m, 3H), 7.33-7.28 (m, 5H), 7.12-7.06 (m, 1H).
Example 742




The title compound was prepared using conditions analogous to those used to make Example 718, Steps A-C using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine in Step A and 2-amino-6-chloropyrazine in Step C. MS (ESI): mass calcd. for C20H15FN6S, 390.11; m/z found, 391.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.28 (s, 1H), 8.21 (s, 1H), 7.84 (m, 1H), 7.73-7.65 (m, 1H), 7.58-7.41 (m, 5H), 7.28-7.21 (m, 2H), 7.20-7.10 (m, 2H).
Example 743




The title compound was prepared using conditions analogous to those used to make Example 718, Steps A-C using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine in Step A and 4-chloropyrimidine in Step C. MS (ESI): mass calcd. for C20H14FN5S, 375.10; m/z found, 375.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.73 (s, 1H), 8.32 (d, J=5.7, 1H), 8.28 (m, 1H), 8.19 (d, J=1.4, 1H), 7.85 (m, 1H), 7.81-7.74 (m, 1H), 7.72-7.63 (m, 1H), 7.63-7.53 (m, 2H), 7.31-7.18 (m, 2H), 6.90 (dd, J=5.6, 1.3, 1H).
Example 744




The title compound was prepared using conditions analogous to those used to make Example 718, Steps A-C using 2-amino-5-chloropyrazine in Step C. MS (ESI): mass calcd. for C2H15FN6S, 390.11; m/z found, 391.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.51 (d, J=1.4, 2H), 7.79 (d, J=1.4, 1H), 7.72 (d, J=1.4, 1H), 7.47 (m, 1H), 7.32-7.17 (m, 6H).
Example 745




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-(2-bromophenoxy)pyrimidin-4-amine. MS (ESI): mass calcd. for C21H14FN7OS2, 399.12; m/z found, 400.2 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.22 (s, 1H), 7.79 (d, J=5.8, 1H), 7.62-7.51 (m, 2H), 7.49-7.38 (m, 3H), 7.38-7.30 (m, 3H), 7.20 (dd, J=8.0, 1.2, 1H), 7.01 (s, 2H), 6.10 (d, J=5.8, 1H).
Example 746




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-(2-bromo-5-(trifluoromethyl)phenoxy)pyrimidine. MS (ESI): mass calcd. for C22H12F4N6O, 452.10; m/z found, 453.1 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.56 (d, J=4.8, 2H), 8.20 (s, 1H), 7.89-7.81 (m, 2H), 7.81-7.75 (m, 1H), 7.61-7.54 (m, 1H), 7.48 (dd, J=11.1, 1.7, 1H), 7.43 (dd, J=8.1, 1.7, 1H), 7.37 (s, 2H), 7.22-7.17 (m, 1H).
Example 747




The title compound was prepared using conditions analogous to those used to make Example 6 utilizing 6-amino-3-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazine-2-carbonitrile and 2-(2-bromophenoxy)pyrimidine. MS (ESI): mass calcd. for C21H13FN6O, 384.11; m/z found, 385.0 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 8.55 (d, J=4.8, 2H), 8.20 (s, 1H), 7.61 (dd, J=7.7, 1.7, 1H), 7.57-7.49 (m, 2H), 7.44-7.37 (m, 3H), 7.35 (s, 2H), 7.32 (dd, J=8.1, 1.2, 1H), 7.19-7.15 (m, 1H).
Example 748




Step A: N-(tert-Butyl)-3′-fluoro-4′-(5-(N-(methylsulfonyl)methylsulfonamido)pyrazin-2-yl)-[1,1′-biphenyl]-2-sulfonamide
To a 20 mL vial were added a stir-bar, 4′-(5-aminopyrazin-2-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide (49 mg, 0.12 mmol), dry DCM (2.0 mL), DIPEA, (0.10 mL, 0.58 mmol), and methanesulfonyl chloride (0.020 mL, 0.25 mmol). The mixture was stirred at rt for 17.25 h before subjecting it to FCC to give impure title compound. The product was used in the next step without further purification.
Step B: N-(tert-Butyl)-3′-fluoro-4′-(5-(methylsulfonamido)pyrazin-2-yl)-[1,1′-biphenyl]-2-sulfonamide
To a 20 mL vial containing N-(tert-butyl)-3′-fluoro-4′-(5-(N-(methylsulfonyl)methylsulfonamido)pyrazin-2-yl)-[1,1′-biphenyl]-2-sulfonamide (38 mg, 0.068 mmol) were added a stir-bar and DMSO (1 mL). The mixture was sonicated until homogeneous, and then treated with NaOH (0.23 mL, 0.23 mmol, 1.0 N). The mixture was stirred at rt for 18.7 h before passing it through a syringe filter and subjecting it to HPLC purification thus yielding the title compound (28 mg, 86%). MS (ESI): mass calcd. for C21H23FN4O4S2, 478.11; m/z found, 479.1 [M+H]+. 1H NMR (600 MHz, DMSO-δ6) δ 11.29 (s, 1H), 8.82-8.72 (m, 1H), 8.46 (d, J=1.5, 1H), 8.07 (dd, J=7.9, 1.4, 1H), 7.98-7.91 (m, 1H), 7.71-7.65 (m, 1H), 7.65-7.58 (m, 1H), 7.43-7.32 (m, 3H), 7.05 (s, 1H), 3.41 (s, 3H), 1.03 (s, 9H).
Example 749




Step A: 5-(6′-(Chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine
A mixture of (4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methanol (1.8 g, 6.1 mmol) and SOCl2 (6 mL) in DCM (20 mL) was stirred at 70° C. for 4 h. The reaction mixture was cooled to rt and concentrated to dryness to give the title compound (1.86 g, 98%). 1H NMR (300 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.04 (s, 1H), 7.96 (m, 1H), 7.66-7.57 (m, 1H), 7.51-7.42 (m, 2H), 7.40-7.30 (m, 3H), 6.89-6.62 (m, 2H), 4.73 (s, 2H).
Step B: S-(4′-(5-Aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate
A mixture of 5-(6′-(chloromethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine (1.86 g, 5.94 mmol) and KSAc (0.81 g, 7.1 mmol) in 1,4-dioxane/H2O (30 mL/6 mL) was stirred at rt for 2 h. The solvent was then removed in vacuo and the residue purified by FCC to give the title compound (1.42 g, 68%). MS (ESI): mass calcd. for C19H16FN3OS, 353.10; m/z found, 353.9 [M+H]+.
Step C: 5-(2′-(Ethylthiomethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine
To a solution of S-(4′-(5-aminopyrazin-2-yl)-5′-fluorobiphenyl-2-yl)methyl ethanethioate (100 mg, 0.280 mmol) in CH3OH (30 mL) were added Ph3P (150 mg, 0.560 mmol), K2CO3 (78 mg, 0.56 mmol), and bromoethane [drop-wise addition (60 mg, 0.56 mmol)] at rt. The reaction mixture was stirred at rt for 16 h, before removing the solvent in vacuo. The crude product was purified first by preparative-TLC followed by HPLC to give the title compound (70 mg HCOOH salt, 73%).
Step D: 5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine
A mixture of 5-(2′-(ethylthiomethyl)-3-fluorobiphenyl-4-yl)pyrazin-2-amine (70 mg, 0.21 mmol), m-CPBA (107 mg, 0.618 mmol) and TFA (0.2 mL) in dry DCM (20 mL) was stirred at rt for 5 h, and then the solvent was removed under vacuum. The residue was purified by HPLC to give the title compound (40 mg, 52%). MS (ESI): mass calcd. for C19H18FN3O2S, 371.11; m/z found, 371.9 [M+H]+. 1H NMR (300 MHz, CD3OD) 8.68 (d, J=1.2, 1H), 8.26 (d, J=1.3, 1H), 8.15 (m, 1H), 7.70-7.61 (m, 1H), 7.53-7.31 (m, 5H), 4.43 (s, 2H), 2.97 (q, J=7.4, 2H), 1.20 (t, J=7.4, 3H).
Example 750




The title compound was prepared using conditions analogous to those used to make Example 749 utilizing 2-iodomethane in Step C. MS (ESI): mass calcd. for C18H16FN3O2S, 357.09; m/z found, 357.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.66 (d, J=1.4, 1H), 8.26 (d, J=1.3, 1H), 8.14 (m, 1H), 7.70-7.61 (m, 1H), 7.54-7.45 (m, 2H), 7.43-7.32 (m, 3H), 4.49 (s, 2H), 2.83 (s, 3H).
Example 751




The title compound was prepared using conditions analogous to those used to make Example 749 utilizing 2-iodopropane in Step C. MS (ESI): mass calcd. for C20H20FN5O3S, 385.13; m/z found, 386.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.72-8.61 (m, 1H), 8.24 (s, 1H), 8.13 (m, 1H), 7.70-7.59 (m, 1H), 7.54-7.28 (m, 5H), 4.40 (s, 2H), 3.18-3.07 (m, 1H), 1.23 (d, J=6.8, 6H).
Example 752




The title compound was prepared using conditions analogous to those used to make Example 749 utilizing 5-(3-fluoro-2′-((pyrimidin-2-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine in Step D. MS (ESI): mass calcd. for C21H16FN5O2S, 421.10; m/z found, 422.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.91 (d, J=4.9, 2H), 8.41 (s, 1H), 8.11 (d, J=1.3, 1H), 7.90 (t, J=8.1, 1H), 7.71 (m, 1H), 7.66-7.59 (m, 1H), 7.52-7.40 (m, 2H), 7.34 (dd, J=7.3, 1.5, 1H), 7.27-7.14 (m, 2H), 5.02 (s, 2H).
Example 753




The title compound was prepared using conditions analogous to those used to make Example 749, Steps A-C utilizing 4-amino-2-chloropyrimidine. MS (ESI): mass calcd. for C21H17FN6S, 404.12; m/z found, 405.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.63 (d, J=1.1, 1H), 8.25 (d, J=1.2, 1H), 8.10 (m, 1H), 7.86 (d, J=7.2, 1H), 7.68-7.58 (m, 1H), 7.51-7.39 (m, 2H), 7.37-7.23 (m, 3H), 6.40 (d, J=7.2, 1H), 4.62 (s, 2H).
Example 754




The title compound was prepared as described in Step C of Example 504 utilizing racemic 2-(trifluoromethyl)morpholine. MS (ESI): mass calcd. for C22H18F4N4O2, 446.14; m/z found, 447.1 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.61 (s), 8.18-7.95 (m), 7.59-7.29 (m), 4.88-4.41 (m), 4.11-3.51 (m), 3.32 (m), 3.17-3.00 (m), 3.00-2.84 (m), 2.68-2.41 (m), 2.37-2.16 (m).
Example 755




The title compound was prepared as described in Step C of Example 504 utilizing 3-hydroxyazetidine. MS (ESI): mass calcd. for C20H17FN4O2, 364.13; m/z found, 364.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.02 (s, 1H), 7.93-7.89 (m, 1H), 7.55-7.38 (m, 4H), 7.36-7.24 (m, 2H), 6.67 (s, 2H), 5.64 (s, 1H), 4.28 (s, 1H), 4.08-4.01 (m, 1H), 3.79-3.75 (m, 1H), 3.58-3.54 (m, 1H), 3.15 (s, 1H).
Example 756




The title compound was prepared as described in Step C of Example 504 utilizing tetrahydro-2H-pyran-4-amine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 392.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.33 (s, 1H), 8.22 (d, J=7.7, 1H), 8.01 (d, J=1.1, 1H), 7.86-7.82 (m, 1H), 7.54-7.38 (m, 4H), 7.29-7.25 (m, 2H), 6.65 (s, 2H), 3.86-3.77 (m, 1H), 3.73-3.70 (m, 2H), 3.26 (s, 2H), 1.61-1.59 (m, 2H), 1.38-1.28 (m, 2H).
Example 757




The title compound was prepared as described in Step C of Example 504 utilizing thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C22H18F4N4O3S, 494.10; m/z found, 494.7 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 8.02-7.90 (m, 4H), 7.78-7.76 (m, 1H), 7.36-7.29 (m, 2H), 6.75 (s, 2H), 4.35-4.20 (m, 1H), 3.59-3.46 (m, 2H), 3.31-3.12 (m, 4H), 3.04-2.90 (m, 1H).
Example 758




The title compound was prepared as described in Step C of Example 504 utilizing a diastereomeric mixture of 1-(piperidin-3-yl)ethanolgiving the title compound. MS (ESI): mass calcd. for C23H23FN4O3, 422.18; m/z found, 422.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ Complex due to the presence of multiple conformations on the NMR time-scale and diastereoisomers, peaks listed for identification purposes only: 8.30 (s), 8.01-7.80 (m), 7.53-7.14 (m), 4.55-4.49 (m), 4.33-4.25 (m), 3.90-3.66 (m), 3.61-3.31 (m), 3.25 (s), 3.16-2.85 (m), 2.84-2.12 (m), 1.07-0.76 (m).
Example 759




The title compound was prepared as described in Step C of Example 504 utilizing a diastereomeric mixture of 1-(piperidin-3-yl)ethanol. MS (ESI): mass calcd. for C23H23FN4O3, 422.18; m/z found, 422.9 [M+H]+. 1H NMR (400 MHz, CD3OD) Complex due to the presence of multiple conformations on the NMR time-scale and diastereoisomers, peaks listed for identification purposes only: δ 8.43 (s), 7.57-7.17 (m), 4.55-4.49 (m), 4.32-4.26 (m), 3.89-3.70 (m), 3.61-3.33 (m), 3.33-3.23 (m), 3.12-2.86 (m), 2.85-2.12 (m), 1.10-0.77 (m).
Example 760




The title compound was prepared as described in Step C of Example 504 utilizing ethanolamine. MS (ESI): mass calcd. for C19H17FN4O2, 352.13; m/z found, 352.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.06 (d, J=1.2, 1H), 7.94-7.83 (m, 1H), 7.59-7.39 (m, 4H), 7.38-7.22 (m, 2H), 3.51 (t, J=6.1, 2H), 3.35-3.31 (m, 2H).
Example 761




The title compound was prepared as described in Step C of Example 504 utilizing ethanolamine. MS (ESI): mass calcd. for C19H17FN4O2, 352.13; m/z found, 352.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.51 (s, 2H), 7.57-7.42 (m, 5H), 7.34-7.27 (m, 5H), 3.52 (t, J=6.0, 2H), 3.35-3.31 (m, 2H).
Example 762




The title compound was prepared as described in Step C of Example 504 utilizing (R)-3-hydroxypiperidine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.37 (s), 8.09 (br s), 8.03-7.87 (m), 7.65-7.45 (m), 7.45-7.23 (m), 4.34-4.20 (m), 4.13-4.09 (m), 3.94-3.80 (m), 3.68-3.31 (m), 3.21-2.84 (m), 2.79-2.48 (m), 1.94-1.65 (m), 1.39-1.08 (m).
Example 763




The title compound was prepared as described in Step C of Example 504 utilizing (cis/trans) 4-aminocyclohexanol. MS (ESI): mass calcd. for C23H23FN4O2, 406.18; m/z found, 407.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 8.07-8.04 (m, 1H), 7.88 (m, 1H), 7.57-7.40 (m, 4H), 7.33-7.24 (m, 2H), 3.69-3.62 (m, 1H), 3.46-3.39 (m, 4H), 3.34 (br s, 1H), 1.87-1.76 (m, 4H), 1.33-1.26 (m, 2H), 1.18-1.08 (m, 2H).
Example 764




The title compound was prepared as described in Step C of Example 504 utilizing (R)-piperidin-3-ol. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.52-8.51 (m), 7.59-7.47 (m), 7.44-7.28 (m), 4.30-4.04 (m), 3.93-3.81 (m), 3.69-3.32 (m), 3.17-2.89 (m), 2.83-2.57 (m), 1.96-1.67 (m), 1.53-1.15 (m).
Example 765




The title compound was prepared as described in Step C of Example 504 utilizing (cis/trans) 4-aminocyclohexanol. MS (ESI): mass calcd. for C23H23FN4O2, 406.18; m/z found, 407.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.49 (d, J=1.2, 2H), 7.58-7.40 (m, 5H), 7.33-7.26 (m, 2H), 3.69-3.61 (m, 1H), 3.51-3.38 (m, 1H), 3.33 (br s, 1H), 1.88-1.76 (m, 4H), 1.35-1.27 (m, 2H), 1.14 (m, 2H).
Example 766




The title compound was prepared as described in Step C of Example 504 utilizing racemic 2-(trifluoromethyl)morpholine. MS (ESI): mass calcd. for C22H18F4N4O2, 446.14; m/z found, 447.1 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.57 (s), 7.62-7.27 (m), 5.21 (s), 4.74 (dd), 4.52 (d), 4.12-3.73 (m), 3.65 (d), 3.48-3.21 (m), 3.21-3.01 (m), 2.94 (m), 2.60 (m), 2.35 (s), 2.16 (s).
Example 767




The title compound was prepared as described in Step C of Example 504 utilizing (S)-piperidin-3-ol. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, CD3OD) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.51 (d), 7.64-7.45 (m), 7.43-7.29 (m), 4.31-4.03 (m), 3.94-3.80 (m), 3.69-3.58 (m), 3.51-3.35 (m), 3.34 (s), 3.22-2.84 (m), 2.84-2.56 (m), 2.44 (dd), 2.10-1.55 (m), 1.52-1.15 (m).
Example 768




The title compound was prepared as described in Step C of Example 504 utilizing (S)piperidin-3-ol. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, CD3OD) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.38 (s), 8.07 (s), 7.97-7.87 (m), 7.59-7.45 (m), 7.44-7.25 (m), 4.30-4.27 (m), 4.11 (dd), 4.30-4.27 (m), 3.66-3.56 (m), 3.49-3.32 (m), 3.20-2.83 (m), 2.79-2.50 (m), 2.36 (dd), 2.04-1.58 (m), 1.50-1.13 (m).
Example 769




The title compound was prepared as described in Step C of Example 504 utilizing (R)-pyrrolidin-3-ol. MS (ESI): mass calcd. for C21H19FN4O2, 378.15; m/z found, 379.0 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.39 (s), 8.00 (s), 7.89-7.79 (m), 7.45-7.22 (m), 5.13 (m), 4.30 (m), 4.14 (m), 3.70-3.36 (m), 3.02-2.96 (m), 2.59 (m), 1.90-1.55 (m).
Example 770




The title compound was prepared as described in Step C of Example 504 utilizing (R)-pyrrolidin-3-ol. MS (ESI): mass calcd. for C21H19FN4O2, 378.15; m/z found, 379.0 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.46 (d), 7.46-7.23 (m), 5.47 (m), 4.31 (m), 4.16 (m), 3.65-3.37 (m), 3.13-2.86 (m), 2.81 (m), 1.86-1.60 (m).
Example 771




The title compound was prepared as described in Step C of Example 504 utilizing (S)-pyrrolidin-3-ol. MS (ESI): mass calcd. for C21H19FN4O2, 378.15; m/z found, 378.9 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.28 (s), 7.96 (s), 7.87-7.78 (m), 7.51-7.18 (m), 4.25-4.16 (m), 4.05 (m), 3.58-3.29 (m), 3.20 (m), 3.11-2.77 (m), 1.73 (m), 1.60 (m).
Example 772




The title compound was prepared as described in Step C of Example 504 utilizing (S)-pyrrolidin-3-ol. MS (ESI): mass calcd. for C21H19FN4O2, 378.15; m/z found, 379.0 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.45 (d), 7.45-7.23 (m), 5.19 (m), 4.33 (m), 4.17 (m), 3.63-3.56 (m), 3.50 (d), 3.06-2.87 (m), 1.79 (m), 1.67 (m).
Example 773




The title compound was prepared as described in Step C of Example 504 utilizing a diastereoisomeric mixture of 2,6-dimethylmorpholine. MS (ESI): mass calcd. for C23H23FN4O2, 406.18; m/z found, 407.0 [M+H]+. 1H NMR (400 MHz, CDCl3) Complex due to the presence of multiple diastereoisomers and conformations on the NMR time-scale, peaks listed for identification purposes only: δ 8.58 (d), 8.11 (s), 8.09-8.00 (m), 7.55-7.29 (m), 4.77 (br s), 4.52 (d), 3.64-3.30 (m), 3.10-3.00 (m), 2.58-2.47 (m), 2.44-2.33 (m), 2.18-2.01 (m), 1.14 (dd), 0.97-0.84 (m).
Example 774




The title compound was prepared as described in Step C of Example 504 utilizing (S)-3-methylmorpholine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.38 (d, J=9.6, 1H), 8.04 (s, 1H), 8.00-7.91 (m, 1H), 7.61-7.45 (m, 3H), 7.45-7.20 (m, 3H), 6.75 (d, J=5.1, 2H), 4.54-4.01 (m, 1H), 3.77-3.39 (m, 2H), 3.25-3.15 (m, 1H), 3.05-2.85 (m, 1H), 2.85-2.63 (m, 1H), 2.22-1.95 (m, 1H), 1.20 (d, J=6.9, 3H).
Example 775




The title compound was prepared as described in Step C of Example 504 utilizing (R)-3-methylmorpholine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.38 (d, J=9.6, 1H), 8.04 (s, 1H), 8.01-7.89 (m, 1H), 7.61-7.46 (m, 3H), 7.45-7.19 (m, 3H), 6.75 (d, J=5.1, 2H), 4.53-4.03 (m, 1H), 3.73-3.58 (m, 1H), 3.54-3.41 (m, 1H), 3.25-3.15 (m, 1H), 3.05-2.86 (m, 1H), 2.84-2.64 (m, 1H), 2.23-1.88 (m, 1H), 1.20 (d, J=6.9, 3H).
Example 776




The title compound was prepared as described in Step C of Example 504 utilizing (S)-2-methylmorpholine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.39 (s, 1H), 8.04 (s, 1H), 7.97-7.95 (m, 1H), 7.65-7.46 (m, 3H), 7.45-7.24 (m, 3H), 6.76 (s, 2H), 4.27 (dd, J=23.7, 13.0, 1H), 3.87-3.38 (m, 2H), 3.13-2.70 (m, 2H), 2.63-2.42 (m, 1H), 2.19-1.90 (m, 1H), 1.04 (d, J=6.0, 3H).
Example 777




The title compound was prepared as described in Step C of Example 504 utilizing (S)-2-methylmorpholine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d. J=5.2, 2H), 7.76-7.60 (m, 1H), 7.60-7.46 (m, 3H), 7.46-7.22 (m, 3H), 6.76 (s, 2H), 4.27 (dd, J=20.9, 12.6, 1H), 3.88-3.52 (m, 1H), 3.43 (m, 1H), 3.17-2.82 (m, 2H), 2.81-2.52 (m, 1H), 2.31-1.97 (m, 1H), 1.05 (d, J=5.9, 3H).
Example 778




The title compound was prepared as described in Step C of Example 504 utilizing (S)-3-methylmorpholine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ 8.54-8.45 (m, 2H), 7.72-7.60 (m, 1H), 7.57-7.47 (m, 3H), 7.42-7.21 (m, 3H), 6.94 (d, J=6.0, 2H), 4.48 (s, 1H), 3.90 (dd, J=13.9, 11.2, 1H), 3.60 (d, J=11.4, 1H), 3.16 (s, 1H), 3.01-2.68 (m, 2H), 2.27-1.96 (m, 1H), 1.20 (d, J=6.8, 3H)
Example 779




The title compound was prepared as described in Step C of Example 504 utilizing (R)-3-methylmorpholine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 393.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J=11.5, 2H), 7.69-7.58 (m, 1H), 7.56-7.42 (m, 3H), 7.40-7.18 (m, 3H), 6.91 (d. J=5.8, 2H), 4.41 (d. J=21.0, 1H), 3.87 (dd, J=13.5, 11.0, 1H), 3.56 (d, J=11.2, 1H), 3.15 (dd, J=8.0, 5.6, 1H), 3.00-2.66 (m, 2H), 2.12 (m, 1H), 1.17 (d, J=6.8, 3H).
Example 780




The title compound was prepared as described in Step C of Example 504 utilizing a diastereoisomeric mixture of 2,6-dimethylmorpholine. MS (ESI): mass calcd. for C23H23FN4O2, 406.18; m/z found, 407.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=9.3, 2H), 7.68-7.59 (m, 1H), 7.54-7.45 (m, 3H), 7.36-7.26 (m, 3H), 6.91 (d, J=10.5, 2H), 4.29 (d, J=12.6, 2H), 3.00 (dd, J=31.3, 12.7, 1H), 2.59-2.50 (m, 1H), 2.40-2.26 (m, 1H), 2.17-2.07 (m, 1H), 1.12-0.96 (m, 3H), 0.89-0.72 (m, 3H).
Example 781




The title compound was prepared as described in Example 376 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine. MS (ESI): mass calcd. for C23H19FN4O2, 402.15; m/z found, 403.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.34 (s, 1H), 8.73-8.64 (m, 1H), 8.55 (s, 1H), 8.18 (m, 1H), 7.88-7.79 (m, 1H), 7.60 (m, 1H), 7.51-7.41 (m, 1H), 7.43-7.32 (m, 3H), 6.65-6.55 (m, 1H), 3.73 (dd, J=5.8, 4.0, 2H), 3.63 (dd, J=5.7, 4.2, 2H), 3.34 (dd, J=5.6, 4.1, 2H), 3.18-3.06 (m, 2H).
Intermediate JE




To a round-bottomed flask that had been purged with nitrogen, were added 3-bromopicolinic acid (500 mg, 2.50 mmol), morpholine (259 mg, 3.00 mmol), EDCl (712 mg, 3.70 mmol), HOBT (501 mg, 3.70 mmol), triethylamine (1.0 mL, 7.4 mmol) and DMF (12 mL). The mixture was stirred at rt for 24 h, before diluting with water (100 mL) and extracting with ethyl acetate (2×100 mL). The combined organic extracts were washed with saturated bicarbonate (1×50 mL), water (2×50 mL), dried with sodium sulfate, and concentrated to dryness. The crude product was purified by FCC to provide the title compound. MS (ESI): mass calcd. for C10H11BrN2O2, 270.00; m/z found, 271.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.57 (dd. J=4.7, 1.4, 1H), 7.93 (dd, J=8.2, 1.4, 1H), 7.23 (dd, J=8.2, 4.7, 1H), 3.90-3.77 (m, 4H), 3.74-3.62 (m, 2H), 3.30-3.15 (m, 2H).
Example 782




The title compound was prepared as described in Example 376 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H18FN5O2, 379.14; m/z found, 380.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.72-8.63 (m, 1H), 8.56 (d, J=1.4, 2H), 7.85-7.75 (m, 1H), 7.53-7.42 (m, 2H), 7.39-7.28 (m, 2H), 5.17 (s, 2H), 3.71 (dd, J=5.6, 3.8, 2H), 3.63 (dd, J=5.6, 3.8, 2H), 3.37 (dd, J=5.6, 4.2, 2H), 3.18-3.06 (m, 2H).
Example 783




The title compound was prepared as described in Example 376 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C20H18FN5O2, 379.14; m/z found, 380.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.67 (dd, J=4.8, 1.6, 1H), 8.61 (m, 1H), 8.12 (d, J=1.4, 1H), 8.06 (m, 1H), 7.81 (dd, J=7.9, 1.6, 1H), 7.44 (dd, J=7.9, 4.8, 1H), 7.38 (dd, J=8.1, 1.8, 1H), 7.32 (dd, J=12.1, 1.8, 1H), 4.72 (s, 2H), 3.69 (dd, J=5.6, 3.9, 2H), 3.60 (dd, J=5.7, 4.1, 2H), 3.30 (dd, J=5.6, 4.1, 2H), 3.07 (dd. J=5.5, 4.1, 2H).
Example 784




The title compound was prepared as described in Step C of Example 504 utilizing t-butylamine. MS (ESI): mass calcd. for C22H20F4N4O, 432.16; m/z found, 432.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37-8.32 (m, 1H), 8.06-8.00 (m, 2H), 7.92-7.88 (m, 1H), 7.83 (d, J=8.2, 1H), 7.68-7.65 (m, 2H), 7.38-7.35 (m, 2H), 6.68 (s, 2H), 1.21 (s, 9H).
Example 785




The title compound was prepared as described in Step C of Example 504 utilizing (R)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C21H18F4N4O2, 434.14; m/z found, 434.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.29 (d, J=7.9, 1H), 8.05 (s, 1H), 7.97-7.84 (m, 2H), 7.77 (s, 1H), 7.71 (d, J=7.9, 1H), 7.37 (d, J=9.4, 2H), 6.71 (s, 2H), 4.70 (s, 1H), 3.93-3.78 (m, 1H), 3.25-3.15 (m, 2H), 1.00 (d, J=6.2, 3H).
Example 786




The title compound was prepared as described in Step C of Example 504 utilizing (S)-2-aminopropan-1-ol. MS (ESI): mass calcd. for C21H18F4N4O2, 434.14; m/z found, 434.9 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.42-8.39 (m, 1H), 8.31 (d, J=8.1, 1H), 8.07 (d, J=1.5, 1H), 7.96-7.89 (m, 2H), 7.79 (s, 1H), 7.74 (d, J=8.0, 1H), 7.41 (s, 1H), 7.38 (dd, J=4.5, 1.6, 1H), 6.74 (s, 2H), 4.72 (t, J=5.7, 1H), 3.92-3.83 (m, 1H), 3.25-3.19 (m, 2H), 1.02 (d, J=6.7, 3H).




The title compound was prepared as described in Step C of Example 504 utilizing (R)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C21H15F7N4O, 472.11; m/z found, 472.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.11 (d, J=8.8, 1H), 8.41-8.35 (m, 1H), 8.04 (d, J=1.4, 1H), 7.94-7.90 (m, 2H), 7.80-7.72 (m, 2H), 7.36-7.28 (m, 2H), 6.72 (s, 2H), 4.70-4.60 (m, 1H), 1.22 (d, J=7.0, 3H).
Example 788




The title compound was prepared as described in Step C of Example 504 utilizing (S)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C21H15F7N4O, 472.11; m/z found, 472.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, J=8.8, 1H), 8.48 (s, 2H), 7.94 (d, J=8.1, 1H), 7.80-7.72 (m, 2H), 7.65-7.61 (m, 1H), 7.34-7.30 (m, 2H), 6.90 (s, 2H), 4.69-4.60 (m, 1H), 1.22 (d, J=7.0, 3H).
Example 789




The title compound was prepared as described in Step C of Example 504 utilizing (R)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C21H15F7N4O, 472.11; m/z found, 472.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (d, J=8.8, 1H), 8.48 (s, 2H), 7.93 (d, J=8.0, 1H), 7.81-7.71 (m, 2H), 7.65-7.61 (m, 1H), 7.37-7.26 (m, 2H), 6.91 (s, 2H), 4.68-4.62 (m, 1H), 1.22 (d, J=7.0, 3H).
Example 790




The title compound was prepared as described in Step C of Example 504 utilizing (S)-1,1,1-trifluoropropan-2-amine. MS (ESI): mass calcd. for C21H15F7N4O, 472.11; m/z found, 472.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.13 (d. J=8.8, 1H), 8.43-8.35 (m, 1H), 8.06 (d, J=1.4, 1H), 7.96-7.91 (m, 2H), 7.77 (d, J=8.8, 2H), 7.37-7.29 (m, 2H), 6.73 (s, 2H), 4.71-4.61 (m, 1H), 1.23 (d, J=7.0, 3H).
Example 791




The title compound was prepared as described in Step C of Example 504 utilizing azetidin-3-. MS (ESI): mass calcd. for C20H17FN4O2, 364.13; m/z found, 364.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (s, 2H), 7.65-7.61 (m, 1H), 7.57-7.40 (m, 4H), 7.35-7.30 (m, 2H), 6.88 (s, 2H), 5.65 (d, J=4.8, 1H), 4.31 (s, 1H), 4.11-4.04 (m, 1H), 3.81 (t, J=7.9, 1H), 3.60 (dd, J=10.2, 4.4, 1H), 3.39 (dd, J=9.1, 4.4, 1H).
Example 792




The title compound was prepared as described in Step C of Example 504 utilizing N-methylpiperidin-4-amine. MS (ESI): mass calcd. for C23H24FN5O, 405.20; m/z found, 405.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.61 (d, J=10.6, 2H), 7.71-7.55 (m, 4H), 7.54-7.32 (m, 3H), 4.57 (d, J=12.6, 1H), 3.45-3.43 (m, 1H), 3.05-2.90 (m, 1H), 2.75-2.63 (m, 1H), 2.59-2.54 (m, 1H), 2.35 (m, 3H), 2.02-1.92 (m, 1H), 1.73-1.62 (m, 1H), 1.41-1.16 (m, 1H), 1.08-0.44 (m, 1H).
Example 793




The title compound was prepared as described in Step C of Example 504 utilizing thiomorpholine 1,1-dioxide. MS (ESI): mass calcd. for C22H18F4N4O3S, 494.10; m/z found, 494.8 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.49 (s, 2H), 8.03 (s, 1H), 7.94 (d, J=8.2H, 1H), 7.80 (d, J=8.1, 1H), 7.72-7.68 (m, 1H), 7.40 (d, J=11.7, 1H), 7.34 (d, J=7.6, 1H), 6.92 (s, 2H), 4.25-4.10 (m, 1H), 3.68-3.65 (m, 1H), 3.59-3.48 (m, 1H), 3.26-3.11 (m, 3H), 3.03-2.92 (m, 1H), 2.42-2.28 (m, 1H).
Example 794




The title compound was prepared as described in Step C of Example 504 utilizing t-butyl amine. MS (ESI): mass calcd. for C22H20F4N4O, 432.16: m/z found, 432.8 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.46 (s, 2H), 8.04 (s, 1H), 7.83 (d, J=8.0, 1H), 7.71-7.58 (m, 3H), 7.41-7.32 (m, 2H), 6.87 (s, 2H), 1.22 (s, 9H).
Example 795




The title compound was prepared as described in Step C of Example 504 utilizing piperidin-4-ol. MS (ESI): mass calcd. for C23H20F4N4O2, 460.15; m/z found, 460.8 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.39-8.33 (m, 1H), 8.03 (s, 1H), 7.98-7.91 (m, 1H), 7.86 (d, J=8.2, 1H), 7.75 (dd, J=8.1, 3.2, 1H), 7.70 (d, J=6.3, 1H), 7.40-7.32 (m, 2H), 6.72 (s, 2H), 4.69-4.61 (m, 1H), 3.99-3.73 (m, 1H), 3.53-3.50 (m, 1H), 3.17-2.59 (m, 3H), 1.66-1.34 (m, 2H), 1.17-0.45 (m, 2H).
Example 796




The title compound was prepared as described in Step C of Example 504 utilizing piperidin-4-ol. MS (ESI): mass calcd. for C23H20F4N4O2, 460.15; m/z found, 460.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.49 (d, J=7.1, 2H), 7.89 (d, J=8.2, 1H), 7.83-7.65 (m, 3H), 7.48-7.33 (m, 2H), 6.91 (s, 2H), 4.05-4.02 (m, 1H), 3.91-3.76 (m, 1H), 3.64-3.48 (m, 1H), 3.23-3.18 (m, 1H), 3.05-2.63 (m, 2H), 1.72-1.40 (m, 2H), 1.20-0.97 (m, 2H).
Example 797




The title compound was prepared as described in Step C of Example 504 utilizing tetrahydro-2H-pyran-4-amine. MS (ESI): mass calcd. for C22H21FN4O2, 392.16; m/z found, 392.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.1, 2H), 8.24 (d, J=7.8, 1H), 7.61-7.49 (m, 2H), 7.48-7.41 (m, 3H), 7.32-7.29 (m, 2H), 6.87 (s, 2H), 3.89-3.79 (m, 1H), 3.76-3.73 (m, 2H), 3.34 (s, 2H), 1.64-1.61 (m, 2H), 1.41-1.29 (m, 2H).
Example 798




The title compound was prepared as described in Step C of Example 504 utilizing morpholin-2-ylmethanol. MS (ESI): mass calcd. for C22H21FN4O3, 408.16; m/z found, 408.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.39 (s, 1H), 8.07 (s, 1H), 7.97-7.91 (m, 1H), 7.58-7.25 (m, 6H), 4.51-4.31 (m, 1H), 3.95-3.56 (m, 1H), 3.55-3.43 (m, 2H), 3.40-3.33 (m, 1H), 3.26-2.96 (m, 2H), 2.90-2.63 (m, 1H), 2.60-2.19 (m, 1H).
Example 799




The title compound was prepared as described in Step C of Example 504 utilizing racemic morpholin-2-ylmethanol. MS (ESI): mass calcd. for C22H21FN4O3, 408.16; m/z found, 409.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.52 (s, 2H), 7.67-7.25 (m, 7H), 4.49-4.33 (m, 1H), 3.96-3.56 (m, 1H), 3.56-3.43 (m, 2H), 3.41-3.31 (m, 1H), 3.23-2.95 (m, 2H), 2.89-2.53 (m, 1H), 2.52-2.13 (m, 1H).
Intermediate JF




3-Bromopyridin-2-amine (500 mg, 2.89 mmol) and pivaloyl chloride (420 mg, 3.48 mmol) were added to a 50 mL round-bottomed flask. Pyridine (10 mL) was then added and the mixture stirred and heated at 80° C. for 4 h. The reaction was then cooled to rt and stirred overnight. The reaction mixture was then concentrated to dryness and the resultant residue subjected to FCC to provide the title compound. MS (ESI): mass calcd. for C10H13BrN2O, 256.02; m/z found, 257.1 [M+H]+.
Example 800




The title compound was prepared as described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine and N-(3-bromopyridin-2-yl)pivalamide. MS (ESI): mass calcd. for C20H20FN5O, 365.17; m/z found, 366.15 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 8.52-8.43 (m, 3H), 7.93-7.83 (m, 1H), 7.56-7.64 (m, 1H), 7.47-7.68 (m, 1H), 7.38-7.26 (m, 2H), 6.93 (s, 2H), 1.05 (s, 9H).
Example 801




The title compound was prepared as described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrazin-2-amine and N-(3-bromopyridin-2-yl)pivalamide. MS (ESI): mass calcd. for C20H20FN5O, 365.17; m/z found, 366.2 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 9.66 (s, 1H), 8.52-8.42 (m, 1H), 8.40-8.30 (m, 1H), 8.03 (d, J=1.4, 1H), 7.95-7.82 (m, 2H), 7.47-7.38 (m, 1H), 7.39-7.30 (m, 1H), 6.73 (s, 2H), 1.05 (s, 9H).
Example 802




The title compound was prepared as described in Example 376 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and N-(3-bromopyridin-2-yl)pivalamide. MS (ESI): mass calcd. for C23H21FN4O, 388.17; m/z found, 389.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.81 (s, 1H), 9.67 (s, 1H), 8.54-8.46 (m, 1H), 8.42-8.33 (m, 1H), 8.18-8.09 (m, 1H), 7.96-7.87 (m, 1H), 7.71-7.62 (m, 1H), 7.55 (d, J=3.5, 1H), 7.50-7.40 (m, 1H), 7.41-7.31 (m, 2H), 6.54 (d, J=3.5, 1H), 1.07 (s, 9H).
Example 803




Step A: 3-Bromopyridine-2-thiol
A mixture of 3-bromo-2-chloropyridine (10 g, 0.050 mol) and Na2S (12 g, 0.15 mol) in DMF (150 mL) was stirred at 120° C. for 16 h. and the reaction mixture was cooled to rt and then concentrated to dryness. The resultant residue was diluted with water (80 mL), acidified to pH=5-6 with conc. HCl, and then extracted with ethyl acetate (3×50 mL). The combined organic extracts were dried over Na2SO4 and concentrated to dryness to give the title compound (6.4 g, crude). MS (ESI): mass calcd. For C5H4BrNS 188.92; m/z found, 191.9 [M+H]+.
Step B: tert-Butyl 3-(3-bromopyridin-2-ylthio)pyrrolidine-1-carboxylate
A mixture of 3-bromopyridine-2-thiol (0.30 g, 1.6 mmol), tert-butyl 3-bromopyrrolidine-1-carboxylate (0.79 g, 3.2 mmol) and K2CO3 (438 mg, 3.20 mmol) in DMF (12 mL) was stirred at rt for 4 h. The reaction mixture was concentrated to dryness and the residue subjected to FCC purification to give partially purified title compound (1.05 g, 63% purity).
Step C: tert-Butyl 3-(3-bromopyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate
To a solution of tert-butyl 3-(3-bromopyridin-2-ylthio)pyrrolidine-1-carboxylate (0.9 g, 63% purity, 1.6 mmol) in DCM/CH3CN (20 mL/20 mL) were added NaIO4 (1.6 g, 7.6 mmol), H2O (20 mL), and RuCl3 (10 mg, 0.070 mmol). The mixture was stirred at rt for 10 minutes and then concentrated to dryness. The resultant residue was diluted with water (50 mL) and extracted with DCM (3×40 mL). The combined extracts were dried over MgSO4, concentrated to dryness to give impure title compound (1.0 g, 60% purity) which was used for next step without any further purification.
Step D: tert-Butyl 3-(3-(4-(5-aminopyrazin-2-yl)-3-fluorophenyl)pyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate
A mixture of tert-butyl 3-(3-bromopyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate (205 mg, 60% purity, 0.320 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (100 mg, 0.320 mmol), Pd(dppf)Cl2.CH2Cl2 (23 mg, 0.030 mmol), and Na2CO3 (101 mg, 0.950 mmol) in DMF (6 mL) was stirred at 100° C. for 16 h under N2 before cooling to rt and concentrating it to dryness. The resultant residue was subjected to FCC followed by HPLC purification to give the title compound (150 mg, 99%). MS (ESI): mass calcd. For C24H26FN5O4S 499.17; m/z found, 521.9 [M+Na]+.
Step E: 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrazin-2-amine hydrochloride.
To a solution consisting of tert-butyl 3-(3-(4-(5-aminopyrazin-2-yl)-3-fluorophenyl)pyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate (150 mg, 0.300 mmol) and DCM (10 mL) was added HCl/EtOH (5 N, 10 mL). The mixture was stirred at rt for 2 h, concentrated to dryness, and the resultant residue subjected to HPLC purification to give the title compound (67 mg, 52%). MS (ESI): mass calcd. For C19H18FN5O2S.HCl 399.12; m/z found, 400.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 9.79 (br s, 1H), 9.42 (br s, 1H), 8.79 (d, J=4.6, 1H), 8.51-8.30 (m, 1H), 8.20-7.78 (m, 3H), 7.51-7.02 (m, 3H), 4.81 (dd, J=14.1, 7.6, 1H), 3.72 (s, 1H), 3.49-3.14 (m, 3H), 2.44-2.20 (m, 2H).
Example 804




The title compound was prepared as described in step E of Example 803 using tert-butyl 3-(3-(4-(5-aminopyrimidin-2-yl)-3-fluorophenyl)pyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate. MS (ESI): mass calcd. for C19H18FN5O2S, 399.12; m/z found, 400.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.71 (dd, J=4.7, 1.6, 1H), 8.52 (d, J=1.4, 2H), 8.41 (br s, 1H), 8.03 (dd, J=7.9, 1.5, 1H), 7.78 (dd, J=7.9, 4.7, 1H), 7.58 (m, 1H), 7.49-7.35 (m, 2H), 4.95-4.90 (m, 1H), 3.81 (dd, J=13.3, 8.9, 1H), 3.66 (dd, J=13.3, 5.4, 1H), 3.44-3.33 (m, 2H), 2.52-2.38 (m, 2H).
Example 805




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclobutylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-. MS (ESI): mass calcd. for C19H17FN4O2S.HCl, 384.11; m/z found, 385.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.80 (d, J=0.8, 2H), 8.70 (dd, J=4.7, 1.6, 1H), 7.99 (dd, J=7.8, 1.6, 1H), 7.74 (dd, J=7.8, 4.7, 1H), 7.69 (m, 1H), 7.53-7.46 (m, 2H), 4.80-4.69 (m, 1H), 2.54-2.41 (m, 2H), 2.41-2.30 (m, 2H), 2.20-2.07 (m, 1H), 2.05-1.94 (m, 1H).
Example 806




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclobutylsulfonyl)pyridine. MS (ESI): mass calcd. for C19H17FN4O2S.HCl, 384.11; m/z found, 385.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.69 (dd, J=4.7, 1.5, 1H), 8.52 (s, 1H), 8.33 (s, 1H), 8.12 (m, 1H), 7.99 (dd, J=7.8, 1.5, 1H), 7.74 (dd, J=7.8, 4.7, 1H), 7.49 (d, J=2.7, 1H), 7.46 (s, 1H), 4.80-4.70 (m, 1H), 2.54-2.42 (m, 2H), 2.40-2.30 (m, 2H), 2.21-2.07 (m, 1H), 2.04-1.94 (m, 1H).
Example 807




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclohexylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H21FN4O2S.HCl, 412.14; m/z found, 413.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.74 (dd, J=4.6, 1.6, 1H), 8.56 (s, 2H), 7.96 (dd, J=7.9, 1.6, 1H), 7.74 (dd, J=7.9, 4.7, 1H), 7.57 (m, 1H), 7.37 (dd, J=3.6, 1.3, 1H), 7.34 (s, 1H), 3.97-3.83 (m, 1H), 2.01-1.63 (m, 5H), 1.52-1.13 (m, 5H).
Example 808




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclohexylsulfonyl)pyridine. MS (ESI): mass calcd. for C21H21FN4O2S.HCl, 412.14; m/z found, 413.1 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 8.78 (d, J=4.4, 1H), 8.39 (s, 1H), 8.02 (d, J=6.3, 2H), 7.90 (m, 1H), 7.80 (dd, J=7.8, 4.6, 1H), 7.35 (dd, J=14.8, 10.8, 2H), 6.75 (s, 2H), 3.98-3.80 (m, 1H), 1.80 (d, J=14.9, 4H), 1.62 (d, J=12.3, 1H), 1.39-1.07 (m, 5H).
Example 809




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclopentylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H19FN4O2S.HCl, 398.12; m/z found, 399.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.88 (s, 2H), 8.73 (dd, J=4.6, 1.5, 1H), 7.96 (dd, J=7.8, 1.5, 1H), 7.80-7.62 (m, 2H), 7.55-7.41 (m, 2H), 4.56-4.40 (m, 1H), 2.09-1.79 (m, 4H), 1.69 (d, J=4.7, 4H).
Example 810




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(cyclopentylsulfonyl)pyridine. MS (ESI): mass calcd. for C20H19FN4O2S.HCl, 398.12; m/z found, 399.10 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.80-8.68 (m, 2H), 8.25 (d, J=1.1, 1H), 8.13 (m, 1H), 7.96 (dd, J=7.8, 1.5, 1H), 7.73 (dd, J=7.8, 4.6, 1H), 7.43 (d, J=10.3, 2H), 4.52-4.39 (m, 1H), 2.10-1.80 (m, 4H), 1.68 (d, J=5.4, 4H).
Example 811




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(tert-butylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H19FN4O2S, 386.12; m/z found, 387.0 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.73 (dd, J=4.6, 1.7, 1H), 8.56 (d, J=1.4, 2H), 7.73 (dd, J=7.8, 1.7, 1H), 7.56 (dd, J=7.8, 4.6, 1H), 7.41 (m, 1H), 7.28 (dd, J=7.9, 1.8, 1H), 7.21 (d, J=1.7, 1H), 5.29 (s, 2H), 1.48 (s, 9H).
Example 812




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(tert-butylsulfonyl)pyridine. MS (ESI): mass calcd. for C19H19FN4O2S, 386.12; m/z found, 387.0 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.73 (dd, J=4.5, 1.7, 1H), 8.54 (s, 1H), 8.12 (s, 1H), 7.98 (m, 1H), 7.74 (dd, J=7.8, 1.7, 1H), 7.56 (dd, J=7.8, 4.6, 1H), 7.28 (d, J=1.7, 1H), 7.20 (d, J=1.7, 1H), 5.01 (s, 2H), 1.45 (s, 9H).
Example 813




The title compound was prepared as described in step D of Example 803 using racemic 3-bromo-2-(sec-butylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H19FN4O2S, 386.12; m/z found, 387.0 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.73 (dd, J=4.6, 1.6, 1H), 8.53 (d, J=1.4, 2H), 7.96 (dd, J=7.8, 1.6, 1H), 7.73 (dd, J=7.8, 4.6, 1H), 7.56 (m, 1H), 7.40-7.32 (m, 2H), 4.00-3.89 (m, 1H), 1.95-1.81 (m, 1H), 1.53-1.43 (m, 1H), 1.23 (d, J=8.3, 3H), 1.01 (t, J=7.5, 3H).
Example 814




The title compound was prepared as described in step D of Example 803 using racemic 3-bromo-2-(sec-butylsulfonyl)pyridine. MS (ESI): mass calcd. for C19H19FN4O2S, 386.12; m/z found, 387.0 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.73 (dd, J=4.6, 1.6, 1H), 8.41-8.35 (m, 1H), 8.20 (d, J=1.4, 1H), 8.03-7.94 (m, 2H), 7.74 (dd, J=7.8, 4.6, 1H), 7.40-7.32 (m, 2H), 3.90 (s, 1H), 1.92-1.82 (m, 1H), 1.53-1.42 (m, 1H), 1.24 (d, J=6.9, 3H), 1.00 (t, J=7.5, 3H).
Example 815




The title compound was prepared as described in step D of Example 803 using 1-(4-((3-bromopyridin-2-yl)sulfonyl)piperidin-1-yl)ethanone and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C22H22FN5O3S.HCl, 455.14; m/z found, 456.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.76 (dd, J=4.6, 1.6, 1H), 8.56 (d, J=1.3, 2H), 8.00 (dd, J=7.9, 1.6, 1H), 7.78 (dd, J=7.9, 4.7, 1H), 7.59 (m, 1H), 7.40 (dd, J=4.3, 1.4, 1H), 7.38 (s, 1H), 4.61 (d, J=13.4, 1H), 4.35 (m, 1H), 4.06 (d, J=14.0, 1H), 3.24 (d, J=13.0, 2.8, 1H), 2.76 (m, 1H), 2.11 (s, 3H), 2.09-1.97 (m, 2H), 1.74 (m, 1H), 1.61 (m, 1H).
Example 816




The title compound was prepared as described in step D of Example 803 using 1-(4-((3-bromopyridin-2-yl)sulfonyl)piperidin-1-yl)ethanone. MS (ESI): mass calcd. for C22H22FN5O3S.HCl, 455.14; m/z found, 456.0 [M+H]+. 1H NMR (400 MHz, CD3OD): δ 8.76 (dd, J=4.6, 1.6, 1H), 8.46-8.39 (m, 1H), 8.10 (d, J=1.4, 1H), 8.01 (dd, J=7.9, 1.6, 1H), 7.96 (m, 1H), 7.78 (dd, J=7.9, 4.7, 1H), 7.39 (s, 1H), 7.37 (dd, J=4.4, 1.5, 1H), 4.60 (d, J=13.5, 1H), 4.37-4.26 (m, 1H), 4.05 (d, J=14.0, 1H), 3.23 (m, 1H), 2.75 (m, 1H), 2.10 (s, 3H), 2.07-1.97 (m, 2H), 1.74 (m, 1H), 1.61 (m, 1H).
Example 817




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-((3-methoxypropyl)sulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.74 (dd, J=4.6, 1.5, 1H), 8.61 (s, 2H), 7.99 (dd, J=7.8, 1.5, 1H), 7.76 (dd, J=7.8, 4.7, 1H), 7.60 (m, 1H), 7.42 (dd, J=3.9, 1.3, 1H), 7.40 (s, 1H), 3.70-3.62 (m, 2H), 3.48 (m, 2H), 3.32 (s, 3H), 2.03-1.94 (m, 2H).
Example 818




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-((3-methoxypropyl)sulfonyl)pyridine. MS (ESI): mass calcd. for C19H19FN4O3S, 402.12; m/z found, 403.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.69 (d, J=3.5, 1H), 8.35 (s, 1H), 8.21 (s, 1H), 8.04-7.90 (m, 2H), 7.72 (dd, J=7.8, 4.7, 1H), 7.39 (s, 1H), 7.35 (d, J=2.0, 1H), 3.68-3.56 (m, 2H), 3.45 (m, 2H), 3.29 (s, 3H), 2.04-1.89 (m, 2H).
Example 819




The title compound was prepared as described in step D of Example 803 using 4-((3-bromopyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine giving the target molecule after purification by HPLC. MS (ESI): mass calcd. for C20H19FN4O4S2.HCOOH, 462.08; m/z found, 463.00 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.67 (d, J=4.1, 1H), 8.58 (s, 2H), 7.87 (d, J=7.3, 1H), 7.72-7.59 (m, 1H), 7.56-7.44 (m, 1H), 7.42-7.29 (d, J=14.6, 2H), 5.22 (s, 2H), 4.52-4.48 (m, 1H), 3.43-3.23 (m, 2H), 3.03 (s, 2H), 2.68-2.47 (m, 4H).
Example 820




The title compound was prepared as described in step D of Example 803 using 4-((3-bromopyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide giving the target molecule after purification by HPLC. MS (ESI): mass calcd. for C20H19FN4O4S2.HCOOH, 462.08; m/z found, 463.00 [M+H]+. 1H NMR (300 MHz, CDCl3): δ 8.66 (dd, J=4.6, 1.6, 1H), 8.63-8.59 (m, 1H), 8.11 (d, J=1.5, 1H), 8.06 (m, 1H), 7.86 (dd, J=7.8, 1.6, 1H), 7.63 (dd, J=7.8, 4.6, 1H), 7.37 (dd, J=8.1, 1.8, 1H), 7.31 (dd, J=11.6, 1.7, 1H), 4.77 (s, 2H), 4.42-4.28 (m, 1H), 3.45-3.27 (m, 2H), 3.10-2.94 (m, 2H), 2.67-2.48 (m, 4H).
Example 821




The title compound was prepared as described in step D of Example 803 using 4-(2-((3-bromopyridin-2-yl)sulfonyl)ethyl)morpholine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H22FN5O3S.HCOOH, 443.14; m/z found, 444.10 [M+H]+. 1H NMR (300 MHz. CDCl3) δ 8.65 (dd, J=4.7, 1.6, 1H), 8.56 (s, 2H), 7.82 (dd, J=7.8, 1.6, 1H), 7.61 (dd, J=7.9, 4.7, 1H), 7.47 (m, 1H), 7.39 (dd, J=8.0, 1.7, 1H), 7.33 (dd, J=11.0, 1.7, 1H), 5.52 (s, 2H), 3.85 (t, J=9, 2H), 3.63 (s, 4H), 2.93 (t, J=9, 2H), 2.54 (s, 4H).
Example 822




The title compound was prepared as described in step D of Example 803 using 4-(2-((3-bromopyridin-2-yl)sulfonyl)ethyl)morpholine giving the target molecule after purification by HPLC. MS (ESI): mass calcd. for C21H22FN5O3S.HCOOH, 443.14; m/z found, 444.10 [M+H]+. 1H NMR (300 MHz, CDCl3): δ 8.65 (dd, J=4.6, 1.6, 1H), 8.51 (s, 1H), 8.14 (d, J=1.5, 1H), 8.04 (m, 1H), 7.83 (dd, J=7.8, 1.6, 1H), 7.61 (dd, J=7.8, 4.7, 1H), 7.43-7.30 (m, 2H), 5.28 (m, 2H), 3.98-3.84 (m, 2H), 3.80-3.58 (m, 4H), 3.09-2.96 (m, 2H), 2.78-2.54 (m, 4H).
Example 823




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.71 (dd, J=4.6, 1.5, 1H), 8.53 (d, J=1.3, 2 H), 7.97 (dd, J=7.8, 1.6, 1H), 7.74 (dd, J=7.9, 4.6, 1H), 7.57 (m, 1H), 7.44-7.35 (m, 2H), 3.96-3.78 (m, 2H), 3.57 (d, J=6.3, 2H), 3.47-3.37 (m, 2H), 2.25-2.10 (m, 1H), 1.85-1.69 (m, 2H), 1.54-1.36 (m, 2H).
Example 824




The title compound was prepared as described in step D of Example 803 using 3-bromo-2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine. MS (ESI): mass calcd. for C21H21FN4O3S, 428.13; m/z found, 429.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.65 (dd, J=4.6, 1.6, 1H), 8.60 (s, 1H), 8.10 (s, 1H), 8.04 (m, 1H), 7.82 (dd, J=7.8, 1.6, 1H), 7.59 (dd, J=7.8, 4.7, 1H), 7.40 (dd, J=8.0, 1.7, 1H), 7.34 (dd, J=11.8, 1.6, 1H), 4.76 (s, 2H), 3.92 (dd, J=10.6, 3.2, 2H), 3.56 (d, J=6.4, 2H), 3.39 (m, 2H), 2.40-2.26 (m, 1H), 1.84 (d, J=11.0, 2H), 1.49 (m, 2H).
Example 825




The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 3-bromo-2-(isopropylsulfonyl)pyridine. MS (ESI): mass calcd. for C18H17FN4O2S, 372.11; m/z found, 373.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.69 (dd, J=4.7, 1.7, 1H), 8.57 (d, J=1.4, 2H), 7.80 (dd, J=7.8, 1.6, 1H), 7.59 (dd, J=7.8, 4.6, 1H), 7.46 (m, 1H), 7.39 (dd, J=7.9, 1.8, 1H), 7.32 (dd, J=11.1, 1.7, 1H), 5.17 (s, 2H), 4.26 (hept, J=6.9, 1H), 1.32 (d, J=6.9, 6H).
Example 826




The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine and 3-bromo-2-(isopropylsulfonyl)pyridine. MS (ESI): mass calcd. for C21H18FN4O2S, 395.11; m/z found, 396.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 9.45 (s, 1H), 8.70 (dd, J=4.6, 1.6, 2H), 8.25-8.17 (m, 1H), 7.84 (dd, J=7.8, 1.7, 1H), 7.64-7.54 (m, 2H), 7.46-7.32 (m, 3H), 6.61 (s, 1H), 4.26 (hept, J=6.8, 1H), 1.34 (d, J=6.9, 6H).
Example 827




The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.91 (s, 2H), 8.78 (m, 1H), 8.03 (m, 1H), 7.82 (m, 1H), 7.75-7.71 (m, 1H), 7.50-7.42 (m, 2H), 4.52-4.46 (m, 1H), 3.57-3.54 (m, 2H), 3.24-3.17 (m, 2H), 2.31-2.28 (m, 2H), 2.13-1.96 (m, 2H).
Example 828




Step A: 3-Bromo-2-((3-chloropropyl)thiopyridine
A mixture of 3-bromopyridine-2-thiol (0.04 g, 0.2 mmol), 1-bromo-3-chloropropane in DMF (0.424 mmol/mL, 2.0 mL), and K2CO3 (60 mg, 0.424 mmol) in DMF (2.0 mL) was stirred at rt for 10 minutes. The reaction mixture was then concentrated to dryness and the resultant residue diluted with water (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic extracts were dried over Na2SO4 and concentrated to dryness to give the title compound (0.05 g, 89% purity). MS (ESI): mass calcd. for C8H9BrClNS, 264.93; m/z found, 265.8 [M+H]+.
Step B: 3-Bromo-2-((3-chloropropyl)sulfonyl)pyridine
To a solution of 3-bromo-2-((3-chloropropyl)thio)pyridine (0.05 g, 89% purity, 0.2 mmol) in DCM/CH3CN (3.0 mL/3.0 mL) were added NaIO4 (0.121 g, 0.567 mmol), H2O (3.0 mL), and RuCl3 (2.0 mg, 0.014 mmol). The mixture was stirred at rt. for 10 minutes and concentrated to dryness. The residue was diluted with water (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic extracts were dried over MgSO4, and concentrated to dryness to give the title compound (0.05 g, 89% purity), which was used in next step without any further purification. MS (ESI): mass calcd. for C8H9BrClNO2S, 296.92; m/z found, 297.9 [M+H]+.
Step C: 3-Bromo-2-(cyclopropylsulfonyl)pyridine
To a solution of 3-bromo-2-((chloropropyl)sulfonyl)pyridine (0.05 g, 89% purity, 0.2 mmol) in THF (20 mL) was added t-BuOK (0.047 g, 0.42 mmol) at −38° C. and the mixture was stirred for an additional 30 minutes. The reaction was quenched by adding saturated NH4Cl aqueous solution (2.5 mL) and concentrated to dryness. The resultant residue was diluted with water (10 mL) and extracted with DCM (2×10 mL). The combined organic extracts were dried over MgSO4, and concentrated to dryness to give the title compound (0.08 g, crude), which was used in the next step without further purification. MS (ESI): mass calcd. for C8H8BrNO2S, 260.95; m/z found, 262.0 [M+H]+.
Step D: 5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine
The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine and 3-bromo-2-(cyclopropylsulfonyl). MS (ESI): mass calcd. for C18H15FN4O2S.HCOOH, 370.09; m/z found, 370.9 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 8.67 (m, 1H), 8.55 (s, 2H), 7.76 (m, 1H), 7.55 (m, 1H), 7.49-7.27 (m, 3H), 5.37 (s, 2H), 3.23-3.08 (m, 1H), 1.25-1.01 (m, 4H).
Example 829




The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrazin-2-amine and 3-bromo-2-(cyclopropylsulfonyl)pyridine. MS (ESI): mass calcd. for C18H15FN4O2S, 370.09; m/z found, 370.9 [M+H]+; 1H NMR (300 MHz, CDCl3) δ 8.66 (m, 1H), 8.55 (s, 1H), 8.06 (d, J=1.4, 1H), 8.02-7.96 (m, 1H), 7.77 (m, 1H), 7.54 (m, 1H), 7.36 (m, 1H), 7.30 (m, 1H), 4.70 (s, 2H), 3.12-3.01 (m, 1H), 1.25-0.97 (m, 4H).
Example 830




The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrazin-2-amine and 3-bromo-2-((tetrahydro-2H-pyran-4-yl)sulfonyl)pyridine. MS (ESI): mass calcd. for C20H19FN4O3S.HCl, 414.12; m/z found, 415.1 [M+H]+; 1H NMR (300 MHz, CDCl3) δ 8.78 (d, J=4.6, 1H), 8.40 (s, 1H), 8.13-7.99 (m, 2H), 7.95-7.89 (m, 1H), 7.87-7.78 (m, 1H), 7.38 (m, 2H), 6.76 (s, 2H), 4.33-4.20 (m, 1H), 3.92 (dd, J=11.1, 3.7, 2H), 3.50-3.35 (m, 2H), 1.85-1.69 (m, 2H), 1.69-1.48 (m, 2H).
Example 831




The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine and 3-bromo-2-((tetrahydro-2H-pyran-4-yl)sulfonyl)pyridine. MS (ESI): mass calcd. for C20H19FN4O3S, 414.12; m/z found, 415.1 [M+H]+; 1H NMR (300 MHz, CD3OD) δ 8.78 (m, 1H), 8.52 (d, J=1.4, 2H), 8.04 (m, 1H), 7.82 (m, 1H), 7.67-7.61 (m, 1H), 7.43 (m, 1H), 7.36 (m, 1H), 6.95 (s, 2H), 4.29-4.24 (m, 1H), 3.94-3.89 (m, 2H), 3.45-3.35 (m, 2H), 1.77-1.73 (m, 2H), 1.77-1.52 (m, 2H).
Example 832




The title compound was prepared as described in step D of Example 803 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.81-8.69 (m, 1H), 8.54 (s, 1H), 8.29 (s, 1H), 8.11-8.06 (m, 1H), 8.01 (m, 1H), 7.78 (m, 1H), 7.42 (s, 1H), 7.39 (d, J=2.1, 1H), 4.55-4.38 (m, 1H), 3.54-3.50 (m, 2H), 3.19-3.12 (m, 2H), 2.30-2.26 (m, 2H), 2.09-1.88 (m, 2H).
Example 833




The title compound was prepared by a method analogous to Example 461 using phenylboronic acid. MS (ESI): mass calcd. for C16H11F2N3, 283.09; m/z found, 284.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.43-8.40 (m, 1H), 8.04 (d, J=1.5, 1H), 7.78-7.72 (m, 1H), 7.65-7.60 (m, 2H), 7.55-7.50 (m, 2H), 7.50-7.41 (m, 2H), 6.83 (s, 2H).
Intermediate JF




Step A: (4-Bromo-2-fluoro-3-methoxyphenyl)boronic acid
A solution of 2,2′,6,6′-tetramethylpiperidine (0.98 ml, 5.8 mmol) in THF (9.8 ml) was cooled to −78° C. under a N2 atmosphere. To the solution was then added n-BuLi (2.21 N in hexanes, 2.45 ml, 5.41 mmol) drop-wise over a couple of minutes, and then the mixture warmed to 0° C. for 20-30 min. The mixture was then cooled back to −78° Celsius and treated with triisopropyl borate (1.25 ml, 5.41 mmol). After 5 minutes 1-bromo-3-fluoro-2-methoxybenzene (1.0 g, 4.9 mmol) was slowly added and the reaction stirred at −78° Celsius for 1.5 h before warming to rt The reaction mixture was then treated with AcOH (2.8 ml, 49 mmol), diluted with water, and extracted with EtOAc. The EtOAc extract was dried over MgSO4, filtered, and concentrated to dryness. The crude product was used without purification.
Step B: 5-(4-Bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine
A mixture of (4-bromo-2-fluoro-3-methoxyphenyl)boronic acid (940 mg, 1.69 mmol) and 5-bromopyrazin-2-amine (1.31 g, 7.56 mmol) was treated with EtOH (12.4 ml), toluene (12.8 ml), and aqueous Na2CO3 (2.0 N, 9.44 ml, 18.9 mmol), and the resulting mixture deoxygenated by sparging with for 10 minutes. Pd(PPh3)4 (218 mg, 0.189 mmol) was then added, and the mixture heated at 80° Celsius for 17 h. The reaction was cooled to rt and then partitioned between saturated aqueous NH4Cl and EtOAc. The organic layer was isolated, dried over MgSO4, and concentrated to dryness. The resultant residue was suspended in DCM and the title compound isolated by filtration (300 mg, 27%), which was used without further purification. Additional product was obtained by concentrating the filtrate to dryness and subjecting the residue to FCC (560 mg, 50%). MS (ESI): mass calcd. for C11H9BrFN3O, 296.99; m/z found, 298.0 [M+H]+. 1H NMR (500 MHz, DMSO-d) δ 8.34 (dd, J=2.6, 1.5, 1H), 8.00 (d, J=1.5, 1H), 7.54-7.49 (m, 2H), 6.78 (s, 2H), 3.90 (d, J=0.6, 3H).
Example 834




The title compound was prepared by a method analogous to Example 461 using phenylboronic acid and 5-(4-bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C17H14FN3O, 295.11; m/z found, 296.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.58-8.55 (m, 1H), 8.12 (d, J=1.5, 1H), 7.65 (dd, J=8.1, 7.5, 1H), 7.61-7.54 (m, 2H), 7.48-7.42 (m, 2H), 7.41-7.34 (m, 1H), 7.23 (dd, J=8.2, 1.4, 1H), 4.69 (s, 2H), 3.74 (d, J=0.9, 3H).
Example 835




The title compound was prepared by a method analogous to Example 461 using 5-(4-bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C18H16FN3O3S, 373.09; m/z found, 374.1 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.58-8.53 (m, 1H), 8.21 (dd, J=8.0, 1.3, 1H), 8.11 (d, J=1.5, 1H), 7.71-7.58 (m, 3H), 7.35 (dd, J=7.5, 1.2, 1H), 7.13 (dd, J=8.1, 1.3, 1H), 4.74 (s, 2H), 3.82 (d, J=1.9, 3H), 2.96 (s, 3H).
Example 836




The title compound was prepared by a method analogous to Example 461 using (2-(N-(tert-butyl)sulfamoyl)phenyl)boronic acid and 5-(4-bromo-2-fluoro-3-methoxyphenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C21H23FN4O3S, 430.15; m/z found, 431.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.53-8.48 (m, 1H), 8.19 (dd, J=7.9, 1.4, 1H), 8.08 (d, J=1.5, 1H), 7.64-7.55 (m, 2H), 7.52 (m, 1H), 7.29 (dd, J=7.4, 1.4, 1H), 7.18 (dd, J=8.2, 1.4, 1H), 4.80 (s, 2H), 4.42 (s, 1H), 3.85 (d, J=1.8, 3H), 1.21 (s, 9H).
Example 837




The title compound was prepared by a method analogous to Example 461 using (2-(methylsulfonamido)phenyl)boronic acid and 5-(4-bromo-2-fluoro-3-methoxyphenyl) pyrazin-2-amine. MS (ESI): mass calcd. for C18H17FN4O3S, 388.10; m/z found, 389.1 [M+H]4. 1H NMR (400 MHz, CDCl3) δ 8.59 (dd, J=2.3, 1.6, 1H), 8.12 (d, J=1.5, 1H), 7.75 (dd, J=8.2, 7.2, 1H), 7.69 (d, J=8.0, 1H), 7.46 (m, 1H), 7.37-7.32 (m, 2H), 7.15 (dd, J=8.2, 1.5, 1H), 7.10 (s, 1H), 4.77 (s, 2H), 3.73 (d, J=1.1, 3H), 2.58 (s, 3H).
Example 838




Step A: 2-(2-Chlorophenyl)pyrazine
2-Bromopyrazine (100 mg, 0.630 mmol) and ((2-chlorophenyl)boronic acid (103 mg, 0.660 mmol) were added to a 5 mL sealable vial equipped with a stir-bar. A solution consisting of 1,4-dioxane (3 mL) and Na2CO3 (1.6 mL, 2 M) was added and the mixture sparged with argon for 10 minutes before adding Pd(ddp)Cl2.CH2Cl2 (23 mg, 0.031 mmol) and heating at 80° Celsius for 15 hours. The reaction was then cooled to rt, diluted with 5 mL of ethyl acetate and 5 mL of water, and the mixture extracted with ethyl acetate (3×20 mL). The combined organic extracts were then dried with sodium sulfate and concentrated to dryness. The resultant residue was subjected to FCC to provide the title compound. 1H NMR (500 MHz, CDCl3) δ 8.98-8.96 (d, J=1.6, 1H), 8.70-8.68 (dd, J=2.5, 1.6, 1H), 8.58-8.56 (d, J=2.6, 1H), 7.66-7.58 (m, 1H), 7.54-7.50 (m, 1H), 7.43-7.39 (m, 2H).
Step B: 5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4-yl)pyrazin-2-amine
2-(2-Chlorophenyl)pyrazine (58 mg, 0.31 mmol), 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine (88 mg, 0.28 mmol) and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (4.4 mg, 0.0060 mmol) were placed into a sealable 5 mL vial equipped with a stir-bar. The vial was sealed, evacuated and backfilled with argon three times. To this vial was added separately deoxygenated THF (0.56 mL) and K3PO4 (1.1 mL, 0.5 M). The vial was then heated at 45° Celsius for 1 hour before cooling to rt diluting with brine (5 mL), and extracting with EtOAc (1×5 mL, 3×10 mL). The combined organic extracts were then dried with sodium sulfate, filtered, and concentrated to dryness. The crude product was purified via FCC to provide the title compound. MS (ESI): mass calcd. for C20H14FN5, 343.12; m/z found, 344.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.65-8.59 (dd, J=2.6, 1.6, 1H), 8.47-8.42 (d, J=2.6, 1H), 8.33-8.31 (dd, J=2.2, 1.4, 1H), 8.31-8.29 (d, J=1.5, 1H), 8.04-8.02 (d, J=1.5, 1H), 7.79-7.73 (m, 1H), 7.72-7.69 (m, 1H), 7.64-7.53 (m, 3H), 7.11-6.87 (m, 2H).
Example 839




The title compound was prepared in a manner similar to that described in Example 838 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C20H14FN5, 343.12; m/z found, 344.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.61 (s, 1H), 8.56 (s, 2H), 8.47-8.40 (d, J=2.6, 1H), 8.31 (s, 1H), 7.74-7.67 (d, J=7.3, 1H), 7.65-7.57 (m, 1H), 7.57-7.54 (d, J=7.3, 1H), 7.46-7.41 (m, 1H), 7.08-7.04 (d, J=11.8, 1H), 7.04-7.00 (d, J=8.0, 1H).
Example 840




The title compound was prepared in a manner similar to that described in Example 847 using 5-bromopyrazin-2-amine in Step A. MS (ESI): mass calcd. for C20H15FN, 358.13; m/z found, 359.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37-8.29 (m, 1H), 8.06-8.02 (d, J=1.5, 1H), 7.93-7.90 (d, J=1.5, 1H), 7.82-7.73 (m, 1H), 7.63-7.55 (m, 2H), 7.53-7.44 (m, 3H), 7.05-6.97 (m, 2H).
Example 841




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrazin-2-amine in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C20H15FN6, 358.13; m/z found, 359.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.50-8.44 (d, J=1.4, 2H), 7.95-7.90 (d, J=1.5, 1H), 7.63-7.55 (m, 2H), 7.52-7.44 (m, 3H), 7.43-7.38 (m, 1H), 7.06-7.03 (m, 1H), 7.03-7.01 (dd, J=6.2, 1.6, 1H).
Example 842




The title compound was prepared in a manner similar to that described in Example 838 using 6-bromopyrazin-2-amine in Step A. MS (ESI): mass calcd. for C20H15FN6, 358.13: m/z found, 359.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.34-8.25 (m, 1H), 8.15-8.08 (d, J=1.5, 1H), 7.86-7.78 (m, 1H), 7.77 (s, 1H), 7.66-7.59 (m, 1H), 7.59-7.48 (m, 3H), 7.40 (s, 1H), 7.10-7.00 (m, 2H).
Example 843




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrimidin-2-amine in Step A. MS (ESI): mass calcd. for C20H15FN6, 358.13; m/z found, 359.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.33 (s, 1H), 8.19-8.14 (m, 2H), 8.12-8.08 (d, J=1.9, 1H), 7.90-7.80 (dd, J=8.8, 7.2, 1H), 7.57-7.41 (m, 4H), 7.12 (s, 1H), 7.10 (s, 1H).
Example 844




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrimidin-2-amine in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C20H15FN6, 358.13; m/z found, 359.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.57 (s, 2H), 8.16 (d, J=2.0, 2H), 7.57-7.45 (m, 5H), 7.14 (t, J=10.3, 2H).
Example 845




The title compound was prepared in a manner similar to that described in Example 838 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-bromo-1-chloro-4-(trifluoromethyl)benzene in Step A and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C21H14F4N6, 426.12; m/z found, 427.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.36 (dd, J=2.1, 1.5, 1H), 8.10 (s, 2H), 8.05 (d, J=1.5, 1H), 7.90-7.85 (m, 1H), 7.81-7.77 (m, 1H), 7.74 (d, J=1.8, 1H), 7.66 (d, J=8.0, 1H), 7.13 (dd, J=2.6, 1.7, 1H), 7.11 (dd, J=6.5, 1.6, 1H).
Example 846




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromo-2-methoxypyrimidine in Step A. MS (ESI): mass calcd. for C21H16FN5O, 373.13; m/z found, 374.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.36 (s, 2H), 8.34 (dd, J=2.1, 1.4, 1H), 8.04 (d, J=1.5, 1H), 7.84-7.74 (m, 1H), 7.56-7.44 (m, 4H), 7.12-6.97 (m, 2H), 3.98 (s, 3H).
Example 847




The title compound was prepared in a manner similar to that described in Example 838 using 4-bromo-1-methyl-1H-pyrazole in Step A. MS (ESI): mass calcd. for C20H16FN5, 345.14; m/z found, 346.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.38-8.35 (m, 1H), 8.06 (d, J=1.5, 1H), 7.85-7.79 (m, 1H), 7.51-7.46 (m, 1H), 7.42-7.37 (m, 1H), 7.37-7.32 (m, 3H), 7.15-7.11 (m, 2H), 7.05 (dd. J=12.2, 1.7, 1H), 3.80 (s, 3H).
Example 848




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrimidine in Step A. MS (ESI): mass calcd. for C20H14FN5, 343.12; m/z found, 344.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 9.01 (s, 1H), 8.61 (s, 2H), 8.32-8.27 (m, 1H), 8.17 (d, J=1.4, 1H), 7.88-7.78 (m, 1H), 7.63-7.50 (m, 4H), 7.11-7.00 (m, 2H).
Example 849




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyrimidine-2-carbonitrile in Step A. MS (ESI): mass calcd. for C21H13FN6, 368.12; m/z found, 369.1 [M+H]+. 1H NMR (500 MHz, CD3OD) 8.73 (s, 2H), 8.37-8.33 (m, 1H), 8.04 (d, J=1.5, 1H), 7.80 (m, J=8.1, 1H), 7.68-7.55 (m, 4H), 7.11 (dd, J=12.1, 1.7, 1H), 7.01 (dd, J=8.1, 1.7, 1H).
Example 850




The title compound was prepared in a manner similar to that described in Example 838 using 4-(5-bromopyrimidin-2-yl)morpholine in Step A. MS (ESI): mass calcd. for C24H21FN6O, 428.18; m/z found, 429.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.36-8.32 (m, 1H), 8.14 (s, 2H), 8.04 (d, J=1.5, 1H), 7.83-7.77 (m, 1H), 7.54-7.38 (m, 4H), 7.09-7.07 (m, 1H), 7.06 (dd, J=7.1, 1.6, 1H), 3.76-3.66 (m, 8H).
Example 851




The title compound was prepared in a manner similar to that described in Example 838 using 1-(4-bromo-1H-pyrazol-1-yl)-2-methylpropan-2-ol in Step A. MS (ESI): mass calcd. for C23H22FN5O, 403.18; m/z found, 404.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.37-8.32 (m, 1H), 8.07 (d, J=1.5, 1H), 7.85-7.78 (m, 1H), 7.53-7.48 (m, 1H), 7.44-7.37 (m, 1H), 7.35 (dd, J=5.0, 1.1, 2H), 7.32 (d, J=0.9, 1H), 7.25 (d, J=0.8, 1H), 7.15 (dd, J=8.0, 1.7, 1H), 7.04 (dd, J=12.3, 1.7, 1H), 3.98 (s, 2H), 1.07 (s, 6H).
Example 852




The title compound was prepared in a manner similar to that described in Example 838 using tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate and 2-bromo-1-chloro-4-(trifluoromethyl)benzene in Step A, followed by removal of the Boc group. To a stirred solution of tert-butyl 4-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (68 mg, 0.13 mmol) in DCM (2 mL) was added TFA (0.56 mL, 7.3 mmol) at room temperature. When analysis by LCMS indicated the reaction was complete, the stir-bar was removed, the reaction mixture concentrated to dryness, and the residue subjected to HPLC purification to provide the title compound. MS (ESI): mass calcd. for C22H18F4N4, 414.15; m/z found, 415.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.41-8.37 (m, 1H), 8.13 (d, J=1.5, 1H), 8.03-7.96 (m, 1H), 7.78-7.72 (m, 1H), 7.64 (d, J=1.8, 1H), 7.61 (d, J=8.0, 1H), 7.37 (dd, J=8.0, 1.7, 1H), 7.33 (dd, J=12.1, 1.7, 1H), 5.89 (m, 1H), 3.85-3.75 (m, 2H), 3.19 (t, J=6.0, 2H), 2.33-2.22 (m, 2H).
Example 853




The title compound was prepared in a manner similar to that described in Example 838 using 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine and 2-bromo-1-chloro-4-(trifluoromethyl)benzene in Step A. MS (ESI): mass calcd. for C21H14F4N6, 426.12; m/z found, 427.0 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.34 (s, 1H), 8.16 (d, J=1.2, 2H), 8.10 (s, 1H), 7.92-7.86 (m, 1H), 7.80 (d, J=8.3, 1H), 7.78 (d, J=1.7, 1H), 7.69 (d, J=8.0, 1H), 7.23-7.08 (m, 2H).
Example 854




The title compound was prepared in a manner similar to that described in Example 427 using (6-(2-aminopyrimidin-5-yl)-5-fluoropyridin-3-yl)boronic acid and 5-(2-chlorophenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H14FN7, 359.13; m/z found, 360.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.93 (s, 2H), 8.31-8.28 (m, 1H), 8.19 (s, 2H), 7.64 (dd, J=12.0, 1.9, 1H), 7.59-7.51 (m, 4H).
Example 855




The title compound was prepared in a manner similar to that described in Example 427 using 5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine and 5-(2-bromophenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H15N7, 341.14; m/z found, 342.1 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 8.97 (s, 2H), 8.47 (dd, J=2.3, 0.9, 1H), 8.16 (s, 2H), 7.86 (dd, J=8.2, 0.9, 1H), 7.80 (dd, J=8.2, 2.3, 1H), 7.59-7.49 (m, 4H).
Example 856




Title compound was prepared using conditions analogous to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-pyrazin-2-amine and 2-(2-bromophenyl)isothiazolidine 1,1-dioxide. MS (ESI): mass calcd. for C19H7FN4O2S, 384.11; m/z found, 385.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.62-8.58 (m, 1H), 8.12 (d, J=1.5, 1H), 7.99 (m, 1H), 7.76-7.71 (m, 1H), 7.49-7.45 (m, 1H), 7.46-7.38 (m, 4H), 4.69 (s, 2H), 3.30-3.04 (m, 4H), 2.39-2.11 (m, 2H).
Example 857




Title compound was prepared using conditions analogous to those described in Example 1 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(2-bromophenyl)-1,2-thiazinane 1,1-dioxide. MS (ESI): mass calcd. for C20H19FN4O2S, 398.12; m/z found, 399.2 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.48-8.43 (m, 1H), 8.38-8.33 (m, 1H), 8.08-8.02 (m, 1H), 7.62 (m, 1H), 7.45-7.39 (m, 4H), 7.34 (dd, J=12.5, 1.7, 1H), 3.76-3.65 (m, 2H), 3.24-3.10 (m, 2H), 3.00-2.89 (m, 2H), 2.35-2.23 (m, 2H), 2.22-2.10 (m, 2H).
Example 858




Title compound was prepared using methods analogous to those described in Example 384 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine and 2-(2-bromophenyl)isothiazolidine 1,1-dioxide. MS (ESI): mass calcd. for C19H17FN4O2S, 384.11; m/z found, 385.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.58 (d, J=1.4, 2H), 7.78-7.71 (m, 1H), 7.69-7.58 (m, 1H), 7.50-7.32 (m, 4H), 7.29-7.20 (m, 1H), 5.21 (s, 2H), 3.77 (t, J=6.8, 1H), 3.43-3.17 (m, 2H), 2.67-2.47 (m, 1H), 2.42-2.17 (m, 2H).
Example 859




Title compound was prepared using methods analogous to those described in Example 377 using (2-(pyrrolidin-1-yl)pyridine-3-yl)boronic acid and 5-(4-bromo-2-fluorophenyl)pyrazin-2-amine in Step B. MS (ESI): mass calcd. for C19H18FN5, 335.15; m/z found, 336.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.61-8.56 (m, 1H), 8.22-8.17 (m, 1H), 8.12 (s, 1H), 7.97-7.88 (m, 1H), 7.45-7.38 (m, 1H), 7.29-7.23 (m, 1H), 7.21-7.14 (m, 1H), 6.75-6.67 (m, 1H), 4.67 (s, 2H), 3.28-3.10 (m, 4H), 1.87-1.73 (m, 4H).
Example 860




Title compound was prepared using analogous conditions to those described in Example 1 utilizing 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 1-(2-bromophenyl)pyrrolidin-2-one. MS (ESI): mass calcd. for C20H17FN4O, 348.14; m/z found, 349.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.03 (s, 1H), 7.91 (m, 1H), 7.54-7.14 (m, 6H), 6.72 (s, 2H), 3.44 (t, J=6.7, 2H), 2.26 (t, J=7.9, 2H), 1.97-1.87 (m, 2H).
Intermediate JF




To a mixture of 2-chlorophenylboronic acid (16.6 g, 106 mmol), tert-butyl 4-bromo-1H-pyrazole-1-carboxylate (17.4 g, 71 mmol) and K2CO3 (14.7 g, 142 mmol) in a 1 L round-bottomed flask were added Pd(dppf)Cl2-DCM (0.58 g, 0.71 mmol), 1,4-dioxane (200 mL) and H2O (50 mL). The mixture was sparged with N2 for 15 min then stirred at 80° C. for 16 h. The reaction mixture was cooled to RT, filtered, and concentrated to dryness. The resulting residue was diluted with water (100 mL), and then extracted with EtOAc (3×100 mL). The combined organic extracts were washed with brine (100 mL), dried over Na2SO4, concentrated to dryness, and the resulting residue was purified by FCC to give the title compound (9.2 g, 73%). MS (ESI): mass calcd. for C9H7ClN2, 178.03; m/z found 179.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 8.59 (s, 1H), 7.52-7.46 (m, 1H), 7.45-7.39 (m, 1H), 7.36-7.25 (m, 2H).
Intermediate JG




To a 50 mL round-bottomed flask, were added 4-(2-chlorophenyl)-1H-pyrazole (1.0 g, 5.6 mmol), 1-bromo-2-methoxyethane (1.17 g, 8.4 mmol). Cs2CO3 (3.64 g, 11.2 mmol) and DMF (10 mL). The mixture was stirred at RT for 16 h and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (3×50 mL), dried over Na2SO4, concentrated to dryness and purified by FCC to afford the title compound (890 mg, 67%). MS (ESI): mass calcd. for C12H13ClN2O, 236.07; m/z found 237.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.93 (s, 1H), 7.87 (s, 1H), 7.47-7.43 (m, 2H), 7.29-7.27 (m, 1H), 7.21-7.17 (m, 1H), 4.39 (t, J=5.2 Hz, 2H), 3.81 (t, J=5.2 Hz, 2H), 3.36 (s, 3H).
Intermediate JH




The title compound was prepared using analogous conditions to those described for 4-(2-chlorophenyl)-1-(2-methoxyethyl)-1H-pyrazole using tert-butyl(2-bromoethyl)carbamate. MS (ESI): mass calcd. for C16H20ClN3O2, 321.12; m/z found 322.1 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J=2.2 Hz, 2H), 7.46-7.42 (m, 2H), 7.32-7.13 (m, 2H), 4.95 (s, 1H), 4.29 (t, J=5.5 Hz, 2H), 3.61 (d, J=5.2 Hz, 2H), 1.44 (s, 9H).
Intermediate JI




A mixture of tert-Butyl 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)ethylcarbamate (1.0 g, 3.1 mmol) and HCl (20 mL, 30% solution in EtOH) was stirred at RT for 16 h. Precipitated solid was collected by filtration and washed with ethyl ether (10 mL) to give the title compound (670 mg, 84%). MS (ESI): mass calcd. for C11H12ClN3, 221.07; m/z found 222.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 8.22 (s, 3H), 7.97 (s, 1H), 7.62 (dd, J=7.7, 1.4 Hz, 1H), 7.52 (d, J=8.0 Hz, 1H), 7.39-7.35 (m, 1H), 7.32-7.24 (m, 1H), 4.46 (t, J=6.2 Hz, 2H), 3.35-3.23 (m, 2H).
Intermediate JJ




A mixture of 4-(2-chlorophenyl)-1H-pyrazole (1.0 g, 5.6 mmol), 2-bromoacetonitrile (1.0 g, 8.4 mmol) and Cs2CO3 (3.64 g, 11.2 mmol) and DMF (10 mL) in a 50 mL round-bottomed flask was stirred at 50° C. After 16 h, additional 2-bromoacetonitrile (1 g, 8.4 mmol) was added. The resulting mixture was stirred at 100° C. for 8 h, cooled to RT and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (3×50 mL), dried over Na2SO4, concentrated to dryness and the resulting residue was purified by FCC to give the title compound (600 mg, 49%). MS (ESI): mass calcd. for C11H8ClN3, 217.04; m/z found 218.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.88 (s, 1H), 7.47-7.44 (m, 2H), 7.32-7.28 (m, 1H), 7.26-7.21 (m, 1H), 5.14 (s, 2H).
Intermediate JK




To a 50 mL round-bottomed flask were added 4-(2-chlorophenyl)-1H-pyrazole (1.0 g, 5.6 mmol), 2-bromoethanol (1.05 g, 8.4 mmol), Cs2CO3 (3.64 g, 11.2 mmol) and DMF (10 mL). The reaction mixture was stirred at 80° C. for 16 h, then treated with additional of 2-bromoethanol (1.05 g, 8.4 mmol) was added. The resulting mixture was stirred at 100° C. for an additional 8 h, cooled to RT and diluted with water (100 mL). The resulting mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (3×50 mL), dried over Na2SO4, concentrated to dryness and the resulting residue was purified by FCC to give the title compound (800 mg, 64%). MS (ESI): mass calcd. for C11H11ClN2O, 222.06; m/z found 223.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.87 (s, 1H), 7.49-7.45 (m, 2H), 7.32-7.29 (m, 1H), 7.24-7.20 (m, 1H), 4.46-4.23 (m, 2H), 4.19-3.99 (m, 2H), 3.31 (s, 1H).
Intermediate JL




Step A: (Z—N-(2-(2-Chlorophenyl)-3-(dimethylamino)allylidene)-N-methyl methanaminium chloride
DMF (27 mL, 0.4 mol) was added drop wise to POCl3 (28 mL, 0.3 mol) in a 250 mL round-bottomed flask at 0° C. After the addition was complete, the resulting mixture was stirred at 0° C. for 20 min, followed by the addition of 2-(2-chlorophenyl)acetic acid (17 g, 0.1 mol). The reaction mixture was stirred at 85° C. for 2 h, cooled to RT and poured into ice water (400 mL). The resulting mixture was extracted with CH2Cl2 (3×150 mL). The combined organic extracts were washed with water (200 mL), dried over Na2SO4, concentrated to dryness and the resulting residue was purified by FCC to give the title compound (26.2 g, 96%). MS (ESI): mass calcd. for C13H18ClN2+, 237.12; m/z found 237.0 [M]+. 1H NMR (300 MHz, CDCl3) δ 8.94 (s, 2H), 7.43-7.38 (m, 1H), 7.36-7.30 (m, 1H), 7.29-7.22 (m, 2H), 3.39 (s, 6H), 2.44 (s, 6H).
Step B: 2-(2-Chlorophenyl)malonaldehyde
To a solution consisting of (Z)—N-(2-(2-chlorophenyl)-3-(dimethylamino)allylidene)-N-methyl methanaminium chloride (8.0 g, 29 mmol) and EtOH (40 mL) in a 250 mL round-bottomed flask was added aqueous NaOH (25%, 40 mL). The resulting mixture was refluxed for 1 h and then cooled to RT. The EtOH was removed by evaporation under vacuum and the aqueous mixture was diluted with ice water (100 mL), acidified to pH=1 by adding HCl (1 N) and then extracted with EtOAc (3×100 mL). The combined organic extracts were washed with brine (100 mL), dried over Na2SO4 and concentrated to dryness to give the title compound (5.37 g, 100%). MS (ESI): mass calcd. for C9H7ClO2, 182.01; m/z found 182.9 [M+H]+. 1H NMR (300 MHz, DMSO-d6) δ 12.05 (s, 1H), 8.58 (s, 2H), 7.47-7.43 (m, 1H), 7.36-7.25 (m, 2H), 7.18-7.10 (m, 1H).
Step C: (Z)-3-Chloro-2-(2-chlorophenyl)acrylaldehyde
To a 0° C. solution consisting of 2-(2-chlorophenyl)malonaldehyde (2.82 g, 15.5 mmol) and CH2Cl2 (20 mL) in a 50 mL round-bottomed flask was added SOCl2 (10 mL, 138 mmol). The resulting mixture was stirred at 0° C. for 30 min, concentrated to dryness and purified by FCC to give the title compound (2.37 g, 76%). 1H NMR (300 MHz, CDCl3) δ 9.66 (s, 1H), 7.51 (s, 1H), 7.51-7.46 (m, 1H), 7.40-7.31 (m, 2H), 7.20-7.13 (m, 1H).
Step D: 4-(2-Chlorophenyl)isothiazole
To a 25 mL round-bottomed flask containing a solution consisting of (Z)-3-chloro-2-(2-chlorophenyl)acryl aldehyde (2.37 g, 11.8 mmol) and DMF (8 mL), was added NH4SCN (3.58 g, 47.2 mmol). The reaction mixture was stirred at 70° C. for 16 h before cooling to RT and diluting with brine (100 mL). The resulting mixture was extracted with ethyl ether (3×100 mL). The combined organic extracts were washed with brine (3×100 mL), dried over Na2SO4, concentrated to dryness and the resulting residue was purified by FCC to provide the title compound (980 mg, 43%). MS (ESI): mass calcd. for C9H6ClNS, 194.99; m/z found 195.9 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 8.69 (s, 1H), 7.54-7.46 (m, 1H), 7.46-7.38 (m, 1H), 7.37-7.27 (m, 2H).
Example 861




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyridin-2-amine in Step A. MS (ESI): mass calcd. for C21H16FN5, 357.14; m/z found, 358.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 1H), 8.06 (s, 1H), 7.80-7.76 (m, 1H), 7.70 (d, J=2.0 Hz, 1H), 7.51-7.39 (m, 4H), 7.28 (dd, J=8.6, 2.2 Hz, 1H), 7.07 (d, J=8.1 Hz, 1H), 7.02 (d. J=12.5 Hz, 1H), 6.51 (d, J=8.6 Hz, 1H).
Example 862




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromo-2-(piperazin-1-yl)pyrimidine in Step A. MS (ESI): mass calcd. for C24H22FN7, 427.19; m/z found, 427.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.34 (s, 1H), 8.22 (s, 2H), 8.06 (d, J=1.3 Hz, 1H), 7.82-7.76 (m, 1H), 7.54-7.47 (m, 4H), 7.17 (d, J=12.6 Hz, 1H), 7.07 (dd, J=8.0, 1.6 Hz, 1H), 4.00-3.83 (m, 4H), 3.21-3.09 (m, 4H).
Example 863




The title compound was prepared in a manner similar to that described in Example 838 using 6-bromopyridazin-3-amine in Step A. MS (ESI): mass calcd. for C20H15FN6, 358.13; m/z found, 358.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.17 (s, 1H), 7.88-7.82 (m, 1H), 7.74-7.57 (m, 4H), 7.51 (d, J=9.6 Hz, 1H), 7.39 (dd, J=9.6, 1.9 Hz, 1H), 7.27 (d, J=12.4 Hz, 1H), 7.05 (d, J=8.0 Hz, 1H).
Example 864




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)ethanamine hydrochloride. MS (ESI): mass calcd. for C21H19FN6, 374.17; m/z found, 375.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.73 (d, J=1.3 Hz, 1H), 8.23 (d, J=1.3 Hz, 1H), 8.08-8.04 (m, 1H), 7.60 (s, 1H), 7.56-7.51 (m, 1H), 7.47-7.34 (m, 3H), 7.26 (s, 1H), 7.23 (dd, J=8.1, 1.6 Hz, 1H), 7.17 (dd, J=12.7, 1.6 Hz, 1H), 4.41 (t. J=5.8 Hz, 2H), 3.38 (t, J=5.8 Hz, 2H).
Example 865




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromopyridin-2-amine in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C21H16FN5, 357.14; m/z found, 358.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J=1.3 Hz, 2H), 7.71 (d, J=2.0 Hz, 1H), 7.53-7.36 (m, 5H), 7.14 (dd, J=8.5, 2.5 Hz, 1H), 7.09 (dd, J=12.1, 1.5 Hz, 1H), 7.03 (dd, J=8.0, 1.7 Hz, 1H), 6.89 (s, 2H), 6.34 (d, J=8.6 Hz, 1H), 5.94 (s, 2H).
Example 866




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromo-N-methylpyrimidin-2-amine in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C21H17FN6, 372.15; m/z found, 373.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.1 Hz, 2H), 8.06 (s, 2H), 7.57-7.40 (m, 5H), 7.19-7.13 (m, 2H), 7.06 (dd, J=8.0, 1.5 Hz, 1H), 6.90 (s, 2H), 2.77 (d, J=4.8 Hz, 3H).
Example 867




The title compound was prepared in a manner similar to that described in Example 838 using 4-bromopyrimidin-2-aminein Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C20H15FN6, 358.13; m/z found, 359.0 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.46 (d, J=1.1 Hz, 2H), 8.04 (d, J=5.0 Hz, 1H), 7.63-7.45 (m, 5H), 7.16 (dd, J=12.0, 1.4 Hz, 1H), 7.04 (dd, J=8.0, 1.6 Hz, 1H), 6.90 (s, 2H), 6.66 (s, 2H), 6.19 (d, J=5.0 Hz, 1H).
Example 868




The title compound was prepared in a manner similar to that described in Example 838 using 4-bromopyrimidin-2-amine in Step A. MS (ESI): mass calcd. for C20H15FN, 358.13; m/z found, 359.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.03 (d, J=5.0 Hz, 1H), 8.00 (s, 1H), 7.81-7.77 (m, 1H), 7.63-7.46 (m, 4H), 7.13 (d, J=12.5 Hz, 1H), 7.05 (d, J=8.7 Hz, 1H), 6.71 (s, 2H), 6.65 (s, 2H), 6.17 (d. J=5.1 Hz, 1H).
Example 869




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 4-(2-chlorophenyl)-1-(2-methoxyethyl)-1H-pyrazole. MS (ESI): mass calcd. for C22H20FN5O, 389.17; m/z found, 390.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.32 (s, 1H), 7.98-7.94 (m, 1H), 7.53 (d, J=7.4 Hz, 1H), 7.47-7.34 (m, 4H), 7.25 (s, 1H), 7.19 (d, J=8.1 Hz, 1H), 7.10 (d, J=12.5 Hz, 1H), 4.21 (t, J=4.9 Hz, 2H), 3.65 (t, J=4.8 Hz, 2H), 3.25 (s, 3H).
Example 870




The title compound was prepared in a manner similar to that described in Example 838 using tert-butyl 4-bromo-1H-pyrazole-1-carboxylate in Step A. MS (ESI): mass calcd. for C19H14FN5, 331.12; m/z found, 332.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) b 12.77 (s, 1H), 8.37 (s, 1H), 8.02 (s, 1H), 7.86-7.82 (m, 1H), 7.54 (d, J=7.6 Hz, 1H), 7.47 (s, 1H), 7.44-7.31 (m, 3H), 7.17 (s, 1H), 7.12 (d, J=5.4 Hz, 1H), 7.10 (s, 1H), 6.71 (s, 2H).
Example 871




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)acetonitrile. MS (ESI): mass calcd. for C21H15FN6, 370.13; m/z found, 370.8 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.02 (d, J=1.3 Hz, 1H), 7.87-7.82 (m, 1H), 7.62 (s, 1H), 7.52 (d, J=7.1 Hz, 1H), 7.47-7.33 (m, 3H), 7.30 (s, 1H), 7.15-7.09 (m, 2H), 6.72 (s, 2H), 5.42 (s, 2H).
Example 872




The title compound was prepared in a manner similar to that described in Example 838 using 5-bromo-N-methylpyrimidin-2-amine in Step A. MS (ESI): mass calcd. for C21H17FN6, 372.15; m/z found, 373.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.09-8.06 (m, 3H), 7.85-7.81 (m, 1H), 7.55-7.44 (m, 4H), 7.13-7.05 (m, 2H), 2.90 (s, 3H).
Example 873




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 4-(2-chlorophenyl)isothiazole. MS (ESI): mass calcd. for C19H13FN4S, 348.08; m/z found, 349.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.30 (s, 1H), 8.23 (s, 1H), 8.10 (d, J=1.4 Hz, 1H), 7.87-7.82 (m, 1H), 7.53-7.39 (m, 4H), 7.03 (dd, J=8.0, 1.7 Hz, 1H), 6.98 (dd, J=12.1, 1.6 Hz, 1H), 4.76 (s, 2H).
Example 874




The title compound was prepared using analogous conditions to those described in Example 287 using 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine and 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)ethanol. MS (ESI): mass calcd. for C21H18FN5O, 375.15; m/z found, 376.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.40-8.35 (m, 1H), 8.02 (d, J=1.5 Hz, 1H), 7.86-7.82 (m, 1H), 7.53-7.50 (m, 2H), 7.45-7.38 (m, 1H), 7.34-7.33 (m, 2H), 7.15-7.11 (m, 2H), 7.08 (d, J=0.6 Hz, 1H), 6.72 (s, 2H), 4.84 (t, J=5.3 Hz, 1H), 4.04 (t, J=5.7 Hz, 2H), 3.66-3.62 (m, 2H).
Example 875




The title compound was prepared using analogous conditions to those described in Example 287 using 2-(4-(2-chlorophenyl)-1H-pyrazol-1-yl)acetonitrile. MS (ESI): mass calcd. for C21H15FN6, 370.13; m/z found, 371.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.49 (d, J=1.0 Hz, 2H), 7.61-7.50 (m, 3H), 7.48-7.31 (m, 4H), 7.16 (dd, J=11.8, 1.3 Hz, 1H), 7.09 (dd, J=7.9, 1.5 Hz, 1H), 6.92 (s, 2H), 5.43 (s, 2H).
Example 876




The title compound was prepared in a manner similar to that described in Example 838 using tert-butyl 4-bromo-1H-pyrazole-1-carboxylate in Step A and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine in Step B. MS (ESI): mass calcd. for C19H14FN5, 331.12; m/z found, 332.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 12.79 (s, 1H), 8.49 (s, 2H), 7.60-7.47 (m, 3H), 7.45-7.39 (m, 1H), 7.39-7.30 (m, 2H), 7.26-7.07 (m, 3H), 6.91 (s, 2H).
Intermediate JM




The title compound was prepared using analogous conditions to those described in Intermediate AU using (S)-1-aminopropan-2-ol. MS (ESI): mass calcd. for C9H12BrNO3S, 292.97; m/z found, 294.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 8.14 (dd, J=7.7, 1.8 Hz, 1H), 7.75 (dd, J=7.7, 1.4 Hz, 1H), 7.53-7.46 (m, 1H), 7.46-7.40 (m, 1H), 5.62 (s, 1H), 3.98-3.78 (m, 1H), 3.02 (d, J=12.9 Hz, 1H), 2.74 (dd, J=13.0, 8.1 Hz, 1H), 2.01 (d, J=4.1 Hz, 1H), 1.16 (d, J=6.3 Hz, 3H).
Intermediate JN




The title compound was prepared using analogous conditions to those described in Intermediate AU using 2-aminoethanol. MS (ESI): mass calcd. for C8H10BrNO3S, 278.96; m/z found, 279.9 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.17-8.11 (dd, J=7.8, 1.8 Hz, 1H), 7.79-7.72 (dd, J=7.8, 1.3 Hz, 1H), 7.52-7.46 (m, 1H), 7.46-7.40 (m, 1H), 5.79-5.66 (t, J=5.7 Hz, 1H), 3.73-3.65 (dd, J=5.6, 4.6 Hz, 2H), 3.13-3.03 (ddd, J=6.0, 5.1, 4.4 Hz, 2H), 2.22-2.10 (s, 1H).
Intermediate JO




Step A: 5-(5-Chloro-3-fluoropyridin-2-yl)pyrimidin-2-amine
A solution consisting of (2-aminopyrimidin-5-yl)boronic acid (3.4 g, 25 mmol), 2-bromo-5-chloro-3-fluoropyridine (5.4 g, 25 mmol), palladium(II)acetate/1,1′-bis(di-t-butylphosphino)ferrocene/potassium phosphate admixture (1.1 g, 1.0 mmol), Na2CO3 (122 mL, 245 mmol, 2 M) and THF (122 mL) was stirred at RT. After 1 h, the THF was removed in vacuo and the residue was diluted with CH2Cl2 (200 mL). The organic extracts were isolated and the aqueous mixture was further extracted with CH2Cl2 (2×200 mL). The combined organic extracts were, concentrated to dryness and triturated with EtOAc to afford the title compound (5.5 g, 44%). MS (ESI): mass calcd. for C9H6ClFN4, 224.03; m/z found, 225.0 [M+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.76 (d, J=1.4 Hz, 2H), 8.57 (m, 1H), 8.18 (dd, J=11.1, 2.0 Hz, 1H), 7.18 (s, 2H).
Step B: 5-(3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine
To a 200 mL round-bottomed flask were added a stirbar, 5-(5-chloro-3-fluoropyridin-2-yl)pyrimidin-2-amine (2.4 g, 11 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (3.4 g, 13 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)(2′-amino-1,1′-biphenyl-2-yl)palladium(II) (161 mg, 0.214 mmol), KOAc (3.1 g, 32 mmol) and 1,4-dioxane (100 mL). The flask was fitted with a septum, sparged with N2 for 10 min and heated at 80° C. for 5 h. The resulting reaction mixture was cooled to RT and then filtered through a Büchner funnel. The filter paper was washed with CH2Cl2 (50 mL) and the filtrate was concentrated directly onto silica and subjected to FCC to give the title compound (2.4 g, 71%). C15H18BFN4O2, 316.15; m/z found, 235.0 [M-pinacol]+. 1H NMR (600 MHz, DMSO-d6) δ 8.83 (d, J=1.2 Hz, 2H), 8.64-8.59 (m, 1H), 7.80 (dd, J=11.7, 1.3 Hz, 1H), 7.19 (s, 2H), 1.32 (s, 12H).
Example 877




A mixture of 5-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)pyrimidin-2-amine (420 mg, 1.32 mmol), (S)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide (480 mg, 1.46 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (100 mg, 10%), THF (4 mL) and aqueous K3PO4 (0.5 M, 4 mL) in a 25 mL sealed tube was sparged with N2 for 10 minutes and then stirred at 70° C. for 16 h. The resulting reaction mixture was cooled to RT and concentrated to dryness. The resulting residue was dissolved in CH2Cl2 (35 mL) and washed with water (3×10 mL). The organic phase was isolated and dried over Na2SO4, concentrated to dryness and the resulting residue was purified by prep-HPLC to give title compound (35 mg hydrochloride, 6%). MS (ESI): mass calcd. for C18H15F4N5O2S, 441.09; m/z found 442.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.24 (s, 2H), 8.50 (s, 1H), 8.13 (d, J=7.7 Hz, 1H), 7.81-7.66 (m, 3H), 7.44 (d, J=6.7 Hz, 1H), 3.94-3.85 (m, 1H), 1.25 (d, J=6.9 Hz, 3H).
Example 878




The title compound was prepared using analogous conditions to those described in Example 877 using 1-bromo-2-(cyclopropylsulfonyl)benzene. MS (ESI): mass calcd. for C18H15FN4O2S, 370.09; m/z found, 371.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 2H), 9.03 (s, 2H), 8.54 (s, 1H), 8.11 (d, J=7.8 Hz, 1H), 7.98 (d, J=12.0 Hz, 1H), 7.86-7.83 (m, 1H), 7.79-7.75 (m, 1H), 7.55 (d, J=7.4 Hz, 1H), 2.63-2.55 (m, 1H), 1.04-0.95 (m, 2H), 0.95-0.88 (m, 2H).
Example 879




The title compound was prepared using analogous conditions to those described in Example 877 using (S)-2-bromo-N-(2-hydroxypropyl)benzenesulfonamide. MS (ESI): mass calcd. for C18H18FN5O3S, 403.11; m/z found, 404.0 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 9.24 (s, 2H), 8.61-8.53 (m, 1H), 8.09 (dd, J=7.7, 1.5 Hz, 1H), 7.90 (dd, J=11.8, 1.7 Hz, 1H), 7.80-7.59 (m, 2H), 7.47 (dd, J=7.3, 1.6 Hz, 1H), 3.76-3.61 (m, 1H), 2.87-2.69 (m, 2H), 1.08 (d, J=6.3 Hz, 3H).
Example 880




The title compound was prepared using analogous conditions to those described in Example 877 using (S)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C18H18FN5O3S, 403.11; m/z found, 404.1 [M+H]+. 1H NMR (300 MHz, CD3OD): δ 9.24 (s, 2H), 8.57-8.56 (m, 1H), 8.17 (dd, J=7.7, 1.3 Hz, 1H), 7.90 (dd, J=12.0, 1.6 Hz, 1H), 7.78-7.61 (m, 2H), 7.45 (dd, J=7.3, 1.3 Hz, 1H), 3.42-3.36 (m, 1H), 3.28-3.18 (m, 2H), 1.05 (d, J=6.5 Hz, 3H).
Example 881




The title compound was prepared using analogous conditions to those described in Example 877 using (R)-2-bromo-N-(1-hydroxypropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C18H18FN5O3S, 403.11; m/z found, 404.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 9.24 (s, 2H), 8.57-8.56 (m, 1H), 8.17 (dd, J=7.7, 1.3 Hz, 1H), 7.90 (dd, J=12.0, 1.6 Hz, 1H), 7.78-7.61 (m, 2H), 7.45 (dd, J=7.3, 1.3 Hz, 1H), 3.42-3.36 (m, 1H), 3.28-3.18 (m, 2H), 1.05 (d, J=6.5 Hz, 3H).
Example 882




The title compound was prepared using analogous conditions to those described in Example 877 using 2-bromo-N-(2-hydroxyethyl)benzenesulfonamide. MS (ESI): mass calcd. for C17H16FN5O3S, 389.10; m/z found, 390.1 [M+H]+. 1H NMR (300 MHz, CD3OD) b 9.23 (s, 2H), 8.55 (s, 1H), 8.10 (d, J=7.6 Hz, 1H), 7.87 (d, J=11.9 Hz, 1H), 7.75-7.64 (m, 2H), 7.45 (d, J=7.2 Hz, 1H), 3.49 (t, J=5.8 Hz, 2H), 2.95 (t, J=5.6 Hz, 2H).
Example 883




The title compound was prepared using analogous conditions to those described in Example 877 using (R)-2-bromo-N-(1,1,1-trifluoropropan-2-yl)benzenesulfonamide. MS (ESI): mass calcd. for C18H15F4N5O2S, 441.09; m/z found, 442.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 9.08 (s, 2H), 8.47 (s, 1H), 8.14 (dd, J=7.8, 1.3 Hz, 1H), 7.77-7.63 (m, 3H), 7.44 (dd, J=7.5, 1.3 Hz, 1H), 3.94-3.85 (m, 1H), 1.25 (d, J=7.0 Hz, 3H).
Intermediate JP




Step A: 4-((2-Bromophenoxy)methyl)tetrahydro-2H-thiopyran
To a solution consisting of 1-bromo-2-fluorobenzene (1.3 g, 7.4 mmol) and DMF (10 mL) were added (tetrahydro-2H-thiopyran-4-yl)methanol (1.0 g, 7.4 mmol), NaH (0.6 g, 14.9 mmol) at 0° C. Then the mixture was stirred at 60° C. under N2 overnight. After which time the reaction mixture was cooled to RT, poured into ice-water, and extracted with ethyl acetate (3×20 mL). The combined organic extracts were washed with brine (20 mL), dried over MgSO4, filtered and concentrated to dryness to give the title compound, which was used in next step without further purification.
Step B: 4-((2-Bromophenoxy)methyl)tetrahydro-2H-thiopyran 1,1-dioxide
To a 0° C. solution consisting of 4-((2-bromophenoxy)methyl)tetrahydro-2H-thiopyran and CH2Cl2 (15 mL) was slowly added meta-chloroperoxybenzoic acid (3.4 g, 14.9 mmol). The resulting reaction mixture was stirred at RT overnight, then diluted with Na2S2O3 (20 mL, 10% aq.) and extracted with CH2Cl2 (3×20 mL). The combined organic extracts were washed with brine (20 mL), dried over MgSO4, filtered and concentrated to dryness. The crude product was recrystallized from ethyl acetate to afford the title compound (1.6 g, 67%). 1H NMR (400 MHz, CDCl3) δ 7.54 (dd, J=8.2, 1.6, 1H), 7.28-7.24 (m, 1H), 6.86 (dd, J=7.5, 6.6, 2H), 3.92 (d, J=5.8, 2H), 3.23-3.12 (m, 2H), 3.05 (dd, J=17.5, 8.9, 2H), 2.37 (d, J=11.2, 2H), 2.09 (m, 3H).
Intermediate JQ




Step A: 4-(2-bromophenoxy)tetrahydro-2H-thiopyran
To a 0° C. solution consisting of 1-bromo-2-fluorobenzene (1.3 g, 7.5 mmol) in DMF (10 mL) was added tetrahydro-2H-thiopyran-4-ol (740 mg, 6.3 mmol) and NaH (750 mg, 18.8 mmol). The mixture was stirred at 60° C. under a N2 atmosphere. After 12 h, the reaction mixture was cooled to RT, poured into ice-water and extracted with ethyl acetate (3×30 mL). The combined organic extracts were washed with brine (30 mL), dried over MgSO4, filtered and concentrated to dryness to give the title compound, which was used without further purification.
Step B: 4-(2-Bromophenoxy)tetrahydro-2H-thiopyran 1,1-dioxide
To a 0° C. solution consisting of 4-(2-bromophenoxy)tetrahydro-2H-thiopyran and CH2Cl2 (20 mL), was slowly added meta-chloroperoxybenzoic acid (3.7 g, 16.5 mmol). The reaction mixture was stirred at RT overnight. After which time the mixture was diluted with Na2S2O3 (20 mL, 10% aq.), basified with NaOH (2 N) to pH=8 and extracted with CH2Cl2 (3×15 mL). The combined organic extracts were concentrated to dryness and the resulting residue was purified by FCC to give the title compound (650 mg, 38%). 1H NMR (400 MHz, CDCl3) 57.58-7.56 (m, 1H), 7.31-7.25 (m, 1H), 6.98-6.85 (m, 2H), 4.72 (s, 1H), 3.62-3.46 (m, 2H), 2.97-2.87 (m, 2H), 2.52-2.43 (m, 2H), 2.41-2.34 (m, 2H).
Intermediate JR




Step A: Methyl 4-(2-bromophenoxy)benzoate
A mixture of methyl 4-fluorobenzoate (3.0 g, 19.5 mmol), 2-bromophenol (6.7 g, 39 mmol), Cs2CO3 (12.7 g, 39 mmol) and DMSO (30 mL) was stirred at RT for 36 h, and then diluted with water (30 mL). The aqueous mixture was extracted with EtOAc (3×50 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated to dryness. The crude residue was purified by FCC to give the title compound (3.6 g, 60%).
Step B: 4-(2-Bromophenoxy)benzoic acid
To a solution consisting of methyl 4-(2-bromophenoxy)benzoate (3.5 g, 11.4 mmol), MeOH (30 mL) and water (10 mL) was added NaOH (910 mg, 22.8 mmol). The reaction mixture was stirred for 10 h at RT. The MeOH was removed by evaporation and the resulting mixture was acidified with HCl (1 N) to pH=7. The resulting solid was isolated by filtration, washed with water, and then dried in a vacuum to provide the title compound (2.9 g, 87%). MS (ESI): mass calcd. for C13H9BrO3, 291.97; m/z found, 293.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.93 (d, J=8.6 Hz, 2H), 7.76 (d, J=8.2 Hz, 1H), 7.50-7.41 (m, 1H), 7.27-7.17 (m, 2H), 6.98-6.85 (m, 2H).
Intermediate JS




To a 100 mL round-bottomed flask, were added SOCl2 (20 mL, 276 mmol) followed by 4-(2-bromophenoxy)benzoic acid (1.8 g, 6.1 mmol) and the reaction mixture was refluxed for 2 h. The reaction mixture was cooled to RT and then concentrated to dryness. The resulting residue was dissolved in THF (30 mL) and treated with NH4OH (10 mL). The reaction mixture was stirred overnight, and then concentrated to dryness to give a solid residue. The resulting residue was collected by filtration washed with water and dried under vacuum to afford the title compound which was used without further purification (1.4 g, 78%). 1H NMR (400 MHz, DMSO-d6) δ 7.92-7.84 (m, 3H), 7.78-7.73 (m, 1H), 7.47-7.41 (m, 1H), 7.26 (s, 1H), 7.23-7.15 (m, 2H), 6.91 (d, J=8.8 Hz, 2H).
Intermediate JT




Step A: Methyl 4-((2-bromophenoxy)methyl)benzoate
To a 10 mL reaction tube equipped with reflux condenser, under N2, were added 2-bromophenol (1.5 g, 8.6 mmol), methyl 4-(bromomethyl)benzoate (2.0 g, 8.6 mmol), K2CO3 (2.4 g, 17.3 mmol) and MeCN (5 mL). The resulting mixture was heated at reflux for 3 h before it was cooled to RT and EtOAc (30 mL) was added and the resulting mixture was filtered then washed with EtOAc (2×10 mL). The combined organic extracts were concentrated to dryness and the residue was purified by FCC to provide the title compound (2.5 g, 90%).
Step B: 4-((2-bromophenoxy)methyl)benzoic acid
To a 150 mL round-bottomed flask, under a N2 atmosphere, were added methyl 4-((2-bromophenoxy)methyl)benzoate (2.5 g, 7.8 mmol), NaOH (0.6 g, 15.6 mmol) and MeOH (50 mL). The resulting mixture was stirred at RT for 10 h. After which time, water (50 mL) was added and the mixture was concentrated in vacuo to remove the MeOH. The aqeuous mixture was adjusted to pH=4 with 1 M HCl, which resulted in formation of a solid that was collected by filtration. The solid was dried under vacuum to obtain the title compound (2.2 g, 92%). MS (ESI): mass calcd. for C14H11BrO3, 305.99; m/z found, 328.2 [M+Na]+. 1H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 7.95 (d, J=8.1, 2H), 7.61-7.48 (m, 3H), 7.35-7.28 (m, 1H), 7.16 (d. J=8.3, 1H), 6.89 (m, 1H), 5.28 (s, 2H).
Intermediate JU




To a 150 mL round-bottomed flask equipped with a reflux condenser under a N2 atmosphere, were added trans-4-aminocyclohexanol (2.3 g, 20 mmol), NaH (2.4 g, 60% purity, 60 mmol) and DMF (25 mL) at 0° C. After 1 h, 1-bromo-2-fluorobenzene (2.051 mL, 19.97 mmol) was added to the solution. The resulting mixture was heated at 60° C. for 5 h. The reaction mixture was cooled to RT, quenched with H2O (2 mL) and concentrated to dryness. The resulting residue was purified using FCC to provide the title compound (1.8 g, 33.4%). MS (ESI): mass calcd. for C12H16BrNO, 269.04; m/z found, 269.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1H), 7.53 (dd, J=7.9, 1.6 Hz, 1H), 7.32-7.24 (m, 1H), 7.17 (dd, J=8.4, 1.4 Hz, 1H), 6.88-6.81 (m, 1H), 4.37-4.25 (m, 1H), 3.00-2.90 (m, 1H), 2.09-2.01 (m, 2H), 1.96-1.88 (m, 2H), 1.50-1.34 (m, 4H).
Example 884




The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromophenoxy)methyl)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C22H22FN3O3S, 427.14; m/z found, 427.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J=1.5 Hz, 1H), 8.01 (d, J=1.3 Hz, 1H), 7.90-7.86 (m, 1H), 7.44-7.32 (m, 4H), 7.13 (d, J=8.3 Hz, 1H), 7.06-7.02 (m, 1H), 6.67 (s, 2H), 3.94 (d, J=5.7 Hz, 2H), 3.17-3.08 (m, 2H), 3.03-3.00 (m, 2H), 2.10-2.00 (m, 3H), 1.79-1.73 (m, 2H).
Example 885




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C21H20FN3O3S, 413.12; m/z found, 413.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 8.04 (s, 1H), 7.95-7.91 (m, 1H), 7.51-7.35 (m, 4H), 7.25 (d, J=8.3 Hz, 1H), 7.13-7.09 (m, 1H), 6.68 (s, 2H), 4.82-4.67 (m, 1H), 3.09-3.06 (m, 2H), 2.92-2.87 (m, 2H), 2.19-2.15 (m, 4H).
Example 886




The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromophenoxy)methyl)benzoic acid. MS (ESI): mass calcd. for C24H18FN3O3, 415.13; m/z found, 415.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (s, 1H), 8.02 (d, J=1.4 Hz, 1H), 7.89-7.84 (m, 1H), 7.79 (d, J=8.1 Hz, 2H), 7.49-7.43 (m, 2H), 7.40 (dd, J=7.5, 1.6 Hz, 1H), 7.37-7.31 (m, 1H), 7.26 (d, J=8.1 Hz, 2H), 7.20 (d, J=8.1 Hz, 1H), 7.06-7.03 (m, 1H), 6.68 (s, 2H), 5.13 (s, 2H).
Example 887




The title compound was prepared in a manner similar to that described in Example 88 using 4-((2-bromophenoxy)methyl)benzoic acid and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C24H18FN3O3, 415.13; m/z found, 415.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J=1.2 Hz, 2H), 7.79 (d, J=8.0 Hz, 2H), 7.58-7.54 (m, 1H), 7.50-7.43 (m, 2H), 7.40-7.31 (m, 2H), 7.25 (d, J=8.0 Hz, 2H), 7.19 (d, J=8.3 Hz, 1H), 7.06-7.02 (m, 1H), 6.85 (s, 2H), 5.14 (s, 2H).
Example 888




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)benzoic acid. MS (ESI): mass calcd. for C23H16FN3O3, 401.12; m/z found, 402.4 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.97 (s, 1H), 7.89-7.79 (m, 3H), 7.64-7.58 (m, 1H), 7.50-7.44 (m, 1H), 7.43-7.35 (m, 3H), 7.19-7.14 (m, 1H), 6.98-6.89 (m, 2H), 6.67 (s, 2H).
Example 889




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)benzoic acid and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C23H18FN3O3, 401.12; m/z found, 401.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.45-8.39 (m, 2H), 7.89-7.85 (m, 2H), 7.61-7.58 (m, 1H), 7.57-7.51 (m, 1H), 7.49-7.44 (m, 1H), 7.43-7.34 (m, 3H), 7.16-7.12 (m, 1H), 6.98-6.93 (m, 2H), 6.86 (s, 2H).
Example 890




The title compound was prepared in a manner similar to that described in Example 88 using 4-(2-bromophenoxy)benzamide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C23H17FN4O2, 400.13; m/z found, 400.9 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.43 (s, 2H), 7.88-7.79 (m, 3H), 7.62-7.50 (m, 2H), 7.48-7.38 (m, 3H), 7.37-7.31 (m, 1H), 7.23 (s, 1H), 7.09 (d, J=7.8 Hz, 1H), 6.94 (d, J=8.8 Hz, 2H), 6.85 (s, 2H).
Example 891




The title compound was prepared in a manner similar to that described in Example 88 using trans 4-(2-bromophenoxy)cyclohexanamine. MS (ESI): mass calcd. for C22H23FN4O, 378.19; m/z found, 379.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.35 (s, 1H), 8.01 (d, J=1.4 Hz, 1H), 7.89-7.83 (m, 1H), 7.43-7.35 (m, 3H), 7.34-7.29 (m, 1H), 7.17 (d, J=8.2 Hz, 1H), 7.05-6.98 (m, 1H), 6.67 (s, 2H), 4.34-4.24 (m, 1H), 2.91-2.83 (m, 1H), 2.08-2.01 (m, 2H), 1.89-1.83 (m, 2H), 1.40-1.29 (m, 4H).
Example 892




The title compound was prepared using analogous conditions to those described in Example 1 using 2-bromo-5-(trifluoromethyl)aniline. MS (ESI): mass calcd. for C17H12F4N4, 348.10; m/z found, 349.0 [M+H]+. 1H NMR (500 MHz, CDCl3) δ 8.59-8.57 (m, 1H), 8.12 (d, J=1.5 Hz, 1H), 8.02 (m, 1H), 7.36-7.33 (m, 1H), 7.31-7.22 (m, 3H), 7.08-7.05 (m, 1H), 7.01-6.99 (m, 1H), 4.75 (s, 2H), 4.00 (s, 2H).
Intermediate JV




Step A: tert-Butyl 4-(3-bromopyridin-2-ylthio)piperidine-1-carboxylate
To a 250 mL round-bottomed flask were added, 3-bromopyridine-2-thiol (3.0 g, 16 mmol), tert-butyl 4-bromopiperidine-1-carboxylate (5.0 g, 19 mmol), K2CO3 (4.3 g, 31 mmol) and DMF (30 mL). The reaction mixture was stirred at RT for 4 h and then concentrated to dryness. The residue was purified by FCC to give the title compound (3.2 g, 54% purity). MS (ESI): mass calcd. for C15H21BrN2O2S, 372.05; m/z found, 373.1 [M+H]+.
Step B: tert-Butyl 4-(3-bromopyridin-2-ylsulfonyl)piperidine-1-carboxylate
To a 250 mL round bottom flask was added, tert-butyl 4-(3-bromopyridin-2-ylthio)piperidine-1-carboxylate (3.0 g, 8.0 mmol, 54% purity), NaIO4 (5.0 g, 24.0 mmol), RuCl3 (10 mg, 0.05 mmol) and H2O/DCM/CH3CN (15 mL/15 mL/15 mL). The reaction mixture was stirred at RT for 1 h and then concentrated to dryness. The residue was diluted with water (50 mL) and extracted with DCM (3×50 mL). The combined organic extracts were dried over Na2SO4, filtered, concentrated to dryness and the resultant residue was purified by FCC to give the title compound (1.61 g, 50%). MS (ESI): mass calcd. for C15H21BrN2O4S, 404.04; m/z found, 405.3 [M+H]+.
Step C: 3-Bromo-2-(piperidin-4-ylsulfonyl)pyridine hydrochloride
To a 100 mL round-bottomed flask were added, tert-butyl 4-(3-bromopyridin-2-ylsulfonyl)piperidine-1-carboxylate (242 mg, 0.6 mmol), MeOH (20 mL) and HCl (4 mL, 6 N in EtOH). The mixture was stirred at RT for 3 h and then concentrated to dryness to give the title compound (210 mg) which was used without further purification. MS (ESI): mass calcd. for C10H14BrClN2O2S, 303.99; m/z found, 304.4 [M+H]+.
Step D: 2-(4-(3-Bromopyridin-2-ylsulfonyl)piperidin-1-yl)ethanol
To a 100 mL round-bottomed flask were added, 3-bromo-2-(piperidin-4-ylsulfonyl)pyridine hydrochloride (500 mg, 1.47 mmol), 1-bromoethan-2-ol (204 mg, 1.5 mmol), K2CO3 (304 mg, 2.2 mmol) and CH3CN (20 mL). The mixture was stirred at 60° C. for 16 h, cooled to RT, concentrated to dryness and the resulting residue was purified by FCC to give the title compound (370 mg, 69%). MS (ESI): mass calcd. for C12H17BrN2O3S, 348.01; m/z found, 349.3 [M+H]+.
Intermediate JW




To a microwave vial were added phenyl boronic acid (76 mg, 0.62 mmol), 2-bromo-3-chloropyridine (100 mg, 0.52 mmol), Pd(dppf)Cl2.CH2Cl2 (20 mg, 0.025 mmol), acetonitrile (2.0 mL) and sat. aq. NaHCO3 (1.5 mL). Nitrogen was bubbled through the biphasic mixture for 2 minutes before the vial was sealed. The reaction vessel was then placed in the microwave and heated at 110° C. for 1.5 h. The resulting reaction mixture was cooled to RT, diluted with ethyl acetate (50 mL), washed with water (1×25 mL), brine (1×25 mL), dried with Na2SO4 and concentrated to dryness. The resultant residue was subjected to prep-HPLC to afford the title compound (48 mg, 49%). MS (ESI): mass calcd. for C11H8ClN, 189.03; m/z found, 190.0 [M+H]+.
Example 893




The title compound was prepared in a manner similar to that described in Step B of Example 838 using 3-chloro-2-phenylpyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C21H15FN4, 342.13; m/z found, 343.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.70 (dd, J=4.8, 1.7 Hz, 1H), 8.45 (d, J=1.5 Hz, 2H), 7.90 (dd, J=7.7, 1.7 Hz, 1H), 7.55-7.44 (m, 2H), 7.41-7.26 (m, 5H), 7.16 (dd, J=11.9, 1.8 Hz, 1H), 7.05 (dd, J=8.0, 1.8 Hz, 1H), 6.92 (s, 2H).
Intermediate JX




To a 50 mL round-bottomed flask under nitrogen were added 2-bromo-3-chloropyridine (250 mg, 1.3 mmol), phenol (145 mg, 1.5 mmol), cesium carbonate (502 mg, 1.5 mmol) and DMSO (5 mL). The mixture was then heated at 60° C. for 24 h. The resulting reaction mixture was then cooled to RT, diluted with ethyl acetate (100 mL), washed with sat. aq. NaHCO3 (1×75 mL), water (1×75 mL). The organic extracts were dried over Na2SO4 and concentrated to dryness. The resultant residue was then purified by FCC to provide the title compound (205 mg, 77%). MS (ESI): mass calcd. for C11H8ClNO, 189.03; m/z found, 190.0 [M+H]+.
Example 894




The title compound was prepared in a manner similar to that described in Step B of Example 838 using 3-chloro-2-phenoxypyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrazin-2-amine. MS (ESI): mass calcd. for C21H15FN4O, 358.12; m/z found, 359.1 [M+H]+. 1H NMR (400 MHz, DMSO-d8) δ 8.39 (dd, J=2.4, 1.5 Hz, 1H), 8.14 (dd, J=4.9, 1.9 Hz, 1H), 8.07-8.00 (m, 2H), 8.00-7.92 (m, 1H), 7.70-7.60 (m, 2H), 7.46-7.37 (m, 2H), 7.27 (dd, J=7.5, 4.8 Hz, 1H), 7.24-7.13 (m, 3H), 6.74 (s, 2H).
Example 895




The title compound was prepared in a manner similar to that described in Step B of Example 838 using 3-chloro-2-phenoxypyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H15FN4O, 358.12; m/z found, 359.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, J=1.5 Hz, 2H), 8.14 (dd, J=4.8, 1.9 Hz, 1H), 8.02 (dd. J=7.5, 1.9 Hz, 1H), 7.70-7.59 (m, 3H), 7.46-7.38 (m, 2H), 7.30-7.13 (m, 4H), 6.93 (s, 2H).
Intermediate JY




To a screw-capped vial was added 3-bromo-2-chloropyridine (250 mg, 1.3 mmol), 3-hydroxy pyridine (150 mg, 1.6 mmol), cesium carbonate (510 mg, 1.6 mmol) and DMSO (5.0 mL). The vial was capped and the mixture was stirred at 60° C. for 24 h. The resulting reaction mixture was cooled to RT, poured into water (100 mL) and extracted with ethyl acetate (2×50 mL). The combined organic extracts were washed with water (1×50 mL) and brine (1×50 mL). The organic extracts were concentrated to dryness and purified by FCC to provide the title compound (214 mg, 66%). MS (ESI): mass calcd. for C10H7BrN2O, 249.97; m/z found, 250.9 [M+H]+.
Example 896




The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(pyridine-3-yloxy)pyridine. MS (ESI): mass calcd. for C20H14FN5O, 359.12; m/z found, 360.1 [M+H]. 1 H NMR (400 MHz, DMSO-d6) δ 8.51 (d, J=2.7 Hz, 1H), 8.44 (dd, J=4.6, 1.4 Hz, 1H), 8.45-8.35 (m, 1H), 8.14 (dd, J=4.9, 1.8 Hz, 1H), 8.09-8.01 (m, 2H), 7.81-7.92 (m, 1H), 7.74-7.62 (m, 3H), 7.48 (dd, J=8.3, 4.7 Hz, 1H), 7.31 (dd, J=7.5, 4.9 Hz, 1H).
Example 897




The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(phenylsulfonyl)pyridine. MS (ESI): mass calcd. for C21H15FN4O2S, 406.09; m/z found, 406.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.63 (dd, J=4.7, 1.6 Hz, 1H), 8.44 (s, 1H), 8.12 (d, J=1.4 Hz, 1H), 7.94-7.88 (m, 2H), 7.74-7.64 (m, 4H), 7.54-7.48 (m, 2H), 7.23 (dd, J=8.0, 1.7 Hz, 1H), 7.17 (dd, J=12.0, 1.6 Hz, 1H).
Example 898




Step A: 3-Bromo-2-(phenylthio)pyridine
The intermediate was prepared in a manner similar to that for Intermediate JZ using thiophenol. MS (ESI): mass calcd. for C11H8BrNS 264.96, m/z found 265.8 [M+H]+.
Step B: 3-Bromo-2-(phenylsulfonyl)pyridine
The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 3-bromo-2-(phenylthio)pyridine. MS (ESI): mass calcd. for C11H8BrNO2S 296.95, m/z found 298.1 [M+H]+.
Step C: 5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(phenylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H15FN4O2S, 406.09; m/z found, 407.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.73 (s, 2H), 8.62 (dd, J=4.6, 1.5 Hz, 1H), 7.92 (dd, J=7.8, 1.5 Hz, 1H), 7.77-7.73 (m, 2H), 7.73-7.67 (m, 2H), 7.64-7.59 (m, 1H), 7.57-7.52 (m, 2H), 7.33-7.25 (m, 2H).
Intermediate JZ




To a 100 mL round-bottomed flask were added 3-bromo-2-chloropyridine (500 mg, 2.6 mmol), pyridine-3-thiol (291 mg, 2.6 mmol), Cs2CO3 (2.4 g, 7.8 mmol) and DMSO (15 mL). The reaction mixture was stirred at 100° C. for 5 h. After which time the reaction mixture was cooled to RT, concentrated to dryness and the resultant residue was purified by FCC to give the title compound (400 mg, 58%). MS (ESI): mass calcd. for C10H7BrN2S, 265.95; m/z found, 267.1 [M+H]+.
Example 899




Step A: 3-Bromo-2-(pyridin-3-ylsulfonyl)pyridine
The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 3-bromo-2-(pyridin-3-ylthio)pyridine. MS (ESI): mass calcd. for C10H7BrN2O2S, 297.94, m/z found 298.6 [M+H]+.
Step B: 5-{2-Fluoro-4-[2-(pyridin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(pyridin-3-ylsulfonyl)pyridine. MS (ESI): mass calcd. for C20H14FN5O2S, 407.09; m/z found, 408.0 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.90 (dd, J=2.3, 0.6 Hz, 1H), 8.81 (dd, J=4.9, 1.6 Hz, 1H), 8.56 (dd, J=4.6, 1.6 Hz, 1H), 8.48-8.42 (m, 1H), 8.21-8.18 (m, 1H), 8.11 (d, J=1.5 Hz, 1H), 8.01-7.94 (m, 2H), 7.70 (dd, J=7.8, 4.7 Hz, 1H), 7.63-7.59 (m, 1H), 7.38-7.29 (m, 2H).
Example 900




Step A: tert-Butyl 3-(3-bromopyridin-2-ylthio)pyrrolidine-1-carboxylate
The intermediate was prepared in a manner similar to that described in Step A of Intermediate JV using tert-butyl 3-bromopyrrolidine-1-carboxylate. MS (ESI): mass calcd. for C14H19BrN2O2S, 358.04, m/z found 381.0 [M+Na]+.
Step B: tert-Butyl 3-(3-bromopyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate
The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using tert-butyl 3-(3-bromopyridin-2-ylthio)pyrrolidine-1-carboxylate. MS (ESI): mass calcd. for C14H19BrN2O4S, 390.02, m/z found 335.0 [M-Me3C]+.
Step C: 3-Bromo-2-(pyrrolidin-3-ylsulfonyl)pyridine
To a 100 mL round-bottomed flask were added, tert-butyl 3-(3-bromopyridin-2-ylsulfonyl)pyrrolidine-1-carboxylate (1.8 g, 4.2 mmol) and DCM (20 mL). A solution of HCl (20 mL, 6 N in EtOH) was then added and the mixture was stirred at RT for 2 h followed by concentration to dryness. The residue was diluted with sat. aq. NaHCO3 (50 mL) and extracted with DCM (6×40 mL). The combined organic extracts were dried over MgSO4 and concentrated to dryness to provide the title compound (1 g, 83%). MS (ESI): mass calcd. for C9H11BrN2O2S, 289.97, m/z found 291.0 [M+H]+.
Step D: 3-Bromo-2-(1-methylpyrrolidin-3-ylsulfonyl)pyridine
To a 100 mL round-bottomed flask was added, 3-bromo-2-(pyrrolidin-3-ylsulfonyl)pyridine (1.0 g, 3.4 mmol) and DCM (20 mL). An aqueous solution of formaldehyde (37%, 280 mg, 10.3 mmol), AcOH (0.5 mL) and NaBH(AcO)3 (2.2 g, 10.3 mmol) were then added. The resulting mixture was stirred at RT for 1 h. then concentrated to dryness. The residue was purified by FCC to give the title compound (240 mg, 23%). MS (ESI): mass calcd. for C10H13BrN2O2S, 303.99, m/z found 305.0 [M+H]+.
Step E: 5-(2-Fluoro-4-{2-[(1-methylpyrrolidin-3-yl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(1-methylpyrrolidin-3-ylsulfonyl)pyridine. MS (ESI): mass calcd. for C20H20FN5O2S, 413.13; m/z found, 414.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.63 (d, J=3.2 Hz, 1H), 8.61 (s, 1H), 8.12 (s, 1H), 8.11-8.07 (m, 1H), 7.89 (d, J=6.7 Hz, 1H), 7.65 (dd, J=7.8, 4.7 Hz, 1H), 7.42-7.35 (m, 2H), 4.89-4.85 (m, 1H), 4.80 (s, 2H), 4.31-4.21 (m, 1H), 3.63-3.59 (m, 1H), 3.29-3.24 (m, 1H), 3.05-2.98 (m, 1H), 2.81 (s, 3H), 2.77-2.58 (m, 2H).
Example 901




Step A: 3-Bromo-6-(trifluoromethyl)pyridine-2-thiol
To a 100 mL round-bottomed flask were added, 3-bromo-2-chloro-6-(trifluoromethyl)pyridine (1.0 g, 3.8 mmol), Na2S.9H2O (2.8 g, 11.5 mmol) and DMSO (15 mL). The reaction mixture was stirred at 100° C. for 48 h, then cooled to RT and filtered. The filtrate was used in the next step without purification.
Step B: 3-Bromo-2-(iso-propylthio-6-(trifluoromethyl)pyridine
The intermediate was prepared in a manner similar to that described in Step A of Intermediate JV using 3-bromo-6-(trifluoromethyl)pyridine-2-thiol and 2-bromopropane. MS (ESI): mass calcd. for C9H9BrF3NS, 298.96; m/z found, 300.0 [M+H]+.
Step C: 3-Bromo-2-(iso-propylsulfonyl)-6-(trifluoromethyl)pyridine
The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 3-bromo-2-(isopropylthio)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C9H9BrF3NO2S, 330.95; m/z found, 331.9 [M+H]+.
Step D: 5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}phenyl)pyrazin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(isopropylsulfonyl)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.71 (d, J=1.3 Hz, 1H), 8.33-8.25 (m, 2H), 8.22-8.18 (m, 2H), 7.57-7.49 (m, 2H), 4.37-4.17 (m, 1H), 1.34 (d, J=6.9 Hz, 6H).
Example 902




The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(isopropylsulfonyl)-6-(trifluoromethyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C19H16F4N4O2S, 440.09; m/z found, 441.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.90 (s, 2H), 8.26 (d, J=8.1 Hz, 1H), 8.19 (d, J=8.1 Hz, 1H), 7.76-7.72 (m, 1H), 7.58-7.49 (m, 2H), 4.30-4.20 (m, 1H), 1.33 (d, J=6.9 Hz, 6H).
Example 903




Step A: tert-Butyl 3-(3-bromopyridin-2-ylthio)piperidine-1-carboxylate
To a 250 mL round-bottomed flask was added, 3-bromopyridine-2-thiol (1.0 g, 5.3 mmol), tert-butyl 3-(tosyloxy)cyclohexanecarboxylate (1.2 g, 3.7 mmol), K2CO3 (720 mg, 5.3 mmol) and DMF (15 mL). The reaction mixture was stirred at 60° C. for 16 h then cooled to RT. The resulting mixture was concentrated to dryness and purified by FCC to give the title compound (300 mg, 21% purity). MS (ESI): mass calcd. for, C15H21BrN2O2S, 372.05; m/z found, 373.1 [M+H]+.
Step B: tert-Butyl 3-(3-bromopyridin-2-ylsulfonyl)piperidine-1-carboxylate
The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using tert-butyl 3-(3-bromopyridin-2-ylthio)piperidine-1-carboxylate. MS (ESI): mass calcd. for, C15H21BrN2O4S, 404.04; m/z found, 405.1 [M+H]+.
Step C: 3-Bromo-2-(piperidin-3-ylsulfonyl)pyridine
The intermediate was prepared in a manner similar to that described in Step C of Intermediate JV using tert-butyl 3-(3-bromopyridin-2-ylsulfonyl)piperidine-1-carboxylate. MS (ESI): mass calcd. for C10H13BrN2O2S, 303.99; m/z found, 305.0 [M+H]+.
Step D: 1-(3-(3-Bromopyridin-2-ylsulfonyl)piperidin-1-yl)ethanone
To a 100 mL round-bottomed flask were added 3-bromo-2-(piperidin-3-ylsulfonyl)pyridine hydrochloride (150 mg, 0.44 mmol), acetyl chloride (52 mg, 0.66 mmol), CH2Cl2 (20 mL) and Et3N (90 mg, 0.88 mmol). The mixture was stirred at RT for 1 h then neutralized to pH=7 by adding sat. aq. NaHCO3 and extracted with DCM (3×10 mL). The combined organic extracts were dried over Na2SO4 and concentrated to dryness to give the title compound (160 mg) which was used in the next step without further purification. MS (ESI): mass calcd. for C12H15BrN2O3S, 346.00; m/z found, 346.9 [M+H]+.
Step E: 5-(4-{2-[(1-Acetylpiperidin-3-yl)sulfonyl]pyridin-3-yl}-2-fluorphenyl)pyrazin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 1-(3-(3-bromopyridin-2-ylsulfonyl)piperidin-1-yl)ethanone. MS (ESI): mass calcd. for C22H22FN5O3S, 455.14; m/z found, 455.9 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.78 (s, 1H), 8.69-8.58 (m, 1H), 8.30 (s, 1H), 8.17-8.11 (m, 1H), 8.03 (dd, J=11.5, 7.9 Hz, 1H), 7.83-7.78 (m, 1H), 7.48-7.43 (m, 2H), 4.67-3.78 (m, 3H), 3.58-3.17 (m, 1H), 3.07-2.92 (m, 1H), 2.19 (s, 1H), 2.13 (m, 3H), 1.99-1.78 (m, 2H), 1.68-1.50 (m, 1H).
Example 904




The title compound was prepared in a manner similar to that described in Step D of Example 803 using 2-(4-(3-bromopyridin-2-ylsulfonyl)piperidin-1-yl)ethanol. MS (ESI): mass calcd. for C22H24FN5O3S, 457.16; m/z found, 458.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.80-8.74 (m, 1H), 8.72 (d, J=1.1 Hz, 1H), 8.25 (d, J=1.2 Hz, 1H), 8.20-8.11 (m, 1H), 8.03 (dd, J=7.8, 1.4 Hz, 1H), 7.79 (dd, J=7.9, 4.6 Hz, 1H), 7.50-7.40 (m, 2H), 4.56-4.42 (m, 1H), 3.96-3.72 (m, 4H), 3.54-3.45 (m, 1H), 3.30-3.11 (m, 4H), 2.39-2.28 (m, 2H), 2.20-2.00 (m, 2H).
Example 905




Step A: 1-(4-(3-Bromopyridin-2-ylsulfonyl)piperidin-1-yl)propan-2-ol
To a 100 mL round-bottomed flask were added, 3-bromo-2-(piperidin-4-ylsulfonyl)pyridine hydrochloride (500 mg, 1.47 mmol), 1-bromopropan-2-ol (204 mg, 1.47 mmol), K2CO3 (304 mg, 2.2 mmol) and CH3CN (20 mL). The mixture was stirred at 60° C. for 16 h. The resulting mixture was cooled to RT, concentrated to dryness and the resultant residue was purified by FCC to give the title compound (370 mg, 69%). MS (ESI): mass calcd. for C13H19BrN2O3S, 362.03; m/z found, 363.3 [M+H]+.
Step B: 1-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}sulfonyl)piperidin-1-yl]propan-2-ol
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 1-(4-(3-bromopyridin-2-ylsulfonyl)piperidin-1-yl)propan-2-ol. MS (ESI): mass calcd. for C23H26FN5O3S, 471.17; m/z found, 472.1 [M+H]+. 1H NMR (300 MHz, CD3OD) δ 8.78-8.73 (m, 1H), 8.72-8.66 (m, 1H), 8.26 (s, 1H), 8.15 (m, 1H), 8.05-8.00 (m, 1H), 7.79 (dd, J=7.9, 4.6 Hz, 1H), 7.48-7.40 (m, 2H), 4.59-4.42 (m, 1H), 4.26-4.11 (m, 1H), 3.79 (t, J=11.4 Hz, 2H), 3.52-3.41 (m, 1H), 3.23-2.94 (m, 4H), 2.39-2.25 (m, 2H), 2.22-2.01 (m, 2H), 1.23 (d, J=6.1 Hz, 3H).
Example 906




Step A: 3-Bromo-2-(tetrahydro-2H-pyran-4-ylthio)-6-(trifluoromethyl)pyridine
The intermediate was prepared in a manner similar to that described in Step A of Intermediate JV using 3-bromo-6-(trifluoromethyl)pyridine-2-thiol and 4-bromotetrahydro-2H-pyran. MS (ESI): mass calcd. for C11H11BrF3NOS, 340.97; m/z found, 342.0 [M+H]+.
Step B: 3-Bromo-2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridine
The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 3-bromo-2-(tetrahydro-2H-pyran-4-ylthio)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C11H11BrF3NO3S2, 372.96; m/z found, 373.6 [M+H]+.
Step C: 5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}pyrazin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridine. MS (ESI): mass calcd. for C21H18F4N4O3S, 482.10; m/z found, 483.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.44 (s, 1H), 8.29 (d, J=8.0 Hz, 1H), 8.20 (d, J=8.1 Hz, 1H), 8.15 (s, 1H), 8.05-8.01 (m, 1H), 7.48 (d, J=4.1 Hz, 1H), 7.46 (s, 1H), 4.38-4.32 (m, 1H), 4.08-4.04 (m, 2H), 3.54-3.49 (m, 2H), 1.96-1.93 (m, 2H), 1.89-1.79 (m, 2H).
Example 907




The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H18F4N4O3S, 482.10; m/z found, 483.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.74 (d, J=0.8 Hz, 2H), 8.27 (d, J=8.1 Hz, 1H), 8.20 (d, J=8.1 Hz, 1H), 7.70-7.66 (m, 1H), 7.53-7.48 (m, 2H), 4.39-4.34 (m, 1H), 4.07-4.03 (m, 2H), 3.54-3.47 (m, 2H), 1.95-1.92 (m, 2H), 1.87-1.78 (m, 2H).
Example 908




Step A: 3-Bromo-2-(1-(methylsulfonyl)piperidin-4-ylsulfonyl)pyridine
The intermediate was prepared in a manner similar to that described in Step D of Intermediate JV using methanesulfonyl chloride. MS (ESI): mass calcd. for C11H15BrN2O4S2, 381.97; m/z found, 382.7 [M+H]+.
Step B: 5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4-yl]sulfonyl}pyridin-3-yl)phenyl]pyrazin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(1-(methylsulfonyl)piperidin-4-ylsulfonyl)pyridine. MS (ESI): mass calcd. for C21H22FN5O4S2, 491.11; m/z found, 492.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.75 (dd, J=4.7, 1.5 Hz, 1H), 8.65 (d, J=1.2 Hz, 1H), 8.26 (d, J=1.2 Hz, 1H), 8.15-8.11 (m, 1H), 8.00 (dd, J=7.9, 1.5 Hz, 1H), 7.77 (dd, J=7.9, 4.7 Hz, 1H), 7.44-7.42 (m, 2H), 4.26-4.21 (m, 1H), 3.84-3.81 (m, 2H), 2.91-2.83 (m, 5H), 2.11-2.08 (m, 2H), 1.83-1.73 (m, 2H).
Example 909




The title compound was prepared in a manner similar to that described in Step D of Example 803 using 3-bromo-2-(1-(methylsulfonyl)piperidin-4-ylsulfonyl)pyridine and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H22FN5O4S2, 491.11; m/z found, 492.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.88 (s, 2H), 8.76 (dd, J=4.6, 1.5 Hz, 1H), 7.99 (dd, J=7.9, 1.5 Hz, 1H), 7.78 (dd, J=7.9, 4.7 Hz, 1H), 7.71-7.67 (m, 1H), 7.46 (dd, J=7.0, 1.4 Hz, 1H), 7.44-7.43 (m, 1H), 4.29-4.23 (m, 1H), 3.84-3.81 (m, 2H), 2.91-2.85 (m, 5H), 2.12-2.09 (m, 2H), 1.83-1.72 (m, 2H).
Example 910




Step A: 1-(4-(3-Bromo-6-(trifluoromethyl)pyridin-2-ylsulfonyl)piperidin-1-yl)ethanone
The intermediate was prepared in a manner similar to that described in Step D of Example 903 using 3-bromo-2-(piperidin-4-ylsulfonyl)-6-(trifluoromethyl)pyridine hydrochloride. MS (ESI): mass calcd. for C13H14BrF3N2O3S 413.99; m/z found, 414.6 [M+H]+.
Step B: 5-(4-{2-[(1-Acetylpiperidin-4-ylsulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 1-(4-(3-bromo-6-(trifluoromethyl)pyridin-2-ylsulfonyl)piperidin-1-yl)ethanone. MS (ESI): mass calcd. for C23H21F4N5O3S, 523.13; m/z found, 524.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.73 (d, J=1.2 Hz, 1H), 8.32-8.29 (m, 2H), 8.25-8.18 (m, 2H), 7.58-7.50 (m, 2H), 4.64-4.61 (m, 1H), 4.42-4.36 (m, 1H), 4.10-4.07 (m, 1H), 3.29-3.23 (m, 1H), 2.83-2.76 (m, 1H), 2.18-2.15 (m, 1H), 2.12-2.07 (m, 4H), 1.81-1.75 (m, 1H), 1.73-1.59 (m, 1H).
Example 911




The title compound was prepared in a manner similar to that described in Step D of Example 803 using 1-(4-(3-bromo-6-(trifluoromethyl)pyridin-2-ylsulfonyl)piperidin-1-yl) ethanone and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C23H21F4N5O3S, 523.13; m/z found, 524.1 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 8.93 (s, 2H), 8.30 (d, J=8.1 Hz, 1H), 8.23 (d. J=8.1 Hz, 1H), 7.79-7.75 (m, 1H), 7.61-7.51 (m, 2H), 4.64-4.61 (m, 1H), 4.45-4.34 (m, 1H), 4.11-4.07 (m, 1H), 3.33-3.26 (m, 1H), 2.84-2.78 (m, 1H), 2.23-2.05 (m, 5H), 1.85-1.76 (m, 1H), 1.71-1.61 (m, 1H).
Example 912




Step A: 4-((3-Bromo-6-(trifluoromethyl)pyridin-2-yl)thio)tetrahydro-2H-thiopyran 1,1-dioxide
The intermediate was prepared in a manner similar to that described in Step A of Intermediate JV using 3-bromo-6-(trifluoromethyl)pyridine-2-thiol and 4-iodotetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C11H11BrF3NO2S2, 388.94; m/z found, 389.5 [M+H]+.
Step B: 4-((3-Bromo-6-(trifluoromethyl)pyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide
The intermediate was prepared in a manner similar to that described in Step B of Intermediate JV using 4-((3-bromo-6-(trifluoromethyl)pyridin-2-yl)thio)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C11H11BrF3NO4S2, 420.93; m/z found, 421.5 [M+H]+.
Step C: 5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine
The title compound was prepared in a manner similar to that described in Step D of Example 803 using 4-((3-bromo-6-(trifluoromethyl)pyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide. MS (ESI): mass calcd. for C21H18F4N4O4S2, 530.07; m/z found, 531.0 [M+H]+. 1H NMR (400 MHz, DMSO-d) δ 8.42-8.37 (m, 3H), 8.06 (s, 1H), 8.00-7.95 (m, 1H), 7.50 (dd, J=12.1, 1.5 Hz, 1H), 7.43 (dd, J=8.1, 1.7 Hz, 1H), 6.83 (s, 2H), 4.33-4.27 (m, 1H), 3.41-3.34 (m, 2H), 3.22-3.19 (m, 2H), 2.38-2.35 (m, 2H), 2.13-2.04 (m, 2H).
Example 913




The title compound was prepared in a manner similar to that described in Step D of Example 803 using 4-((3-bromo-6-(trifluoromethyl)pyridin-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide and 5-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboralan-2-yl)phenyl)pyrimidin-2-amine. MS (ESI): mass calcd. for C21H18F4N4O4S2, 530.07; m/z found, 531.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.65-8.62 (m, 2H), 8.39 (s, 2H), 7.75-7.71 (m, 1H), 7.54 (d, J=11.6 Hz, 1H), 7.44 (d, J=8.0 Hz, 1H), 5.10 (s, 2H), 4.34-4.28 (m, 1H), 3.40-3.34 (m, 2H), 3.22-3.19 (m, 2H), 2.38-2.35 (m, 2H), 2.13-2.04 (m, 2H).
The following Examples 1-13 summarized in Table 4 are prophetic and unless otherwise specified, can be readily synthesized by a person skilled in the art utilizing the above described reaction schemes or by synthesis routes generally known to a person skilled in the art. One skilled in the art based on presently disclosed compounds would conclude the following prophetic compounds to be active against FLAP.







TABLE 4







Prophetic Examples









STRUCTURE
No.
NAME
















1
4′-(6-Aminopyridazin-3-yl)-3′- fluorobiphenyl-2-sulfonamide


 






2
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′- fluoro-5-(trifluoromethyl)biphenyl-2- sulfonamide


 






4
N-[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]methanesulfonamide


 






5
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′- fluoro-5-methoxybiphenyl-2-sulfonamide


 






6
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3- carboxamide


 






7
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3- carboxamide


 






8
5-[3-Fluoro-2′-(morpholin-4- ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine


 






9
5-{2′-[(Cyclopropylmethyl)sulfonyl]-3- fluorobiphenyl-4-yl}pyrazin-2-amine


 






10
1-{[4′-(2-Aminopyrimidin-5-yl)-3′- fluorobiphenyl-2-yl]sulfonyl}-4- (pentafluoroethyl)piperidin-4-ol


 






11
tert-Butyl (1-{[3′-fluoro-4′-(5H-pyrrolo[2,3- b]pyrazin-2-yl)biphenyl-2- yl]sulfonyl}piperidin-4-yl)carbamate


 






12
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4- difluorobiphenyl-2-sulfonamide


 






13
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′- fluoro-4-(trifluoromethyl)biphenyl-2- sulfonamide









D) General Administration, Formulation, and Dosages
The present invention provides substituted heteroaryl ketone compounds which are useful as FLAP modulators.
The invention features a method for treating a subject in need thereof with an FLAP-mediated disease and/or disorder, said method comprising administering to the subject a therapeutically effective amount of a compound of the invention. In particular, the invention also provides a method for treating or inhibiting the progression of an FLAP-mediated disease and/or disorder, or associated symptoms or complications thereof in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of the invention.
Embodiments of the present invention include a method wherein the compound of Formula (I) is a FLAP modulator.
Embodiments of the present invention include a use of the compound of Formula (I) in the manufacture of a medicament for treating an FLAP-mediated disease and/or disorder.
Embodiments of the present invention include a use of the compound of Formula (I) as a medicine.
The compounds of Formula (I) have an FLAP-modulating effect and are useful as therapeutic agents for various FLAP-mediated disorders and/or disorders, or associated symptoms or complications, for example, respiratory disorders, cardiac and cardiovascular diseases, autoimmune disorders, carcinogenesis, and associated symptoms or complications thereof.
The compounds of Formula (I) may be administered orally or parenterally, and after formulation into preparations suitable for the intended administration route, they can be used as therapeutic agents for treating an FLAP-mediated disease and/or disorder. FLAP-mediated diseases and/or disorders include, but are not limited, diseases and/or disorders that are related to leukotriene synthesis pathway, and therefore may be treated, controlled or in some cases prevented, by treatment with the compounds of this invention.
One aspect of the present invention provides a method for the treatment of diseases and/or disorders, or associated symptoms or complications thereof, responsive to the modulation of FLAP in a subject in need thereof which comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.
Another aspect of the present invention provides a method for the treatment of a disease and/or disorder selected from the group consisting of respiratory diseases and/or disorders, cardiac and cardiovascular diseases and/or disorders, autoimmune diseases and/or disorders, carcinogenesis, and associated symptoms or complications thereof, in a subject in need thereof which comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.
More specifically, this invention is directed to a method of treating exacerbations, non-allergic asthma, aspirin exacerbated respiratory disease, pulmonary arterial hypertension, fibrotic lung diseases, acute respiratory distress syndrome, obstructive sleep apnea and chronic obstructive pulmonary disease, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.
Furthermore, this invention is directed to a method of treating myocardial infarction, atherosclerosis and coronary artery disease, stroke, aortic aneurisms, atherosclerosis, or associated symptoms or complications thereof, in a subject afflicted with such a disease and/or disorder, wherein the method comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.
Yet, this invention is also directed to a method of treating rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis, allergic rhinitis, chronic sinusitis, allergic dermatitis and asthma, wherein the method comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.
Finally, this invention is also directed to a method of treating tumor cell proliferation, differentiation, and apoptosis, tumor-associated angiogenesis, as well as the migration and invasion of carcinoma cells, wherein the method comprises administering to the subject a therapeutically or prophylactically effective amount of a compound of Formula (I) or a form thereof.
Another aspect of the present invention provides a pharmaceutical composition comprising at least one compound of Formula (I) or a form thereof, and a pharmaceutically acceptable carrier.
The invention also features a method for treating a subject in need thereof with an FLAP-mediated disease and/or disorder, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one compound of the invention.
Yet another aspect of the present invention relates to the use of a compound of Formula (I) or a form thereof, for the manufacture of a medicament useful for the treatment of an FLAP-mediated disease and/or disorder in a subject in need thereof.
In a clinical use of the compounds of the invention, pharmaceutically-acceptable additives may be added thereto to formulate various preparations in accordance with the intended administration route thereof, and the preparations may be administered.
Various additives generally used in the field of pharmaceutical compositions may be used herein, including, for example, gelatin, lactose, sucrose, titanium oxide, starch, crystalline cellulose, methyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, corn starch, microcrystalline wax, white petrolatum, magnesium metasilicate aluminate, anhydrous calcium phosphate, citric acid, trisodium citrate, hydroxypropyl cellulose, sorbitol, sorbitan fatty acid ester, polysorbate, sucrose fatty acid ester, polyoxyethylene, hardened castor oil, polyvinylpyrrolidone, magnesium stearate, palmitoleic acid, light silicic acid anhydride, talc, vegetable oil, benzyl alcohol, gum arabic, propylene glycol, polyalkylene glycol, cyclodextrin, and hydroxypropylcyclodextrin.
Combined with such additives, the compound of the invention may be formulated into various forms of preparations, for example, solid preparations such as tablets, capsules, granules, powders and suppositories; and liquid preparations such as syrups, elixirs and injections. These preparations can be produced in any method known in the field of pharmaceutical compositions. The liquid preparations may be in such a form that is dissolved or suspended in water or in any other suitable medium before use. Especially for injections, the preparation may be dissolved or suspended, if desired, in a physiological saline or glucose solution, and a buffer and a preservative may be added thereto.
The compounds of the invention are effective for animals, including humans and other mammals. Any ordinary physician, veterinarian or clinician may readily determine the necessity, if any, of treatment with an instant compound.
Those of skill in the treatment of diseases and/or disorders, or associated symptoms or complications thereof, mediated by FLAP can determine the effective daily amount from the test results presented hereinafter and other information. The exact dosage and frequency of administration depends on the particular compound of invention used, the particular disease and/or disorder, or associated symptoms or complications thereof, being treated, the severity of the disease and/or disorder, or associated symptoms or complications thereof, being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned herein are therefore only guidelines in practicing the present invention.
Preferably, the method for the treatment of the FLAP diseases and/or disorders described in the present invention using any of the compounds as defined herein, the dosage form will contain a pharmaceutically acceptable carrier containing between from about 1 mg to about 1000 mg; particularly from about 0.5 mg to about 500 mg of the compound, and may be constituted into any form suitable for the mode of administration selected. The dosages, however, may be varied depending upon the requirement of the subjects, the severity of the disease and/or disorder, or associated symptoms or complications thereof, being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.
When the compound of the invention is, for example, put into clinical use, then its dose and its administration frequency may vary depending on the sex, the age, the body weight and the condition of the patient and on the type and the range of the necessary treatment with the compound. For oral administration, in general, the dose of the compound may be in a range of from about 0.01 mg/kg/day to about 100 mg/kg of body weight/day or in a range of from about 0.03 mg/kg/day to about 1 mg/kg/day. The oral administration frequency is preferably from one to a few times per day. For parenteral administration, the dose may be in a range of from about 0.001 mg/kg/day to about 10 mg/kg/day, in a range of from about 0.001 mg/kg/day to about 0.1 mg/kg/day or, in a range of from about 0.01 mg/kg/day to about 0.1 mg/kg/day. The parenteral administration frequency is preferably from one to a few times per day. For oral administration, the compositions are preferably provided in the form of tablets containing from about 1.0 mg to about 1000 mg of the active ingredient, particularly 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 600 mg, 750 mg, 800 mg, 900 mg, and 1000 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
Ordinary physicians, veterinarians and clinicians may readily determine the effective dose of the pharmaceutical compound necessary to treat, prevent, inhibit, retard or stop the intended disease, and may readily treat the diseased patient with the compound.
The pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.001 mg/kg/day to about 10 mg/kg/day (particularly from about 0.01 mg/kg/day to about 1 mg/kg/day; and, more particularly, from about 0.1 mg/kg/day to about 0.5 mg/kg/day) and may be given at a dosage of from about 0.001 mg/kg/day to about 30 mg/kg/day (particularly from about 0.01 mg/kg/day to about 2 mg/kg/day, more particularly from about 0.1 mg/kg/day to about 1 mg/kg/day and even more particularly from about 0.5 mg/kg/day to about 1 mg/kg/day).
Preferably these compositions are in unit dosage forms from such as tablets, pills, capsules, dry powders for reconstitution or inhalation, granules, lozenges, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories for administration by oral, intranasal, sublingual, intraocular, transdermal, parenteral, rectal, vaginal, dry powder inhaler or other inhalation or insufflation means. Alternatively, the composition may be presented in a form suitable for 1 to 4 times per day, preferably once or twice per day administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
The preparation may contain the compound of the invention in an amount in a range of from about 1.0 to about 100% by weight or, in a range of from about 1.0 to about 60% by weight of the preparation. The preparation may contain any other therapeutically-effective compound.
The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
Some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are intended to be encompassed within the scope of this invention.
Where the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form or as individual enantiomers or diasteromers by either stereospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers or diastereomers by standard techniques, such as the formation of stereoisomeric pairs by salt formation with an optically active base, followed by fractional crystallization and regeneration of the free acid. The compounds may also be resolved by formation of stereoisomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alliteratively, the compounds may be resolved using a chiral HPLC column. It is to be understood that all stereoisomers, racemic mixtures, diastereomers, cis-trans isomers, and enantiomers thereof are encompassed within the scope of the present invention.
E) Use
Dosages
For preparing pharmaceutical compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as diluents, binders, adhesives, disintegrants, lubricants, antiadherents and gildants. Suitable diluents include, but are not limited to, starch (i.e. corn, wheat, or potato starch, which may be hydrolized), lactose (granulated, spray dried or anhydrous), sucrose, sucrose-based diluents (confectioner's sugar; sucrose plus about 7 to 10 weight percent invert sugar; sucrose plus about 3 weight percent modified dextrins; sucrose plus invert sugar, about 4 weight percent invert sugar, about 0.1 to 0.2 weight percent cornstarch and magnesium stearate), dextrose, inositol, mannitol, sorbitol, microcrystalline cellulose (i.e. AVICELTM microcrystalline cellulose available from FMC Corp.), dicalcium phosphate, calcium sulfate dihydrate, calcium lactate trihydrate and the like. Suitable binders and adhesives include, but are not limited to acacia gum, guar gum, tragacanth gum, sucrose, gelatin, glucose, starch, and cellulosics (i.e. methylcellulose, sodium carboxymethylcellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, and the like), water soluble or dispersible binders (i.e. alginic acid and salts thereof, magnesium aluminum silicate, hydroxyethylcellulose [i.e. TYLOSETM available from Hoechst Celanese], polyethylene glycol, polysaccharide acids, bentonites, polyvinylpyrrolidone, polymethacrylates and pregelatinized starch) and the like. Suitable disintegrants include, but are not limited to, starches (corn, potato, etc.), sodium starch glycolates, pregelatinized starches, clays (magnesium aluminum silicate), celluloses (such as crosslinked sodium carboxymethylcellulose and microcrystalline cellulose), alginates, pregelatinized starches (i.e. corn starch, etc.), gums (i.e. agar, guar, locust bean, karaya, pectin, and tragacanth gum), cross-linked polyvinylpyrrolidone and the like. Suitable lubricants and antiadherents include, but are not limited to, stearates (magnesium, calcium and sodium), stearic acid, talc waxes, stearowet, boric acid, sodium chloride, DL-leucine, carbowax 4000, carbowax 6000, sodium oleate, sodium benzoate, sodium acetate, sodium lauryl sulfate, magnesium lauryl sulfate and the like. Suitable gildants include, but are not limited to, talc, comstarch, silica (i.e. CAB-O-SILTM rusilica available from Cabot, SYLOIDTM silica available from W.R. Grace/Davison, and AEROSILTM silica available from Degussa) and the like. Sweeteners and flavorants may be added to chewable solid dosage forms to improve the palatability of the oral dosage form. Additionally, colorants and coatings may be added or applied to the solid dosage form for ease of identification of the drug or for aesthetic purposes. These carriers are formulated with the pharmaceutical active to provide an accurate, appropriate dose of the pharmaceutical active with a therapeutic release profile.
Generally these carriers are mixed with the pharmaceutical active to form a solid preformulation composition containing a homogeneous mixture of the pharmaceutical active form of the present invention, or a pharmaceutically acceptable salt thereof. Generally the preformulation will be formed by one of three common methods: (a) wet granulation, (b) dry granulation and (c) dry blending. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from about 0.1 mg to about 500 mg of the active ingredient of the present invention. The tablets or pills containing the novel compositions may also be formulated in multilayer tablets or pills to provide a sustained or provide dual-release products. For example, a dual release tablet or pill can comprise an inner dosage and an outer dosage component the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric materials such as shellac, cellulose acetate (i.e. cellulose acetate phthalate, cellulose acetate trimetllitate), polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, methacrylate and ethylacrylate copolymers, methacrylate and methyl methacrylate copolymers and the like. Sustained release tablets may also be made by film coating or wet granulation using slightly soluble or insoluble substances in solution (which for a wet granulation acts as the binding agents) or low melting solids a molten form (which in a wet granulation may incorporate the active ingredient). These materials include natural and synthetic polymers waxes, hydrogenated oils, fatty acids and alcohols (i.e. beeswax, carnauba wax, cetyl alcohol, cetylstearyl alcohol, and the like), esters of fatty acids metallic soaps, and other acceptable materials that can be used to granulate, coat, entrap or otherwise limit the solubility of an active ingredient to achieve a prolonged or sustained release product.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, but are not limited to aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable suspending agents for aqueous suspensions, include synthetic and natural gums such as, acacia, agar, alginate (i.e. propylene alginate, sodium alginate and the like), guar, karaya, locust bean, pectin, tragacanth, and xanthan gum, cellulosics such as sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose, and combinations thereof, synthetic polymers such as polyvinyl pyrrolidone, carbomer (i.e. carboxypolymethylene), and polyethylene glycol; clays such as bentonite, hectorite, attapulgite or sepiolite; and other pharmaceutically acceptable suspending agents such as lecithin, gelatin or the like. Suitable surfactants include but are not limited to sodium docusate, sodium lauryl sulfate, polysorbate, octoxynol-9, nonoxynol-10, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxamer 188, polyoxamer 235 and combinations thereof. Suitable deflocculating or dispersing agents include pharmaceutical grade lecithins. Suitable flocculating agents include but are not limited to simple neutral electrolytes (i.e. sodium chloride, potassium, chloride, and the like), highly charged insoluble polymers and polyelectrolyte species, water soluble divalent or trivalent ions (i.e. calcium salts, alums or sulfates, citrates and phosphates (which can be used jointly in formulations as pH buffers and flocculating agents). Suitable preservatives include but are not limited to parabens (i.e. methyl, ethyl, n-propyl and n-butyl), sorbic acid, thimerosal, quaternary ammonium salts, benzyl alcohol, benzoic acid, chlorhexidine gluconate, phenylethanol and the like. There are many liquid vehicles that may be used in liquid pharmaceutical dosage forms; however, the liquid vehicle that is used in a particular dosage form must be compatible with the suspending agent(s). For example, nonpolar liquid vehicles such as fatty esters and oils liquid vehicles are best used with suspending agents such as low HLB (Hydrophile-Lipophile Balance) surfactants, stearalkonium hectorite, water insoluble resins, water insoluble film forming polymers and the like. Conversely, polar liquids such as water, alcohols, polyols and glycols are best used with suspending agents such as higher HLB surfactants, clays silicates, gums, water soluble cellulosics, water soluble polymers and the like. For parenteral administration, sterile suspensions and solutions are desired. Liquid forms useful for parenteral administration include sterile solutions, emulsions and suspensions. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
Furthermore, compounds of the present invention can be administered in an intranasal dosage form via topical use of suitable intranasal vehicles or via transdermal skin patches, the composition of which are well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the administration of a therapeutic dose will, of course, be continuous rather than intermittent throughout the dosage regimen.
Compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, multilamellar vesicles and the like. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, phosphatidylcholines and the like.
The daily dose of a pharmaceutical composition of the present invention may be varied over a wide range from about 0.1 mg to about 5000 mg; preferably, the dose will be in the range of from about 1 mg to about 100 mg per day for an average human. For oral administration, the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 or 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. Advantageously, a compound of the present invention may be administered in a single daily dose or the total daily dosage may be administered in divided doses of two, three or four times daily.
It is also apparent to one skilled in the art that the therapeutically effective dose for active compounds of the invention or a pharmaceutical composition thereof will vary according to the desired effect. Therefore, optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level. The above dosages are thus exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
Compounds of this invention may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of the compounds of the invention as FLAP modulators is required for a subject in need thereof.
In their use, the compounds of the invention may be combined with any other therapeutic agents that are useful for the treatment of an FLAP-mediated disorder.
The combination includes not only the composition of compounds of the invention and one other active substance but also the composition of compounds of the invention and two or more other active substances or non-drug therapy. The scope of possible combinations of a compound of the invention and one, two or more active substances are within the knowledge of one skilled in the art for the treatment of an FLAP-mediated disorder.
Specifically, the combination of a FLAP modulator with prostaglandin modulators, cyclooxygenase-1 modulators, or cyclooxygenase-2 modulators might be used to treat inflammatory and autoimmune diseases and/or disorders as well as cardiovascular diseases and/or disorders, or vascular injury (Z. Yu et al., “Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice,” Proc. Natl. Acad. Sci. USA, 2012, 109(17), 6727-32; Z. Yu et al., “Myeloid Cell 5-Lipoxygenase Activating Protein Modulates the Response to Vascular Injury,” Circ. Res., 2012, Epub December 18). Due to the synergy of histamine and leukotrienes, the combination of a FLAP modulator and a histamine receptor 1 or 4 antagonist might have utility in treating respiratory, allergic, dermatological and autoimmune disorders (A. Reicin et al., “Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma,” Arch. Intern. Med., 2000, 160(16), 2418-88; S. Sanada et al., “The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria,” Arch. Dermatol. Res., 2005, 297(3), 134-38).
Formulations
To prepare the pharmaceutical compositions of this invention, one or more compounds of Formula (I) or salt thereof as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration (e.g. oral or parenteral). Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers may be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.
The compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes. Methods of formulating pharmaceutical compositions have been described in numerous publications such as Pharmaceutical Dosage Forms: Tablets. Second Edition. Revised and Expanded, Volumes 1-3, edited by Lieberman et al; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2, edited by Avis et al; and Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1-2, edited by Lieberman et al; published by Marcel Dekker, Inc.
F) Biological Examples
The ability of the compounds of the present invention to treat a FLAP-mediated disease and/or disorder, or associated symptoms or complications thereof, was determined using the following procedures. Binding assay data represent the average value obtained from two different assay plates, with samples run in duplicate on each plate. Human whole blood assay data represent a single replicate on an assay plate using whole blood from at least one healthy donor. Certain FLAP binding and human whole blood assay data are presented in Table 5.
FLAP Binding Assay
The assay below is used to test the modulatory activity of compounds against FLAP. Human and mouse FLAP-encoding DNA was amplified by polymerase chain reaction and cloned into pFastBac1 (Invitrogen) with a NH2-terminal 6-His tag for expression in Spodoptera frugiperda (Sf-9) cells. FLAP-containing membranes were prepared as was a FITC-labeled FLAP modulator [5-[({[2-(2-{3-[3-(tert-Butylsulfanyl)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoyl}hydrazino)-2-oxoethyl]sulfanyl}acetyl)amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid]. The FLAP binding assay is performed in HTRF format (homogeneous time resolved fluorescence). FLAP-containing membranes (1 μg/well final for human) are incubated in the presence of the HTRF ligand. [5-[({[2-(2-{3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoyl}hydrazino)-2-oxoethyl]sulfanyl}acetyl)amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid] (25 nM final), a terbium labeled anti-His tag antibody (0.5 ng/well final, from Cisbio) and compounds. The reaction is allowed to proceed for two hours after which the plate is read on an Envision plate reader in HTRF mode. Data are expressed as a HTRF ratio.
For human FLAP binding assays, data are analyzed with 3DX Explorer software. A ratio is calculated with the relative light units at 520 nm over the relative light units at 495 nm. For analysis, data from multiple runs are averaged and each compound may be tested in 2 to 20 runs. Each run comprises two plates and each plate includes duplicates. Data from each plate is averaged and data are imported into 3DX. The data from multiple runs are aggregated as the average of duplicates of the calculated ratios in order to calculate Ki and IC50 values. It will be understood that a calculated value of 0.000 in Table 5 indicates that the Ki is less than 1 nM. The letters ND and/or the absence of data in any of the boxes in Table 5 and Table 6 indicates that Ki or IC50 values were not determined.
Human Whole Blood Assay
An in vitro cellular assay was performed using human whole blood collected in heparin-containing tubes, which was used to test the ability of compounds to modulate the leukotriene pathway in human whole blood. The blood was diluted 1:1 in RPMI medium, pre-incubated for 15 min at 37° Celsius with test compounds at various concentrations, and then stimulated with calcium ionophore, A23187 (7 μg/mL), for 30 min at 37° Celsius. The samples were then centrifuged and plasma was removed. The plasma was diluted in assay buffer and LTB4 levels were measured using a commercial kit (Enzo Life Sciences). The concentration of each compound that was required for half-maximal inhibition (modulation) of recombinant enzyme activity (IC50) was calculated by a 4-parameter equation using the program GraphPad Prism (GraphPad software).







TABLE 5







FLAP binding and Human Whole Blood assay data









Cmp
FLAP Binding wild type HTRF
Human Whole Blood LTB4 IC50


No.
Ki (μM)
1:1 (μM)












1
0.217
0.860


2
0.286
0.358


3
>10


4
0.001
0.018


5
0.035
0.370


6
0.001
0.033


7
0.002
0.014


8
0.001
0.012


9
0.003
0.060


10
0.003
0.053


11
0.002
0.015


12
0.002
0.021


13
0.001
0.018


14
0.003
0.032


15
0.010
0.059


16
0.006
0.018


17
0.002
0.025


18
0.002
0.070


19
0.002
0.050


20
0.001
0.009


21
0.002
0.035


22
0.002
0.048


23
0.001
0.013


24
0.002
0.048


25
0.003
0.023


26
0.001
0.026


27
0.029
10.000


28
0.090
0.325


29
0.059
0.030


30
0.095


31
0.004
0.036


32
0.008
0.030


33
0.304


34
0.031
0.334


35
0.036
0.094


36
0.010
0.120


37
0.030
0.676


38
0.033
0.177


39
0.008
0.075


40
0.014
0.112


41
0.014
2.687


42
0.011
0.149


43
0.002
0.111


44
0.007
0.058


45
0.003
0.010


46
0.057
0.194


47
0.001
0.017


48
0.011
0.158


49
0.002
0.021


50
0.001
0.015


51
0.004
0.042


52
0.004
0.155


53
0.003
0.238


54
0.020
0.023


55
0.001
1.232


56
0.011
3.516


57
0.015
0.252


58
0.005
0.991


59
0.020
1.017


60
0.028
0.464


61
0.011
0.117


62
0.142
0.111


63
0.006
0.028


64
0.002
0.006


65
0.049
0.322


66
0.021
0.069


67
0.003
0.012


68
0.001
0.006


69
0.001
0.008


70
0.002
0.010


71
0.002
0.023


72
0.111
0.168


73
0.062
0.077


74
0.006
0.061


75
0.012
0.185


76
0.002
0.027


77
0.003
0.342


78
0.001
0.166


79
0.005
0.150


80
0.004
0.088


81
0.006
0.152


82
0.001
0.018


83
0.001
0.019


84
0.003
0.097


85
0.002
0.020


86
0.003
0.027


87
0.003
0.075


88
0.007
0.036


89
0.006
0.043


90
0.001
0.012


91
0.005
0.028


92
0.325
0.222


93
0.127
0.128


94
0.076
0.235


95
0.010
0.053


96
0.354
>10


97
0.008
0.042


98
0.008
0.039


99
0.002
0.030


100
0.001
0.024


101
0.002
0.014


102
0.000
0.035


103
0.000
0.017


104
0.012
>1


105
0.025
0.481


106
0.019
>1


107
0.016
0.132


108
0.010
0.049


109
0.001
0.018


110
0.003
0.029


111
0.004
0.058


112
0.007
0.154


113
0.010
0.145


114
0.012
0.221


115
0.004
0.108


116
0.001
0.012


117
0.001
0.007


118
0.000
0.006


119
0.003
0.022


120
0.001
0.017


121
0.000
0.010


122
0.001
0.018


123
0.083
1.125


124
0.035
0.217


125
0.050
>10


126
0.141
0.572


127
0.002
0.035


128
0.001
0.038


129
0.004
0.534


130
0.129
0.633


131
0.144
0.695


132
0.002
0.011


133
0.001
0.032


134
0.001
>1


135
0.000
0.016


136
0.001
0.015


137
0.003
0.044


138
0.011
0.174


139
0.133
0.341


140
0.001
0.011


141
0.001
0.003


142
0.015
0.041


143
0.008
0.049


144
0.015
0.097


145
0.017
0.021


146
0.019
0.168


147
0.001
0.102


148
0.002
0.008


149
0.005
0.082


150
0.001
0.011


151
0.001
0.114


152
0.081
0.537


153
0.003
0.007


154
0.029
1.044


155
0.012
0.103


156
0.351
>10


157
0.010
1.841


158
0.001
0.001


159
0.001
0.001


160
0.000
0.005


161
0.000
0.048


162
0.005
0.122


163
0.001
0.595


164
0.001
0.333


165
0.018
0.879


166
0.164
4.463


167
0.047
0.442


168
0.014
0.135


169
0.003
0.023


170
0.001
0.012


171
0.002
0.013


172
0.004
0.020


173
0.001
0.017


174
0.002
0.023


175
0.001
0.017


176
0.000
0.010


177
0.000
0.302


178
1.323


179
0.000
0.002


180
0.002
0.037


181
0.007
0.240


182
0.020
0.217


183
0.034
0.130


184
0.009
0.021


185
0.010
0.051


186
0.019
0.021


187
0.066
0.069


188
0.201
1.185


189
0.173
1.649


190
0.058
0.471


191
0.658


192
0.058
0.171


193
0.026
0.144


194
0.733


195
0.003
0.093


196
0.010
0.104


197
0.010
0.083


198
0.083
0.375


199
0.039
0.250


200
0.035
0.176


201
0.021
0.358


202
0.072
0.172


203
0.005
0.052


204
0.004
0.128


205
0.008
0.066


206
0.002
0.043


207
0.017
0.205


208
0.000
0.014


209
0.001
0.034


210
0.000
0.020


211
0.001
0.006


212
0.001
0.005


213
0.002
0.025


214
0.012
0.138


215
0.002
0.012


216
0.002
0.016


217
0.001
0.009


218
0.003
0.029


219
0.005
0.031


220
0.205
0.219


221
0.300
0.854


222
0.118
0.638


223
0.663


224
0.293
0.516


225
0.856


226
0.211
0.329


227
0.670


228
1.055


229
1.067


230
1.205
5.000


231
0.135
0.564


232
0.358


233
0.637


234
0.025
0.238


235
0.036
0.285


236
0.057
0.443


237
0.008
0.134


238
0.005
0.038


239
0.006


240
0.002
0.021


241
0.015
0.061


242
0.001
0.004


243
0.003
0.120


244
0.029
0.211


245
0.045
0.233


246
0.199
0.302


247
0.089
0.197


248
0.050
0.124


249
0.059
0.094


250
0.038
0.077


251
0.005
0.068


252
0.127
0.206


253
0.134
0.191


254
0.080
0.586


255
0.008
0.076


256
0.035
0.073


257
0.154
1.125


258
0.243
0.202


259
0.005
0.034


260
0.010
0.057


261
0.006
0.075


262
0.018
0.046


263
0.169
0.207


264
0.028
0.144


265
0.045
0.160


266
0.184
0.464


267
0.154
0.350


268
0.011
0.056


269
0.015
0.087


270
0.057
1.065


271
0.051
0.606


272
0.032
0.125


273
0.009
0.105


274


275
0.065
0.192


276
0.023
0.325


277
0.052
>1


278
0.036
0.095


279
0.070
0.149


280
0.003
0.087


281
0.061
0.044


282
0.750
0.280


283
0.009
0.119


284
0.042
1.037


285
0.003
0.111


286
0.142
0.206


287
0.009
0.074


288
0.103
0.420


289
0.022
0.036


290
0.940


291
0.007
0.421


292
0.012
1.029


293
>10


294
0.002
0.248


295
0.025
0.110


296
0.005
0.066


297
0.005
0.045


298
0.081
1.166


299
0.121


300
0.013
0.120


301
0.013
0.204


302
2.500


303
0.612


304
>10


305
0.002
0.078


306
0.397


307
0.004
0.416


308
>10


309
0.214
1.785


310
0.492


311
0.747


312
0.262
0.376


313
0.397
0.574


314
0.089
0.178


315
0.001
0.027


316
0.746


317
0.335
>10


318
0.689
2.001


319
0.204
3.263


320
0.129
1.084


321
0.505
8.486


322
0.032
0.138


323
0.770
6.644


324
0.019
0.101


325
0.004
0.091


326
0.003
0.029


327
0.002
0.039


328
0.015
0.119


329
0.012
0.066


330
0.012
0.088


331
0.014
0.062


332
0.065
0.125


333
0.045
0.671


334
0.012
0.067


335
0.002
0.037


336
0.004
0.065


337
2.500


338
0.199
1.094


339
2.500


340
0.104
0.321


341
>10


342
0.002
0.117


343
0.004
0.057


344
0.081
>10


345
0.028
0.259


346
0.005
0.095


347
0.077
0.161


348
0.005
0.106


349
0.001
0.013


350
0.002
0.026


351
0.017
0.297


352
0.016
0.064


353
0.001
0.020


354
0.037
0.093


355
0.005
0.029


356
0.032
0.107


357
0.114
1.128


358
0.055
>10


359
0.004
0.054


360
0.022
0.067


361
0.005
0.026


362
0.001
0.047


363
0.001
0.184


364
0.003
0.150


365
0.003
0.060


366
0.001
0.040


367
0.001
0.006


368
0.013
0.178


369
0.017
0.375


370
0.002
0.088


371
0.001
0.015


372
0.025
0.031


373
0.001
0.007


374
0.001
0.011


375
0.002
0.031


376
0.000
0.010


377
0.033
0.979


378
0.001
0.016


379
0.001
0.033


380
0.001
0.046


381
0.005
0.141


382
0.000
0.011


383
0.008
1.633


384
0.004
0.082


385
0.042
1.083


386
0.002
0.077


387
0.008
0.253


388
0.002
0.037


389
0.013
0.137


390
0.000
0.010


391
0.002
0.056


392
0.001
0.016


393
0.001
0.012


394
>10


395
0.009
0.032


396
0.008
0.137


397
>10


398
0.034
1.132


399
0.028
0.358


400
0.014
0.729


401
0.158
0.538


402
0.092
0.522


403
0.070
0.389


404
0.155
1.490


405
0.100
2.708


406
0.135
4.314


407
>10


408
0.128
1.142


409
>10


410
0.004
0.088


411
0.036
1.968


412
0.019
0.509


413
0.019
0.448


414
0.065
0.120


415
0.011
0.037


416
1.249


417
0.108
0.726


418
1.250


419
1.369


420
0.086
3.280


421
0.028
>10


422
0.003
0.146


423
0.284
4.795


424
0.010
>10


425
0.002
0.111


426
0.002
0.073


427
0.054
1.599


428
0.004
0.004


429
0.013
0.209


430
0.005
0.059


431
0.001
0.009


432
0.004
0.019


433
0.001
0.025


434
0.001
0.036


435
0.009
0.166


436
0.308
3.277


437
0.023
0.381


438
0.001
0.017


439
0.063
0.300


440
0.031
0.215


441
0.001
0.006


442
0.001
0.009


443
0.343
3.331


444
0.183
>10


445
0.001
0.008


446
0.304
1.371


447
0.003
0.144


448
0.010
0.112


449
0.022
0.079


450
0.074
0.340


451
0.002
0.038


452
0.081
1.954


453
>10
>10


454
0.012
0.345


455
0.001
0.094


456
0.003
0.114


457
0.003
0.140


458
0.004
0.053


459
>10


460
>10


461
0.041
0.209


462
0.002
0.062


463
0.982


464
0.121
>10


465
0.186
0.957


466
0.254
0.990


467
0.250
2.827


468
0.620


469
0.250
2.347


470
0.620


471
0.250
3.395


472
0.145
2.524


473
0.113
1.411


474
0.021
2.653


475
0.750


476
0.032
0.891


477
0.016
0.738


478
0.250


479
0.006
0.571


480
0.354


481
1.912


482
0.120


483
0.354


484
0.078
3.465


485
>10


486
2.500


487
0.054
0.444


488
0.097
1.653


489
0.020
0.307


490
0.354
0.269


491
0.015
0.215


492
0.015
0.155


493
0.007
0.303


494
0.032
0.099


495
0.004
0.509


496
0.019
0.165


497
0.025
0.510


498
0.016
0.111


499
0.433


500
0.048
0.139


501
0.359


502
0.083
0.363


503
0.014
0.092


504
0.768


505
0.018
0.071


506
>10


507
>10


508
0.790


509
0.147
0.093


510
1.939


511
0.213
0.323


512
0.443
0.470


513
>10


514
0.132
0.148


515
>10


516
>10


517
>10


518
>10


519
>10


520
>10


521
0.005
0.013


522
0.348
0.393


523
0.001
0.025


524
0.001
0.018


525
0.003
0.036


526
0.008
0.019


527
0.074
0.183


528
0.005
0.034


529
0.036
0.090


530
0.034
1.112


531
0.008
0.323


532
0.006
0.032


533
0.005
0.023


534
0.012
0.069


535
0.001
0.017


536
0.021
0.068


537
0.003
0.042


538
0.020
0.330


539
0.002
0.052


540
0.016
0.085


541
0.012
0.066


542
0.107
0.311


543
0.444
4.165


544
0.028
1.652


545
0.012
0.050


546
0.148
0.253


547
0.035
0.104


548
0.467
0.741


549
0.009
0.123


550
0.002
0.016


551
0.000
0.021


552
0.005
0.102


553
0.019
0.430


554
0.002
0.039


555
0.002
0.024


556
0.001
0.013


557
0.147
1.066


558
0.012
0.210


559
0.002
0.055


560
0.005
0.095


561
0.004
0.043


562
0.055
0.226


563
0.020
0.328


564
0.200
0.583


565
0.081
0.984


566
>10


567
1.135


568
2.500


569
0.070
0.335


570
0.035
1.183


571
0.002
0.091


572
0.370


573
0.114


574
0.015
0.494


575
0.750


576
0.008
0.116


577
0.010
0.091


578
0.025
0.956


579
0.095
1.544


580
0.055
5.000


581
0.060
2.823


582
>10


583
>10


584
>10


585
>10


586
>10


587
>10


588
0.133
>10


589
>10


590
>10


591
~2.49


592
>10


593
>10


594
>10


595
~2.49


596
>10


597
~2.49


598
>10


599
>10


600
>10


601
>10


602
0.0006
0.0167


603
0.0276
>10


604
0.0050
0.0894


605
0.0019
0.0978


606
0.0463
2.624


607
0.1384
0.1520


608
0.0287
0.0539


609
0.2464
0.7677


610
0.0274
0.1170


611
0.2489
0.5626


612
0.0146
0.0420


613
0.2146
0.5565


614


615


616


617


618
0.0146
0.2109


619
0.0034
0.0451


620
0.0019
0.0132


621
0.0050
0.1006


622
0.0461
0.3401


623
0.0049
0.0935


624


625
0.0078
0.1727


626
0.0062
0.0453


627
0.0437
0.3661


628
0.3362


629
0.8358


630
1.8950


631
>10


632
1.2677


633
>10


634
0.3108
1.470


635
1.0869


636
0.0046
0.1072


637
0.0188
0.3975


638
0.0014
0.0148


639
0.0072
0.0670


640
1.3397


641
>10


642
0.0788
0.9806


643
0.3225
4.2874


644
>10


645


646


647


648


649
>10


650
0.8316


651
0.3062
1.5363


652
0.0627
0.8425


653
0.0173
0.5267


654
0.1303
1.0459


655
0.5034
1.8302


656
1.3957


657
0.0735
2.3415


658
0.5717


659
~0.7500


660
0.0833
>10


661
~2.49


662
~1.22


663
0.0058
0.0347


664
0.0050
>1


665
0.0026
0.0224


666
0.0032
0.0361


667
0.0060
0.0396


668
0.0230
0.1897


669
0.0040
0.1064


670
0.0977
0.5255


671
0.0157
0.1645


672
0.0137
0.1964


673
0.1343
0.1013


674
0.0024
0.0174


675
0.0007
0.0551


676
0.2339
3.7145


677
>10


678
>10


679
0.1316
0.2054


680
0.6097
1.0502


681
0.0522
0.1057


682
0.2239
0.2638


683
0.6021
0.2800


684
0.0463
0.1342


685
0.0523
0.1148


686
0.3343
1.4900


687
0.7399
3.5456


688
0.6955
1.1844


689
0.4846
0.7872


690
0.1771
0.1175


691
>10


692
0.0533
0.1097


693
0.0495
0.1032


694
0.6762
1.0115


695
0.0084
0.3355


696
~0.2499
3.27492


697
>10


698
0.0087
0.1117


699


700
>10


701
~1.41


702
~0.3041


703
>10


704
0.1025
0.1906


705
0.0869
0.2891


706
0.0796
0.3620


707
0.0327
0.1266


708
0.0235
0.1416


709
0.0054
0.2682


710
0.0137
0.05651


711
0.0417
0.1420


712
0.0019
0.05233


713
0.0017
0.05339


714
0.0024
0.03311


715
0.0082
0.1858


716
>10


717
1.0083


718
>10


719
>10


720
>10


721
>10


722
>10


723
>10


724
>10


725
1.2960


726
0.9041


727
0.4838
1.1740


728
0.7813


729
0.0647
0.8609


730
0.0067
0.1359


731
0.0147
0.05132


732
0.5571


733
>10


734
>10


735
0.0320
0.2722


736
0.3303
0.4144


737
0.9842


738
0.2400
2.9546


739
0.3701
1.1132


740
>10


741
0.0046
0.02633


742
0.0029
0.02572


743
0.0016
0.02165


744
0.0155
0.13173


745
0.0117
0.11073


746
0.0020
0.13699


747
0.0271
0.26224


748
>10


749
0.2455
0.46752


750
1.1582


751
0.0809
1.05657


752
0.1352
0.29915


753
0.0044
0.02130


754
0.0699
0.37722


755
0.9395


756
>10


757
0.0052
0.016206


758
0.5569


759
>10


760
1.1559


761
>10


762
0.1589
0.44177


763
1.1148


764
>10


765
>10


766
1.9090


767
>10


768
0.5728


769
1.5449


770
>10


771
>10


772
>10


773
0.2227
0.63899


774


775


776


777


778
>10


779
~2.49


780
>10


781
0.7295


782
>10


783
>10


784
0.0079
0.1105


785
0.0085
0.0575


786
0.0607
0.10485


787
0.0091
0.0979


788
0.0178
0.2715


789
0.1303
0.9392


790
0.0015
0.02533


791
>10


792
>10


793
0.2795
0.6419


794
0.0328
3.9355


795
0.0085
0.0686


796
0.3912


797
>10


798
0.2573
0.220039


799
>10


800
>10


801
>10


802
>10
0.000993574


803
0.1065
0.241268


804
0.6359


805
0.0297
0.352777


806
0.0018
0.048395


807
0.0058
0.0721606


808
0.0004
0.00637236


809
0.0038
0.0376964


810
0.0006
0.00563897


811
0.3149
0.541252


812
0.0085
0.0120393


813
0.0339
0.0750585


814
0.0028
0.0209218


815
0.2555
0.128115


816
0.0218
0.0460044


817
0.4629


818
0.0272
0.051606


819
0.0405
0.0474898


820
0.0033
0.041639


821
>10


822
0.2804
0.099106


823
0.1923
0.0950605


824
0.0103
0.0180053


825
0.2732
0.122321


826
0.0007
0.0199205


827
>10


828
0.1153
0.259777


829
0.0032
0.00596486


830
0.0029
0.00555393


831
0.1309
0.0791589


832
1.3119


833
~0.500034


834
0.0489
1.09069


835
~0.35359
0.417157


836
0.0255
0.595114


837
~1.74985


838
0.0286
0.350106


839
0.8297
2.78805


840
0.0127
0.0995864


841
0.1458
0.369658


842
0.0053
0.061038


843
0.0156
0.0442792


844
0.5093
0.907193


845
>10


846
0.0105
0.0418215


847
0.0081
0.0991289


848
0.0968
0.321736


849
0.0356
>1


850
0.0377
0.195434


851
0.0326
0.359335


852
0.1179
1.34555


853
0.0047
0.0456037


854
1.2773


855
>10


856
0.0605
0.083888


857
0.0280
0.205494


858
0.2097
0.369743


859
~1.249


860
~1.479









Certain compounds were tested in additional runs for the assays described above and the data is provided in Table 6.







TABLE 6







FLAP binding and Human Whole Blood assay data









Cmp
FLAP Binding wild type HTRF
Human Whole Blood LTB4 IC50


No.
Ki (μM)
1:1 (μM)












1
0.3521
0.8596


2
0.1785
0.3582


3
>10


4
0.0004
0.0184


5
0.0366
0.3698


6
0.0011
0.0328


7
0.0008
0.0136


8
0.0013
0.0120


9
0.0015
0.0603


10
0.0027
0.0531


11
0.0016
0.0154


12
0.0019
0.0213


13
0.0012
0.0178


14
0.0035
0.0324


15
0.0111
0.0590


16
0.0050
0.0184


17
0.0017
0.0251


18
0.0018
0.0703


19
0.0022
0.0498


20
0.0009
0.0085


21
0.0021
0.0347


22
0.0021
0.0481


23
0.0012
0.0129


24
0.0023
0.0482


25
0.0032
0.0263


26
0.0009
0.0258


27
0.0263
~10


28
0.0822
0.3246


29
0.0632
0.0301


30
0.0950


31
0.0040
0.0358


32
0.0062
0.0299


33
~0.3041


34
0.0308
0.3340


35
0.0361
0.0944


36
0.0081
0.1366


37
0.0296
0.6761


38
0.0288
0.1773


39
0.0081
0.0751


40
0.0144
0.1118


41
0.0106
2.6866


42
0.0102
0.1493


43
0.0030
0.0381


44
0.0065
0.0582


45
0.0031
0.0102


46
0.0615
0.1774


47
0.0016
0.0166


48
0.0070
0.1583


49
0.0020
0.0211


50
0.0013
0.0154


51
0.0038
0.0424


52
0.0037
0.1551


53
0.0033
0.2377


54
0.0249
0.0413


55
0.0011
1.2317


56
0.0088
3.5164


57
0.0134
0.2517


58
0.0046
0.9911


59
0.0204
1.0170


60
0.0280
0.4638


61
0.0159
0.1173


62
0.1418
0.1111


63
0.0061
0.0284


64
0.0019
0.0131


65
0.0633
0.3224


66
0.0266
0.0689


67
0.0042
0.0168


68
0.0011
0.0109


69
0.0009
0.0081


70
0.0023
0.0100


71
0.0019
0.0227


72
0.1200
0.1682


73
0.0620
0.0769


74
0.0057
0.0610


75
0.0107
0.1851


76
0.0017
0.0267


77
0.0032
0.3416


78
0.0007
0.1663


79
0.0053
0.1498


80
0.0039
0.0881


81
0.0064
0.1518


82
0.0007
0.0181


83
0.0007
0.0191


84
0.0031
0.0975


85
0.0019
0.0199


86
0.0026
0.0266


87
0.0032
0.0752


88
0.0062
0.0364


89
0.0049
0.0432


90
0.0009
0.0125


91
0.0047
0.0383


92
0.2802
0.3092


93
0.0833
0.1275


94
0.0760
0.2347


95
0.0097
0.0515


96
0.3537
>10


97
0.0066
0.0422


98
0.0061
0.0391


99
0.0016
0.0301


100
0.0008
0.0245


101
0.0018
0.0137


102
0.0004
0.0345


103
0.0003
0.0165


104
0.0117
>1


105
0.0247
0.4805


106
0.0191
>1


107
0.0164
0.1316


108
0.0095
0.0486


109
0.0015
0.0181


110
0.0026
0.0294


111
0.0042
0.0576


112
0.0069
0.1543


113
0.0105
0.1451


114
0.0120
0.2215


115
0.0041
0.1080


116
0.0007
0.0122


117
0.0007
0.0066


118
0.0004
0.0063


119
0.0027
0.0217


120
0.0011
0.0171


121
0.0005
0.0096


122
0.0007
0.0179


123
0.0827
1.1249


124
0.0353
0.2172


125
0.0497
>10


126
0.1408
0.5717


127
0.0020
0.0346


128
0.0008
0.0382


129
0.0039
0.5341


130
0.1295
0.6326


131
0.1438
0.6947


132
0.0024
0.0111


133
0.0010
0.0320


134
0.0013
>1


135
0.0004
0.0161


136
0.0005
0.0155


137
0.0029
0.0438


138
0.0114
0.1737


139
0.1330
0.3409


140
0.0014
0.0106


141
0.0007
0.0033


142
0.0151
0.0406


143
0.0085
0.0488


144
0.0148
0.0971


145
0.0167
0.0209


146
0.0191
0.1684


147
0.0006
0.1021


148
0.0025
0.0083


149
0.0052
0.0824


150
0.0015
0.0113


151
0.0013
0.1140


152
0.0807
0.5365


153
0.0025
0.0069


154
0.0293
1.0445


155
0.0116
0.1025


156
0.3513
>10


157
0.0098
1.8408


158
0.0006
0.0014


159
0.0008
0.0013


160
0.0004
0.0053


161
0.0004
0.0478


162
0.0051
0.1223


163
0.0005
0.5953


164
0.0008
0.3332


165
0.0184
0.8790


166
0.1645
4.4627


167
0.0468
0.4416


168
0.0143
0.1348


169
0.0029
0.0229


170
0.0013
0.0118


171
0.0020
0.0135


172
0.0036
0.0201


173
0.0008
0.0165


174
0.0024
0.0231


175
0.0014
0.0170


176
0.0005
0.0100


177
0.0005
0.3016


178
~1.3228


179
0.0004
0.0021


180
0.0021
0.0369


181
0.0067
0.2397


182
0.0199
0.2171


183
0.0344
0.1300


184
0.0089
0.0206


185
0.0095
0.0507


186
0.0188
0.0207


187
0.0657
0.0689


188
0.2014
1.1849


189
0.0632
1.6493


190
0.0662
0.4710


191
~0.6579


192
0.0483
0.1708


193
0.0309
0.1439


194
0.1558


195
0.0023
0.0690


196
0.0078
0.0963


197
0.0071
0.0831


198
0.0721
0.8194


199
0.0386
0.2518


200
0.0349
0.1762


201
0.0207
0.3582


202
0.0716
0.1721


203
0.0050
0.0523


204
0.0045
0.1282


205
0.0076
0.0656


206
0.0020
0.0427


207
0.0171
0.2046


208
0.0004
0.0137


209
0.0010
0.0340


210
0.0004
0.0196


211
0.0005
0.0058


212
0.0008
0.0053


213
0.0024
0.0246


214
0.0116
0.1378


215
0.0024
0.0116


216
0.0022
0.0160


217
0.0012
0.0089


218
0.0033
0.0291


219
0.0048
0.0312


220
0.2052
0.2186


221
0.3001
0.8543


222
0.1176
0.6381


223
0.6628


224
0.2926
0.5158


225
0.8561


226
0.2108
0.3289


227
0.6699


228
1.0554


229
1.0673


230
1.2050
~5.00034


231
0.1354
0.5639


232
0.3575


233
0.6365


234
0.0255
0.2382


235
0.0357
0.2848


236
0.0571
0.4431


237
0.0078
0.1338


238
0.0050
0.0379


239
0.0059


240
0.0024
0.0215


241
0.0146
0.0605


242
0.0007
0.0039


243
0.0033
0.1199


244
0.0294
0.2109


245
0.0453
0.2330


246
0.1990
0.3017


247
0.0894
0.1968


248
0.0568
0.1237


249
0.0595
0.0940


250
0.0382
0.0774


251
0.0045
0.0678


252
0.1267
0.2055


253
0.1344
0.1906


254
0.0800
0.5856


255
0.0081
0.0761


256
0.0350
0.0734


257
0.1537
1.1249


258
0.2430
0.2021


259
0.0078
0.0340


260
0.0089
0.0566


261
0.0056
0.0749


262
0.0183
0.0456


263
0.1272
0.2074


264
0.0276
0.1439


265
0.0355
0.1600


266
0.1330
0.4639


267
0.1854
0.3504


268
0.0114
0.0559


269
0.0149
0.0873


270
0.0573
1.0654


271
0.0505
0.6062


272
0.0269
0.1246


273
0.0093
0.1047


274


275
0.0648
0.1921


276
0.0235
0.3248


277
0.0516
>1


278
0.0356
0.0945


279
0.0700
0.1176


280
0.0033
0.0872


281
0.0608
0.0445


282
~0.7500
0.2799


283
0.0090
0.1187


284
0.0423
1.0373


285
0.0033
0.1110


286
0.1419
0.2060


287
0.0085
0.0744


288
0.1028
0.4201


289
0.0216
0.0361


290
~0.9401


291
0.0067
0.4205


292
0.0099
1.0294


293
>10


294
0.0024
0.2477


295
0.0200
0.1097


296
0.0031
0.0660


297
0.0032
0.0446


298
0.0806
1.1657


299
0.1212


300
0.0128
0.1205


301
0.0126
0.2044


302
~2.4997


303
~0.612351


304
>10


305
0.0016
0.0776


306
0.3974


307
0.0045
0.4158


308
>10


309
0.2143
1.7848


310
0.4919


311
0.7466


312
0.3226
0.3764


313
0.3877
0.5739


314
0.0888
0.1776


315
0.0013
0.0272


316
0.7456


317
0.3346
>10


318
0.6890
2.0012


319
0.2036
3.2629


320
0.1293
1.0839


321
0.5055
8.4859


322
0.0324
0.1382


323
0.7702
6.6435


324
0.0188
0.1014


325
0.0047
0.0908


326
0.0031
0.0287


327
0.0018
0.0386


328
0.0154
0.1187


329
0.0120
0.0658


330
0.0119
0.0883


331
0.0144
0.0619


332
0.0654
0.1245


333
0.0448
0.6710


334
0.0117
0.0672


335
0.0019
0.0370


336
0.0042
0.0651


337
~2.49977


338
0.1992
1.0937


339
~2.49977


340
0.1043
0.3210


341
>10


342
0.0018
0.1167


343
0.0043
0.0568


344
0.0812
>10


345
0.0277
0.2591


346
0.0045
0.0946


347
0.0769
0.1612


348
0.0050
0.1059


349
0.0009
0.0128


350
0.0024
0.0259


351
0.0165
0.2966


352
0.0158
0.0642


353
0.0014
0.0198


354
0.0365
0.0930


355
0.0049
0.0294


356
0.0320
0.1066


357
0.1139
1.1282


358
0.0550
>10


359
0.0043
0.0541


360
0.0216
0.0675


361
0.0052
0.0262


362
0.0012
0.0472


363
0.0006
0.1840


364
0.0025
0.1498


365
0.0029
0.0600


366
0.0010
0.0399


367
0.0009
0.0056


368
0.0132
0.1780


369
0.0173
0.3751


370
0.0019
0.0880


371
0.0007
0.0150


372
~0.0249977
0.0313


373
0.0008
0.0066


374
0.0012
0.0115


375
0.0021
0.0313


376
0.0005
0.0099


377
0.0330
0.9786


378
0.0006
0.0163


379
0.0013
0.0334


380
0.0011
0.0460


381
0.0048
0.1405


382
0.0005
0.0110


383
0.0079
1.6334


384
0.0039
0.0819


385
0.0419
1.0829


386
0.0018
0.0773


387
0.0080
0.2528


388
0.0017
0.0367


389
0.0131
0.1371


390
0.0004
0.0096


391
0.0020
0.0563


392
0.0009
0.0163


393
0.0010
0.0124


394
>10


395
0.0088
0.0269


396
0.0076
0.1372


397
>10


398
0.0344
1.1316


399
0.0285
0.3583


400
0.0141
0.7291


401
0.1581
0.5379


402
0.0921
0.5223


403
0.0698
0.3889


404
0.1547
1.4904


405
0.0998
2.7077


406
0.1347
4.3142


407
>10


408
0.1284
1.1424


409
>10


410
0.0037
0.0884


411
0.0360
1.9679


412
0.0193
0.5087


413
0.0186
0.4476


414
0.0655
0.1204


415
0.0109
0.0370


416
1.2485


417
0.1082
0.7264


418
~1.2499


419
~1.3693


420
0.0856
3.2802


421
0.0283
>10


422
0.0031
0.1460


423
0.2841
4.7951


424
0.0103
>10


425
0.0023
0.1108


426
0.0020
0.0731


427
0.0439
1.5992


428
0.0043
0.0044


429
0.0131
0.2089


430
0.0051
0.0592


431
0.0008
0.0094


432
0.0042
0.0188


433
0.0011
0.0254


434
0.0011
0.0362


435
0.0094
0.1657


436
0.3075
3.2772


437
0.0233
0.3809


438
0.0007
0.0166


439
0.0629
0.3005


440
0.0309
0.2155


441
0.0008
0.0065


442
0.0009
0.0090


443
0.3430
3.3312


444
0.1826
>10


445
0.0005
0.0077


446
0.3044
1.3709


447
0.0031
0.1441


448
0.0101
0.1119


449
0.0216
0.0788


450
~0.0740
0.3398


451
0.0024
0.0385


452
~0.0805
1.9543


453
>10
>10


454
0.0115
0.3450


455
0.0007
0.0943


456
0.0026
0.1139


457
0.0027
0.1400


458
0.0042
0.0530


459
>10


460
>10


461
0.0405
0.2088


462
0.0023
0.0616


463
~0.9819


464
0.1209
>10


465
0.1860
0.9565


466
~0.2544
0.9901


467
0.0535
2.8275


468
0.3317


469
0.1790
2.3469


470
0.3973


471
0.0558
3.3947


472
0.1360
2.5241


473
0.0730
1.4109


474
0.0215
2.6534


475
0.0896
4.1812


476
0.0241
0.3500


477
0.0147
0.2678


478
~0.2499


479
0.0077
0.5710


480
~0.3535


481
1.9116


482
0.0609
0.3203


483
~0.35359


484
0.0759
3.4650


485
>10


486
~2.4997


487
0.0543
0.4443


488
0.0975
1.6527


489
0.0196
0.3069


490
~0.3535
0.2691


491
0.0146
0.2147


492
0.0154
0.1555


493
0.0069
0.3030


494
0.0316
0.0993


495
0.0041
0.5091


496
0.0188
0.1653


497
0.0251
0.5103


498
0.0157
0.1113


499
0.4330


500
0.0485
0.1386


501
0.3591


502
0.0833
0.3626


503
0.0140
0.0923


504
0.7679


505
0.0181
0.0705


506
>10


507
>10


508
0.7905


509
0.1473
0.1598


510
1.9387


511
0.2128
0.3231


512
0.4430
0.4699


513
>10


514
0.1319
0.1477


515
>10


516
>10


517
>10


518
>10


519
>10


520
>10


521
0.0054
0.0133


522
0.2861
0.2639


523
0.0013
0.0251


524
0.0007
0.0182


525
0.0030
0.0365


526
0.0083
0.0188


527
0.0743
0.1829


528
0.0055
0.0340


529
0.0362
0.0796


530
0.0344
1.1117


531
0.0085
0.3234


532
0.0060
0.0318


533
0.0045
0.0227


534
0.0118
0.0689


535
0.0015
0.0155


536
0.0214
0.0678


537
0.0030
0.0421


538
0.0202
0.3298


539
0.0016
0.0521


540
0.0163
0.0850


541
0.0118
0.0660


542
0.1070
0.3112


543
0.4438
4.1649


544
0.0282
1.6516


545
0.0115
0.0504


546
0.1480
0.2531


547
0.0348
0.1042


548
0.4672
0.7408


549
0.0094
0.1228


550
0.0017
0.0160


551
0.0004
0.0209


552
0.0055
0.1020


553
0.0193
0.4304


554
0.0021
0.0390


555
0.0016
0.0245


556
0.0007
0.0131


557
0.1471
1.0659


558
0.0120
0.2100


559
0.0015
0.0547


560
0.0052
0.0951


561
0.0044
0.0429


562
0.0548
0.2259


563
0.0197
0.3276


564
0.2001
0.5828


565
0.0813
0.9836


566
>10


567
1.1347


568
~2.499


569
~0.0700
0.3345


570
0.0355
1.1833


571
0.0017
0.0907


572
~0.3699


573
0.1136


574
0.0139
0.4942


575
~0.7500


576
0.0079
0.1157


577
0.0102
0.0907


578
0.0252
0.9557


579
0.0951
1.5442


580
0.0548
~5.00034


581
0.0596
2.8229


582
>10


583
>10


584
>10


585
>10


586
>10


587
>10


588
0.1333
>10


589
>10


590
>10


591
~2.4997


592
>10


593
>10


594
>10


595
~2.4997


596
>10


597
~2.4997


598
>10


599
>10


600
>10


601
>10


602
0.0006
0.0167


603
0.0276
>10


604
0.0050
0.0895


605
0.0019
0.0979


606
0.0463
2.6242


607
0.1384
0.1521


608
0.0287
0.0539


609
0.2464
0.7677


610
0.0274
0.1171


611
0.2489
0.5626


612
0.0146
0.0420


613
0.2146
0.5565


614
0.0098


615
0.0509


616
0.0164


617
0.1615


618
0.0146
0.2109


619
0.0034
0.0451


620
0.0019
0.0132


621
0.0050
0.1007


622
0.0461
0.3402


623
0.0049
0.0935


624
0.0327


625
0.0078
0.1727


626
0.0062
0.0454


627
0.0437
0.3662


628
0.3362


629
0.8358


630
1.8950


631
>10


632
1.2677


633
>10


634
0.3108
1.4706


635
1.0869


636
0.0046
0.1073


637
0.0188
0.3976


638
0.0014
0.0148


639
0.0072
0.0671


640
1.3397


641
>10


642
0.0788
0.9806


643
0.3225
4.2875


644
>10


645
>10


646
>10


647
0.2271


648
0.8339


649
>10


650
0.8316


651
0.3062
1.5364


652
0.0627
0.8426


653
0.0173
0.5267


654
0.1303
1.0459


655
0.5034
1.8302


656
1.3957


657
0.0735
2.3415


658
0.5717


659
~0.7500


660
0.0833
>10


661
~2.4997


662
~1.2246


663
0.0058
0.0347


664
0.0050
>1


665
0.0026
0.0224


666
0.0032
0.0361


667
0.0060
0.0396


668
0.0230
0.1897


669
0.0040
0.1064


670
0.0977
0.5255


671
0.0157
0.1646


672
0.0137
0.1965


673
0.1343
0.1013


674
0.0036
0.0133


675
0.0010
0.0551


676
0.2339
3.7145


677
>10


678
>10


679
0.1316
0.2054


680
0.6097
1.0503


681
0.0522
0.1058


682
0.2239
0.2638


683
0.6021
0.2800


684
0.0463
0.1343


685
0.0592
0.1150


686
0.3343
1.4900


687
0.7399
3.5457


688
0.6955
1.1844


689
0.4846
0.7872


690
0.1771
0.1175


691
>10


692
0.0533
0.1098


693
0.0495
0.1033


694
0.6762
1.0116


695
0.0084
0.3356


696
0.1410
3.2749


697
>10


698
0.0087
0.1117


699


700
>10


701
0.1318


702
~0.3041


703
>10


704
0.1025
0.1907


705
0.0869
0.2891


706
0.0796
0.3621


707
0.0327
0.1267


708
0.0235
0.1416


709
0.0054
0.2682


710
0.0137
0.0565


711
0.0417
0.1420


712
0.0019
0.0523


713
0.0017
0.0534


714
0.0024
0.0331


715
0.0082
0.1858


716
>10


717
1.0083


718
>10


719
>10


720
>10


721
>10


722
>10


723
>10


724
>10


725
1.2960


726
0.9041


727
0.4838
1.1741


728
0.7813


729
0.0647
0.8610


730
0.0067
0.1359


731
0.0147
0.0513


732
0.5571


733
>10


734
>10


735
0.0320
0.2723


736
0.3303
0.4145


737
0.9842


738
0.2400
2.9546


739
0.3701
1.1133


740
>10


741
0.0046
0.0263


742
0.0029
0.0257


743
0.0016
0.0217


744
0.0155
0.1317


745
0.0117
0.1107


746
0.0020
0.1370


747
0.0271
0.2622


748
>10


749
0.2455
0.4675


750
1.1582


751
0.0809
1.0566


752
0.1352
0.2992


753
0.0044
0.0213


754
0.0699
0.3772


755
0.9395


756
>10


757
0.0052
0.0162


758
0.5569


759
>10


760
1.1558


761
>10


762
0.1589
0.4418


763
1.1148


764
>10


765
>10


766
1.9090


767
>10


768
0.5728


769
1.5449


770
>10


771
>10


772
>10


773
0.2227
0.6390


774
1.2975


775
0.0304


776
0.1497


777
1.6211


778
>10


779
~2.4997


780
>10


781
0.7295


782
>10


783
>10


784
0.0079
0.1105


785
0.0085
0.0576


786
0.0607
0.1049


787
0.0091
0.0980


788
0.0178
1.8026


789
0.1303
0.9386


790
0.0015
0.0253


791
>10


792
>10


793
0.2795
0.6419


794
0.0328
3.9355


795
0.0085
0.0686


796
0.3912


797
>10


798
0.2573
0.2200


799
>10


800
>10


801
>10


802
>10
>1


803
0.1065
0.2413


804
0.6359


805
0.0297
0.3528


806
0.0018
0.0484


807
0.0058
0.0722


808
0.0004
0.0064


809
0.0038
0.0377


810
0.0006
0.0056


811
0.3149
0.5413


812
0.0085
0.0120


813
0.0339
0.0751


814
0.0028
0.0209


815
0.2555
0.1281


816
0.0370
0.0610


817
0.4629


818
0.0272
0.0516


819
0.0743
0.0475


820
0.0033
0.0416


821
>10


822
0.2804
0.0991


823
0.1923
0.0951


824
0.0103
0.0180


825
0.2732
0.1223


826
0.0007
0.0199


827
>10


828
0.1153
0.2598


829
0.0057
0.0090


830
0.0029
0.0056


831
0.1492
0.0725


832
1.3119


833
~0.5000


834
0.0489
1.0907


835
~0.35359
0.4172


836
0.0255
0.5951


837
~1.74985


838
0.0286
0.3501


839
0.8297
2.7880


840
0.0127
0.0996


841
0.1458
0.3697


842
0.0053
0.0610


843
0.0156
0.0443


844
0.5093
0.9072


845
>10


846
0.0105
0.0418


847
0.0081
0.0991


848
0.0968
0.3217


849
0.0383
3.9030


850
0.0377
0.1954


851
0.0326
0.3593


852
0.1179
1.3456


853
0.0047
0.0456


854
1.2773


855
>10


856
0.0605
0.0839


857
0.0280
0.2055


858
0.2097
0.3697


859
~1.2499


860
~1.4791


861
0.0040
0.0449


862
0.1221
0.1210


863
0.0411
0.1401


864
0.2164
0.4128


865
0.0962
0.1924


866
0.1705
0.5388


867
0.2463
0.7930


868
0.0215
0.3446


869
0.1412
0.8437


870
0.0143
0.0867


871
0.0250
0.3714


872
0.0083
0.0530


873
0.0231
0.3355


874
0.0511
0.3588


875
0.1699
0.8511


876
0.0803
1.0770


877
0.0047
0.0105


878
0.2762
0.3202


879
0.1681
0.1064


880
0.0867
0.1796


881
0.0760
0.1282


882
0.1666
0.0688


883
0.0342
0.0695


884
0.2387
0.7055


885
0.0408
1.0573


886
0.0058
>1


887
0.0304
>1


888
0.0007
0.3666


889
0.0039
0.2358


890
0.0037
0.0623


891
0.0315
0.7516


892
0.0774
0.7311


893
0.0303
0.6027


894
0.0038
0.1411


895
0.0132
0.2220


896
0.0221
0.4664


897
0.0070
0.0903


898
0.0797
0.9281


899
0.0770
0.0873


900
0.0351
0.0408


901
0.0018
0.0016


902
0.0184
0.0886


903
0.0387
0.0634


904
0.2547
0.1046


905
0.0579
0.0529


906
0.0003
0.0020


907
0.0060
0.0120


908
0.0266
0.0437


909
0.2528
0.1166


910
0.0029
0.0092


911
0.1663
0.0287


912
0.0005
0.0088


913
0.0063
0.0119









Throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

## Claims

1. A compound of Formula (I)



wherein
L is a bond, —CH2—, —SO2—, —CH2—SO2—, —SO2—CH2—, —SO2—NR—,

—SO2—NR—CH2—, —CH2—SO2—NR—, —NR—, —NR—SO2—, —NR—SO2—NR—, —S—, —S—CH2—, —CH2—S—,
—C(═O)—, —C(═O)—O—, —O—, —O—CH2—, —NR—C(═O)—, —NR—C(═O)—NR—, or —C(═O)—NR—, wherein R is H,
C1-2alkyl, C1-2alkyl-OH or cyclopropyl;
R1 is H, halo, methyl, CF3, —O—CF3, or —O—CH3;
R2 is H, cyano, halo, —SO2—CH3, 2-(trimethylsilyl)ethoxy, phenyl, C1-6alkyl, heteroaryl, heterocyclyl, C3-9cycloalkyl, provided R2 is not H if L is a bond, and wherein said phenyl, C1-6alkyl, heteroaryl, heterocyclyl or C3-9cycloalkyl is optionally and independently substituted with 1-4 substituents selected from the group consisting of:

methyl, ethyl, oxo, fluoro, hydroxyl, cyano, amino, methoxy, tert-butoxy, acetyl, cyclopropyl, cyclobutyl, cyclohexyl, phenyl, azetidin-1-yl, azetidin-3-yl, pyrrolidin-1-yl, 2,4-dihydro-3H-1,2,4-triazol-3-one-4-yl, 1H-imidazol-4-yl, pyrazin-2-yl, pyrimidin-2-yl, 1,3-oxazolidin-2-one-5-yl, N-benzamide, benzo[d]imidazol-2(3H)-one, 4-methylpiperazin-1-yl, morpholin-4-yl, CF3, —SO2—CH3, —C(═O)-cyclopropyl, —SO2-cyclohexyl, —NHCH3, —N(CH3)2, —NHAc, —NHCO2t-Bu, —CH2—NH2, —C(═O)—NH2, —C(═O)—N(ethyl)2, —NH—C(═O)—NH2, —NH—C(═O)—CH3, —C(═O)—(C1-C4alkyl), —C(═O)—OH, —C(═O)—NH(C1-C4alkyl)-(CH2)n—OH, and —(CH2)n—CN, wherein n is 1 or 2;
V is CH, CR′, or N, wherein R′ is methyl or F;
W is CR′′ or N, wherein R′′ is H, F, hydroxyl, amino, CH3 or —O—CH3;
ring A is selected from the group consisting of:









R3 is H, F, methyl, or —O—CH3;
R3′ is H or F;
R4 is H, methyl, cyano, amino, halo, —COOH, or —O—CH3;
R5 is H, methyl, cyano, or —CF3;
R6 is H, cyano, amino, halo, or —CF3; and
R7 is halo, amino, —CONH2, cyano, —O—CH3, —CF3, or —COO-ethyl;


or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein
L is a bond, —O—, —SO2—NH—, —NH—SO2—, —SO2—, —S—, —C(═O)—, fluoro or —C(═O)—NH—;
R1 is H, bromo or CF3;
R2 is H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, tetrahydro-2H-thiopyran-4-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, pyrazin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl, provided R2 is not H if L is a bond, and wherein R2 is optionally substituted with hydroxyl, fluoro, amino, oxo, methyl, or —CH2—NH2;
V is CH or N;
W is CR′′ or N, wherein R′′ is H or F;
ring A is




R3 is H;
R3′ is H;
R4 is H or cyano; and
R5 is H or cyano;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein
L is a bond, —O—, —SO2—NH—, —NH—SO2—, —SO2—, —S—, or —C(═O)—;
R1 is H or CF3;
R2 is H, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclopropyl, cyclohexyl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperazin-1-yl, tetrahydro-2H-thiopyran-4-yl, morpholin-2-yl, morpholin-4-yl, thiomorpholin-4-yl, pyrazin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl, provided R2 is not H if L is a bond, and wherein R2 is optionally substituted with hydroxyl, fluoro, amino, oxo, methyl, or —CH2—NH2;
V is CH or N;
W is CR′′ or N, wherein R′′ is H or F;
ring A is




R3 is H; and
R3′ is H;

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is selected from:
5-(3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide,
6-Amino-3-[3-fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazine-2-carbonitrile,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-methylethyl)biphenyl-2-sulfonamide (racemic),
4′-(5-Aminopyrazin-2-yl)-N-(cyclobutylmethyl)-3′-fluorobiphenyl-2-sulfonamide,
(endo)-4′-(5-Aminopyrazin-2-yl)-N-bicyclo[2.2.1]hept-2-yl-3′-fluorobiphenyl-2-sulfonamide (racemic),
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-methylcyclobutyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-(1,1-dimethylpropyl)-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1-dimethylethyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-cyclopentyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-phenylethyl)biphenyl-2-sulfonamide,
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide,
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide,
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-(2,3-dihydro-1H-inden-2-yl)-3′-fluorobiphenyl-2-sulfonamide,
(S)-4′-(5-Aminopyrazin-2-yl)-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-3′-fluorobiphenyl-2-sulfonamide,
(R)-4′-(5-Aminopyrazin-2-yl)-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-3′-fluorobiphenyl-2-sulfonamide,
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-phenylethyl]biphenyl-2-sulfonamide,
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide,
(S)-4′-(5-Aminopyrazin-2-yl)-N-[(3S)-1-ethyl-2-oxoazepan-3-yl]-3′-fluorobiphenyl-2-sulfonamide,
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-2-oxoazepan-3-yl]biphenyl-2-sulfonamide,
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-1-methyl-2-oxoazepan-3-yl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-pyridin-3-ylbiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfamide,
N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1, 1′-biphenyl]-2-yl)propane-2-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanesulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]propane-1-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-2-methylpropane-1-sulfonamide,
N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)cyclopropanesulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]hexane-1-sulfonamide,
N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)cyclobutanesulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1,1,1-trifluoromethanesulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-dimethylbiphenyl-2-sulfonamide,
5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide,
5-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
5-{2′-[(4,4-Difluoropiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(3,3-Difluoropiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(3,3-Difluoroazetidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-[2′-(Azepan-1-ylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(trifluoromethyl)piperidin-4-ol,
5-(3-Fluoro-2′-{[4-(methylsulfonyl)piperazin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine,
5-{2′-[(4-Acetylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-(2′-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine,
2-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)ethanol,
5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
racemic 5-[3-Fluoro-2′-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
5-{2′-[(3,5-Dimethylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-3-carbonitrile,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-4-carbonitrile,
5-{2′-[(4-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-one,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-ol,
(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)methanol,
2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)ethanol,
racemic 1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-ol,
racemic 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)ethanol,
5-(3-Fluoro-2′-{[4-(methylamino)piperidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine,
5-(2′-{[4-(Dimethylamino)piperidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine,
racemic 5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
N-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)acetamide,
racemic (1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)methanol,
racemic tert-Butyl (1-{[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)carbamate,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxypropyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-phenylethyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-phenylethyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2R)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)propyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2S)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2-sulfonamide,
(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-2-yl)methanol,
(R)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
(S)-5-(2′-((3-aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
(R) 5-(2′-{[2-(Aminomethyl)pyrrolidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine,
(S)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-2-yl)methanol,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(methylsulfonyl)biphenyl-2-sulfonamide,
(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′-biphenyl]-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1-hydroxycyclohexyl)methyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-1,1-dimethylethyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-methylpropyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-1,1-dimethylpropyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
(R)-4′-(5-aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
(trans)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3,4-diol,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopyrrolidin-3-yl)-[1,1′-biphenyl]-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)-[1,1′-biphenyl]-2-sulfonamide,
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide,
trans 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-sulfonamide,
(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-3-yl)methanol,
(S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-3-yl)methanol,
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)biphenyl-2-sulfonamide,
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3-ylbiphenyl-2-sulfonamide,
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3-ylbiphenyl-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-phenylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-phenylethyl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-3-ol,
racemic (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxycyclohexyl)biphenyl-2-sulfonamide,
racemic (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide,
racemic (cis)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-piperidin-4-ylbiphenyl-2-sulfonamide,
5-(2′-{[3-(Aminomethyl)azetidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N-(azetidin-3-ylmethyl)-3′-fluorobiphenyl-2-sulfonamide,
(R)-5-(3-Fluoro-2′-{[3-(methylamino)pyrrolidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine,
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-methylethyl)biphenyl-2-sulfonamide,
5-[3-Fluoro-2′-(1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
4-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one,
5-(2′-((1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
5-(2′-((1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-hydroxypentyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(6-hydroxyhexyl)biphenyl-2-sulfonamide,
N-(4-Aminocyclohexyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide,
(S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2,3-dihydro-1H-indol-2-yl)methanol,
4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide,
(S)-5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-bis(2-hydroxyethyl)biphenyl-2-sulfonamide,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidine-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluoro-N-(tetrahydro-2H-pyran-4-yl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1-methylethyl)biphenyl-2-sulfonamide,
racemic (4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}morpholin-2-yl)methanol,
(1R,5S)-3-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-azabicyclo[3.1.0]hexan-6-amine,
(S)-5-(3-fluoro-2′-((2-methylpiperazin-1-yl)sulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
(R)-5-(3-fluoro-2′-((2-methylpiperazin-1-yl)sulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
(R)-(1-((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperazin-2-yl)methanol,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]biphenyl-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-methyl butan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
(R)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
tert-Butyl [2-({[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}amino)ethyl]carbamate,
N-(2-Aminoethyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxybutan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(pyrrolidin-3-yl)-[1,1′-biphenyl]-2-sulfonamide,
N-[2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}amino)ethyl]acetamide,
(S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-ylsulfonamido)propanoic acid,
4′-(5-Aminopyrazin-2-yl)-N-[2-(carbamoylamino)ethyl]-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxycyclohexyl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[6-(trifluoromethyl)pyridin-3-yl]biphenyl-2-sulfonamide,
5-(3-Fluoro-2′-{[4-(1H-imidazol-4-yl)piperidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine,
N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-(2,6-dimethoxypyrimidin-4-yl)-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-methylpyrazin-2-yl)biphenyl-2-sulfonamide,
(S)-2-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-ylsulfonamido)-4-methylpentanamide,
4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-sulfonamide,
(R)-4′-(5-aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
(S)-4′-(5-aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-methyloxetan-3-yl)biphenyl-2-sulfonamide,
3-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)propanenitrile,
(S)-4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(1-methoxypropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
5-{3-Fluoro-2′-[(4-pyrazin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,
5-{3-Fluoro-2′-[(4-pyrimidin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,
5-(2′-Amino-3-fluorobiphenyl-4-yl)pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3-phenylpyrrolidin-3-ol,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1-sulfonamide,
N′-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,N-dimethylsulfamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]morpholine-4-sulfonamide,
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-3-ol,
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-3-ol,
(3S,4S)-1′-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-1,3′-bipyrrolidin-4′-ol,
(3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-morpholin-4-ylpyrrolidin-3-ol,
(3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(4-methylpiperazin-1-yl)pyrrolidin-3-ol,
5-{3-Fluoro-2′-[(trifluoromethyl)-sulfanyl]biphenyl-4-yl}pyrazin-2-amine,
5-[2′-(tert-Butylsulfanyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[2′-(Ethylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(propylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
5-{3-Fluoro-2′-[(2-methylpropyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,
5-[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[2′-(Cyclopentylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[2′-(Cyclobutylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-{3-Fluoro-2′-[(1-methylethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,
5-{3-Fluoro-2′-[(trifluoromethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}acetamide,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}-N,N-diethylacetamide,
5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfanyl]biphenyl-4-yl}pyrazin-2-amine,
(racemic) 5-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}methyl)-1,3-oxazolidin-2-one,
N-(2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}ethyl)benzamide,
5-(3-Fluoro-2′-{[4-(methylsulfonyl)benzyl]sulfanyl}biphenyl-4-yl)pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide,
5-[3-Fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-4-(trifluoromethyl)biphenyl-2-sulfonamide,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]sulfonyl}piperazin-2-one,
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide,
5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine,
5-[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine hydrochloride,
5-[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine formate salt,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4-amine hydrochloride,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4-amine hydrochloride,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-amine hydrochloride,
5-[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine hydrochloride,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-amine hydrochloride,
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methyl methanesulfonamide formic acid salt,
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(2-hydroxyethyl)methanesulfonamide formic acid salt,
1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)azetidin-3-ol formic acid salt,
4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperazin-2-one formic acid salt,
(S)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1-hydroxypropan-2-yl)methanesulfonamide,
(R)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1-hydroxypropan-2-yl)methanesulfonamide hydrochloride,
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(trans-4-hydroxycyclohexyl)methanesulfonamide,
(S)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2-hydroxypropyl]methanesulfonamide hydrochloride,
(R)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2-hydroxypropyl]methanesulfonamide,
5-(2′-{[(4-Aminopiperidin-1-yl)sulfonyl]methyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine hydrochloride,
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide hydrochloride,
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-ethylmethanesulfonamide formate salt,
1-[1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperidin-4-yl]urea hydrochloride,
N-[1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperidin-4-yl]acetamide formate salt,
5-{2′-[(Ethylsulfanyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine formate salt,
5-{3-Fluoro-2′-[(methylsulfanyl)methyl]biphenyl-4-yl}pyrazin-2-amine hydrochloride,
5-(3-Fluoro-2′-{[(1-methylethyl)sulfanyl]methyl}biphenyl-4-yl)pyrazin-2-amine hydrochloride,
2-(((4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methyl)thio)pyrimidin-4-amine hydrochloride,
6-(((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methyl)thio)pyrimidin-4-amine hydrochloride,
5-(3-fluoro-2′-((pyridazin-3-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine hydrochloride,
6-(((4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methyl)thio)pyridazin-3-amine hydrochloride,
5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2-amine hydrochloride,
5-(3-fluoro-2′-((pyrimidin-4-ylthio)methyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine hydrochloride,
5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfonyl)biphenyl-4-yl]pyrazin-2-amine hydrochloride,
5-(3-Fluoro-2′-{[3-(methylsulfonyl)propyl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine hydrochloride,
5-(3-Fluoro-2′-{[(2R)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4-yl)pyrimidin-2-amine,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)propyl]biphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide,
racemic (4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}morpholin-2-yl)methanol,
5-(3-Fluoro-2′-{[(2S)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4-yl)pyrimidin-2-amine,
5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]biphenyl-2-sulfonamide,
4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3S)-piperidin-3-yl]biphenyl-2-sulfonamide,
4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3R)-piperidin-3-yl]biphenyl-2-sulfonamide,
[(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-yl]methanol,
racemic cis 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(cis)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide,
racemis trans 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(trans)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1-methylethyl)biphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(trans-4-hydroxycyclohexyl)biphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]biphenyl-2-sulfonamide,
5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-3-ol trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3R)-2-oxopiperidin-3-yl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopiperidin-3-yl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)-2,2-dimethylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-2-methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-N-[(2S)-2,3-dihydroxypropyl]-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,
[(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt,
[(2S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-2-yl]methanol trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-1,1-dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,
5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine trifluoroacetic acid salt,
2-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)ethanol trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid,
4′-(2-Aminopyrimidin-5-yl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-N-tert-butyl-3′-fluoro-3-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
5-[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2,2,2-trifluoro-1,1-dimethylethyl)biphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-sulfonamide trifluoroacetic acid salt,
5-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N,N-dimethylbiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt,
5-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine trifluoroacetic acid salt,
4′-(2-aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide trifluoroacetic acid salt,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-one trifluoroacetic acid salt,
tert-Butyl N-{[4′-(2-aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L-alaninate,
N-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L-alanine,
N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1-sulfonamide,
N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]morpholine-4-sulfonamide,
N′-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N,N-dimethylsulfamide,
5-(2′-(2-oxa-6-azaspiro[3.3]heptan-6-ylsulfony)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrimidin-2-amine,
6-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-2-thia-6-azaspiro[3.3]heptane 2,2-dioxide,
1-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)azetidine-3-carbonitrile,
1-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-3-(trifluoromethyl)azetidin-3-ol,
5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine hydrochloride,
2-(((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)methyl)quinazolin-4(3H)-one,
1-(3-((4′-(2-aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one,
5-(2′-{[3-(Cyclohexylsulfonyl)propyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine,
5-{3-Fluoro-2′-[(1-methyl-1H-benzimidazol-2-yl)sulfonyl]biphenyl-4-yl}pyrimidin-2-amine,
5-(2′-{[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine,
4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide,
5-[3-fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine,
4-{[4′-(2-aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]sulfonyl}piperazin-2-one,
4′-(2-aminopyrimidin-5-yl)-3′-fluoro-N-methyl-4-(trifluoromethyl)biphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide,
5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(5-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt,
5-{2′-[(4-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt,
5-{2′-[(5-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt,
5-[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine hydrochloride,
5-[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine hydrochloride,
5-{2′-[(6-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2-amine formate salt,
5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine formate salt,
5-{2′-[(5-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine hydrochloride,
5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfonyl)biphenyl-4-yl]pyrimidin-2-amine formate salt,
5-{2′-[(5-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine hydrochloride,
5-[3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4-yl]pyrimidin-2-amine,
5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine,
4′-(6-aminopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-aminopyridin-3-yl)-N,N-diethyl-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
5-(3-fluoro-2′-(pyrrolidin-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine,
5-(3-fluoro-2′-(piperidin-1-ylsulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine,
4′-(6-aminopyridin-3-yl)-N-cyclohexyl-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-aminopyridin-3-yl)-3′-fluoro-N-isobutyl-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(tert-pentyl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1,1,1-trifluoro-2-methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-phenylethyl)-[1,1′-biphenyl]-2-sulfonamide,
(R)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1-methylcyclobutyl)-[1,1′-biphenyl]-2-sulfonamide,
4-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)thiomorpholine 1,1-dioxide,
(S)-4′-(6-aminopyridin-3-yl)-3′-fluoro-N-(1,1,1-trifluoropropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
5-(2′-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2-amine,
tert-butyl 3-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-ylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate,
4′-(6-aminopyridin-3-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)-[1,1′-biphenyl]-2-sulfonamide,
2-(1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-yl)ethanol,
1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-ol,
(1-((4′-(6-aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-yl)methanol,
3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,
3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,
3′-Fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,
5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]-1H-pyrrolo[2,3-b]pyridine,
3′-Fluoro-N-(2-hydroxyethyl)-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,
3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]methanesulfonamide,
3′-Fluoro-N,N-dimethyl-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide,
2-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
N,N-Diethyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide,
2-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
2-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-N-(2,2,2-trifluoro-1-methylethyl)biphenyl-2-sulfonamide,
2-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
3′-Fluoro-N-[(1R)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide,
3′-Fluoro-N-methyl-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide,
3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide,
1-{[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]sulfonyl}piperidin-4-amine,
2-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-5H-pyrrolo[2,3-b]pyrazine,
2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
2-[2′-(Ethylsulfanyl)-3-fluorobiphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
7-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine,
7-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine,
4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2-sulfonamide,
4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
1-{[4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-amine,
4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide,
7-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine,
N-tert-Butyl-4′-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2-sulfonamide,
2-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]-5-(trifluoromethyl)pyridin-3-yl}phenyl)-5H-pyrrolo[2,3-b]pyrazine,
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine,
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]pyridin-3-yl}phenyl)pyrazin-2-amine,
2-{2-Fluoro-4-[2-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine,
2-{2-Fluoro-4-[2-(2-methylpropoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine,
2-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine,
2-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}-5H-pyrrolo[2,3-b]pyrazine,
5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-{4-[2-(Cyclopentyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,
5-{4-[2-(Cyclohexyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,
5-[2-Fluoro-4-(2-methoxypyridin-3-yl)phenyl]pyrazin-2-amine,
5-{4-[2-(Cyclobutyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,
tert-Butyl 3-[({3-[4-(5-aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)methyl]pyrrolidine-1-carboxylate,
5-{2-Fluoro-4-[2-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrimidin-2-amine,
5-[4-(2-Aminopyridin-3-yl)-2-fluorophenyl]pyrimidin-2-amine,
4′-(5-amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
3-Amino-6-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carbonitrile,
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide,
3-Amino-6-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazine-2-carbonitrile,
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide,
3-Amino-6-[3-fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazine-2-carbonitrile,
4′-(6-Aminopyridazin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(7H-pyrrolo[2,3-d]pyrimidin-2-yl)biphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(1,8-naphthyridin-3-yl)biphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-quinoxalin-6-ylbiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(1H-indol-5-yl)biphenyl-2-sulfonamide,
4′-(1H-Benzimidazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(1H-Benzimidazol-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide,
4′-(1,3-Benzothiazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(1H-pyrrolo[3,2-b]pyridin-6-yl)biphenyl-2-sulfonamide,
3′-Fluoro-N-methyl-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,
4′-(5-Aminopyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-4′-(5,6-diaminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyrazin-5-yl)biphenyl-2-sulfonamide,
4′-(6-Amino-5-fluoropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-4′-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(3H-imidazo[4,5-b]pyridin-6-yl)biphenyl-2-sulfonamide,
4′-(5-Amino-6-methoxypyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Amino-6-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(6-Amino-4-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(6-amino-2-cyanopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-Amino-6-chloropyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Amino-6-bromopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
6-amino-3-(2′-(cyclopropylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)picolinonitrile,
N-tert-Butyl-3′-fluoro-4′-[1,2,4]triazolo[4,3-a]pyridin-7-ylbiphenyl-2-sulfonamide,
4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(1H-imidazo[4,5-b]pyrazin-5-yl)biphenyl-2-sulfonamide,
N-tert-Butyl-4′-(5,6-diaminopyridin-3-yl)-3′-fluorobiphenyl-2-sulfonamide,
4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide,
4′-(6-Amino-5-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(6-Amino-5-chloropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-[6-Amino-5-(trifluoromethyl)pyridin-3-yl]-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-[2-Amino-4-(trifluoromethyl)pyrimidin-5-yl]-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Amino-4-methylpyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
N-tert-Butyl-3′-fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]biphenyl-2-sulfonamide,
4′-(7-Amino-1H-indol-5-yl)-3′-fluoro-N-[1-(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide,
3′-Fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methylbiphenyl-2-sulfonamide,
4′-(7-Amino-1H-indol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]acetamide,
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]urea,
5-[2,3-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methylbiphenyl-2-yl]methanesulfonamide,
4′-(5-Aminopyrazin-2-yl)-2′,3′-difluorobiphenyl-2-sulfonamide,
4′-(2-Aminopyrimidin-5-yl)-2′,3′-difluoro-N-methylbiphenyl-2-sulfonamide trifluoroacetic acid salt,
4′-(2-Aminopyrimidin-5-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-sulfonamide trifluoroacetic acid salt,
5-[2′,3-Difluoro-4′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine,
5-(2′,3-Difluorobiphenyl-4-yl)pyrazin-2-amine,
5-(2′-Chloro-3-fluorobiphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-methylbiphenyl-4-yl)pyrazin-2-amine,
5-[2′,3-Difluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
5-(3-Fluoro-2′-methoxybiphenyl-4-yl)pyrazin-2-amine,
5-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-ol,
5-[3-Fluoro-2′-(phenylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
5-(2′,3,6′-Trifluorobiphenyl-4-yl)pyrazin-2-amine,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]benzenesulfonamide,
5-(2′-Ethyl-3-fluorobiphenyl-4-yl)pyrazin-2-amine,
{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid,
5-[3-Fluoro-2′-(1-methylethyl)biphenyl-4-yl]pyrazin-2-amine,
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanone,
5-[3-Fluoro-2′-(2,2,2-trifluoroethoxy)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxylic acid,
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxamide,
5-[3-Fluoro-2′-(1-methylethoxy)biphenyl-4-yl]pyrazin-2-amine,
5-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,
2-[3,4′-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylmethanesulfonamide,
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]ethanesulfonamide,
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N-methylmethanesulfonamide,
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N-methylethanesulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylethanesulfonamide,
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-2-methylpropane-1-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-ethylmethanesulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,2-dimethylpropane-1-sulfonamide,
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-1H-pyrrolo[2,3-b]pyridine,
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrimidin-2-amine,
2-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-carboxamide,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[((1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide,
5-[3-Fluoro-2′-(piperazin-1-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine,
5-{2′-[(4-Acetylpiperazin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2-carboxamide,
5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[((1R)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-4-ol,
5-{2′-[(4-Aminopiperidin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperazin-2-one,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperazin-2-one,
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine,
4-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-yl]oxy}pyrimidin-2-amine,
2-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-yl]oxy}pyrimidin-4-amine,
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-pyrrolo[2,3-b]pyridine,
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrimidin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4-amine,
5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
6-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)pyridine-2-carbonitrile,
2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)pyridine-3-carbonitrile,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-amine,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-amine,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4-amine,
5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile,
5-{2′-[(6-Azetidin-1-ylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(6-Azetidin-1-ylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrazin-2-amine,
5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine,
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-benzimidazole,
6-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-3H-imidazo[4,5-b]pyridine,
5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2-amine,
5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine,
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}biphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine,
5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2-amine,
5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine,
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine,
5-[3-Fluoro-2′-methoxy-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-4-amine,
5-[3-Fluoro-4′-(trifluoromethyl)-2′-{[2-(trimethylsilyl)ethoxy]methoxy}biphenyl-4-yl]pyrimidin-2-amine,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol,
5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-2-amine,
5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine,
5-[3-Fluoro-2′,4′-bis(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carbonitrile,
5-{5-[2-(Pyrimidin-2-yloxy)-4-(trifluoromethyl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-5-(trifluoromethyl) phenoxy}pyrimidin-2-amine,
5-{5-[2-(Pyrimidin-2-yloxy)phenyl]pyridin-2-yl}pyrimidin-2-amine,
4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenoxy}pyrimidin-2-amine,
5-(5-{2-[(4-Aminopyrimidin-2-yl)oxy]phenyl}pyridin-2-yl)pyrimidin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methylbiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methoxybiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-N,N-dimethylbiphenyl-2-sulfonamide,
5-[2′-(Morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′-fluorobiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-2′-fluoro-N,N-dimethylbiphenyl-2-sulfonamide,
4′-(2-Amino-1,3-oxazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(8-fluoroimidazo[1,2-a]pyridin-2-yl)biphenyl-2-sulfonamide,
4′-(5-Aminoimidazo[1,2-a]pyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-6-carboxamide,
2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-6-carboxamide,
N-tert-Butyl-4′-(5-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-4′-(6-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-[6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]biphenyl-2-sulfonamide,
Ethyl 2-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-5-carboxylate,
N-tert-Butyl-3′-fluoro-4′-(5-methoxyimidazo[1,2-a]pyridin-2-yl)biphenyl-2-sulfonamide,
5-[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide,
4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide,
4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-indol-5-yl)biphenyl-2-sulfonamide,
N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′-fluorobiphenyl-2-sulfonamide,
4′-(3-Amino-1H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carboxylic acid,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}acetamide,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N-diethylacetamide,
5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4-yl}pyrimidin-2-amine,
5,5′-(3,3′′-Difluoro-1,1′:2′,1′′-terphenyl-4,4′′-diyl)dipyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxylic acid,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carbaldehyde,
5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine,
2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)ethanol,
5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine,
5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5-amine,
5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6-methylpyrimidin-4-amine,
5-{2′-[(4-Amino-6-methyl pyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile,
5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(6-Amino-2-methylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-2-methylpyrimidin-4-amine,
5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine,
5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile,
6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol,
5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine,
5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine,
5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine,
5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine,
5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine,
{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile,
{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile,
{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid,
5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine,
5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine,
5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine,
2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol,
2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol,
5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine,
5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine formic acid salt,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine,
(2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol,
(2R)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol,
(2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol,
(2I)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol,
N-(4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)methanesulfonamide,
5-(3-Fluoro-2′-(morpholinosulfonyl)-[1,1′-biphenyl]-4-yl)pyridin-2-amine,
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methyl-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide trifluoroacetate,
5-(2′-((1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2-amine,
4′-(6-Aminopyrazin-2-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide,
4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
(racemic)-1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1, 1′-biphenyl]-2-yl)sulfonyl)piperidin-3-ol,
4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide,
N-(1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-yl)acetamide,
racemic 2-(1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-3-yl)ethanol,
racemic 1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidin-3-yl)methanol,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert-butylbenzenesulfonamide,
5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine,
5-(5-{2-[(3,3-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine trifluoroacetic acid salt,
5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine trifluoroacetic acid salt,
5-{5-[2-(Azepan-1-ylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine trifluoroacetic acid salt,
5-(5-{2-[(4,4-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine trifluoroacetic acid salt,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide trifluoroacetic acid salt,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(dicyclopropylmethyl)benzenesulfonamide trifluoroacetic acid salt,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide trifluoroacetic acid salt,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide trifluoroacetic acid salt,
4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin-2-one,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2-hydroxypropyl]benzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide,
5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine trifluoroacetic acid salt,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide trifluoroacetic acid salt,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-tert-butylbenzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide,
3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile trifluoroacetic acid salt,
5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)pyrazin-2-amine,
5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1H-pyrrolo[2,3-b]pyridine,
5-(3-fluoro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
5-(2′,3,4′-Trifluorobiphenyl-4-yl)pyrazin-2-amine,
racemic 5-[3-Fluoro-2′-(methylsulfinyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile,
1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1, 1′-biphenyl]-2-yl)imidazolidin-2-one,
4′-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
6-Amino-3-{2′-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N-methylazetidine-3-carboxamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-2-sulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide,
1-((4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperidine-4-carboxamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)-[1,1′-biphenyl]-2-sulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide,
6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile,
N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}ethyl)benzamide,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3,3-dimethylbutan-2-one,
5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine,
5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine,
5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine,
5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-2-amine,
5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine,
5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
6-Amino-3-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carbonitrile,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanenitrile,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide,
5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanenitrile,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide,
5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide,
5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine,
5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrazin-2-amine,
5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-(3-Fluoro-2′-(pyrimidin-4-ylthio)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
5-{2′-[(5-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine
6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile,
6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazine-2-carbonitrile,
6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2-carbonitrile,
N-(ter-Butyl)-3′-fluoro-4′-(5-(methylsulfonamido)pyrazin-2-yl)-[1,1′-biphenyl]-2-sulfonamide,
5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine hydrogen chloride salt,
5-{3-Fluoro-2′-[(methylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine,
5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyl}biphenyl-4-yl)pyrazin-2-amine,
5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine,
2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfanyl)pyrimidin-4-amine,
racemic 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}azetidin-3-ol,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4-yl)biphenyl-2-carboxamide,
5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine,
1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture),
1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture),
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide,
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol,
(cis/trans) 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide,
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol,
(cis/trans) 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide,
racemic 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine,
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol,
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol,
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol,
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol,
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol,
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrolidin-3-ol,
5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine (diastereoisomeric mixture),
5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine,
5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine,
5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine,
5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine (diastereoisomeric mixture),
5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H-pyrrolo[2,3-b]pyridine,
5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine,
5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin-2-amine,
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-tert-butyl-5-(trifluoromethyl)benzamide,
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1R)-2-hydroxy-1-methyl-ethyl]-5-(trifluoromethyl)benzamide,
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1S)-2-hydroxy-1-methyl-ethyl]-5-(trifluoromethyl)benzamide,
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1R)-2,2,2-trifluoro-1-methyl-ethyl]benzamide,
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1S)-2,2,2-trifluoro-1-methyl-ethyl]benzamide,
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1R)-2,2,2-trifluoro-1-methyl-ethyl]benzamide,
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1S)-2,2,2-trifluoro-1-methyl-ethyl]benzamide,
[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-(3-hydroxyazetidin-1-yl)methanone,
[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[4-(methylamino)-1-piperidyl]methanone,
[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(1,1-dioxo-1,4-thiazinan-4-yl)methanone,
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tert-butyl-5-(trifluoromethyl)benzamide,
[2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone,
[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone,
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tetrahydropyran-4-yl-benzamide,
[2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]phenyl]-[2-(hydroxymethyl)morpholin-4-yl]methanone,
racemic [2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[2-(hydroxymethyl)morpholin-4-yl]methanone,
N-{3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-dimethylpropanamide,
N-{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-dimethylpropanamide,
N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2-yl}-2,2-dimethylpropanamide,
racemic 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrazin-2-amine hydrochloride,
5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrimidin-2-amine formic acid salt,
5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine hydrochloride,
5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine hydrochloride,
5-(4-(2-(Cyclohexylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine hydrochloride,
5-(4-(2-(Cyclohexylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine hydrochloride,
5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidine-2-amine hydrochloride,
5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine hydrochloride,
5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine formic acid salt,
5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine formic acid salt,
racemic 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine formate,
racemic 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine formate,
1-((3-(4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)piperidin-1-yl)ethanone,
1-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)piperidin-1-yl)ethanone hydrogen chloride salt,
5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3-yl)phenyl)pyrimidin-2-amine hydrogen chloride salt,
5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3-yl)phenyl)pyrazin-2-amine hydrogen chloride salt,
4-((3-(4-(2-aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide,
4-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide,
5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3-yl)phenyl)pyrimidin-2-amine formic acid salt,
5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3-yl)phenyl)pyrazin-2-amine,
5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3-yl)pyrimidin-2-amine formic acid salt,
5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3-yl)pyrazin-2-amine formic acid salt,
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine,
5-(2-Fluoro-4-(2-(isopropylsulfonyl)pyridine-3-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine,
5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine formic acid salt,
5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine formic acid salt,
5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine formic acid salt,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-aminehydrochloride
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine formic acid salt,
5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-aminehydrochloride,
5-(2,3-Difluorobiphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2-methoxybiphenyl-4-yl)pyrazin-2-amine,
5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methoxybiphenyl-2-yl]methanesulfonamide,
5-(3-Fluoro-2′-(pyrazin-2-yl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4-yl)pyrimidin-2-amine,
5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrazin-2-amine,
5-[2′-(5-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine,
5-[2′-(6-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine,
5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrimidin-2-amine,
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2-yl]pyrimidin-2-amine,
5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Fluoro-2′-(1-methyl-1H-pyrazol-4-yl)biphenyl-4-yl]pyrazin-2-amine,
5-(3-Fluoro-2′-pyrimidin-5-ylbiphenyl-4-yl)pyrazin-2-amine,
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidine-2-carbonitrile,
5-[3-Fluoro-2′-(2-morpholin-4-ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine,
1-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}-2-methylpropan-2-ol,
5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]pyrimidin-2-amine,
5-{2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]phenyl}pyrimidin-2-amine,
5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[2′-(1,1-Dioxido-1,2-thiazinan-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[2′-(1,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine,
5-[2-Fluoro-4-(2-pyrrolidin-1-ylpyridin-3-yl)phenyl]pyrazin-2-amine,
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidin-2-one,
5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1H-pyrrolo[2,3-b]pyridine,
5-(2′,3,4′-Trifluorobiphenyl-4-yl)pyrazin-2-amine,
5-[3-Fluoro-2′-(methylsulfinyl)biphenyl-4-yl]pyrazin-2-amine,
5-[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
5-[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide,
N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide,
4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide,
4′-(6-Aminopyridazin-3-yl)-3′-fluorobiphenyl-2-sulfonamide,
N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′-fluorobiphenyl-2-sulfonamide,
3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carboxylicacid,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-(trifluoromethyl)biphenyl-2-sulfonamide,
5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}acetamide,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N-diethylacetamide,
5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4-yl}pyrimidin-2-amine,
5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine,
5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
4′-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine,
5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine,
N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}ethyl)benzamide,
5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine,
5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-(2-Fluoro-4-{2-[(2-morpholin-4-ylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine,
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2-yl]pyrimidin-2-amine,
5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-2-amine,
5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine,
5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine,
5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine,
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol,
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol,
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol,
2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol,
5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol,
5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide,
5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine,
5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide,
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol,
{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid,
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4-yl)biphenyl-2-carboxamide,
5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine,
2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide,
4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide,
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide,
N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1H-indol-5-yl)biphenyl-2-sulfonamide,
4′-(3-Amino-1H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide,
5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine,
5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine,
5-[3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine,
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methoxybiphenyl-2-yl]methanesulfonamide,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}azetidin-3-ol,
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol,
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile,
(2R)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol,
5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
4′-(6-Aminopyridin-3-yl)-3′-fluorobiphenyl-2-sulfonamide,
5-{3-Fluoro-2′-[(methylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine,
5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-3,3-dimethylbutan-2-one,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol,
2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol,
5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
N-[4′-(6-Aminopyridin-3-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide,
4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin-2-one,
5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H-pyrrolo[2,3-b]pyridine,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2-hydroxypropyl]benzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide,
5-{2-Fluoro-4-[2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine,
5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide,
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol,
(2S)-2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol,
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanenitrile,
(2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-methoxybiphenyl-2-sulfonamide,
5-(2-Fluoro-4-{2-[(3-methoxypropyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide,
5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide,
{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile,
5-{4-[2-(tert-Butylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine,
5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine,
5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine,
5-(2-Fluoro-4-{2-[(2-morpholin-4-ylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine,
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine,
5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine,
5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)pyrazin-2-amine,
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine,
5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile,
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3-carboxamide,
5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
5-(5-{2-[(4,4-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine,
5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine,
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3-carboxamide,
5-(2-Fluoro-4-{2-[(tetrahydro-2H-pyran-4-ylmethyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide,
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol,
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine,
2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)ethanol,
5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methyl]biphenyl-4-yl}pyrazin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide,
5-(5-{2-[(3,3-Difluoropiperidin-1-yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine,
5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine,
5-{2-Fluoro-4-[2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine,
6-Amino-3-{2′-[(1,1-dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile,
N-(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)acetamide,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-N-methylazetidine-3-carboxamide,
5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyridin-2-amine,
5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyl}biphenyl-4-yl)pyrazin-2-amine,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide,
{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile,
(2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}propan-1-ol,
6-Amino-3-[2′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carbonitrile,
5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide,
5-{5-[2-(Azepan-1-ylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-tert-butylbenzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(dicyclopropylmethyl)benzenesulfonamide,
5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(6-Amino-2-methyl pyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine,
5-(2-Fluoro-4-{2-[(1-methylpropyl)sulfonyl]pyridin-3-yl}phenyl)pyrimidin-2-amine,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-2-sulfonamide,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanenitrile,
5-{4-[2-(Cyclobutylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine,
5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxylic acid,
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-yl)pyrazin-2-amine,
5-(2-Fluoro-4-{2-[(3-methoxypropyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine,
6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2-carbonitrile,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2-sulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide,
1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-ol,
5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine,
5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine,
2-(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)ethanol,
5-{2′-[(5-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide,
6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile,
5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide,
(1-{[4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)methanol,
6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile,
5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine
5-(2-Fluoro-4-{2-[(tetrahydro-2H-pyran-4-ylmethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine,
5-{4-[2-(tert-Butylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine
3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile,
6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxamide,
5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine,
5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile,
4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-(2-hydroxy-1,1-dimethylethyl)biphenyl-2-sulfonamide,
5-{4-[2-(Cyclohexylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine,
5-{3-Fluoro-2′-[(l S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylsulfonyl]biphenyl-4-yl}pyrazin-2-amine,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-4-carboxamide,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carbaldehyde,
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3-hydroxyazetidin-3-yl)methyl]biphenyl-2-sulfonamide,
5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrazin-2-amine,
5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfanyl)pyrimidin-4-amine,
4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylbiphenyl-2-sulfonamide,
5-{4-[2-(Cyclopentylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine,
2-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine,
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile,
5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine,
5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylbiphenyl-2-sulfonamide,
5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine,
N,N-Diethyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-(2-Fluoro-4-{2-[(1-methylpropyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine,
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(2-hydroxy-1,1-dimethylethyl)biphenyl-2-sulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide,
6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazine-2-carbonitrile,
5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4
5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{4-[2-(Cyclobutylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,
4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide,
5-[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine,
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(pentafluoroethyl)piperidin-4-ol,
5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)-1H-pyrrolo[2,3-b]pyridine,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert-butylbenzenesulfonamide,
tert-Butyl (1-{[3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]sulfonyl}piperidin-4-yl)carbamate,
5-{4-[2-(Cyclopentylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3,3′-difluorobiphenyl-2-sulfonamide,
5-{4-[2-(Cyclohexylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2-sulfonamide,
5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine,
5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5-amine,
5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-(2-fluoro-4-(2-(piperidin-4-yloxy)pyridin-3-yl)phenyl)pyrazin-2-amine,
5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine,
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6-methylpyrimidin-4-amine,
5-{2′-[(4-Amino-6-methylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine,
5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine,
5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine,
5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine,
5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine,
5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine,
1-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol,
1-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol,
5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine,
N-{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-dimethylpropanamide,
N-{3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}-2,2-dimethylpropanamide,
5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine,
N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2-yl}-2,2-dimethylpropanamide,
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide,
5-[2′-Amino-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine,
5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)methoxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)benzoic acid,
4-({[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)benzoic acid,
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic acid,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic acid,
2-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}sulfonyl)piperidin-1-yl]ethanol,
4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine,
1-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}sulfonyl)piperidin-1-yl]propan-2-ol,
5-[3-Fluoro-2′-(1H-pyrazol-4-yl)biphenyl-4-yl]pyrazin-2-amine,
5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine,
5-{3-Fluoro-2′-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]biphenyl-4-yl}pyrazin-2-amine,
5-{5-[2-(Cyclopropylsulfonyl)phenyl]-3-fluoropyridin-2-yl}pyrimidin-2-amine,
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}benzamide,
5-{2′-[(trans-4-Aminocyclohexyl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine,
6-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyridazin-3-amine,
{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}acetonitrile,
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylpyrimidin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide,
5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine,
5-[3-Fluoro-2′-(2-piperazin-1-ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine,
5-{2′-[1-(2-Aminoethyl)-1H-pyrazol-4-yl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2S)-2-hydroxypropyl]benzenesulfonamide,
5-(3-Fluoro-2′-isothiazol-4-ylbiphenyl-4-yl)pyrazin-2-amine,
5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrazin-2-amine,
5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrimidin-2-amine,
2-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}ethanol,
5-(4-{2-[(1-Acetylpiperidin-3-yl)sulfonyl]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine,
5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2-hydroxy-1-methylethyl]benzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide,
5-[2-Fluoro-4-(2-phenylpyridin-3-yl)phenyl]pyrazin-2-amine,
5-(2-Fluoro-4-{2-[(1-methylpyrrolidin-3-yl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine,
5-{2-Fluoro-4-[2-(pyridin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}phenyl)pyrazin-2-amine,
5-(4-{2-[(1-Acetylpiperidin-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine,
5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine,
5-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N-methylpyrimidin-2-amine,
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}phenyl)pyrimidin-2-amine,
{4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}acetonitrile
5-[3-Fluoro-2′-(1H-pyrazol-4-yl)biphenyl-4-yl]pyrimidin-2-amine,
4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine,
5-{2-Fluoro-4-[2-(pyridin-3-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrimidin-2-amine,
5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4-yl]sulfonyl}pyridin-3-yl)phenyl]pyrazin-2-amine,
5-(4-{2-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}pyrazin-2-amine,
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}pyrimidin-2-amine,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-(2-hydroxyethyl)benzenesulfonamide,
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide, and
5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4-yl]sulfonyl}pyridin-3-yl)phenyl]pyrimidin-2-amine.

5. A pharmaceutical composition comprising at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5 comprising at least one compound of claim 4.

7. A compound selected from the group consisting of:
5-(3-Fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide;
6-Amino-3 -[3-fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazine-2-carbonitrile;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-methylbiphenyl-2-sulfonamide;
(racemic)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-methylethyl)biphenyl-2-sulfonamide racemic;
4′-(5-Aminopyrazin-2-yl)-N-(cyclobutylmethyl)-3′-fluorobiphenyl-2-sulfonamide;
(racemic) -(endo)-4′-(5-Aminopyrazin-2-yl)-N-bicyclo[221]hept-2-yl-3′-fluorobiphenyl-2-sulfonamide racemic;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-methylcyclobutyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-(1 ,1-dimethylpropyl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1 ,1-dimethylethyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-cyclopentyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-phenylethyl)biphenyl-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-(2,3-dihydro-1H-inden-2-yl)-3′-fluorobiphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-3′-fluorobiphenyl-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-3′-fluorobiphenyl-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-phenylethyl]biphenyl-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1 -methylethyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-N-[(3S)-1-ethyl-2-oxoazepan-3-yl]-3′-fluorobiphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-2-oxoazepan-3-yl]biphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(3S)-1-methyl-2-oxoazepan-3-yl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1 ,2,2,6,6-pentamethylpiperidin-4-yl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-pyridin-3-ylbiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfamide;
N-(4′-(5-aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)propane-2-sulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanesulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]propane-1-sulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-2-methylpropane-1-sulfonamide;
N-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1 ,1-biphenyl]-2-yl)cyclopropanesulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]hexane-1-sulfonamide;
N-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)cyclobutanesulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1,1,1-trifluoromethanesulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N,N-dimethylbiphenyl-2-sulfonamide;
5-[3-Fluoro-2′-(piperidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-[3-Fluoro-2′-(piperazin-1-ylsulfonyl)biphenyl -4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide;
5-8 3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5-{2′-[(4,4-Difluoropipenclin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(3,3-Difluoropipenclin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(3,3-Difluoroazetidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-[2′-(Azepan-1-ylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5-{3-Fluoro-2′-[(4-methylpiperazin-1-0)sulfonyl]piphenyl-4-yl}pyrazin-2-amine;
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(trifluoromethyl)}pipendin-4-ol;
5-(3-Fluoro-2′-{[4-(methylsulfonyl)piperazin-1-yl]sulfonyl}biphenyl-4-0)pyrazin-2-amine;
5-{2′-[(4-Acetylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-(2′-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine;
2-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)ethanol;
5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
(racemic) 5-[3-Fluoro-2′-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5-{2′-[(3,5-Dimethylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
(racemic) 1 -{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-3-carbonitrile;
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidine-4-carbonitrile;
5-{2′-[(4-Aminopipenclin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-one;
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-ol;
(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)methanol;
2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)pethanol;
(racemic) 1 -{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-ol;
(racemic) 2-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)ethanol;
5-(3-Fluoro-2′-{[4-(methylamino)piperidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine;
5-(2′-{[4-(Dimethylamino)piperidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine;
(racemic) 5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
N-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)acetamide;
(racemic) (1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)methanol;
(racemic) tert-Butyl (1-{[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-3-yl)carbamate;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]piphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]biphenyl- 2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxypropyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-phenylethyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-phenylethyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]piphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2R)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-1-(hydroxymethyl)propyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R,2S)-2-hydroxycyclohexyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2-sulfonamide;
(R)-(1((4′-(5-Aminopyrazin-2-yl)-3′-fluoro1 ,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-2-yl)methanol;
(R)-5-(2′4(3-Aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1 ,1 biphenyl]-4-yl)pyrazin-2-amine;
(S)-5-(2′4(3-Aminopyrrolidin-1-yl)sulfonyl)-3-fluoro-[1 ,1 biphenyl]-4-yl)pyrazin-2-amine;
(R) 5(2′-{[2-(Aminomethyl)pyrrolidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrazin-2-amine;
(S)-(1-((4′-(5-Aminopyrazin-2-yl)-3′-fluoro41 ,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-2-yl)methanol;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(methylsulfonyl)biphenyl-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)41 ,1′-biphenyl]-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxypropyl)41 ,1′-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1-hydroxycyclohexyl)methyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-1 ,1-dimethylethyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-methylpropyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-1 ,1-dimethylpropyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-N-(2,3-dihydroxypropyl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide;
(trans)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3,4-diol;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopyrrolidin-3-yl)1,1′-biphenyl]-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)-1 ,1′-biphenyl]-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide;
trans 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-sulfonamide;
(R)-(1-((4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)pyrrolidin-3-yl)methanol;
(S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl)}pyrrolidin-3-yl)methanol;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-oxopiperidin-3-yl)biphenyl-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3-yl)biphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-N-piperidin-3-yl)biphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-phenylpropan-2-yl)-1,1′-biphenyl]-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxy-2-phenylethyl)-1,1′-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide;
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-3-ol;
(racemic) (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxycyclohexyl)biphenyl-2-sulfonamide;
(racemic) (trans)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N42-(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide;
(racemic) (cis)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N42-(hydroxymethyl)cyclohexyl]biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-piperidin-4-ylbiphenyl-2-sulfonamide;
5-(2′-{[3-(Aminomethyl)azetidin-1-yl]sulfonyl}-3-fluorobiphenyl-4-ly) pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-N-(azetidin-3-ylmethyl)-3′-fluorobiphenyl-2-sulfonamide;
(R)-5-(3-Fluoro-2′-{[3-(methylamino)pyrrolidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-methylethyl)biphenyl-2-sulfonamide;
5-[3-Fluoro-2′-(1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
4-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperidin-4-yl)-2,4-dihydro-3H-1,2,4-triazol-3- one;
5-(2′-((1R,4R)-2,5-Diazabicyclo[221]heptan-2-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine;
5-(2′-((1S,4S)-2,5-Diazabicyclo[221]heptan-2-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-hydroxypentyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(6-hydroxyhexyl)biphenyl-2-sulfonamide;
N-(4-Aminocyclohexyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide;
(S)-(1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2,3-dihydro-1H-indol-2-yl)methanol;
4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide;
(S)-5-{2′-[(3-Aminopiperidin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N, N-bis(2-hydroxyethyl)biphenyl-2-sulfonamide;
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidine-2-carboxamide;
4′-(5-Aminopyrazin-2-yl)-N-cyclopropyl-3′-fluoro-N-(tetrahydro-2H-pyran-4-yl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1-methylethyl)biphenyl-2-sulfonamide;
racemic (4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}morpholin-2-yl)methanol;
(1R,5S)-3-((4′-(5-Aminopyrazin-2-yl)-3′-fluoro- [1′-biphenyl]-2-yl)sulfonyl)-3-azabicyclo[310]hexan-6-amine;
(S)-5-(3-Fluoro-2′-((2-methylpiperazin-1 -yl)sulfonyl)1 ,1 ′biphenyl]-4-yl)pyrazin-2-amine;
(R)-5-(3-Fluoro-2′4(2-methylpiperazin-1-yl)sulfonyl)41 ,1 -biphenyl]-4-yl)pyrazin-2-amine;
(R)-(1-((4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)piperazin-2-yl)methanol;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]biphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3-methylbutan-2-yl)-1,1′-biphenyl]-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan-2-yl)-[1, 1′-biphenyl]-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxy-3,3-dimethylbutan-2-yl)[1,1′-biphenyl]-2-sulfonamide;
tert-Butyl [2-({[4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}amino)ethyl]carbamate;
N-(2-Aminoethyl)-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-hydroxybutan-2-yl)1,1′-biphenyl]-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(pyrrolidin-3-yl)1, 1-biphenyl]-2-sulfonamide;
N-[2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}amino)ethyl]acetamide;
(S)-2-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro1,1′-biphenyl]-2-ylsulfonamido)propanoic acid;
4′-(5-Aminopyrazin-2-yl)-N-[2-(carbamoylamino)ethyl]-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-((1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-y1)1,1′-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-((1R,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)[1,′-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-[1, ′′-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)′1 ,1-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-((1 S,2S)-2-hydroxycyclohexyl)40 ,1-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[6-(trifluoromethyl)pyridin-3-yl]biphenyl-2-sulfonamide;
5-(3-Fluoro-2′-{[4-(1H-imidazol-4yl)piperidin-1-yl]sulfonyl}biphenyl-4-yl)pyrazin-2-amine;
N-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-4′-(5-aminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-(2,6-dimethoxypyrim idin-4-yl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(5-methylpyrazin-2-yl)biphenyl-2-sulfonamide;
(S)-2-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1 ,1′-biphenyl]-2-ylsulfonamido)-4-methylpentanamide;
4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-sulfonamide;
(R)-4′-(5-Aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-sulfonamide;
(S)-4′-(5-Aminopyrazin-2-yl)-N-(1-cyanopropan-2-yl)-3′-fluoro-[1 , l-biphenyl]-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(3-methyloxetan-3-yl)biphenyl-2-sulfonamide;
3-(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)propanenitrile;
(S)-4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(1-methoxypropan-2-041 ,1′-biphenyl]-2-sulfonamide;
5-{3-Fluoro-2′-[(4-pyrazin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine;
5-{3-Fluoro-2′-[(4-pyrimidin-2-ylpiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine;
5-(2′-Amino-3-fluorobiphenyl-4-yl)pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[1 -(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide;
1 -{[4′-(5-Aminopyrazin-2-0-3′-fluorobiphenyl-2-yl]sulfonyl}-3-phenylpyrrolidin-3-ol;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1-sulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,N-dimethylsulfamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]morpholine-4-sulfonamide;
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-3-ol;
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-3-ol;
(3′S,4′S)-1′-{[4′-(5-Aminopyrazin-2-0-3′-fluorobiphenyl-2-yl]sulfonyl}-1 ,3′-bipyrrolidin-4′-ol;
(3S,4S)-1-{[4′-(5-Aminopyrazin-2-0-3′-fluorobiphenyl-2-yl]sulfonyl}-4-morpholin-4-ylpyrrolidin-3-ol;
(3S,4S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(4-methylpiperazin-1)pyrrolidin-3-ol;
5-{3-Fluoro-2′-[(trifluoromethyl)-sulfanyl]biphenyl-4-yl}pyrazin-2-amine;
5[2′-(tert-Butylsulfanyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5[2′-(Ethylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5[3-Fluoro-2′-(propylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5-{3-Fluoro-2′-[(2-methylpropyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine;
5[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5[2′-(Cyclopentylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5[2′-(Cyclobutylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5[3-Fluoro-2′-(hexylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5-{3-Fluoro-2′-[(1-methylethyl)sulfonyl]biphenyl-4-yl}pyrazin-2-amine;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}acetamide;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}-N, N-diethylacetamide;
5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfanyl]biphenyl-4-yl}pyrazin-2-amine;
(racemic) 5-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}methyl)-1 ,3-oxazolidin-2-one;
N-(2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}ethyl)benzamide;
5-(3-Fluoro-2′-{[4-(methylsulfonyl)benzyl]sulfanyl}biphenyl-4yl)pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide;
5[3-Fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methyl-4-(trifluoromethyl)biphenyl-2-sulfonamide;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]sulfonyl}piperazin-2-one;
4′-(5-aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide;
5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine;
5[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine;
5[3-Fluoro-2′-(pyrimidin-4-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine;
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4-amine;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-4-amine;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-amine;
5[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrazin-2-amine;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-5-amine;
1[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylmethanesulfonamide;
1[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(2-hydroxyethyl)methanesulfonamide;
1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)azetidin-3-ol;
4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperazin-2-one;
(S)-1-(4′45-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1-hydroxypropan-2-yl)methanesulfonamide;
(R)-1-(4′-(5-Aminopyrazin-2-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)-N-(1-hydroxypropan-2-yl)methanesulfonamide;
1 -[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-(trans-4-hydroxycyclohexyl)methanesulfonamide;
(S)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2-hydroxypropyl]methanesulfonamide;
(R)-1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-[(2S)-2-hydroxypropyl]methanesulfonamide;
5-(2′-{[(4-Aminopiperidin-1-yl)sulfonyl]methyl1-3-fluorobiphenyl-4-}pyrazin-2-amine;
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide;
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-ethylmethanesulfonamide;
1-[1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperidin-4-yl]urea;
N- [1-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfonyl)piperidin-4-yl]acetamide;
5-{2′-[(Ethylsulfanyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{3-Fluoro-2′-[(methylsulfanyl)methyl]biphenyl-4-yl}pyrazin-2-amine;
5-(3-Fluoro-2′-{[(1-methylethyl)sulfanyl]methyl}biphenyl-4-yl)pyrazin-2-amine;
2-(((4′-(5-Aminopyrazin-2-yl)-3′-fluoro41 ,1′-biphenyl]-2-yl)methyl)thio)pyrimidin-4-amine;
6-(((4′-(5-Aminopyrazin-2-yl)-3′-fluoro41 ,1′-biphenyl]-2-yl)methyl)thio)pyrimidin-4-amine;
5-(3-Fluoro-2′-((pyridazin-3-ylthio)methyl)41 ,1′-biphenyl]-4-yl)pyrazin-2-amine;
6-(((4′-(5-Aminopyrazin-2-yl)-3′-fluoro41 ,1 -biphenyl]-2-yl)methyl)thio)pyridazin-3-amine;
5-{2′-[(1 ,1 -Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2-amine;
5-(3-Fluoro-2′-((pyrimidin-4-ylthio)methyl)41 ,1′-biphenyl]-4-yl)pyrazin-2-amine;
5[3-Fluoro-2′-({[2-(trimethylsily)ethoxy]methyl}sulfanyl)biphenyl-4-yl]pyrazin-2-amine;
5[3-Fluoro-2′-({[2-(trimethylsily)ethoxy]methyl}sulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5-(3-Fluoro-2′-{[3-(methylsulfonyl)propyl]sulfonyl}biphenyl)-4-pyrazin-2-amine;
5-(3-Fluoro-2′-{[(2R)-2-methylpiperazin-1-yl]sulfonyl}biphenyl-4-yl)pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)propyl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-N-(2-cyanoethyl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide;
(racemic) (4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-sulfonyl}morpholin-2-yl)methanol;
5-(3-Fluoro-2′-{[(2S)-2-methylpiperazin-1-yl]sulfonyllbiphenyl-4-Opyrimidin-2-amine;
5[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[2-hydroxy-1-(hydroxymethyl)-1-biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3S)-piperidin-3-yl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methyl-N-[(3R)-piperidin-3-yl]biphenyl-2-sulfonamide;
[(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-yl]methanol;
(racemic) (cis) 4′-(2-Aminopyrimidin-5-0-3′-fluoro-N- (cis)-2-hydroxycyclohexylpiphenyl-2- sulfonamide;
(racemic) (trans) 4′-(2-Aminopyrimidin-5-0-3′-fluoro-N- (trans)-2-hydroxycyclohexylpiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-N-(1-methylethyl)biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(trans-4-hydroxycyclohexyl)biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]biphenyl-2-sulfonamide;
5-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}azetidin-3-ol;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3R)-2-oxopiperidin-3-yl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(3S)-2-oxopiperidin-3-yl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1 R)-2,2,2-trifluoro-1 -methylethyl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1 R)-1-(hydroxymethyl)-2,2-dimethylpropyl]piphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]piphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-2-methylpropyl)biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1 R)-1-(hydroxymethyl)-2-methylpropyl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-N-[(2S)-2, 3-dihydroxypropyl]-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide;
[(2R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-2-yl]methanol;
[(2S)-1 -{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidin-2-yl]methanol;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxy-1 ,1 -dimethylethyl)biphenyl-2-sulfonamide;
5-{2′-[(4-Cyclopropylpiperazin-1-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
2-(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-1-yl)ethanol;
4′-(2-Aminopyrimidin-5-yl)-N-(cyclopropylmethyl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-N-cyclopropyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-phenylbiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)--N-tert-butyl-3′-fluoro-3-methylbiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1 R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide;
5-[3-Fluoro-2′-(piperazin-1 -ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1 R)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-phenylethyl]biphenyl-2-sulfonamide;
5[2′-(tert-Butylsulfonyl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-methylpropyl)biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Aminopyrim idin-5-yl)-3′-fluoro-N-(2,2,2-trifluoro-1 ,1-dimethylethyl)biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-sulfonamide;
5-[3-Fluoro-2′-(pyrrolidin-1 -ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N,N-dimethyl)biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide;
5-[3-Fluoro-2′-(piperidin-1 -ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-sulfonamide;
5[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine;
5[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-N-(tert-butyl)-3′-fluoro-[1, 1′-biphenyl]-2-sulfonamide;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}piperazin-2-one;
tert-Butyl N-{[4′-(2-aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L- alaninate;
N-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-L-alanine;
N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrrolidine-1-sulfonamide;
N-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]morpholine-4-sulfonamide;
N′-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N,N-dimethylsulfamide;
5-(2′-(2-Oxa-6-azaspiro[33]heptan-6-ylsulfonyl)-3-fluoro-[1 ,1′-biphenyl]-4-yl)pyrimidin-2-amine;
6-((4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)-2-thia-6-azaspiro[33]heptane 2,2-dioxide;
1-((4′-(2-Aminopyrim ,1′-biphenyl]-2-yl)sulfonyl)azetidine-3-carbonitrile;
1-((4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1 , l-biphenyl]-2-yl)sulfonyl)-3-(trifluoromethyl)azetidin-3-ol;
5-{2′-[(1 ,1-Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
2-(((4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1,1′-biphenyl]-2-yl)sulfonyl)methyl)quinazolin-4(3H)-one;
1-(34(4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-[1 ,1′-biphenyl]-2-yl)sulfonyl)propyl)-1H-benzo[d]imidazol-2(3H)-one;
5-(2′-{[3-(Cyclohexylsulfonyl)propyl]sulfonyl}1-3-fluorobiphenyl-4yl}pyrimidin-2-amine;
5-{3-Fluoro-2′-[(1-methyl-1H-benzimidazol-2-yl)sulfonyl]biphenyl-4-yl}pyrimidin-2-amine;
5-(2′-{[(3-Cyclopropyl-1 ,2,4-oxadiazol-5-yl)methyl]sulfonyl}-3-fluorobiphenyl-4-yl)pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide;
5[3-Fluoro-2′-(methylsulfonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]sulfonyl}piperazin-2-one;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-methyl-4-(trifluoromethyl)biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide;
5-{3-Fluoro-2′-[(4-methylpiperazin-1-yl)sulfonyl]-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(5-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(4-Aminopyrimidin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(5-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5[3-Fluoro-2′-(pyrimidin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine;
5[3-Fluoro-2′-(pyrazin-2-ylsulfanyl)biphenyl-4-yl]pyrimidin-2-amine;
5-{2′-[(6-Aminopyrimidin-4-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
4-{[’4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrimidin-2-amine;
5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(5-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5{3-Fluoro-2′-({[2-(trimethylsilypethoxy]methyl}sulfonyl)biphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(5-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5{3-Fluoro-2′-({[2-(trimethylsilyl)ethoxy]methyl}sulfanyl)biphenyl-4-yl}pyrimidin-2-amine;
5-(3-Fluoro-Z-(methylsulfonyl)41 ,1′-biphenyl]-4-yl)pyridin-2-amine;
4′-(6-Aminopyridin-3-yl)-N-(tert-butyl)-3′-fluoro-[1 ,1′-biphenyl]-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-N,N-diethyl-3′-fluoro-[1 , l-biphenyl]-2-sulfonamide;
5-(3-Fluoro-2′-(pyrrolidin-1 -ylsulfonyl)41 ,1′-biphenyl]-4-yl)pyridin-2-amine;
5-(3-Fluoro-2′-(piperidin-1 -ylsulfonyl)41 ,1′-biphenyl]-4-yl)pyridin-2-amine;
4′-(6-Aminopyridin-3-yl)-N-cyclohexyl-3′-fluoro-[l,1′-biphenyl]-2-sulfonamide;
(S)-4′-(6-Aminopyridin-3-yl)-3-fluoro-N-(1-hydroxypropan-2yl)-1,1′-biphenyl]-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-isobutyl-[l ,1′-biphenyl]-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(tert-pentyl)-[1 ,1′-biphenyl]-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1 ,1 ,1-trifluoro-2-methylpropan-2-yl)41 ,t-biphenyl]-2-sulfonamide;
(S)-4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(2,2,2-trifluoro-1-phenylethyl)-[1 ,1′-biphenyl]-2-sulfonamide;
(R)-4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)41 ,1′-biphenyl]-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1-methylcyclobutyl)-[1 ,1′-biphenyl]-2-sulfonamide;
4-((4′-(6-Aminopyridin-3-yl)-3′-fluoroql ,1′-biphenyl]-2-yl)sulfonyl)thiomorpholine1,1-dioxide;
(S)-4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1 ,1 ,1-trifluoropropan-2-yl)41 ,1′-biphenyl]-2-sulfonamide;
5-(2′-((1S,4S)-2-Oxa-5-azabicyclo[221]heptan-5-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2-amine;
tert-Butyl 34(4′-(6-aminopyridin-3-yl)-3′-fluoro-[1 ,1′-biphenyl]-2-ylsulfonamido)methyl)-3-hydroxyazetidine-1-carboxylate;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)-[1,1′-biphenyl]-2-sulfonamide;
2-(1-((4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1 ,t-biphenyl]-2-yl)sulfonyl)piperidin-4-y1)ethanol;
1 -((4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1 ,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-ol;
(1-((4′-(6-Aminopyridin-3-yl)-3′-fluoro-[1 ,1′-biphenyl]-2-yl)sulfonyl)piperidin-4-y1)methanol;
3′-Fluoro-N-[(1S)-2-hydroxy-1-methylethyl]-4′41 H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide;
3′-Fluoro-N-[(1 R)-2-hydroxy-1-methylethyl]-4′-(1H-pyrrolo[2,3-b]pyridin-5-y1)biphenyl-2-sulfonamide;
3′-Fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]-4′-(1 H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide;
5-[2′-(Cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]-1 H-pyrrolo[2,3-b]pyridine;
3′-Fluoro-N-(2-hydroxyethyl)-4′-(1 H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(1 H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide;
3′-Fluoro-4′-(1 H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide;
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]methanesulfonamide;
3′-Fluoro-N, N-dimethyl-4′-(5H-pyrrolo[2, 3-b]pyrazin-2-yl)biphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide;
2-[3-Fluoro-2′-(pyrrolidin-1 -ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine;
N,N-Diethyl-3′-fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide;
2-[3-Fluoro-2′-(piperidin-1 -ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine;
2-[3-Fluoro-2′-(morpholin-4-ylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine;
3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)N--N-(2,2,2-trifluoro-1 -methylethyl)biphenyl-2-sulfonamide;
2-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2, 3-b]pyrazine;
3′-Fluoro-N-[(1 R)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-sulfonamide;
3′-Fluoro-N-methyl-4′-(5H-pyrrolo[2, 3-b]pyrazin-2-yl)biphenyl-2-sulfonamide;
3′-Fluoro-N-[(1 S)-2-hydroxy-1-methylethyl]-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2- sulfonamide;
1 -{[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]sulfonyllpiperidin-4-amine;
2-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-5H-pyrrolo[2,3-b]pyrazine;
2-[3,5′-Difluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine;
2-[2′-(Ethylsulfanyl)-3-fluorobiphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine;
7-[3-Fluoro-2′-(methylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine;
7-[3-Fluoro-2′-(piperidin-1 -ylsulfonyl)biphenyl-4-yl]-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine;
4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide;
1 -{[4′-(3,4-Dihydro-2H-pyrido[3,2-b][1 ,4]oxazin-7-yl)-3′-fluorobiphenyl-2-yl]sulfonyllpiperidin-4-amine;
4′-(3,4-Dihydro-2H-pyrido[3,2-b][1 ,4]oxazin-7-yl)-3′-fluoro-N-[(1 R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide;
4′-(3,4-Dihydro-2H-pyrido[3,2-b][1 ,4]oxazin-7-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide;
7-{2′-[(1,1-Dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}-3,4-dihydro-2H-pyrido[3,2-b][1 ,4]oxazine;
N-tert-Butyl-4′-(3,4-dihydro-2H-pyrido[3,2-b][1 ,4]oxazin-7-yl)-3′-fluorobiphenyl-2-sulfonamide;
2-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]-5-(trifluoromethyl)pyridin-3-yl}phenyl)-5H-pyrrolo[2,3-b]pyrazine;
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine;
5-(2-Fluoro-4-{2-[(1-methylethyl)sulfanyl]pyridin-3-yl}phenyl)pyrazin-2-amine;
2-{2-Fluoro-4[2-(2,2,2-trifluoroethoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine;
2-{2-Fluoro-4[2-(2-methylpropoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine;
2-{2-Fluoro-4[2-(1-methylethoxy)pyridin-3-yl]phenyl}-5H-pyrrolo[2,3-b]pyrazine;
2-{4-[2-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}-5H-pyrrolo[2,3-b]pyrazine;
5-{4-[2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-{4[2-(Cyclopentyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine;
5-{2[2-(Cyclohexyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine;
5-[2-Fluoro-4-(2-methoxypyridin-3-yl)phenyl]pyrazin-2-amine;
5-{4-[2-(Cyclobutyloxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-am ine;
tert-Butyl 3-[({3-[4-(5-aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)methyl]pyrrolidine-1-carboxylate;
5-{2-Fluoro-4-[2-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-{2-Fluoro-4-[2-(1-methylethoxy)pyridin-3-yl]phenyl}pyrimidin-2-amine;
5-[4-(2-Aminopyridin-3-yl)-2-fluorophenyl]pyrim idin-2-am ine;
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide;
3-Amino-642′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carbonitrile;
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide;
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide;
3-Amino-6-{3-fluoro-2′-[(3-oxopiperazin-1-yl)sulfonyl]biphenyl-4-yl}pyrazine-2-carbonitrile;
4′-(5-Amino-6-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide;
3-Amino-643-fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazine-2-carbonitrile;
4′-(6-Aminopyridazin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(7H-pyrrolo[2,3-d]pyrimidin-2-yl)biphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(1 ,8-naphthyridin-3-yl)biphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-quinoxalin-6-yl)biphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(1 H-indo1-5-yl)biphenyl-2-sulfonamide;
4′-(1 H-Benzimidazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(1 H-Benzimidazol-5-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide;
4′-(1,3-Benzothiazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(1 H-pyrrolo[3,2-b]pyridin-6-yl)biphenyl-2-sulfonamide;
3′-Fluoro-N-methyl-4′-(1 H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide;
4′-(5-Aminopyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-4′-(5,6-diaminopyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1 H-imidazo[4,5-b]pyrazin-5-yl)biphenyl-2-sulfonamide;
4′-(6-Amino-5-fluoropyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonam ide;
N-tert-Butyl-4′-(2,3-dihydro-1 H-pyrrolo[2,3-b]pyridin-5-yl)-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(3H-im idazo[4, 5-b]pyridin-6-yl)bipheyl-2-sulfonamide;
4′-(5-Amino-6-methoxypyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Amino-6-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Amino-3-cyanopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(6-Amino-4-cyanopyridin-3-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(6-Amino-2-cyanopyridin-3-yl)-N-(tert-butyl)-3′-fluoroql ,t-biphenyl]-2-sulfonamide;
4′-(5-Amino-1 ,3,4-thiadiazol-2-yl)-N-(tert-butyl)-3′-fluoroql ,1′-biphenyl]-2-sulfonamide;
(R)-4′-(5-Amino-1 ,3,4-thiadiazol-2-yl)-3′-fluoro-N-(1-hydroxypropan-2-yl)41 ,t-biphenyl]-2-sulfonamide;
4-((4′-(5-Amino-1 ,3,4-thiadiazol-2-yl)-3′-fluoro41 ,1′-biphenyl]-2-yl)sulfonyl)thiomorpholine 1 ,1 -dioxide;
4′-(5-Amino-6-chloropyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Amino-6-bromopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
6-Amino-3-(2′-(cyclopropylsulfonyl)-3-fluoro41 ,1′-biphenyl]-4-yl)picolinonitrile;
N-tert-Butyl-3′-fluoro-4′41 ,2,4]triazolo[4,3-a]pyridin-7-ylbiphenyl-2-sulfonamide;
4′-(5-Amino-6-methylpyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(1H-imidazo[4,5-b]pyrazin-5-yl)biphenyl-2-sulfonamide;
N-tert-Butyl-4′-(5,6-diaminopyridin-3-yl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Amino-6-methylpyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-sulfonamide;
4′-(6-Amino-5-cyanopyridin-3-yl)--N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(6-Amino-5-chloropyridin-3-yl)--N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-[6-Amino-5-(trifluoromethyl)pyridin-3-yl]--N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-[2-Amino-4-(trifluoromethyl)pyrimidin-5-yl]-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Amino-4-methylpyrimidin-5-yl)--N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-[3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]biphenyl-2-sulfonamide;
4′-(7-Amino-1 H-indo1-5-yl)-3′-fluoro-N41 -(hydroxymethyl)cyclopentyl]biphenyl-2-sulfonamide;
3′-Fluoro-4′-[3-(hydroxymethyl)-1 H-pyrrolo[2,3-b]pyridin-5-yl]-N-methylbiphenyl-2-sulfonamide;
4′-(7-Amino-1 H-indol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]acetamide;
1 44′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]urea;
5-[2,3-D ifluoro-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′,3′-difluorobiphenyl-2-sulfonamide;
N-[4′-(5-Am nopyrazin-2-yl)-3′-fluoro-2′-methylbiphenyl-2-yl]methanesulfonam ide;
4′-(5-Aminopyrazin-2-yl)-2′,3′-difluorobiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)-2′,3′-difluoro-N-methylbiphenyl-2-sulfonamide;
4′-(2-Aminopyrimidin-5-yl)--N-tert-butyl-2′,3′-difluorobiphenyl-2-sulfonamide;
5 [2′,3-Difluoro-4′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine;
5-(2′,3-Difluorobiphenyl-4-yl)pyrazin-2-amine;
5-(2′-Chloro-3-fluorobiphenyl-4-yl)pyrazin-2-amine;
5-(3-Fluoro-2′-methylbiphenyl-4-yl)pyrazin-2-amine;
5[2′,3-Difluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
5[3-Fluoro-2′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
5-(3-Fluoro-2′-methoxybiphenyl-4-yl)pyrazin-2-amine;
5-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]pyrazin-2-amine;
5-[3-Fluoro-2′-(trifluoromethoxy)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-ol;
5-[3-Fluoro-2′-(phenylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5-(2′,3,6′-Trifluorobiphenyl-4-yl)pyrazin-2-amine;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]benzenesulfonamide;
5-(2′-Ethyl-3-fluorobiphenyl-4-yl)pyrazin-2-amine;
{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid;
5-[3-Fluoro-2′-(1-methylethyl)biphenyl-4-yl]pyrazin-2-amine;
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]ethanone;
5-[3-Fluoro-2′-(2,2,2-trifluoroethoxy)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxylicacid;
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carboxamide;
5-[3-Fluoro-2′-(1-methylethoxy)biphenyl-4-yl]pyrazin-2-amine;
5-{442-(Cyclopropylmethoxy)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine;
2-[3,4′-Difluoro-2′-(methylsulfonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylmethanesulfonmide;
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]ethanesulfonamide;
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]N--N-methylmethanesulfonamide;
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-N-methylethanesulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylethanesulfonam ide;
N-[3′-Fluoro-4′-(5H-pyrrolo[2,3-b]pyrazin-2-yl)biphenyl-2-yl]-2-methylpropane-1-sulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-ethylmethanesulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N,2-dimethylpropane-1 -sulfonamide;
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-1 H-pyrrolo[2,3-b]pyridine;
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrimidin-2-amine;
2-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]-5H-pyrrolo[2,3-b]pyrazine;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-carboxamide;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2-carboxamide;
4′-(5-Aminopyrazin-2-yl)-N, N-diethyl-3′-fluorobiphenyl-2-carboxamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide;
5-[3-Fluoro-2′-(piperazin-1 -ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine;
5-{2′-[(4-Acetylpiperazin-1-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-N-cyclohexyl-3′-fluorobiphenyl-2-carboxamide;
5-{2′-[(1 ,1 -Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-methylbiphenyl-2-carboxamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide;
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-4-ol;
5-{2′-[(4-Aminopiperidin-1 -yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(1 ,1 -Dioxidothiomorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-carboxamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]biphenyl-2-carboxamide;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperazin-2-one;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperazin-2-one;
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine;
4-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-yl]oxy}pyrimidin-2-amine;
2-{[3′-Fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-yl]oxy}pyrimidin-4-amine;
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1 H-pyrrolo[2,3-b]pyridine;
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazin-2-amine;
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrimidin-2-amine;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4-amine;
5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
6-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)pyridine-2-carbonitrile;
2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}methyl)pyridine-3-carbonitrile;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-amine;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-2-amine;
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-4-amine;
5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile;
5-{2′-[(6-Azetidin-1-ylpyrim idin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(6-Azetidin-1-ylpyrim idin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrazin-2-amine;
5-{3-Fluoro-2′-[(2-methylpyrimidin-4-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine;
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-1H-benzimidazole;
6-[3-Fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]-3H-imidazo[4,5-b]pyridine;
5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2-amine;
5-{3-Fluoro-2′-[(4-methylpyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine;
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrim idin-4-yl]oxy}biphenyl-4-yl}pyrazin-2-amine;
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyrim idin-4-yl]oxy}biphenyl-4-yl}pyrimidin-2-amine;
5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrazin-2-amine;
5-{3-Fluoro-2′-[(5-methoxypyrimidin-2-yl)oxy]biphenyl-4-yl}pyrimidin-2-amine;
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
5-[3-Fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrimidin-2-amine;
5-[3-Fluoro-2′-methoxy-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-2-amine;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-4-amine;
5-[3-Fluoro-4′-(trifluoromethyl)-2′-{[2-(trimethylsilyl)ethoxy]methoxy}biphenyl-4-yl]pyrimidin-2-amine;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-ol;
5-{2′-[(4-Aminopyrimidin-2-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]oxy}pyrimidin-2-amine;
5-{2′-[(6-Aminopyrimidin-4-yl)oxy]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrimidin-2-amine;
5-[3-Fluoro-2′,4′-bis(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carbonitrile;
5-{5-[2-(Pyrimidin-2-yloxy)-4-(trifluoromethyl)phenyl]pyridin-2-yl}pyrimidin-2-amine;
4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-5-(trifluoromethyl)phenoxy}pyrimidin-2-amine;
5-{5-[2-(Pyrimidin-2-yloxy)phenyl]pyridin-2-yl}pyrimidin-2-amine;
4-{2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenoxy}pyrimidin-2-amine;
5-(5-{2-[(4-Aminopyrimidin-2-yl)oxy]phenyl}pyridin-2-yl)pyrimidin-2-amine;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methylbiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-methoxybiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-tert-butylbiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N,N-dimethylbiphenyl-2-sulfonamide;
5[2′-(Morpholin-4-ylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-2′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-2′-fluoro-N,N-dimethylbiphenyl-2-sulfonamide;
4′-(2-Amino-1,3-oxazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Amino-1,3-thiazol-4-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
4′-(2-Amino-1,3-thiazol-4-yl)-N,N-diethyl-3′-fluorobiphenyl-2-sulfonamide;
4-[3-Fluoro-2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl]-1,3-thiazol-2-amine;
N-tert-Butyl-3′-fluoro-4′-(8-fluoroimidazo[1,2-a]pyridin-2-yl)biphenyl-2-sulfonamide;
4′-(5-Aminoimidazo[1,2-a]pyridin-2-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-6-carboxamide;
2-[2′-(tert-Butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-6-carboxamide;
N-tert-Butyl-4′-(5-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-4′-(6-cyanoimidazo[1,2-a]pyridin-2-yl)-3′-fluorobiphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′46-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]biphenyl-2-sulfonamide;
Ethyl 2-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]imidazo[1,2-a]pyridine-5-carboxylate;
N-tert-Butyl-3′-fluoro-4′-(5-methoxyimidazo[1,2-a]pyridin-2-yl)biphenyl-2-sulfonamide;
5[2′-(Methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
5[3-Methyl-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-N,N,3′-trimethylbiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-3′-hydroxybiphenyl-2-sulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)biphenyl-2-yl]methanesulfonamide;
4′-(5-Aminopyrazin-2-yl)biphenyl-2-sulfonamide;
N-tert-Butyl-3′-fluoro-4′-(2-oxo-2,3-dihydro-1 H-indol-5-yl)biphenyl-2-sulfonamide;
N-tert-Butyl-4′-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(3-Amino-1 H-indazol-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
3-Amino-6-[2′-(tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carboxylic acid;
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}acetamide;
2-{[4′-(2-Aminopyrimidin-5-0-3′-fluorobiphenyl-2-yl]sulfonyl}-N,N-diethylacetamide;
5-{3-Fluoro-2′-[(2-morpholin-4-yl-2-oxoethyl)sulfonyl]biphenyl-4-yl}pyrimidin-2-amine;
5,5′-(3,3′′-Difluoro-1,1′:2′,1′′-terphenyl-4,4′′-diyl)dipyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carboxylic acid;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-carbaldehyde;
5-[3-Fluoro-2′-(morpholin-4-ylmethyl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
5-{2′-[(4-Aminopiperidin-1-yl)methyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl}pyrazin-2-amine;
2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]methyl}amino)ethanol;
5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yllpyrazin-2-amine;
5-{2′-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yllpyrimidin-2-amine;
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-Opyrazin-2-amine;
5-(3-Fluoro-2′-{[2-(trifluoromethyl)pyridin-4-yl]oxy}biphenyl-4-Opyrimidin-2-amine;
5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-Opyrazin-2-amine;
5-(3-Fluoro-2′-{[4-(trifluoromethyl)pyrimidin-2-yl]oxy}biphenyl-4-Opyrimidin-2-amine;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyrimidin-5-amine;
5-{2′-[(5-Aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-6-methylpyrim idin-4-amine;
5-{2′-[(4-Amino-6-methylpyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile;
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-2-carbonitrile;
5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(5-Aminopyridin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(6-Amino-2-methylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}-2-methylpyrim idin-4-amine;
5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrimidin-2-amine;
5-(3-Fluoro-2′-{[6-(trifluoromethyl)pyridin-2-yl]oxy}biphenyl-4-yl)pyrazin-2-amine;
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile;
6-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}pyridine-3-carbonitrile;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol;
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}ethanol;
5(3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrazin-2-amine;
5(3-Fluoro-2′-(piperidin-4-yloxy)biphenyl-4-yl]pyrimidin-2-amine;
5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine;
5-{3-Fluoro-2′-[(3R)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine;
5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrazin-2-amine;
5-{3-Fluoro-2′-[(3S)-piperidin-3-yloxy]biphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(6-Cyclopropylpyrimidin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(2-Aminopyridin-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5-[2′-(2-Aminoethoxy)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine;
{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile;
{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetonitrile;
{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}acetic acid;
5-{2-Fluoro-4-[2-(piperidin-4-yl]oxy)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-{2-Fluoro-4-[2-(piperidin-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine;
5-(4-{2-[(1 ,1 -Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl]-2-fluorophenyl)pyrazin-2-amine;
5-(4-{2-[(1 ,1 -Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]pyridin-3-yl]-2-fluorophenyl)pyrimidin-2-amine;
2-({3-[4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol;
2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)ethanol;
5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl1-2-fluorophenyl)pyrim idin-2-amine;
5-(4-{2-[(trans-4-Aminocyclohexyl)oxy]pyridin-3-yl}-2-fluorophenyl)pyrazin-2-amine;
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl]phenyl}pyrimidin-2-amine;
(2R)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-ol;
(2R)-2-({344-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-01;
(2S)-2-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-o1;
(21)-2-({344-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-yl}oxy)propan-1-01;
N-(4′-(6-Aminopyridin-3-yl)-3′-fluoro41 ,1′-biphenyl]-2-yl)methanesulfonamide;
5-(3-Fluoro-2′-(morpholinosulfonyl)41 ,t-biphenyl]-4-yl)pyridin-2-amine;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-methyl41 ,1′-biphenyl]-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-3′-fluoroql ,1′-biphenyl]-2-sulfonamide;
5-(2′-((1S,4S)-2-Oxa-5-azabicyclo[221]heptan-5-ylsulfonyl)-3-fluoro-[1,1′-biphenyl]-4-yl)pyridin-2-amine;
4′-(6-Aminopyrazin-2-yl)-3′-fluoro-N-((3-hydroxyazetidin-3-yl)methyl)41 ,1′-biphenyl]-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-(1-hydroxy-2-methylpropan-2-yl)41 ,t-biphenyl]-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2-sulfonamide;
4′-(6-Amino-5-fluoropyridin-3-yI)-3′-fluoro-N-(1 -hydroxy-2-methylpropan-2-yI)-[1 ,t-biphenyl]-2-sulfonamide;
(racemic)-1-((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[1,1′-biphenyl]-2-y1)sulfonyl)piperidin-3-ol;
4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-[1,1′-biphenyl]-2- sulfonamide;
N-(1 -((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro41 ,1′-biphenyI]-2-yl)sulfonyl)piperidin-4-yl)acetamide;
racemic 2-[1 -((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoroql ,t-biphenyl]-2-yl)sulfonyl)piperidin-3-yl)ethanol;
racemic 1 -((4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-[l ,1′-biphenyI]-2-yl)sulfonyl)piperidin-3-yl)methanol;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-ethyl-5-(trifluoromethyl)benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-tert-butylbenzenesulfonamide;
5-{5-[2-(Morpholin-4-ylmethyl)-4-(trifluoromethyl)phenyl]pyridin-2-yl}pyrimidin-2-amine;
5-{5-[2-(Morpholin-4-ylcarbonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine;
5-[5-(2-Methoxyphenyl)pyridin-2-yl]pyrimidin-2-amine;
5-(5-{2-[(3,3-Difluoropiperidin-1 -yl)sulfonyl]phenyl]pyridin-2-yl)pyrimidin-2-amine;
5-(5-{2-[(3,3-Difluoropyrrolidin-1-yl)sulfonyl]phenyl]pyridin-2-yl)pyrimidin-2-amine;
5-{5-[2-(Azepan-1-yl)sulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine;
5-(5-{2-[(4,4-Difluoropiperidin-1 -yl)sulfonyl]phenyl}pyridin-2-yl)pyrimidin-2-amine;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethylbenzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-(dicyclopropylmethyl)benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1 R)-2,2,2-trifluoro-1 -methylethyl]benzenesulfonamide;
4-({2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]phenyl}sulfonyl)piperazin-2-one;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2S)-2-hydroxypropyl]benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(2R)-2-hydroxypropyl]benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N -(2-hydroxyethyl)-5-(trifluoromethyl)benzenesulfonamide;
5-{5-[2-(Cyclopropylsulfonyl)phenyl]pyridin-2-yl}pyrimidin-2-amine;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-ethyl-5-(trifluorom ethyl)benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-tert-butylbenzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)pyridin-3-yl]-N-[(1 R)-2-hydroxy-1 -methylethyl]benzenesulfonamide;
3-Amino-6-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile;
5-(4′-Bromo-2′, 3-difluorobiphenyl-4-yl)pyrazin-2-amine;
5-(4′-Bromo-2′,3-difluorobiphenyl-4-yl)-1 H-pyrrolo[2,3-b]pyridine;
5-(3-fluoro-2-methoxy-4′-(trifluoromethyl)41 ,t-biphenyl]-4-yl)pyrazin-2-amine;
5-(2′,3,4′-Trifluorobiphenyl-4-yl]pyrazin-2-amine;
(racemic) 5-[3-Fluoro-2′-(methylsulfinyl)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-carbonitrile;
1 -(4′-(5-Aminopyrazin-2-yl)-3′-fluoro41 , 1 ‘-biphenyl]-2-yl)imidazolidin-2-one;
4’-(2-Amino-4-cyanopyrimidin-5-yl)-N-tert-butyl-3′-fluorobiphenyl-2-sulfonamide;
6-Amino-3-{2′-[(1 , 1 -dioxidothiomorpholin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yllpyrazine-2-carbonitrile;
1 -{[4′-(2-Aminopyrimidin-5-0-3′-fluorobiphenyl-2-yl]sulfonyl}-N-methylazetidine-3-carboxamide;
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-sulfonamide;
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2S)-2-hydroxypropyl]biphenyl-2-sulfonamide;
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(2R)-2-hydroxypropyl]biphenyl-2-sulfonamide;
1-((4′-(2-Aminopyrim idin-5-yl)-3′-fluoro41 , 1 Lbiphenyl]-2-yl)sulfonyl)piperidine-4-carboxamide;
4′-(5-Amino-3-cyanopyrazin-2-yI)-3′-fluoro-N-[(1R)-2-hydroxy-1 -methylethyl]biphenyl-2-sulfonamide;
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-[(1S)-2-hydroxy-1-methylethyl]biphenyl-2-sulfonamide;
4′-(5-Amino-3-cyanopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)-4-(trifluoromethyl)biphenyl-2-sulfonamide;
4′-(5-Amino-3-cyanopyrazin-2-yl)-N-ethyl-3′-fluoro-4-(trifluoromethyl)41 , 1‘-biphenyl]-2-sulfonamide;
4’-(5-Amino-3-cyanopyrazin-2-yI)-3′-fluoro-N-(3-hydroxy-2,2-dimethylpropyl)biphenyl-2-sulfonamide;
6-Amino-3-{3-fluoro-2′-[(3-oxopiperazin-1 -yl)sulfonyI]-4′-(trifluoromethyl)biphenyl-4-yl}pyrazine-2-carbonitrile;
N-(2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyllethyl)benzamide;
b 1-{[4′-(2-Aminopyrimidin-5-0-3′-fluorobiphenyl-2-yl]sulfonyl1-3,3-dimethylbutan-2-one;
5-[3-Fluoro-2′-(pyrimidin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine;
5-[3-Fluoro-2′-(pyrazin-2-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine;
5-[3-Fluoro-2′-(pyrimidin-4-ylsulfonyl)biphenyl-4-yl]pyrimidin-2-amine;
5-{2′-[(6-Aminopyrimidin-4-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(4-Aminopyrimidin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
5-{2′-[(5-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-2-amine;
5-{2′-[(6-Aminopyrazin-2-yl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
6-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrimidin-4-amine;
5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
6-Amino-342′-(cyclopropylsulfonyl)-3-fluorobiphenyl-4-yl]pyrazine-2-carbonitrile;
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile;
1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide;
2-{[4′-(2-Aminopyrimidin-5-0-3′-fluorobiphenyl-2-yl]sulfonyl}2-methylpropanenitrile;
2-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide;
5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
2-{[4′-(5-Aminopyrazin-2-0-3′-fluorobiphenyl-2-yl]sulfonyl1-2-methylpropanenitrile;
2-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-2-methylpropanamide;
5-{2′-[(2-Amino-1,1-dimethylethyl)sulfonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarbonitrile;
1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}cyclopentanecarboxamide;
5-(2′-{[1-(Aminomethyl)cyclopentyl]sulfonyl1-3-fluorobiphenyl-4-yl)pyrimidin-2-amine;
5-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]sulfanyl}pyrazin-2-amine;
5-{2′-[(6-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-(3-Fluoro-2′-(pyrimidin-4-ylthio)-[1,1′-biphenyl]-4-yl)pyrazin-2-amine;
5-{2′-[(5-Aminopyrazin-2-yl)sulfanyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine;
6-Amino-3-{2′-[(4-aminopyrimidin-2-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazine-2-carbonitrile;
6-Amino-3-[3-fluoro-2′-(pyrimidin-2-yloxy)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazine-2-carbonitrile;
6-Amino-3′-fluoro-2′-(pyrimidin-2-yloxy)biphenyl-4-yl]pyrazine-2-carbonitrile;
N-(tert-Butyl)-3′-fluoro-4′-(5-(methylsulfonamido)pyrazin-2-yl)41,1′-biphenyl]-2-sulfonamide;
5-{2′-[(Ethylsulfonyl)methyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{3-Fluoro-2′-[(methylsulfonyl)methypiphenyl-4-yl}pyrazin-2-amine;
5-(3-Fluoro-2′-{[(1-methylethyl)sulfonyl]methyllbiphenyl-4-yl)pyrazin-2-amine;
5-{3-Fluoro-2′-[(pyrimidin-2-ylsulfonyl)methypiphenyl-4-yl}pyrazin-2-amine;
2-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]methyl}sulfanyl)pyrimidin-4-amine;
(racemic) 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine;
1 -{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}azetidin-3-ol;
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(tetrahydro-2H-pyran-4-yl)biphenyl-2-carboxamide;
5-{2′-[(1,1 -Dioxidothiomorpholin-4-yl)carbonyl]-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yllpyrazin-2-amine;
1 -(4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-ypethanol (diastereomeric mixture);
1 -(4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}morpholin-2-yl)ethanol (diastereomeric mixture);
4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide;
4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(2-hydroxyethyl)biphenyl-2-carboxamide;
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol;
(cis/trans) 4′-(5-Aminopyrazin-2-yl)-3′-fluoro-N-(4-hydroxycyclohexyl)biphenyl-2-carboxamide;
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol;
(cis/trans) 4′-(2-Aminopyrimidin-5-yl)-3′-fluoro-N-(4-hydroxycyclohexyl}biphenyl-2-carboxamide;
(racemic) 5-(3-Fluoro-2′-{[2-(trifluoromethyl)morpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine;
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol;
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}piperidin-3-ol;
(3R)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol;
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol;
(3S)-1-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol;
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]carbonyl}pyrrolidin-3-ol;
5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine (diastereoisomeric mixture);
5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine;
5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrazin-2-amine;
5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}piphenyl-4-yl)pyrazin-2-amine;
5-(3-Fluoro-2′-{[(2S)-2-methylmorpholin-4-yl]carbonyl}piphenyl-4-yl)pyrimidin-2-amine;
5-(3-Fluoro-2′-{[(3S)-3-methylmorpholin-4-yl]carbonyl}piphenyl-4-yl)pyrimidin-2-amine;
5-(3-Fluoro-2′-{[(3R)-3-methylmorpholin-4-yl]carbonyl}biphenyl-4-yl)pyrimidin-2-amine;
5-{2′-[(2,6-Dimethylmorpholin-4-yl)carbonyl]-3-fluorobiphenyl-4-yl}pyrimidin-2-amine (diastereoisomeric mixture);
5-{2-Fluoro-4-[2-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}-1H-pyrrolo[2,3-1D]pyridine;
5-{2-Fluoro-442-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine;
5-{2-Fluoro-442-(morpholin-4-ylcarbonyl)pyridin-3-yl]phenyl}pyrazin-2-amine;
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-tert-butyl-5-(trifluoromethyl)benzamide;
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1R)-2-hydroxy-1-methyl-ethyl]-5-(trifluoromethyl)benzamide;
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-N-[(1S)-2-hydroxy-1-methyl-ethyl]-5-(trifluoromethyl)benzamide;
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1 R)-2,2,2-trifluoro-1-methyl-ethyl]benzamide;
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1 S)-2,2,2-trifluoro-1-methyl-ethyl]benzamide;
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1 R)-2,2,2-trifluoro-1-methyl-ethyl]benzamide;
2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)-N-[(1 S)-2,2,2-trifluoro-1-methyl-ethyl]benzamide;
[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-(3-hydroxyazetidin-1 -yl)methanone;
[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenylH4-(methylamino)-1-piperidyl]methanone;
[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(1 ,1-dioxo-1 ,4-thiazinan-4-yl)methanone;
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tert-butyl-5-(trifluoromethyl)benzamide;
[2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(4-hydroxy-1 -piperidyl)methanone;
[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-5-(trifluoromethyl)phenyl]-(4-hydroxy-1-piperidyl)methanone;
2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]-N-tetrahydropyran-4-yl-benzam ide;
(racemic) [2-[4-(5-Aminopyrazin-2-yl)-3-fluoro-phenyl]phenyl-2-(hydroxymethyl)morpholin-4-yl]methanone;
(racemic)[2-[4-(2-Aminopyrimidin-5-yl)-3-fluoro-phenyl]phenyl]-[2-(hydroxymethyl)morpholin-4-yl]methanone;
N-{3-[4-(2-Aminopyrimidin-5-0-3-fluorophenyl]pyridin-2-}-2,2-dimethylpropanamide;
N-{3-[4-(5-Aminopyrazin-2-0-3-fluorophenyl]pyridin-2-}-2,2-dimethylpropanamide;
N-{3-[3-Fluoro-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]pyridin-2yl}-2,2-dimethylpropanamide;
(racemic) 5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrazin-2-amine;
5-(2-Fluoro-4-(2-(pyrrolidin-3-ylsulfonyl)pyridin-3-yl)phenyl)pyrimidin-2-amine;
5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine;
5-(4-(2-(Cyclobutylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine;
5-(4-(2-(CyclohexIsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine;
5-(4-(2-(Cyclohexylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine;
5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidine-2-amine;
5-(4-(2-(Cyclopentylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine;
5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine;
5-(4-(2-(tert-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine;
(racemic) 5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrimidin-2-amine;
(racemic)5-(4-(2-(sec-Butylsulfonyl)pyridin-3-yl)-2-fluorophenyl)pyrazin-2-amine;
1-((3-(4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)piperidin-1-yl)ethanone;
1-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)piperidin-1-yl)ethanone;
5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3-yl)phenyl)pyrimidin-2-amine;
5-(2-Fluoro-4-(2-((3-methoxypropyl)sulfonyl)pyridine-3-yl)phenyl)pyrazin-2-amine;
4-((3-(4-(2-Aminopyrimidin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide;
4-((3-(4-(2-Aminopyrazin-5-yl)-3-fluorophenyl)pyridine-2-yl)sulfonyl)tetrahydro-2H-thiopyran 1,1-dioxide;
5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3-yl)phenyl)pyrimidin-2-amine;
5-(2-Fluoro-4-(2-((2-morpholinoethyl)sulfonyl)pyridine-3-yl)phenyl)pyrazin-2-amine;
5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3-yl)pyrimidin-2-amine;
5-(2-Fluoro-4-(2-(((tetrahydro-2H-pyran-4-yl)methyl)sulfonyl)pyridine-3-yl)pyrazin-2-amine;
5-(2-Fluoro-4-{2-[(1 -methylethyl)sulfonyl]pyridin-3-yllphenyl)pyrimidin-2-amine;
5-(2-Fluoro-4-(2-(isopropylsulfonyl)pyridine-3-yl)phenyl)-1 H-pyrrolo[2,3-b]pyridine;
5-{2-Fluoro-442-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyllpyrimidin-2-amine;
5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrimidin-2-amine;
5-{4-[2-(Cyclopropylsulfonyl)pyridin-3-yl]-2-fluorophenyl}pyrazin-2-amine;
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine;
5-{2-Fluoro-4-[2-(piperidin-4-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-(2,3-Difluorobiphenyl-4-yl)pyrazin-2-amine;
5-(3-Fluoro-2-methoxybiphenyl-4-yl)pyrazin-2-amine;
5-[3-Fluoro-2-methoxy-2′-(methylsulfonyl)biphenyl-4-yl]pyrazin-2-amine;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-2′-methoxybiphenyl-2-sulfonamide;
N-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-2′-methoxybiphenyl-2-yl]methanesulfonamide;
5-(3-Fluoro-2′-(pyrazin-2-yl)41 ,t-biphenyl]-4-yl)pyrazin-2-amine;
5-(3-Fluoro-2′-pyrazin-2-ylbiphenyl-4-yl)pyrimidin-2-amine;
5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrazin-2-amine;
5-[2′-(5-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine;
5-[2′-(6-Aminopyrazin-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine;
5,5′-(3′-Fluorobiphenyl-2,4′-diyl)dipyrimidin-2-amine;
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-5-(trifluoromethyl)biphenyl-2-yl]pyrimidin-2-amine;
5-[3-Fluoro-2′-(2-methoxypyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine;
5-[3-Fluoro-2′-(1-methyl-1 H-pyrazol-4-yl)biphenyl-4-yl]pyrazin-2-amine;
5-(3-Fluoro-2′-pyrimidin-5-ylbiphenyl-4-yl)pyrazin-2-amine;
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidine-2-carbonitrile;
5-[3-Fluoro-2′-(2-morpholin-4-ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine;
1-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1 H-pyrazol-l-yl}-2-methylpropan-2-ol;
5-[3-Fluoro-2′-(1,2,3,6-tetrahydropyridin-4-yl)-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluoro-4-(trifluoromethyl)biphenyl-2-yl]pyrimidin-2-amine;
5-{2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]phenyl}pyrimidin-2-amine;
5-{5-[2-(2-Aminopyrimidin-5-yl)phenyl]pyridin-2-yl}pyrimidin-2-amine;
5-[2′41 ,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5-[2′41 ,1-Dioxido-1 ,2-thiazinan-2-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5-[2′41 ,1-Dioxidoisothiazolidin-2-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine;
5-[2-Fluoro-4-(2-pyrrolidin-1-ylpyridin-3-yl)phenyl]pyrazin-2-amine;
1-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrrolidin-2-one;
(2S)-2-({344-(2-Aminopyrimidin-5-yl)-3-fluorophenyl]pyridin-2-ylloxy)propan-1-ol;
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3-carboxamide;
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3-carboxamide;
5-{3-Fluoro-2′-[(1 S,4S)-2-oxa-5-azabicyclo[2.2.1 ]hept-5-ylsulfonyl]biphenyl-4-yl}pyrazin-2-amine;
4′-(6-Amino-5-fluoropyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylbiphenyl-2-sulfonamide;
4′-(6-Aminopyridin-3-yl)-3′-fluoro-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylbiphenyl-2-sulfonamide;
4′-(6-Aminopyridazin-3-yl)-3′-fluorobiphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-(trifluoromethyl)biphenyl-2-sulfonamide;
N4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]methanesulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-5-methoxybiphenyl-2-sulfonamide;
(3S)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3-carboxamide;
(3R)-1-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}pyrrolidine-3-carboxamide;
5-[3-Fluoro-2′-(morpholin-4-ylcarbonyl)biphenyl-4-yl]pyrazin-2-amine;
5-{2′-[(Cyclopropylmethyl)sulfonyl]-3-fluorobiphenyl-4-yllpyrazin-2-amine;
1-{[4′-(2-Am inopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]sulfonyl}-4-(pentafluoroethyl)piperidin-4-ol;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′-fluoro-4-(trifluoromethyl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3′,4-difluorobiphenyl-2-sulfonamide;
2-[3-Fluoro-2′-(methylsulfanyl)biphenyl-4-yl]-5H-pyrrolo[2, 3-b]pyrazine;
N,N-Diethyl-3′-fluoro-4′-(1H-pyrrolo[2,3-b]pyridin-5-yl)biphenyl-2-sulfonamide;
4′-(5-Aminopyrazin-2-yl)-N-tert-butyl-3, 3′-difluorobiphenyl-2-sulfonamide;
5-2′-Amino-3-fluoro-4′-(trifluoromethyl)biphenyl-4-yl]pyrazin-2-amine;
5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)methoxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2′-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
4-({[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxylmethyl)benzoic acid;
4-({[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxylmethyl)benzoic acid;
4-{[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic acid;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxy}benzoic acid;
2-[4-({3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}sulfonyl)piperidin-1-yl]ethanol;
4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyrimidin-2-amine;
1-[4{3-[4-(5-Aminopyrazin-2-yl)-3-fluorophenyl]pyridin-2-yl}sulfonyl)pipendin-1 -yl]propan-2-ol;
5-[3-Fluoro-2′-(1 H-pyrazol-4-yl)biphenyl-4-yl]pyrazin-2-amine;
5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrazin-2-amine;
5-{3-Fluoro-2′41-(2-methoxyethyl)-1 H-pyrazol-4-yl]biphenyl-4-yl}pyrazin-2-amine;
5-{5-[2-(Cyclopropylsulfonyl)phenyl]-3-fluoropyridin-2-yl}pyrimidin-2-amine;
4-{[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]oxylbenzamide;
5-{2′-[(trans-4-Aminocyclohexyl)oxy]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine;
6-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]pyridazin-3-amine;
{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1 -yl}acetonitrile;
5-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-N-methylpyrimidin-2-amine;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzenesulfonamide;
5-{2-Fluoro-4-[2-(phenylsulfonyl)pyridin-3-yl]phenyl}pyrimidin-2-amine;
5-[3-Fluoro-2′-(2-piperazin-1-ylpyrimidin-5-yl)biphenyl-4-yl]pyrazin-2-amine;
5-{2′-[1-(2-Aminoethyl)-1H-pyrazol-4-yl]-3-fluorobiphenyl-4-yl}pyrazin-2-amine;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(2S)-2-hydroxypropyl]benzenesulfonamide;
5-(3-Fluoro-2′-isothiazol-4-ylbiphenyl-4-yl)pyrazin-2-amine;
5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrazin-2-amine;
5-[2-Fluoro-4-(2-phenoxypyridin-3-yl)phenyl]pyrimidin-2-amine;
2-{4-[4′-(5-Aminopyrazin-2-yl)-3′-fluorobiphenyl-2-yl]-1H-pyrazol-1-yl}ethanol;
5-(4-{2-[(1 -Acetylpipendin-3-yl)sulfonyl]pyridin-3-yl1-2-fluorophenyl)pyrazin-2-amine;
5-(4-{2-[(1 -Acetylpipendin-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-yl1-2-fluorophenyl)pyrazin-2-amine;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1S)-2-hydroxy-1-methylethyl]benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide;
5-[2-Fluoro-4-(2-phenyl]pyridin-3-yl)phenyl]pyrazin-2-amine;
5-(2-Fluoro-4-{2-[(1 -methylpyrrolidin-3-yl)sulfonyl]pyridin-3-yl}phenyl)pyrazin-2-amine;
5-{2-Fluoro-4-[2-(pyridin-3-ylsulfonyl)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-(2-Fluoro-4-{2-[(1 -methylethyl)sulfonyI]-6-(trifluoromethyl)pyridin-3-yl}phenyl)pyrazin-2-amine;
5-(4-{2-[(1 -Acetylpiperidin-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-01-2-fluorophenyl)pyrimidin-2-amine;
5-[2′-(6-Aminopyridin-3-yl)-3-fluorobiphenyl-4-yl]pyrimidin-2-amine;
5-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-N-methylpyrimidin-2-amine;
5-(2-Fluoro-4-{2-[(1 -methylethyl)sulfonyI]-6-(trifluoromethyl)pyridin-3-yl}phenyl)pyrimidin-2-amine;
{4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]-1 H-pyrazol-1 -yl}acetonitrile;
5-[3-Fluoro-2′-(1 H-pyrazol-4-yl)biphenyl-4-yl]pyrimidin-2-amine;
4-[4′-(2-Aminopyrimidin-5-yl)-3′-fluorobiphenyl-2-yl]pyrim din-2-amine;
5-{2-Fluoro-4-[2-(pyridin-3-yloxy)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-(4-{2-[(1 ,1 -Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-01-2-fluorophenyl)pyrimidin-2-amine;
5-[2-Fluoro-4-(2-{[1 -(methylsulfonyl)piperidin-4-yl]sulfonyl}pyridin-3-yl)phenyl]pyrazin-2-amine;
5-(4-{2-[(1 ,1 -Dioxidotetrahydro-2H-thiopyran-4-yl)sulfonyl]-6-(trifluoromethyl)pyridin-3-01-2-fluorophenyl)pyrazin-2-amine;
5-{2-Fluoro-4-[2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}pyrazin-2-amine;
5-{2-Fluoro-4-2-(tetrahydro-2H-pyran-4-ylsulfonyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}pyrimidin-2-amine;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-(2-hydroxyethyl)benzenesulfonamide;
2-[6-(2-Aminopyrimidin-5-yl)-5-fluoropyridin-3-yl]-N-[(1 R)-2,2,2-trifluoro-1 -methylethyl]benzenesulfonamide; and
5-[2-Fluoro-4-(2-{[1-(methylsulfonyl)piperidin-4-yl]sulfonyllpyridin-3-yl)phenyl]pyrimidin-2-amine;

and pharmaceutically acceptable salts thereof.

8. The pharmaceutical composition of claim 5 comprising at least one compound of claim 7.

9. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition medicated by FLAP activity, comprising administering to the subject a therapeutically effective amount of at least one compound of claim 1.

10. The method according to claim 9, wherein the disease, disorder, or medical condition is selected from the group consisting of respiratory disorders, cardiac and cardiovascular diseases, autoimmune and allergic disorders, and carcinogenesis disorders.

11. The method according to claim 10, wherein respiratory disorder is selected from the group consisting of non-allergic asthma, fibrotic lung diseases, acute respiratory distress syndrome and chronic obstructive pulmonary disease.

12. The method according to claim 10, wherein the cardiac and cardiovascular disease is selected from the group consisting of myocardial infarction, atherosclerosis and stroke aortic aneurisms, and atherosclerosis.

13. The method according to claim 10, wherein the autoimmune and allergic disease is selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, nephritis, spondyloarthritis, polymyositis, dermatomyositis, gouty effusions, systemic lupus erythematosus, systemic sclerosis, Alzheimer's disease, multiple sclerosis, allergic rhinitis, allergic dermatitis and asthma.

14. The method according to claim 10, wherein the carcinogenesis disorder is selected from the group consisting of tumor cell proliferation, tumor cell differentiation, apoptosis, tumor-associated angiogenesis, and the migration or invasion of carcinoma cells.

15. The method of claim 9, wherein the therapeutically effective amount of the compound of Formula (I) is from about 0.1 mg/dose to about 5 g/dose.

16. A process for making a pharmaceutical composition comprising admixing any of the compounds according to claim 1 and a pharmaceutically acceptable carrier.